PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 18435210-1 2008 OBJECTIVE: In this study, we aim to determine the false-positive rate & specificity in normal subjects and carpal tunnel syndrome (CTS) patients of five provocative maneuvers used to diagnose thoracic outlet syndrome (TOS). Adenosine Monophosphate 71-74 transthyretin Homo sapiens 135-138 18435210-4 2008 RESULTS: In the CTS group, false positive tests were observed in 42% in the Adson A test, 45% in the Adson B test, 48% in the CCM, 77% in the Roos test, and 61% in the SCP 94% of the CTS patients had at least 1 positive TOS diagnostic maneuver. Sulfachlorpyridazine 168-171 transthyretin Homo sapiens 16-19 18441837-1 2008 Our previous study demonstrated that compounds in indoor dusts strongly inhibit thyroxine (T4) binding to the human thyroid hormone transport protein transthyretin (TTR) in vitro. Thyroxine 80-89 transthyretin Homo sapiens 150-163 18441837-1 2008 Our previous study demonstrated that compounds in indoor dusts strongly inhibit thyroxine (T4) binding to the human thyroid hormone transport protein transthyretin (TTR) in vitro. Thyroxine 80-89 transthyretin Homo sapiens 165-168 18441837-3 2008 Here, we used chemical fractionation with in vitro competitive human TTR-binding assay and GC-MS to analyze the TTR-binding compounds in a sulfuric-acid-treated dust extract. sulfuric acid 139-152 transthyretin Homo sapiens 69-72 18441837-3 2008 Here, we used chemical fractionation with in vitro competitive human TTR-binding assay and GC-MS to analyze the TTR-binding compounds in a sulfuric-acid-treated dust extract. sulfuric acid 139-152 transthyretin Homo sapiens 112-115 18441837-4 2008 2,4,6-Tribromophenol (TriBPh) and 2,3,4,5,6-pentachlorophenol (PeCPh) were potent TTR-binding compounds in all dust samples. 2,4,6-tribromophenol 0-20 transthyretin Homo sapiens 82-85 18441837-4 2008 2,4,6-Tribromophenol (TriBPh) and 2,3,4,5,6-pentachlorophenol (PeCPh) were potent TTR-binding compounds in all dust samples. 2,4,6-tribromophenol 22-28 transthyretin Homo sapiens 82-85 18441837-4 2008 2,4,6-Tribromophenol (TriBPh) and 2,3,4,5,6-pentachlorophenol (PeCPh) were potent TTR-binding compounds in all dust samples. Pentachlorophenol 34-61 transthyretin Homo sapiens 82-85 18441837-4 2008 2,4,6-Tribromophenol (TriBPh) and 2,3,4,5,6-pentachlorophenol (PeCPh) were potent TTR-binding compounds in all dust samples. Pentachlorophenol 63-68 transthyretin Homo sapiens 82-85 18441837-5 2008 2,4,6-TriBPh- and 2,3,4,5,6-PeCPh-derived theoretical T4 equivalents (T4EQs), calculated arithmetically from the concentrations and relative potencies, accounted for about 40-70% of experimental T4EQs detected in indoor dusts, indicating that these compounds contributed strongly to the TTR-binding potency of indoor dust. 2,4,6-tribph 0-12 transthyretin Homo sapiens 287-290 18441837-5 2008 2,4,6-TriBPh- and 2,3,4,5,6-PeCPh-derived theoretical T4 equivalents (T4EQs), calculated arithmetically from the concentrations and relative potencies, accounted for about 40-70% of experimental T4EQs detected in indoor dusts, indicating that these compounds contributed strongly to the TTR-binding potency of indoor dust. 2,3,4,5,6-pecph 18-33 transthyretin Homo sapiens 287-290 18441837-5 2008 2,4,6-TriBPh- and 2,3,4,5,6-PeCPh-derived theoretical T4 equivalents (T4EQs), calculated arithmetically from the concentrations and relative potencies, accounted for about 40-70% of experimental T4EQs detected in indoor dusts, indicating that these compounds contributed strongly to the TTR-binding potency of indoor dust. t4eqs 70-75 transthyretin Homo sapiens 287-290 18237193-1 2008 Transthyretin (TTR) is a 55 kDa homotetrameric protein known for the transport of thyroxine and the indirect transportation of retinol. Thyroxine 82-91 transthyretin Homo sapiens 0-13 18709962-7 2008 Bi-directional sequencing of exon 3 showed a single base-pair substitution, which results in an amino acid substitution at position83, glycine to arginine (TTR Arg-83). Arginine 160-163 transthyretin Homo sapiens 156-159 18709962-8 2008 TTR Arg-83 may be a new pathologic mutation in vitreous amyloidosis. Arginine 4-7 transthyretin Homo sapiens 0-3 18709962-0 2008 [Transthyretin Arg-83 mutation in vitreous amyloidosis]. Arginine 15-18 transthyretin Homo sapiens 1-14 18709962-7 2008 Bi-directional sequencing of exon 3 showed a single base-pair substitution, which results in an amino acid substitution at position83, glycine to arginine (TTR Arg-83). Glycine 135-142 transthyretin Homo sapiens 156-159 18709962-7 2008 Bi-directional sequencing of exon 3 showed a single base-pair substitution, which results in an amino acid substitution at position83, glycine to arginine (TTR Arg-83). Arginine 146-154 transthyretin Homo sapiens 156-159 18237193-1 2008 Transthyretin (TTR) is a 55 kDa homotetrameric protein known for the transport of thyroxine and the indirect transportation of retinol. Thyroxine 82-91 transthyretin Homo sapiens 15-18 18237193-1 2008 Transthyretin (TTR) is a 55 kDa homotetrameric protein known for the transport of thyroxine and the indirect transportation of retinol. Vitamin A 127-134 transthyretin Homo sapiens 0-13 18237193-1 2008 Transthyretin (TTR) is a 55 kDa homotetrameric protein known for the transport of thyroxine and the indirect transportation of retinol. Vitamin A 127-134 transthyretin Homo sapiens 15-18 18061140-0 2008 Cholesterol and anionic phospholipids increase the binding of amyloidogenic transthyretin to lipid membranes. Cholesterol 0-11 transthyretin Homo sapiens 76-89 18023404-5 2008 The capabilities of the UFRD method are demonstrated using the binding of 2,4-dinitrophenol (DNP) to transthyretin (TTR), as well as preliminary measurements in several other systems. 2,4-Dinitrophenol 74-91 transthyretin Homo sapiens 101-114 18023404-5 2008 The capabilities of the UFRD method are demonstrated using the binding of 2,4-dinitrophenol (DNP) to transthyretin (TTR), as well as preliminary measurements in several other systems. 2,4-Dinitrophenol 74-91 transthyretin Homo sapiens 116-119 18023404-5 2008 The capabilities of the UFRD method are demonstrated using the binding of 2,4-dinitrophenol (DNP) to transthyretin (TTR), as well as preliminary measurements in several other systems. 2,4-Dinitrophenol 93-96 transthyretin Homo sapiens 101-114 18023404-5 2008 The capabilities of the UFRD method are demonstrated using the binding of 2,4-dinitrophenol (DNP) to transthyretin (TTR), as well as preliminary measurements in several other systems. 2,4-Dinitrophenol 93-96 transthyretin Homo sapiens 116-119 18095641-0 2008 Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. 2-arylbenzoxazole 58-75 transthyretin Homo sapiens 82-95 18061140-0 2008 Cholesterol and anionic phospholipids increase the binding of amyloidogenic transthyretin to lipid membranes. Phospholipids 24-37 transthyretin Homo sapiens 76-89 18061140-5 2008 Increasing the mole fraction of cholesterol in the bilayer led to an increase in the amount of high-affinity binding of an amyloidogenic mutant (L55P) TTR. Cholesterol 32-43 transthyretin Homo sapiens 151-154 18061140-6 2008 In addition, a greater amount of L55P TTR bound with high affinity to membranes made from anionic phospholipids, phosphatidylglycerol (PG) and phosphatidylserine (PS), than to membranes made from zwitterionic phospholipid phosphatidylcholine (PC). Phospholipids 98-111 transthyretin Homo sapiens 38-41 18061140-6 2008 In addition, a greater amount of L55P TTR bound with high affinity to membranes made from anionic phospholipids, phosphatidylglycerol (PG) and phosphatidylserine (PS), than to membranes made from zwitterionic phospholipid phosphatidylcholine (PC). Phosphatidylglycerols 113-133 transthyretin Homo sapiens 38-41 18061140-6 2008 In addition, a greater amount of L55P TTR bound with high affinity to membranes made from anionic phospholipids, phosphatidylglycerol (PG) and phosphatidylserine (PS), than to membranes made from zwitterionic phospholipid phosphatidylcholine (PC). Phosphatidylglycerols 135-137 transthyretin Homo sapiens 38-41 18061140-6 2008 In addition, a greater amount of L55P TTR bound with high affinity to membranes made from anionic phospholipids, phosphatidylglycerol (PG) and phosphatidylserine (PS), than to membranes made from zwitterionic phospholipid phosphatidylcholine (PC). Phosphatidylserines 143-161 transthyretin Homo sapiens 38-41 18061140-6 2008 In addition, a greater amount of L55P TTR bound with high affinity to membranes made from anionic phospholipids, phosphatidylglycerol (PG) and phosphatidylserine (PS), than to membranes made from zwitterionic phospholipid phosphatidylcholine (PC). Phosphatidylserines 163-165 transthyretin Homo sapiens 38-41 18061140-6 2008 In addition, a greater amount of L55P TTR bound with high affinity to membranes made from anionic phospholipids, phosphatidylglycerol (PG) and phosphatidylserine (PS), than to membranes made from zwitterionic phospholipid phosphatidylcholine (PC). Phospholipids 98-110 transthyretin Homo sapiens 38-41 18061140-6 2008 In addition, a greater amount of L55P TTR bound with high affinity to membranes made from anionic phospholipids, phosphatidylglycerol (PG) and phosphatidylserine (PS), than to membranes made from zwitterionic phospholipid phosphatidylcholine (PC). Phosphatidylcholines 222-241 transthyretin Homo sapiens 38-41 18061140-6 2008 In addition, a greater amount of L55P TTR bound with high affinity to membranes made from anionic phospholipids, phosphatidylglycerol (PG) and phosphatidylserine (PS), than to membranes made from zwitterionic phospholipid phosphatidylcholine (PC). Phosphatidylcholines 243-245 transthyretin Homo sapiens 38-41 18061140-7 2008 The anionic phospholipids (PS and PG) promoted the aggregation of L55P TTR by accelerating the nucleation phase of aggregation, whereas the zwitterionic phospholipid PC had little effect. Phospholipids 12-25 transthyretin Homo sapiens 71-74 18061140-7 2008 The anionic phospholipids (PS and PG) promoted the aggregation of L55P TTR by accelerating the nucleation phase of aggregation, whereas the zwitterionic phospholipid PC had little effect. Phosphatidylglycerols 34-36 transthyretin Homo sapiens 71-74 18061140-7 2008 The anionic phospholipids (PS and PG) promoted the aggregation of L55P TTR by accelerating the nucleation phase of aggregation, whereas the zwitterionic phospholipid PC had little effect. Phospholipids 12-24 transthyretin Homo sapiens 71-74 18061140-8 2008 These results suggest that cholesterol and anionic phospholipids may be important for TTR aggregation and TTR-induced cytotoxicity. Cholesterol 27-38 transthyretin Homo sapiens 86-89 18061140-8 2008 These results suggest that cholesterol and anionic phospholipids may be important for TTR aggregation and TTR-induced cytotoxicity. Cholesterol 27-38 transthyretin Homo sapiens 106-109 18061140-8 2008 These results suggest that cholesterol and anionic phospholipids may be important for TTR aggregation and TTR-induced cytotoxicity. Phospholipids 51-64 transthyretin Homo sapiens 86-89 18061140-8 2008 These results suggest that cholesterol and anionic phospholipids may be important for TTR aggregation and TTR-induced cytotoxicity. Phospholipids 51-64 transthyretin Homo sapiens 106-109 18269111-12 2008 The patient with mild symptoms of CTS can be managed with conservative treatment, particularly local injection of steroids. Steroids 114-122 transthyretin Homo sapiens 34-37 19075702-1 2008 Transthyretin (TTR) is a homotetrameric serum and cerebrospinal fluid protein that transports both thyroxine (T(4)) and the retinol-retinol binding protein complex (holoRBP). Thyroxine 99-108 transthyretin Homo sapiens 0-13 19075702-1 2008 Transthyretin (TTR) is a homotetrameric serum and cerebrospinal fluid protein that transports both thyroxine (T(4)) and the retinol-retinol binding protein complex (holoRBP). Thyroxine 99-108 transthyretin Homo sapiens 15-18 18776590-5 2008 Mice treated with doxycycline, a TTR fibril disrupter, presented lower levels of MMP-9, TIMP-1 and NGAL, suggestive of matrix recovery. Doxycycline 18-29 transthyretin Homo sapiens 33-36 18786882-2 2008 TTR is a normal plasma protein (previously called prealbumin) that functions as a transport protein binding tiroxine and retinol. Oxafun 108-116 transthyretin Homo sapiens 0-3 18786882-2 2008 TTR is a normal plasma protein (previously called prealbumin) that functions as a transport protein binding tiroxine and retinol. Vitamin A 121-128 transthyretin Homo sapiens 0-3 17968688-5 2007 Endomyocardial biopsy in 2006 revealed transthyretin amyloidosis by Congo red and immunohistochemical staining, as well as Val94Ala substitution by transthyretin gene analysis. Congo Red 68-77 transthyretin Homo sapiens 39-52 17767913-1 2007 Here, molecular dynamics (MD) simulations are performed to study the differences of binding channel shapes of TTR with two inhibitors, flufenamic acid (FLU) and one kind of N-phenyl phenoxazine (BPD). Flufenamic Acid 135-150 transthyretin Homo sapiens 110-113 17948976-0 2007 Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates. biphenyl ethers 80-95 transthyretin Homo sapiens 40-53 17948976-7 2007 The present study thus establishes biphenyl ethers and compounds 11 and 12 as very potent inhibitors of TTR fibrillization and inducible cytotoxicity. biphenyl ethers 35-50 transthyretin Homo sapiens 104-107 17693625-6 2007 In similar assays, TTR-containing HDL from mice expressing human TTR in a TTR knockout background had a decreased ability to perform reverse cholesterol transport compared with similar particles from TTR knockout mice, reinforcing the notion that cleavage by TTR reduces the ability of apoA-I to promote cholesterol efflux. Cholesterol 141-152 transthyretin Homo sapiens 65-68 17693625-6 2007 In similar assays, TTR-containing HDL from mice expressing human TTR in a TTR knockout background had a decreased ability to perform reverse cholesterol transport compared with similar particles from TTR knockout mice, reinforcing the notion that cleavage by TTR reduces the ability of apoA-I to promote cholesterol efflux. Cholesterol 141-152 transthyretin Homo sapiens 65-68 17693625-6 2007 In similar assays, TTR-containing HDL from mice expressing human TTR in a TTR knockout background had a decreased ability to perform reverse cholesterol transport compared with similar particles from TTR knockout mice, reinforcing the notion that cleavage by TTR reduces the ability of apoA-I to promote cholesterol efflux. Cholesterol 141-152 transthyretin Homo sapiens 65-68 17693625-6 2007 In similar assays, TTR-containing HDL from mice expressing human TTR in a TTR knockout background had a decreased ability to perform reverse cholesterol transport compared with similar particles from TTR knockout mice, reinforcing the notion that cleavage by TTR reduces the ability of apoA-I to promote cholesterol efflux. Cholesterol 304-315 transthyretin Homo sapiens 65-68 17693625-6 2007 In similar assays, TTR-containing HDL from mice expressing human TTR in a TTR knockout background had a decreased ability to perform reverse cholesterol transport compared with similar particles from TTR knockout mice, reinforcing the notion that cleavage by TTR reduces the ability of apoA-I to promote cholesterol efflux. Cholesterol 304-315 transthyretin Homo sapiens 65-68 17693625-6 2007 In similar assays, TTR-containing HDL from mice expressing human TTR in a TTR knockout background had a decreased ability to perform reverse cholesterol transport compared with similar particles from TTR knockout mice, reinforcing the notion that cleavage by TTR reduces the ability of apoA-I to promote cholesterol efflux. Cholesterol 304-315 transthyretin Homo sapiens 65-68 17761149-4 2007 We have studied the amyloid fibril formation process of TTR (105-115) by introducing a pair of FRET probes into the peptide with a dansyl group at the N-terminal and a tryptophan residue at the C-terminal. Tryptophan 168-178 transthyretin Homo sapiens 56-59 17767913-1 2007 Here, molecular dynamics (MD) simulations are performed to study the differences of binding channel shapes of TTR with two inhibitors, flufenamic acid (FLU) and one kind of N-phenyl phenoxazine (BPD). Flufenamic Acid 152-155 transthyretin Homo sapiens 110-113 17767913-1 2007 Here, molecular dynamics (MD) simulations are performed to study the differences of binding channel shapes of TTR with two inhibitors, flufenamic acid (FLU) and one kind of N-phenyl phenoxazine (BPD). 10-phenyl-10H-phenoxazine 173-193 transthyretin Homo sapiens 110-113 17767913-1 2007 Here, molecular dynamics (MD) simulations are performed to study the differences of binding channel shapes of TTR with two inhibitors, flufenamic acid (FLU) and one kind of N-phenyl phenoxazine (BPD). benzo(a)pyrene 7,8-dihydrodiol 195-198 transthyretin Homo sapiens 110-113 17767913-5 2007 For FLU, when the first ligand binds with TTR, it leads to expansion of the second binding site which may weaken the interaction of the second FLU with TTR. Flufenamic Acid 4-7 transthyretin Homo sapiens 42-45 17767913-5 2007 For FLU, when the first ligand binds with TTR, it leads to expansion of the second binding site which may weaken the interaction of the second FLU with TTR. Flufenamic Acid 4-7 transthyretin Homo sapiens 152-155 17767913-5 2007 For FLU, when the first ligand binds with TTR, it leads to expansion of the second binding site which may weaken the interaction of the second FLU with TTR. Flufenamic Acid 143-146 transthyretin Homo sapiens 42-45 17767913-5 2007 For FLU, when the first ligand binds with TTR, it leads to expansion of the second binding site which may weaken the interaction of the second FLU with TTR. Flufenamic Acid 143-146 transthyretin Homo sapiens 152-155 19662213-8 2007 The occurrence of this variant was not associated with the severity of trauma or the intensity of the acute-phase response, but was associated with oxidative stress as evidenced by Trolox.Our results demonstrate that changes in microheterogeneity of TTR occur in a substantial number of ICU trauma patients. 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid 181-187 transthyretin Homo sapiens 250-253 17712141-10 2007 Furthermore, enteral administration of the glutamine tracer resulted in higher arterial enrichments of [(15)N]citrulline (TTR% IV: 5.52 +/- 0.44 vs EN: 8.81 +/- 1.1; p = .02), and both routes of administration generated a significant enrichment of [(15)N]arginine (TTR% IV: 1.43 +/- 0.12 vs EN: 1.68 +/- 0.18). Glutamine 43-52 transthyretin Homo sapiens 122-125 17712141-10 2007 Furthermore, enteral administration of the glutamine tracer resulted in higher arterial enrichments of [(15)N]citrulline (TTR% IV: 5.52 +/- 0.44 vs EN: 8.81 +/- 1.1; p = .02), and both routes of administration generated a significant enrichment of [(15)N]arginine (TTR% IV: 1.43 +/- 0.12 vs EN: 1.68 +/- 0.18). Glutamine 43-52 transthyretin Homo sapiens 265-268 17712141-10 2007 Furthermore, enteral administration of the glutamine tracer resulted in higher arterial enrichments of [(15)N]citrulline (TTR% IV: 5.52 +/- 0.44 vs EN: 8.81 +/- 1.1; p = .02), and both routes of administration generated a significant enrichment of [(15)N]arginine (TTR% IV: 1.43 +/- 0.12 vs EN: 1.68 +/- 0.18). [(15)n]citrulline 103-120 transthyretin Homo sapiens 122-125 17683510-4 2007 The peaks were identified as native transthyretin (TTR) and its two variants by one-dimensional polyacrylamide gel electrophoresis, ESI-MS/MS, immunoprecipitation and western blot analysis. polyacrylamide gels 96-114 transthyretin Homo sapiens 36-49 17683510-4 2007 The peaks were identified as native transthyretin (TTR) and its two variants by one-dimensional polyacrylamide gel electrophoresis, ESI-MS/MS, immunoprecipitation and western blot analysis. polyacrylamide gels 96-114 transthyretin Homo sapiens 51-54 17701470-6 2007 Intraperitoneal administration of diflunisal, a non-steroidal anti-inflammatory drug that binds to TTR in its T4-binding site and inhibits fibril formation in vitro, to human L55P TTR transgenic animals in which the murine TTR gene had been silenced, also stabilizes the circulating mutant protein to in vitro urea denaturation. Diflunisal 34-44 transthyretin Homo sapiens 99-102 17503405-6 2007 Most of the electrically neutral amyloidogenic TTR variants had in common a reduced conformational stability of monomers by the activity of protons and urea. Urea 152-156 transthyretin Homo sapiens 47-50 17438025-1 2007 The transferrin iron acquisition system of Neisseria gonorrhoeae is necessary for iron uptake from transferrin in the human host and requires the participation of two distinct proteins: TbpA and TbpB. Iron 16-20 transthyretin Homo sapiens 186-190 17438025-1 2007 The transferrin iron acquisition system of Neisseria gonorrhoeae is necessary for iron uptake from transferrin in the human host and requires the participation of two distinct proteins: TbpA and TbpB. Iron 82-86 transthyretin Homo sapiens 186-190 17438025-2 2007 TbpA is a TonB-dependent outer membrane transporter responsible for the transport of iron into the cell. Iron 85-89 transthyretin Homo sapiens 0-4 17317215-0 2007 Expression, purification, and in vitro cysteine-10 modification of native sequence recombinant human transthyretin. Cysteine 39-47 transthyretin Homo sapiens 101-114 17317215-10 2007 Furthermore, we describe the thiol modification of the recombinant protein to achieve exact replication of the several prominent post-translationally modified forms of TTR that have been identified in human serum. Sulfhydryl Compounds 29-34 transthyretin Homo sapiens 168-171 17381508-6 2007 As for other amyloidogenic proteins, the most toxic forms of aggregated TTR are likely to be the low-molecular-mass diffusible species, and there is increasing evidence that this toxicity is mediated by disturbances in calcium homeostasis. Calcium 219-226 transthyretin Homo sapiens 72-75 17315201-3 2007 One of the proteins that is known to form amyloids is transthyretin (TTR), the secondary transporter of thyroxine, and transporter of retinol-binding protein. Thyroxine 104-113 transthyretin Homo sapiens 54-67 17315201-3 2007 One of the proteins that is known to form amyloids is transthyretin (TTR), the secondary transporter of thyroxine, and transporter of retinol-binding protein. Thyroxine 104-113 transthyretin Homo sapiens 69-72 17360344-0 2007 Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores. carborane 76-85 transthyretin Homo sapiens 28-41 17360344-8 2007 The replacement of a phenyl ring in the NSAIDs with a carborane moiety greatly decreases their COX activity with the retention of similar efficacy as an inhibitor of TTR dissociation. carborane 54-63 transthyretin Homo sapiens 166-169 17498342-5 2007 Plasma glutathione peroxidase, tetranectin, apolipoprotein A-I and transthyretin were equally expressed in the serum of control group and silica-exposed population group, but decreased in the suspect of silicosis (0+) and phase (I) group. Silicon Dioxide 138-144 transthyretin Homo sapiens 67-80 17261023-8 2007 The relative levels of the three TTR species in the SSA group were comparable to amounts present in sera from age-matched control groups. SerSA 52-55 transthyretin Homo sapiens 33-36 17261023-12 2007 We also determined that the deposits in all samples contained Cys10 disulfide-linkedhomodimers composed of full-length TTR monomers. Disulfides 68-77 transthyretin Homo sapiens 119-122 17175208-7 2007 The structure of TTR pre-incubated with sulfite at physiological pH, was determined by X-ray crystallography to provide structural insight for the stabilizing effect of sulfite. Sulfites 40-47 transthyretin Homo sapiens 17-20 17593761-6 2007 Dioxin-like and TTR-binding activities in sulfuric acid treatment extracts of house and office dust were investigated using Dioxin-Responsive Chemical-Activated LUciferase gene eXpression assay (DR-CALUX) and TTR-binding assay (in vitro competitive human TTR-binding assay). Dioxins 0-6 transthyretin Homo sapiens 209-212 17593761-6 2007 Dioxin-like and TTR-binding activities in sulfuric acid treatment extracts of house and office dust were investigated using Dioxin-Responsive Chemical-Activated LUciferase gene eXpression assay (DR-CALUX) and TTR-binding assay (in vitro competitive human TTR-binding assay). Dioxins 0-6 transthyretin Homo sapiens 209-212 17593761-6 2007 Dioxin-like and TTR-binding activities in sulfuric acid treatment extracts of house and office dust were investigated using Dioxin-Responsive Chemical-Activated LUciferase gene eXpression assay (DR-CALUX) and TTR-binding assay (in vitro competitive human TTR-binding assay). sulfuric acid 42-55 transthyretin Homo sapiens 16-19 17593761-6 2007 Dioxin-like and TTR-binding activities in sulfuric acid treatment extracts of house and office dust were investigated using Dioxin-Responsive Chemical-Activated LUciferase gene eXpression assay (DR-CALUX) and TTR-binding assay (in vitro competitive human TTR-binding assay). sulfuric acid 42-55 transthyretin Homo sapiens 209-212 17593761-6 2007 Dioxin-like and TTR-binding activities in sulfuric acid treatment extracts of house and office dust were investigated using Dioxin-Responsive Chemical-Activated LUciferase gene eXpression assay (DR-CALUX) and TTR-binding assay (in vitro competitive human TTR-binding assay). sulfuric acid 42-55 transthyretin Homo sapiens 209-212 17593761-6 2007 Dioxin-like and TTR-binding activities in sulfuric acid treatment extracts of house and office dust were investigated using Dioxin-Responsive Chemical-Activated LUciferase gene eXpression assay (DR-CALUX) and TTR-binding assay (in vitro competitive human TTR-binding assay). Dioxins 124-130 transthyretin Homo sapiens 16-19 17593761-6 2007 Dioxin-like and TTR-binding activities in sulfuric acid treatment extracts of house and office dust were investigated using Dioxin-Responsive Chemical-Activated LUciferase gene eXpression assay (DR-CALUX) and TTR-binding assay (in vitro competitive human TTR-binding assay). Dioxins 124-130 transthyretin Homo sapiens 209-212 17593761-6 2007 Dioxin-like and TTR-binding activities in sulfuric acid treatment extracts of house and office dust were investigated using Dioxin-Responsive Chemical-Activated LUciferase gene eXpression assay (DR-CALUX) and TTR-binding assay (in vitro competitive human TTR-binding assay). Dioxins 124-130 transthyretin Homo sapiens 209-212 17593761-7 2007 Dioxin-like activities in indoor dust were 38-1400 pg CALUX-TEQ (2,3,7,8-TCDD equivalent)/g (median 160 pg CALUX-TEQ/g) and TTR-binding potencies were 300-5000 pmol T4EQ (thyroxine (T4) equivalent)/g (median 1000 pmol T4EQ/g), which are higher values than those in other environmental samples, e.g., contaminated sediments. Dioxins 0-6 transthyretin Homo sapiens 124-127 17175208-9 2007 The sulfonated cysteines have two sulfite oxygens involved in intramonomer hydrogen bonds that bridge Cys10, the amino acid immediately before beta-strand A, to the amino acids immediately after the edge beta-strand D. Implications of the newly observed interactions in the inhibition of fibril formation are discussed in light of the recent structural models of TTR amyloid fibrils. Oxygen 42-49 transthyretin Homo sapiens 363-366 17175208-9 2007 The sulfonated cysteines have two sulfite oxygens involved in intramonomer hydrogen bonds that bridge Cys10, the amino acid immediately before beta-strand A, to the amino acids immediately after the edge beta-strand D. Implications of the newly observed interactions in the inhibition of fibril formation are discussed in light of the recent structural models of TTR amyloid fibrils. Hydrogen 75-83 transthyretin Homo sapiens 363-366 17175208-7 2007 The structure of TTR pre-incubated with sulfite at physiological pH, was determined by X-ray crystallography to provide structural insight for the stabilizing effect of sulfite. Sulfites 169-176 transthyretin Homo sapiens 17-20 17175208-9 2007 The sulfonated cysteines have two sulfite oxygens involved in intramonomer hydrogen bonds that bridge Cys10, the amino acid immediately before beta-strand A, to the amino acids immediately after the edge beta-strand D. Implications of the newly observed interactions in the inhibition of fibril formation are discussed in light of the recent structural models of TTR amyloid fibrils. Cysteine 15-24 transthyretin Homo sapiens 363-366 17107884-0 2006 Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Diflunisal 20-30 transthyretin Homo sapiens 42-55 17203960-5 2007 Besides the implementation of the previously published AF proteomic maps, our results show that transthyretin (TTR), the protein responsible for transporting both the thyroid hormone tyroxine and the retinol binding protein, is present in the AF of both preeclamptic and control women as a mixture of dimeric and post-translationally modified monomeric forms. tyroxine 183-191 transthyretin Homo sapiens 96-109 17203960-5 2007 Besides the implementation of the previously published AF proteomic maps, our results show that transthyretin (TTR), the protein responsible for transporting both the thyroid hormone tyroxine and the retinol binding protein, is present in the AF of both preeclamptic and control women as a mixture of dimeric and post-translationally modified monomeric forms. tyroxine 183-191 transthyretin Homo sapiens 111-114 17203960-5 2007 Besides the implementation of the previously published AF proteomic maps, our results show that transthyretin (TTR), the protein responsible for transporting both the thyroid hormone tyroxine and the retinol binding protein, is present in the AF of both preeclamptic and control women as a mixture of dimeric and post-translationally modified monomeric forms. Vitamin A 200-207 transthyretin Homo sapiens 96-109 17203960-5 2007 Besides the implementation of the previously published AF proteomic maps, our results show that transthyretin (TTR), the protein responsible for transporting both the thyroid hormone tyroxine and the retinol binding protein, is present in the AF of both preeclamptic and control women as a mixture of dimeric and post-translationally modified monomeric forms. Vitamin A 200-207 transthyretin Homo sapiens 111-114 17107884-3 2006 Diflunisal binding to the 99% unoccupied L-thyroxine binding sites in TTR also increases the tetramer dissociation barrier; hence, we investigated the feasibility of using diflunisal for the treatment of human TTR amyloidosis using healthy volunteers. Thyroxine 41-52 transthyretin Homo sapiens 70-73 17484624-5 2007 Sequence analysis of the TTR-encoding DNA identified a single mutation, causing a valine to alanine substitution (V32A). Valine 82-88 transthyretin Homo sapiens 25-28 17484624-5 2007 Sequence analysis of the TTR-encoding DNA identified a single mutation, causing a valine to alanine substitution (V32A). Alanine 92-99 transthyretin Homo sapiens 25-28 17076759-0 2007 Transthyretin oligomers induce calcium influx via voltage-gated calcium channels. Calcium 31-38 transthyretin Homo sapiens 0-13 17107884-3 2006 Diflunisal binding to the 99% unoccupied L-thyroxine binding sites in TTR also increases the tetramer dissociation barrier; hence, we investigated the feasibility of using diflunisal for the treatment of human TTR amyloidosis using healthy volunteers. Diflunisal 0-10 transthyretin Homo sapiens 70-73 17107884-3 2006 Diflunisal binding to the 99% unoccupied L-thyroxine binding sites in TTR also increases the tetramer dissociation barrier; hence, we investigated the feasibility of using diflunisal for the treatment of human TTR amyloidosis using healthy volunteers. Diflunisal 0-10 transthyretin Homo sapiens 210-213 17107884-6 2006 RESULTS: In the 250 mg bid group, 12 h after the 13th oral dose, the diflunisal serum concentration of 146 +/- 39 microM was sufficient to afford a TTR binding stoichiometry exceeding 0.95 +/- 0.13 ( approximately 1.75 corrected). Diflunisal 69-79 transthyretin Homo sapiens 148-151 17107884-7 2006 Diflunisal binding to TTR at this dose slowed urea-mediated dissociation and acid-mediated TTR aggregation at least, threefold (p < 0.05) in serum and in vitro, consistent with kinetic stabilization of TTR. Diflunisal 0-10 transthyretin Homo sapiens 22-25 17107884-7 2006 Diflunisal binding to TTR at this dose slowed urea-mediated dissociation and acid-mediated TTR aggregation at least, threefold (p < 0.05) in serum and in vitro, consistent with kinetic stabilization of TTR. Diflunisal 0-10 transthyretin Homo sapiens 91-94 17107884-7 2006 Diflunisal binding to TTR at this dose slowed urea-mediated dissociation and acid-mediated TTR aggregation at least, threefold (p < 0.05) in serum and in vitro, consistent with kinetic stabilization of TTR. Diflunisal 0-10 transthyretin Homo sapiens 91-94 17107884-7 2006 Diflunisal binding to TTR at this dose slowed urea-mediated dissociation and acid-mediated TTR aggregation at least, threefold (p < 0.05) in serum and in vitro, consistent with kinetic stabilization of TTR. Urea 46-50 transthyretin Homo sapiens 22-25 17107884-8 2006 CONCLUSION: Diflunisal-mediated kinetic stabilization of TTR should ameliorate TTR amyloidoses, provided that the nonsteroidal anti-inflammatory drug liabilities can be managed clinically. Diflunisal 12-22 transthyretin Homo sapiens 57-60 17107884-8 2006 CONCLUSION: Diflunisal-mediated kinetic stabilization of TTR should ameliorate TTR amyloidoses, provided that the nonsteroidal anti-inflammatory drug liabilities can be managed clinically. Diflunisal 12-22 transthyretin Homo sapiens 79-82 17062380-10 2006 This follow-up study of ATTR patients carrying a wide range of mutations indicates that (1) cardiac involvement is a very important component of phenotypic expression; and (2) genotype is an important source of heterogeneity in myocardial involvement, with Glu89Gln being associated with a severe, heart-driven prognosis. glu89gln 257-265 transthyretin Homo sapiens 24-28 17028027-0 2006 Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Diflunisal 0-10 transthyretin Homo sapiens 65-78 17028027-6 2006 We also demonstrated that therapeutic serum concentrations of diflunisal (100-200 microM) stabilized serum variant TTR tetramer better than those of flufenamic acid (35-70 microM). Diflunisal 62-72 transthyretin Homo sapiens 115-118 17028027-8 2006 Importantly, diflunisal increased serum TTR stability in FAP patients beyond the level of normal controls. Diflunisal 13-23 transthyretin Homo sapiens 40-43 17042514-2 2006 Fibrils of the short peptide TTR105-115 were encapsulated inside water droplets of a water-in-perfluorocarbon oil emulsion and retained their rod morphology. Water 65-70 transthyretin Homo sapiens 29-32 17042514-2 2006 Fibrils of the short peptide TTR105-115 were encapsulated inside water droplets of a water-in-perfluorocarbon oil emulsion and retained their rod morphology. Water 85-90 transthyretin Homo sapiens 29-32 17042514-2 2006 Fibrils of the short peptide TTR105-115 were encapsulated inside water droplets of a water-in-perfluorocarbon oil emulsion and retained their rod morphology. perfluorocarbon oil 94-113 transthyretin Homo sapiens 29-32 17116243-7 2006 The WT and V30M TTR mutant (valine 30 substituted with methionine) were allowed to react over a time range of 10 min to 12 h with hydroxy radical and other reactive oxygen species. Water 130-145 transthyretin Homo sapiens 16-19 17116243-7 2006 The WT and V30M TTR mutant (valine 30 substituted with methionine) were allowed to react over a time range of 10 min to 12 h with hydroxy radical and other reactive oxygen species. reactive oxygen 156-171 transthyretin Homo sapiens 16-19 17116243-8 2006 In these timescales, up to five oxygen atoms were incorporated into WT and V30M TTR proteins. Oxygen 32-38 transthyretin Homo sapiens 80-83 17116243-10 2006 Side chain modification of methionine residues at position 13 and 30 (the latter for V30M TTR only) were dominant oxidative products. Methionine 27-37 transthyretin Homo sapiens 90-93 17122946-0 2006 Fatal cerebral haemorrhage after liver transplantation in a patient with transthyretin variant (gly53glu) amyloidosis. gly53glu 96-104 transthyretin Homo sapiens 73-86 17122946-3 2006 We describe the clinical and pathological features of a patient with TTR variant (gly53glu) with TTR amyloid infiltration of the leptomeningeal vessels in whom fatal cerebral haemorrhage occurred two months after OLT, soon after severe viral pneumonia. gly53glu 82-90 transthyretin Homo sapiens 69-72 17122946-3 2006 We describe the clinical and pathological features of a patient with TTR variant (gly53glu) with TTR amyloid infiltration of the leptomeningeal vessels in whom fatal cerebral haemorrhage occurred two months after OLT, soon after severe viral pneumonia. gly53glu 82-90 transthyretin Homo sapiens 97-100 17063874-4 2006 During the process of TTR analysis, we found unique isoforms of TTR, which showed changes of the cysteine (10th from amino terminal) residue to glycine, dehydroalanine, and S-sulfocysteine residues. Cysteine 97-105 transthyretin Homo sapiens 22-25 16487493-0 2006 Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Serotonin 104-113 transthyretin Homo sapiens 24-37 16487493-8 2006 In the entire sample of depressed and healthy individuals, CSF 5-hydroxyindoleacetic acid (5-HIAA) correlated positively (beta = .34, p < .05) with CSF TTR. Hydroxyindoleacetic Acid 63-89 transthyretin Homo sapiens 155-158 16487493-8 2006 In the entire sample of depressed and healthy individuals, CSF 5-hydroxyindoleacetic acid (5-HIAA) correlated positively (beta = .34, p < .05) with CSF TTR. Hydroxyindoleacetic Acid 91-97 transthyretin Homo sapiens 155-158 16879610-4 2006 Analysis of the binding affinity to thyroid hormones of recombinant human TTR showed a dissociation constant (Kd) for triiodothyronine (T3) of 53.26+/-3.97 nM and for thyroxine (T4) of 19.73+/-0.13 nM. Triiodothyronine 118-134 transthyretin Homo sapiens 74-77 16879610-4 2006 Analysis of the binding affinity to thyroid hormones of recombinant human TTR showed a dissociation constant (Kd) for triiodothyronine (T3) of 53.26+/-3.97 nM and for thyroxine (T4) of 19.73+/-0.13 nM. Triiodothyronine 136-138 transthyretin Homo sapiens 74-77 16879610-4 2006 Analysis of the binding affinity to thyroid hormones of recombinant human TTR showed a dissociation constant (Kd) for triiodothyronine (T3) of 53.26+/-3.97 nM and for thyroxine (T4) of 19.73+/-0.13 nM. Thyroxine 167-176 transthyretin Homo sapiens 74-77 17063874-4 2006 During the process of TTR analysis, we found unique isoforms of TTR, which showed changes of the cysteine (10th from amino terminal) residue to glycine, dehydroalanine, and S-sulfocysteine residues. Cysteine 97-105 transthyretin Homo sapiens 64-67 17063874-4 2006 During the process of TTR analysis, we found unique isoforms of TTR, which showed changes of the cysteine (10th from amino terminal) residue to glycine, dehydroalanine, and S-sulfocysteine residues. Glycine 144-151 transthyretin Homo sapiens 22-25 17063874-4 2006 During the process of TTR analysis, we found unique isoforms of TTR, which showed changes of the cysteine (10th from amino terminal) residue to glycine, dehydroalanine, and S-sulfocysteine residues. Glycine 144-151 transthyretin Homo sapiens 64-67 17063874-4 2006 During the process of TTR analysis, we found unique isoforms of TTR, which showed changes of the cysteine (10th from amino terminal) residue to glycine, dehydroalanine, and S-sulfocysteine residues. dehydroalanine 153-167 transthyretin Homo sapiens 22-25 17063874-4 2006 During the process of TTR analysis, we found unique isoforms of TTR, which showed changes of the cysteine (10th from amino terminal) residue to glycine, dehydroalanine, and S-sulfocysteine residues. dehydroalanine 153-167 transthyretin Homo sapiens 64-67 17063874-4 2006 During the process of TTR analysis, we found unique isoforms of TTR, which showed changes of the cysteine (10th from amino terminal) residue to glycine, dehydroalanine, and S-sulfocysteine residues. S-sulphocysteine 173-188 transthyretin Homo sapiens 22-25 17063874-4 2006 During the process of TTR analysis, we found unique isoforms of TTR, which showed changes of the cysteine (10th from amino terminal) residue to glycine, dehydroalanine, and S-sulfocysteine residues. S-sulphocysteine 173-188 transthyretin Homo sapiens 64-67 16627944-0 2006 The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin. 2,4-Dinitrophenol 15-32 transthyretin Homo sapiens 64-77 16362527-2 2006 Transthyretin (TTR) transports between 20% and 30% of serum thyroxine in normal individuals and it is the main T(4)-binding protein in CSF. Thyroxine 60-69 transthyretin Homo sapiens 0-13 16362527-2 2006 Transthyretin (TTR) transports between 20% and 30% of serum thyroxine in normal individuals and it is the main T(4)-binding protein in CSF. Thyroxine 60-69 transthyretin Homo sapiens 15-18 16362527-3 2006 Variability in the TTR gene may influence risk for iodine-deficiency-based MR. Iodine 51-57 transthyretin Homo sapiens 19-22 16702331-1 2006 The ratio of retinol-binding protein (RBP) to transthyretin (TTR) has been proposed as an indirect method with which to assess vitamin A status in the context of inflammation. Vitamin A 127-136 transthyretin Homo sapiens 43-59 16702331-1 2006 The ratio of retinol-binding protein (RBP) to transthyretin (TTR) has been proposed as an indirect method with which to assess vitamin A status in the context of inflammation. Vitamin A 127-136 transthyretin Homo sapiens 61-64 16530227-9 2006 1H-MRSI showed N-acetylaspartate to creatine ratio (NAA/Cr) decreases in the central brain VOI in all TTR-FAP patients (p < 0.005). Hydrogen 0-2 transthyretin Homo sapiens 102-105 16530227-9 2006 1H-MRSI showed N-acetylaspartate to creatine ratio (NAA/Cr) decreases in the central brain VOI in all TTR-FAP patients (p < 0.005). N-acetylaspartate 15-32 transthyretin Homo sapiens 102-105 16530227-9 2006 1H-MRSI showed N-acetylaspartate to creatine ratio (NAA/Cr) decreases in the central brain VOI in all TTR-FAP patients (p < 0.005). Creatine 36-44 transthyretin Homo sapiens 102-105 16530227-9 2006 1H-MRSI showed N-acetylaspartate to creatine ratio (NAA/Cr) decreases in the central brain VOI in all TTR-FAP patients (p < 0.005). N-acetylaspartate 52-55 transthyretin Homo sapiens 102-105 16530227-9 2006 1H-MRSI showed N-acetylaspartate to creatine ratio (NAA/Cr) decreases in the central brain VOI in all TTR-FAP patients (p < 0.005). Chromium 56-58 transthyretin Homo sapiens 102-105 16530227-11 2006 CONCLUSIONS: 1H-MRSI findings suggest that diffuse metabolic changes, probably related to axonal damage, are present in brains of TTR-FAP patients even when they have no or minimal clinical and MRI signs of CNS involvement. Hydrogen 13-15 transthyretin Homo sapiens 130-133 16768841-0 2006 Genistein and other soya isoflavones are potent ligands for transthyretin in serum and cerebrospinal fluid. Genistein 0-9 transthyretin Homo sapiens 60-73 16768841-0 2006 Genistein and other soya isoflavones are potent ligands for transthyretin in serum and cerebrospinal fluid. soya isoflavones 20-36 transthyretin Homo sapiens 60-73 16768841-6 2006 Complete displacement of [(125)I]T4 binding to transthyretin (TTR) was observed in human serum incubated with genistein at concentrations >10 microM; interference started at >0.1 microM. Genistein 110-119 transthyretin Homo sapiens 47-60 16768841-6 2006 Complete displacement of [(125)I]T4 binding to transthyretin (TTR) was observed in human serum incubated with genistein at concentrations >10 microM; interference started at >0.1 microM. Genistein 110-119 transthyretin Homo sapiens 62-65 16768841-9 2006 Soya isoflavones also obstruct [(125)I]T4 binding to TTR in human cerebrospinal fluid (CSF). soya isoflavones 0-16 transthyretin Homo sapiens 53-56 16768841-10 2006 The inhibitory effect was confirmed in direct binding assays using purified TTR with 50% inhibitory concentration values of 0.07 microM for genistein, 0.2 microM for glycitein and 1.8 microM for daidzein. Genistein 140-149 transthyretin Homo sapiens 76-79 16768841-10 2006 The inhibitory effect was confirmed in direct binding assays using purified TTR with 50% inhibitory concentration values of 0.07 microM for genistein, 0.2 microM for glycitein and 1.8 microM for daidzein. glycitein 166-175 transthyretin Homo sapiens 76-79 16768841-10 2006 The inhibitory effect was confirmed in direct binding assays using purified TTR with 50% inhibitory concentration values of 0.07 microM for genistein, 0.2 microM for glycitein and 1.8 microM for daidzein. daidzein 195-203 transthyretin Homo sapiens 76-79 16768841-11 2006 The present study underlined a potent competition of soya isoflavones for T4 binding to TTR in serum and CSF. soya isoflavones 53-69 transthyretin Homo sapiens 88-91 16702331-10 2006 Serum retinol increased with vitamin A supplementation among those with a low RBP:TTR ratio, although the effect was small and was not present among those with concurrent inflammation. Vitamin A 6-13 transthyretin Homo sapiens 82-85 16702331-10 2006 Serum retinol increased with vitamin A supplementation among those with a low RBP:TTR ratio, although the effect was small and was not present among those with concurrent inflammation. Vitamin A 29-38 transthyretin Homo sapiens 82-85 16627944-5 2006 This work provides insight into the structural determinants of the highly stabilizing effects of 2,4-dinitrophenol on wild-type TTR. 2,4-Dinitrophenol 97-114 transthyretin Homo sapiens 128-131 16627944-7 2006 In the three crystal complexes, 2,4-dinitrophenol occupies the two hormone-binding sites of the TTR tetramer. 2,4-Dinitrophenol 32-49 transthyretin Homo sapiens 96-99 16627944-8 2006 As a result of 2,4-dinitrophenol binding, the two dimers in the TTR tetramer become closer, increasing the stability of the protein. 2,4-Dinitrophenol 15-32 transthyretin Homo sapiens 64-67 16627944-9 2006 The three-dimensional structures now determined allow a comprehensive description of key interactions between transthyretin and 2,4-dinitrophenol, a small compound that holds promise as a template for the design of a therapeutical drug for amyloid diseases. 2,4-Dinitrophenol 128-145 transthyretin Homo sapiens 110-123 16276348-8 2006 Ad-CTS1, Ad-PCTAIRE3 or Ad-PIG3 induced the formation of free reactive oxygen species (ROS). Reactive Oxygen Species 62-85 transthyretin Homo sapiens 3-7 16276348-8 2006 Ad-CTS1, Ad-PCTAIRE3 or Ad-PIG3 induced the formation of free reactive oxygen species (ROS). Reactive Oxygen Species 87-90 transthyretin Homo sapiens 3-7 16276348-9 2006 However, the prevention of ROS formation induced by Ad-PCTAIRE3 and Ad-CTS-1 did not block growth arrest and cell death, suggesting that ROS formation is not essential for these effects. Reactive Oxygen Species 27-30 transthyretin Homo sapiens 68-76 16564782-2 2006 SUBJECTS AND METHODS: 123I-labeled human SAP was injected intravenously into 20 controls and 189 consecutive patients with histologically proven amyloidosis: of AA type in 60 cases, AL type in 80, hereditary ATTR type in 27, and localized amyloidosis in 22 cases. Iodine-123 22-26 transthyretin Homo sapiens 208-212 16421881-0 2006 Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Oligonucleotides 70-86 transthyretin Homo sapiens 41-54 16421881-5 2006 As a first step toward medical treatment of this disease, we have employed antisense oligonucleotides (ASOs) to inhibit hepatic expression of TTR. Oligonucleotides 85-101 transthyretin Homo sapiens 142-145 16421881-5 2006 As a first step toward medical treatment of this disease, we have employed antisense oligonucleotides (ASOs) to inhibit hepatic expression of TTR. Oligonucleotides, Antisense 103-107 transthyretin Homo sapiens 142-145 16300401-8 2005 Both tethered constructs and wild-type TTR exhibit analogous stability based on guanidine hydrochloride denaturation curves. Guanidine 80-103 transthyretin Homo sapiens 39-42 16510054-10 2006 CONCLUSIONS: This pilot trial demonstrated that the lidocaine patch 5% was efficacious in reducing pain associated with CTS and was well tolerated. Lidocaine 52-61 transthyretin Homo sapiens 120-123 16510054-11 2006 The lidocaine patch 5% may offer patients with CTS effective, noninvasive treatment for the management of their symptoms. Lidocaine 4-13 transthyretin Homo sapiens 47-50 16386248-0 2006 Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. Thyroxine 22-31 transthyretin Homo sapiens 59-72 16386248-2 2006 Binding of thyroxine (T(4)), a native ligand of TTR, stabilizes the tetramer, but the bioavailability of T(4) for TTR binding is limited due to the preferential binding of T(4) to globulin, the major T(4) carrier in plasma. Thyroxine 11-20 transthyretin Homo sapiens 48-51 16183049-5 2005 CONCLUSIONS: The findings imply that experimental systems investigating Abeta-induced cytotoxicity consider the protective interaction of transthyretin with Abeta; an interaction to be considered also in vivo in view of the fact that transthyretin immunoreactivity has been previously demonstrated in amyloid plaques of brains from Alzheimer"s disease patients. UNII-042A8N37WH 72-77 transthyretin Homo sapiens 138-151 16183049-5 2005 CONCLUSIONS: The findings imply that experimental systems investigating Abeta-induced cytotoxicity consider the protective interaction of transthyretin with Abeta; an interaction to be considered also in vivo in view of the fact that transthyretin immunoreactivity has been previously demonstrated in amyloid plaques of brains from Alzheimer"s disease patients. UNII-042A8N37WH 72-77 transthyretin Homo sapiens 234-247 16317126-1 2005 Free holo-retinol binding protein (RBP) [i.e., unbound to transthyretin (TTR)] plays a role in transporting vitamin A across the placenta during pregnancy. Vitamin A 108-117 transthyretin Homo sapiens 73-76 16690499-3 2006 This is the first Japanese case displaying TTR mutation at codon 25, replacing alanine with threonine. Alanine 79-86 transthyretin Homo sapiens 43-46 16690499-3 2006 This is the first Japanese case displaying TTR mutation at codon 25, replacing alanine with threonine. Threonine 92-101 transthyretin Homo sapiens 43-46 15994046-4 2005 In this study, we aimed to investigate whether US has a diagnostic value for CTS in patients with negative EDT findings or not. edt 107-110 transthyretin Homo sapiens 77-80 15994046-12 2005 We confirmed the usefulness of quantitative US assessment in the diagnosis of CTS in the patients with negative EDT findings. edt 112-115 transthyretin Homo sapiens 78-81 16300401-9 2005 The latter denaturant can denature the tetramer, unlike urea, which can only denature monomeric TTR; hence urea requires dissociation to monomers to function. Urea 56-60 transthyretin Homo sapiens 96-99 16300401-9 2005 The latter denaturant can denature the tetramer, unlike urea, which can only denature monomeric TTR; hence urea requires dissociation to monomers to function. Urea 107-111 transthyretin Homo sapiens 96-99 16300401-11 2005 In contrast, the (TTR-L-TTR)(2) construct is unable to exchange any subunits, even after 180 h. All of the data presented herein and elsewhere demonstrate that the pathway of TTR tetramer dissociation occurs by scission of the tetramer along the crystallographic C(2) axis affording AB and CD dimers that rapidly dissociate into monomers. Cadmium 290-292 transthyretin Homo sapiens 18-21 16300401-11 2005 In contrast, the (TTR-L-TTR)(2) construct is unable to exchange any subunits, even after 180 h. All of the data presented herein and elsewhere demonstrate that the pathway of TTR tetramer dissociation occurs by scission of the tetramer along the crystallographic C(2) axis affording AB and CD dimers that rapidly dissociate into monomers. Cadmium 290-292 transthyretin Homo sapiens 24-27 16300401-11 2005 In contrast, the (TTR-L-TTR)(2) construct is unable to exchange any subunits, even after 180 h. All of the data presented herein and elsewhere demonstrate that the pathway of TTR tetramer dissociation occurs by scission of the tetramer along the crystallographic C(2) axis affording AB and CD dimers that rapidly dissociate into monomers. Cadmium 290-292 transthyretin Homo sapiens 24-27 16300401-12 2005 Determination of the mechanism of dissociation provides an explanation for why small molecules that bind at the AB/CD dimer-dimer interface impose kinetic stabilization upon TTR and disease-associated variants thereof. Cadmium 115-117 transthyretin Homo sapiens 174-177 16185074-2 2005 In a previous study we demonstrated that ATTR Tyr114Cys forms intermolecular disulfide bonds, which partly impair fibril formation and result in a more amorphous morphology. Disulfides 77-86 transthyretin Homo sapiens 41-45 16300401-2 2005 The TTR quaternary structure contains two distinct dimer interfaces, one of which creates the two binding sites for the natural ligand thyroxine. Thyroxine 135-144 transthyretin Homo sapiens 4-7 16300401-6 2005 We demonstrate that tethering the A and B subunits of TTR with a disulfide bond (as well as the symmetrically disposed C and D subunits) allows urea-mediated dissociation of the resulting (TTR-S-S-TTR)(2) construct, affording (TTR-S-S-TTR)(1) retaining a stable 16-stranded beta-sheet structure that is equivalent to the dimer not possessing a thyroid binding site. Disulfides 65-74 transthyretin Homo sapiens 54-57 16300401-6 2005 We demonstrate that tethering the A and B subunits of TTR with a disulfide bond (as well as the symmetrically disposed C and D subunits) allows urea-mediated dissociation of the resulting (TTR-S-S-TTR)(2) construct, affording (TTR-S-S-TTR)(1) retaining a stable 16-stranded beta-sheet structure that is equivalent to the dimer not possessing a thyroid binding site. Disulfides 65-74 transthyretin Homo sapiens 189-192 16300401-6 2005 We demonstrate that tethering the A and B subunits of TTR with a disulfide bond (as well as the symmetrically disposed C and D subunits) allows urea-mediated dissociation of the resulting (TTR-S-S-TTR)(2) construct, affording (TTR-S-S-TTR)(1) retaining a stable 16-stranded beta-sheet structure that is equivalent to the dimer not possessing a thyroid binding site. Disulfides 65-74 transthyretin Homo sapiens 189-192 16300401-6 2005 We demonstrate that tethering the A and B subunits of TTR with a disulfide bond (as well as the symmetrically disposed C and D subunits) allows urea-mediated dissociation of the resulting (TTR-S-S-TTR)(2) construct, affording (TTR-S-S-TTR)(1) retaining a stable 16-stranded beta-sheet structure that is equivalent to the dimer not possessing a thyroid binding site. Disulfides 65-74 transthyretin Homo sapiens 189-192 16300401-6 2005 We demonstrate that tethering the A and B subunits of TTR with a disulfide bond (as well as the symmetrically disposed C and D subunits) allows urea-mediated dissociation of the resulting (TTR-S-S-TTR)(2) construct, affording (TTR-S-S-TTR)(1) retaining a stable 16-stranded beta-sheet structure that is equivalent to the dimer not possessing a thyroid binding site. Disulfides 65-74 transthyretin Homo sapiens 189-192 16300401-6 2005 We demonstrate that tethering the A and B subunits of TTR with a disulfide bond (as well as the symmetrically disposed C and D subunits) allows urea-mediated dissociation of the resulting (TTR-S-S-TTR)(2) construct, affording (TTR-S-S-TTR)(1) retaining a stable 16-stranded beta-sheet structure that is equivalent to the dimer not possessing a thyroid binding site. Urea 144-148 transthyretin Homo sapiens 54-57 16300401-6 2005 We demonstrate that tethering the A and B subunits of TTR with a disulfide bond (as well as the symmetrically disposed C and D subunits) allows urea-mediated dissociation of the resulting (TTR-S-S-TTR)(2) construct, affording (TTR-S-S-TTR)(1) retaining a stable 16-stranded beta-sheet structure that is equivalent to the dimer not possessing a thyroid binding site. Urea 144-148 transthyretin Homo sapiens 189-192 16300401-6 2005 We demonstrate that tethering the A and B subunits of TTR with a disulfide bond (as well as the symmetrically disposed C and D subunits) allows urea-mediated dissociation of the resulting (TTR-S-S-TTR)(2) construct, affording (TTR-S-S-TTR)(1) retaining a stable 16-stranded beta-sheet structure that is equivalent to the dimer not possessing a thyroid binding site. Urea 144-148 transthyretin Homo sapiens 189-192 16300401-6 2005 We demonstrate that tethering the A and B subunits of TTR with a disulfide bond (as well as the symmetrically disposed C and D subunits) allows urea-mediated dissociation of the resulting (TTR-S-S-TTR)(2) construct, affording (TTR-S-S-TTR)(1) retaining a stable 16-stranded beta-sheet structure that is equivalent to the dimer not possessing a thyroid binding site. Urea 144-148 transthyretin Homo sapiens 189-192 16300401-6 2005 We demonstrate that tethering the A and B subunits of TTR with a disulfide bond (as well as the symmetrically disposed C and D subunits) allows urea-mediated dissociation of the resulting (TTR-S-S-TTR)(2) construct, affording (TTR-S-S-TTR)(1) retaining a stable 16-stranded beta-sheet structure that is equivalent to the dimer not possessing a thyroid binding site. Urea 144-148 transthyretin Homo sapiens 189-192 16300401-7 2005 In contrast, linking the A and C subunits employing a peptide tether (TTR-L-TTR)(2) affords a kinetically stable quaternary structure that does not dissociate or denature in urea. Urea 174-178 transthyretin Homo sapiens 70-73 16286652-1 2005 Transthyretin (TTR) is a transport protein for thyroxine and, in association with retinol-binding protein, for retinol, mainly existing as a tetramer in vivo. Thyroxine 47-56 transthyretin Homo sapiens 0-13 16286652-1 2005 Transthyretin (TTR) is a transport protein for thyroxine and, in association with retinol-binding protein, for retinol, mainly existing as a tetramer in vivo. Thyroxine 47-56 transthyretin Homo sapiens 15-18 16286652-1 2005 Transthyretin (TTR) is a transport protein for thyroxine and, in association with retinol-binding protein, for retinol, mainly existing as a tetramer in vivo. Vitamin A 82-89 transthyretin Homo sapiens 0-13 16286652-1 2005 Transthyretin (TTR) is a transport protein for thyroxine and, in association with retinol-binding protein, for retinol, mainly existing as a tetramer in vivo. Vitamin A 82-89 transthyretin Homo sapiens 15-18 16286652-3 2005 TTR promoted glucose-induced increases in cytoplasmic free Ca(2+) concentration ([Ca(2+)](i)) and insulin release. Glucose 13-20 transthyretin Homo sapiens 0-3 16157297-1 2005 Retinol-binding protein (RBP) is the retinol-specific carrier protein present in plasma, where it circulates almost entirely bound to thyroxine-binding transthyretin (TTR). Vitamin A 37-44 transthyretin Homo sapiens 167-170 16185074-4 2005 To deduce the role of intermolecular disulfide bridging in fibril formation we generated and characterized the TTR Cys10Ala/Tyr114Cys double mutant. Disulfides 37-46 transthyretin Homo sapiens 111-114 16185074-6 2005 We also purified a disulfide-linked dimeric form of TTR Cys10Ala/Tyr114Cys, which was recognized by the anti-TTR amyloid-specific monoclonal antibody MAb (39-44). Disulfides 19-28 transthyretin Homo sapiens 52-55 16185074-6 2005 We also purified a disulfide-linked dimeric form of TTR Cys10Ala/Tyr114Cys, which was recognized by the anti-TTR amyloid-specific monoclonal antibody MAb (39-44). Disulfides 19-28 transthyretin Homo sapiens 109-112 16266291-9 2005 Based on the proposed mechanism for TTR amyloid fibril formation we discuss the action of some of the proposed TTR stabilizers such as derivatives of some NSAIDs (diflunisal, diclofenac, flufenamic acid, and derivatives) and the action of amyloid disrupters such as 4"-iodo-4"-deoxydoxorubicin (I-DOX) and tetracyclines. Diflunisal 163-173 transthyretin Homo sapiens 36-39 16204882-1 2005 The crystal structure of the complex of human transthyretin (hTTR) with 3,3",5,5"-tetraiodothyroacetic acid (T4Ac) has been determined to 2.2 Angstrom resolution. tetraiodothyroacetic acid 72-107 transthyretin Homo sapiens 61-65 16204882-1 2005 The crystal structure of the complex of human transthyretin (hTTR) with 3,3",5,5"-tetraiodothyroacetic acid (T4Ac) has been determined to 2.2 Angstrom resolution. t4ac 109-113 transthyretin Homo sapiens 61-65 16204882-4 2005 T4Ac is bound in both the forward and the reverse mode in the two binding sites of hTTR. t4ac 0-4 transthyretin Homo sapiens 83-87 16204882-5 2005 In the forward orientation, T4Ac binds in a position similar to that described for thyroxine (T4) in the orthorhombic hTTR-T4 complex. Thyroxine 83-92 transthyretin Homo sapiens 118-122 16204882-7 2005 In the reverse orientation, which is the major binding mode of T4Ac, the ligand is bound deep in the TTR channel, with the carboxylic group bound in the P3" pocket and forming simultaneous polar interactions with the residues constituting the two hormone-binding sites. t4ac 63-67 transthyretin Homo sapiens 101-104 16204882-8 2005 Such interactions of a thyroxine-analogue ligand bound in the reverse mode have never been observed in TTR complexes previously. Thyroxine 23-32 transthyretin Homo sapiens 103-106 16195386-0 2005 Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Genistein 0-9 transthyretin Homo sapiens 64-77 16195386-3 2005 Herein we demonstrate that genistein, the major isoflavone natural product in soy, works in this fashion and is an excellent inhibitor of transthyretin tetramer dissociation and amyloidogenesis, reducing acid-mediated fibril formation to <10% of that exhibited by TTR alone. Genistein 27-36 transthyretin Homo sapiens 138-151 16195386-3 2005 Herein we demonstrate that genistein, the major isoflavone natural product in soy, works in this fashion and is an excellent inhibitor of transthyretin tetramer dissociation and amyloidogenesis, reducing acid-mediated fibril formation to <10% of that exhibited by TTR alone. Genistein 27-36 transthyretin Homo sapiens 267-270 16195386-4 2005 Genistein also inhibits the amyloidogenesis of the most common familial amyloid polyneuropathy and familial amyloid cardiomyopathy mutations in TTR: V30M and V122I, respectively. Genistein 0-9 transthyretin Homo sapiens 144-147 16195386-8 2005 The benefits of using a nutraceutical such as genistein to treat orphan diseases such as the TTR amyloidoses include known oral bioavailability and safety data. Genistein 46-55 transthyretin Homo sapiens 93-96 16266291-9 2005 Based on the proposed mechanism for TTR amyloid fibril formation we discuss the action of some of the proposed TTR stabilizers such as derivatives of some NSAIDs (diflunisal, diclofenac, flufenamic acid, and derivatives) and the action of amyloid disrupters such as 4"-iodo-4"-deoxydoxorubicin (I-DOX) and tetracyclines. Diflunisal 163-173 transthyretin Homo sapiens 111-114 16266291-9 2005 Based on the proposed mechanism for TTR amyloid fibril formation we discuss the action of some of the proposed TTR stabilizers such as derivatives of some NSAIDs (diflunisal, diclofenac, flufenamic acid, and derivatives) and the action of amyloid disrupters such as 4"-iodo-4"-deoxydoxorubicin (I-DOX) and tetracyclines. Diclofenac 175-185 transthyretin Homo sapiens 111-114 16266291-9 2005 Based on the proposed mechanism for TTR amyloid fibril formation we discuss the action of some of the proposed TTR stabilizers such as derivatives of some NSAIDs (diflunisal, diclofenac, flufenamic acid, and derivatives) and the action of amyloid disrupters such as 4"-iodo-4"-deoxydoxorubicin (I-DOX) and tetracyclines. 4'-deoxy-4'-iododoxorubicin 266-293 transthyretin Homo sapiens 111-114 16266291-9 2005 Based on the proposed mechanism for TTR amyloid fibril formation we discuss the action of some of the proposed TTR stabilizers such as derivatives of some NSAIDs (diflunisal, diclofenac, flufenamic acid, and derivatives) and the action of amyloid disrupters such as 4"-iodo-4"-deoxydoxorubicin (I-DOX) and tetracyclines. 4'-deoxy-4'-iododoxorubicin 295-300 transthyretin Homo sapiens 111-114 16266291-9 2005 Based on the proposed mechanism for TTR amyloid fibril formation we discuss the action of some of the proposed TTR stabilizers such as derivatives of some NSAIDs (diflunisal, diclofenac, flufenamic acid, and derivatives) and the action of amyloid disrupters such as 4"-iodo-4"-deoxydoxorubicin (I-DOX) and tetracyclines. Tetracyclines 306-319 transthyretin Homo sapiens 111-114 16382573-0 2005 Use of a 13C tracer to investigate lutein as a ligand for plasma transthyretin in humans. 13c 9-12 transthyretin Homo sapiens 65-78 16382573-5 2005 For three subjects, the plasma TTR-retinol-binding protein (RBP) complex was partially purified by anion-exchange (diethylaminoethyl, DEAE) chromatography and then dissociated by hydrophobic-interaction chromatography to yield the TTR component. diethylaminoethyl 115-132 transthyretin Homo sapiens 31-34 16382573-5 2005 For three subjects, the plasma TTR-retinol-binding protein (RBP) complex was partially purified by anion-exchange (diethylaminoethyl, DEAE) chromatography and then dissociated by hydrophobic-interaction chromatography to yield the TTR component. 2-diethylaminoethanol 134-138 transthyretin Homo sapiens 31-34 15981995-3 2005 Crucial for TTR"s ligand-binding properties are its three halogen-binding sites situated at the hormone-binding channel. Halogens 58-65 transthyretin Homo sapiens 12-15 16170462-8 2005 BSB, a Congo red derivative that binds to amyloid fibrils in FAP as well as to those in senile plaques in Alzheimer"s disease, effectively suppressed TTR amyloid formation in vitro. Congo Red 7-16 transthyretin Homo sapiens 150-153 16101296-0 2005 Effect of nitric oxide in amyloid fibril formation on transthyretin-related amyloidosis. Nitric Oxide 10-22 transthyretin Homo sapiens 54-67 16101296-4 2005 S-Nitrosylation of amyloidogenic transthyretin V30M via the cysteine at position 10 was 2 times more extensive than that of wild-type transthyretin in a nitric oxide-generating solution. Cysteine 60-68 transthyretin Homo sapiens 33-46 16101296-4 2005 S-Nitrosylation of amyloidogenic transthyretin V30M via the cysteine at position 10 was 2 times more extensive than that of wild-type transthyretin in a nitric oxide-generating solution. Nitric Oxide 153-165 transthyretin Homo sapiens 33-46 16101296-8 2005 These results suggest that the nitric oxide-mediated modification of transthyretin, especially variant transthyretin, may play an important role in amyloid formation in senile systemic amyloidosis and familial amyloidotic polyneuropathy. Nitric Oxide 31-43 transthyretin Homo sapiens 69-82 16101296-8 2005 These results suggest that the nitric oxide-mediated modification of transthyretin, especially variant transthyretin, may play an important role in amyloid formation in senile systemic amyloidosis and familial amyloidotic polyneuropathy. Nitric Oxide 31-43 transthyretin Homo sapiens 103-116 16053476-0 2005 An aggressive form of familial amyloid polyneuropathy caused by a Glu54Gly mutation in the transthyretin gene. glu54gly 66-74 transthyretin Homo sapiens 91-104 16053476-2 2005 Gene analysis revealed a heterozygous Glu54Gly substitution (A-to-G change) in the transthyretin gene. glu54gly 38-46 transthyretin Homo sapiens 83-96 15981995-4 2005 In this study, we have performed a structural characterization of the binding of two halides, iodide and chloride, to TTR. halides 85-92 transthyretin Homo sapiens 118-121 15981995-4 2005 In this study, we have performed a structural characterization of the binding of two halides, iodide and chloride, to TTR. Iodides 94-100 transthyretin Homo sapiens 118-121 15981995-4 2005 In this study, we have performed a structural characterization of the binding of two halides, iodide and chloride, to TTR. Chlorides 105-113 transthyretin Homo sapiens 118-121 15981995-5 2005 Chlorides are known to shield charge repulsions at the tetrameric interface of TTR, which improve tetramer stability of the protein. Chlorides 0-9 transthyretin Homo sapiens 79-82 15981995-7 2005 To elucidate binding sites of the halides, we took advantage of the anomalous scattering of iodide and used the single-wavelength anomalous dispersion (SAD) method to solve the iodide-bound TTR structure at 1.8 A resolution. halides 34-41 transthyretin Homo sapiens 190-193 15981995-7 2005 To elucidate binding sites of the halides, we took advantage of the anomalous scattering of iodide and used the single-wavelength anomalous dispersion (SAD) method to solve the iodide-bound TTR structure at 1.8 A resolution. Iodides 177-183 transthyretin Homo sapiens 190-193 15981995-8 2005 The structure of chloride-bound TTR was determined at 1.9 A resolution using difference Fourier techniques. Chlorides 17-25 transthyretin Homo sapiens 32-35 15966731-9 2005 Given the high proportion of TTR subunits having mixed disulfide modifications in human plasma ( approximately 50%), and the data within demonstrating their increased amyloidogenicity, we submit that disulfide metabolite modifications have the potential to influence the course of amyloidoses, including TTR amyloidoses caused by mutations. Disulfides 55-64 transthyretin Homo sapiens 29-32 15809979-1 2005 The NMR-derived solution structure of trans-3,4",5-trihydroxystilbene (resveratrol) was compared with two recent literature crystal x-ray structures, resveratrol in complex with human transthyretin (TTR-RES) from 1DVS.pdb and resveratrol bound to chalcone synthase (CHS-RES) from 1CGZ.pdb. Resveratrol 71-82 transthyretin Homo sapiens 184-197 15809979-1 2005 The NMR-derived solution structure of trans-3,4",5-trihydroxystilbene (resveratrol) was compared with two recent literature crystal x-ray structures, resveratrol in complex with human transthyretin (TTR-RES) from 1DVS.pdb and resveratrol bound to chalcone synthase (CHS-RES) from 1CGZ.pdb. Resveratrol 150-161 transthyretin Homo sapiens 184-197 15809979-1 2005 The NMR-derived solution structure of trans-3,4",5-trihydroxystilbene (resveratrol) was compared with two recent literature crystal x-ray structures, resveratrol in complex with human transthyretin (TTR-RES) from 1DVS.pdb and resveratrol bound to chalcone synthase (CHS-RES) from 1CGZ.pdb. Resveratrol 150-161 transthyretin Homo sapiens 184-197 15966731-9 2005 Given the high proportion of TTR subunits having mixed disulfide modifications in human plasma ( approximately 50%), and the data within demonstrating their increased amyloidogenicity, we submit that disulfide metabolite modifications have the potential to influence the course of amyloidoses, including TTR amyloidoses caused by mutations. Disulfides 200-209 transthyretin Homo sapiens 29-32 15966731-9 2005 Given the high proportion of TTR subunits having mixed disulfide modifications in human plasma ( approximately 50%), and the data within demonstrating their increased amyloidogenicity, we submit that disulfide metabolite modifications have the potential to influence the course of amyloidoses, including TTR amyloidoses caused by mutations. Disulfides 200-209 transthyretin Homo sapiens 304-307 15846516-9 2005 Since the monomeric and tetrameric forms of TTR migrate as bands of 14 kDa and 40 kDa by SDS-polyacrylamide gel electrophoresis, a commercial preparation of human TTR was run, with both bands being reactive with this antibody. Sodium Dodecyl Sulfate 89-92 transthyretin Homo sapiens 44-47 15966751-4 2005 Small molecule kinetic stabilization of TTR has been established by concentration-dependent inhibition of acid-mediated amyloidogenesis and urea-induced tetramer dissociation. Urea 140-144 transthyretin Homo sapiens 40-43 15764666-4 2005 Prefibrillar amyloidogenic oligomers and protofibrils of misfolded TTR were generated in vitro through induction of the molten globule type A-state from acid unfolded TTR through the addition of NaCl. Sodium Chloride 195-199 transthyretin Homo sapiens 67-70 15846516-9 2005 Since the monomeric and tetrameric forms of TTR migrate as bands of 14 kDa and 40 kDa by SDS-polyacrylamide gel electrophoresis, a commercial preparation of human TTR was run, with both bands being reactive with this antibody. polyacrylamide 93-107 transthyretin Homo sapiens 44-47 15933496-2 2005 However, the most sensitive electrophysiological parameters at follow-up, and most effective type of different methods of steroid treatment for CTS, remain unknown. Steroids 122-129 transthyretin Homo sapiens 144-147 15833783-1 2005 Rare mutant forms of circulating albumin and prealbumin [transthyretin (TTR)] have increased binding affinity for thyroxine (T4). Thyroxine 114-123 transthyretin Homo sapiens 72-75 15689188-0 2005 Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor. iododiflunisal 36-50 transthyretin Homo sapiens 6-19 15689188-1 2005 Ex vivo and in vitro studies have revealed the remarkable amyloid inhibitory potency and specificity of iododiflunisal in relation to transthyretin [Almeida, Macedo, Cardoso, Alves, Valencia, Arsequell, Planas and Saraiva (2004) Biochem. iododiflunisal 104-118 transthyretin Homo sapiens 134-147 15689188-4 2005 In the present paper, the crystal structure of transthyretin complexed with this diflunisal derivative is reported, which enables a detailed analysis of the protein-ligand interactions. Diflunisal 81-91 transthyretin Homo sapiens 47-60 15933496-9 2005 These findings show that steroid injection is superior to iontophoresis and phonophoresis in the treatment of CTS, and that the most sensitive neurophysiologic parameters in follow-up are D4M-D4U and D2M-D5U, being the objective measures of the outcome of CTS treatment. Steroids 25-32 transthyretin Homo sapiens 110-113 16609671-4 2005 OH-PCBs have emerged as important classes of environmental contaminants in wildlife and humans because of their ability to bind with the thyroxin transport protein, transthyretin (TTR), and their interaction with thyroid hormone receptors. oh-pcbs 0-7 transthyretin Homo sapiens 165-178 15869287-0 2005 Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. dibenzofuran 37-49 transthyretin Homo sapiens 64-77 15869287-2 2005 This process has been followed by turbidity to identify transthyretin amyloidogenesis inhibitors including dibenzofuran-4,6-dicarboxylic acid (1). dibenzofuran-4,6-dicarboxylic acid 107-141 transthyretin Homo sapiens 56-69 15869287-3 2005 An X-ray cocrystal structure of TTR.1(2) reveals that it only utilizes the outer portion of the two thyroxine binding pockets to bind to and inhibit TTR amyloidogenesis. Thyroxine 100-109 transthyretin Homo sapiens 32-35 15869287-3 2005 An X-ray cocrystal structure of TTR.1(2) reveals that it only utilizes the outer portion of the two thyroxine binding pockets to bind to and inhibit TTR amyloidogenesis. Thyroxine 100-109 transthyretin Homo sapiens 149-152 15869287-7 2005 Since kinetic stabilization of the TTR native state by interallelic trans suppression is known to ameliorate disease, there is reason to be optimistic that the dibenzofuran-based inhibitors will do the same. dibenzofuran 160-172 transthyretin Homo sapiens 35-38 15951260-4 2005 Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/Transthyretin molar ratio = 0.40 +/- 0.08). Vitamin A 74-83 transthyretin Homo sapiens 133-146 15951260-4 2005 Results showed that 96 children (36.6%) presented a vitamin A deficiency (vitamin A < 200 microg/L with a retinol binding protein/transthyretin molar ratio = 0.29 +/- 0.06) while 166 (63.3%) children presented normal blood concentrations of vitamin A (vitamin A > or = 200 microg/L with a Retinol Binding Protein/Transthyretin molar ratio = 0.40 +/- 0.08). Vitamin A 74-83 transthyretin Homo sapiens 133-146 15826192-3 2005 Selective stabilization of the native TTR tetramer over the dissociative transition state by small molecule binding to both thyroxine binding sites raises the kinetic barrier of tetramer dissociation, preventing amyloidogenesis. Thyroxine 124-133 transthyretin Homo sapiens 38-41 15826192-5 2005 Herein, we report a method to tether one fibril formation inhibitor to TTR by disulfide bond formation. Disulfides 78-87 transthyretin Homo sapiens 71-74 15692981-2 2005 This study compared the effects of local steroid injection versus surgical decompression in new-onset CTS of at least 3 months" duration. Steroids 41-48 transthyretin Homo sapiens 102-105 15664936-1 2005 Neisseria meningitidis, a causative agent of bacterial meningitis and septicemia, obtains transferrin-bound iron by expressing two outer membrane-located transferrin-binding proteins, TbpA and TbpB. Iron 108-112 transthyretin Homo sapiens 184-188 15664936-6 2005 Kinetic data for diferric human transferrin binding showed that recombined TbpA-TbpB had K(a) and K(d) values similar to those of copurified TbpA-TbpB. tert-butyl peroxybenzoate 80-84 transthyretin Homo sapiens 75-79 15664936-6 2005 Kinetic data for diferric human transferrin binding showed that recombined TbpA-TbpB had K(a) and K(d) values similar to those of copurified TbpA-TbpB. tert-butyl peroxybenzoate 146-150 transthyretin Homo sapiens 141-145 15664936-7 2005 Individual TbpA and TbpB also displayed K(a) values similar to those of copurified TbpA-TbpB, but their K(d) values were one order of magnitude higher. tert-butyl peroxybenzoate 88-92 transthyretin Homo sapiens 83-87 15664936-11 2005 However, iron loss from the diferric human transferrin-TbpA-TbpB complex was not greater than that from human transferrin alone, suggesting that additional meningococcal transport components are involved in the process of iron removal. Iron 9-13 transthyretin Homo sapiens 55-59 15664936-11 2005 However, iron loss from the diferric human transferrin-TbpA-TbpB complex was not greater than that from human transferrin alone, suggesting that additional meningococcal transport components are involved in the process of iron removal. Iron 222-226 transthyretin Homo sapiens 55-59 15743199-0 2005 Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. bisaryloxime ethers 0-19 transthyretin Homo sapiens 44-57 15743199-5 2005 The bisaryloxime ethers selectively stabilize the native tetrameric state of TTR over the dissociative transition state under amyloidogenic conditions, leading to an increase in the dissociation activation barrier. bisaryloxime ethers 4-23 transthyretin Homo sapiens 77-80 15743199-6 2005 Several bisaryloxime ethers bind selectively to TTR in human blood plasma over the plethora of other plasma proteins, a necessary attribute for efficacy in vivo. bisaryloxime ethers 8-27 transthyretin Homo sapiens 48-51 15743199-7 2005 While bisarylaldoxime ethers are susceptible to degradation by N-O bond cleavage, this process is slowed by their binding to TTR. bisarylaldoxime ethers 6-28 transthyretin Homo sapiens 125-128 15686915-0 2005 Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors. Oxazoles 37-44 transthyretin Homo sapiens 45-58 15686915-1 2005 Ten oxazoles bearing a C(4) carboxyl group were synthesized and evaluated as transthyretin (TTR) amyloid fibril inhibitors. Oxazoles 4-12 transthyretin Homo sapiens 77-90 15686915-1 2005 Ten oxazoles bearing a C(4) carboxyl group were synthesized and evaluated as transthyretin (TTR) amyloid fibril inhibitors. Oxazoles 4-12 transthyretin Homo sapiens 92-95 15692981-13 2005 CONCLUSION: Over the short term, local steroid injection is better than surgical decompression for the symptomatic relief of CTS. Steroids 39-46 transthyretin Homo sapiens 125-128 15692981-14 2005 At 1 year, local steroid injection is as effective as surgical decompression for the symptomatic relief of CTS. Steroids 17-24 transthyretin Homo sapiens 107-110 16197301-5 2005 Albumin, fibronectin, transthyretin, annexin II, and factor V have now been identified as molecular targets for homocysteine, and in the case of albumin, the mechanism of targeting has been elucidated. Homocysteine 112-124 transthyretin Homo sapiens 22-35 16609671-4 2005 OH-PCBs have emerged as important classes of environmental contaminants in wildlife and humans because of their ability to bind with the thyroxin transport protein, transthyretin (TTR), and their interaction with thyroid hormone receptors. oh-pcbs 0-7 transthyretin Homo sapiens 180-183 15678762-1 2004 We report a characteristic finding in gadolinium-enhanced magnetic resonance images (MRIs) of the central nervous system (CNS) in a 61-year-old man with a homozygous transthyretin (TTR) Val30Met mutation. Gadolinium 38-48 transthyretin Homo sapiens 181-184 15469931-0 2004 The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors. Diethylstilbestrol 55-73 transthyretin Homo sapiens 25-38 15469931-3 2004 The ability of diethylstilbestrol (DES) to act as a competitive inhibitor for the thyroid hormone binding to TTR indicated a possible stabilizing effect of DES upon binding. Diethylstilbestrol 15-33 transthyretin Homo sapiens 109-112 15469931-3 2004 The ability of diethylstilbestrol (DES) to act as a competitive inhibitor for the thyroid hormone binding to TTR indicated a possible stabilizing effect of DES upon binding. Diethylstilbestrol 35-38 transthyretin Homo sapiens 109-112 15469931-3 2004 The ability of diethylstilbestrol (DES) to act as a competitive inhibitor for the thyroid hormone binding to TTR indicated a possible stabilizing effect of DES upon binding. Diethylstilbestrol 156-159 transthyretin Homo sapiens 109-112 15469931-4 2004 Here we report the crystallographic study of DES binding to TTR. Diethylstilbestrol 45-48 transthyretin Homo sapiens 60-63 15469931-7 2004 The most remarkable features of DES interaction with TTR are its hydrophobic interactions within the protein halogen binding pockets, where its ethyl groups are snugly fitted, and the hydrogen bonds established at the center of the tetramer with Ser-117. Diethylstilbestrol 32-35 transthyretin Homo sapiens 53-56 15469931-7 2004 The most remarkable features of DES interaction with TTR are its hydrophobic interactions within the protein halogen binding pockets, where its ethyl groups are snugly fitted, and the hydrogen bonds established at the center of the tetramer with Ser-117. Halogens 109-116 transthyretin Homo sapiens 53-56 15469931-7 2004 The most remarkable features of DES interaction with TTR are its hydrophobic interactions within the protein halogen binding pockets, where its ethyl groups are snugly fitted, and the hydrogen bonds established at the center of the tetramer with Ser-117. Hydrogen 184-192 transthyretin Homo sapiens 53-56 15469931-7 2004 The most remarkable features of DES interaction with TTR are its hydrophobic interactions within the protein halogen binding pockets, where its ethyl groups are snugly fitted, and the hydrogen bonds established at the center of the tetramer with Ser-117. Serine 246-249 transthyretin Homo sapiens 53-56 15469931-9 2004 The present study gave us further insight in the molecular mechanism by which DES competes with thyroid hormone binding to TTR and highlights key interactions between DES and TTR that oppose amyloid formation. Diethylstilbestrol 78-81 transthyretin Homo sapiens 123-126 15469931-9 2004 The present study gave us further insight in the molecular mechanism by which DES competes with thyroid hormone binding to TTR and highlights key interactions between DES and TTR that oppose amyloid formation. Diethylstilbestrol 78-81 transthyretin Homo sapiens 175-178 15678762-4 2004 In the gadolinium-enhanced T1-weighted MRIs of the brain and spinal cord, leptomeningeal enhancement was seen along the surfaces of the brain stem and more clearly in the spinal cord, suggesting leptomeningeal TTR-related amyloid deposition. Gadolinium 7-17 transthyretin Homo sapiens 210-213 15610856-1 2004 Polychlorinated biphenyls (PCBs) and their hydroxylated metabolites (OH-PCBs) are known to bind to transthyretin (TTR) in vitro, possibly explaining their bioaccumulation, rodent toxicity, and presumed human toxicity. Polychlorinated Biphenyls 0-25 transthyretin Homo sapiens 114-117 15588697-0 2004 Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis. Vitamin A 102-111 transthyretin Homo sapiens 53-66 15588697-1 2004 Retinol transport complex consisting of retinol-binding protein (RBP) and transthyretin (TTR) is involved in the transport of retinol (vitamin A) and thyroxine (T(4)) in the human plasma. Vitamin A 0-7 transthyretin Homo sapiens 74-87 15588697-1 2004 Retinol transport complex consisting of retinol-binding protein (RBP) and transthyretin (TTR) is involved in the transport of retinol (vitamin A) and thyroxine (T(4)) in the human plasma. Vitamin A 0-7 transthyretin Homo sapiens 89-92 15588697-1 2004 Retinol transport complex consisting of retinol-binding protein (RBP) and transthyretin (TTR) is involved in the transport of retinol (vitamin A) and thyroxine (T(4)) in the human plasma. Vitamin A 40-47 transthyretin Homo sapiens 89-92 15588697-1 2004 Retinol transport complex consisting of retinol-binding protein (RBP) and transthyretin (TTR) is involved in the transport of retinol (vitamin A) and thyroxine (T(4)) in the human plasma. Vitamin A 135-144 transthyretin Homo sapiens 74-87 15588697-1 2004 Retinol transport complex consisting of retinol-binding protein (RBP) and transthyretin (TTR) is involved in the transport of retinol (vitamin A) and thyroxine (T(4)) in the human plasma. Vitamin A 135-144 transthyretin Homo sapiens 89-92 15588697-1 2004 Retinol transport complex consisting of retinol-binding protein (RBP) and transthyretin (TTR) is involved in the transport of retinol (vitamin A) and thyroxine (T(4)) in the human plasma. Thyroxine 150-159 transthyretin Homo sapiens 74-87 15588697-1 2004 Retinol transport complex consisting of retinol-binding protein (RBP) and transthyretin (TTR) is involved in the transport of retinol (vitamin A) and thyroxine (T(4)) in the human plasma. Thyroxine 150-159 transthyretin Homo sapiens 89-92 15588697-8 2004 Furthermore, knockout models of both RBP and TTR unequivocally demonstrated the importance of this protein-protein complex in retinoid transport. Retinoids 126-134 transthyretin Homo sapiens 45-48 15588697-9 2004 Thus, interactions amongst multiple components of retinol transport play critical roles in vitamin A homeostasis and TTR amyloidosis. Vitamin A 50-57 transthyretin Homo sapiens 117-120 15610856-3 2004 Some of the OH-PCBs displace thyroid hormone (T4) from TTR, rationalizing the toxicity observed in rodents, where TTR is the major T4 transporter. oh-pcbs 12-19 transthyretin Homo sapiens 114-117 15610856-5 2004 OH-PCBs are excellent TTR amyloidogenesis inhibitors in vitro because they bind to the TTR tetramer, imparting kinetic stability under amyloidogenic denaturing conditions. oh-pcbs 0-7 transthyretin Homo sapiens 22-25 15610856-5 2004 OH-PCBs are excellent TTR amyloidogenesis inhibitors in vitro because they bind to the TTR tetramer, imparting kinetic stability under amyloidogenic denaturing conditions. oh-pcbs 0-7 transthyretin Homo sapiens 87-90 15610856-1 2004 Polychlorinated biphenyls (PCBs) and their hydroxylated metabolites (OH-PCBs) are known to bind to transthyretin (TTR) in vitro, possibly explaining their bioaccumulation, rodent toxicity, and presumed human toxicity. Polychlorinated Biphenyls 27-31 transthyretin Homo sapiens 114-117 15610856-1 2004 Polychlorinated biphenyls (PCBs) and their hydroxylated metabolites (OH-PCBs) are known to bind to transthyretin (TTR) in vitro, possibly explaining their bioaccumulation, rodent toxicity, and presumed human toxicity. oh-pcbs 69-76 transthyretin Homo sapiens 114-117 15610856-2 2004 Herein, we show that several OH-PCBs bind selectively to TTR in blood plasma; however, only one of the PCBs tested binds TTR in plasma. oh-pcbs 29-36 transthyretin Homo sapiens 57-60 15610856-2 2004 Herein, we show that several OH-PCBs bind selectively to TTR in blood plasma; however, only one of the PCBs tested binds TTR in plasma. Polychlorinated Biphenyls 32-36 transthyretin Homo sapiens 57-60 15610856-3 2004 Some of the OH-PCBs displace thyroid hormone (T4) from TTR, rationalizing the toxicity observed in rodents, where TTR is the major T4 transporter. oh-pcbs 12-19 transthyretin Homo sapiens 55-58 15205369-1 2004 BACKGROUND: One of the numerous proteins causing amyloidosis is transthyretin (TTR), a protein usually responsible for the transport of thyroxine and retinol-binding protein. Thyroxine 136-145 transthyretin Homo sapiens 64-77 15461573-5 2004 The first is inhibition of variant TTR mRNA expression by antisense or ribozymes, and the other is the repair of mutated TTR gene by chimaeraplasts or single-stranded oligonucleotides. Oligonucleotides 167-183 transthyretin Homo sapiens 121-124 15477096-9 2004 The central channel of L55P-TTR undergoes opening and closing fluctuations, which may provide an explanation for the fact that while the mutation is far from the channel, the mutant shows a substantial low binding affinity of thyroxine. Thyroxine 226-235 transthyretin Homo sapiens 28-31 15205369-1 2004 BACKGROUND: One of the numerous proteins causing amyloidosis is transthyretin (TTR), a protein usually responsible for the transport of thyroxine and retinol-binding protein. Thyroxine 136-145 transthyretin Homo sapiens 79-82 15205369-3 2004 METHODS: TTR was immunoprecipitated from serum by use of a polyclonal antibody and subsequently reduced with tris(2-carboxyethyl)phosphine. tris(2-carboxyethyl)phosphine 109-138 transthyretin Homo sapiens 9-12 15217993-5 2004 The purified TTR was reduced with tris(2-carboxyethyl)phosphine and analyzed by MS. tris(2-carboxyethyl)phosphine 34-63 transthyretin Homo sapiens 13-16 15341658-3 2004 RESULTS: TTR levels as determined by ELISA in plasma and urine of healthy individuals were 489 +/- 155 microg/ml plasma and 46 +/- 24 ng/g creatinine, respectively. Creatinine 139-149 transthyretin Homo sapiens 9-12 15082720-1 2004 Transthyretin (TTR) is an extracellular transport protein involved in the distribution of thyroid hormones and vitamin A. Vitamin A 111-120 transthyretin Homo sapiens 15-18 15080795-0 2004 Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Diflunisal 142-152 transthyretin Homo sapiens 21-34 15080795-4 2004 Several small compounds, such as diclofenac, diflunisal and flufenamic acid, have been reported to bind to TTR in vitro, in the T4 (thyroxine) binding channel that runs through the TTR tetramer, and consequently are considered to stabilize TTR. Diclofenac 33-43 transthyretin Homo sapiens 107-110 15080795-4 2004 Several small compounds, such as diclofenac, diflunisal and flufenamic acid, have been reported to bind to TTR in vitro, in the T4 (thyroxine) binding channel that runs through the TTR tetramer, and consequently are considered to stabilize TTR. Diclofenac 33-43 transthyretin Homo sapiens 181-184 15080795-4 2004 Several small compounds, such as diclofenac, diflunisal and flufenamic acid, have been reported to bind to TTR in vitro, in the T4 (thyroxine) binding channel that runs through the TTR tetramer, and consequently are considered to stabilize TTR. Diclofenac 33-43 transthyretin Homo sapiens 181-184 15080795-4 2004 Several small compounds, such as diclofenac, diflunisal and flufenamic acid, have been reported to bind to TTR in vitro, in the T4 (thyroxine) binding channel that runs through the TTR tetramer, and consequently are considered to stabilize TTR. Diflunisal 45-55 transthyretin Homo sapiens 107-110 15080795-4 2004 Several small compounds, such as diclofenac, diflunisal and flufenamic acid, have been reported to bind to TTR in vitro, in the T4 (thyroxine) binding channel that runs through the TTR tetramer, and consequently are considered to stabilize TTR. Diflunisal 45-55 transthyretin Homo sapiens 181-184 15080795-4 2004 Several small compounds, such as diclofenac, diflunisal and flufenamic acid, have been reported to bind to TTR in vitro, in the T4 (thyroxine) binding channel that runs through the TTR tetramer, and consequently are considered to stabilize TTR. Diflunisal 45-55 transthyretin Homo sapiens 181-184 15080795-4 2004 Several small compounds, such as diclofenac, diflunisal and flufenamic acid, have been reported to bind to TTR in vitro, in the T4 (thyroxine) binding channel that runs through the TTR tetramer, and consequently are considered to stabilize TTR. Flufenamic Acid 60-75 transthyretin Homo sapiens 107-110 15080795-4 2004 Several small compounds, such as diclofenac, diflunisal and flufenamic acid, have been reported to bind to TTR in vitro, in the T4 (thyroxine) binding channel that runs through the TTR tetramer, and consequently are considered to stabilize TTR. Flufenamic Acid 60-75 transthyretin Homo sapiens 181-184 15080795-4 2004 Several small compounds, such as diclofenac, diflunisal and flufenamic acid, have been reported to bind to TTR in vitro, in the T4 (thyroxine) binding channel that runs through the TTR tetramer, and consequently are considered to stabilize TTR. Flufenamic Acid 60-75 transthyretin Homo sapiens 181-184 15080795-4 2004 Several small compounds, such as diclofenac, diflunisal and flufenamic acid, have been reported to bind to TTR in vitro, in the T4 (thyroxine) binding channel that runs through the TTR tetramer, and consequently are considered to stabilize TTR. Thyroxine 132-141 transthyretin Homo sapiens 107-110 15080795-4 2004 Several small compounds, such as diclofenac, diflunisal and flufenamic acid, have been reported to bind to TTR in vitro, in the T4 (thyroxine) binding channel that runs through the TTR tetramer, and consequently are considered to stabilize TTR. Thyroxine 132-141 transthyretin Homo sapiens 181-184 15080795-4 2004 Several small compounds, such as diclofenac, diflunisal and flufenamic acid, have been reported to bind to TTR in vitro, in the T4 (thyroxine) binding channel that runs through the TTR tetramer, and consequently are considered to stabilize TTR. Thyroxine 132-141 transthyretin Homo sapiens 181-184 15080795-7 2004 We found two diflunisal derivatives that, in contrast with diclofenac, flufenamic acid and diflunisal, displaced T4 from TTR in plasma preferentially over binding to albumin and thyroxine binding globulin. Diflunisal 13-23 transthyretin Homo sapiens 121-124 15080795-7 2004 We found two diflunisal derivatives that, in contrast with diclofenac, flufenamic acid and diflunisal, displaced T4 from TTR in plasma preferentially over binding to albumin and thyroxine binding globulin. Flufenamic Acid 71-86 transthyretin Homo sapiens 121-124 15080795-7 2004 We found two diflunisal derivatives that, in contrast with diclofenac, flufenamic acid and diflunisal, displaced T4 from TTR in plasma preferentially over binding to albumin and thyroxine binding globulin. Diflunisal 91-101 transthyretin Homo sapiens 121-124 15080795-8 2004 The same diflunisal derivatives also had a stabilizing effect on TTR tetramers in plasma, as studied by isoelectric focusing of whole plasma under semi-denaturing conditions. Diflunisal 9-19 transthyretin Homo sapiens 65-68 15080795-9 2004 In addition, by transmission electron microscopy, we demonstrated that, in contrast with other proposed TTR stabilizers (namely diclofenac, flufenamic acid and diflunisal), one of the diflunisal derivatives tested efficiently inhibited TTR aggregation. Diflunisal 184-194 transthyretin Homo sapiens 236-239 15080795-10 2004 Taken together, our ex vivo and in vitro studies present evidence for the selectivity and efficiency of novel diflunisal derivates as TTR stabilizers and as inhibitors of fibril formation. Diflunisal 110-120 transthyretin Homo sapiens 134-137 15210129-3 2004 In this study, we characterise an engineered variant of transthyretin, Ala108Tyr/Leu110Glu, which is kinetically and thermodynamically more stable than wild-type transthyretin, and as a consequence less amyloidogenic. leu110glu 81-90 transthyretin Homo sapiens 56-69 15210129-3 2004 In this study, we characterise an engineered variant of transthyretin, Ala108Tyr/Leu110Glu, which is kinetically and thermodynamically more stable than wild-type transthyretin, and as a consequence less amyloidogenic. leu110glu 81-90 transthyretin Homo sapiens 162-175 15122304-2 2004 Prior to amyloid fibrils, nonfibrillar TTR aggregates are deposited inducing oxidative stress with increased nitration (3-NT). 3-nitrotyrosine 120-124 transthyretin Homo sapiens 39-42 15082720-3 2004 Human and piscine TTR bind both thyroid hormones 3,5,3"-triiodo-l-thyronine (T(3)) and 3,5,3",5"-tetraiodo-l-thyronine (thyroxine, T(4)). Triiodothyronine 49-75 transthyretin Homo sapiens 18-21 15082720-3 2004 Human and piscine TTR bind both thyroid hormones 3,5,3"-triiodo-l-thyronine (T(3)) and 3,5,3",5"-tetraiodo-l-thyronine (thyroxine, T(4)). Thyroxine 87-118 transthyretin Homo sapiens 18-21 15082720-3 2004 Human and piscine TTR bind both thyroid hormones 3,5,3"-triiodo-l-thyronine (T(3)) and 3,5,3",5"-tetraiodo-l-thyronine (thyroxine, T(4)). Thyroxine 120-129 transthyretin Homo sapiens 18-21 14961068-4 2004 In this study, we used HepG2 cells to show in vitro conversion of the TTR gene by single-stranded oligonucleotides (SSOs), embedded in atelocollagen, designed to promote endogenous repair of genomic DNA. Oligonucleotides 98-114 transthyretin Homo sapiens 70-73 15155653-1 2004 Neisseria meningitidis acquires iron through the action of the transferrin (Tf) receptor, which is composed of the Tf-binding proteins A and B (TbpA and TbpB). Iron 32-36 transthyretin Homo sapiens 144-148 15155653-5 2004 We show that TbpA is essential in both strains for iron uptake and growth with iron-loaded human Tf as a sole iron source. Iron 51-55 transthyretin Homo sapiens 13-17 15155653-5 2004 We show that TbpA is essential in both strains for iron uptake and growth with iron-loaded human Tf as a sole iron source. Iron 79-83 transthyretin Homo sapiens 13-17 15155653-5 2004 We show that TbpA is essential in both strains for iron uptake and growth with iron-loaded human Tf as a sole iron source. Iron 79-83 transthyretin Homo sapiens 13-17 15033978-1 2004 Transthyretin (TTR) is a plasma homotetrameric protein that acts physiologically as a transporter of thyroxine (T(4)) and retinol, in the latter case through binding to retinol-binding protein (RBP). Thyroxine 101-110 transthyretin Homo sapiens 0-13 15033978-1 2004 Transthyretin (TTR) is a plasma homotetrameric protein that acts physiologically as a transporter of thyroxine (T(4)) and retinol, in the latter case through binding to retinol-binding protein (RBP). Thyroxine 101-110 transthyretin Homo sapiens 15-18 15033978-1 2004 Transthyretin (TTR) is a plasma homotetrameric protein that acts physiologically as a transporter of thyroxine (T(4)) and retinol, in the latter case through binding to retinol-binding protein (RBP). Vitamin A 122-129 transthyretin Homo sapiens 0-13 15033978-1 2004 Transthyretin (TTR) is a plasma homotetrameric protein that acts physiologically as a transporter of thyroxine (T(4)) and retinol, in the latter case through binding to retinol-binding protein (RBP). Vitamin A 122-129 transthyretin Homo sapiens 15-18 15033978-3 2004 We further investigated the nature of the TTR-apoA-I interaction and found that TTR from different sources (recombinant and plasmatic) is able to process proteolytically apoA-I, cleaving its C terminus after Phe-225. Phenylalanine 208-211 transthyretin Homo sapiens 80-83 15033978-4 2004 TTR-mediated proteolysis was inhibited by serine protease inhibitors (phenylmethanesulfonyl fluoride, Pefabloc, diisopropyl fluorophosphate, chymostatin, and N(alpha)-p-tosyl-l-phenylala-nine-chloromethyl ketone), suggesting a chymotrypsin-like activity. Phenylmethylsulfonyl Fluoride 70-100 transthyretin Homo sapiens 0-3 15033978-4 2004 TTR-mediated proteolysis was inhibited by serine protease inhibitors (phenylmethanesulfonyl fluoride, Pefabloc, diisopropyl fluorophosphate, chymostatin, and N(alpha)-p-tosyl-l-phenylala-nine-chloromethyl ketone), suggesting a chymotrypsin-like activity. 4-(2-aminoethyl)benzenesulfonylfluoride 102-110 transthyretin Homo sapiens 0-3 15033978-4 2004 TTR-mediated proteolysis was inhibited by serine protease inhibitors (phenylmethanesulfonyl fluoride, Pefabloc, diisopropyl fluorophosphate, chymostatin, and N(alpha)-p-tosyl-l-phenylala-nine-chloromethyl ketone), suggesting a chymotrypsin-like activity. Isoflurophate 112-139 transthyretin Homo sapiens 0-3 15033978-4 2004 TTR-mediated proteolysis was inhibited by serine protease inhibitors (phenylmethanesulfonyl fluoride, Pefabloc, diisopropyl fluorophosphate, chymostatin, and N(alpha)-p-tosyl-l-phenylala-nine-chloromethyl ketone), suggesting a chymotrypsin-like activity. chymostatin 141-152 transthyretin Homo sapiens 0-3 15033978-4 2004 TTR-mediated proteolysis was inhibited by serine protease inhibitors (phenylmethanesulfonyl fluoride, Pefabloc, diisopropyl fluorophosphate, chymostatin, and N(alpha)-p-tosyl-l-phenylala-nine-chloromethyl ketone), suggesting a chymotrypsin-like activity. n(alpha)-p-tosyl-l-phenylala-nine-chloromethyl ketone 158-211 transthyretin Homo sapiens 0-3 15063314-0 2004 Modification of cysteine residue in transthyretin and a synthetic peptide: analyses by electrospray ionization mass spectrometry. Cysteine 16-24 transthyretin Homo sapiens 36-49 14968122-5 2004 The effectiveness of several NSAIDs, including diclofenac, diflunisal, and flufenamic acid, as well as the diclofenac analog, 2-[(3,5-dichlorophenyl) amino] benzoic acid (inhibitor 1), has been demonstrated against WT TTR amyloidogenesis. 2-[(3,5-dichlorophenyl) amino] benzoic acid 126-169 transthyretin Homo sapiens 218-221 14968122-6 2004 Herein, the efficacy of these compounds at preventing acid-induced fibril formation and urea-induced tetramer dissociation of the most common disease-associated TTR variants (V30M, V122I, T60A, L58H, and I84S) was evaluated. Urea 88-92 transthyretin Homo sapiens 161-164 14968122-8 2004 The most common familial TTR variants were stabilized substantially by flufenamic acid and inhibitor 1, and to a lesser extent by diflunisal, against acid-mediated fibril formation and chaotrope denaturation, suggesting that this chemotherapeutic option is viable for patients with familial transthyretin amyloidosis. Flufenamic Acid 71-86 transthyretin Homo sapiens 25-28 14968122-8 2004 The most common familial TTR variants were stabilized substantially by flufenamic acid and inhibitor 1, and to a lesser extent by diflunisal, against acid-mediated fibril formation and chaotrope denaturation, suggesting that this chemotherapeutic option is viable for patients with familial transthyretin amyloidosis. Diflunisal 130-140 transthyretin Homo sapiens 25-28 15111112-1 2004 Transferrin binding protein A (TbpA) is a TonB-dependent outer membrane protein expressed by pathogenic bacteria for iron acquisition from human transferrin. Iron 117-121 transthyretin Homo sapiens 0-29 15111112-1 2004 Transferrin binding protein A (TbpA) is a TonB-dependent outer membrane protein expressed by pathogenic bacteria for iron acquisition from human transferrin. Iron 117-121 transthyretin Homo sapiens 31-35 15063314-2 2004 By electrospray ionization mass spectrometry (ESI-MS), we previously found derivatives of serum transthyretin (TTR) in which cysteine residue at position 10 was changed to glycine residue and sulfocysteine residue. S-sulphocysteine 192-205 transthyretin Homo sapiens 96-109 15063314-2 2004 By electrospray ionization mass spectrometry (ESI-MS), we previously found derivatives of serum transthyretin (TTR) in which cysteine residue at position 10 was changed to glycine residue and sulfocysteine residue. S-sulphocysteine 192-205 transthyretin Homo sapiens 111-114 15063314-4 2004 In the present paper, we show the molecular masses of various TTR derivatives including these two, and the modification process was studied using a synthetic peptide with the same sequence as cysteine containing part of TTR, i.e., SKCPLMVK. Cysteine 192-200 transthyretin Homo sapiens 220-223 14711308-0 2004 Diflunisal analogues stabilize the native state of transthyretin. Diflunisal 0-10 transthyretin Homo sapiens 51-64 14673473-1 2004 Familial amyloid polyneuropathy (FAP) is a lethal autosomal dominant disorder in which fibrils derived from mutant forms of transthyretin (TTR), the normal plasma carrier of thyroxine (T(4)) and retinol-binding protein, are deposited in tissues. Thyroxine 174-183 transthyretin Homo sapiens 124-137 14673473-1 2004 Familial amyloid polyneuropathy (FAP) is a lethal autosomal dominant disorder in which fibrils derived from mutant forms of transthyretin (TTR), the normal plasma carrier of thyroxine (T(4)) and retinol-binding protein, are deposited in tissues. Thyroxine 174-183 transthyretin Homo sapiens 139-142 15110620-3 2004 Four CHLTs were performed for amyloidogenic transthyretin-related (variant Glu89Gln-ATTR Glu89Gln) cardiomyopathy in our center. glu89gln 75-83 transthyretin Homo sapiens 84-88 15110620-3 2004 Four CHLTs were performed for amyloidogenic transthyretin-related (variant Glu89Gln-ATTR Glu89Gln) cardiomyopathy in our center. glu89gln 89-97 transthyretin Homo sapiens 84-88 15110620-12 2004 In conclusion, CHLT for ATTR Glu89Gln may be performed even in patients with advanced disease. glu89gln 29-37 transthyretin Homo sapiens 24-28 14534839-0 2004 Sulfite and base for the treatment of familial amyloidotic polyneuropathy: two additive approaches to stabilize the conformation of human amyloidogenic transthyretin. Sulfites 0-7 transthyretin Homo sapiens 152-165 14534839-1 2004 Recently, we presented evidence that sulfite protects transthyretin (TTR) from normal human individuals and heterozygotes with amyloidogenic TTR mutations against the decay of tetramers into monomers. Sulfites 37-44 transthyretin Homo sapiens 54-67 14534839-1 2004 Recently, we presented evidence that sulfite protects transthyretin (TTR) from normal human individuals and heterozygotes with amyloidogenic TTR mutations against the decay of tetramers into monomers. Sulfites 37-44 transthyretin Homo sapiens 69-72 14534839-1 2004 Recently, we presented evidence that sulfite protects transthyretin (TTR) from normal human individuals and heterozygotes with amyloidogenic TTR mutations against the decay of tetramers into monomers. Sulfites 37-44 transthyretin Homo sapiens 141-144 14534839-2 2004 In this paper we demonstrate a stabilizing effect of sulfite on TTR tetramers from a familial amyloidotic polyneuropathy (FAP) patient homozygous for the most-common amyloidogenic TTR-V30 M mutation. Sulfites 53-60 transthyretin Homo sapiens 64-67 14534839-2 2004 In this paper we demonstrate a stabilizing effect of sulfite on TTR tetramers from a familial amyloidotic polyneuropathy (FAP) patient homozygous for the most-common amyloidogenic TTR-V30 M mutation. Sulfites 53-60 transthyretin Homo sapiens 180-183 14534839-4 2004 Using a combination of polyacrylamide gel electrophoresis (PAGE) and sodium dodecyl sulfate (SDS) gradient PAGE we demonstrate that TTR dimers containing amyloidogenic TTR mutations decay into monomers at pH<7.4. polyacrylamide 23-37 transthyretin Homo sapiens 132-135 14534839-4 2004 Using a combination of polyacrylamide gel electrophoresis (PAGE) and sodium dodecyl sulfate (SDS) gradient PAGE we demonstrate that TTR dimers containing amyloidogenic TTR mutations decay into monomers at pH<7.4. Sodium Dodecyl Sulfate 69-91 transthyretin Homo sapiens 132-135 14534839-4 2004 Using a combination of polyacrylamide gel electrophoresis (PAGE) and sodium dodecyl sulfate (SDS) gradient PAGE we demonstrate that TTR dimers containing amyloidogenic TTR mutations decay into monomers at pH<7.4. Sodium Dodecyl Sulfate 93-96 transthyretin Homo sapiens 132-135 14534839-4 2004 Using a combination of polyacrylamide gel electrophoresis (PAGE) and sodium dodecyl sulfate (SDS) gradient PAGE we demonstrate that TTR dimers containing amyloidogenic TTR mutations decay into monomers at pH<7.4. Sodium Dodecyl Sulfate 93-96 transthyretin Homo sapiens 168-171 14711308-2 2004 Analogues of diflunisal, an FDA-approved nonsteroidal antiinflammatory drug (NSAID), were synthesized and evaluated as inhibitors of transthyretin (TTR) aggregation, including amyloid fibril formation. Diflunisal 13-23 transthyretin Homo sapiens 133-146 14711308-2 2004 Analogues of diflunisal, an FDA-approved nonsteroidal antiinflammatory drug (NSAID), were synthesized and evaluated as inhibitors of transthyretin (TTR) aggregation, including amyloid fibril formation. Diflunisal 13-23 transthyretin Homo sapiens 148-151 14711308-11 2004 Structure-activity relationships reveal that para-carboxylate substitution on the hydrophilic ring and dihalogen substitution on the hydrophobic ring afford the most active TTR amyloid inhibitors. para-carboxylate 45-61 transthyretin Homo sapiens 173-176 14711308-11 2004 Structure-activity relationships reveal that para-carboxylate substitution on the hydrophilic ring and dihalogen substitution on the hydrophobic ring afford the most active TTR amyloid inhibitors. dihalogen 103-112 transthyretin Homo sapiens 173-176 15196886-0 2004 Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin. Vitamin A 7-14 transthyretin Homo sapiens 88-101 14694502-1 2004 A double-blinded placebo-controlled trial was performed to evaluate the use of steroid injections beneath the transverse carpal ligament in the treatment of carpal tunnel syndrome (CTS) refractory to nonsurgical therapy. Steroids 79-86 transthyretin Homo sapiens 181-184 14694502-8 2004 We conclude that although steroid injections are safe and effective for temporary relief of CTS, most patients will eventually require surgery for long-term control of their symptoms. Steroids 26-33 transthyretin Homo sapiens 92-95 14695346-0 2004 Cysteine 10 is a key residue in amyloidogenesis of human transthyretin Val30Met. Cysteine 0-8 transthyretin Homo sapiens 57-70 14695346-5 2004 X-ray crystallography of normal and amyloidogenic human TTR Val30Met in type I FAP showed that the -SH side chain of cysteine at position 10 (Cys10) forms a hydrogen bond with Gly57 in normal TTR but not in TTR Val30Met. Cysteine 117-125 transthyretin Homo sapiens 56-59 14695346-5 2004 X-ray crystallography of normal and amyloidogenic human TTR Val30Met in type I FAP showed that the -SH side chain of cysteine at position 10 (Cys10) forms a hydrogen bond with Gly57 in normal TTR but not in TTR Val30Met. Cysteine 117-125 transthyretin Homo sapiens 192-195 14695346-5 2004 X-ray crystallography of normal and amyloidogenic human TTR Val30Met in type I FAP showed that the -SH side chain of cysteine at position 10 (Cys10) forms a hydrogen bond with Gly57 in normal TTR but not in TTR Val30Met. Cysteine 117-125 transthyretin Homo sapiens 192-195 14695346-5 2004 X-ray crystallography of normal and amyloidogenic human TTR Val30Met in type I FAP showed that the -SH side chain of cysteine at position 10 (Cys10) forms a hydrogen bond with Gly57 in normal TTR but not in TTR Val30Met. Hydrogen 157-165 transthyretin Homo sapiens 56-59 15196886-5 2004 The stability of the retinol-RBP complex appears to be further enhanced when holo-RBP is bound to TTR. Vitamin A 21-28 transthyretin Homo sapiens 98-101 15196886-7 2004 Limited protein conformational changes affecting the entrance loops, which lead to a decrease or loss of the binding affinity of RBP for TTR, have been demonstrated for apo-RBP and RBP in complex with retinoids modified in the area of the retinol hydroxyl. Retinoids 201-210 transthyretin Homo sapiens 137-140 15196886-7 2004 Limited protein conformational changes affecting the entrance loops, which lead to a decrease or loss of the binding affinity of RBP for TTR, have been demonstrated for apo-RBP and RBP in complex with retinoids modified in the area of the retinol hydroxyl. retinol hydroxyl 239-255 transthyretin Homo sapiens 137-140 14507924-0 2003 In vitro and in vivo interactions of homocysteine with human plasma transthyretin. Homocysteine 37-49 transthyretin Homo sapiens 68-81 14690414-6 2003 Our results also indicated that the unfolding of Y114H and Y116S is less cooperative than that of the wild-type transthyretin. y116s 59-64 transthyretin Homo sapiens 112-125 14507924-4 2003 The amyloidogenic protein transthyretin (prealbumin), as we now report, undergoes homocysteinylation at its single cysteine residue (Cys10) both in vitro and in vivo. Cysteine 115-123 transthyretin Homo sapiens 26-39 14507924-9 2003 The hyperhomocysteinemic burden is thus reflected in the plasma levels of transthyretin-Cys10-S-S-homocysteine, which in turn may contribute to the pathological consequences of amyloid disease. cys10-s-s-homocysteine 88-110 transthyretin Homo sapiens 74-87 14507924-5 2003 Thus, when human plasma or highly purified transthyretin was incubated with 35S-L-homocysteine followed by SDS-PAGE and PhosphorImaging, two bands corresponding to transthyretin dimer and tetramer were observed. 35s-l-homocysteine 76-94 transthyretin Homo sapiens 43-56 14507924-5 2003 Thus, when human plasma or highly purified transthyretin was incubated with 35S-L-homocysteine followed by SDS-PAGE and PhosphorImaging, two bands corresponding to transthyretin dimer and tetramer were observed. 35s-l-homocysteine 76-94 transthyretin Homo sapiens 164-177 14507924-5 2003 Thus, when human plasma or highly purified transthyretin was incubated with 35S-L-homocysteine followed by SDS-PAGE and PhosphorImaging, two bands corresponding to transthyretin dimer and tetramer were observed. Sodium Dodecyl Sulfate 107-110 transthyretin Homo sapiens 43-56 14507924-7 2003 Transthyretin-Cys10-S-S-homocysteine was then identified in vivo in plasma from normal donors, patients with end-stage renal disease, and homocystinurics by immunoprecipitation and high performance liquid chromatography/electrospray mass spectrometry. cys10-s-s-homocysteine 14-36 transthyretin Homo sapiens 0-13 14507924-8 2003 The ratios of transthyretin-Cys10-S-S-homocysteine and transthyretin-Cys10-S-S-sulfonate to that of unmodified transthyretin increased with increasing homocysteine plasma concentrations, whereas the ratio of transthyretin-Cys10-S-S-cysteine to that of unmodified transthyretin decreased. cys10-s-s-homocysteine 28-50 transthyretin Homo sapiens 14-27 14507924-8 2003 The ratios of transthyretin-Cys10-S-S-homocysteine and transthyretin-Cys10-S-S-sulfonate to that of unmodified transthyretin increased with increasing homocysteine plasma concentrations, whereas the ratio of transthyretin-Cys10-S-S-cysteine to that of unmodified transthyretin decreased. cys10-s-s-sulfonate 69-88 transthyretin Homo sapiens 55-68 14507924-8 2003 The ratios of transthyretin-Cys10-S-S-homocysteine and transthyretin-Cys10-S-S-sulfonate to that of unmodified transthyretin increased with increasing homocysteine plasma concentrations, whereas the ratio of transthyretin-Cys10-S-S-cysteine to that of unmodified transthyretin decreased. cys10-s-s-sulfonate 69-88 transthyretin Homo sapiens 55-68 14507924-8 2003 The ratios of transthyretin-Cys10-S-S-homocysteine and transthyretin-Cys10-S-S-sulfonate to that of unmodified transthyretin increased with increasing homocysteine plasma concentrations, whereas the ratio of transthyretin-Cys10-S-S-cysteine to that of unmodified transthyretin decreased. cys10-s-s-sulfonate 69-88 transthyretin Homo sapiens 55-68 14507924-8 2003 The ratios of transthyretin-Cys10-S-S-homocysteine and transthyretin-Cys10-S-S-sulfonate to that of unmodified transthyretin increased with increasing homocysteine plasma concentrations, whereas the ratio of transthyretin-Cys10-S-S-cysteine to that of unmodified transthyretin decreased. cys10-s-s-sulfonate 69-88 transthyretin Homo sapiens 55-68 14507924-8 2003 The ratios of transthyretin-Cys10-S-S-homocysteine and transthyretin-Cys10-S-S-sulfonate to that of unmodified transthyretin increased with increasing homocysteine plasma concentrations, whereas the ratio of transthyretin-Cys10-S-S-cysteine to that of unmodified transthyretin decreased. Homocysteine 38-50 transthyretin Homo sapiens 14-27 14507924-8 2003 The ratios of transthyretin-Cys10-S-S-homocysteine and transthyretin-Cys10-S-S-sulfonate to that of unmodified transthyretin increased with increasing homocysteine plasma concentrations, whereas the ratio of transthyretin-Cys10-S-S-cysteine to that of unmodified transthyretin decreased. cys10-s-s 28-37 transthyretin Homo sapiens 14-27 14507924-8 2003 The ratios of transthyretin-Cys10-S-S-homocysteine and transthyretin-Cys10-S-S-sulfonate to that of unmodified transthyretin increased with increasing homocysteine plasma concentrations, whereas the ratio of transthyretin-Cys10-S-S-cysteine to that of unmodified transthyretin decreased. Cysteine 42-50 transthyretin Homo sapiens 14-27 14583036-6 2003 Some of the wild-type TTR.bivalent inhibitor complexes prepared in this fashion retain a tetrameric structure when subjected to substantial denaturation stresses (8 M urea, 120 h). Urea 167-171 transthyretin Homo sapiens 22-25 14644428-1 2003 The thyroid hormone binding protein transthyretin (TTR) forms a macromolecular complex with the retinol-specific carrier retinol binding protein (RBP) in the blood of higher vertebrates. Vitamin A 96-103 transthyretin Homo sapiens 51-54 14644428-2 2003 Piscine TTR is shown here to exhibit high binding affinity for L-thyroxine and negligible affinity for RBP. Thyroxine 63-74 transthyretin Homo sapiens 8-11 14511677-5 2003 We did not detect any N-homocysteinylation, but found pronounced S-homocysteinylation of TTR, if the concentration of total homocysteine was high. Homocysteine 124-136 transthyretin Homo sapiens 89-92 14592420-6 2003 In in vitro amyloid formation test measured with thioflavin T and electron microscopy, in the presence of VLDL/CM, amyloid formation of TTR was enhanced more than in the presence LDL or in the absence of lipoprotein species. thioflavin T 49-61 transthyretin Homo sapiens 136-139 14578606-0 2003 Cardiac amyloidosis associated with a novel transthyretin aspartic acid-18 glutamic acid de novo mutation. Glutamic Acid 75-88 transthyretin Homo sapiens 44-57 14578606-1 2003 A 40-year-old man presented with initial symptoms of syncope caused by restrictive cardiomyopathy and autonomic nervous system impairment, but it was confirmed that he had a novel transthyretin (TTR) variant, aspartic acid-18 glutamic acid (Glu), and a de novo gene mutation. aspartic acid-18 glutamic acid 209-239 transthyretin Homo sapiens 180-193 14578606-1 2003 A 40-year-old man presented with initial symptoms of syncope caused by restrictive cardiomyopathy and autonomic nervous system impairment, but it was confirmed that he had a novel transthyretin (TTR) variant, aspartic acid-18 glutamic acid (Glu), and a de novo gene mutation. Glutamic Acid 241-244 transthyretin Homo sapiens 180-193 14578606-1 2003 A 40-year-old man presented with initial symptoms of syncope caused by restrictive cardiomyopathy and autonomic nervous system impairment, but it was confirmed that he had a novel transthyretin (TTR) variant, aspartic acid-18 glutamic acid (Glu), and a de novo gene mutation. Glutamic Acid 241-244 transthyretin Homo sapiens 195-198 14578606-2 2003 A polymerase chain reaction-induced mutation restriction analysis with a mismatched sense primer demonstrated that he was heterozygous for TTR Glu 18. Glutamic Acid 143-146 transthyretin Homo sapiens 139-142 14640032-5 2003 Free TTR as well as TTR-cysteine and TTR-cysteinylglycine adducts are clearly evident. Cysteine 24-32 transthyretin Homo sapiens 20-23 15115956-8 2003 All of the patients presented with deposits of amyloid substance in the lymph nodes and the nerves of the hepatic hilium These deposits were Congo red positive with a greenish birefringence to polarized light Deposits show immunoreactivity with antihuman TTR. Congo Red 141-150 transthyretin Homo sapiens 255-258 14506715-3 2003 The relative amounts of variant and wild-type TTR in the purified protein were estimated from the recovered amounts of tryptic peptides with Ser25 or Ala25. Peptides 127-135 transthyretin Homo sapiens 46-49 12966927-0 2003 Restrictive cardiomyopathy in familial amyloidosis TTR-Arg-50. Arginine 55-58 transthyretin Homo sapiens 51-54 12963686-0 2003 Restrictive cardiomyopathy in familial amyloidosis TTR-Arg-50. Arginine 55-58 transthyretin Homo sapiens 51-54 14640032-5 2003 Free TTR as well as TTR-cysteine and TTR-cysteinylglycine adducts are clearly evident. Cysteine 24-32 transthyretin Homo sapiens 20-23 14623537-9 2003 Anastrozole showed improved TTR compared with tamoxifen (HR=0.79, CI (0.67-0.94), P=0.008), which improved even further in the ER+ and/or PR+ subgroup (HR=0.73, CI (0.59-0.90), P=0.003). Anastrozole 0-11 transthyretin Homo sapiens 28-31 14623537-14 2003 Anastrozole showed superior efficacy to tamoxifen for DFS, TTR and contralateral breast cancer. Anastrozole 0-11 transthyretin Homo sapiens 59-62 12900507-0 2003 Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Water 134-139 transthyretin Homo sapiens 55-68 12783587-6 2003 The most common measures employed in the initial treatment of CTS are NSAIDs, local and systemic corticosteroids, diuretics and pyridoxine. Pyridoxine 128-138 transthyretin Homo sapiens 62-65 14640043-9 2003 (Trans, trans)-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), a Congo red derivative that binds to amyloid fibrils in FAP, as well as to those in senile plaques in Alzheimer"s disease, effectively suppressed TTR amyloid formation in vitro. (trans, trans)-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene 0-71 transthyretin Homo sapiens 225-228 14640043-9 2003 (Trans, trans)-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), a Congo red derivative that binds to amyloid fibrils in FAP, as well as to those in senile plaques in Alzheimer"s disease, effectively suppressed TTR amyloid formation in vitro. bsb 73-76 transthyretin Homo sapiens 225-228 14640043-9 2003 (Trans, trans)-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), a Congo red derivative that binds to amyloid fibrils in FAP, as well as to those in senile plaques in Alzheimer"s disease, effectively suppressed TTR amyloid formation in vitro. Congo Red 81-90 transthyretin Homo sapiens 225-228 12873136-5 2003 The TTR-Cys, TTR-GSH, and TTR-CysGly isoforms are more amyloidogenic than WT at the higher end of the acidic pH range (pH 4.4-5.0), and they are similarly destabilized relative to WT TTR toward urea denaturation. Cysteine 8-11 transthyretin Homo sapiens 4-7 12873136-5 2003 The TTR-Cys, TTR-GSH, and TTR-CysGly isoforms are more amyloidogenic than WT at the higher end of the acidic pH range (pH 4.4-5.0), and they are similarly destabilized relative to WT TTR toward urea denaturation. Glutathione 17-20 transthyretin Homo sapiens 13-16 12873136-5 2003 The TTR-Cys, TTR-GSH, and TTR-CysGly isoforms are more amyloidogenic than WT at the higher end of the acidic pH range (pH 4.4-5.0), and they are similarly destabilized relative to WT TTR toward urea denaturation. Glutathione 17-20 transthyretin Homo sapiens 13-16 12873136-5 2003 The TTR-Cys, TTR-GSH, and TTR-CysGly isoforms are more amyloidogenic than WT at the higher end of the acidic pH range (pH 4.4-5.0), and they are similarly destabilized relative to WT TTR toward urea denaturation. Glutathione 17-20 transthyretin Homo sapiens 13-16 12873136-5 2003 The TTR-Cys, TTR-GSH, and TTR-CysGly isoforms are more amyloidogenic than WT at the higher end of the acidic pH range (pH 4.4-5.0), and they are similarly destabilized relative to WT TTR toward urea denaturation. Urea 194-198 transthyretin Homo sapiens 4-7 12873136-7 2003 Under mildly acidic conditions (pH 4.8), the amyloidogenesis rates of the mixed disulfide TTR variants are much faster than the WT rate. Disulfides 80-89 transthyretin Homo sapiens 90-93 12873136-8 2003 S-Sulfonated TTR is less amyloidogenic and forms fibrils more slowly than WT under acidic conditions, yet it exhibits a stability and rates of tetramer dissociation similar to those of WT TTR when subjected to urea denaturation. Urea 210-214 transthyretin Homo sapiens 13-16 12873136-9 2003 Conversion of the Cys10 SH group to a mixed disulfide with the amino acid Cys, the CysGly peptide, or glutathione increases amyloidogenicity and the amyloidogenesis rate above pH 4.6, conditions under which TTR probably forms fibrils in humans. Disulfides 44-53 transthyretin Homo sapiens 207-210 12873136-9 2003 Conversion of the Cys10 SH group to a mixed disulfide with the amino acid Cys, the CysGly peptide, or glutathione increases amyloidogenicity and the amyloidogenesis rate above pH 4.6, conditions under which TTR probably forms fibrils in humans. Glutathione 102-113 transthyretin Homo sapiens 207-210 12874858-0 2003 Polyacrylamide gel electrophoresis followed by sodium dodecyl sulfate gradient polyacrylamide gel electrophoresis for the study of the dimer to monomer transition of human transthyretin. polyacrylamide 0-14 transthyretin Homo sapiens 172-185 12874858-0 2003 Polyacrylamide gel electrophoresis followed by sodium dodecyl sulfate gradient polyacrylamide gel electrophoresis for the study of the dimer to monomer transition of human transthyretin. Sodium Dodecyl Sulfate 47-69 transthyretin Homo sapiens 172-185 12874858-5 2003 The gel strip containing the TTR fraction is incubated in 2% SDS under varying conditions of temperature, buffer composition, pH, and additives like urea and/or a sulfhydryl-reactive agent, followed by SDS-gradient PAGE for the separation of TTR dimers and monomers. Sodium Dodecyl Sulfate 61-64 transthyretin Homo sapiens 29-32 12874858-5 2003 The gel strip containing the TTR fraction is incubated in 2% SDS under varying conditions of temperature, buffer composition, pH, and additives like urea and/or a sulfhydryl-reactive agent, followed by SDS-gradient PAGE for the separation of TTR dimers and monomers. Urea 149-153 transthyretin Homo sapiens 29-32 12874858-5 2003 The gel strip containing the TTR fraction is incubated in 2% SDS under varying conditions of temperature, buffer composition, pH, and additives like urea and/or a sulfhydryl-reactive agent, followed by SDS-gradient PAGE for the separation of TTR dimers and monomers. Sodium Dodecyl Sulfate 202-205 transthyretin Homo sapiens 29-32 12821321-3 2003 The transthyretin gene was constructed by an assembly of eight chemically synthesized oligonucleotides and amplified by polymerase chain reaction, and the amplified gene was inserted into an Escherichia coli expression vector. Oligonucleotides 86-102 transthyretin Homo sapiens 4-17 12821321-5 2003 Purified recombinant transthyretin was obtained by one-step nickel chelation affinity chromatography and the production level of the protein was 130mg per 1L of culture. Nickel 60-66 transthyretin Homo sapiens 21-34 12757474-5 2003 It showed a substitution of thymine by cytosine in the second base of codon 30 in exon 2 of the TTR gene, with the creation of a novel HhaI restriction endonuclease site. Thymine 28-35 transthyretin Homo sapiens 96-99 12757474-5 2003 It showed a substitution of thymine by cytosine in the second base of codon 30 in exon 2 of the TTR gene, with the creation of a novel HhaI restriction endonuclease site. Cytosine 39-47 transthyretin Homo sapiens 96-99 12757474-6 2003 Valine is substituted by alanine (V30A) in the mutant TTR. Valine 0-6 transthyretin Homo sapiens 54-57 12757474-6 2003 Valine is substituted by alanine (V30A) in the mutant TTR. Alanine 25-32 transthyretin Homo sapiens 54-57 12593674-1 2003 Retinol is transported in the blood bound to a specific carrier protein called retinol-binding protein (RBP), which in turn binds to another protein, transthyretin (TTR), a homotetrameric, thyroid-hormone-transporting protein. Vitamin A 0-7 transthyretin Homo sapiens 150-163 12593674-1 2003 Retinol is transported in the blood bound to a specific carrier protein called retinol-binding protein (RBP), which in turn binds to another protein, transthyretin (TTR), a homotetrameric, thyroid-hormone-transporting protein. Vitamin A 0-7 transthyretin Homo sapiens 165-168 12593674-7 2003 TTR, which was eluted in 60 kDa fractions during urea/Sephadex G-100 chromatography, was further purified to homogeneity using a combination of two dye-affinity chromatographic steps on Reactive Yellow and Cibacron Blue coupled to agarose columns. Urea 49-53 transthyretin Homo sapiens 0-3 12593674-7 2003 TTR, which was eluted in 60 kDa fractions during urea/Sephadex G-100 chromatography, was further purified to homogeneity using a combination of two dye-affinity chromatographic steps on Reactive Yellow and Cibacron Blue coupled to agarose columns. sephadex 54-62 transthyretin Homo sapiens 0-3 12593674-7 2003 TTR, which was eluted in 60 kDa fractions during urea/Sephadex G-100 chromatography, was further purified to homogeneity using a combination of two dye-affinity chromatographic steps on Reactive Yellow and Cibacron Blue coupled to agarose columns. Cibacron Blue 206-219 transthyretin Homo sapiens 0-3 12593674-7 2003 TTR, which was eluted in 60 kDa fractions during urea/Sephadex G-100 chromatography, was further purified to homogeneity using a combination of two dye-affinity chromatographic steps on Reactive Yellow and Cibacron Blue coupled to agarose columns. Sepharose 231-238 transthyretin Homo sapiens 0-3 12873136-0 2003 Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions. Disulfides 12-22 transthyretin Homo sapiens 28-41 12873136-4 2003 Homotetrameric Cys10 TTR variants, including TTR-Cys, TTR-GSH, TTR-CysGly, and S-sulfonated TTR, were chemically synthesized starting with WT TTR. Cysteine 15-18 transthyretin Homo sapiens 21-24 12729768-6 2003 On the other hand, glucose, a chemical chaperone, can mimic the trans-suppression mutation by stabilizing the native state and by decreasing the amyloidogenic potential of the wt TTR at pH 5.0. Glucose 19-26 transthyretin Homo sapiens 179-182 12771253-12 2003 This resulted in heterozygosity for normal tyrosine and variant histidine (ATTR Tyr69His) in affected family members. Histidine 64-73 transthyretin Homo sapiens 75-79 14618140-7 2003 However, more cases should be studied before considering TCL reconstruction with poliesterurethane patch as a useful option in secondary surgery of true recurrence of CTS. Triclosan 57-60 transthyretin Homo sapiens 167-170 14618140-7 2003 However, more cases should be studied before considering TCL reconstruction with poliesterurethane patch as a useful option in secondary surgery of true recurrence of CTS. poliesterurethane 81-98 transthyretin Homo sapiens 167-170 12724338-0 2003 4"-iodo-4"-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. 4'-deoxy-4'-iododoxorubicin 0-27 transthyretin Homo sapiens 139-142 12700102-7 2003 TbpA is a member of a family of TonB-dependent transporters, others of which accomplish ferric-siderophore and vitamin B12 uptake at the expense of a proton gradient across the cytoplasmic membrane. Vitamin B 12 111-122 transthyretin Homo sapiens 0-4 12724338-3 2003 We studied by transmission electron microscopy the effect of the drug 4"-iodo-4"-deoxydoxorubicin (I-DOX) on the in vitro assembly of TTR Leu55Pro fibrils by following fibril growth over a 15 day period. 4'-deoxy-4'-iododoxorubicin 70-97 transthyretin Homo sapiens 134-137 12724338-3 2003 We studied by transmission electron microscopy the effect of the drug 4"-iodo-4"-deoxydoxorubicin (I-DOX) on the in vitro assembly of TTR Leu55Pro fibrils by following fibril growth over a 15 day period. 4'-deoxy-4'-iododoxorubicin 99-104 transthyretin Homo sapiens 134-137 12724338-7 2003 The species generated upon I-DOX and tetracyclines treatments were nontoxic, as revealed by the lack of significant caspase-3 activation on a Schwannoma cell line, making them potential therapeutic drugs in TTR-related and other amyloidosis. 4'-deoxy-4'-iododoxorubicin 27-32 transthyretin Homo sapiens 207-210 12724338-7 2003 The species generated upon I-DOX and tetracyclines treatments were nontoxic, as revealed by the lack of significant caspase-3 activation on a Schwannoma cell line, making them potential therapeutic drugs in TTR-related and other amyloidosis. Tetracyclines 37-50 transthyretin Homo sapiens 207-210 12697331-1 2003 The human transthyretin (TTR) gene encodes a protein composed of four identical subunits with an important role in the plasma transport of thyroid hormone T4 and retinol. Vitamin A 162-169 transthyretin Homo sapiens 10-23 12697331-1 2003 The human transthyretin (TTR) gene encodes a protein composed of four identical subunits with an important role in the plasma transport of thyroid hormone T4 and retinol. Vitamin A 162-169 transthyretin Homo sapiens 25-28 12553418-1 2002 As introduction to the First International Congress on Transthyretin in Health and Disease, this lecture traces the origin of the subjectfrom the discovery in the 1950s that a serum protein migrating ahead of albumin in an electrical field binds the thyroid hormone, thyroxine. Thyroxine 267-276 transthyretin Homo sapiens 55-68 12762139-11 2003 Sequence analysis of TTR exon 3 revealed heterozygosity in both subjects for a single basepair transversion from A to T in codon 78 (TAC-->TTC) indicating a tyrosine to phenylalanine change. Tyrosine 160-168 transthyretin Homo sapiens 21-24 12762139-11 2003 Sequence analysis of TTR exon 3 revealed heterozygosity in both subjects for a single basepair transversion from A to T in codon 78 (TAC-->TTC) indicating a tyrosine to phenylalanine change. Phenylalanine 172-185 transthyretin Homo sapiens 21-24 12649341-15 2003 Specifically, 2-[(3,5-dichlorophenyl)amino]benzoic acid is an excellent inhibitor of A25T TTR amyloidosis in vitro. Dichlorophenyl-ABA 14-55 transthyretin Homo sapiens 90-93 12566380-1 2003 Restrictive cardiomyopathy in familial amyloidosis TTR-Arg-50. Arginine 55-58 transthyretin Homo sapiens 51-54 12481032-2 2002 13C and 15N linewidth measurements indicate that TTR(105-115) forms a highly ordered structure with each amino acid in a unique environment. 13c 0-3 transthyretin Homo sapiens 49-52 12481032-2 2002 13C and 15N linewidth measurements indicate that TTR(105-115) forms a highly ordered structure with each amino acid in a unique environment. 15n 8-11 transthyretin Homo sapiens 49-52 12481032-6 2002 The results show that TTR(105-115) adopts an extended beta-strand conformation that is similar to that found in the native protein except for substantial differences in the vicinity of the proline residue. Proline 189-196 transthyretin Homo sapiens 22-25 12538647-0 2003 X-ray absorption spectroscopy reveals a substantial increase of sulfur oxidation in transthyretin (TTR) upon fibrillization. Sulfur 64-70 transthyretin Homo sapiens 84-97 12538647-0 2003 X-ray absorption spectroscopy reveals a substantial increase of sulfur oxidation in transthyretin (TTR) upon fibrillization. Sulfur 64-70 transthyretin Homo sapiens 99-102 12538647-4 2003 Disulfide bonds are frequently considered essential for the stability of protein aggregates and since in the TTR monomers there is one cysteine residue, it is important to determine unambiguously the redox state of sulfur present in the fibrils. Disulfides 0-9 transthyretin Homo sapiens 109-112 12538647-4 2003 Disulfide bonds are frequently considered essential for the stability of protein aggregates and since in the TTR monomers there is one cysteine residue, it is important to determine unambiguously the redox state of sulfur present in the fibrils. Cysteine 135-143 transthyretin Homo sapiens 109-112 12538647-4 2003 Disulfide bonds are frequently considered essential for the stability of protein aggregates and since in the TTR monomers there is one cysteine residue, it is important to determine unambiguously the redox state of sulfur present in the fibrils. Sulfur 215-221 transthyretin Homo sapiens 109-112 12538647-7 2003 Whereas in the soluble proteins the thiol group from cysteine (R-SH) and the thioether group from methionine (R-S-CH(3)) are the most abundant forms, in the TTR fibrils there is a significant oxidation of sulfur to the sulfonate form in the cysteine residue and a partial oxidation of sulfur to sulfoxide in the methionine residues. Sulfides 77-86 transthyretin Homo sapiens 157-160 12538647-7 2003 Whereas in the soluble proteins the thiol group from cysteine (R-SH) and the thioether group from methionine (R-S-CH(3)) are the most abundant forms, in the TTR fibrils there is a significant oxidation of sulfur to the sulfonate form in the cysteine residue and a partial oxidation of sulfur to sulfoxide in the methionine residues. Methionine 98-108 transthyretin Homo sapiens 157-160 12538647-7 2003 Whereas in the soluble proteins the thiol group from cysteine (R-SH) and the thioether group from methionine (R-S-CH(3)) are the most abundant forms, in the TTR fibrils there is a significant oxidation of sulfur to the sulfonate form in the cysteine residue and a partial oxidation of sulfur to sulfoxide in the methionine residues. r-s-ch 110-116 transthyretin Homo sapiens 157-160 12538647-7 2003 Whereas in the soluble proteins the thiol group from cysteine (R-SH) and the thioether group from methionine (R-S-CH(3)) are the most abundant forms, in the TTR fibrils there is a significant oxidation of sulfur to the sulfonate form in the cysteine residue and a partial oxidation of sulfur to sulfoxide in the methionine residues. Sulfur 205-211 transthyretin Homo sapiens 157-160 12538647-7 2003 Whereas in the soluble proteins the thiol group from cysteine (R-SH) and the thioether group from methionine (R-S-CH(3)) are the most abundant forms, in the TTR fibrils there is a significant oxidation of sulfur to the sulfonate form in the cysteine residue and a partial oxidation of sulfur to sulfoxide in the methionine residues. sulfonate 219-228 transthyretin Homo sapiens 157-160 12538647-7 2003 Whereas in the soluble proteins the thiol group from cysteine (R-SH) and the thioether group from methionine (R-S-CH(3)) are the most abundant forms, in the TTR fibrils there is a significant oxidation of sulfur to the sulfonate form in the cysteine residue and a partial oxidation of sulfur to sulfoxide in the methionine residues. Cysteine 241-249 transthyretin Homo sapiens 157-160 12538647-7 2003 Whereas in the soluble proteins the thiol group from cysteine (R-SH) and the thioether group from methionine (R-S-CH(3)) are the most abundant forms, in the TTR fibrils there is a significant oxidation of sulfur to the sulfonate form in the cysteine residue and a partial oxidation of sulfur to sulfoxide in the methionine residues. Sulfur 285-291 transthyretin Homo sapiens 157-160 12538647-7 2003 Whereas in the soluble proteins the thiol group from cysteine (R-SH) and the thioether group from methionine (R-S-CH(3)) are the most abundant forms, in the TTR fibrils there is a significant oxidation of sulfur to the sulfonate form in the cysteine residue and a partial oxidation of sulfur to sulfoxide in the methionine residues. sulfoxide 295-304 transthyretin Homo sapiens 157-160 12538647-7 2003 Whereas in the soluble proteins the thiol group from cysteine (R-SH) and the thioether group from methionine (R-S-CH(3)) are the most abundant forms, in the TTR fibrils there is a significant oxidation of sulfur to the sulfonate form in the cysteine residue and a partial oxidation of sulfur to sulfoxide in the methionine residues. Methionine 312-322 transthyretin Homo sapiens 157-160 12553418-5 2002 Late in the 1960s it was learned that TBPA also carries vitamin A in the circulation by interacting with retinol-binding protein (RBP). Vitamin A 56-65 transthyretin Homo sapiens 38-42 12553418-6 2002 TBPA then was renamed transthyretin (TTR), in recognition of its dual transport function, and it was shown that retinol-RBP-TTR interactions are mutually enhancing. Vitamin A 112-119 transthyretin Homo sapiens 0-4 12553418-6 2002 TBPA then was renamed transthyretin (TTR), in recognition of its dual transport function, and it was shown that retinol-RBP-TTR interactions are mutually enhancing. Vitamin A 112-119 transthyretin Homo sapiens 124-127 12553418-9 2002 Seizing on this discovery, structural biologists are now investigating why mutated TTR changes from a compact, soluble molecule into a fibrillar, insoluble polymer, and how this pathological transformation might be prevented. Polymers 156-163 transthyretin Homo sapiens 83-86 12553420-5 2002 Thyroxine-binding globulin (TBG), TTR and albumin form a "buffering" system for plasma [T4] because of their overlapping affinities and on/off rates for L-thyroxine (T4)-binding. Thyroxine 153-164 transthyretin Homo sapiens 34-37 12553422-1 2002 Transthyretin (TTR) is a 55 kDa protein responsible for the transport of thyroid hormones and retinol in human serum. Vitamin A 94-101 transthyretin Homo sapiens 0-13 12557756-2 2002 Congo red staining of vitrectomy specimens revealed that the vitreous fluid contained amyloid fibrils, which were strongly positive for immunohistochemical staining using anti-human TTR antiserum. Congo Red 0-9 transthyretin Homo sapiens 182-185 12553422-1 2002 Transthyretin (TTR) is a 55 kDa protein responsible for the transport of thyroid hormones and retinol in human serum. Vitamin A 94-101 transthyretin Homo sapiens 15-18 12557756-3 2002 DNA analysis of the TTR gene showed a G to T transversion at the second nucleotide of codon 41, indicating a replacement of tryptophan (TGG) by leucine (TTG). Tryptophan 124-134 transthyretin Homo sapiens 20-23 12553422-6 2002 The synthetic protein was folded and assembled to a tetrameric structure in the presence of the TTR"s native ligand, thyroxine, as shown by gel filtration chromatography, native gel electrophoresis, TTR antibody recognition and thyroid hormone binding. Thyroxine 117-126 transthyretin Homo sapiens 96-99 12553422-6 2002 The synthetic protein was folded and assembled to a tetrameric structure in the presence of the TTR"s native ligand, thyroxine, as shown by gel filtration chromatography, native gel electrophoresis, TTR antibody recognition and thyroid hormone binding. Thyroxine 117-126 transthyretin Homo sapiens 199-202 12553423-1 2002 Transthyretin (TTR), formerly called prealbumin, one of the transporters of the hormone thyroxine and retinol-binding protein (RBP), the specific carrier of vitamin A, forms, under physiological conditions, a macromolecular complex that prevents glomerular filtration of the low-molecular-weight RBP in the kidneys. Thyroxine 88-97 transthyretin Homo sapiens 0-13 12557756-3 2002 DNA analysis of the TTR gene showed a G to T transversion at the second nucleotide of codon 41, indicating a replacement of tryptophan (TGG) by leucine (TTG). GAMMA-GLUTAMYL-S-(1,2-DICARBOXYETHYL)CYSTEINYLGLYCINE 136-139 transthyretin Homo sapiens 20-23 12553423-1 2002 Transthyretin (TTR), formerly called prealbumin, one of the transporters of the hormone thyroxine and retinol-binding protein (RBP), the specific carrier of vitamin A, forms, under physiological conditions, a macromolecular complex that prevents glomerular filtration of the low-molecular-weight RBP in the kidneys. Thyroxine 88-97 transthyretin Homo sapiens 15-18 12557756-3 2002 DNA analysis of the TTR gene showed a G to T transversion at the second nucleotide of codon 41, indicating a replacement of tryptophan (TGG) by leucine (TTG). Leucine 144-151 transthyretin Homo sapiens 20-23 12553423-1 2002 Transthyretin (TTR), formerly called prealbumin, one of the transporters of the hormone thyroxine and retinol-binding protein (RBP), the specific carrier of vitamin A, forms, under physiological conditions, a macromolecular complex that prevents glomerular filtration of the low-molecular-weight RBP in the kidneys. Vitamin A 157-166 transthyretin Homo sapiens 0-13 12557756-3 2002 DNA analysis of the TTR gene showed a G to T transversion at the second nucleotide of codon 41, indicating a replacement of tryptophan (TGG) by leucine (TTG). Hydrotopotecan 153-156 transthyretin Homo sapiens 20-23 12553423-1 2002 Transthyretin (TTR), formerly called prealbumin, one of the transporters of the hormone thyroxine and retinol-binding protein (RBP), the specific carrier of vitamin A, forms, under physiological conditions, a macromolecular complex that prevents glomerular filtration of the low-molecular-weight RBP in the kidneys. Vitamin A 157-166 transthyretin Homo sapiens 15-18 12557757-4 2002 Sequencing of the patient"s DNA revealed the substitution of A for T at the second position of codon 55 of the TTR gene indicating an amino acid change from leucine to glutamine. Leucine 157-164 transthyretin Homo sapiens 111-114 12557757-4 2002 Sequencing of the patient"s DNA revealed the substitution of A for T at the second position of codon 55 of the TTR gene indicating an amino acid change from leucine to glutamine. Glutamine 168-177 transthyretin Homo sapiens 111-114 12553424-1 2002 Structure-activity data show that many pharmacological agents are strong competitive inhibitors for thyroxine (T4) binding to transthyretin (TTR) and that this competition can interfere with their normal pharmacological actions. Thyroxine 100-109 transthyretin Homo sapiens 141-144 12553424-5 2002 Analysis of TTR crystal complexes with several classes of competitors (hormone metabolites, flavonoids, fluorescent probes, analgesics and cardiac agents) revealed multiple modes of binding with both forward and reverse ligand binding orientations. Flavonoids 92-102 transthyretin Homo sapiens 12-15 12553424-7 2002 Data for the human TTR complex with the bromoflavone EMD21388 incubated at different times revealed variable binding positions and occupancies dependent upon incubation time. 4h-1-benzopyran-4-one,3-bromo-2-phenyl- 40-52 transthyretin Homo sapiens 19-22 12553430-5 2002 The discovery of the role of prealbumin in retinol binding led to a change in its name, prealbumin becoming transthyretin. Vitamin A 43-50 transthyretin Homo sapiens 108-121 12553432-9 2002 Despite distinct etiopathogenic mechanisms, TTR concentrations appear to reflect the loss or gain of TBN in body pools and they predict later outcome in malnutrition and in conditions of acute and/or chronic inflammation. 2-Propanamine, 2-methyl-N-[(3,5,6-trimethyl-2-pyrazinyl)methylene]-, N-oxide 101-104 transthyretin Homo sapiens 44-47 12553436-2 2002 Elevated serum transthyretin during renal insufficiency is secondary to the lack of retinol-binding protein degradation in renal tubules and to the subsequent increase in the fraction of transthyretin bound to retinol-binding protein. Vitamin A 84-91 transthyretin Homo sapiens 15-28 12553436-2 2002 Elevated serum transthyretin during renal insufficiency is secondary to the lack of retinol-binding protein degradation in renal tubules and to the subsequent increase in the fraction of transthyretin bound to retinol-binding protein. Vitamin A 210-217 transthyretin Homo sapiens 15-28 12553436-2 2002 Elevated serum transthyretin during renal insufficiency is secondary to the lack of retinol-binding protein degradation in renal tubules and to the subsequent increase in the fraction of transthyretin bound to retinol-binding protein. Vitamin A 210-217 transthyretin Homo sapiens 187-200 12553437-9 2002 We found significantly lower transthyretin levels in alcohol-related CPthan in other forms (18.5 +/- 8.3 vs. 30.2 +/- 5.7, p < 0.01). Alcohols 53-60 transthyretin Homo sapiens 29-42 12553437-9 2002 We found significantly lower transthyretin levels in alcohol-related CPthan in other forms (18.5 +/- 8.3 vs. 30.2 +/- 5.7, p < 0.01). cpthan 69-75 transthyretin Homo sapiens 29-42 12403615-0 2002 Disulfide-bond formation in the transthyretin mutant Y114C prevents amyloid fibril formation in vivo and in vitro. Disulfides 0-9 transthyretin Homo sapiens 32-45 12414539-11 2002 We observed that these TTR deposits mimic the toxic effect of TTR deposits in FAP: animals with TTR deposition, present approximately twofold increased levels of nitrotyrosine in sites related to deposition. 3-nitrotyrosine 162-175 transthyretin Homo sapiens 23-26 12414539-11 2002 We observed that these TTR deposits mimic the toxic effect of TTR deposits in FAP: animals with TTR deposition, present approximately twofold increased levels of nitrotyrosine in sites related to deposition. 3-nitrotyrosine 162-175 transthyretin Homo sapiens 62-65 12414539-11 2002 We observed that these TTR deposits mimic the toxic effect of TTR deposits in FAP: animals with TTR deposition, present approximately twofold increased levels of nitrotyrosine in sites related to deposition. 3-nitrotyrosine 162-175 transthyretin Homo sapiens 62-65 12468608-0 2002 Determination of a cut-off value for the molar ratio of retinol-binding protein to transthyretin (RBP:TTR) in Bangladeshi patients with low hepatic vitamin A stores. Vitamin A 148-157 transthyretin Homo sapiens 102-105 12468608-1 2002 The purpose of this study was to determine a cut-off value of the molar ratio of retinol-binding protein to transthyretin (RBP:TTR) to indicate marginal vitamin A (VA) deficiency. Vitamin A 153-162 transthyretin Homo sapiens 127-130 12468608-1 2002 The purpose of this study was to determine a cut-off value of the molar ratio of retinol-binding protein to transthyretin (RBP:TTR) to indicate marginal vitamin A (VA) deficiency. Vitamin A 164-166 transthyretin Homo sapiens 127-130 12403615-3 2002 Furthermore, we demonstrate in vitro that the ATTR Y114C mutant exists in three forms: one unstable but nativelike tetrameric form, one highly aggregated form in which a network of disulfide bonds is formed, and one fibrillar form. Disulfides 181-190 transthyretin Homo sapiens 46-50 12403615-6 2002 In a previous study, we have linked exposure of this epitope in TTR to a three-residue shift in beta-strand D. The X-ray crystallographic structure of reduced tetrameric ATTR Y114C shows a structure similar to that of the wild type but with a more buried position of Cys10 and with beta-mercaptoethanol associated with Cys114, verifying the strong tendency for this residue to form disulfide bonds. Mercaptoethanol 282-302 transthyretin Homo sapiens 64-67 12403615-6 2002 In a previous study, we have linked exposure of this epitope in TTR to a three-residue shift in beta-strand D. The X-ray crystallographic structure of reduced tetrameric ATTR Y114C shows a structure similar to that of the wild type but with a more buried position of Cys10 and with beta-mercaptoethanol associated with Cys114, verifying the strong tendency for this residue to form disulfide bonds. Mercaptoethanol 282-302 transthyretin Homo sapiens 170-174 12403615-6 2002 In a previous study, we have linked exposure of this epitope in TTR to a three-residue shift in beta-strand D. The X-ray crystallographic structure of reduced tetrameric ATTR Y114C shows a structure similar to that of the wild type but with a more buried position of Cys10 and with beta-mercaptoethanol associated with Cys114, verifying the strong tendency for this residue to form disulfide bonds. Disulfides 382-391 transthyretin Homo sapiens 64-67 12403615-6 2002 In a previous study, we have linked exposure of this epitope in TTR to a three-residue shift in beta-strand D. The X-ray crystallographic structure of reduced tetrameric ATTR Y114C shows a structure similar to that of the wild type but with a more buried position of Cys10 and with beta-mercaptoethanol associated with Cys114, verifying the strong tendency for this residue to form disulfide bonds. Disulfides 382-391 transthyretin Homo sapiens 170-174 12403615-7 2002 Combined with the ex vivo data, our in vitro findings suggest that ATTR Y114C can lead to disease either by forming regular unbranched amyloid fibrils or by forming disulfide-linked aggregates that maintain amyloid-like properties but are unable to form regular amyloid fibrils. Disulfides 165-174 transthyretin Homo sapiens 67-71 11972452-2 2002 TbpA is highly conserved among meningococcal strains, and is thought to be a porin-like integral protein that functions as a gated channel for the passage of iron into the periplasm. Iron 158-162 transthyretin Homo sapiens 0-4 12151632-1 2002 Earlier studies at our laboratory indicated that several hydroxylated polychlorinated biphenyls (OH-PCBs) detected in human blood could specifically inhibit thyroxine (T(4)) transport by competitive binding to the thyroid hormone transport protein transthyretin (TTR) in vitro. Polychlorinated Biphenyls 70-95 transthyretin Homo sapiens 248-261 12151632-1 2002 Earlier studies at our laboratory indicated that several hydroxylated polychlorinated biphenyls (OH-PCBs) detected in human blood could specifically inhibit thyroxine (T(4)) transport by competitive binding to the thyroid hormone transport protein transthyretin (TTR) in vitro. Polychlorinated Biphenyls 70-95 transthyretin Homo sapiens 263-266 12151632-1 2002 Earlier studies at our laboratory indicated that several hydroxylated polychlorinated biphenyls (OH-PCBs) detected in human blood could specifically inhibit thyroxine (T(4)) transport by competitive binding to the thyroid hormone transport protein transthyretin (TTR) in vitro. oh-pcbs 97-104 transthyretin Homo sapiens 248-261 12151632-1 2002 Earlier studies at our laboratory indicated that several hydroxylated polychlorinated biphenyls (OH-PCBs) detected in human blood could specifically inhibit thyroxine (T(4)) transport by competitive binding to the thyroid hormone transport protein transthyretin (TTR) in vitro. oh-pcbs 97-104 transthyretin Homo sapiens 263-266 12151632-1 2002 Earlier studies at our laboratory indicated that several hydroxylated polychlorinated biphenyls (OH-PCBs) detected in human blood could specifically inhibit thyroxine (T(4)) transport by competitive binding to the thyroid hormone transport protein transthyretin (TTR) in vitro. Thyroxine 157-166 transthyretin Homo sapiens 248-261 12151632-1 2002 Earlier studies at our laboratory indicated that several hydroxylated polychlorinated biphenyls (OH-PCBs) detected in human blood could specifically inhibit thyroxine (T(4)) transport by competitive binding to the thyroid hormone transport protein transthyretin (TTR) in vitro. Thyroxine 157-166 transthyretin Homo sapiens 263-266 12095258-0 2002 Native state hydrogen exchange study of suppressor and pathogenic variants of transthyretin. Hydrogen 13-21 transthyretin Homo sapiens 78-91 11560492-6 2001 M-TTR exhibits stability toward acid and urea denaturation that is nearly identical to that characterizing wild-type (WT) TTR at low concentrations (0.01-0.1 mg/mL), where monomeric WT TTR is significantly populated at intermediate urea concentrations prior to the tertiary structural transition. Urea 41-45 transthyretin Homo sapiens 2-5 12039669-1 2002 A 70-year-old Japanese man with amyloid polyneuropathy associated with a Val 107 transthyretin (TTR) mutation is reported. val 107 73-80 transthyretin Homo sapiens 96-99 12039669-3 2002 DNA analysis of the TTR gene revealed a point mutation responsible for substitution of valine for isoleucine at position 107 of the TTR molecule. Valine 87-93 transthyretin Homo sapiens 20-23 12039669-3 2002 DNA analysis of the TTR gene revealed a point mutation responsible for substitution of valine for isoleucine at position 107 of the TTR molecule. Valine 87-93 transthyretin Homo sapiens 132-135 12039669-3 2002 DNA analysis of the TTR gene revealed a point mutation responsible for substitution of valine for isoleucine at position 107 of the TTR molecule. Isoleucine 98-108 transthyretin Homo sapiens 20-23 12039669-3 2002 DNA analysis of the TTR gene revealed a point mutation responsible for substitution of valine for isoleucine at position 107 of the TTR molecule. Isoleucine 98-108 transthyretin Homo sapiens 132-135 12039669-5 2002 This case implies a worldwide distribution of the Val 107 TTR mutation with a common clinical phenotype, despite different ethnic background. Valine 50-53 transthyretin Homo sapiens 58-61 12440486-3 2002 In plasma, TTR circulates as a homotetramer and transports the hormone thyroxine and the retinol-binding protein-vitamin A complex. Thyroxine 71-80 transthyretin Homo sapiens 11-14 12440486-3 2002 In plasma, TTR circulates as a homotetramer and transports the hormone thyroxine and the retinol-binding protein-vitamin A complex. Vitamin A 113-122 transthyretin Homo sapiens 11-14 11913969-0 2002 Inhibition of transthyretin amyloid fibril formation by 2,4-dinitrophenol through tetramer stabilization. 2,4-Dinitrophenol 56-73 transthyretin Homo sapiens 14-27 11913969-5 2002 The effect of small water-soluble, hydrophobic ligand 2,4-dinitrophenol (2,4-DNP) on TTR amyloid formation has been tested. Water 20-25 transthyretin Homo sapiens 85-88 11913969-5 2002 The effect of small water-soluble, hydrophobic ligand 2,4-dinitrophenol (2,4-DNP) on TTR amyloid formation has been tested. 2,4-Dinitrophenol 54-71 transthyretin Homo sapiens 85-88 11913969-5 2002 The effect of small water-soluble, hydrophobic ligand 2,4-dinitrophenol (2,4-DNP) on TTR amyloid formation has been tested. 2,4-Dinitrophenol 73-80 transthyretin Homo sapiens 85-88 11913969-6 2002 2,4-DNP binds to TTR both at acidic and physiological pH, as shown by the quenching of TTR intrinsic fluorescence. 2,4-Dinitrophenol 0-7 transthyretin Homo sapiens 17-20 11913969-6 2002 2,4-DNP binds to TTR both at acidic and physiological pH, as shown by the quenching of TTR intrinsic fluorescence. 2,4-Dinitrophenol 0-7 transthyretin Homo sapiens 87-90 11913969-7 2002 Interestingly, 2,4-DNP not only binds to TTR at acidic pH but also inhibits amyloid fibril formation as shown by the light scattering and Congo red-binding assay. 2,4-Dinitrophenol 15-22 transthyretin Homo sapiens 41-44 11913969-8 2002 Inhibition of fibril formation by 2,4-DNP appears to be through the stabilization of TTR tetramer upon binding to the protein, which includes active site. 2,4-Dinitrophenol 34-41 transthyretin Homo sapiens 85-88 12000196-0 2002 Familial amyloid polyneuropathy with genetic anticipation associated to a gly47glu transthyretin variant in an Italian kindred. gly47glu 74-82 transthyretin Homo sapiens 83-96 12000196-4 2002 This paper deals with a point mutation in exon 2 position 47 of the TTR gene, encoding the substitution of glycine with glutamate. Glycine 107-114 transthyretin Homo sapiens 68-71 12000196-4 2002 This paper deals with a point mutation in exon 2 position 47 of the TTR gene, encoding the substitution of glycine with glutamate. Glutamic Acid 120-129 transthyretin Homo sapiens 68-71 14987380-1 2002 Transthyretin (TTR) is a transport protein for thyroid hormones and vitamin A and might have an important role in the nervous system. Vitamin A 68-77 transthyretin Homo sapiens 0-13 14987380-1 2002 Transthyretin (TTR) is a transport protein for thyroid hormones and vitamin A and might have an important role in the nervous system. Vitamin A 68-77 transthyretin Homo sapiens 15-18 11955017-2 2002 The TTR Leu55Pro variant occurs in the most aggressive forms of this disease. leu55pro 8-16 transthyretin Homo sapiens 4-7 11955017-11 2002 The in vitro system operating at physiological pH for TTR Leu55Pro and the model presented for the molecular arrangement of TTR monomers within fibrils may, therefore, describe early fibril assembly events in vivo. leu55pro 58-66 transthyretin Homo sapiens 54-57 11907422-0 2002 Presence of autoantibody against ATTR Val30Met after sequential liver transplantation. val30met 38-46 transthyretin Homo sapiens 33-37 11907422-7 2002 In addition, the presence of an autoantibody against ATTR Val30Met was evaluated via ELISA using purified ATTR Val30Met from homozygotic FAP patients" sera. val30met 58-66 transthyretin Homo sapiens 53-57 11907422-7 2002 In addition, the presence of an autoantibody against ATTR Val30Met was evaluated via ELISA using purified ATTR Val30Met from homozygotic FAP patients" sera. val30met 111-119 transthyretin Homo sapiens 53-57 11907422-7 2002 In addition, the presence of an autoantibody against ATTR Val30Met was evaluated via ELISA using purified ATTR Val30Met from homozygotic FAP patients" sera. val30met 111-119 transthyretin Homo sapiens 106-110 12071453-11 2002 RESULTS: Primary risk factors in the development of CTS are: being a woman of menopausal age, obesity or lack of fitness, diabetes or having a family history of diabetes, osteoarthritis of the carpometacarpal joint of the thumb, smoking, and lifetime alcohol intake. Alcohols 251-258 transthyretin Homo sapiens 52-55 12071453-15 2002 It would also relieve individuals of the responsibility of addressing correctable lifestyle factors and treatable illnesses such as obesity, diabetes, smoking and increased alcohol intake which may have contributed to their CTS more that their work. Alcohols 173-180 transthyretin Homo sapiens 224-227 11866053-2 2002 In plasma, TTR exists as a tetramer and binds the hormone thyroxine and the retinol-binding protein-vitamin A complex. Thyroxine 58-67 transthyretin Homo sapiens 11-14 11866053-2 2002 In plasma, TTR exists as a tetramer and binds the hormone thyroxine and the retinol-binding protein-vitamin A complex. Vitamin A 76-83 transthyretin Homo sapiens 11-14 11866053-2 2002 In plasma, TTR exists as a tetramer and binds the hormone thyroxine and the retinol-binding protein-vitamin A complex. Vitamin A 100-109 transthyretin Homo sapiens 11-14 11812437-0 2002 Transthyretin Ser-44 mutation in a case with vitreous amyloidosis. Serine 14-17 transthyretin Homo sapiens 0-13 11812437-1 2002 PURPOSE: To report a case of vitreous amyloidosis associated with a transthyretin Ser-44 mutation. Serine 82-85 transthyretin Homo sapiens 68-81 11812437-8 2002 Direct sequencing of the transthyretin gene revealed a single base-pair substitution, which results in an amino acid substitution at position 44, phenylalanine to serine (transthyretin Ser-44). Phenylalanine 146-159 transthyretin Homo sapiens 25-38 11812437-8 2002 Direct sequencing of the transthyretin gene revealed a single base-pair substitution, which results in an amino acid substitution at position 44, phenylalanine to serine (transthyretin Ser-44). Phenylalanine 146-159 transthyretin Homo sapiens 171-184 11812437-8 2002 Direct sequencing of the transthyretin gene revealed a single base-pair substitution, which results in an amino acid substitution at position 44, phenylalanine to serine (transthyretin Ser-44). Serine 163-169 transthyretin Homo sapiens 25-38 11812437-8 2002 Direct sequencing of the transthyretin gene revealed a single base-pair substitution, which results in an amino acid substitution at position 44, phenylalanine to serine (transthyretin Ser-44). Serine 163-169 transthyretin Homo sapiens 171-184 11812437-8 2002 Direct sequencing of the transthyretin gene revealed a single base-pair substitution, which results in an amino acid substitution at position 44, phenylalanine to serine (transthyretin Ser-44). Serine 185-188 transthyretin Homo sapiens 25-38 11812437-8 2002 Direct sequencing of the transthyretin gene revealed a single base-pair substitution, which results in an amino acid substitution at position 44, phenylalanine to serine (transthyretin Ser-44). Serine 185-188 transthyretin Homo sapiens 171-184 11870693-1 2002 We report a 52-year-old woman with a novel transthyretin (TTR) variant serine replacing alanine at residue 25 [Ala25Ser (Serine 25)], who showed a unique clinical picture with a relatively acute onset neuropathy within a few days of an influenza vaccination, progressing to a severe degree within 2 years. Serine 121-127 transthyretin Homo sapiens 43-56 11870693-1 2002 We report a 52-year-old woman with a novel transthyretin (TTR) variant serine replacing alanine at residue 25 [Ala25Ser (Serine 25)], who showed a unique clinical picture with a relatively acute onset neuropathy within a few days of an influenza vaccination, progressing to a severe degree within 2 years. Serine 121-127 transthyretin Homo sapiens 58-61 11784137-0 2002 Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. Diclofenac 38-48 transthyretin Homo sapiens 62-75 11784137-1 2002 Twelve analogues of diclofenac (1), a nonsteroidal antiinflammatory drug and known inhibitor of transthyretin (TTR) amyloid formation, were prepared and evaluated as TTR amyloid formation inhibitors. Diclofenac 20-30 transthyretin Homo sapiens 96-109 11784137-1 2002 Twelve analogues of diclofenac (1), a nonsteroidal antiinflammatory drug and known inhibitor of transthyretin (TTR) amyloid formation, were prepared and evaluated as TTR amyloid formation inhibitors. Diclofenac 20-30 transthyretin Homo sapiens 111-114 11560493-2 2001 The two symmetrical anion interaction sites in TTR are comprised of residues Lys15 and Lys15" from opposing subunits on the periphery of the two thyroxine binding sites. Thyroxine 145-154 transthyretin Homo sapiens 47-50 11560493-4 2001 Chaotrope denaturation of TTR exhibits unusual behavior in that urea appears to be a stronger denaturant than GdmCl (guanidinium chloride), even though GdmCl is typically twice as powerful as a denaturant. Urea 64-68 transthyretin Homo sapiens 26-29 11560493-4 2001 Chaotrope denaturation of TTR exhibits unusual behavior in that urea appears to be a stronger denaturant than GdmCl (guanidinium chloride), even though GdmCl is typically twice as powerful as a denaturant. Guanidine 110-115 transthyretin Homo sapiens 26-29 11560493-4 2001 Chaotrope denaturation of TTR exhibits unusual behavior in that urea appears to be a stronger denaturant than GdmCl (guanidinium chloride), even though GdmCl is typically twice as powerful as a denaturant. Guanidine 117-137 transthyretin Homo sapiens 26-29 11560493-4 2001 Chaotrope denaturation of TTR exhibits unusual behavior in that urea appears to be a stronger denaturant than GdmCl (guanidinium chloride), even though GdmCl is typically twice as powerful as a denaturant. Guanidine 152-157 transthyretin Homo sapiens 26-29 11560493-5 2001 The shift in the midpoint of the urea denaturation curve to higher concentrations as well as the increase in the mole fraction of tetramer that is highly resistant to denaturation with increasing KCl concentration provides strong evidence that anion shielding stabilizes the TTR tetramer. Potassium Chloride 196-199 transthyretin Homo sapiens 275-278 11409037-1 2001 Transthyretin (TTR) is a plasma protein that transports thyroid hormone and retinol binding protein-vitamin A complex. Vitamin A 100-109 transthyretin Homo sapiens 0-13 11479223-8 2001 This is because Ad-CTS1 promotes neither caspase activation nor mitochondrial cytochrome c release and because the caspase inhibitors, z-val-Ala-DL-Asp-fluoromethylketone (zVAD)-fmk or z-Ile-Glu-Thr-Asp- fluoromethylketone (z-IETD)-fmk, do not block CTS1-induced cell death. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 172-176 transthyretin Homo sapiens 250-254 11306576-9 2001 Additionally, the soluble aggregates formed by the amyloidogenic TTR variants showed morphological and thioflavin-T fluorescence properties characteristic of amyloid. thioflavin T 103-115 transthyretin Homo sapiens 65-68 11518010-0 2001 Low cardiac 123I-MIBG uptake in late-onset familial amyloid polyneuropathy type I (TTR Met30). 3-Iodobenzylguanidine 17-21 transthyretin Homo sapiens 83-86 11352912-1 2001 Transthyretin is an essential protein responsible for the transport of thyroid hormones and retinol in human serum and is also implicated in the amyloid diseases familial amyloidotic polyneuropathy and senile systemic amyloidosis. Vitamin A 92-99 transthyretin Homo sapiens 0-13 11352912-5 2001 The synthetic protein was folded and assembled to a tetrameric structure in the presence of transthyretin"s native ligand, thyroxine, as shown by gel filtration chromatography, native gel electrophoresis, transthyretin antibody recognition, and thyroid hormone binding. Thyroxine 123-132 transthyretin Homo sapiens 92-105 11352912-5 2001 The synthetic protein was folded and assembled to a tetrameric structure in the presence of transthyretin"s native ligand, thyroxine, as shown by gel filtration chromatography, native gel electrophoresis, transthyretin antibody recognition, and thyroid hormone binding. Thyroxine 123-132 transthyretin Homo sapiens 205-218 11445644-3 2001 Brain specimens showed that the leptomeningeal vessels walls were thickened by amyloid deposits, and sequencing of the TTR exons showed a heterozygous single base-pair transition from G to A (codon 53), resulting in a glycine for glutamic acid substitution (G53E). Glycine 218-225 transthyretin Homo sapiens 119-122 11445644-3 2001 Brain specimens showed that the leptomeningeal vessels walls were thickened by amyloid deposits, and sequencing of the TTR exons showed a heterozygous single base-pair transition from G to A (codon 53), resulting in a glycine for glutamic acid substitution (G53E). Glutamic Acid 230-243 transthyretin Homo sapiens 119-122 11418763-8 2001 The electron-density maps revealed residual thyroxine (T(4)) bound in only one of the two unique tetrameric TTR molecules, with an occupancy of 53%, while the second tetramer is unliganded. Thyroxine 44-53 transthyretin Homo sapiens 108-111 11409037-1 2001 Transthyretin (TTR) is a plasma protein that transports thyroid hormone and retinol binding protein-vitamin A complex. Vitamin A 100-109 transthyretin Homo sapiens 15-18 11294981-7 2001 CSF TTR concentrations, however, were inversely associated with CSF Pb concentrations (r = -0.29, p < 0.05). Lead 68-70 transthyretin Homo sapiens 4-7 11385707-4 2001 Among these are mutations responsible for hyperthyroxinemia, presenting high affinity for thyroxine (a TTR ligand). Thyroxine 47-56 transthyretin Homo sapiens 103-106 11294981-10 2001 Unlike TTR, CSF RBP concentrations were not influenced by PB: These human data are consistent with our earlier observations in animals, which suggest that TTR is required for thyroxine transport in the CSF and that Pb exposure is likely associated with diminished TTR levels in the CSF. Thyroxine 175-184 transthyretin Homo sapiens 155-158 11294981-10 2001 Unlike TTR, CSF RBP concentrations were not influenced by PB: These human data are consistent with our earlier observations in animals, which suggest that TTR is required for thyroxine transport in the CSF and that Pb exposure is likely associated with diminished TTR levels in the CSF. Thyroxine 175-184 transthyretin Homo sapiens 155-158 11995999-4 2001 The position of the dibromoflavone in the B/D site is similar to that reported for dibromoaurone in human TTR. dibromoflavone 20-34 transthyretin Homo sapiens 106-109 11278770-2 2001 Transthyretin (TTR) is a plasma carrier of thyroxine and retinol-binding protein (RBP). Thyroxine 43-52 transthyretin Homo sapiens 15-18 11291357-10 2001 Naproxen treatment, irrespective of type of operation, did not require rescue analgesics, while two patients after CTS treated with paracetamol did. Acetaminophen 132-143 transthyretin Homo sapiens 115-118 11243784-3 2001 In order to understand this effect, we have determined the structures of the TTR Val30Met/Thr119Met double mutant isolated from the serum of one patient and of both the native and thyroxine complex of TTR Thr119Met. Thyroxine 180-189 transthyretin Homo sapiens 201-204 11230714-0 2001 A case of late onset cardiac amyloidosis with a new transthyretin variant (lysine 92). Lysine 75-81 transthyretin Homo sapiens 52-65 11036082-8 2001 However, human retinol-RBP injected intravenously was more rapidly cleared from the circulation (t(12) = 0.5 h for TTR(-) versus t(12) >6 h for WT) and accumulated faster in the kidneys of TTR(-) compared with WT mice. Vitamin A 15-22 transthyretin Homo sapiens 115-118 11036082-8 2001 However, human retinol-RBP injected intravenously was more rapidly cleared from the circulation (t(12) = 0.5 h for TTR(-) versus t(12) >6 h for WT) and accumulated faster in the kidneys of TTR(-) compared with WT mice. Vitamin A 15-22 transthyretin Homo sapiens 192-195 11995999-4 2001 The position of the dibromoflavone in the B/D site is similar to that reported for dibromoaurone in human TTR. dibromoaurone 83-96 transthyretin Homo sapiens 106-109 11995999-7 2001 The C3* methyl group of EMD21388 mediates the bridging interactions between two TTR subunits in the P2 pockets. 3-methyl-4',6-dihydroxy-3',5'-dibromoflavone 24-32 transthyretin Homo sapiens 80-83 11135445-8 2001 The affinity of transthyretin for thyroxine increased and that for triiodothyronine decreased during evolution. Thyroxine 34-43 transthyretin Homo sapiens 16-29 11083823-3 2000 can sequester iron from this protein, dependent upon two iron-repressible, transferrin-binding proteins (TbpA and TbpB). Iron 14-18 transthyretin Homo sapiens 105-109 11162459-0 2000 Inhibition of transthyretin-met30 expression using Inosine(15.1)-Hammerhead ribozymes in cell culture. Inosine 51-58 transthyretin Homo sapiens 14-27 11162459-3 2000 The most common mutation is the val30met mutation in the transthyretin protein (TTR-met30) caused by a mononucleic substitution from G to A (GUC to AUC) in the transthyretin gene resulting in the exchange for the amino acids valine to methionine in the corresponding protein sequence. val30met 32-40 transthyretin Homo sapiens 57-70 11162459-3 2000 The most common mutation is the val30met mutation in the transthyretin protein (TTR-met30) caused by a mononucleic substitution from G to A (GUC to AUC) in the transthyretin gene resulting in the exchange for the amino acids valine to methionine in the corresponding protein sequence. val30met 32-40 transthyretin Homo sapiens 80-83 11162459-3 2000 The most common mutation is the val30met mutation in the transthyretin protein (TTR-met30) caused by a mononucleic substitution from G to A (GUC to AUC) in the transthyretin gene resulting in the exchange for the amino acids valine to methionine in the corresponding protein sequence. val30met 32-40 transthyretin Homo sapiens 160-173 11162459-3 2000 The most common mutation is the val30met mutation in the transthyretin protein (TTR-met30) caused by a mononucleic substitution from G to A (GUC to AUC) in the transthyretin gene resulting in the exchange for the amino acids valine to methionine in the corresponding protein sequence. Valine 225-231 transthyretin Homo sapiens 57-70 11162459-3 2000 The most common mutation is the val30met mutation in the transthyretin protein (TTR-met30) caused by a mononucleic substitution from G to A (GUC to AUC) in the transthyretin gene resulting in the exchange for the amino acids valine to methionine in the corresponding protein sequence. Valine 225-231 transthyretin Homo sapiens 80-83 11162459-3 2000 The most common mutation is the val30met mutation in the transthyretin protein (TTR-met30) caused by a mononucleic substitution from G to A (GUC to AUC) in the transthyretin gene resulting in the exchange for the amino acids valine to methionine in the corresponding protein sequence. Valine 225-231 transthyretin Homo sapiens 160-173 11162459-3 2000 The most common mutation is the val30met mutation in the transthyretin protein (TTR-met30) caused by a mononucleic substitution from G to A (GUC to AUC) in the transthyretin gene resulting in the exchange for the amino acids valine to methionine in the corresponding protein sequence. Methionine 235-245 transthyretin Homo sapiens 57-70 11162459-3 2000 The most common mutation is the val30met mutation in the transthyretin protein (TTR-met30) caused by a mononucleic substitution from G to A (GUC to AUC) in the transthyretin gene resulting in the exchange for the amino acids valine to methionine in the corresponding protein sequence. Methionine 235-245 transthyretin Homo sapiens 80-83 11162459-3 2000 The most common mutation is the val30met mutation in the transthyretin protein (TTR-met30) caused by a mononucleic substitution from G to A (GUC to AUC) in the transthyretin gene resulting in the exchange for the amino acids valine to methionine in the corresponding protein sequence. Methionine 235-245 transthyretin Homo sapiens 160-173 11162459-5 2000 We showed previously that chemically modified nuclease stable Inosine(15.1)-Hammerhead ribozymes are able to target the TTR-met30 mRNA with high specificity on the RNA level (Biochem. Inosine 62-69 transthyretin Homo sapiens 120-123 11162459-12 2000 We cleaved the TTR-met30 and hnTTR mRNA with specific nuclease stable chemically modified Inosine(15.1)-Hammerhead ribozymes and analyzed the protein after immunoprecipitation and subsequent Western blotting. Inosine 90-97 transthyretin Homo sapiens 15-18 10982792-3 2000 In the present study we observed that TTR, the transporter of both T(4) and retinol-binding protein, binds to megalin, the multiligand receptor expressed on the luminal surface of various epithelia including the renal proximal tubules. Vitamin A 76-83 transthyretin Homo sapiens 38-41 10982792-6 2000 Radiolabeled TTR, free as well as in complex with thyroxine or retinol-binding protein, was rapidly taken up by the cells, and the uptake was strongly inhibited by a polyclonal megalin antibody and by the receptor-associated protein, a chaperone-like protein inhibiting ligand binding to megalin. Thyroxine 50-59 transthyretin Homo sapiens 13-16 10982792-6 2000 Radiolabeled TTR, free as well as in complex with thyroxine or retinol-binding protein, was rapidly taken up by the cells, and the uptake was strongly inhibited by a polyclonal megalin antibody and by the receptor-associated protein, a chaperone-like protein inhibiting ligand binding to megalin. Vitamin A 63-70 transthyretin Homo sapiens 13-16 11083823-3 2000 can sequester iron from this protein, dependent upon two iron-repressible, transferrin-binding proteins (TbpA and TbpB). Iron 57-61 transthyretin Homo sapiens 105-109 11083823-9 2000 These data implicate putative loops 4 and 5 as critical determinants for receptor function and transferrin-iron uptake by gonococcal TbpA. Iron 107-111 transthyretin Homo sapiens 133-137 10998371-0 2000 The molecular interaction of 4"-iodo-4"-deoxydoxorubicin with Leu-55Pro transthyretin "amyloid-like" oligomer leading to disaggregation. 4'-deoxy-4'-iododoxorubicin 29-56 transthyretin Homo sapiens 72-85 11058748-1 2000 Transthyretin (TTR, formerly called prealbumin), one of the transporters of the hormone thyroxine and the lipocalin retinol-binding protein (RBP), the specific carrier of the vitamin, are known to form, under physiological conditions, a macromolecular complex that is believed to play an important physiological role: prevention of glomerular filtration of the low molecular weight RBP in the kidneys. Thyroxine 88-97 transthyretin Homo sapiens 0-13 11058748-1 2000 Transthyretin (TTR, formerly called prealbumin), one of the transporters of the hormone thyroxine and the lipocalin retinol-binding protein (RBP), the specific carrier of the vitamin, are known to form, under physiological conditions, a macromolecular complex that is believed to play an important physiological role: prevention of glomerular filtration of the low molecular weight RBP in the kidneys. Thyroxine 88-97 transthyretin Homo sapiens 15-18 11054291-0 2000 Deuterium-proton exchange on the native wild-type transthyretin tetramer identifies the stable core of the individual subunits and indicates mobility at the subunit interface. Deuterium 0-9 transthyretin Homo sapiens 50-63 10998371-15 2000 In this model the IDOX iodine atom is buried in a pocket located between the two beta-sheets of the Leu-55Pro TTR monomer with the IDOX aromatic-moiety long axis nearly perpendicular to the direction of the beta-sheets. idox iodine 18-29 transthyretin Homo sapiens 110-113 10966644-2 2000 In this study, we used hydrogen exchange measurements to show that there is selective destabilization of one half of the beta-sandwich structure of TTR under such conditions. Hydrogen 23-31 transthyretin Homo sapiens 148-151 10957627-0 2000 Structure of human transthyretin complexed with bromophenols: a new mode of binding. bromophenols 48-60 transthyretin Homo sapiens 19-32 10957627-1 2000 The binding of two organohalogen substances, pentabromophenol (PBP) and 2,4,6-tribromophenol (TBP), to human transthyretin (TTR), a thyroid hormone transport protein, has been studied by in vitro competitive binding assays and by X-ray crystallography. pentabromophenol 45-61 transthyretin Homo sapiens 109-122 10957627-1 2000 The binding of two organohalogen substances, pentabromophenol (PBP) and 2,4,6-tribromophenol (TBP), to human transthyretin (TTR), a thyroid hormone transport protein, has been studied by in vitro competitive binding assays and by X-ray crystallography. pentabromophenol 45-61 transthyretin Homo sapiens 124-127 10957627-1 2000 The binding of two organohalogen substances, pentabromophenol (PBP) and 2,4,6-tribromophenol (TBP), to human transthyretin (TTR), a thyroid hormone transport protein, has been studied by in vitro competitive binding assays and by X-ray crystallography. pentabromophenol 63-66 transthyretin Homo sapiens 109-122 10957627-1 2000 The binding of two organohalogen substances, pentabromophenol (PBP) and 2,4,6-tribromophenol (TBP), to human transthyretin (TTR), a thyroid hormone transport protein, has been studied by in vitro competitive binding assays and by X-ray crystallography. pentabromophenol 63-66 transthyretin Homo sapiens 124-127 10957627-1 2000 The binding of two organohalogen substances, pentabromophenol (PBP) and 2,4,6-tribromophenol (TBP), to human transthyretin (TTR), a thyroid hormone transport protein, has been studied by in vitro competitive binding assays and by X-ray crystallography. 2,4,6-tribromophenol 72-92 transthyretin Homo sapiens 109-122 10957627-1 2000 The binding of two organohalogen substances, pentabromophenol (PBP) and 2,4,6-tribromophenol (TBP), to human transthyretin (TTR), a thyroid hormone transport protein, has been studied by in vitro competitive binding assays and by X-ray crystallography. 2,4,6-tribromophenol 72-92 transthyretin Homo sapiens 124-127 10957627-1 2000 The binding of two organohalogen substances, pentabromophenol (PBP) and 2,4,6-tribromophenol (TBP), to human transthyretin (TTR), a thyroid hormone transport protein, has been studied by in vitro competitive binding assays and by X-ray crystallography. 2,4,6-tribromophenol 94-97 transthyretin Homo sapiens 109-122 10957627-1 2000 The binding of two organohalogen substances, pentabromophenol (PBP) and 2,4,6-tribromophenol (TBP), to human transthyretin (TTR), a thyroid hormone transport protein, has been studied by in vitro competitive binding assays and by X-ray crystallography. 2,4,6-tribromophenol 94-97 transthyretin Homo sapiens 124-127 10957627-2 2000 Both compounds bind to TTR with high affinity, in competition with the natural ligand thyroxine (T(4)). Thyroxine 86-95 transthyretin Homo sapiens 23-26 10957627-7 2000 The interactions with the halogens are smaller in number in TTR-TBP and there is a decrease in affinity, even though the interaction with the hydroxyl group is stronger than that in the TTR-PBP complex. 2,4,6-tribromophenol 64-67 transthyretin Homo sapiens 60-63 10957627-7 2000 The interactions with the halogens are smaller in number in TTR-TBP and there is a decrease in affinity, even though the interaction with the hydroxyl group is stronger than that in the TTR-PBP complex. 2,4,6-tribromophenol 64-67 transthyretin Homo sapiens 186-189 11017772-2 2000 TTR is also indirectly implicated in the carriage of vitamin A through the mediation of retinol-binding protein (RBP). Vitamin A 53-62 transthyretin Homo sapiens 0-3 10899879-1 2000 Transferrin-iron utilization involves specific binding of human transferrin at the cell surface to what is believed to be a complex of two iron-regulated, transferrin-binding proteins, TbpA and TbpB. Iron 12-16 transthyretin Homo sapiens 185-189 10899879-1 2000 Transferrin-iron utilization involves specific binding of human transferrin at the cell surface to what is believed to be a complex of two iron-regulated, transferrin-binding proteins, TbpA and TbpB. Iron 139-143 transthyretin Homo sapiens 185-189 11062844-1 2000 The aim of this study was to evaluate the effects of local steroid injection on both the clinical symptoms and motor and sensory conduction of the median nerve in carpal tunnel syndrome (CTS). Steroids 59-66 transthyretin Homo sapiens 187-190 10908640-5 2000 Transthyretin was identified by thyroxine binding and Western analysis in the blood of adult shrews, hedgehogs, and moles. Thyroxine 32-41 transthyretin Homo sapiens 0-13 10869517-1 2000 Transthyretin (TTR) is involved in the transport of thyroxine (T4) and retinol-binding protein (RBP) in cerebrospinal fluid (CSF) and serum. Thyroxine 52-61 transthyretin Homo sapiens 15-18 10869517-7 2000 Endocytosis of TTR was inhibited by high sucrose concentration (0.45 M). Sucrose 41-48 transthyretin Homo sapiens 15-18 10869457-2 2000 Because these compounds have some structural resemblance to the thyroid hormone thyroxine (T(4)), it was suggested that they may interfere with thyroid hormone metabolism and transport, e.g., by competition with T(4) on transthyretin (TTR). Thyroxine 80-89 transthyretin Homo sapiens 220-233 10869457-2 2000 Because these compounds have some structural resemblance to the thyroid hormone thyroxine (T(4)), it was suggested that they may interfere with thyroid hormone metabolism and transport, e.g., by competition with T(4) on transthyretin (TTR). Thyroxine 80-89 transthyretin Homo sapiens 235-238 10869457-9 2000 These results indicate that brominated flame retardants, especially the brominated phenols and tetrabromobisphenol A, are very potent competitors for T(4) binding to human transthyretin in vitro and may have effects on thyroid hormone homeostasis in vivo comparable to the thyroid-disrupting effects of PCBs. Phenols 83-90 transthyretin Homo sapiens 172-185 10869457-9 2000 These results indicate that brominated flame retardants, especially the brominated phenols and tetrabromobisphenol A, are very potent competitors for T(4) binding to human transthyretin in vitro and may have effects on thyroid hormone homeostasis in vivo comparable to the thyroid-disrupting effects of PCBs. tetrabromobisphenol A 95-116 transthyretin Homo sapiens 172-185 10869457-9 2000 These results indicate that brominated flame retardants, especially the brominated phenols and tetrabromobisphenol A, are very potent competitors for T(4) binding to human transthyretin in vitro and may have effects on thyroid hormone homeostasis in vivo comparable to the thyroid-disrupting effects of PCBs. Polychlorinated Biphenyls 303-307 transthyretin Homo sapiens 172-185 10842718-7 2000 This transversion results in an amino acid substitution at codon 45, alanine to serine (ATTR Ala45Ser). Alanine 69-76 transthyretin Homo sapiens 88-92 10842718-7 2000 This transversion results in an amino acid substitution at codon 45, alanine to serine (ATTR Ala45Ser). Serine 80-86 transthyretin Homo sapiens 88-92 10742177-5 2000 Using a structure-based drug design approach ortho-trifluormethylphenyl anthranilic acid and N-(meta-trifluoromethylphenyl) phenoxazine 4, 6-dicarboxylic acid have been discovered to be very potent and specific TTR fibril formation inhibitors. ortho-trifluormethylphenyl anthranilic acid 45-88 transthyretin Homo sapiens 211-214 10854215-0 2000 4"-Iodo-4"-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. 4'-deoxy-4'-iododoxorubicin 0-27 transthyretin Homo sapiens 64-77 10854215-7 2000 We investigated 1) whether I-DOX has affinity for TTR amyloid in tissues, 2) determined the I-DOX binding constants to TTR synthetic fibrils, and 3) determined the nature of the effect of I-DOX on TTR fibrils. 4'-deoxy-4'-iododoxorubicin 27-32 transthyretin Homo sapiens 50-53 10854215-7 2000 We investigated 1) whether I-DOX has affinity for TTR amyloid in tissues, 2) determined the I-DOX binding constants to TTR synthetic fibrils, and 3) determined the nature of the effect of I-DOX on TTR fibrils. 4'-deoxy-4'-iododoxorubicin 92-97 transthyretin Homo sapiens 119-122 10854215-7 2000 We investigated 1) whether I-DOX has affinity for TTR amyloid in tissues, 2) determined the I-DOX binding constants to TTR synthetic fibrils, and 3) determined the nature of the effect of I-DOX on TTR fibrils. 4'-deoxy-4'-iododoxorubicin 92-97 transthyretin Homo sapiens 119-122 10854215-7 2000 We investigated 1) whether I-DOX has affinity for TTR amyloid in tissues, 2) determined the I-DOX binding constants to TTR synthetic fibrils, and 3) determined the nature of the effect of I-DOX on TTR fibrils. 4'-deoxy-4'-iododoxorubicin 92-97 transthyretin Homo sapiens 119-122 10854215-7 2000 We investigated 1) whether I-DOX has affinity for TTR amyloid in tissues, 2) determined the I-DOX binding constants to TTR synthetic fibrils, and 3) determined the nature of the effect of I-DOX on TTR fibrils. 4'-deoxy-4'-iododoxorubicin 92-97 transthyretin Homo sapiens 119-122 10854215-9 2000 These data support the hypothesis that I-DOX and less toxic derivatives can prove efficient in the treatment of TTR-related amyloidosis. 4'-deoxy-4'-iododoxorubicin 39-44 transthyretin Homo sapiens 112-115 10869412-1 2000 The isoflavones tectoridin (TTR) and 3"-hydroxy TTR (3"-TTR) were isolated from an Ayurvedic herbal preparation Vaca and evaluated for their affinity and effect on ryanodine receptors (RyR) using junctional sarcoplasmic reticulum vesicles (JSRVs). tectoridin 16-26 transthyretin Homo sapiens 28-31 10869412-2 2000 In [(3)H]ryanodine displacement binding affinity assays, TTR and 3"-TTR exhibited IC(50) values of 17.3 +/- 1.3 microM (K(d) = 6.7 +/- 0.4 microM) and 6.6 +/- 1.4 microM (K(d) = 2.4 +/- 0.2 microM), respectively, for fast skeletal muscle RyR (RyR1) compared with an IC(50) value for ryanodine of 6.2 +/- 0.4 nM (K(d) = 2.4 nM). Ryanodine 9-18 transthyretin Homo sapiens 57-71 10869412-2 2000 In [(3)H]ryanodine displacement binding affinity assays, TTR and 3"-TTR exhibited IC(50) values of 17.3 +/- 1.3 microM (K(d) = 6.7 +/- 0.4 microM) and 6.6 +/- 1.4 microM (K(d) = 2.4 +/- 0.2 microM), respectively, for fast skeletal muscle RyR (RyR1) compared with an IC(50) value for ryanodine of 6.2 +/- 0.4 nM (K(d) = 2.4 nM). Ryanodine 283-292 transthyretin Homo sapiens 57-71 10742545-0 2000 Effect of sildenafil citrate (Viagra) on erectile dysfunction in a patient with familial amyloidotic polyneuropathy ATTR Val30Met. Sildenafil Citrate 10-28 transthyretin Homo sapiens 116-120 10742545-1 2000 A 34-year-old male patient with familial amyloidotic polyneuropathy (FAP) amyloidogenic transthyretin (ATTR) Valine30Methionine (Val30Met), who underwent a liver transplantation in Sweden in 1994, was treated with sildenafil citrate (Viagra) to ameliorate his erectile dysfunction (ED). Sildenafil Citrate 214-232 transthyretin Homo sapiens 103-107 10742545-1 2000 A 34-year-old male patient with familial amyloidotic polyneuropathy (FAP) amyloidogenic transthyretin (ATTR) Valine30Methionine (Val30Met), who underwent a liver transplantation in Sweden in 1994, was treated with sildenafil citrate (Viagra) to ameliorate his erectile dysfunction (ED). Sildenafil Citrate 234-240 transthyretin Homo sapiens 103-107 10759156-1 2000 Serum transthyretin has several isoforms, most of which are caused by disulfide linkage with cysteine residue at position 10. Disulfides 70-79 transthyretin Homo sapiens 6-19 10759156-1 2000 Serum transthyretin has several isoforms, most of which are caused by disulfide linkage with cysteine residue at position 10. Cysteine 93-101 transthyretin Homo sapiens 6-19 10841549-4 2000 Native TTR tetramers (T(4)) were denatured by high pressure into a conformation that exposes tryptophan residues to the aqueous environment. Tryptophan 93-103 transthyretin Homo sapiens 7-10 19078583-5 2000 The use of MRI for guiding treatment deosions in individuals with clinical signs and symptoms of CTS but with normal electrodiagnostic studies remains undetermined. deosions 37-45 transthyretin Homo sapiens 97-100 10869412-6 2000 In calcium efflux assays, TTR (up to 1 mM) enhanced the release of (45)Ca(2+) from JSRVs in a concentration-dependent manner (EC(50act) of 750 microM). Calcium 3-10 transthyretin Homo sapiens 26-29 10869412-9 2000 Using passive calcium influx assays, TTR activated and deactivated RyR1 in a time- and concentration-dependent manner. Calcium 14-21 transthyretin Homo sapiens 37-40 10953676-1 2000 The ratio plasma retinol-binding protein (RBP):transthyretin (TTR) has been proposed as a means to improve the assessment of vitamin A status of individuals with concurrent infection or inflammation. Vitamin A 125-134 transthyretin Homo sapiens 62-65 10953676-6 2000 The RBP:TTR value was significantly decreased by both illness and low liver retinol stores. Vitamin A 76-83 transthyretin Homo sapiens 8-11 10953676-12 2000 Overall, although a trend supporting the theory behind the use of the RBP:TTR for assessment of vitamin A status in infection was observed in the current study, the ratio did not provide adequate sensitivity and specificity to be a useful assessment tool. Vitamin A 96-105 transthyretin Homo sapiens 74-77 10742177-5 2000 Using a structure-based drug design approach ortho-trifluormethylphenyl anthranilic acid and N-(meta-trifluoromethylphenyl) phenoxazine 4, 6-dicarboxylic acid have been discovered to be very potent and specific TTR fibril formation inhibitors. n-(meta-trifluoromethylphenyl) phenoxazine 4, 6-dicarboxylic acid 93-158 transthyretin Homo sapiens 211-214 10718550-1 2000 The slow clearance, prolonged half-life, and high serum concentration of thyroxine (T4) are largely due to strong binding by the principal plasma thyroid hormone-binding proteins, thyroxine-binding globulin (TBG), transthyretin (TTR), and albumin. Thyroxine 73-82 transthyretin Homo sapiens 214-227 10675660-4 2000 After incubation with the antibody, the samples were passed through a 1000 kDa cut off centrifugal concentrator to retain the antibody, thereafter, the filtrate was analyzed by ESI-MS. Several forms of normal and variant TTR were detected in the serum samples: unconjugated TTR, cysteine and cysteine-glycine conjugated TTR. Cysteine 279-287 transthyretin Homo sapiens 221-224 10675660-4 2000 After incubation with the antibody, the samples were passed through a 1000 kDa cut off centrifugal concentrator to retain the antibody, thereafter, the filtrate was analyzed by ESI-MS. Several forms of normal and variant TTR were detected in the serum samples: unconjugated TTR, cysteine and cysteine-glycine conjugated TTR. cysteine-glycine 292-308 transthyretin Homo sapiens 221-224 10834537-0 2000 Familial amyloidotic polyneuropathy (ATTR Ser50Ile): the first autopsy case report. ser50ile 42-50 transthyretin Homo sapiens 37-41 10834537-1 2000 We report an autopsy case of a pedigree of familial amyloidotic polyneuropathy (FAP) with a mutation of isoleucine-50 transthyretin (ATTR Ser50Ile). ser50ile 138-146 transthyretin Homo sapiens 133-137 10842705-3 2000 Direct DNA sequencing showed both a normal GAG (Glu) and a variant AAG (Lys) codon at amino acid position 89 of mature TTR, which has not been previously reported. Lysine 72-75 transthyretin Homo sapiens 119-122 10718550-1 2000 The slow clearance, prolonged half-life, and high serum concentration of thyroxine (T4) are largely due to strong binding by the principal plasma thyroid hormone-binding proteins, thyroxine-binding globulin (TBG), transthyretin (TTR), and albumin. Thyroxine 73-82 transthyretin Homo sapiens 229-232 10677864-1 2000 We describe two Italian first cousins with familial amyloidotic polyneuropathy associated with transthyretin variant consisting of the substitution of alanine for glycine at codon 47 (TTR Ala-47), from a family with a history of cardiac failure. Alanine 188-191 transthyretin Homo sapiens 184-187 10677864-4 2000 Since a similar clinical picture has been described in another Italian family, the cardiac involvement must be regarded as a salient and early feature of the TTR Ala-47 mutation. Alanine 162-165 transthyretin Homo sapiens 158-161 11111990-0 2000 Long-term results of liver transplantation in four siblings from the same family with familial amyloidotic polyneuropathy type I TTR Ala-71. Alanine 133-136 transthyretin Homo sapiens 129-132 10631123-13 2000 The binding potencies of ortho-PCBs to TTR may represent a signature SAR that predicts specific biologic/toxic effects. Polychlorinated Biphenyls 30-35 transthyretin Homo sapiens 39-42 10639416-5 2000 Of these transformants, only B16B6(Str(r))/tbpA(ap)B(ap) could grow in the presence of porcine transferrin as the sole iron source, achieving a growth rate similar to that of the B16B6 parent strain in the presence of human transferrin. Iron 119-123 transthyretin Homo sapiens 43-47 11111990-3 2000 The four siblings are alive 2-5 years after LT. After the operation, the seriated determinations of TTR-Ala-71 variant showed a constant decrease in serum levels in all cases. Alanine 104-107 transthyretin Homo sapiens 100-103 10611949-5 1999 Direct genomic DNA sequencing of TTR exon 2 showed both adenine and cytosine in the position corresponding to the second base of codon 38. Adenine 56-63 transthyretin Homo sapiens 33-36 10551861-4 1999 In certain forms of FAP, the amyloid fibrils are mostly constituted by variants of transthyretin (TTR), a homotetrameric plasma protein implicated in the transport of thyroxine and retinol. Thyroxine 167-176 transthyretin Homo sapiens 83-96 10551861-4 1999 In certain forms of FAP, the amyloid fibrils are mostly constituted by variants of transthyretin (TTR), a homotetrameric plasma protein implicated in the transport of thyroxine and retinol. Thyroxine 167-176 transthyretin Homo sapiens 98-101 10551861-4 1999 In certain forms of FAP, the amyloid fibrils are mostly constituted by variants of transthyretin (TTR), a homotetrameric plasma protein implicated in the transport of thyroxine and retinol. Vitamin A 181-188 transthyretin Homo sapiens 83-96 10551861-4 1999 In certain forms of FAP, the amyloid fibrils are mostly constituted by variants of transthyretin (TTR), a homotetrameric plasma protein implicated in the transport of thyroxine and retinol. Vitamin A 181-188 transthyretin Homo sapiens 98-101 10518788-9 1999 Scatchard analysis revealed that masu salmon transthyretin possesses a single class of binding site for L-3,5,3"-triiodothyronine, with a Kd of 13.8 nM at 0 degrees C. Taken together with the data reported by Chang et al. Triiodothyronine 104-129 transthyretin Homo sapiens 45-58 10531234-5 1999 In vitro growth studies, comparing all three mutants, demonstrated that the tbpA mutant and the tbpAB mutant were severely limited in their ability to grow with human holotransferrin as the sole source of iron. Iron 205-209 transthyretin Homo sapiens 76-80 10531234-9 1999 These data suggest that the M. catarrhalis TbpA is necessary for the acquisition of iron from transferrin. Iron 84-88 transthyretin Homo sapiens 43-47 10521263-7 1999 The L55P-TTR protofilaments formed in vitro bind Congo red and thioflavin T (albeit more weakly than the fibrils produced at acidic pH), suggesting that the structure observed probably represents an amyloid precursor. Congo Red 49-58 transthyretin Homo sapiens 9-12 10521263-7 1999 The L55P-TTR protofilaments formed in vitro bind Congo red and thioflavin T (albeit more weakly than the fibrils produced at acidic pH), suggesting that the structure observed probably represents an amyloid precursor. thioflavin T 63-75 transthyretin Homo sapiens 9-12 10611949-5 1999 Direct genomic DNA sequencing of TTR exon 2 showed both adenine and cytosine in the position corresponding to the second base of codon 38. Cytosine 68-76 transthyretin Homo sapiens 33-36 10489791-8 1999 The aims of the study were to identify carriers and non-carriers of the mutant transthyretin methionine 111 linked familial amyloid disease, to detect early signs of the restrictive cardiomyopathy and other clinical manifestations of this disease. Methionine 93-103 transthyretin Homo sapiens 79-92 10659375-2 1999 In this study combined infusion therapy with procain, pentoxyphyllin and magnesium sulphuricum in patients with CTS was evaluated retrospectively. Procaine 45-52 transthyretin Homo sapiens 112-115 10659375-2 1999 In this study combined infusion therapy with procain, pentoxyphyllin and magnesium sulphuricum in patients with CTS was evaluated retrospectively. Pentoxifylline 54-68 transthyretin Homo sapiens 112-115 10659375-2 1999 In this study combined infusion therapy with procain, pentoxyphyllin and magnesium sulphuricum in patients with CTS was evaluated retrospectively. Magnesium 73-82 transthyretin Homo sapiens 112-115 10489791-11 1999 Twenty-five persons were heterozygous carriers of the mutant transthyretin methionine 111 genotype, while 74 were non-carriers. Methionine 75-85 transthyretin Homo sapiens 61-74 10524282-2 1999 We have analyzed wild-type and variant TTRs by mass spectrometry and found that TTR preparations from all individuals demonstrated free TTR, TTR conjugated with thiol compounds and several minor components. Sulfhydryl Compounds 161-166 transthyretin Homo sapiens 80-83 10524282-2 1999 We have analyzed wild-type and variant TTRs by mass spectrometry and found that TTR preparations from all individuals demonstrated free TTR, TTR conjugated with thiol compounds and several minor components. Sulfhydryl Compounds 161-166 transthyretin Homo sapiens 80-83 10524282-3 1999 We previously described a component which had a molecular mass 80 Da larger than free TTR and was proved to be TTR conjugated with sulfite. Sulfites 131-138 transthyretin Homo sapiens 86-89 10524282-3 1999 We previously described a component which had a molecular mass 80 Da larger than free TTR and was proved to be TTR conjugated with sulfite. Sulfites 131-138 transthyretin Homo sapiens 111-114 10524282-4 1999 Here, the amyloid fibril formation of the TTR isoforms was monitored by the turbidity at 330 nm, and by a Congo red-binding assay as a function of pH, according to the method of Lai et al. Congo Red 106-115 transthyretin Homo sapiens 42-45 10524282-6 1999 In contrast, TTR reduced by dithiothreitol, which was free of the S-sulfonated component, showed neither elevation of the turbidity nor the Congo red binding. Dithiothreitol 28-42 transthyretin Homo sapiens 13-16 10524283-0 1999 Impact of age and amyloidosis on thiol conjugation of transthyretin in hereditary transthyretin amyloidosis. Sulfhydryl Compounds 33-38 transthyretin Homo sapiens 54-67 10524283-2 1999 The aim of the present study was to investigate thiol conjugation of transthyretin and it"s relation to age and symptomatic amyloid disease in different populations of variant TTR carriers. Sulfhydryl Compounds 48-53 transthyretin Homo sapiens 69-82 10524283-2 1999 The aim of the present study was to investigate thiol conjugation of transthyretin and it"s relation to age and symptomatic amyloid disease in different populations of variant TTR carriers. Sulfhydryl Compounds 48-53 transthyretin Homo sapiens 176-179 10524283-4 1999 The percentage cysteine (Cys) conjugated wild and variant TTR were calculated from the corresponding peaks of the spectra, and multiple regression analysis was employed to disclose relationships between age, symptomatic amyloid disease and origin. Cysteine 25-28 transthyretin Homo sapiens 58-61 10524283-7 1999 In summary: Thiol conjugation of TTR is dependent on age and presence of symptomatic amyloid disease. Sulfhydryl Compounds 12-17 transthyretin Homo sapiens 33-36 10524283-9 1999 Variant TTR is more susceptible to thiol conjugation than the wild type. Sulfhydryl Compounds 35-40 transthyretin Homo sapiens 8-11 10541593-3 1999 Using isoelectric focusing in urea gradients we were able to demonstrate a stabilizing effect of sulfite on TTR monomers and tetramers, as well as an increase in the tetramer/monomer ratio. Sulfites 97-104 transthyretin Homo sapiens 108-111 10403767-0 1999 Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation. Inosine 0-7 transthyretin Homo sapiens 53-66 10500684-0 1999 Long-term results of liver transplantation in four siblings from the same family with familial amyloidotic polyneuropathy type I TTR ALA-71. Alanine 133-136 transthyretin Homo sapiens 129-132 10449136-3 1999 Sequencing revealed G to A transition in the codon 54 causing TTR Lys 54. Lysine 66-69 transthyretin Homo sapiens 62-65 10403767-1 1999 The most common cause of hereditary amyloidosis (HA) is the val30met mutation in the transthyretin protein (TTR-met30). val30met 60-68 transthyretin Homo sapiens 85-98 10403767-1 1999 The most common cause of hereditary amyloidosis (HA) is the val30met mutation in the transthyretin protein (TTR-met30). val30met 60-68 transthyretin Homo sapiens 108-111 10403767-2 1999 The mutation is caused by a mononucleic substitution from G to A (GUC to AUC) in the transthyretin gene resulting in the exchange for the amino acids valine to methionine in the corresponding protein sequence. Valine 150-156 transthyretin Homo sapiens 85-98 10403767-2 1999 The mutation is caused by a mononucleic substitution from G to A (GUC to AUC) in the transthyretin gene resulting in the exchange for the amino acids valine to methionine in the corresponding protein sequence. Methionine 160-170 transthyretin Homo sapiens 85-98 10403767-9 1999 In vitro experiments with TTR-30 mRNA demonstrated that the RNase stable inosine(15.1) hammerhead ribozyme cleaved the TTR-30 mRNA with 100% specificity and with a velocity of 0.23 min(-1), whereas no cleavage occured in the wildtype mRNA of TTR. Inosine 73-80 transthyretin Homo sapiens 26-29 10403767-9 1999 In vitro experiments with TTR-30 mRNA demonstrated that the RNase stable inosine(15.1) hammerhead ribozyme cleaved the TTR-30 mRNA with 100% specificity and with a velocity of 0.23 min(-1), whereas no cleavage occured in the wildtype mRNA of TTR. Inosine 73-80 transthyretin Homo sapiens 119-122 10403767-9 1999 In vitro experiments with TTR-30 mRNA demonstrated that the RNase stable inosine(15.1) hammerhead ribozyme cleaved the TTR-30 mRNA with 100% specificity and with a velocity of 0.23 min(-1), whereas no cleavage occured in the wildtype mRNA of TTR. Inosine 73-80 transthyretin Homo sapiens 119-122 10465408-0 1999 Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Flufenamic Acid 125-140 transthyretin Homo sapiens 42-55 10465408-4 1999 The ring or fused ring system occupying the outermost TTR binding pocket needs to be substituted with an acidic functional group (e.g. a carboxylic acid) to interact with complimentary charges in the TTR binding site. Carboxylic Acids 137-152 transthyretin Homo sapiens 54-57 10465408-4 1999 The ring or fused ring system occupying the outermost TTR binding pocket needs to be substituted with an acidic functional group (e.g. a carboxylic acid) to interact with complimentary charges in the TTR binding site. Carboxylic Acids 137-152 transthyretin Homo sapiens 200-203 10424456-0 1999 Electrically neutral microheterogeneity of human plasma transthyretin (prealbumin) detected by isoelectric focusing in urea gradients. Urea 119-123 transthyretin Homo sapiens 56-69 10439118-4 1999 The two peaks showing -57, and -157 (or 156) Da from ATTR Val30Met corresponded to the -Gly, and -Gly-Pro sequences of ATTR Val30Met from the N-terminal. Glycine 88-91 transthyretin Homo sapiens 53-57 10424456-6 1999 We demonstrate that the normal TTR monomer exists in different forms of variable stability and/or charge due to binding of sulfhydryls from plasma to the unique cysteine at position 10 of the primary structure as well as due to modification by treatment with an oxidant. Sulfhydryl Compounds 123-134 transthyretin Homo sapiens 31-34 10336646-0 1999 1H-NMR structural studies of a cystine-linked peptide containing residues 71-93 of transthyretin and effects of a Ser84 substitution implicated in familial amyloidotic polyneuropathy. Hydrogen 0-2 transthyretin Homo sapiens 83-96 10424456-6 1999 We demonstrate that the normal TTR monomer exists in different forms of variable stability and/or charge due to binding of sulfhydryls from plasma to the unique cysteine at position 10 of the primary structure as well as due to modification by treatment with an oxidant. Cysteine 161-169 transthyretin Homo sapiens 31-34 10424456-8 1999 The conformational changes of TTR induced by isoelectric focusing in a urea gradient were found to be associated by a gain of three positive charge units. Urea 71-75 transthyretin Homo sapiens 30-33 10439118-4 1999 The two peaks showing -57, and -157 (or 156) Da from ATTR Val30Met corresponded to the -Gly, and -Gly-Pro sequences of ATTR Val30Met from the N-terminal. Glycine 88-91 transthyretin Homo sapiens 119-123 10439118-4 1999 The two peaks showing -57, and -157 (or 156) Da from ATTR Val30Met corresponded to the -Gly, and -Gly-Pro sequences of ATTR Val30Met from the N-terminal. Glycine 98-101 transthyretin Homo sapiens 53-57 10439118-4 1999 The two peaks showing -57, and -157 (or 156) Da from ATTR Val30Met corresponded to the -Gly, and -Gly-Pro sequences of ATTR Val30Met from the N-terminal. Glycine 98-101 transthyretin Homo sapiens 119-123 10336646-3 1999 The peptide, containing residues 71-93 of transthyretin with its termini linked via a disulfide bond, was found to possess the same helix-turn motif as in the corresponding region of the crystallographically derived structure of transthyretin in 20% trifluoroethanol (TFE) solution. Disulfides 86-95 transthyretin Homo sapiens 42-55 10336646-3 1999 The peptide, containing residues 71-93 of transthyretin with its termini linked via a disulfide bond, was found to possess the same helix-turn motif as in the corresponding region of the crystallographically derived structure of transthyretin in 20% trifluoroethanol (TFE) solution. Disulfides 86-95 transthyretin Homo sapiens 229-242 10336646-3 1999 The peptide, containing residues 71-93 of transthyretin with its termini linked via a disulfide bond, was found to possess the same helix-turn motif as in the corresponding region of the crystallographically derived structure of transthyretin in 20% trifluoroethanol (TFE) solution. Trifluoroethanol 250-266 transthyretin Homo sapiens 42-55 10336646-3 1999 The peptide, containing residues 71-93 of transthyretin with its termini linked via a disulfide bond, was found to possess the same helix-turn motif as in the corresponding region of the crystallographically derived structure of transthyretin in 20% trifluoroethanol (TFE) solution. Trifluoroethanol 250-266 transthyretin Homo sapiens 229-242 10336646-3 1999 The peptide, containing residues 71-93 of transthyretin with its termini linked via a disulfide bond, was found to possess the same helix-turn motif as in the corresponding region of the crystallographically derived structure of transthyretin in 20% trifluoroethanol (TFE) solution. Trifluoroethanol 268-271 transthyretin Homo sapiens 42-55 10336646-3 1999 The peptide, containing residues 71-93 of transthyretin with its termini linked via a disulfide bond, was found to possess the same helix-turn motif as in the corresponding region of the crystallographically derived structure of transthyretin in 20% trifluoroethanol (TFE) solution. Trifluoroethanol 268-271 transthyretin Homo sapiens 229-242 10226117-0 1999 Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant. Tyrosine 137-145 transthyretin Homo sapiens 149-162 10346938-6 1999 Docking studies for the phenoxythiophenes with transthyretin as a receptor model show their preferred attack at the L-T4/L-T3 binding channel. phenoxythiophenes 24-41 transthyretin Homo sapiens 47-60 10085238-1 1999 Neisseria meningitidis, grown in iron-limited conditions, produces two transferrin-binding proteins (TbpA and TbpB) that independently and specifically bind human serum transferrin (hTF) but not bovine serum transferrin (bTF). Iron 33-37 transthyretin Homo sapiens 101-105 10319941-2 1999 The present study is the first to examine and compare salsalate and salicylate binding to human thyroxine-binding globulin (TBG), transthyretin (TTR), albumin (ALB), and whole human serum, and displacement by salsalate and salicylate of T4 from isolated TBG, TTR, ALB. salicylsalicylic acid 54-63 transthyretin Homo sapiens 130-143 10090705-0 1999 Potential mechanisms of thyroid disruption in humans: interaction of organochlorine compounds with thyroid receptor, transthyretin, and thyroid-binding globulin. Hydrocarbons, Chlorinated 69-83 transthyretin Homo sapiens 117-130 10090705-2 1999 Hydroxylated organochlorines have relatively high affinities for the serum transport protein transthyretin, but the ability of these compounds to interact with the human thyroid receptor is unknown. Hydrocarbons, Chlorinated 13-28 transthyretin Homo sapiens 93-106 10090705-7 1999 Because their relative affinity for the receptor was low, we tested the ability of OH-PCBs to interact with the serum transport proteins--transthyretin and thyroid-binding globulin (TBG). oh-pcbs 83-90 transthyretin Homo sapiens 138-151 10090705-8 1999 With the exception of one compound, the OH-PCBs had the same affinity (Ki = 10-80 nM) for transthyretin as thyroid hormone (thyroxine; T4). oh-pcbs 40-47 transthyretin Homo sapiens 90-103 10090705-10 1999 Hydroxylated PCBs have relatively low affinities for the human thyroid receptor in vitro, but they have a thyroid hormonelike affinity for the serum transport protein transthyretin. Polychlorinated Biphenyls 13-17 transthyretin Homo sapiens 167-180 10090705-10 1999 Hydroxylated PCBs have relatively low affinities for the human thyroid receptor in vitro, but they have a thyroid hormonelike affinity for the serum transport protein transthyretin. thyroid hormonelike 106-125 transthyretin Homo sapiens 167-180 10319365-6 1999 Cytokines stimulate liver 5"-DA and suppress the synthesis of transthyretin (TTR), causing the drop of retinol-binding protein (RBP) and the leakage of increased amounts of T4 and retinol in free form. Vitamin A 103-110 transthyretin Homo sapiens 62-75 10319365-6 1999 Cytokines stimulate liver 5"-DA and suppress the synthesis of transthyretin (TTR), causing the drop of retinol-binding protein (RBP) and the leakage of increased amounts of T4 and retinol in free form. Vitamin A 103-110 transthyretin Homo sapiens 77-80 10319365-7 1999 TTR and RBP thus work as prohormonal reservoirs of precursor molecules which need to be converted into bioactive derivatives (T3 and retinoic acids) to reach transcriptional efficiency. t3 and retinoic acids 126-147 transthyretin Homo sapiens 0-3 10319365-12 1999 The production rate of TTR by the liver is the main determinant of both the hepatic release and blood transport of holoRBP, which explains why poor nutritional status concomitantly impairs thyroid- and retinoid-dependent acute-phase responses, hindering the stressed body to appropriately face the survival crisis. holorbp 115-122 transthyretin Homo sapiens 23-26 10319365-12 1999 The production rate of TTR by the liver is the main determinant of both the hepatic release and blood transport of holoRBP, which explains why poor nutritional status concomitantly impairs thyroid- and retinoid-dependent acute-phase responses, hindering the stressed body to appropriately face the survival crisis. Retinoids 202-210 transthyretin Homo sapiens 23-26 10319941-2 1999 The present study is the first to examine and compare salsalate and salicylate binding to human thyroxine-binding globulin (TBG), transthyretin (TTR), albumin (ALB), and whole human serum, and displacement by salsalate and salicylate of T4 from isolated TBG, TTR, ALB. salicylsalicylic acid 54-63 transthyretin Homo sapiens 145-148 10319941-2 1999 The present study is the first to examine and compare salsalate and salicylate binding to human thyroxine-binding globulin (TBG), transthyretin (TTR), albumin (ALB), and whole human serum, and displacement by salsalate and salicylate of T4 from isolated TBG, TTR, ALB. Salicylates 68-78 transthyretin Homo sapiens 130-143 10319941-2 1999 The present study is the first to examine and compare salsalate and salicylate binding to human thyroxine-binding globulin (TBG), transthyretin (TTR), albumin (ALB), and whole human serum, and displacement by salsalate and salicylate of T4 from isolated TBG, TTR, ALB. Salicylates 68-78 transthyretin Homo sapiens 145-148 10319941-4 1999 T4 displacement by salsalate and salicylate from TBG, TTR, and ALB was studied by equilibrium dialysis at salsalate concentrations of 0 to 1.52 mM (0-393 microg/mL) and salicylate concentrations of 0 to 60 mM (0-9600 microg/mL). salicylsalicylic acid 19-28 transthyretin Homo sapiens 54-57 10319941-4 1999 T4 displacement by salsalate and salicylate from TBG, TTR, and ALB was studied by equilibrium dialysis at salsalate concentrations of 0 to 1.52 mM (0-393 microg/mL) and salicylate concentrations of 0 to 60 mM (0-9600 microg/mL). Salicylates 33-43 transthyretin Homo sapiens 54-57 9990446-0 1999 Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. anthranilic acid 28-44 transthyretin Homo sapiens 51-64 10052934-7 1999 Amino acids Trp-67, Phe-96, and Leu-63 and -97 from RBP are flanked by the symmetry-related side chains from TTR. Tryptophan 12-15 transthyretin Homo sapiens 109-112 10052934-7 1999 Amino acids Trp-67, Phe-96, and Leu-63 and -97 from RBP are flanked by the symmetry-related side chains from TTR. Phenylalanine 20-23 transthyretin Homo sapiens 109-112 10052934-10 1999 Complex formation prevents extensive loss of RBP through glomerular filtration, and the loss of Leu-182 and Leu-183 would result in a decreased affinity of RBP for TTR. Leucine 96-99 transthyretin Homo sapiens 164-167 10052934-10 1999 Complex formation prevents extensive loss of RBP through glomerular filtration, and the loss of Leu-182 and Leu-183 would result in a decreased affinity of RBP for TTR. Leucine 108-111 transthyretin Homo sapiens 164-167 10052934-2 1999 Circulating in the plasma, RBP itself is bound to transthyretin (TTR, previously referred to as thyroxine-binding prealbumin). Thyroxine 96-105 transthyretin Homo sapiens 50-63 10052934-2 1999 Circulating in the plasma, RBP itself is bound to transthyretin (TTR, previously referred to as thyroxine-binding prealbumin). Thyroxine 96-105 transthyretin Homo sapiens 65-68 16130282-1 1999 PURPOSE: To evaluate the presence of transthyretin (TTR, prealbumin) a protein which binds retinol to retinol-binding protein in various ocular tissues and to study its quantitative changes in the vitreous humor in various diseases. Vitamin A 91-98 transthyretin Homo sapiens 37-50 16130282-1 1999 PURPOSE: To evaluate the presence of transthyretin (TTR, prealbumin) a protein which binds retinol to retinol-binding protein in various ocular tissues and to study its quantitative changes in the vitreous humor in various diseases. Vitamin A 91-98 transthyretin Homo sapiens 52-55 16130282-1 1999 PURPOSE: To evaluate the presence of transthyretin (TTR, prealbumin) a protein which binds retinol to retinol-binding protein in various ocular tissues and to study its quantitative changes in the vitreous humor in various diseases. Vitamin A 102-109 transthyretin Homo sapiens 37-50 16130282-1 1999 PURPOSE: To evaluate the presence of transthyretin (TTR, prealbumin) a protein which binds retinol to retinol-binding protein in various ocular tissues and to study its quantitative changes in the vitreous humor in various diseases. Vitamin A 102-109 transthyretin Homo sapiens 52-55 9949732-8 1999 A new TTR variant, Ser23-->Asn, was detected and identified using the above method where isoelectric focusing and restriction enzyme analysis failed to identify the nature of the variant. Asparagine 30-33 transthyretin Homo sapiens 6-9 10089423-3 1999 Based on a 2:2:1 stoichiometry for the Fab-retinol-binding-protein-transthyretin complex and the presence of one such complex per asymmetric unit, a reasonable Vm coefficient of 2.74 A3 Da-1 could be estimated. Vitamin A 43-50 transthyretin Homo sapiens 67-80 9914537-7 1999 The affinity of thyroxine binding to transthyretin is lowest in avians (mean Kd of about 30 nm), intermediate in metatherians (mean Kd of about 17 nm) and highest in eutherians (mean Kd of about 11 nm). Thyroxine 16-25 transthyretin Homo sapiens 37-50 10482900-0 1999 Analysis of t-butylphenol acetylene condensed resin with methyl-methine linkages in vulcanized rubber by pyrolysis-gas chromatography/mass spectrometry Methyl-methine linkages of Novolac, a commercially available t-butylphenol acetylene condensed (TBPA) resin, have been identified by recognition of pyrolysis pathways using pyrolysis-gas chromatography/mass spectrometry (Py-GC/mS) in vulcanized rubber. methyl-methine 57-71 transthyretin Homo sapiens 12-45 10482900-0 1999 Analysis of t-butylphenol acetylene condensed resin with methyl-methine linkages in vulcanized rubber by pyrolysis-gas chromatography/mass spectrometry Methyl-methine linkages of Novolac, a commercially available t-butylphenol acetylene condensed (TBPA) resin, have been identified by recognition of pyrolysis pathways using pyrolysis-gas chromatography/mass spectrometry (Py-GC/mS) in vulcanized rubber. methyl-methine 152-166 transthyretin Homo sapiens 12-45 10482900-3 1999 The ion at m/z 192 in the TBPA resin was observed to be characteristic for methyl-methine linkages between the phenolic groups, and the analytical pyrolysis-GC/mS method was thus able to identify the resin at low levels in vulcanized rubber. methyl-methine 75-89 transthyretin Homo sapiens 26-30 9789022-3 1998 Here we demonstrate that flufenamic acid (Flu) inhibits the conformational changes of TTR associated with amyloid fibril formation. Flufenamic Acid 25-40 transthyretin Homo sapiens 86-89 9922152-3 1998 From neutral to slightly acidic conditions (pH 7.5-5.1), wild-type transthyretin (0.2-0.3 mg/mL, 100 mM KCl, 37 degrees C) exists as a tetramer and is incapable of fibril formation. Potassium Chloride 104-107 transthyretin Homo sapiens 67-80 9832644-3 1998 The aim of this study is to investigate whether pentosidine accumulates in the carpal ligament in patients undergoing HD with CTS in comparison with idiopathic CTS. pentosidine 48-59 transthyretin Homo sapiens 126-129 9832644-6 1998 RESULTS: Pentosidine levels in ligament and skin were significantly higher in HD CTS than ID CTS. pentosidine 9-20 transthyretin Homo sapiens 81-84 9832644-6 1998 RESULTS: Pentosidine levels in ligament and skin were significantly higher in HD CTS than ID CTS. pentosidine 9-20 transthyretin Homo sapiens 93-96 9832644-10 1998 CONCLUSION: A greater concentration of pentosidine in the carpal ligament in HD patients compared with idiopathic patients suggests that an accumulation of AGEs contributes to one of the pathologies of occurrence of CTS in patients undergoing HD. pentosidine 39-50 transthyretin Homo sapiens 216-219 9789022-3 1998 Here we demonstrate that flufenamic acid (Flu) inhibits the conformational changes of TTR associated with amyloid fibril formation. Flufenamic Acid 42-45 transthyretin Homo sapiens 86-89 9789022-4 1998 The crystal structure of TTR complexed with Flu demonstrates that Flu mediates intersubunit hydrophobic interactions and intersubunit hydrogen bonds that stabilize the normal tetrameric fold of TTR. Flufenamic Acid 44-47 transthyretin Homo sapiens 25-28 9789022-4 1998 The crystal structure of TTR complexed with Flu demonstrates that Flu mediates intersubunit hydrophobic interactions and intersubunit hydrogen bonds that stabilize the normal tetrameric fold of TTR. Flufenamic Acid 44-47 transthyretin Homo sapiens 194-197 9789022-4 1998 The crystal structure of TTR complexed with Flu demonstrates that Flu mediates intersubunit hydrophobic interactions and intersubunit hydrogen bonds that stabilize the normal tetrameric fold of TTR. Flufenamic Acid 66-69 transthyretin Homo sapiens 25-28 9789022-4 1998 The crystal structure of TTR complexed with Flu demonstrates that Flu mediates intersubunit hydrophobic interactions and intersubunit hydrogen bonds that stabilize the normal tetrameric fold of TTR. Flufenamic Acid 66-69 transthyretin Homo sapiens 194-197 9789022-4 1998 The crystal structure of TTR complexed with Flu demonstrates that Flu mediates intersubunit hydrophobic interactions and intersubunit hydrogen bonds that stabilize the normal tetrameric fold of TTR. Hydrogen 134-142 transthyretin Homo sapiens 25-28 9789022-4 1998 The crystal structure of TTR complexed with Flu demonstrates that Flu mediates intersubunit hydrophobic interactions and intersubunit hydrogen bonds that stabilize the normal tetrameric fold of TTR. Hydrogen 134-142 transthyretin Homo sapiens 194-197 9750964-8 1998 The affinity of transthyretin for thyroxine increases and that for 3,5,3"-triiodothyronine decreases during the evolution of eutherians from reptile/bird-like common ancestors. Thyroxine 34-43 transthyretin Homo sapiens 16-29 9772136-5 1998 The ratio of RBP:TTR was selectively reduced in children in the placebo group with low plasma retinol (<0.35 micromol/L) and elevated CRP (>40 mg/L). Vitamin A 94-101 transthyretin Homo sapiens 17-20 9818053-8 1998 The x-ray intensity distribution indicated that the unit structure, which is similar to a TTR monomer, is composed of a pair of beta-sheets consisting of four hydrogen-bonded beta-chains per sheet, with the beta-chains oriented approximately normal to the fiber axis. Hydrogen 159-167 transthyretin Homo sapiens 90-93 9818883-0 1998 Transthyretin amyloidosis (serine 44) with headache, hearing loss, and peripheral neuropathy. Serine 27-33 transthyretin Homo sapiens 0-13 9818883-5 1998 Direct DNA sequencing revealed both the normal TTT (phenylalanine) and a new variant TCT (serine) at position 44 of the TTR gene. Serine 90-96 transthyretin Homo sapiens 120-123 9750964-15 1998 As the N termini are located on the surface of transthyretin near the entrance to its central channel leading to the thyroxine binding sites, it is possible that a change in the structure of this region could influence the access of thyroxine to the binding sites. Thyroxine 117-126 transthyretin Homo sapiens 47-60 9750964-15 1998 As the N termini are located on the surface of transthyretin near the entrance to its central channel leading to the thyroxine binding sites, it is possible that a change in the structure of this region could influence the access of thyroxine to the binding sites. Thyroxine 233-242 transthyretin Homo sapiens 47-60 9786151-4 1998 Staging of CTS was done on the basis of clinical and electrophysiological testing, including evaluation of the number of previous steroid infiltrations in conservative treatment. Steroids 130-137 transthyretin Homo sapiens 11-14 9694837-7 1998 High pressure liquid chromatography fractionation of the CHYLO infranate proteins identified the critical protein as transthyretin (TTR), which binds retinol-binding protein and complexes thyroxine and retinol. Thyroxine 188-197 transthyretin Homo sapiens 117-130 9840068-6 1998 The amyloid protein is the variant transthyretin (TTR) in which methionine (MET) is a substitute for valine in position 30 (TTR MET 30). Methionine 64-74 transthyretin Homo sapiens 35-48 9840068-6 1998 The amyloid protein is the variant transthyretin (TTR) in which methionine (MET) is a substitute for valine in position 30 (TTR MET 30). Methionine 64-74 transthyretin Homo sapiens 50-53 9840068-6 1998 The amyloid protein is the variant transthyretin (TTR) in which methionine (MET) is a substitute for valine in position 30 (TTR MET 30). Methionine 64-74 transthyretin Homo sapiens 124-127 9840068-6 1998 The amyloid protein is the variant transthyretin (TTR) in which methionine (MET) is a substitute for valine in position 30 (TTR MET 30). Methionine 76-79 transthyretin Homo sapiens 35-48 9840068-6 1998 The amyloid protein is the variant transthyretin (TTR) in which methionine (MET) is a substitute for valine in position 30 (TTR MET 30). Methionine 76-79 transthyretin Homo sapiens 50-53 9840068-6 1998 The amyloid protein is the variant transthyretin (TTR) in which methionine (MET) is a substitute for valine in position 30 (TTR MET 30). Valine 101-107 transthyretin Homo sapiens 35-48 9840068-6 1998 The amyloid protein is the variant transthyretin (TTR) in which methionine (MET) is a substitute for valine in position 30 (TTR MET 30). Valine 101-107 transthyretin Homo sapiens 50-53 9840068-6 1998 The amyloid protein is the variant transthyretin (TTR) in which methionine (MET) is a substitute for valine in position 30 (TTR MET 30). Valine 101-107 transthyretin Homo sapiens 124-127 9748014-7 1998 Seven kindreds (24%) had previously unreported TTR variants, namely asparagine 35, serine (Ser) 91, phenylalanine (Phe) 77, and Ser 116. Asparagine 68-78 transthyretin Homo sapiens 47-50 9748014-7 1998 Seven kindreds (24%) had previously unreported TTR variants, namely asparagine 35, serine (Ser) 91, phenylalanine (Phe) 77, and Ser 116. Serine 83-89 transthyretin Homo sapiens 47-50 9748014-7 1998 Seven kindreds (24%) had previously unreported TTR variants, namely asparagine 35, serine (Ser) 91, phenylalanine (Phe) 77, and Ser 116. Serine 91-94 transthyretin Homo sapiens 47-50 9748014-7 1998 Seven kindreds (24%) had previously unreported TTR variants, namely asparagine 35, serine (Ser) 91, phenylalanine (Phe) 77, and Ser 116. Phenylalanine 100-113 transthyretin Homo sapiens 47-50 9748014-7 1998 Seven kindreds (24%) had previously unreported TTR variants, namely asparagine 35, serine (Ser) 91, phenylalanine (Phe) 77, and Ser 116. Phenylalanine 115-118 transthyretin Homo sapiens 47-50 9716454-4 1998 Transthyretin synthesized in HepG2 cells appeared after SDS-PAGE analysis in mostly tetrameric form, while that synthesized in transfected COS-1 cells appeared mainly as dimers. Sodium Dodecyl Sulfate 56-59 transthyretin Homo sapiens 0-13 9716454-5 1998 Brefeldin A treatment and pulse-chase experiments in HepG2 cells showed that transthyretin tetramer was formed in the endoplasmic reticulum. Brefeldin A 0-11 transthyretin Homo sapiens 77-90 9694837-7 1998 High pressure liquid chromatography fractionation of the CHYLO infranate proteins identified the critical protein as transthyretin (TTR), which binds retinol-binding protein and complexes thyroxine and retinol. Thyroxine 188-197 transthyretin Homo sapiens 132-135 9694837-7 1998 High pressure liquid chromatography fractionation of the CHYLO infranate proteins identified the critical protein as transthyretin (TTR), which binds retinol-binding protein and complexes thyroxine and retinol. Vitamin A 150-157 transthyretin Homo sapiens 117-130 9694837-7 1998 High pressure liquid chromatography fractionation of the CHYLO infranate proteins identified the critical protein as transthyretin (TTR), which binds retinol-binding protein and complexes thyroxine and retinol. Vitamin A 150-157 transthyretin Homo sapiens 132-135 9674983-0 1998 Is transthyretin (TTR) disrupted by a trinucleotide repeat expansion in a schizophrenia kindred? trinucleotide 38-51 transthyretin Homo sapiens 3-16 9767365-0 1998 Investigation into thiol conjugation of transthyretin in hereditary transthyretin amyloidosis. Sulfhydryl Compounds 19-24 transthyretin Homo sapiens 40-53 9767365-7 1998 CONCLUSION: The finding of a decreased ratio of unconjugated to conjugated TTR Met-30 in plasma samples from symptomatic TTR Met-30 carriers indicates that thiol conjugation of TTR could be involved in amyloid formation. Sulfhydryl Compounds 156-161 transthyretin Homo sapiens 75-78 9767365-7 1998 CONCLUSION: The finding of a decreased ratio of unconjugated to conjugated TTR Met-30 in plasma samples from symptomatic TTR Met-30 carriers indicates that thiol conjugation of TTR could be involved in amyloid formation. Sulfhydryl Compounds 156-161 transthyretin Homo sapiens 121-124 9767365-7 1998 CONCLUSION: The finding of a decreased ratio of unconjugated to conjugated TTR Met-30 in plasma samples from symptomatic TTR Met-30 carriers indicates that thiol conjugation of TTR could be involved in amyloid formation. Sulfhydryl Compounds 156-161 transthyretin Homo sapiens 121-124 9710008-2 1998 OBJECTIVE: To evaluate the effectiveness of commonly used oral medications such as diuretics, nonsteroid anti-inflammatory drugs (NSAIDs), and steroids in the treatment of CTS. Steroids 143-151 transthyretin Homo sapiens 172-175 9698569-5 1998 The solution structure of monomeric transthyretin under fibril-forming conditions was studied using hydrogen exchange monitored by mass spectrometry. Hydrogen 100-108 transthyretin Homo sapiens 36-49 9698569-6 1998 The results show that Val30Met transthyretin, the commonest amyloidogenic variant, exhibits loss of hydrogen exchange protection substantially more rapidly than the wild-type protein, suggesting partial unfolding of the beta-sheet structure. Hydrogen 100-108 transthyretin Homo sapiens 31-44 9674983-0 1998 Is transthyretin (TTR) disrupted by a trinucleotide repeat expansion in a schizophrenia kindred? trinucleotide 38-51 transthyretin Homo sapiens 18-21 9717013-0 1998 A clinical, echocardiographic and genetic characterization of a Danish kindred with familial amyloid transthyretin methionine 111 linked cardiomyopathy. Methionine 115-125 transthyretin Homo sapiens 101-114 9766237-0 1998 Cooperation between the components of the meningococcal transferrin receptor, TbpA and TbpB, in the uptake of transferrin iron by the 37-kDa ferric-binding protein (FbpA). Iron 122-126 transthyretin Homo sapiens 78-82 9766237-1 1998 Meningococcal TbpAB complexes TbpA, TbpB and FbpA were purified and used to study their role in the uptake of iron from transferrin to FbpA. Iron 110-114 transthyretin Homo sapiens 14-18 9766237-4 1998 FbpA was able to bind iron from transferrin only when TbpAB complexes, TbpA and/or TbpB, were also present during the interaction. Iron 22-26 transthyretin Homo sapiens 54-58 9766237-6 1998 We conclude that the TbpA and TbpB molecules form true functional transferrin receptors, that FbpA is able to take iron directly from transferrin when in the presence of the components of the receptor, and that both Tbps are necessary for an optimal operation of the uptake system. tert-butylbicyclophosphorothionate 216-220 transthyretin Homo sapiens 21-25 9717013-1 1998 AIMS: To identify carriers and non-carriers of the mutant transthyretin methionine 111 linked familial amyloid disease, to detect early signs of the restrictive cardiomyopathy and other clinical manifestations characteristic of this inheritable disease. Methionine 72-82 transthyretin Homo sapiens 58-71 9717013-3 1998 Twenty-five family members were heterozygous carriers of the mutant transthyretin methionine 111 genotype, while 74 were non-carriers. Methionine 82-92 transthyretin Homo sapiens 68-81 9521557-4 1998 Immunoadsorbents were constructed by immobilizing murine anti-TTR monoclonal antibody 88.6.BA9 onto agarose gel supports via several different coupling chemistries. umirolimus 91-94 transthyretin Homo sapiens 62-65 9547003-0 1998 Transthyretin mutation (serine 84) associated with familial amyloid polyneuropathy in a Hungarian family. Serine 24-30 transthyretin Homo sapiens 0-13 9547003-4 1998 Single strand conformation polymorphism analysis and direct DNA sequencing revealed a variant AGC (serine) codon at amino acid position 84 of the amyloid precursor protein, transthyretin (TTR). Serine 99-105 transthyretin Homo sapiens 173-186 9547003-4 1998 Single strand conformation polymorphism analysis and direct DNA sequencing revealed a variant AGC (serine) codon at amino acid position 84 of the amyloid precursor protein, transthyretin (TTR). Serine 99-105 transthyretin Homo sapiens 188-191 9521557-6 1998 Cyanogen bromide-, carbonyldiimidazole- and aldehyde-activated (ALD) supports conjugated with antibody at optimal pH, provided immunoadsorbents with comparable TTR binding capacities. Aldehydes 44-52 transthyretin Homo sapiens 160-163 9460170-5 1998 Maternal exposure to PHAHs during pregnancy resulted in a considerable fetal transfer of hydroxylated PHAHs, which are known to compete with thyroxine (T4) for plasma transthyretin (TTR) binding sites, and thus may be transported to the fetus with those carrier proteins that normally mediate the delivery of T4 to the fetus. Thyroxine 141-150 transthyretin Homo sapiens 167-180 9546683-7 1998 Pentosidine levels were significantly elevated in the DSA, CTS, and DRA groups (patients in the DRA group had either DSA and/or CTS). pentosidine 0-11 transthyretin Homo sapiens 59-62 9546683-7 1998 Pentosidine levels were significantly elevated in the DSA, CTS, and DRA groups (patients in the DRA group had either DSA and/or CTS). pentosidine 0-11 transthyretin Homo sapiens 128-131 9480790-3 1998 Previous studies have demonstrated that affinity isolation of TbpB from Neisseria meningitidis or Haemophilus influenzae with immobilized human transferrin required the homologous TbpA, implicating a TbpA-TbpB interaction. tert-butyl peroxybenzoate 62-66 transthyretin Homo sapiens 180-184 9480790-3 1998 Previous studies have demonstrated that affinity isolation of TbpB from Neisseria meningitidis or Haemophilus influenzae with immobilized human transferrin required the homologous TbpA, implicating a TbpA-TbpB interaction. tert-butyl peroxybenzoate 62-66 transthyretin Homo sapiens 200-204 9480790-5 1998 Extension of these studies to veterinary pathogens in which a TbpA-Tf complex is used to affinity isolate heterologous TbpBs, demonstrated an interaction between the receptor proteins from N. meningitidis and Actinobacillus pleuropneumoniae. tert-butyl peroxybenzoate 119-124 transthyretin Homo sapiens 62-66 10627135-0 1998 New transthyretin variants SER 91 and SER 116 associated with familial amyloidotic polyneuropathy. Serine 27-30 transthyretin Homo sapiens 4-17 10627135-14 1998 The clinical immunohistochemical and molecular studies in both patients are highly suggestive of an association between the Ser 91 and Ser 116 TTR variants with amyloidosis. Serine 124-127 transthyretin Homo sapiens 143-146 10627135-14 1998 The clinical immunohistochemical and molecular studies in both patients are highly suggestive of an association between the Ser 91 and Ser 116 TTR variants with amyloidosis. Serine 135-138 transthyretin Homo sapiens 143-146 9546683-7 1998 Pentosidine levels were significantly elevated in the DSA, CTS, and DRA groups (patients in the DRA group had either DSA and/or CTS). dra 96-99 transthyretin Homo sapiens 128-131 9245618-0 1997 Sequence analysis of the structural tbpA gene: protein topology and variable regions within neisserial receptors for transferrin iron acquisition. Iron 129-133 transthyretin Homo sapiens 36-40 9383187-4 1997 One of these proteins, TbpA, is homologous to the TonB-dependent family of outer membrane receptors that are required for high-affinity uptake of vitamin B12 and ferric siderophores. Vitamin B 12 146-157 transthyretin Homo sapiens 23-27 9383187-4 1997 One of these proteins, TbpA, is homologous to the TonB-dependent family of outer membrane receptors that are required for high-affinity uptake of vitamin B12 and ferric siderophores. Ferric enterobactin ion 162-168 transthyretin Homo sapiens 23-27 9307034-1 1997 Transthyretin is one of two specific proteins involved in the transport of thyroid hormones in plasma; it possesses two binding sites for serum retinol-binding protein. Vitamin A 144-151 transthyretin Homo sapiens 0-13 9307034-2 1997 In the present study we demonstrate that transthyretin also interacts in vitro with [35S]sulphate-labelled material from the medium of HepG2 cells. Sulfur-35 85-88 transthyretin Homo sapiens 41-54 9307034-2 1997 In the present study we demonstrate that transthyretin also interacts in vitro with [35S]sulphate-labelled material from the medium of HepG2 cells. Sulfates 89-97 transthyretin Homo sapiens 41-54 9307034-3 1997 By using the same strategy as for purifying serum retinol-binding protein, [35S]sulphate-labelled medium was specifically eluted from a transthyretin-affinity column. Sulfur-35 76-79 transthyretin Homo sapiens 136-149 9307034-3 1997 By using the same strategy as for purifying serum retinol-binding protein, [35S]sulphate-labelled medium was specifically eluted from a transthyretin-affinity column. Sulfates 80-88 transthyretin Homo sapiens 136-149 9307034-9 1997 Because inhibition of sulphation by treating HepG2 cells with sodium chlorate increased the affinity of the perlecan for transthyretin, and [3H]heparin was not retained by the transthyretin affinity column, the binding is probably mediated by the core protein and is not a protein-glycosaminoglycan interaction. sodium chlorate 62-77 transthyretin Homo sapiens 121-134 9307034-10 1997 Because perlecan is released from transthyretin in water, the binding might be due to hydrophobic interactions. Water 51-56 transthyretin Homo sapiens 34-47 9268242-0 1997 Detection of three transthyretin gene mutations in familial amyloidotic polyneuropathy by analysis of DNA extracted from formalin-fixed and paraffin-embedded tissues. Formaldehyde 121-129 transthyretin Homo sapiens 19-32 9268242-0 1997 Detection of three transthyretin gene mutations in familial amyloidotic polyneuropathy by analysis of DNA extracted from formalin-fixed and paraffin-embedded tissues. Paraffin 140-148 transthyretin Homo sapiens 19-32 9268242-1 1997 We identified three different missense mutations of the transthyretin (TTR) gene in three Japanese patients with familial amyloidotic polyneuropathy by analysis of their DNAs extracted from formalin-fixed and paraffin-embedded tissues. Formaldehyde 190-198 transthyretin Homo sapiens 56-69 9268242-1 1997 We identified three different missense mutations of the transthyretin (TTR) gene in three Japanese patients with familial amyloidotic polyneuropathy by analysis of their DNAs extracted from formalin-fixed and paraffin-embedded tissues. Formaldehyde 190-198 transthyretin Homo sapiens 71-74 9268242-1 1997 We identified three different missense mutations of the transthyretin (TTR) gene in three Japanese patients with familial amyloidotic polyneuropathy by analysis of their DNAs extracted from formalin-fixed and paraffin-embedded tissues. Paraffin 209-217 transthyretin Homo sapiens 56-69 9268242-1 1997 We identified three different missense mutations of the transthyretin (TTR) gene in three Japanese patients with familial amyloidotic polyneuropathy by analysis of their DNAs extracted from formalin-fixed and paraffin-embedded tissues. Paraffin 209-217 transthyretin Homo sapiens 71-74 9268242-2 1997 Patient 1 carried the TTR methionine-30 (Met) mutation (G to A transition at position 1679). Methionine 26-36 transthyretin Homo sapiens 22-25 9268242-3 1997 DNA sequencing analysis of the TTR gene from patient 2 showed a G to T transversion at position 3830 in exon 3, resulting in an amino acid replacement of serine-50 (Ser) with isoleucine (Ile). Serine 154-160 transthyretin Homo sapiens 31-34 9268242-3 1997 DNA sequencing analysis of the TTR gene from patient 2 showed a G to T transversion at position 3830 in exon 3, resulting in an amino acid replacement of serine-50 (Ser) with isoleucine (Ile). Serine 165-168 transthyretin Homo sapiens 31-34 9268242-3 1997 DNA sequencing analysis of the TTR gene from patient 2 showed a G to T transversion at position 3830 in exon 3, resulting in an amino acid replacement of serine-50 (Ser) with isoleucine (Ile). Isoleucine 175-185 transthyretin Homo sapiens 31-34 9268242-3 1997 DNA sequencing analysis of the TTR gene from patient 2 showed a G to T transversion at position 3830 in exon 3, resulting in an amino acid replacement of serine-50 (Ser) with isoleucine (Ile). Isoleucine 187-190 transthyretin Homo sapiens 31-34 9395793-1 1997 We have used a new and rapid method to detect three variant forms of transthyretin (TTR): methionine for valine at position 30 (Met-30), serine for cysteine at position 6 (Ser-6) and methionine for leucine at position 111 (Met-111). Methionine 128-131 transthyretin Homo sapiens 69-82 9395793-1 1997 We have used a new and rapid method to detect three variant forms of transthyretin (TTR): methionine for valine at position 30 (Met-30), serine for cysteine at position 6 (Ser-6) and methionine for leucine at position 111 (Met-111). Methionine 128-131 transthyretin Homo sapiens 84-87 9395793-1 1997 We have used a new and rapid method to detect three variant forms of transthyretin (TTR): methionine for valine at position 30 (Met-30), serine for cysteine at position 6 (Ser-6) and methionine for leucine at position 111 (Met-111). Serine 172-175 transthyretin Homo sapiens 69-82 9395793-1 1997 We have used a new and rapid method to detect three variant forms of transthyretin (TTR): methionine for valine at position 30 (Met-30), serine for cysteine at position 6 (Ser-6) and methionine for leucine at position 111 (Met-111). Methionine 223-226 transthyretin Homo sapiens 69-82 9395793-1 1997 We have used a new and rapid method to detect three variant forms of transthyretin (TTR): methionine for valine at position 30 (Met-30), serine for cysteine at position 6 (Ser-6) and methionine for leucine at position 111 (Met-111). Methionine 223-226 transthyretin Homo sapiens 84-87 9254621-0 1997 Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers. Guanidine 0-23 transthyretin Homo sapiens 62-75 9254621-2 1997 These results demonstrate that the GdnHCl-mediated denaturation and reconstitution of TTR is reversible. Guanidine 35-41 transthyretin Homo sapiens 86-89 9254621-3 1997 However, the lowest GdnHCl concentration that dissociates and unfolds transthyretin does not allow the unfolded monomer to refold to tetramer at a rate that is measurable. Guanidine 20-26 transthyretin Homo sapiens 70-83 9254621-5 1997 The TTR tetramer does not dissociate into unfolded monomer until the denaturant concentration exceeds 4 M GdnHCl, whereas unfolded monomeric TTR (denatured in 7 M GdnHCl) does not refold and assemble into a native tetrameric structure until the GdnHCl concentration is reduced to less than 2 M. These results imply that a significant kinetic barrier intervenes between the folded tetramer and unfolded monomer in both the denaturation and reconstitution directions at pH 7. Guanidine 106-112 transthyretin Homo sapiens 4-7 9254621-5 1997 The TTR tetramer does not dissociate into unfolded monomer until the denaturant concentration exceeds 4 M GdnHCl, whereas unfolded monomeric TTR (denatured in 7 M GdnHCl) does not refold and assemble into a native tetrameric structure until the GdnHCl concentration is reduced to less than 2 M. These results imply that a significant kinetic barrier intervenes between the folded tetramer and unfolded monomer in both the denaturation and reconstitution directions at pH 7. Guanidine 163-169 transthyretin Homo sapiens 141-144 9254621-5 1997 The TTR tetramer does not dissociate into unfolded monomer until the denaturant concentration exceeds 4 M GdnHCl, whereas unfolded monomeric TTR (denatured in 7 M GdnHCl) does not refold and assemble into a native tetrameric structure until the GdnHCl concentration is reduced to less than 2 M. These results imply that a significant kinetic barrier intervenes between the folded tetramer and unfolded monomer in both the denaturation and reconstitution directions at pH 7. Guanidine 163-169 transthyretin Homo sapiens 141-144 9254621-6 1997 A kinetics study of the denaturation of TTR as a function of GdnHCl concentration yields a first-order rate constant for unfolding of (9.0 +/- 7.5) x 10(-11) s-1, estimated by extrapolation of the rate constants for the tetramer to unfolded monomer transition as a function of GdnHCl to 0 M GdnHCl. Guanidine 61-67 transthyretin Homo sapiens 40-43 9254621-6 1997 A kinetics study of the denaturation of TTR as a function of GdnHCl concentration yields a first-order rate constant for unfolding of (9.0 +/- 7.5) x 10(-11) s-1, estimated by extrapolation of the rate constants for the tetramer to unfolded monomer transition as a function of GdnHCl to 0 M GdnHCl. Guanidine 277-283 transthyretin Homo sapiens 40-43 9254621-6 1997 A kinetics study of the denaturation of TTR as a function of GdnHCl concentration yields a first-order rate constant for unfolding of (9.0 +/- 7.5) x 10(-11) s-1, estimated by extrapolation of the rate constants for the tetramer to unfolded monomer transition as a function of GdnHCl to 0 M GdnHCl. Guanidine 277-283 transthyretin Homo sapiens 40-43 9178822-11 1997 When the medium from cells incubated with either 4-HPR or retinol was applied to a TTR affinity column, we found that RBP from cells incubated with 4-HPR had a considerably reduced affinity for TTR. Vitamin A 58-65 transthyretin Homo sapiens 83-86 9333604-3 1997 An alanine 47 transthyretin variant of Familial Amyloid Polyneuropathy with hypertrophic cardiomyopathy, peripheral sensory-motor polyneuropathy, I, degree AV heart block was diagnosed. Alanine 3-10 transthyretin Homo sapiens 14-27 9368688-0 1997 Thyroxine binding to transthyretin Met 119. Thyroxine 0-9 transthyretin Homo sapiens 21-34 9368688-4 1997 Previous studies on thyroxine (T4) binding to semi-purified TTR from heterozygotic carriers of TTR Met 119, reported by us and other groups, revealed different results. Thyroxine 20-29 transthyretin Homo sapiens 60-63 9368688-4 1997 Previous studies on thyroxine (T4) binding to semi-purified TTR from heterozygotic carriers of TTR Met 119, reported by us and other groups, revealed different results. Thyroxine 20-29 transthyretin Homo sapiens 95-98 9368688-9 1997 X-ray crystallography studies performed on the recombinant TTR Met 119 variant revealed structural alterations mainly at the level of residue Leu 110 allowing a closer contact between the hormone and the mutant protein. Leucine 142-145 transthyretin Homo sapiens 59-62 9191784-4 1997 Direct DNA sequencing of the transthyretin gene of the patient showed a trinucleotide deletion in exon 4. trinucleotide 72-85 transthyretin Homo sapiens 29-42 9191784-10 1997 We speculate that the loss of valine in the carboxyl terminal region of the transthyretin monomer alters stability of the tetrameric protein, which leads to rapid clearance from the plasma and amyloid deposition in the tissue. Valine 30-36 transthyretin Homo sapiens 76-89 9178822-11 1997 When the medium from cells incubated with either 4-HPR or retinol was applied to a TTR affinity column, we found that RBP from cells incubated with 4-HPR had a considerably reduced affinity for TTR. Vitamin A 58-65 transthyretin Homo sapiens 194-197 8784093-12 1996 These results are in agreement with the observations based on the crystallographic structure of TTR-Thr109 indicating that the extra atoms in Val as in Thr, which are absent in the Ala of the wild type TTR, widen the ligand binding site. Valine 142-145 transthyretin Homo sapiens 96-99 9154974-4 1997 The interaction of the calcium antagonists with transthyretin (TTR) is discussed in relation to thyroid hormones. Calcium 23-30 transthyretin Homo sapiens 48-61 9154974-4 1997 The interaction of the calcium antagonists with transthyretin (TTR) is discussed in relation to thyroid hormones. Calcium 23-30 transthyretin Homo sapiens 63-66 9095004-7 1997 The introduction of 6.0-hMet 30 into the ttr-/- mice significantly increased their depressed serum levels of T4 and retinol-binding protein, suggesting that human TTR Met 30 binds T4 and retinol-binding protein in vivo. Vitamin A 116-123 transthyretin Homo sapiens 163-166 9066351-4 1997 This condition, previously labeled oculoleptomeningeal amyloidosis, is linked to a mutation at codon 30 of TTR gene, resulting in the substitution of valine with glycine in this family, TTR amyloid deposits were present in the leptomeninges, especially the leptomeningeal vessels, and in the subependymal regions of the ventricular system where they disrupted the ependymal lining and resulted in amyloid-glial formations protruding into and narrowing the ventricular system. Valine 150-156 transthyretin Homo sapiens 107-110 9066351-4 1997 This condition, previously labeled oculoleptomeningeal amyloidosis, is linked to a mutation at codon 30 of TTR gene, resulting in the substitution of valine with glycine in this family, TTR amyloid deposits were present in the leptomeninges, especially the leptomeningeal vessels, and in the subependymal regions of the ventricular system where they disrupted the ependymal lining and resulted in amyloid-glial formations protruding into and narrowing the ventricular system. Glycine 162-169 transthyretin Homo sapiens 107-110 9017939-0 1997 Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. Isoleucine 32-42 transthyretin Homo sapiens 17-30 9090525-7 1997 The individuals were found to be carriers of TTR Ile 122 and TTR Thr 190, respectively. Threonine 65-68 transthyretin Homo sapiens 61-64 8986762-2 1996 Herein, we demonstrate conclusively that thyroxine (10.8 microM) inhibits TTR fibril formation efficiently in vitro and does so by stabilizing the tetramer against dissociation and the subsequent conformational changes required for amyloid fibril formation. Thyroxine 41-50 transthyretin Homo sapiens 74-77 8986762-3 1996 In addition, the nonnative ligand 2,4,6-triiodophenol, which binds to TTR with slightly increased affinity also inhibits TTR fibril formation by this mechanism. 2,4,6-triiodophenol 34-53 transthyretin Homo sapiens 70-73 8986762-3 1996 In addition, the nonnative ligand 2,4,6-triiodophenol, which binds to TTR with slightly increased affinity also inhibits TTR fibril formation by this mechanism. 2,4,6-triiodophenol 34-53 transthyretin Homo sapiens 121-124 8986762-4 1996 Sedimentation velocity experiments were employed to show that TTR undergoes dissociation (linked to a conformational change) to form the monomeric amyloidogenic intermediate, which self-assembles into amyloid in the absence, but not in the presence of thyroxine. Thyroxine 252-261 transthyretin Homo sapiens 62-65 9159878-4 1997 In larger eutherians, proteins specifically binding thyroxine are albumin, transthyretin, and thyroxine-binding globulin. Thyroxine 52-61 transthyretin Homo sapiens 75-88 8784093-12 1996 These results are in agreement with the observations based on the crystallographic structure of TTR-Thr109 indicating that the extra atoms in Val as in Thr, which are absent in the Ala of the wild type TTR, widen the ligand binding site. Valine 142-145 transthyretin Homo sapiens 202-205 8784093-12 1996 These results are in agreement with the observations based on the crystallographic structure of TTR-Thr109 indicating that the extra atoms in Val as in Thr, which are absent in the Ala of the wild type TTR, widen the ligand binding site. Threonine 100-103 transthyretin Homo sapiens 96-99 8784093-12 1996 These results are in agreement with the observations based on the crystallographic structure of TTR-Thr109 indicating that the extra atoms in Val as in Thr, which are absent in the Ala of the wild type TTR, widen the ligand binding site. Threonine 100-103 transthyretin Homo sapiens 202-205 8784093-12 1996 These results are in agreement with the observations based on the crystallographic structure of TTR-Thr109 indicating that the extra atoms in Val as in Thr, which are absent in the Ala of the wild type TTR, widen the ligand binding site. Alanine 181-184 transthyretin Homo sapiens 96-99 8784093-12 1996 These results are in agreement with the observations based on the crystallographic structure of TTR-Thr109 indicating that the extra atoms in Val as in Thr, which are absent in the Ala of the wild type TTR, widen the ligand binding site. Alanine 181-184 transthyretin Homo sapiens 202-205 8976129-15 1996 A variant TTR, characterized by a Glu61-->Lys substitution (a basic-for-acidic amino acid substitution) found in this family, has not been reported in the literature. Lysine 45-48 transthyretin Homo sapiens 10-13 15299640-0 1996 Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3",5"-dinitro-N-acetyl-L-thyronine at 2.2 A resolution. Thyroxine 49-58 transthyretin Homo sapiens 20-33 8810738-0 1996 Thyroxine binding to transthyretin (TTR) variants--two variants (TTR Pro 55 and TTR Met 111) with a particularly low binding affinity. Thyroxine 0-9 transthyretin Homo sapiens 21-34 8810738-0 1996 Thyroxine binding to transthyretin (TTR) variants--two variants (TTR Pro 55 and TTR Met 111) with a particularly low binding affinity. Thyroxine 0-9 transthyretin Homo sapiens 36-39 8810738-0 1996 Thyroxine binding to transthyretin (TTR) variants--two variants (TTR Pro 55 and TTR Met 111) with a particularly low binding affinity. Thyroxine 0-9 transthyretin Homo sapiens 65-68 8810738-0 1996 Thyroxine binding to transthyretin (TTR) variants--two variants (TTR Pro 55 and TTR Met 111) with a particularly low binding affinity. Thyroxine 0-9 transthyretin Homo sapiens 65-68 8810738-1 1996 Thyroxine (T4) binding is a well-characterized function of transthyretin (TTR) and has been used to assess structural alterations of TTR variants. Thyroxine 0-9 transthyretin Homo sapiens 59-72 8810738-1 1996 Thyroxine (T4) binding is a well-characterized function of transthyretin (TTR) and has been used to assess structural alterations of TTR variants. Thyroxine 0-9 transthyretin Homo sapiens 74-77 8810738-1 1996 Thyroxine (T4) binding is a well-characterized function of transthyretin (TTR) and has been used to assess structural alterations of TTR variants. Thyroxine 0-9 transthyretin Homo sapiens 133-136 8810738-5 1996 The results obtained indicated a normal T4 binding affinity for heterozygotic TTR Ala 49, TTR Leu 68, TTR Ala 71 and TTR Arg 102. Alanine 82-85 transthyretin Homo sapiens 78-81 8810738-5 1996 The results obtained indicated a normal T4 binding affinity for heterozygotic TTR Ala 49, TTR Leu 68, TTR Ala 71 and TTR Arg 102. Leucine 94-97 transthyretin Homo sapiens 90-93 8810738-5 1996 The results obtained indicated a normal T4 binding affinity for heterozygotic TTR Ala 49, TTR Leu 68, TTR Ala 71 and TTR Arg 102. Leucine 94-97 transthyretin Homo sapiens 90-93 8810738-5 1996 The results obtained indicated a normal T4 binding affinity for heterozygotic TTR Ala 49, TTR Leu 68, TTR Ala 71 and TTR Arg 102. Leucine 94-97 transthyretin Homo sapiens 90-93 8958572-4 1996 The purification of TTR was carried out in a few simple steps involving serum precipitation, anion exchange, Thyroxine affinity chromatography and gel filtration. Thyroxine 109-118 transthyretin Homo sapiens 20-23 8958572-6 1996 When TTR was administrated to the culture medium DMEM of liver tumor strain SMMC-7721, a true inhibition of cell growth (ca. dmem 49-53 transthyretin Homo sapiens 5-8 15299640-0 1996 Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3",5"-dinitro-N-acetyl-L-thyronine at 2.2 A resolution. 3",5"-dinitro-n-acetyl-l-thyronine 83-117 transthyretin Homo sapiens 20-33 15299640-1 1996 The molecular structures of two human transthyretin (hTTR, prealbumin) complexes, co-crystallized with thyroxine (3,5,3",5"-tetraiodo-L-thyronine; T(4)), and with 3",5"-dinitro-N-acetyl-LL-thyronine (DNNAT), were determined by X-ray diffraction methods. Thyroxine 103-112 transthyretin Homo sapiens 38-51 15299640-1 1996 The molecular structures of two human transthyretin (hTTR, prealbumin) complexes, co-crystallized with thyroxine (3,5,3",5"-tetraiodo-L-thyronine; T(4)), and with 3",5"-dinitro-N-acetyl-LL-thyronine (DNNAT), were determined by X-ray diffraction methods. Thyroxine 114-145 transthyretin Homo sapiens 38-51 15299640-1 1996 The molecular structures of two human transthyretin (hTTR, prealbumin) complexes, co-crystallized with thyroxine (3,5,3",5"-tetraiodo-L-thyronine; T(4)), and with 3",5"-dinitro-N-acetyl-LL-thyronine (DNNAT), were determined by X-ray diffraction methods. 3",5"-dinitro-n-acetyl-ll-thyronine 163-198 transthyretin Homo sapiens 38-51 15299640-1 1996 The molecular structures of two human transthyretin (hTTR, prealbumin) complexes, co-crystallized with thyroxine (3,5,3",5"-tetraiodo-L-thyronine; T(4)), and with 3",5"-dinitro-N-acetyl-LL-thyronine (DNNAT), were determined by X-ray diffraction methods. dnnat 200-205 transthyretin Homo sapiens 38-51 15299640-7 1996 Results for the co-crystallized T(4) complex show that T(4) binds deep in the hormone-binding channel and displaces the bound water previously reported for T(4) soaked into a native transthyretin crystal [Blake & Oatley (1977). Water 126-131 transthyretin Homo sapiens 182-195 15299640-12 1996 These data suggest that the halogen-binding sites toward the tetramer center are of primary importance as they are occupied by analogues with weak affinity to TTR, and are therefore selected over the other halogen sites which contribute more strongly to the overall binding affinity. Halogens 28-35 transthyretin Homo sapiens 159-162 15299640-12 1996 These data suggest that the halogen-binding sites toward the tetramer center are of primary importance as they are occupied by analogues with weak affinity to TTR, and are therefore selected over the other halogen sites which contribute more strongly to the overall binding affinity. Halogens 206-213 transthyretin Homo sapiens 159-162 8639713-0 1996 Retinoid binding to retinol-binding protein and the interference with the interaction with transthyretin. Retinoids 0-8 transthyretin Homo sapiens 91-104 8692810-7 1996 Conformational stability and unfolding behavior of the Ile-20 monomer in urea gradients was found to be almost indistinguishable from that of wild-type TTR. Isoleucine 55-58 transthyretin Homo sapiens 152-155 8771476-1 1996 We studied the medium- to long-term results of steroid injection into the carpal tunnel of women with the carpal tunnel syndrome (CTS). Steroids 47-54 transthyretin Homo sapiens 130-133 8639594-6 1996 The inherent Trp fluorescence-monitored denaturation curve of TTR exhibits a plateau over the pH range where amyloid fibril formation is observed (albeit at a higher concentration), implying that a steady-state concentration of the amyloidogenic intermediate with an altered tertiary structure is being detected. Tryptophan 13-16 transthyretin Homo sapiens 62-65 8639594-8 1996 Transthyretin has two Trp residues in its primary structure, Trp-41 and Trp-79, which are conveniently located far apart in the tertiary structure of TTR. Tryptophan 22-25 transthyretin Homo sapiens 0-13 8639594-8 1996 Transthyretin has two Trp residues in its primary structure, Trp-41 and Trp-79, which are conveniently located far apart in the tertiary structure of TTR. Tryptophan 22-25 transthyretin Homo sapiens 150-153 8639594-8 1996 Transthyretin has two Trp residues in its primary structure, Trp-41 and Trp-79, which are conveniently located far apart in the tertiary structure of TTR. Tryptophan 61-64 transthyretin Homo sapiens 0-13 8639594-8 1996 Transthyretin has two Trp residues in its primary structure, Trp-41 and Trp-79, which are conveniently located far apart in the tertiary structure of TTR. Tryptophan 61-64 transthyretin Homo sapiens 150-153 8639594-8 1996 Transthyretin has two Trp residues in its primary structure, Trp-41 and Trp-79, which are conveniently located far apart in the tertiary structure of TTR. Tryptophan 61-64 transthyretin Homo sapiens 0-13 8639594-8 1996 Transthyretin has two Trp residues in its primary structure, Trp-41 and Trp-79, which are conveniently located far apart in the tertiary structure of TTR. Tryptophan 61-64 transthyretin Homo sapiens 150-153 8634341-4 1996 The effect of different ions such as metal and sulphate ions in the process of amyloid formation from wild type TTR was compared using a kinetic assay. Metals 37-42 transthyretin Homo sapiens 112-115 8634341-4 1996 The effect of different ions such as metal and sulphate ions in the process of amyloid formation from wild type TTR was compared using a kinetic assay. Sulfates 47-55 transthyretin Homo sapiens 112-115 8634341-5 1996 Under the conditions tested sulphate diminishes the amount of amyloid formed from wild type TTR and in addition appears to promote aggregation of preexisting amyloid fibrils. Sulfates 28-36 transthyretin Homo sapiens 92-95 8639713-1 1996 The retinol carrier retinol-binding protein (RBP) forms a complex with the thyroid hormone binding protein transthyretin in the plasma of a number of vertebrate species. Vitamin A 4-11 transthyretin Homo sapiens 107-120 8639713-2 1996 The interactions of retinoid-RBP complexes, as well as of unliganded RBP, with transthyretin have been investigated by means of fluorescence anisotropy studies. Retinoids 20-28 transthyretin Homo sapiens 79-92 8639713-4 1996 Although the natural ligand retinol participates in the interaction between retinol-RBP and transthyretin, its binding to RBP is not a prerequisite for protein-protein interaction. Vitamin A 28-35 transthyretin Homo sapiens 92-105 8639713-7 1996 The replacement of RBP-bound retinol with synthetic retinoids affects RBP-transthyretin recognition to an extent that appears to be well correlated with the nature and steric hindrance of the groups substituting the retinol hydroxyl group, consistent with their location at the interface between the contact areas of RBP and transthyretin. Vitamin A 29-36 transthyretin Homo sapiens 74-87 8639713-7 1996 The replacement of RBP-bound retinol with synthetic retinoids affects RBP-transthyretin recognition to an extent that appears to be well correlated with the nature and steric hindrance of the groups substituting the retinol hydroxyl group, consistent with their location at the interface between the contact areas of RBP and transthyretin. Vitamin A 29-36 transthyretin Homo sapiens 325-338 8915609-4 1996 Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation. Sodium Dodecyl Sulfate 56-59 transthyretin Homo sapiens 0-13 8639713-7 1996 The replacement of RBP-bound retinol with synthetic retinoids affects RBP-transthyretin recognition to an extent that appears to be well correlated with the nature and steric hindrance of the groups substituting the retinol hydroxyl group, consistent with their location at the interface between the contact areas of RBP and transthyretin. Retinoids 52-61 transthyretin Homo sapiens 74-87 8639713-7 1996 The replacement of RBP-bound retinol with synthetic retinoids affects RBP-transthyretin recognition to an extent that appears to be well correlated with the nature and steric hindrance of the groups substituting the retinol hydroxyl group, consistent with their location at the interface between the contact areas of RBP and transthyretin. Retinoids 52-61 transthyretin Homo sapiens 325-338 8639713-7 1996 The replacement of RBP-bound retinol with synthetic retinoids affects RBP-transthyretin recognition to an extent that appears to be well correlated with the nature and steric hindrance of the groups substituting the retinol hydroxyl group, consistent with their location at the interface between the contact areas of RBP and transthyretin. retinol hydroxyl 216-232 transthyretin Homo sapiens 74-87 8733640-1 1996 Case reports and small case series suggest that vitamin B6 deficiency is an important etiologic factor in carpal tunnel syndrome (CTS). Vitamin B 6 48-58 transthyretin Homo sapiens 130-133 8733640-8 1996 Furthermore, in our opinion, empiric prescription of vitamin B6 to patients with CTS is unwarranted and potentially hazardous. Vitamin B 6 53-63 transthyretin Homo sapiens 81-84 8612621-8 1996 Compared with wild-type human transthyretin the avian transthyretin shows quite large differences in the region known to be involved in binding to retinol-binding protein, it has a much shorter helical component than the human protein and some of the monomer-monomer interactions are different. Vitamin A 147-154 transthyretin Homo sapiens 54-67 8549676-1 1996 Retinol binding protein (RBP), the retinol-specific carrier, circulates in blood as a 1:1 complex with the homotetrameric protein transthyretin (TTR). Vitamin A 35-42 transthyretin Homo sapiens 130-143 8549676-1 1996 Retinol binding protein (RBP), the retinol-specific carrier, circulates in blood as a 1:1 complex with the homotetrameric protein transthyretin (TTR). Vitamin A 35-42 transthyretin Homo sapiens 145-148 8915609-4 1996 Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation. Sodium Dodecyl Sulfate 56-59 transthyretin Homo sapiens 15-18 7488876-8 1995 Of all the NEFAs tested, only arachidonic acid inhibited [125I]T4 binding to TTR, with an affinity relative to unlabeled T4 of 0.49%. Arachidonic Acid 30-46 transthyretin Homo sapiens 77-80 7477994-1 1995 We evaluated the effectiveness of low-dose, short-term oral prednisone in ameliorating the pain and other symptoms of carpal tunnel syndrome (CTS) in a randomized, double-blind, placebo-controlled study of patients with mild to moderate CTS. Prednisone 60-70 transthyretin Homo sapiens 142-145 7656439-1 1995 Retinol-binding protein (RBP), the principal carrier for vitamin A, is known to form a complex with transthyretin (TTR) for transport in plasma. Vitamin A 57-66 transthyretin Homo sapiens 100-113 7656439-1 1995 Retinol-binding protein (RBP), the principal carrier for vitamin A, is known to form a complex with transthyretin (TTR) for transport in plasma. Vitamin A 57-66 transthyretin Homo sapiens 115-118 8535286-0 1995 1H NMR studies of peptide fragments from the N-terminus of chicken and human transthyretin. Hydrogen 0-2 transthyretin Homo sapiens 77-90 8821901-1 1995 Increased thyroxine (T4) binding to thyroid binding prealbumin (TBPA) or albumin causes a biochemical picture suggestive of thyrotoxicosis with increased total T4 (TT4). Thyroxine 10-19 transthyretin Homo sapiens 36-62 8821901-1 1995 Increased thyroxine (T4) binding to thyroid binding prealbumin (TBPA) or albumin causes a biochemical picture suggestive of thyrotoxicosis with increased total T4 (TT4). Thyroxine 10-19 transthyretin Homo sapiens 64-68 8632835-1 1995 Transthyretin is a protein crucial to the transport of lipophilic molecules such as thyroid hormones and retinoids. Retinoids 105-114 transthyretin Homo sapiens 0-13 7488876-13 1995 The affinities of lysolecithins for the T4 binding sites of TBG and TTR are lower than those of NEFAs and depend on the fatty acid component. Lysophosphatidylcholines 18-31 transthyretin Homo sapiens 68-71 7488876-13 1995 The affinities of lysolecithins for the T4 binding sites of TBG and TTR are lower than those of NEFAs and depend on the fatty acid component. Fatty Acids 120-130 transthyretin Homo sapiens 68-71 7643356-0 1995 A new transthyretin variant (Ser 24) associated with familial amyloid polyneuropathy. Serine 29-32 transthyretin Homo sapiens 6-19 7608709-2 1995 Two patients from this region have been shown to have the ala 60 mutation in the transthyretin gene. Alanine 58-61 transthyretin Homo sapiens 81-94 7633183-4 1995 In this work, 22 different known TTR mutations were discriminated and studies on 210 samples from patients with peripheral neuropathies detected one polymorphic mutation (TTR Ser 6), TTR Asn 90, found previously in the normal Portuguese and German populations, and three other mutations, one of them TTR Ala 60. Serine 175-178 transthyretin Homo sapiens 33-36 7633183-4 1995 In this work, 22 different known TTR mutations were discriminated and studies on 210 samples from patients with peripheral neuropathies detected one polymorphic mutation (TTR Ser 6), TTR Asn 90, found previously in the normal Portuguese and German populations, and three other mutations, one of them TTR Ala 60. Serine 175-178 transthyretin Homo sapiens 171-174 7633183-4 1995 In this work, 22 different known TTR mutations were discriminated and studies on 210 samples from patients with peripheral neuropathies detected one polymorphic mutation (TTR Ser 6), TTR Asn 90, found previously in the normal Portuguese and German populations, and three other mutations, one of them TTR Ala 60. Serine 175-178 transthyretin Homo sapiens 171-174 7633183-4 1995 In this work, 22 different known TTR mutations were discriminated and studies on 210 samples from patients with peripheral neuropathies detected one polymorphic mutation (TTR Ser 6), TTR Asn 90, found previously in the normal Portuguese and German populations, and three other mutations, one of them TTR Ala 60. Serine 175-178 transthyretin Homo sapiens 171-174 7633183-4 1995 In this work, 22 different known TTR mutations were discriminated and studies on 210 samples from patients with peripheral neuropathies detected one polymorphic mutation (TTR Ser 6), TTR Asn 90, found previously in the normal Portuguese and German populations, and three other mutations, one of them TTR Ala 60. Asparagine 187-190 transthyretin Homo sapiens 33-36 7633183-4 1995 In this work, 22 different known TTR mutations were discriminated and studies on 210 samples from patients with peripheral neuropathies detected one polymorphic mutation (TTR Ser 6), TTR Asn 90, found previously in the normal Portuguese and German populations, and three other mutations, one of them TTR Ala 60. Asparagine 187-190 transthyretin Homo sapiens 171-174 7633183-4 1995 In this work, 22 different known TTR mutations were discriminated and studies on 210 samples from patients with peripheral neuropathies detected one polymorphic mutation (TTR Ser 6), TTR Asn 90, found previously in the normal Portuguese and German populations, and three other mutations, one of them TTR Ala 60. Asparagine 187-190 transthyretin Homo sapiens 171-174 7633183-4 1995 In this work, 22 different known TTR mutations were discriminated and studies on 210 samples from patients with peripheral neuropathies detected one polymorphic mutation (TTR Ser 6), TTR Asn 90, found previously in the normal Portuguese and German populations, and three other mutations, one of them TTR Ala 60. Asparagine 187-190 transthyretin Homo sapiens 171-174 7633183-4 1995 In this work, 22 different known TTR mutations were discriminated and studies on 210 samples from patients with peripheral neuropathies detected one polymorphic mutation (TTR Ser 6), TTR Asn 90, found previously in the normal Portuguese and German populations, and three other mutations, one of them TTR Ala 60. Alanine 304-307 transthyretin Homo sapiens 33-36 7633183-4 1995 In this work, 22 different known TTR mutations were discriminated and studies on 210 samples from patients with peripheral neuropathies detected one polymorphic mutation (TTR Ser 6), TTR Asn 90, found previously in the normal Portuguese and German populations, and three other mutations, one of them TTR Ala 60. Alanine 304-307 transthyretin Homo sapiens 171-174 7633183-4 1995 In this work, 22 different known TTR mutations were discriminated and studies on 210 samples from patients with peripheral neuropathies detected one polymorphic mutation (TTR Ser 6), TTR Asn 90, found previously in the normal Portuguese and German populations, and three other mutations, one of them TTR Ala 60. Alanine 304-307 transthyretin Homo sapiens 171-174 7633183-4 1995 In this work, 22 different known TTR mutations were discriminated and studies on 210 samples from patients with peripheral neuropathies detected one polymorphic mutation (TTR Ser 6), TTR Asn 90, found previously in the normal Portuguese and German populations, and three other mutations, one of them TTR Ala 60. Alanine 304-307 transthyretin Homo sapiens 171-174 7599954-0 1995 13C NMR relaxation studies of molecular motion in peptide fragments from human transthyretin. 13c 0-3 transthyretin Homo sapiens 79-92 7599954-1 1995 Natural-abundance 13C T1 and NOE measurements have been made for backbone and side-chain sites in peptide fragments of transthyretin (TTR 10-20, TTR 105-115, and TTR 105-115Met111) at 13C Larmor frequencies of 125 and 75 MHz. 13c 18-21 transthyretin Homo sapiens 119-132 7599954-1 1995 Natural-abundance 13C T1 and NOE measurements have been made for backbone and side-chain sites in peptide fragments of transthyretin (TTR 10-20, TTR 105-115, and TTR 105-115Met111) at 13C Larmor frequencies of 125 and 75 MHz. 13c 184-187 transthyretin Homo sapiens 119-132 7599954-1 1995 Natural-abundance 13C T1 and NOE measurements have been made for backbone and side-chain sites in peptide fragments of transthyretin (TTR 10-20, TTR 105-115, and TTR 105-115Met111) at 13C Larmor frequencies of 125 and 75 MHz. 13c 184-187 transthyretin Homo sapiens 134-137 7643356-2 1995 The transthyretin gene of a patient was analysed by direct DNA sequencing and both cytosine and thymine were present at the first base of codon 24. Cytosine 83-91 transthyretin Homo sapiens 4-17 7643356-2 1995 The transthyretin gene of a patient was analysed by direct DNA sequencing and both cytosine and thymine were present at the first base of codon 24. Thymine 96-103 transthyretin Homo sapiens 4-17 7643356-3 1995 This new point mutation in exon 2 results in the amino acid substitution of serine for proline in the A-B loop of the transthyretin molecule. Serine 76-82 transthyretin Homo sapiens 118-131 7643356-3 1995 This new point mutation in exon 2 results in the amino acid substitution of serine for proline in the A-B loop of the transthyretin molecule. Proline 87-94 transthyretin Homo sapiens 118-131 7868124-1 1995 Transthyretin (TTR) Ser 6 was originally described in a Scottish kindred without amyloidosis. Serine 20-23 transthyretin Homo sapiens 0-13 7868124-1 1995 Transthyretin (TTR) Ser 6 was originally described in a Scottish kindred without amyloidosis. Serine 20-23 transthyretin Homo sapiens 15-18 7868124-5 1995 The TTR Ser 6 allele frequency was 33/558 (.060) in Caucasians (including 8/192 (.04) in North American Ashkenazic Jews, 16/218 (.07) in North American non-Jews, and 9/148 (.06) in Portuguese), 3(242 (.01) in African Americans, 0/140 in Africans, and 0/208 in Asians. Serine 8-11 transthyretin Homo sapiens 4-7 7868124-8 1995 These data indicate that TTR Ser 6 is a common non-amyloidogenic population polymorphism in Caucasians. Serine 29-32 transthyretin Homo sapiens 25-28 7850982-11 1995 In fact, the amyloid fibrils were composed of transthyretin, and the two affected individuals from whom DNA was available were both heterozygotes for a single base change in exon 3 of the transthyretin gene, encoding substitution of Lys for the wild-type Thr residue at position 59 in the mature protein. Lysine 233-236 transthyretin Homo sapiens 188-201 7862129-5 1995 We show that in HepG2 cells the AP-1 sequence confers 12-O-tetradecanoylphorbol-13-acetate inducibility to the TTR promoter and contributes to normal TTR transcriptional activity. Tetradecanoylphorbol Acetate 54-90 transthyretin Homo sapiens 111-114 7862129-7 1995 In addition, 12-O-tetradecanoylphorbol-13-acetate exposure of HepG2 cells results in a reciprocal decrease in HNF-3 alpha and -3 gamma expression which may facilitate interaction of AP-1 with the TTR AP-1-HNF-3 site. Tetradecanoylphorbol Acetate 13-49 transthyretin Homo sapiens 196-199 7584829-3 1995 The derived amino-acid sequence showed 68% overall similarity to that of human transthyretin, with 86% similarity in the thyroxine binding site. Thyroxine 121-130 transthyretin Homo sapiens 79-92 7875325-0 1995 A yellow component associated with human transthyretin has properties like a pterin derivative, 7,8-dihydropterin-6-carboxaldehyde. Pterins 77-83 transthyretin Homo sapiens 41-54 7875325-0 1995 A yellow component associated with human transthyretin has properties like a pterin derivative, 7,8-dihydropterin-6-carboxaldehyde. 7,8-dihydropterin-6-carboxaldehyde 96-130 transthyretin Homo sapiens 41-54 7875325-3 1995 We now show that the major yellow component extracted from human TTR has properties like a pterin derivative, 7,8-dihydropterin-6-carboxyaldehyde (2-amino-4-hydroxy-6-formyl-7,8-dihydropteridine). Pterins 91-97 transthyretin Homo sapiens 65-68 7875325-3 1995 We now show that the major yellow component extracted from human TTR has properties like a pterin derivative, 7,8-dihydropterin-6-carboxyaldehyde (2-amino-4-hydroxy-6-formyl-7,8-dihydropteridine). 7,8-dihydropterin-6-carboxyaldehyde 110-145 transthyretin Homo sapiens 65-68 7875325-3 1995 We now show that the major yellow component extracted from human TTR has properties like a pterin derivative, 7,8-dihydropterin-6-carboxyaldehyde (2-amino-4-hydroxy-6-formyl-7,8-dihydropteridine). 7,8-dihydropterin-6-carboxaldehyde 147-194 transthyretin Homo sapiens 65-68 7875325-4 1995 The human TTR derivative has chromatographic and spectral properties identical to a yellow photochemical degradation product of biopterin and a spectrum like that of the pterin aldehyde. Biopterin 128-137 transthyretin Homo sapiens 10-13 7875325-4 1995 The human TTR derivative has chromatographic and spectral properties identical to a yellow photochemical degradation product of biopterin and a spectrum like that of the pterin aldehyde. pterin aldehyde 170-185 transthyretin Homo sapiens 10-13 7850982-11 1995 In fact, the amyloid fibrils were composed of transthyretin, and the two affected individuals from whom DNA was available were both heterozygotes for a single base change in exon 3 of the transthyretin gene, encoding substitution of Lys for the wild-type Thr residue at position 59 in the mature protein. Threonine 255-258 transthyretin Homo sapiens 188-201 7851620-4 1994 When approximately half of the native TBG was denatured by heat, the mean percentage of T4 bound to thyroxine-binding prealbumin (TBPA), measured by a single immunoprecipitation method, was increased from 15.3% to 25.7% and the percentage of T4 bound to albumin was increased from 4.7% to 7.5%. Thyroxine 100-109 transthyretin Homo sapiens 130-134 7553078-8 1995 The structure of the domains of TTR involved in thyroxine (TR) T4 binding has been completely conserved for 350 million years. Thyroxine 48-57 transthyretin Homo sapiens 32-35 7814033-9 1995 TTR transports both thyroxine and retinol and is therefore important for normal fetal development. Thyroxine 20-29 transthyretin Homo sapiens 0-3 7814033-9 1995 TTR transports both thyroxine and retinol and is therefore important for normal fetal development. Vitamin A 34-41 transthyretin Homo sapiens 0-3 7851414-12 1995 This change might affect the accessibility of the thyroxine-binding site in the central channel of transthyretin, since, at least in humans, the N-termini of the subunits of transthyretin are located in the vicinity of the channel entrance [Hamilton, J. Thyroxine 50-59 transthyretin Homo sapiens 99-112 7851414-12 1995 This change might affect the accessibility of the thyroxine-binding site in the central channel of transthyretin, since, at least in humans, the N-termini of the subunits of transthyretin are located in the vicinity of the channel entrance [Hamilton, J. Thyroxine 50-59 transthyretin Homo sapiens 174-187 7875942-2 1994 TTR 10-20, TTR 105-115 as well as a substituted analogue, (TTR 105-115Met111) all formed amyloid-like fibrils readily in 20-30% acetonitrile/water at room temperature. acetonitrile 128-140 transthyretin Homo sapiens 0-3 7966314-2 1994 Transthyretin is a carrier of the hormone thyroxine in plasma whereas retinol-binding protein is the specific transporter of the alcohol form of vitamin A in the same medium. Thyroxine 42-51 transthyretin Homo sapiens 0-13 7966314-2 1994 Transthyretin is a carrier of the hormone thyroxine in plasma whereas retinol-binding protein is the specific transporter of the alcohol form of vitamin A in the same medium. Alcohols 129-136 transthyretin Homo sapiens 0-13 7966314-2 1994 Transthyretin is a carrier of the hormone thyroxine in plasma whereas retinol-binding protein is the specific transporter of the alcohol form of vitamin A in the same medium. Vitamin A 145-154 transthyretin Homo sapiens 0-13 7875942-2 1994 TTR 10-20, TTR 105-115 as well as a substituted analogue, (TTR 105-115Met111) all formed amyloid-like fibrils readily in 20-30% acetonitrile/water at room temperature. acetonitrile 128-140 transthyretin Homo sapiens 11-14 7875942-2 1994 TTR 10-20, TTR 105-115 as well as a substituted analogue, (TTR 105-115Met111) all formed amyloid-like fibrils readily in 20-30% acetonitrile/water at room temperature. acetonitrile 128-140 transthyretin Homo sapiens 11-14 7875942-2 1994 TTR 10-20, TTR 105-115 as well as a substituted analogue, (TTR 105-115Met111) all formed amyloid-like fibrils readily in 20-30% acetonitrile/water at room temperature. Water 141-146 transthyretin Homo sapiens 0-3 7875942-2 1994 TTR 10-20, TTR 105-115 as well as a substituted analogue, (TTR 105-115Met111) all formed amyloid-like fibrils readily in 20-30% acetonitrile/water at room temperature. Water 141-146 transthyretin Homo sapiens 11-14 7875942-2 1994 TTR 10-20, TTR 105-115 as well as a substituted analogue, (TTR 105-115Met111) all formed amyloid-like fibrils readily in 20-30% acetonitrile/water at room temperature. Water 141-146 transthyretin Homo sapiens 11-14 8089102-0 1994 The Ile-84-->Ser amino acid substitution in transthyretin interferes with the interaction with plasma retinol-binding protein. Isoleucine 4-7 transthyretin Homo sapiens 47-60 8089102-0 1994 The Ile-84-->Ser amino acid substitution in transthyretin interferes with the interaction with plasma retinol-binding protein. ser amino acid 16-30 transthyretin Homo sapiens 47-60 8089102-1 1994 In plasma the thyroid hormone-binding protein transthyretin (TTR) forms a tight complex with the specific retinol carrier retinol-binding protein (RBP). Vitamin A 106-113 transthyretin Homo sapiens 46-59 8089102-1 1994 In plasma the thyroid hormone-binding protein transthyretin (TTR) forms a tight complex with the specific retinol carrier retinol-binding protein (RBP). Vitamin A 106-113 transthyretin Homo sapiens 61-64 8089102-2 1994 The Ile-84-->Ser mutation and several other point mutations in TTR are associated with familial amyloidotic polyneuropathy, which is characterized by extracellular depositions of amyloid fibrils mainly consisting of mutated TTRs. Isoleucine 4-7 transthyretin Homo sapiens 66-69 8089102-5 1994 This result indicates the participation of a region on the outer surface of TTR that comprises Ile-84 in the recognition of RBP. Isoleucine 95-98 transthyretin Homo sapiens 76-79 8089102-6 1994 In preliminary studies the Ser-84 TTR was the only one among several amyloidogenic variant TTRs to display negligible interaction with RBP. Serine 27-30 transthyretin Homo sapiens 34-37 8089102-8 1994 Instead, the altered binding of Ser-84 TTR to RBP appears to be responsible for an abnormal plasma transport of RBP. Serine 32-35 transthyretin Homo sapiens 39-42 8002949-8 1994 In contrast, the double mutant in which leucine residues at positions 63 and 64 of the loop C-D were changed to arginine and serine respectively partially retained its TTR-binding ability, but completely lost its affinity for the RBP receptor. Leucine 40-47 transthyretin Homo sapiens 168-171 8203468-7 1994 Our results show that the antigenic sites on normal plasma TTR include the AB loop and the CD loop. Cadmium 91-93 transthyretin Homo sapiens 59-62 8002949-8 1994 In contrast, the double mutant in which leucine residues at positions 63 and 64 of the loop C-D were changed to arginine and serine respectively partially retained its TTR-binding ability, but completely lost its affinity for the RBP receptor. Arginine 112-120 transthyretin Homo sapiens 168-171 8002949-8 1994 In contrast, the double mutant in which leucine residues at positions 63 and 64 of the loop C-D were changed to arginine and serine respectively partially retained its TTR-binding ability, but completely lost its affinity for the RBP receptor. Serine 125-131 transthyretin Homo sapiens 168-171 7923855-0 1994 Two transthyretin mutations (glu42gly, his90asn) in an Italian family with amyloidosis. glu42gly 29-37 transthyretin Homo sapiens 4-17 7923855-0 1994 Two transthyretin mutations (glu42gly, his90asn) in an Italian family with amyloidosis. his90asn 39-47 transthyretin Homo sapiens 4-17 7923855-3 1994 However, close examination of the transthyretin gene revealed that glu42gly is coinherited with his90asn in this family. glu42gly 67-75 transthyretin Homo sapiens 34-47 8196175-1 1994 Some of the point mutations in transthyretin (TTR) exhibit increased affinity for thyroxine (T4) and result in euthyroid hyperthyroxinemia in affected individuals. Thyroxine 82-91 transthyretin Homo sapiens 31-44 8039542-0 1994 Different competition of thyroxine binding to transthyretin and thyroxine-binding globulin by hydroxy-PCBs, PCDDs and PCDFs. Thyroxine 25-34 transthyretin Homo sapiens 46-59 8039542-0 1994 Different competition of thyroxine binding to transthyretin and thyroxine-binding globulin by hydroxy-PCBs, PCDDs and PCDFs. hydroxy-pcbs 94-106 transthyretin Homo sapiens 46-59 8039542-0 1994 Different competition of thyroxine binding to transthyretin and thyroxine-binding globulin by hydroxy-PCBs, PCDDs and PCDFs. Polychlorinated Dibenzodioxins 108-113 transthyretin Homo sapiens 46-59 8039542-0 1994 Different competition of thyroxine binding to transthyretin and thyroxine-binding globulin by hydroxy-PCBs, PCDDs and PCDFs. pcdfs 118-123 transthyretin Homo sapiens 46-59 8039542-1 1994 In an earlier study several hydroxylated polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) competitively displaced [125I]thyroxine (T4) from transthyretin with different potencies. Polychlorinated Biphenyls 41-66 transthyretin Homo sapiens 177-190 8039542-1 1994 In an earlier study several hydroxylated polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) competitively displaced [125I]thyroxine (T4) from transthyretin with different potencies. Polychlorinated Biphenyls 68-72 transthyretin Homo sapiens 177-190 8039542-1 1994 In an earlier study several hydroxylated polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) competitively displaced [125I]thyroxine (T4) from transthyretin with different potencies. dibenzo(1,4)dioxin 75-92 transthyretin Homo sapiens 177-190 8039542-1 1994 In an earlier study several hydroxylated polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) competitively displaced [125I]thyroxine (T4) from transthyretin with different potencies. Polychlorinated Dibenzodioxins 94-99 transthyretin Homo sapiens 177-190 8039542-1 1994 In an earlier study several hydroxylated polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) competitively displaced [125I]thyroxine (T4) from transthyretin with different potencies. Dibenzofurans 105-118 transthyretin Homo sapiens 177-190 8039542-1 1994 In an earlier study several hydroxylated polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) competitively displaced [125I]thyroxine (T4) from transthyretin with different potencies. pcdfs 120-125 transthyretin Homo sapiens 177-190 8039542-1 1994 In an earlier study several hydroxylated polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) competitively displaced [125I]thyroxine (T4) from transthyretin with different potencies. [125I]-Thyroxine 151-166 transthyretin Homo sapiens 177-190 7910950-2 1994 Transthyretin (TTR) gene analysis showed one point mutation (T-->C change) in the second base of codon 55, and the corresponding amino acid substitution of proline (Pro) for leucine (Leu) was confirmed at the protein level. Proline 159-166 transthyretin Homo sapiens 0-13 7910950-2 1994 Transthyretin (TTR) gene analysis showed one point mutation (T-->C change) in the second base of codon 55, and the corresponding amino acid substitution of proline (Pro) for leucine (Leu) was confirmed at the protein level. Proline 159-166 transthyretin Homo sapiens 15-18 7910950-2 1994 Transthyretin (TTR) gene analysis showed one point mutation (T-->C change) in the second base of codon 55, and the corresponding amino acid substitution of proline (Pro) for leucine (Leu) was confirmed at the protein level. Proline 168-171 transthyretin Homo sapiens 0-13 7910950-2 1994 Transthyretin (TTR) gene analysis showed one point mutation (T-->C change) in the second base of codon 55, and the corresponding amino acid substitution of proline (Pro) for leucine (Leu) was confirmed at the protein level. Proline 168-171 transthyretin Homo sapiens 15-18 7910950-2 1994 Transthyretin (TTR) gene analysis showed one point mutation (T-->C change) in the second base of codon 55, and the corresponding amino acid substitution of proline (Pro) for leucine (Leu) was confirmed at the protein level. Leucine 177-184 transthyretin Homo sapiens 0-13 7910950-2 1994 Transthyretin (TTR) gene analysis showed one point mutation (T-->C change) in the second base of codon 55, and the corresponding amino acid substitution of proline (Pro) for leucine (Leu) was confirmed at the protein level. Leucine 177-184 transthyretin Homo sapiens 15-18 7910950-2 1994 Transthyretin (TTR) gene analysis showed one point mutation (T-->C change) in the second base of codon 55, and the corresponding amino acid substitution of proline (Pro) for leucine (Leu) was confirmed at the protein level. Leucine 186-189 transthyretin Homo sapiens 0-13 7910950-2 1994 Transthyretin (TTR) gene analysis showed one point mutation (T-->C change) in the second base of codon 55, and the corresponding amino acid substitution of proline (Pro) for leucine (Leu) was confirmed at the protein level. Leucine 186-189 transthyretin Homo sapiens 15-18 8039542-6 1994 In addition, some T4 derived compounds, e.g., tyrosine, mono-iodotyrosine, di-iodotyrosine and tri-iodophenol were tested on both transthyretin and thyroxine-binding globulin to investigate possible differences in structural characteristics determining T4 binding to thyroxine-binding globulin and transthyretin. tri-iodophenol 95-109 transthyretin Homo sapiens 130-143 8039542-8 1994 However, tri-iodophenol and to a lesser extent di-iodotyrosine inhibited [125I]T4-transthyretin binding. tri-iodophenol 9-23 transthyretin Homo sapiens 82-95 8039542-8 1994 However, tri-iodophenol and to a lesser extent di-iodotyrosine inhibited [125I]T4-transthyretin binding. Diiodotyrosine 47-62 transthyretin Homo sapiens 82-95 8039542-10 1994 The hydroxylated PCBs, PCDDs and PCDFs can inhibit T4 binding to transthyretin, but not to thyroxine-binding globulin, and thus may cause different effects in rodents and man. Polychlorinated Biphenyls 17-21 transthyretin Homo sapiens 65-78 8039542-10 1994 The hydroxylated PCBs, PCDDs and PCDFs can inhibit T4 binding to transthyretin, but not to thyroxine-binding globulin, and thus may cause different effects in rodents and man. Polychlorinated Dibenzodioxins 23-28 transthyretin Homo sapiens 65-78 8039542-10 1994 The hydroxylated PCBs, PCDDs and PCDFs can inhibit T4 binding to transthyretin, but not to thyroxine-binding globulin, and thus may cause different effects in rodents and man. pcdfs 33-38 transthyretin Homo sapiens 65-78 8196175-1 1994 Some of the point mutations in transthyretin (TTR) exhibit increased affinity for thyroxine (T4) and result in euthyroid hyperthyroxinemia in affected individuals. Thyroxine 82-91 transthyretin Homo sapiens 46-49 8196175-2 1994 TTR, also known as thyroxine binding prealbumin, is a homotetrameric plasma protein of MW 55,000 that transports 15% of serum T4. Thyroxine 19-28 transthyretin Homo sapiens 0-3 7906282-0 1994 Thyroxine binding by human transthyretin variants: mutations at position 119, but not position 54, increase thyroxine binding affinity. Thyroxine 0-9 transthyretin Homo sapiens 27-40 7906282-0 1994 Thyroxine binding by human transthyretin variants: mutations at position 119, but not position 54, increase thyroxine binding affinity. Thyroxine 108-117 transthyretin Homo sapiens 27-40 7906282-1 1994 A mutation at codon 119 in the transthyretin (TTR) gene leads to a substitution of methionine for threonine at this position in the circulating protein. Methionine 83-93 transthyretin Homo sapiens 31-44 7906282-1 1994 A mutation at codon 119 in the transthyretin (TTR) gene leads to a substitution of methionine for threonine at this position in the circulating protein. Methionine 83-93 transthyretin Homo sapiens 46-49 7906282-1 1994 A mutation at codon 119 in the transthyretin (TTR) gene leads to a substitution of methionine for threonine at this position in the circulating protein. Threonine 98-107 transthyretin Homo sapiens 31-44 7906282-1 1994 A mutation at codon 119 in the transthyretin (TTR) gene leads to a substitution of methionine for threonine at this position in the circulating protein. Threonine 98-107 transthyretin Homo sapiens 46-49 8125059-1 1993 Transthyretin isolated by polyacrylamide gel electrophoresis from human serum and cerebrospinal fluid, dissociated into its subunits, was subjected to isoelectric focusing in polyacrylamide gels containing 8 mole/L urea. polyacrylamide 26-40 transthyretin Homo sapiens 0-13 8280758-0 1994 Retinoic acid inhibition of thyroxine binding to human transthyretin. Tretinoin 0-13 transthyretin Homo sapiens 55-68 8280758-0 1994 Retinoic acid inhibition of thyroxine binding to human transthyretin. Thyroxine 28-37 transthyretin Homo sapiens 55-68 8280758-4 1994 In the present studies, retinoic acid was examined for its ability to displace thyroxine from binding sites on human transthyretin (TTR). Tretinoin 24-37 transthyretin Homo sapiens 117-130 8280758-4 1994 In the present studies, retinoic acid was examined for its ability to displace thyroxine from binding sites on human transthyretin (TTR). Tretinoin 24-37 transthyretin Homo sapiens 132-135 8280758-4 1994 In the present studies, retinoic acid was examined for its ability to displace thyroxine from binding sites on human transthyretin (TTR). Thyroxine 79-88 transthyretin Homo sapiens 117-130 8280758-4 1994 In the present studies, retinoic acid was examined for its ability to displace thyroxine from binding sites on human transthyretin (TTR). Thyroxine 79-88 transthyretin Homo sapiens 132-135 8280758-8 1994 8-Anilinonaphthalene-1-sulfonate (ANS), a strongly fluorescing dye, binds to the thyroxine binding sites on TTR. 8-anilino-1-naphthalenesulfonic acid 0-32 transthyretin Homo sapiens 108-111 8280758-8 1994 8-Anilinonaphthalene-1-sulfonate (ANS), a strongly fluorescing dye, binds to the thyroxine binding sites on TTR. 8-anilino-1-naphthalenesulfonic acid 34-37 transthyretin Homo sapiens 108-111 8280758-8 1994 8-Anilinonaphthalene-1-sulfonate (ANS), a strongly fluorescing dye, binds to the thyroxine binding sites on TTR. Thyroxine 81-90 transthyretin Homo sapiens 108-111 8280758-9 1994 T4 and 3,5,3"-L-triiodothyronine (T3) shifted the fluorescence emission maximum and intensity of an ANS-TTR solution toward the spectrum obtained from uncomplexed ANS. 3,5,3"-l-triiodothyronine 7-32 transthyretin Homo sapiens 104-107 8280758-9 1994 T4 and 3,5,3"-L-triiodothyronine (T3) shifted the fluorescence emission maximum and intensity of an ANS-TTR solution toward the spectrum obtained from uncomplexed ANS. Triiodothyronine 34-36 transthyretin Homo sapiens 104-107 8280758-9 1994 T4 and 3,5,3"-L-triiodothyronine (T3) shifted the fluorescence emission maximum and intensity of an ANS-TTR solution toward the spectrum obtained from uncomplexed ANS. 8-anilino-1-naphthalenesulfonic acid 100-103 transthyretin Homo sapiens 104-107 8280758-9 1994 T4 and 3,5,3"-L-triiodothyronine (T3) shifted the fluorescence emission maximum and intensity of an ANS-TTR solution toward the spectrum obtained from uncomplexed ANS. 8-anilino-1-naphthalenesulfonic acid 163-166 transthyretin Homo sapiens 104-107 8280758-11 1994 Retinol failed to quench the emission intensity of the ANS-TTR complex, while 13-cis-retinoic acid was less effective than all-trans retinoic acid. 8-anilino-1-naphthalenesulfonic acid 55-58 transthyretin Homo sapiens 59-62 7946531-2 1994 TTR is one of three specific carrier proteins involved in the transport of both thyroid hormones and of retinol through the mediation of RBP. Vitamin A 104-111 transthyretin Homo sapiens 0-3 7951260-0 1994 A new mutation (TTR Ala-47) in the transthyretin gene associated with hereditary amyloidosis. Alanine 20-23 transthyretin Homo sapiens 16-19 7951260-0 1994 A new mutation (TTR Ala-47) in the transthyretin gene associated with hereditary amyloidosis. Alanine 20-23 transthyretin Homo sapiens 35-48 8019560-0 1994 A double-variant transthyretin allele (Ser 6, Ile 33) in the Israeli patient "SKO" with familial amyloidotic polyneuropathy. Serine 39-42 transthyretin Homo sapiens 17-30 8019560-0 1994 A double-variant transthyretin allele (Ser 6, Ile 33) in the Israeli patient "SKO" with familial amyloidotic polyneuropathy. Isoleucine 46-49 transthyretin Homo sapiens 17-30 7973484-1 1994 In order to assess the prevalence of the carpal tunnel syndrome (CTS) suggestive of beta 2 microglobulin amyloid deposit in patients undergoing hemodialysis with cuprophan and acetate membrane, we studied 30 patients who had been receiving hemodialysis for varying lengths of time. cuprammonium cellulose 162-171 transthyretin Homo sapiens 65-68 7973484-1 1994 In order to assess the prevalence of the carpal tunnel syndrome (CTS) suggestive of beta 2 microglobulin amyloid deposit in patients undergoing hemodialysis with cuprophan and acetate membrane, we studied 30 patients who had been receiving hemodialysis for varying lengths of time. Acetates 176-183 transthyretin Homo sapiens 65-68 8218290-4 1993 Transthyretin"s resistance to sodium dodecyl sulfate- (SDS-) induced denaturation was utilized to measure the quaternary stability as a function of pH employing SDS-polyacrylamide gel electrophoresis (PAGE) in the presence and absence of an amyloid fibril inhibitor, Z 3-14. Sodium Dodecyl Sulfate 30-52 transthyretin Homo sapiens 0-13 8218290-4 1993 Transthyretin"s resistance to sodium dodecyl sulfate- (SDS-) induced denaturation was utilized to measure the quaternary stability as a function of pH employing SDS-polyacrylamide gel electrophoresis (PAGE) in the presence and absence of an amyloid fibril inhibitor, Z 3-14. Sodium Dodecyl Sulfate 55-58 transthyretin Homo sapiens 0-13 8218290-4 1993 Transthyretin"s resistance to sodium dodecyl sulfate- (SDS-) induced denaturation was utilized to measure the quaternary stability as a function of pH employing SDS-polyacrylamide gel electrophoresis (PAGE) in the presence and absence of an amyloid fibril inhibitor, Z 3-14. Sodium Dodecyl Sulfate 161-164 transthyretin Homo sapiens 0-13 8218290-4 1993 Transthyretin"s resistance to sodium dodecyl sulfate- (SDS-) induced denaturation was utilized to measure the quaternary stability as a function of pH employing SDS-polyacrylamide gel electrophoresis (PAGE) in the presence and absence of an amyloid fibril inhibitor, Z 3-14. polyacrylamide 165-179 transthyretin Homo sapiens 0-13 8176515-4 1994 Iontophoresis of dexamethasone sodium phosphate has been used for years in the treatment of many musculoskeletal inflammatory disorders and clinicians have reported using this modality in the treatment of CTS. dexamethasone 21-phosphate 17-47 transthyretin Homo sapiens 205-208 8275943-0 1994 Threonine for alanine substitution at position 109 of transthyretin differentially alters human transthyretin"s affinity for iodothyronines. Threonine 0-9 transthyretin Homo sapiens 54-67 8275943-0 1994 Threonine for alanine substitution at position 109 of transthyretin differentially alters human transthyretin"s affinity for iodothyronines. Threonine 0-9 transthyretin Homo sapiens 96-109 8275943-0 1994 Threonine for alanine substitution at position 109 of transthyretin differentially alters human transthyretin"s affinity for iodothyronines. Alanine 14-21 transthyretin Homo sapiens 54-67 8275943-0 1994 Threonine for alanine substitution at position 109 of transthyretin differentially alters human transthyretin"s affinity for iodothyronines. Alanine 14-21 transthyretin Homo sapiens 96-109 8275943-0 1994 Threonine for alanine substitution at position 109 of transthyretin differentially alters human transthyretin"s affinity for iodothyronines. iodothyronines 125-139 transthyretin Homo sapiens 54-67 8275943-0 1994 Threonine for alanine substitution at position 109 of transthyretin differentially alters human transthyretin"s affinity for iodothyronines. iodothyronines 125-139 transthyretin Homo sapiens 96-109 8275943-4 1994 The affinities of the iodothyronines for TTR were determined by measuring [125I]T4 bound by TTR in the presence of increasing concentrations of unlabeled iodothyronines. iodothyronines 22-36 transthyretin Homo sapiens 41-44 8275943-4 1994 The affinities of the iodothyronines for TTR were determined by measuring [125I]T4 bound by TTR in the presence of increasing concentrations of unlabeled iodothyronines. iodothyronines 22-36 transthyretin Homo sapiens 92-95 8275943-4 1994 The affinities of the iodothyronines for TTR were determined by measuring [125I]T4 bound by TTR in the presence of increasing concentrations of unlabeled iodothyronines. iodothyronines 154-168 transthyretin Homo sapiens 41-44 8275943-6 1994 The affinity of Thr109-TTR for all iodothyronines was higher than that of WT TTR. iodothyronines 35-49 transthyretin Homo sapiens 23-26 8275943-7 1994 However, the Thr109 mutation increased TTR"s affinity for T4, Triac (triiodothyroacetic acid), and T3 to a greater extent than it did for Tetrac (tetraiodothyroacetic acid), EMD21388 (3",5"-dibromo-4",6"-dihydroxy-3-methylflavone), and dextro-T4. 3,3',5-triiodothyroacetic acid 62-67 transthyretin Homo sapiens 39-42 8275943-7 1994 However, the Thr109 mutation increased TTR"s affinity for T4, Triac (triiodothyroacetic acid), and T3 to a greater extent than it did for Tetrac (tetraiodothyroacetic acid), EMD21388 (3",5"-dibromo-4",6"-dihydroxy-3-methylflavone), and dextro-T4. 3,3',5-triiodothyroacetic acid 69-92 transthyretin Homo sapiens 39-42 8275943-7 1994 However, the Thr109 mutation increased TTR"s affinity for T4, Triac (triiodothyroacetic acid), and T3 to a greater extent than it did for Tetrac (tetraiodothyroacetic acid), EMD21388 (3",5"-dibromo-4",6"-dihydroxy-3-methylflavone), and dextro-T4. tetraiodothyroacetic acid 146-171 transthyretin Homo sapiens 39-42 8275943-7 1994 However, the Thr109 mutation increased TTR"s affinity for T4, Triac (triiodothyroacetic acid), and T3 to a greater extent than it did for Tetrac (tetraiodothyroacetic acid), EMD21388 (3",5"-dibromo-4",6"-dihydroxy-3-methylflavone), and dextro-T4. 3",5"-dibromo-4",6"-dihydroxy-3-methylflavone 184-229 transthyretin Homo sapiens 39-42 8275943-7 1994 However, the Thr109 mutation increased TTR"s affinity for T4, Triac (triiodothyroacetic acid), and T3 to a greater extent than it did for Tetrac (tetraiodothyroacetic acid), EMD21388 (3",5"-dibromo-4",6"-dihydroxy-3-methylflavone), and dextro-T4. dextro-t4 236-245 transthyretin Homo sapiens 39-42 8275943-8 1994 These data demonstrate that a subtle change in the structure of the T4-binding channel in TTR differentially alters the affinity of binding of various iodothyronines and suggests that site-directed mutagenesis of residues within the binding channel might clarify the relative importance of specific domains of this binding channel. iodothyronines 151-165 transthyretin Homo sapiens 90-93 8267575-1 1993 The role of intermolecular disulfide linkages in transthyretin (TTR) amyloid fibril formation was investigated by comparing wild type TTR to Cys-10-Ala TTR which is incapable of disulfide formation. Disulfides 27-36 transthyretin Homo sapiens 49-62 8267575-1 1993 The role of intermolecular disulfide linkages in transthyretin (TTR) amyloid fibril formation was investigated by comparing wild type TTR to Cys-10-Ala TTR which is incapable of disulfide formation. Disulfides 27-36 transthyretin Homo sapiens 64-67 8125059-1 1993 Transthyretin isolated by polyacrylamide gel electrophoresis from human serum and cerebrospinal fluid, dissociated into its subunits, was subjected to isoelectric focusing in polyacrylamide gels containing 8 mole/L urea. polyacrylamide 175-189 transthyretin Homo sapiens 0-13 8125059-1 1993 Transthyretin isolated by polyacrylamide gel electrophoresis from human serum and cerebrospinal fluid, dissociated into its subunits, was subjected to isoelectric focusing in polyacrylamide gels containing 8 mole/L urea. Urea 215-219 transthyretin Homo sapiens 0-13 8406434-0 1993 Retrospective molecular detection of Transthyretin Met 111 mutation in a Danish kindred with familial amyloid cardiomyopathy, using DNA from formalin-fixed and paraffin-embedded tissues. Formaldehyde 141-149 transthyretin Homo sapiens 37-50 8406434-0 1993 Retrospective molecular detection of Transthyretin Met 111 mutation in a Danish kindred with familial amyloid cardiomyopathy, using DNA from formalin-fixed and paraffin-embedded tissues. Paraffin 160-168 transthyretin Homo sapiens 37-50 8260484-5 1993 Hb was strongly correlated with retinol, ferritin, MCHC, MCH, packed cell volume and erythrocyte count while retinol formed a triad with transthyretin (TTR) and retinol-binding protein (RBP) which were all correlated with one another. Vitamin A 109-116 transthyretin Homo sapiens 137-150 8260484-5 1993 Hb was strongly correlated with retinol, ferritin, MCHC, MCH, packed cell volume and erythrocyte count while retinol formed a triad with transthyretin (TTR) and retinol-binding protein (RBP) which were all correlated with one another. Vitamin A 109-116 transthyretin Homo sapiens 152-155 8260484-8 1993 Thyroxin and triiodothyronine in both free and combined forms were all correlated with thyroxin-binding globulin which in turn was negatively correlated with the triad retinol, RBP and TTR. Thyroxine 0-8 transthyretin Homo sapiens 185-188 8345041-0 1993 Thyroxine interactions with transthyretin: a comparison of 10 different naturally occurring human transthyretin variants. Thyroxine 0-9 transthyretin Homo sapiens 28-41 8260484-8 1993 Thyroxin and triiodothyronine in both free and combined forms were all correlated with thyroxin-binding globulin which in turn was negatively correlated with the triad retinol, RBP and TTR. Triiodothyronine 13-29 transthyretin Homo sapiens 185-188 8352764-4 1993 This substitution, verified by direct DNA sequencing, was the result of a guanine to adenine change on exon 3 of the TTR gene. Guanine 74-81 transthyretin Homo sapiens 117-120 8352764-4 1993 This substitution, verified by direct DNA sequencing, was the result of a guanine to adenine change on exon 3 of the TTR gene. Adenine 85-92 transthyretin Homo sapiens 117-120 8352764-6 1993 TTR-Lys61 is the first variant TTR with a replacement of the acidic with basic amino acid to be found in the amyloid precursor proteins of FAP. Amino Acids, Basic 73-89 transthyretin Homo sapiens 0-3 8352764-6 1993 TTR-Lys61 is the first variant TTR with a replacement of the acidic with basic amino acid to be found in the amyloid precursor proteins of FAP. Amino Acids, Basic 73-89 transthyretin Homo sapiens 31-34 8401513-2 1993 Valine30-->methionine (TTR M30) is by far the most common mutation in patients with FAP. valine30 0-8 transthyretin Homo sapiens 26-29 8401513-2 1993 Valine30-->methionine (TTR M30) is by far the most common mutation in patients with FAP. Methionine 14-24 transthyretin Homo sapiens 26-29 8102146-0 1993 Thyroxine binding in a TTR Met 119 kindred. Thyroxine 0-9 transthyretin Homo sapiens 23-26 8102146-1 1993 Recently, a transthyretin variant, TTR Met 119, in which methionine substitutes for threonine 119, a component of the protein"s iodothyronine binding site, was identified in individuals with transient euthyroid hyperthyroxinemia. iodothyronine 128-141 transthyretin Homo sapiens 35-38 8102146-4 1993 Cyanogen bromide peptide mapping and DNA restriction length polymorphism analyses showed that the propositus was a compound heterozygote for two TTR variants: Asn 90 and Met 119. Cyanogen Bromide 0-16 transthyretin Homo sapiens 145-148 8102146-4 1993 Cyanogen bromide peptide mapping and DNA restriction length polymorphism analyses showed that the propositus was a compound heterozygote for two TTR variants: Asn 90 and Met 119. Asparagine 159-162 transthyretin Homo sapiens 145-148 8102146-5 1993 Family analysis revealed that he inherited the TTR Met 119 variant from the mother and the TTR Asn 90 variant from the father. Asparagine 95-98 transthyretin Homo sapiens 91-94 8102146-7 1993 Serum dialysis with stepwise saturation of iodothyronine binding sites confirmed that TTR binding of T4 is increased in TTR Met 119. iodothyronine 43-56 transthyretin Homo sapiens 86-89 8102146-7 1993 Serum dialysis with stepwise saturation of iodothyronine binding sites confirmed that TTR binding of T4 is increased in TTR Met 119. iodothyronine 43-56 transthyretin Homo sapiens 120-123 8345041-0 1993 Thyroxine interactions with transthyretin: a comparison of 10 different naturally occurring human transthyretin variants. Thyroxine 0-9 transthyretin Homo sapiens 98-111 8330325-4 1993 All hydroxylated PCBs, but not the single PCB tested, competitively displaced [125I]T4 from TTR with differential potency. Polychlorinated Biphenyls 17-21 transthyretin Homo sapiens 92-95 8330325-8 1993 Marked differences in TTR-T4 binding competition potency were observed between the limited number of hydroxylated PCDDs and PCDFs tested. Polychlorinated Dibenzodioxins 114-119 transthyretin Homo sapiens 22-25 8330325-0 1993 Structure-dependent, competitive interaction of hydroxy-polychlorobiphenyls, -dibenzo-p-dioxins and -dibenzofurans with human transthyretin. hydroxy-polychlorobiphenyls, -dibenzo-p-dioxins 48-95 transthyretin Homo sapiens 126-139 8330325-0 1993 Structure-dependent, competitive interaction of hydroxy-polychlorobiphenyls, -dibenzo-p-dioxins and -dibenzofurans with human transthyretin. Dibenzofurans 100-114 transthyretin Homo sapiens 126-139 8330325-2 1993 In the present study the structural requirements for competition with thyroxine (T4) for TTR-binding were investigated in more detail. Thyroxine 70-79 transthyretin Homo sapiens 89-92 8330325-8 1993 Marked differences in TTR-T4 binding competition potency were observed between the limited number of hydroxylated PCDDs and PCDFs tested. pcdfs 124-129 transthyretin Homo sapiens 22-25 8330325-11 1993 These results indicate a profound similarity in structural requirements for TTR binding between hydroxy-PCB, -PCDD and -PCDF metabolites and the physiological ligand, T4, e.g. halogen substitution adjacent to the para hydroxy group, while planarity does not seem to influence the ligand-binding potency. Polychlorinated Dibenzodioxins 109-114 transthyretin Homo sapiens 76-79 8330325-11 1993 These results indicate a profound similarity in structural requirements for TTR binding between hydroxy-PCB, -PCDD and -PCDF metabolites and the physiological ligand, T4, e.g. halogen substitution adjacent to the para hydroxy group, while planarity does not seem to influence the ligand-binding potency. -pcdf 119-124 transthyretin Homo sapiens 76-79 8268724-0 1993 Retrovirus-mediated gene transfer of transthyretin and transthyretin-methionine 30: a potential tool for the study of amyloidogenesis. Methionine 69-79 transthyretin Homo sapiens 55-68 8454595-1 1993 Crystal structure determination to 1.9 A of the human serum transthyretin-milrinone complex. Milrinone 74-83 transthyretin Homo sapiens 60-73 8454595-2 1993 The crystal structure of human transthyretin (TTR) complexed with milrinone (2-methyl-5-cyano-3,4"-bipyridin-6(1H)-one), a positive inotropic cardiac agent, has been refined to R = 17.4% for 8-1.9-A resolution data. Milrinone 66-75 transthyretin Homo sapiens 31-44 8454595-2 1993 The crystal structure of human transthyretin (TTR) complexed with milrinone (2-methyl-5-cyano-3,4"-bipyridin-6(1H)-one), a positive inotropic cardiac agent, has been refined to R = 17.4% for 8-1.9-A resolution data. Milrinone 66-75 transthyretin Homo sapiens 46-49 8454595-2 1993 The crystal structure of human transthyretin (TTR) complexed with milrinone (2-methyl-5-cyano-3,4"-bipyridin-6(1H)-one), a positive inotropic cardiac agent, has been refined to R = 17.4% for 8-1.9-A resolution data. 2-methyl-5-cyano-3,4"-bipyridin-6(1h)-one 77-118 transthyretin Homo sapiens 31-44 8454595-2 1993 The crystal structure of human transthyretin (TTR) complexed with milrinone (2-methyl-5-cyano-3,4"-bipyridin-6(1H)-one), a positive inotropic cardiac agent, has been refined to R = 17.4% for 8-1.9-A resolution data. 2-methyl-5-cyano-3,4"-bipyridin-6(1h)-one 77-118 transthyretin Homo sapiens 46-49 8454595-3 1993 This report provides the first detailed description of protein interactions for an inotropic bipyridine agent which is an effective thyroid hormone binding competitor to transthyretin. 2,2'-Dipyridyl 93-103 transthyretin Homo sapiens 170-183 8454595-4 1993 Milrinone is bound along the 2-fold axis in the binding site with its substituted pyridone ring located deep within the channel of the two identical binding domains of the TTR tetramer. Milrinone 0-9 transthyretin Homo sapiens 172-175 8454595-4 1993 Milrinone is bound along the 2-fold axis in the binding site with its substituted pyridone ring located deep within the channel of the two identical binding domains of the TTR tetramer. Pyridones 82-90 transthyretin Homo sapiens 172-175 8454595-5 1993 In this orientation the 5-cyano group occupies the same site as the 3"-iodine in the TTR complex with 3,3"-diiodothyronine (Wojtczak, A., Luft, J., and Cody, V. (1992) J. Biol. 3"-iodine 68-77 transthyretin Homo sapiens 85-88 8454595-5 1993 In this orientation the 5-cyano group occupies the same site as the 3"-iodine in the TTR complex with 3,3"-diiodothyronine (Wojtczak, A., Luft, J., and Cody, V. (1992) J. Biol. 3,3'-diiodothyronine 102-122 transthyretin Homo sapiens 85-88 8454595-8 1993 These structural results confirm computer modeling studies of milrinone structural homology with thyroxine and its TTR binding interactions and explain the effectiveness of milrinone competition for thyroxine binding to TTR. Milrinone 62-71 transthyretin Homo sapiens 115-118 8454595-8 1993 These structural results confirm computer modeling studies of milrinone structural homology with thyroxine and its TTR binding interactions and explain the effectiveness of milrinone competition for thyroxine binding to TTR. Milrinone 62-71 transthyretin Homo sapiens 220-223 8454595-8 1993 These structural results confirm computer modeling studies of milrinone structural homology with thyroxine and its TTR binding interactions and explain the effectiveness of milrinone competition for thyroxine binding to TTR. Thyroxine 97-106 transthyretin Homo sapiens 220-223 8454595-8 1993 These structural results confirm computer modeling studies of milrinone structural homology with thyroxine and its TTR binding interactions and explain the effectiveness of milrinone competition for thyroxine binding to TTR. Milrinone 173-182 transthyretin Homo sapiens 220-223 8454595-8 1993 These structural results confirm computer modeling studies of milrinone structural homology with thyroxine and its TTR binding interactions and explain the effectiveness of milrinone competition for thyroxine binding to TTR. Thyroxine 199-208 transthyretin Homo sapiens 220-223 8454595-9 1993 To understand the weaker binding affinity of the parent inotropic drug, amrinone (5-amino-3,4"-bipyridin-6(1H)-one), modeling studies of its TTR binding were carried out which indicate that the 5-amino group cannot participate in strong interactions with TTR and the lack of the 2-methyl further weakens amrinone binding. Amrinone 72-80 transthyretin Homo sapiens 141-144 8454595-9 1993 To understand the weaker binding affinity of the parent inotropic drug, amrinone (5-amino-3,4"-bipyridin-6(1H)-one), modeling studies of its TTR binding were carried out which indicate that the 5-amino group cannot participate in strong interactions with TTR and the lack of the 2-methyl further weakens amrinone binding. Amrinone 72-80 transthyretin Homo sapiens 255-258 8428916-0 1993 X-ray crystal structure of the Ala-109-->Thr variant of human transthyretin which produces euthyroid hyperthyroxinemia. Alanine 31-34 transthyretin Homo sapiens 65-78 8428916-1 1993 The structure of the Ala-109-->Thr mutation of human transthyretin, a nonamyloidogenic variant with enhanced thyroxine binding, has been determined by x-ray diffraction to a resolution of 1.7 A. Threonine 34-37 transthyretin Homo sapiens 56-69 8345958-4 1993 In all patients belonging to the TTR Ala 49 family the vitreous body, the heart and the peripheral nervous system were massively infiltrated by amyloid matter. Alanine 37-40 transthyretin Homo sapiens 33-36 8428916-1 1993 The structure of the Ala-109-->Thr mutation of human transthyretin, a nonamyloidogenic variant with enhanced thyroxine binding, has been determined by x-ray diffraction to a resolution of 1.7 A. Thyroxine 112-121 transthyretin Homo sapiens 56-69 8428916-0 1993 X-ray crystal structure of the Ala-109-->Thr variant of human transthyretin which produces euthyroid hyperthyroxinemia. Threonine 44-47 transthyretin Homo sapiens 65-78 8428916-1 1993 The structure of the Ala-109-->Thr mutation of human transthyretin, a nonamyloidogenic variant with enhanced thyroxine binding, has been determined by x-ray diffraction to a resolution of 1.7 A. Alanine 21-24 transthyretin Homo sapiens 56-69 8382610-4 1993 The comparison shows that the effect of the substitution at position 30 is transmitted through the protein core to Cys10, the only thiol group in the TTR subunit, which becomes slightly more exposed. Sulfhydryl Compounds 131-136 transthyretin Homo sapiens 150-153 8095018-7 1993 This cysteine seemed to be involved in an interchain disulfide bridge both between intact TTR molecules and between small fragments. Cysteine 5-13 transthyretin Homo sapiens 90-93 8095018-7 1993 This cysteine seemed to be involved in an interchain disulfide bridge both between intact TTR molecules and between small fragments. Disulfides 53-62 transthyretin Homo sapiens 90-93 8382610-6 1993 Use of computer graphics has shown that it is possible to model a linear aggregate of TTR molecules, each linked to the next by a pair of disulphide bonds involving Cys10 residues. disulphide 138-148 transthyretin Homo sapiens 86-89 8382610-7 1993 Formation of these disulphide bonds involves a small number of slightly short molecular contacts with native TTR molecules, most of which are relieved in the Met30 variant. disulphide 19-29 transthyretin Homo sapiens 109-112 8095302-0 1993 A transthyretin variant (alanine 71) associated with familial amyloidotic polyneuropathy in a French family. Alanine 25-32 transthyretin Homo sapiens 2-15 8095302-4 1993 Direct genomic DNA sequencing of TTR exon 3 showed both thymine and cytosine in the position corresponding to the second base of codon 71. Thymine 56-63 transthyretin Homo sapiens 33-36 8095302-4 1993 Direct genomic DNA sequencing of TTR exon 3 showed both thymine and cytosine in the position corresponding to the second base of codon 71. Cytosine 68-76 transthyretin Homo sapiens 33-36 8482993-1 1993 A clinical and electrophysiological study evaluated the usefulness of local steroid therapy for carpal tunnel syndrome (CTS). Steroids 76-83 transthyretin Homo sapiens 120-123 8482993-7 1993 In order to appraise the long-term effect of local steroid treatment on CTS, 53 patients (91 nerves) were studied and followed up by means of clinical and electrophysiological examinations performed every 2 months for 2 years. Steroids 51-58 transthyretin Homo sapiens 72-75 1631168-10 1992 Comparison of structural data for bromoaurone- and thyroxine-TTR complexes indicates that bromoaurone binding mode I is 3 A deeper in the channel and binding mode II is 4 A further from the channel center than thyroxine. bromoaurone 90-101 transthyretin Homo sapiens 61-64 1362222-0 1992 A new mutant transthyretin (Arg 10) associated with familial amyloid polyneuropathy. Arginine 28-31 transthyretin Homo sapiens 13-26 1362222-4 1992 The point mutation (cytosine for thymine at position 1038 of the TTR gene) is responsible for substitution of arginine for cysteine at position 10 of the TTR molecule. Cytosine 20-28 transthyretin Homo sapiens 65-68 1362222-4 1992 The point mutation (cytosine for thymine at position 1038 of the TTR gene) is responsible for substitution of arginine for cysteine at position 10 of the TTR molecule. Cytosine 20-28 transthyretin Homo sapiens 154-157 1362222-4 1992 The point mutation (cytosine for thymine at position 1038 of the TTR gene) is responsible for substitution of arginine for cysteine at position 10 of the TTR molecule. Thymine 33-40 transthyretin Homo sapiens 65-68 1362222-4 1992 The point mutation (cytosine for thymine at position 1038 of the TTR gene) is responsible for substitution of arginine for cysteine at position 10 of the TTR molecule. Thymine 33-40 transthyretin Homo sapiens 154-157 1362222-5 1992 It is hypothesised that the TTR molecules which have no cysteine have a unique structure in heterozygous TTR polymers and are responsible for amyloid fibril formation. Cysteine 56-64 transthyretin Homo sapiens 28-31 1362222-5 1992 It is hypothesised that the TTR molecules which have no cysteine have a unique structure in heterozygous TTR polymers and are responsible for amyloid fibril formation. Polymers 109-117 transthyretin Homo sapiens 28-31 1362222-5 1992 It is hypothesised that the TTR molecules which have no cysteine have a unique structure in heterozygous TTR polymers and are responsible for amyloid fibril formation. Polymers 109-117 transthyretin Homo sapiens 105-108 1436517-0 1992 Familial amyloidotic polyneuropathy presenting with carpal tunnel syndrome and a new transthyretin mutation, asparagine 70. Asparagine 109-119 transthyretin Homo sapiens 85-98 1386578-3 1992 The remarkable early reduction in plasma retinol level induced by fenretinide administration may be associated with the high binding affinity of this retinoid to RBP and to its interference with the RBP-TTR complex formation. Vitamin A 41-48 transthyretin Homo sapiens 203-206 1386578-3 1992 The remarkable early reduction in plasma retinol level induced by fenretinide administration may be associated with the high binding affinity of this retinoid to RBP and to its interference with the RBP-TTR complex formation. Fenretinide 66-77 transthyretin Homo sapiens 203-206 1633877-2 1992 The amino acid substitution was proven to result from a guanine-to-cytosine change at the first base of codon 30 located in exon 2 in the mutated transthyretin gene by restriction fragment length analysis on the amplified transthyretin gene using Cfr13 I. Guanine 56-63 transthyretin Homo sapiens 146-159 1633877-2 1992 The amino acid substitution was proven to result from a guanine-to-cytosine change at the first base of codon 30 located in exon 2 in the mutated transthyretin gene by restriction fragment length analysis on the amplified transthyretin gene using Cfr13 I. Guanine 56-63 transthyretin Homo sapiens 222-235 1633877-2 1992 The amino acid substitution was proven to result from a guanine-to-cytosine change at the first base of codon 30 located in exon 2 in the mutated transthyretin gene by restriction fragment length analysis on the amplified transthyretin gene using Cfr13 I. Cytosine 67-75 transthyretin Homo sapiens 146-159 1633877-2 1992 The amino acid substitution was proven to result from a guanine-to-cytosine change at the first base of codon 30 located in exon 2 in the mutated transthyretin gene by restriction fragment length analysis on the amplified transthyretin gene using Cfr13 I. Cytosine 67-75 transthyretin Homo sapiens 222-235 1487520-2 1992 The dye leaching from Remazol Yellow GGL-Sepharose used for the affinity chromatography of human plasma transthyretin was quantitatively studied by a sensitive competitive enzyme immunoassay. reactive yellow 13 22-40 transthyretin Homo sapiens 104-117 1487520-2 1992 The dye leaching from Remazol Yellow GGL-Sepharose used for the affinity chromatography of human plasma transthyretin was quantitatively studied by a sensitive competitive enzyme immunoassay. Sepharose 41-50 transthyretin Homo sapiens 104-117 1445851-0 1992 Interactions of retinol with binding proteins: studies with retinol-binding protein and with transthyretin. Vitamin A 16-23 transthyretin Homo sapiens 93-106 1445851-2 1992 To monitor binding between retinol-binding protein (RBP) and transthyretin (TTR), TTR was labeled with a long-lived fluorescence probe (pyrene). pyrene 136-142 transthyretin Homo sapiens 61-74 1445851-2 1992 To monitor binding between retinol-binding protein (RBP) and transthyretin (TTR), TTR was labeled with a long-lived fluorescence probe (pyrene). pyrene 136-142 transthyretin Homo sapiens 82-85 1445851-5 1992 At 0.15 M NaCl, binding of RBP to TTR showed an absolute requirement for the native ligand, retinol. Sodium Chloride 10-14 transthyretin Homo sapiens 34-37 1445851-5 1992 At 0.15 M NaCl, binding of RBP to TTR showed an absolute requirement for the native ligand, retinol. Vitamin A 92-99 transthyretin Homo sapiens 34-37 1445851-6 1992 At higher ionic strength (0.5 M NaCl), RBP complexed with retinal also bound to TTR with high affinity (Kd = 0.134 microM). Sodium Chloride 32-36 transthyretin Homo sapiens 80-83 1445851-8 1992 The data suggest that the TTR binding site on RBP is in close proximity to the retinoid binding site and that the head group of retinoic acid, when bound to RBP, presents steric hindrance for the interactions with TTR. Retinoids 79-87 transthyretin Homo sapiens 26-29 1445851-8 1992 The data suggest that the TTR binding site on RBP is in close proximity to the retinoid binding site and that the head group of retinoic acid, when bound to RBP, presents steric hindrance for the interactions with TTR. Retinoids 79-87 transthyretin Homo sapiens 214-217 1445851-8 1992 The data suggest that the TTR binding site on RBP is in close proximity to the retinoid binding site and that the head group of retinoic acid, when bound to RBP, presents steric hindrance for the interactions with TTR. Tretinoin 128-141 transthyretin Homo sapiens 26-29 1445851-8 1992 The data suggest that the TTR binding site on RBP is in close proximity to the retinoid binding site and that the head group of retinoic acid, when bound to RBP, presents steric hindrance for the interactions with TTR. Tretinoin 128-141 transthyretin Homo sapiens 214-217 1445851-13 1992 The rate of dissociation is slow (k = 0.055/h), however, indicating that the complex apo-RBP-TTR will be an important factor in regulating serum levels of retinol. Vitamin A 155-162 transthyretin Homo sapiens 93-96 1335038-6 1992 A genetic mutation, causing a Ser50-->Arg substitution of the TTR molecule, was identified in another family member. Arginine 41-44 transthyretin Homo sapiens 65-68 1390650-7 1992 Near-UV CD studies demonstrate that transthyretin has retained the majority of its tertiary structure during fibril formation as well. Cadmium 8-10 transthyretin Homo sapiens 36-49 1520336-2 1992 The PCR products of the transthyretin gene were denatured in the presence of formamide and electrophoresed in a non-denaturing polyacrylamide gel to detect an electrophoretic change due to a sequence variation. formamide 77-86 transthyretin Homo sapiens 24-37 1520336-2 1992 The PCR products of the transthyretin gene were denatured in the presence of formamide and electrophoresed in a non-denaturing polyacrylamide gel to detect an electrophoretic change due to a sequence variation. polyacrylamide 127-141 transthyretin Homo sapiens 24-37 1644839-5 1992 These recombinant transthyretin (r-TTR) proteins showed the correct size (14 kilodaltons) on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western analysis and self-associated into tetramers as determined by size exclusion chromatography. Sodium Dodecyl Sulfate 93-115 transthyretin Homo sapiens 18-31 1644839-5 1992 These recombinant transthyretin (r-TTR) proteins showed the correct size (14 kilodaltons) on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western analysis and self-associated into tetramers as determined by size exclusion chromatography. Sodium Dodecyl Sulfate 93-115 transthyretin Homo sapiens 35-38 1644839-5 1992 These recombinant transthyretin (r-TTR) proteins showed the correct size (14 kilodaltons) on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western analysis and self-associated into tetramers as determined by size exclusion chromatography. polyacrylamide 116-130 transthyretin Homo sapiens 18-31 1644839-5 1992 These recombinant transthyretin (r-TTR) proteins showed the correct size (14 kilodaltons) on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western analysis and self-associated into tetramers as determined by size exclusion chromatography. polyacrylamide 116-130 transthyretin Homo sapiens 35-38 1644839-6 1992 Recombinant normal, Ser6, and Ala60 r-TTRs had an affinity for thyroxine indistinguishable from normal human TTR purified from plasma, whereas His58 and Ser84 r-TTRs had significantly reduced affinity. Thyroxine 63-72 transthyretin Homo sapiens 38-41 1644839-7 1992 On the other hand, Thr109 r-TTR had a much higher affinity, probably due to its position within the thyroxine-binding pocket. Thyroxine 100-109 transthyretin Homo sapiens 28-31 1631168-1 1992 The crystal structure of the complex of 3",5"-dibromo-2",4,4",6-tetrahydroxyaurone, a flavone derivative, with human transthyretin (TTR), a serum thyroid hormone transport protein, has been determined and refined to R = 17.9% for data to 2.3-A resolution and provides a detailed description of a protein-bound flavonoid structure. 3',5'-dibromo-2',4,4',6-tetrahydroxyaurone 40-82 transthyretin Homo sapiens 117-130 1631168-1 1992 The crystal structure of the complex of 3",5"-dibromo-2",4,4",6-tetrahydroxyaurone, a flavone derivative, with human transthyretin (TTR), a serum thyroid hormone transport protein, has been determined and refined to R = 17.9% for data to 2.3-A resolution and provides a detailed description of a protein-bound flavonoid structure. 3',5'-dibromo-2',4,4',6-tetrahydroxyaurone 40-82 transthyretin Homo sapiens 132-135 1631168-1 1992 The crystal structure of the complex of 3",5"-dibromo-2",4,4",6-tetrahydroxyaurone, a flavone derivative, with human transthyretin (TTR), a serum thyroid hormone transport protein, has been determined and refined to R = 17.9% for data to 2.3-A resolution and provides a detailed description of a protein-bound flavonoid structure. flavone 86-93 transthyretin Homo sapiens 117-130 1631168-1 1992 The crystal structure of the complex of 3",5"-dibromo-2",4,4",6-tetrahydroxyaurone, a flavone derivative, with human transthyretin (TTR), a serum thyroid hormone transport protein, has been determined and refined to R = 17.9% for data to 2.3-A resolution and provides a detailed description of a protein-bound flavonoid structure. flavone 86-93 transthyretin Homo sapiens 132-135 1631168-1 1992 The crystal structure of the complex of 3",5"-dibromo-2",4,4",6-tetrahydroxyaurone, a flavone derivative, with human transthyretin (TTR), a serum thyroid hormone transport protein, has been determined and refined to R = 17.9% for data to 2.3-A resolution and provides a detailed description of a protein-bound flavonoid structure. Flavonoids 310-319 transthyretin Homo sapiens 117-130 1631168-2 1992 This bromoaurone is a potent competitor for thyroid hormone binding to TTR, a 54,980-dalton alpha 4 tetrameric protein of 222 molecular symmetry, as well as an inhibitor of iodothyronine deiodinase. bromoaurone 5-16 transthyretin Homo sapiens 71-74 1631168-3 1992 Crystals of the TTR-bromoaurone complex are isomorphous to those of native TTR. bromoaurone 20-31 transthyretin Homo sapiens 16-19 1631168-3 1992 Crystals of the TTR-bromoaurone complex are isomorphous to those of native TTR. bromoaurone 20-31 transthyretin Homo sapiens 75-78 1631168-4 1992 Interpretation of difference Fourier electron density maps revealed two binding modes for the bromoaurone in each of the two independent binding sites of the TTR tetramer: deep in the channel near Ser-117 (mode I) and near the channel entrance (mode II). bromoaurone 94-105 transthyretin Homo sapiens 158-161 1631168-4 1992 Interpretation of difference Fourier electron density maps revealed two binding modes for the bromoaurone in each of the two independent binding sites of the TTR tetramer: deep in the channel near Ser-117 (mode I) and near the channel entrance (mode II). Serine 197-200 transthyretin Homo sapiens 158-161 1631168-9 1992 The molecular pattern for TTR binding consists of halogen groups able to anchor between beta-sheets to form both hydrophobic and hydrophilic contacts. Halogens 50-57 transthyretin Homo sapiens 26-29 1631168-10 1992 Comparison of structural data for bromoaurone- and thyroxine-TTR complexes indicates that bromoaurone binding mode I is 3 A deeper in the channel and binding mode II is 4 A further from the channel center than thyroxine. Thyroxine 51-60 transthyretin Homo sapiens 61-64 1626570-0 1992 A Danish kindred with familial amyloid cardiomyopathy revisited: identification of a mutant transthyretin-methionine111 variant in serum from patients and carriers. methionine111 106-119 transthyretin Homo sapiens 92-105 1631168-11 1992 The bromoaurone binding observed in this TTR complex differs significantly from that based upon computer modeling studies. bromoaurone 4-15 transthyretin Homo sapiens 41-44 1626570-1 1992 PURPOSE: In familial amyloid cardiomyopathy of Danish origin, the amyloid microfibrils contain a mutant transthyretin (TTR) with a methionine-for-leucine substitution at the molecular position 111. Methionine 131-141 transthyretin Homo sapiens 104-117 1500461-1 1992 Dye-affinity chromatography of human plasma transthyretin on Remazol Yellow GGL-Sepharose from an unexploited by-product of chromatographic fractionation of plasma was optimized for large-scale preparation of a therapeutic product. remazol yellow ggl-sepharose 61-89 transthyretin Homo sapiens 44-57 1626570-1 1992 PURPOSE: In familial amyloid cardiomyopathy of Danish origin, the amyloid microfibrils contain a mutant transthyretin (TTR) with a methionine-for-leucine substitution at the molecular position 111. Methionine 131-141 transthyretin Homo sapiens 119-122 1626570-4 1992 The method employed to detect the abnormal TTR was based on the electrophoretic separation of fragments produced by cyanogen bromide cleavage at the two methionine sites. Cyanogen Bromide 116-132 transthyretin Homo sapiens 43-46 1626570-4 1992 The method employed to detect the abnormal TTR was based on the electrophoretic separation of fragments produced by cyanogen bromide cleavage at the two methionine sites. Methionine 153-163 transthyretin Homo sapiens 43-46 1610922-3 1992 Comparison to the known structure of the normal transthyretin tetramer shows that the bulkier methionine residue 30 which lies between the nearly orthogonal beta sheets of the dimer, results in the sheets being displaced an average of 0.4 A. Methionine 94-104 transthyretin Homo sapiens 48-61 1570831-2 1992 Comparative peptide mapping by high-performance liquid chromatography of the patient"s plasma TTR together with normal TTR showed the presence of an abnormal tryptic peptide in the patient"s TTR. Peptides 12-19 transthyretin Homo sapiens 94-97 1570831-4 1992 This change can be explained by a single base change of adenine for guanine in the Ala-45 codon and was demonstrated directly by DNA sequence analysis of PCR-amplified exon 2 of the TTR gene; allele-specific oligonucleotide hybridization both in the patient and in fixed heart tissue from his aunt confirmed the base change. Adenine 56-63 transthyretin Homo sapiens 182-185 1570831-4 1992 This change can be explained by a single base change of adenine for guanine in the Ala-45 codon and was demonstrated directly by DNA sequence analysis of PCR-amplified exon 2 of the TTR gene; allele-specific oligonucleotide hybridization both in the patient and in fixed heart tissue from his aunt confirmed the base change. Guanine 68-75 transthyretin Homo sapiens 182-185 1570831-4 1992 This change can be explained by a single base change of adenine for guanine in the Ala-45 codon and was demonstrated directly by DNA sequence analysis of PCR-amplified exon 2 of the TTR gene; allele-specific oligonucleotide hybridization both in the patient and in fixed heart tissue from his aunt confirmed the base change. Alanine 83-86 transthyretin Homo sapiens 182-185 1570831-4 1992 This change can be explained by a single base change of adenine for guanine in the Ala-45 codon and was demonstrated directly by DNA sequence analysis of PCR-amplified exon 2 of the TTR gene; allele-specific oligonucleotide hybridization both in the patient and in fixed heart tissue from his aunt confirmed the base change. Oligonucleotides 208-223 transthyretin Homo sapiens 182-185 1351039-3 1992 Single-strand conformation polymorphism analysis revealed a variant in the transthyretin gene, which was found on sequencing to be a T----C transversion at position 2 of codon 55, corresponding to a Leu----Pro substitution. leucylproline 199-209 transthyretin Homo sapiens 75-88 1575761-4 1992 The expressed hybrid molecule bound to the TTR-Sepharose. Sepharose 47-56 transthyretin Homo sapiens 43-46 1355416-0 1992 Amyloidogenic and non-amyloidogenic transthyretin Asn 90 variants. Asparagine 50-53 transthyretin Homo sapiens 36-49 1355416-5 1992 Comparative isoelectric focusing between the variants and TTR Asn 90 produced by recombinant techniques indicated that the non-pathogenic variant has the electrophoretic behaviour expected for the mutation. Asparagine 62-65 transthyretin Homo sapiens 58-61 1637142-3 1992 Direct DNA sequencing of the proband"s TTR gene revealed a guanine-for-adenine substitution in the second base of codon 42, producing a glycine for glutamate substitution in the plasma protein. guanine-for-adenine 59-78 transthyretin Homo sapiens 39-42 1569433-9 1992 The overall diagnostic value of BPN for CTS was 38%, while for women only this was 45% (95% CI: 31-60%). bpn 32-35 transthyretin Homo sapiens 40-43 1356051-0 1992 A novel variant of transthyretin (prealbumin), Thr119 to Met, associated with increased thyroxine binding. Thyroxine 88-97 transthyretin Homo sapiens 19-32 1356051-4 1992 This variant transthyretin is inherited in an autosomal dominant manner and is apparently not amyloidogenic but is associated with increased thyroxine binding. Thyroxine 141-150 transthyretin Homo sapiens 13-26 1637142-3 1992 Direct DNA sequencing of the proband"s TTR gene revealed a guanine-for-adenine substitution in the second base of codon 42, producing a glycine for glutamate substitution in the plasma protein. Glycine 136-143 transthyretin Homo sapiens 39-42 1637142-3 1992 Direct DNA sequencing of the proband"s TTR gene revealed a guanine-for-adenine substitution in the second base of codon 42, producing a glycine for glutamate substitution in the plasma protein. Glutamic Acid 148-157 transthyretin Homo sapiens 39-42 1730601-1 1992 Structural aspects of 3,3"-diiodo-L-thyronine binding to human serum transthyretin. 3,3'-diiodothyronine 22-45 transthyretin Homo sapiens 69-82 1544405-0 1992 Fluorescence study of the thyroxine-dependent conformational changes in human serum transthyretin. Thyroxine 26-35 transthyretin Homo sapiens 84-97 1544405-1 1992 Fluorescence studies of transthyretin (TTR) were conducted to detect structural changes associated with the environment of its two tryptophans, induced by binding of thyroxine (T4). Tryptophan 131-142 transthyretin Homo sapiens 24-37 1544405-1 1992 Fluorescence studies of transthyretin (TTR) were conducted to detect structural changes associated with the environment of its two tryptophans, induced by binding of thyroxine (T4). Tryptophan 131-142 transthyretin Homo sapiens 39-42 1544405-1 1992 Fluorescence studies of transthyretin (TTR) were conducted to detect structural changes associated with the environment of its two tryptophans, induced by binding of thyroxine (T4). Thyroxine 166-175 transthyretin Homo sapiens 24-37 1544405-1 1992 Fluorescence studies of transthyretin (TTR) were conducted to detect structural changes associated with the environment of its two tryptophans, induced by binding of thyroxine (T4). Thyroxine 166-175 transthyretin Homo sapiens 39-42 1544405-2 1992 Non-radiative tryptophans relaxation rate has an activation energy of 6.4 kcal/mol for TTR, which is decreased to 4.4 kcal/mol for TTR-T4 complex. Tryptophan 14-25 transthyretin Homo sapiens 87-90 1544405-2 1992 Non-radiative tryptophans relaxation rate has an activation energy of 6.4 kcal/mol for TTR, which is decreased to 4.4 kcal/mol for TTR-T4 complex. Tryptophan 14-25 transthyretin Homo sapiens 131-134 1544214-3 1992 The TTR gene from a patient suffering from this disorder was asymmetrically amplified and directly sequenced, revealing a cytosine for thymine substitution in the second base of codon 30 and the creation of a novel Cfo I restriction endonuclease site in exon 2. Cytosine 122-130 transthyretin Homo sapiens 4-7 1544214-3 1992 The TTR gene from a patient suffering from this disorder was asymmetrically amplified and directly sequenced, revealing a cytosine for thymine substitution in the second base of codon 30 and the creation of a novel Cfo I restriction endonuclease site in exon 2. Thymine 135-142 transthyretin Homo sapiens 4-7 1544214-4 1992 This mutation results in a previously undescribed substitution of an alanine for valine in the final TTR protein. Alanine 69-76 transthyretin Homo sapiens 101-104 1544214-4 1992 This mutation results in a previously undescribed substitution of an alanine for valine in the final TTR protein. Valine 81-87 transthyretin Homo sapiens 101-104 1544214-6 1992 Alanine at position 30 represents the second FAP-associated mutation at position 30 in TTR. Alanine 0-7 transthyretin Homo sapiens 87-90 1350578-1 1992 We describe a case of carpal tunnel syndrome (CTS) in a hypertensive man on long term treatment with a beta-blocker, propranolol. Propranolol 117-128 transthyretin Homo sapiens 46-49 1519448-2 1992 The secretion of transthyretin by the choroid plexus into the cerebrospinal fluid may have an important function in the transport of thyroxine from the blood to the brain. Thyroxine 133-142 transthyretin Homo sapiens 17-30 1730601-2 1992 The three-dimensional structure of the thyroid hormone metabolite, 3,3"-diiodo-L-thyronine (3,3"-T2), complex with human serum transthyretin (TTR) has been refined to R = 18.5% for 8-2 A resolution data. 3,3'-diiodothyronine 67-90 transthyretin Homo sapiens 127-140 1730601-2 1992 The three-dimensional structure of the thyroid hormone metabolite, 3,3"-diiodo-L-thyronine (3,3"-T2), complex with human serum transthyretin (TTR) has been refined to R = 18.5% for 8-2 A resolution data. 3,3'-diiodothyronine 67-90 transthyretin Homo sapiens 142-145 1730601-2 1992 The three-dimensional structure of the thyroid hormone metabolite, 3,3"-diiodo-L-thyronine (3,3"-T2), complex with human serum transthyretin (TTR) has been refined to R = 18.5% for 8-2 A resolution data. 3,3'-diiodothyronine 92-99 transthyretin Homo sapiens 127-140 1730601-2 1992 The three-dimensional structure of the thyroid hormone metabolite, 3,3"-diiodo-L-thyronine (3,3"-T2), complex with human serum transthyretin (TTR) has been refined to R = 18.5% for 8-2 A resolution data. 3,3'-diiodothyronine 92-99 transthyretin Homo sapiens 142-145 1915658-0 1991 Retinol-binding protein and transthyretin expressed in HeLa cells form a complex in the endoplasmic reticulum in both the absence and the presence of retinol. Vitamin A 150-157 transthyretin Homo sapiens 28-41 1301926-0 1992 Two transthyretin variants (TTR Ala-49 and TTR Gln-89) in two Sicilian kindreds with hereditary amyloidosis. Glutamine 47-50 transthyretin Homo sapiens 4-17 1301926-0 1992 Two transthyretin variants (TTR Ala-49 and TTR Gln-89) in two Sicilian kindreds with hereditary amyloidosis. Glutamine 47-50 transthyretin Homo sapiens 43-46 1301926-5 1992 The basic variant has a glutamine residue replacing glutamate at position 89 (TTR Gln-89). Glutamine 24-33 transthyretin Homo sapiens 78-81 1301926-5 1992 The basic variant has a glutamine residue replacing glutamate at position 89 (TTR Gln-89). Glutamic Acid 52-61 transthyretin Homo sapiens 78-81 1301926-5 1992 The basic variant has a glutamine residue replacing glutamate at position 89 (TTR Gln-89). Glutamine 82-85 transthyretin Homo sapiens 78-81 1479024-2 1992 In particular, the purification of transthyretin can be efficiently achieved by affinity chromatography on immobilized Reactive Yellow 13. reactive yellow 13 119-137 transthyretin Homo sapiens 35-48 1479024-6 1992 The assay is specific sensitive to 1 ng/ml of Reactive Yellow 13, has a good reproducibility and allows the accurate detection of the dye in the presence of transthyretin. reactive yellow 13 46-64 transthyretin Homo sapiens 157-170 1786038-0 1991 Transthyretin Leu 68 in a form of cardiac amyloidosis. Leucine 14-17 transthyretin Homo sapiens 0-13 1915658-7 1991 The effect of the vitamin A status on the secretion of TTR and RBP was examined. Vitamin A 18-27 transthyretin Homo sapiens 55-58 1915658-8 1991 While TTR expressed alone was not retained intracellularly, TTR was retained in vitamin A-deficient cells when co-expressed with RBP. Vitamin A 80-89 transthyretin Homo sapiens 60-63 1666289-8 1991 After sequencing of the clone of 572 bp, it was unexpectedly found that pG8 was completely homologous to the coding sequence of transthyretin, TTR gene, as TTR (or prealbumin) gene has been known to be linked to a hereditary disorder, familial amyloidosis (FAP), and related to thyroxine transport and binding to retinol-RBP (the retinol binding protein) complex. Thyroxine 278-287 transthyretin Homo sapiens 128-141 1666289-8 1991 After sequencing of the clone of 572 bp, it was unexpectedly found that pG8 was completely homologous to the coding sequence of transthyretin, TTR gene, as TTR (or prealbumin) gene has been known to be linked to a hereditary disorder, familial amyloidosis (FAP), and related to thyroxine transport and binding to retinol-RBP (the retinol binding protein) complex. Thyroxine 278-287 transthyretin Homo sapiens 143-146 1666289-8 1991 After sequencing of the clone of 572 bp, it was unexpectedly found that pG8 was completely homologous to the coding sequence of transthyretin, TTR gene, as TTR (or prealbumin) gene has been known to be linked to a hereditary disorder, familial amyloidosis (FAP), and related to thyroxine transport and binding to retinol-RBP (the retinol binding protein) complex. Thyroxine 278-287 transthyretin Homo sapiens 156-159 1666289-8 1991 After sequencing of the clone of 572 bp, it was unexpectedly found that pG8 was completely homologous to the coding sequence of transthyretin, TTR gene, as TTR (or prealbumin) gene has been known to be linked to a hereditary disorder, familial amyloidosis (FAP), and related to thyroxine transport and binding to retinol-RBP (the retinol binding protein) complex. Vitamin A 313-320 transthyretin Homo sapiens 128-141 1666289-8 1991 After sequencing of the clone of 572 bp, it was unexpectedly found that pG8 was completely homologous to the coding sequence of transthyretin, TTR gene, as TTR (or prealbumin) gene has been known to be linked to a hereditary disorder, familial amyloidosis (FAP), and related to thyroxine transport and binding to retinol-RBP (the retinol binding protein) complex. Vitamin A 313-320 transthyretin Homo sapiens 143-146 1666289-8 1991 After sequencing of the clone of 572 bp, it was unexpectedly found that pG8 was completely homologous to the coding sequence of transthyretin, TTR gene, as TTR (or prealbumin) gene has been known to be linked to a hereditary disorder, familial amyloidosis (FAP), and related to thyroxine transport and binding to retinol-RBP (the retinol binding protein) complex. Vitamin A 313-320 transthyretin Homo sapiens 156-159 1666289-8 1991 After sequencing of the clone of 572 bp, it was unexpectedly found that pG8 was completely homologous to the coding sequence of transthyretin, TTR gene, as TTR (or prealbumin) gene has been known to be linked to a hereditary disorder, familial amyloidosis (FAP), and related to thyroxine transport and binding to retinol-RBP (the retinol binding protein) complex. Vitamin A 330-337 transthyretin Homo sapiens 128-141 1666289-8 1991 After sequencing of the clone of 572 bp, it was unexpectedly found that pG8 was completely homologous to the coding sequence of transthyretin, TTR gene, as TTR (or prealbumin) gene has been known to be linked to a hereditary disorder, familial amyloidosis (FAP), and related to thyroxine transport and binding to retinol-RBP (the retinol binding protein) complex. Vitamin A 330-337 transthyretin Homo sapiens 143-146 1666289-8 1991 After sequencing of the clone of 572 bp, it was unexpectedly found that pG8 was completely homologous to the coding sequence of transthyretin, TTR gene, as TTR (or prealbumin) gene has been known to be linked to a hereditary disorder, familial amyloidosis (FAP), and related to thyroxine transport and binding to retinol-RBP (the retinol binding protein) complex. Vitamin A 330-337 transthyretin Homo sapiens 156-159 1932142-0 1991 A second transthyretin mutation at position 33 (Leu/Phe) associated with familial amyloidotic polyneuropathy. Phenylalanine 52-55 transthyretin Homo sapiens 9-22 1681909-0 1991 Characterization of a basic transthyretin variant--TTR Arg 102--in the German population. Arginine 55-58 transthyretin Homo sapiens 28-41 1681909-0 1991 Characterization of a basic transthyretin variant--TTR Arg 102--in the German population. Arginine 55-58 transthyretin Homo sapiens 51-54 1932142-0 1991 A second transthyretin mutation at position 33 (Leu/Phe) associated with familial amyloidotic polyneuropathy. Leucine 48-51 transthyretin Homo sapiens 9-22 1939470-1 1991 We describe a reversed-phase high-performance liquid chromatographic method for the determination of vitamin A-transporting (holo) transthyretin-bound (TTR) retinol-binding protein (RBP) concentrations in serum or plasma. Vitamin A 101-110 transthyretin Homo sapiens 152-155 1656975-0 1991 New mutant gene (transthyretin Arg 58) in cases with hereditary polyneuropathy detected by non-isotope method of single-strand conformation polymorphism analysis. Arginine 31-34 transthyretin Homo sapiens 17-30 1656975-6 1991 TTR Arg 58 is the first mutant TTR gene that has been detected by SSCP analysis. Arginine 4-7 transthyretin Homo sapiens 0-3 1656975-6 1991 TTR Arg 58 is the first mutant TTR gene that has been detected by SSCP analysis. Arginine 4-7 transthyretin Homo sapiens 31-34 1898403-1 1991 Naturally occurring variants of human serum transthyretin (prealbumin) have been prepared by recombinant DNA methods and crystallized from ammonium sulfate solutions to give crystals suitable for x-ray crystallographic analysis. Ammonium Sulfate 139-155 transthyretin Homo sapiens 44-57 1652460-1 1991 Transthyretin (TTR) is a circulatory protein which plays an important role in the transport of both thyroid hormone and retinol. Vitamin A 120-127 transthyretin Homo sapiens 15-18 1652460-7 1991 When Hep G2 cells were cultured in [35S]methionine-containing medium, the cells were found both to synthesize and to secrete immunoprecipitable [35S]TTR. Sulfur-35 36-39 transthyretin Homo sapiens 149-152 1652460-7 1991 When Hep G2 cells were cultured in [35S]methionine-containing medium, the cells were found both to synthesize and to secrete immunoprecipitable [35S]TTR. Methionine 40-50 transthyretin Homo sapiens 149-152 1652460-7 1991 When Hep G2 cells were cultured in [35S]methionine-containing medium, the cells were found both to synthesize and to secrete immunoprecipitable [35S]TTR. Sulfur-35 145-148 transthyretin Homo sapiens 149-152 1939470-5 1991 The percentage of RBP circulating as holo-TTR-RBP decreased significantly as the total concentration of RBP or retinol increased. Vitamin A 111-118 transthyretin Homo sapiens 42-45 2040864-0 1991 An inherited non-amyloidogenic transthyretin variant, [Ser6]-TTR, with increased thyroxine-binding affinity, characterized by DNA sequencing. Thyroxine 81-90 transthyretin Homo sapiens 31-44 1850190-5 1991 Comparative peptide mapping, by HPLC, of the acidic variant carriers and of normal TTR showed the presence of an abnormal tryptic peptide, not present in the normal TTR digests, with an asparagine-for-histidine substitution at position 90 explained by a single base change of adenine for cytosine in the histidine codon. Histidine 201-210 transthyretin Homo sapiens 83-86 1850191-0 1991 Proline at position 36: a new transthyretin mutation associated with familial amyloidotic polyneuropathy. Proline 0-7 transthyretin Homo sapiens 30-43 1850191-3 1991 The proband"s TTR gene was asymmetrically amplified by using PCR and then was sequenced directly, to reveal a cytosine-for-guanine substitution in codon 36. Cytosine 110-118 transthyretin Homo sapiens 14-17 1850191-3 1991 The proband"s TTR gene was asymmetrically amplified by using PCR and then was sequenced directly, to reveal a cytosine-for-guanine substitution in codon 36. Guanine 123-130 transthyretin Homo sapiens 14-17 1850190-1 1991 A mutation in transthyretin (TTR Asn 90) has been identified in the Portuguese and German populations. Asparagine 33-36 transthyretin Homo sapiens 29-32 1649243-3 1991 Enhancement of [3H]retinol uptake was also observed in cells incubated with these fatty acids, but this increase was relatively small for the dispersed form as compared to that observed for [3H]retinol bound to RBP or RBP-TTR. Fatty Acids 82-93 transthyretin Homo sapiens 222-225 1649243-4 1991 Comparing equal concentrations of the [3H]retinol donors, cell uptake and esterification was greatest from the dispersed form and least from that bound to RBP-TTR. Tritium 39-41 transthyretin Homo sapiens 159-162 1649243-4 1991 Comparing equal concentrations of the [3H]retinol donors, cell uptake and esterification was greatest from the dispersed form and least from that bound to RBP-TTR. Vitamin A 42-49 transthyretin Homo sapiens 159-162 2040864-0 1991 An inherited non-amyloidogenic transthyretin variant, [Ser6]-TTR, with increased thyroxine-binding affinity, characterized by DNA sequencing. Thyroxine 81-90 transthyretin Homo sapiens 61-64 2040864-1 1991 Amplification and sequencing of the four transthyretin (TTR) exons of a subject with a variant TTR with four-fold increased affinity for thyroxine revealed a heterozygous G to A point mutation at base 7 of exon 2. Thyroxine 137-146 transthyretin Homo sapiens 41-54 2040864-1 1991 Amplification and sequencing of the four transthyretin (TTR) exons of a subject with a variant TTR with four-fold increased affinity for thyroxine revealed a heterozygous G to A point mutation at base 7 of exon 2. Thyroxine 137-146 transthyretin Homo sapiens 56-59 2040864-1 1991 Amplification and sequencing of the four transthyretin (TTR) exons of a subject with a variant TTR with four-fold increased affinity for thyroxine revealed a heterozygous G to A point mutation at base 7 of exon 2. Thyroxine 137-146 transthyretin Homo sapiens 95-98 1909468-8 1991 There is an alternative explanation for low plasma retinol levels in malaria patients because retinol is bound to the negative acute phase proteins, retinol binding protein and transthyretin. Vitamin A 94-101 transthyretin Homo sapiens 177-190 1909468-8 1991 There is an alternative explanation for low plasma retinol levels in malaria patients because retinol is bound to the negative acute phase proteins, retinol binding protein and transthyretin. Vitamin A 94-101 transthyretin Homo sapiens 177-190 1979335-9 1990 PCR amplification of exon 4 of TTR and restriction digestion with Fnu 4H I confirmed that five affected family members with increased binding of 125I-T4 to TTR are heterozygous for the threonine 109 substitution that increases the affinity of this abnormal TTR for T4. 4h 70-72 transthyretin Homo sapiens 156-159 2279702-1 1990 HNF-4 (hepatocyte nuclear factor 4) is a protein enriched in liver extracts that binds to sites required for the transcription of the genes for transthyretin (TTR), the carrier protein in the serum for vitamin A and thyroid hormone, and for apolipoprotein CIII (apoCIII), a major constituent of chylomicrons and very low-density lipoproteins (VLDL). Vitamin A 202-211 transthyretin Homo sapiens 144-157 2279702-1 1990 HNF-4 (hepatocyte nuclear factor 4) is a protein enriched in liver extracts that binds to sites required for the transcription of the genes for transthyretin (TTR), the carrier protein in the serum for vitamin A and thyroid hormone, and for apolipoprotein CIII (apoCIII), a major constituent of chylomicrons and very low-density lipoproteins (VLDL). Vitamin A 202-211 transthyretin Homo sapiens 159-162 1979335-0 1990 A point mutation in transthyretin increases affinity for thyroxine and produces euthyroid hyperthyroxinemia. Thyroxine 57-66 transthyretin Homo sapiens 20-33 1979335-1 1990 In a family expressing euthyroid hyperthyroxinemia, an increased association of plasma thyroxine (T4) with transthyretin (TTR) is transmitted by autosomal dominant inheritance and is secondary to a mutant TTR molecule with increased affinity for T4. Thyroxine 38-47 transthyretin Homo sapiens 107-120 1979335-9 1990 PCR amplification of exon 4 of TTR and restriction digestion with Fnu 4H I confirmed that five affected family members with increased binding of 125I-T4 to TTR are heterozygous for the threonine 109 substitution that increases the affinity of this abnormal TTR for T4. 4h 70-72 transthyretin Homo sapiens 156-159 1979335-1 1990 In a family expressing euthyroid hyperthyroxinemia, an increased association of plasma thyroxine (T4) with transthyretin (TTR) is transmitted by autosomal dominant inheritance and is secondary to a mutant TTR molecule with increased affinity for T4. Thyroxine 38-47 transthyretin Homo sapiens 122-125 1979335-9 1990 PCR amplification of exon 4 of TTR and restriction digestion with Fnu 4H I confirmed that five affected family members with increased binding of 125I-T4 to TTR are heterozygous for the threonine 109 substitution that increases the affinity of this abnormal TTR for T4. Threonine 185-194 transthyretin Homo sapiens 31-34 1979335-1 1990 In a family expressing euthyroid hyperthyroxinemia, an increased association of plasma thyroxine (T4) with transthyretin (TTR) is transmitted by autosomal dominant inheritance and is secondary to a mutant TTR molecule with increased affinity for T4. Thyroxine 38-47 transthyretin Homo sapiens 205-208 1979335-9 1990 PCR amplification of exon 4 of TTR and restriction digestion with Fnu 4H I confirmed that five affected family members with increased binding of 125I-T4 to TTR are heterozygous for the threonine 109 substitution that increases the affinity of this abnormal TTR for T4. Threonine 185-194 transthyretin Homo sapiens 156-159 1979335-9 1990 PCR amplification of exon 4 of TTR and restriction digestion with Fnu 4H I confirmed that five affected family members with increased binding of 125I-T4 to TTR are heterozygous for the threonine 109 substitution that increases the affinity of this abnormal TTR for T4. Threonine 185-194 transthyretin Homo sapiens 156-159 1979335-4 1990 Purified TTR from the propositus had an affinity for 125I-T4 three times that of control TTR. 125i-t4 53-60 transthyretin Homo sapiens 9-12 1977686-1 1990 Transthyretin methionine 30 (TTR Met 30), which is associated with familial amyloidotic polyneuropathy, originates in a single base substitution (A for G) in the second exon of the TTR gene. Methionine 14-24 transthyretin Homo sapiens 29-32 1979335-7 1990 In 50% of clones amplified from exon 4, a substitution of adenine (ACC) for guanine (GCC) in codon 109 resulted in the replacement of threonine-for-alanine, a mutation confirmed by amino acid sequencing of tryptic peptides derived from purified plasma TTR. Adenine 58-65 transthyretin Homo sapiens 252-255 1979335-7 1990 In 50% of clones amplified from exon 4, a substitution of adenine (ACC) for guanine (GCC) in codon 109 resulted in the replacement of threonine-for-alanine, a mutation confirmed by amino acid sequencing of tryptic peptides derived from purified plasma TTR. 1-aminocyclopropane-1-carboxylic acid 67-70 transthyretin Homo sapiens 252-255 1979335-7 1990 In 50% of clones amplified from exon 4, a substitution of adenine (ACC) for guanine (GCC) in codon 109 resulted in the replacement of threonine-for-alanine, a mutation confirmed by amino acid sequencing of tryptic peptides derived from purified plasma TTR. Guanine 76-83 transthyretin Homo sapiens 252-255 1979335-7 1990 In 50% of clones amplified from exon 4, a substitution of adenine (ACC) for guanine (GCC) in codon 109 resulted in the replacement of threonine-for-alanine, a mutation confirmed by amino acid sequencing of tryptic peptides derived from purified plasma TTR. Threonine 134-143 transthyretin Homo sapiens 252-255 1979335-7 1990 In 50% of clones amplified from exon 4, a substitution of adenine (ACC) for guanine (GCC) in codon 109 resulted in the replacement of threonine-for-alanine, a mutation confirmed by amino acid sequencing of tryptic peptides derived from purified plasma TTR. Alanine 148-155 transthyretin Homo sapiens 252-255 2122246-0 1990 Familial amyloid polyneuropathy: alanine-for-threonine substitution in the transthyretin (prealbumin) molecule. Alanine 33-40 transthyretin Homo sapiens 75-88 2122246-0 1990 Familial amyloid polyneuropathy: alanine-for-threonine substitution in the transthyretin (prealbumin) molecule. Threonine 45-54 transthyretin Homo sapiens 75-88 1977686-1 1990 Transthyretin methionine 30 (TTR Met 30), which is associated with familial amyloidotic polyneuropathy, originates in a single base substitution (A for G) in the second exon of the TTR gene. Methionine 14-24 transthyretin Homo sapiens 181-184 18211908-2 2008 In this study, we investigated the development of CTS in iron-steel industry workers. Iron 57-61 transthyretin Homo sapiens 50-53 2356863-5 1990 The authors have reported that the CP is the unique site of synthesis within the brain of transthyretin (TTR, prealbumin), a transport protein for thyroxine and retinol. Thyroxine 147-156 transthyretin Homo sapiens 90-103 2356863-5 1990 The authors have reported that the CP is the unique site of synthesis within the brain of transthyretin (TTR, prealbumin), a transport protein for thyroxine and retinol. Thyroxine 147-156 transthyretin Homo sapiens 105-108 2356863-5 1990 The authors have reported that the CP is the unique site of synthesis within the brain of transthyretin (TTR, prealbumin), a transport protein for thyroxine and retinol. Vitamin A 161-168 transthyretin Homo sapiens 90-103 2356863-5 1990 The authors have reported that the CP is the unique site of synthesis within the brain of transthyretin (TTR, prealbumin), a transport protein for thyroxine and retinol. Vitamin A 161-168 transthyretin Homo sapiens 105-108 2393944-3 1990 Pharmacol., 85 (1986) 301) indicated preferential binding of a hydroxylated metabolite of tetrachlorobiphenyl to transthyretin (TTR) a carrier of thyroxine (T4). tetrachlorobiphenyl 90-109 transthyretin Homo sapiens 128-131 2393944-3 1990 Pharmacol., 85 (1986) 301) indicated preferential binding of a hydroxylated metabolite of tetrachlorobiphenyl to transthyretin (TTR) a carrier of thyroxine (T4). Thyroxine 146-155 transthyretin Homo sapiens 128-131 2393944-4 1990 In the present study it was investigated whether the T4 binding site of TTR could be occupied specifically by hydroxylated chlorinated aromatic compounds using chlorinated phenol congeners as model compounds in a competition assay with [125I]T4. Phenol 172-178 transthyretin Homo sapiens 72-75 2393944-9 1990 The relative affinity of binding of pentachlorophenol (PCP) to TTR was about twice that of T4. Pentachlorophenol 36-53 transthyretin Homo sapiens 63-66 2393944-9 1990 The relative affinity of binding of pentachlorophenol (PCP) to TTR was about twice that of T4. Pentachlorophenol 55-58 transthyretin Homo sapiens 63-66 2393944-13 1990 The results indicate a specific interaction of chlorophenols with the T4 binding site of TTR. Chlorophenols 47-60 transthyretin Homo sapiens 89-92 33770392-0 2021 Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis. tafamidis 144-153 transthyretin Homo sapiens 94-107 29261619-2 2018 Bone scintigraphy with [Tc]hydroxymethylene diphosphonate (Tc-HDP) and [F]sodium fluoride (F-NaF) have been investigated in the noninvasive diagnosis of transthyretin (ATTR)-related cardiac amyloidosis. [tc]hydroxymethylene diphosphonate 23-57 transthyretin Homo sapiens 168-172 29261619-2 2018 Bone scintigraphy with [Tc]hydroxymethylene diphosphonate (Tc-HDP) and [F]sodium fluoride (F-NaF) have been investigated in the noninvasive diagnosis of transthyretin (ATTR)-related cardiac amyloidosis. [f]sodium fluoride 71-89 transthyretin Homo sapiens 168-172 29261619-5 2018 This example suggests that the mechanism of uptake of Tc-HDP and F-NaF may differ in patients with ATTR cardiac amyloidosis. tc-hdp 54-60 transthyretin Homo sapiens 99-103 1977535-1 1990 The human thyroxine-binding prealbumin (TBPA) gene was examined for restriction fragment length polymorphism (RFLP) in normal subjects and a subject with euthyroid hyperthyroxinaemia, due to increased thyroxine binding by TBPA, using 16 restriction enzymes. Thyroxine 10-19 transthyretin Homo sapiens 40-44 2349941-2 1990 Amino acid sequencing of protein isolated from the amyloid fibrils of a patient with SSA identified TTR containing a position - 122 isoleucine-for-valine substitution. Valine 147-153 transthyretin Homo sapiens 100-103 2363408-9 1990 It was concluded that the TTR should be reasonably higher than the oral temperature for clinical application of the shape-memory phenomenon of nickel-titanium alloys. Nickel 143-149 transthyretin Homo sapiens 26-29 2363408-9 1990 It was concluded that the TTR should be reasonably higher than the oral temperature for clinical application of the shape-memory phenomenon of nickel-titanium alloys. Titanium 150-158 transthyretin Homo sapiens 26-29 2354158-9 1990 The calculated value was 7.5 X 10(-8) M. Kd was also measured directly by fluorometric titration and was found to be 7 X 10(-8) M. The relative avidities of retinol for RBP, the complex RBP-transthyretin (RBP-TTR), and serum albumin were also studied. Vitamin A 157-164 transthyretin Homo sapiens 209-212 2354158-10 1990 It was found that binding of RBP to TTR increased its avidity for retinol by about 2-fold. Vitamin A 66-73 transthyretin Homo sapiens 36-39 2153133-7 1990 Internalization was dependent on receptor binding and was more markedly inhibited than surface binding at 0 degrees C. Concentrations of thyroxine within a range that saturated a significant proportion of the primary and secondary TTR iodothyronine binding sites increased the uptake and internalization of transthyretin in a dose-dependent manner. Thyroxine 137-146 transthyretin Homo sapiens 231-234 2153133-7 1990 Internalization was dependent on receptor binding and was more markedly inhibited than surface binding at 0 degrees C. Concentrations of thyroxine within a range that saturated a significant proportion of the primary and secondary TTR iodothyronine binding sites increased the uptake and internalization of transthyretin in a dose-dependent manner. Thyroxine 137-146 transthyretin Homo sapiens 307-320 2153133-7 1990 Internalization was dependent on receptor binding and was more markedly inhibited than surface binding at 0 degrees C. Concentrations of thyroxine within a range that saturated a significant proportion of the primary and secondary TTR iodothyronine binding sites increased the uptake and internalization of transthyretin in a dose-dependent manner. iodothyronine 235-248 transthyretin Homo sapiens 231-234 33800546-0 2021 Diphenyl-Methane Based Thyromimetic Inhibitors for Transthyretin Amyloidosis. diphenylmethane 0-16 transthyretin Homo sapiens 51-64 33800546-5 2021 By combining nuclear magnetic resonance (NMR) spectroscopy, computational simulation, and biochemical assays, we found that GC-1 and newly designed diphenyl-methane-based thyromimetics, namely IS25 and TG68, are TTR stabilizers and efficient suppressors of TTR aggregation. diphenylmethane 148-164 transthyretin Homo sapiens 212-215 33800546-5 2021 By combining nuclear magnetic resonance (NMR) spectroscopy, computational simulation, and biochemical assays, we found that GC-1 and newly designed diphenyl-methane-based thyromimetics, namely IS25 and TG68, are TTR stabilizers and efficient suppressors of TTR aggregation. diphenylmethane 148-164 transthyretin Homo sapiens 257-260 33032630-1 2020 BACKGROUND: The diagnostic accuracy of histopathological detection of transthyretin amyloid (ATTR) by Congo red staining of abdominal fat samples has been questioned since low sensitivity has been reported, especially for patients with ATTR cardiomyopathy. Congo Red 102-111 transthyretin Homo sapiens 70-83 24966028-9 2015 Furthermore, the T-W-C (51.2 %, p < 0.001) and C-W-C (15.9 %, p = 0.005) inferred haplotypes were significantly over- and under-represented in the CON compared to the CTS (34.9 % T-W-C, 26.8 % C-W-C). c-w-c 50-55 transthyretin Homo sapiens 170-173 34841715-2 2022 The implementation of 99m technetium (99m Tc)-labelled bone radiotracer scintigraphy for diagnosing ATTR-CM has enabled accurate diagnosis of the disease with high sensitivity and specificity and positioned this diagnostic modality as an integral part of disease diagnostic algorithms. Technetium 26-36 transthyretin Homo sapiens 100-104 34879513-6 2022 With the optimized materials, a carrageenan/chitosan/calcium ion physically cross-linked double network hydrogel (KC/CTS/Ca2+ PCDNH) was successfully prepared by the semi-soluble-acidified sol-gel conversion method. Carrageenan 32-43 transthyretin Homo sapiens 117-120 34879513-6 2022 With the optimized materials, a carrageenan/chitosan/calcium ion physically cross-linked double network hydrogel (KC/CTS/Ca2+ PCDNH) was successfully prepared by the semi-soluble-acidified sol-gel conversion method. Chitosan 44-52 transthyretin Homo sapiens 117-120 34879513-6 2022 With the optimized materials, a carrageenan/chitosan/calcium ion physically cross-linked double network hydrogel (KC/CTS/Ca2+ PCDNH) was successfully prepared by the semi-soluble-acidified sol-gel conversion method. Calcium 53-60 transthyretin Homo sapiens 117-120 34879513-6 2022 With the optimized materials, a carrageenan/chitosan/calcium ion physically cross-linked double network hydrogel (KC/CTS/Ca2+ PCDNH) was successfully prepared by the semi-soluble-acidified sol-gel conversion method. ca2+ pcdnh 121-131 transthyretin Homo sapiens 117-120 15769474-2 2005 TTR contains two distinct quaternary interfaces, one of which defines the binding sites for thyroxine and small-molecule amyloidogenesis inhibitors. Thyroxine 92-101 transthyretin Homo sapiens 0-3 34595711-2 2022 Our aim was to evaluate how the urinary free-BPA(fBPA) and total-BPA(tBPA) levels were associated with the use of medical devices in the PICU in a prospective study. bisphenol A 65-68 transthyretin Homo sapiens 69-73 34595711-8 2022 Mean urinary levels were 189.2 mug/g-creatinine for tBPA and 27.8 mug/g-creatinine for fBPA, and the fBPA/tBPA ratio was 27.9%. Creatinine 37-47 transthyretin Homo sapiens 52-56 34595711-12 2022 CONCLUSIONS: fBPA levels and the fBPA/tBPA ratio varied according to the procedure and level of BPA exposure in children. bisphenol A 96-99 transthyretin Homo sapiens 38-42 34841715-2 2022 The implementation of 99m technetium (99m Tc)-labelled bone radiotracer scintigraphy for diagnosing ATTR-CM has enabled accurate diagnosis of the disease with high sensitivity and specificity and positioned this diagnostic modality as an integral part of disease diagnostic algorithms. Technetium 42-44 transthyretin Homo sapiens 100-104 34841715-3 2022 In 2020, 99m Tc-pyrophosphate scintigraphy received exceptional approval for Japanese national health insurance reimbursement as a diagnostic method of ATTR-CM. tc-pyrophosphate 13-29 transthyretin Homo sapiens 152-156 34397154-5 2022 2D-thiol-DIGE analysis of human plasma incubated with CEES and subsequent matrix-assisted laser desorption/ionization time-of-flight (tandem) mass-spectrometry, MALDI-TOF MS(/MS), revealed transthyretin (TTR) as a target of alkylating agents. 2d-thiol 0-8 transthyretin Homo sapiens 189-202 34890995-0 2022 Synthesis and biological evaluation of quinolone derivatives as transthyretin amyloidogenesis inhibitors and fluorescence sensors. Quinolones 39-48 transthyretin Homo sapiens 64-77 34890995-4 2022 Here, we describe the design and synthesis of quinolin-2(1H)-one derivatives that could be structurally complementary to the thyroxine-binding site within tetrameric TTR. quinolin-2(1h) 46-60 transthyretin Homo sapiens 166-169 34890995-4 2022 Here, we describe the design and synthesis of quinolin-2(1H)-one derivatives that could be structurally complementary to the thyroxine-binding site within tetrameric TTR. Thyroxine 125-134 transthyretin Homo sapiens 166-169 34890995-5 2022 Among these quinolin-2(1H)-one derivatives, compound 7a allowed 16.7% of V30M-TTR (3.6 muM) fibril formation at the same concentration and 49.6% at a concentration of 1.8 muM. quinoline 12-20 transthyretin Homo sapiens 78-81 34890995-5 2022 Among these quinolin-2(1H)-one derivatives, compound 7a allowed 16.7% of V30M-TTR (3.6 muM) fibril formation at the same concentration and 49.6% at a concentration of 1.8 muM. Hydrogen 23-25 transthyretin Homo sapiens 78-81 34397154-5 2022 2D-thiol-DIGE analysis of human plasma incubated with CEES and subsequent matrix-assisted laser desorption/ionization time-of-flight (tandem) mass-spectrometry, MALDI-TOF MS(/MS), revealed transthyretin (TTR) as a target of alkylating agents. 2d-thiol 0-8 transthyretin Homo sapiens 204-207 34397154-6 2022 TTR was extracted from SM-treated plasma by immunomagnetic separation (IMS) and analyzed after tryptic cleavage by microbore liquid chromatography-electrospray ionization high-resolution tandem-mass spectrometry (muLC-ESI MS/HR MS). Mustard Gas 23-25 transthyretin Homo sapiens 0-3 34397154-7 2022 It was found that the Cys10 -residue of TTR present in the hexapeptide C(-HETE)PLMVK was alkylated by the hydroxyethylthioethyl (HETE)-moiety, which is characteristic for SM exposure. Mustard Gas 171-173 transthyretin Homo sapiens 40-43 34397154-8 2022 It was shown that alkylated TTR is stable in plasma in vitro at 37 C for at least 14 d. In addition, C(-HETE)PLMVK can be selectively detected, is stable in the autosampler over 24 h and shows linearity in a broad concentration range from 15.63 muM to 2 mM SM in plasma in vitro. Mustard Gas 257-259 transthyretin Homo sapiens 28-31 34688163-5 2022 Results from the computational studies endorsed that the resveratrol constitutes a restorative potential to subjugate TTR mediated amyloidosis, besides EGCG. Resveratrol 57-68 transthyretin Homo sapiens 118-121 34688163-6 2022 Hence, this study could be a reminiscent aspect in understanding the inhibitory role of key polyphenols against the mutant TTR aggregates, which could be an aid towards structure-based drug design in the upcoming research era on familial amyloid disorders. Polyphenols 92-103 transthyretin Homo sapiens 123-126 34688163-0 2022 Molecular simulation probes the potency of resveratrol in regulating the toxic aggregation of mutant V30M TTR fibrils in Transthyretin mediated amyloidosis. Resveratrol 43-54 transthyretin Homo sapiens 106-109 34688163-4 2022 Besides, we probed the association of naturally occurring polyphenols: EGCG (a proven anti TTR aggregation agent as positive control), resveratrol and curcumin in mitigating the pathogenic repercussions of mutant TTR. Curcumin 151-159 transthyretin Homo sapiens 213-216 34964085-2 2021 We retrospectively investigated the frequency of PYP uptake in the subcutaneous abdominal fat of patients with ATTR-CA and its relevance to the results of fine-needle aspiration biopsy (FNAB) of this tissue. PYP 49-52 transthyretin Homo sapiens 111-115 34688163-0 2022 Molecular simulation probes the potency of resveratrol in regulating the toxic aggregation of mutant V30M TTR fibrils in Transthyretin mediated amyloidosis. Resveratrol 43-54 transthyretin Homo sapiens 121-134 34974181-1 2021 BACKGROUND: The valine-to-isoleucine substitution (Val122Ile) is the most common variant of transthyretin (TTR) amyloidosis in the U.S., primarily affecting individuals of African descent. Valine 16-22 transthyretin Homo sapiens 92-105 34974181-1 2021 BACKGROUND: The valine-to-isoleucine substitution (Val122Ile) is the most common variant of transthyretin (TTR) amyloidosis in the U.S., primarily affecting individuals of African descent. Valine 16-22 transthyretin Homo sapiens 107-110 34974181-1 2021 BACKGROUND: The valine-to-isoleucine substitution (Val122Ile) is the most common variant of transthyretin (TTR) amyloidosis in the U.S., primarily affecting individuals of African descent. Isoleucine 26-36 transthyretin Homo sapiens 92-105 34974181-1 2021 BACKGROUND: The valine-to-isoleucine substitution (Val122Ile) is the most common variant of transthyretin (TTR) amyloidosis in the U.S., primarily affecting individuals of African descent. Isoleucine 26-36 transthyretin Homo sapiens 107-110 34964085-8 2021 CONCLUSIONS: In patients with ATTR-CA, abnormal PYP uptake in the subcutaneous abdominal fat could reflect the regional amyloid deposition confirmed by FNAB of this tissue. PYP 48-51 transthyretin Homo sapiens 30-34 34933921-0 2022 Global and Regional Variations in Transthyretin Cardiac Amyloidosis: A Comparison of Longitudinal Strain and 99mTechnetium Pyrophosphate Imaging. 99mtechnetium pyrophosphate 109-136 transthyretin Homo sapiens 34-47 34940989-7 2021 Sex-dependent inverse associations between exposure to maternal T1D in utero and ApoD and TTR were significant after adjusting for age, BMI-SDS and Tanner stage (OR = 0.252 (95% CI 0.085, 0.745), p = 0.013 and OR = 0.149 (95% CI 0.040, 0.553), p = 0.004). Sodium Dodecyl Sulfate 140-143 transthyretin Homo sapiens 90-93 34921561-8 2022 In multiple regression analysis, low body weight, rivaroxaban, apixaban, and AM session had significant associations with time and heparin dose to achieve target ACT, and there were positive associations of dabigatran and apixaban with ACT-TTR within the first 1 hour. Dabigatran 207-217 transthyretin Homo sapiens 240-243 34921561-8 2022 In multiple regression analysis, low body weight, rivaroxaban, apixaban, and AM session had significant associations with time and heparin dose to achieve target ACT, and there were positive associations of dabigatran and apixaban with ACT-TTR within the first 1 hour. apixaban 222-230 transthyretin Homo sapiens 240-243 34379010-0 2021 Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis. tafamidis 76-85 transthyretin Homo sapiens 41-54 34907500-0 2021 Volumetric evaluation of 99mTc-pyrophosphate SPECT/CT for transthyretin cardiac amyloidosis: Methodology and correlation with cardiac functional parameters. Technetium Tc 99m Pyrophosphate 25-44 transthyretin Homo sapiens 58-71 34907500-1 2021 BACKGROUND: Volumetric evaluation of 99mTechnetium-pyrophosphate (99mTc-PYP) SPECT/CT is a useful method for assessing transthyretin cardiac amyloidosis (ATTR-CA). 99mtechnetium-pyrophosphate 37-64 transthyretin Homo sapiens 119-132 34907500-1 2021 BACKGROUND: Volumetric evaluation of 99mTechnetium-pyrophosphate (99mTc-PYP) SPECT/CT is a useful method for assessing transthyretin cardiac amyloidosis (ATTR-CA). 99mtechnetium-pyrophosphate 37-64 transthyretin Homo sapiens 154-158 34907500-1 2021 BACKGROUND: Volumetric evaluation of 99mTechnetium-pyrophosphate (99mTc-PYP) SPECT/CT is a useful method for assessing transthyretin cardiac amyloidosis (ATTR-CA). 99mtc-pyp 66-75 transthyretin Homo sapiens 119-132 34907500-1 2021 BACKGROUND: Volumetric evaluation of 99mTechnetium-pyrophosphate (99mTc-PYP) SPECT/CT is a useful method for assessing transthyretin cardiac amyloidosis (ATTR-CA). 99mtc-pyp 66-75 transthyretin Homo sapiens 154-158 34396857-8 2021 NT-proBNP and aldosterone were univariate predictors of the primary endpoint in patients with ATTR-CA, but not in matched controls. Aldosterone 14-25 transthyretin Homo sapiens 94-98 34633220-6 2021 Based on knowledge of the binding of thyroxine to TTR tetramer, many stabilizers have been screened to dock into the thyroxine binding sites, leading to TTR tetramer stabilization. Thyroxine 37-46 transthyretin Homo sapiens 50-53 34364217-5 2021 RESULTS: All PFASs listed in the German guideline for drinking water (German Environment Agency, 2017) affected the T4 binding to TTR, an important plasma thyroid hormone transport protein. Water 63-68 transthyretin Homo sapiens 130-133 34364217-11 2021 Additionally, CMS (which have been used in the electroplating chromium industry since the 1950s) as well as PFOS-free, but not PFAS-free fume suppressants (such as Fumetrol 21) have been tested in the TTR-TRbeta CALUX assay and showed much lower activity levels then the AFFFs, confirmed by the similar potency determination based on chemical PFASs analysis followed by transformation to PFOA-EQ for comparison. fumetrol 21 164-176 transthyretin Homo sapiens 202-205 34364217-15 2021 PFOA and PFOS showed high responses in the TTR-TRbeta CALUX assay and had the largest contributions to the PFOA-EQs in the AFFF surfactants and CMS applications. perfluorooctanoic acid 0-4 transthyretin Homo sapiens 43-46 34364217-15 2021 PFOA and PFOS showed high responses in the TTR-TRbeta CALUX assay and had the largest contributions to the PFOA-EQs in the AFFF surfactants and CMS applications. perfluorooctane sulfonic acid 9-13 transthyretin Homo sapiens 43-46 34982455-11 2021 Warfarin adherence illustrates its positive association with TTR and INR as a measure of anticoagulation control. Warfarin 0-8 transthyretin Homo sapiens 61-64 34633220-6 2021 Based on knowledge of the binding of thyroxine to TTR tetramer, many stabilizers have been screened to dock into the thyroxine binding sites, leading to TTR tetramer stabilization. Thyroxine 37-46 transthyretin Homo sapiens 153-156 34633220-6 2021 Based on knowledge of the binding of thyroxine to TTR tetramer, many stabilizers have been screened to dock into the thyroxine binding sites, leading to TTR tetramer stabilization. Thyroxine 117-126 transthyretin Homo sapiens 50-53 34633220-6 2021 Based on knowledge of the binding of thyroxine to TTR tetramer, many stabilizers have been screened to dock into the thyroxine binding sites, leading to TTR tetramer stabilization. Thyroxine 117-126 transthyretin Homo sapiens 153-156 34562536-1 2021 Wild-type human transthyretin (TTR) is a tetrameric protein that transports thyroxine and retinol in the blood and brain. Thyroxine 76-85 transthyretin Homo sapiens 16-29 34562536-1 2021 Wild-type human transthyretin (TTR) is a tetrameric protein that transports thyroxine and retinol in the blood and brain. Thyroxine 76-85 transthyretin Homo sapiens 31-34 34562536-1 2021 Wild-type human transthyretin (TTR) is a tetrameric protein that transports thyroxine and retinol in the blood and brain. Vitamin A 90-97 transthyretin Homo sapiens 16-29 34562536-1 2021 Wild-type human transthyretin (TTR) is a tetrameric protein that transports thyroxine and retinol in the blood and brain. Vitamin A 90-97 transthyretin Homo sapiens 31-34 34562536-7 2021 Dithiothreitol (DTT), in the presence of Ca2+, enhances the formation of complex autofluorophore which displays maxima at 412 nm and 438 nm in the emission spectrum of TTR. Dithiothreitol 0-14 transthyretin Homo sapiens 168-171 34562536-7 2021 Dithiothreitol (DTT), in the presence of Ca2+, enhances the formation of complex autofluorophore which displays maxima at 412 nm and 438 nm in the emission spectrum of TTR. Dithiothreitol 16-19 transthyretin Homo sapiens 168-171 34626785-0 2021 A quinoline derived D-A-D type fluorescent probe for sensing tetrameric transthyretin. quinoline 2-11 transthyretin Homo sapiens 72-85 34626785-2 2021 In this study, a quinoline-derived D-A-D type chemosensor was rationally designed and synthesized as a probe for the sensitive detection of tetrameric transthyretin (WT-TTR). quinoline 17-26 transthyretin Homo sapiens 151-164 34626785-2 2021 In this study, a quinoline-derived D-A-D type chemosensor was rationally designed and synthesized as a probe for the sensitive detection of tetrameric transthyretin (WT-TTR). quinoline 17-26 transthyretin Homo sapiens 169-172 34779246-4 2022 In ATTR-ACT, 441 people with ATTR-CM from 13 different countries took either tafamidis or placebo by mouth for 30 months. tafamidis 77-86 transthyretin Homo sapiens 29-33 34766598-10 2021 In addition, deficiency in retinoic acid and thyroxine transport was exhibited by the dramatic increase of transthyretin (TTHY). Tretinoin 27-40 transthyretin Homo sapiens 107-120 34766598-10 2021 In addition, deficiency in retinoic acid and thyroxine transport was exhibited by the dramatic increase of transthyretin (TTHY). Tretinoin 27-40 transthyretin Homo sapiens 122-126 34766598-10 2021 In addition, deficiency in retinoic acid and thyroxine transport was exhibited by the dramatic increase of transthyretin (TTHY). Thyroxine 45-54 transthyretin Homo sapiens 107-120 34766598-10 2021 In addition, deficiency in retinoic acid and thyroxine transport was exhibited by the dramatic increase of transthyretin (TTHY). Thyroxine 45-54 transthyretin Homo sapiens 122-126 34772213-4 2021 Diflunisal stabilizes the transthyretin (TTR) tetramer and prevents the misfolding of monomers and dimers from forming amyloid deposits in the heart. Diflunisal 0-10 transthyretin Homo sapiens 26-39 34772213-4 2021 Diflunisal stabilizes the transthyretin (TTR) tetramer and prevents the misfolding of monomers and dimers from forming amyloid deposits in the heart. Diflunisal 0-10 transthyretin Homo sapiens 41-44 34407213-7 2021 Threshold gold thickness (Ttr ) was established for the 0.13 mm diameter CDMAM discs. cdmam 73-78 transthyretin Homo sapiens 26-29 34254119-1 2021 AIMS: Technetium-99m-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD scintigraphy) is recognized as highly accurate for the non-invasive diagnosis of transthyretin (ATTR) cardiac amyloidosis (CA). Technetium 6-20 transthyretin Homo sapiens 182-186 34254119-1 2021 AIMS: Technetium-99m-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD scintigraphy) is recognized as highly accurate for the non-invasive diagnosis of transthyretin (ATTR) cardiac amyloidosis (CA). 3,3-diphosphono-1,2-propanodicarboxylic acid 30-74 transthyretin Homo sapiens 182-186 34390104-3 2021 For this we use the Cytolysin A nanopore and equip it with an engineered periplasmic thiamine binding protein (TbpA). Thiamine 85-93 transthyretin Homo sapiens 111-115 34390104-4 2021 To allow fast measurements we tuned the affinity of TbpA for thiamine by redesigning the pi-pi stacking interactions between the thiazole group of thiamine and TbpA. Thiamine 61-69 transthyretin Homo sapiens 52-56 34390104-4 2021 To allow fast measurements we tuned the affinity of TbpA for thiamine by redesigning the pi-pi stacking interactions between the thiazole group of thiamine and TbpA. Thiamine 61-69 transthyretin Homo sapiens 160-164 34390104-4 2021 To allow fast measurements we tuned the affinity of TbpA for thiamine by redesigning the pi-pi stacking interactions between the thiazole group of thiamine and TbpA. Thiazoles 129-137 transthyretin Homo sapiens 52-56 34390104-4 2021 To allow fast measurements we tuned the affinity of TbpA for thiamine by redesigning the pi-pi stacking interactions between the thiazole group of thiamine and TbpA. Thiazoles 129-137 transthyretin Homo sapiens 160-164 34390104-4 2021 To allow fast measurements we tuned the affinity of TbpA for thiamine by redesigning the pi-pi stacking interactions between the thiazole group of thiamine and TbpA. Thiamine 147-155 transthyretin Homo sapiens 52-56 34390104-4 2021 To allow fast measurements we tuned the affinity of TbpA for thiamine by redesigning the pi-pi stacking interactions between the thiazole group of thiamine and TbpA. Thiamine 147-155 transthyretin Homo sapiens 160-164 34693047-0 2021 Glavonoid, a possible supplement for prevention of ATTR amyloidosis. glavonoid 0-9 transthyretin Homo sapiens 51-55 34693047-5 2021 Glabridin, a prenylated isoflavan isolated from Glycyrrhiza glabra L., stabilized the TTR tetramer in vitro. glabridin 0-9 transthyretin Homo sapiens 86-89 34693047-5 2021 Glabridin, a prenylated isoflavan isolated from Glycyrrhiza glabra L., stabilized the TTR tetramer in vitro. isoflavan 24-33 transthyretin Homo sapiens 86-89 34693047-6 2021 The effects of licorice-derived flavonoid oil-Glavonoid, a natural substance that includes glabridin and several polyphenols-on stabilizing the TTR tetramer must still be elucidated. flavonoid oil 32-45 transthyretin Homo sapiens 144-147 34693047-6 2021 The effects of licorice-derived flavonoid oil-Glavonoid, a natural substance that includes glabridin and several polyphenols-on stabilizing the TTR tetramer must still be elucidated. glavonoid 46-55 transthyretin Homo sapiens 144-147 34693047-6 2021 The effects of licorice-derived flavonoid oil-Glavonoid, a natural substance that includes glabridin and several polyphenols-on stabilizing the TTR tetramer must still be elucidated. glabridin 91-100 transthyretin Homo sapiens 144-147 34693047-6 2021 The effects of licorice-derived flavonoid oil-Glavonoid, a natural substance that includes glabridin and several polyphenols-on stabilizing the TTR tetramer must still be elucidated. Polyphenols 113-124 transthyretin Homo sapiens 144-147 34693047-7 2021 To examine plasma TTR stabilization by Glavonoid in vitro, we investigated the feasibility of utilizing glabridin plus Glavonoid to prevent TTR amyloid fibril formation. glavonoid 39-48 transthyretin Homo sapiens 18-21 34693047-7 2021 To examine plasma TTR stabilization by Glavonoid in vitro, we investigated the feasibility of utilizing glabridin plus Glavonoid to prevent TTR amyloid fibril formation. glabridin 104-113 transthyretin Homo sapiens 140-143 34693047-8 2021 Glavonoid mixed with human plasma samples at 24 h incubation in vitro increased the tetramer level (P < 0.05) and reduced the monomer level (P < 0.01) and the monomer/tetramer ratio (P < 0.05) of TTR compared to those without Glavonoid by immunoblot analysis, such effect could not observe in the presence of glabridin. glavonoid 0-9 transthyretin Homo sapiens 196-199 34693047-8 2021 Glavonoid mixed with human plasma samples at 24 h incubation in vitro increased the tetramer level (P < 0.05) and reduced the monomer level (P < 0.01) and the monomer/tetramer ratio (P < 0.05) of TTR compared to those without Glavonoid by immunoblot analysis, such effect could not observe in the presence of glabridin. glabridin 309-318 transthyretin Homo sapiens 196-199 34693047-10 2021 Glavonoid increased the TTR tetramer level and reduced the monomer/tetramer ratio of TTR (P < 0.05) in plasma at 12 weeks in healthy volunteers compared to those of age matched control subjects without the supplement. glavonoid 0-9 transthyretin Homo sapiens 24-27 34693047-10 2021 Glavonoid increased the TTR tetramer level and reduced the monomer/tetramer ratio of TTR (P < 0.05) in plasma at 12 weeks in healthy volunteers compared to those of age matched control subjects without the supplement. glavonoid 0-9 transthyretin Homo sapiens 85-88 34693047-11 2021 Thus, oral Glavonoid may effectively prevent TTR amyloid fibril formation via TTR tetramer stabilization. glavonoid 11-20 transthyretin Homo sapiens 45-48 34693047-11 2021 Thus, oral Glavonoid may effectively prevent TTR amyloid fibril formation via TTR tetramer stabilization. glavonoid 11-20 transthyretin Homo sapiens 78-81 34729530-0 2021 Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy. tafamidis 10-19 transthyretin Homo sapiens 29-42 34729530-5 2021 Results: Among 72 patients with ATTR cardiomyopathy (67 patients with wild-type and 5 patients with variant TTR), administration of tafamidis increased serum TTR from 21.8 mg +- 0.7 mg/dL to 29.3 +- 0.86 mg/dL, an increase of 34.5%. tafamidis 132-141 transthyretin Homo sapiens 32-36 34729530-5 2021 Results: Among 72 patients with ATTR cardiomyopathy (67 patients with wild-type and 5 patients with variant TTR), administration of tafamidis increased serum TTR from 21.8 mg +- 0.7 mg/dL to 29.3 +- 0.86 mg/dL, an increase of 34.5%. tafamidis 132-141 transthyretin Homo sapiens 108-111 34729530-5 2021 Results: Among 72 patients with ATTR cardiomyopathy (67 patients with wild-type and 5 patients with variant TTR), administration of tafamidis increased serum TTR from 21.8 mg +- 0.7 mg/dL to 29.3 +- 0.86 mg/dL, an increase of 34.5%. tafamidis 132-141 transthyretin Homo sapiens 158-161 34729530-9 2021 Conclusions: Tafamidis consistently increases serum TTR levels in patients with ATTR cardiomyopathy, consistent with its effect on stabilizing TTR. tafamidis 13-22 transthyretin Homo sapiens 52-55 34729530-9 2021 Conclusions: Tafamidis consistently increases serum TTR levels in patients with ATTR cardiomyopathy, consistent with its effect on stabilizing TTR. tafamidis 13-22 transthyretin Homo sapiens 143-146 34746852-5 2021 ATTR-CA diagnosis was based on preoperative 99m-technetium pyrophosphate (PYP) scan and intraoperatively obtained basal interventricular septum biopsy for myocardial ATTR-CA, and excised native aortic valve for isolated valvular ATTR-CA. 99m-technetium pyrophosphate 44-72 transthyretin Homo sapiens 0-4 34746852-5 2021 ATTR-CA diagnosis was based on preoperative 99m-technetium pyrophosphate (PYP) scan and intraoperatively obtained basal interventricular septum biopsy for myocardial ATTR-CA, and excised native aortic valve for isolated valvular ATTR-CA. diphosphoric acid 74-77 transthyretin Homo sapiens 0-4 34547896-0 2021 Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors. Bithionol 40-49 transthyretin Homo sapiens 73-86 34547896-0 2021 Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors. Triclabendazole 54-69 transthyretin Homo sapiens 73-86 34547896-3 2021 Here, we show that the clinical anthelmintic drugs bithionol (42) and triclabendazole (43) potently inhibit aggregation of the amyloidogenic variant V30M-TTR. Bithionol 51-60 transthyretin Homo sapiens 154-157 34547896-3 2021 Here, we show that the clinical anthelmintic drugs bithionol (42) and triclabendazole (43) potently inhibit aggregation of the amyloidogenic variant V30M-TTR. Triclabendazole 70-85 transthyretin Homo sapiens 154-157 34547896-4 2021 A competitive binding assay using a fluorescence probe showed that the binding affinity of 42 with V30M-TTR was significantly higher than that of the first-in-class drug tafamidis (1), and the binding affinity of 43 was similar to that of 1. tafamidis 170-179 transthyretin Homo sapiens 104-107 34547896-5 2021 The crystallographic and thermodynamic analysis revealed that 42 efficiently occupied the halogen-binding grooves of TTR, resulting in the favorable binding entropy. Halogens 90-97 transthyretin Homo sapiens 117-120 34604925-11 2021 99mTc-pyrophosphate quantitation may have a role in ATTR-CM disease staging, guiding treatment, or following response to therapy. Technetium Tc 99m Pyrophosphate 0-19 transthyretin Homo sapiens 52-56 34630348-3 2021 The iron-bound form of these glycoproteins is initially captured by the surface lipoproteins Tf or Lf binding protein B (TbpB or LbpB) and delivered to the integral outer membrane TonB-dependent transport (TBDT) proteins, Tf binding protein A (TbpA) or Lf binding protein A (LbpA). Iron 4-8 transthyretin Homo sapiens 222-242 34703707-13 2021 In both RCT and non-RCTs, Tafamidis was established as a safe and tolerable drug for patients with TTR-CM. tafamidis 26-35 transthyretin Homo sapiens 99-102 34630348-3 2021 The iron-bound form of these glycoproteins is initially captured by the surface lipoproteins Tf or Lf binding protein B (TbpB or LbpB) and delivered to the integral outer membrane TonB-dependent transport (TBDT) proteins, Tf binding protein A (TbpA) or Lf binding protein A (LbpA). Iron 4-8 transthyretin Homo sapiens 244-248 34587698-12 2021 Alcohol consumption and anemia played an interactive role in the association between BPPV and low TTR levels. Alcohols 0-7 transthyretin Homo sapiens 98-101 34487268-1 2021 BACKGROUND: 99mTc-labelled bisphosphonates are used for imaging assessment of patients with transthyretin cardiac amyloidosis (ATTR). 99mtc-labelled bisphosphonates 12-42 transthyretin Homo sapiens 127-131 34487268-2 2021 Present study evaluates whether quantitative SPECT/CT measurement of absolute myocardial 99mTc-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (Tc-DPD) uptake can diagnose patients with suspected ATTR. 3,3-diphosphono-1,2-propanodicarboxylic acid 104-148 transthyretin Homo sapiens 202-206 34587698-13 2021 After adjustments for triglycerides, BMI, uric acid, HbA1C, 25-OH vitamin D3, alcohol consumption, and anemia, the multiple logistic regression revealed that participants with low TTR levels had a significantly increased risk of BPPV (OR: 5.5; 95% CI, 2.55-11.9; p<0.001). Uric Acid 42-51 transthyretin Homo sapiens 180-183 34587698-13 2021 After adjustments for triglycerides, BMI, uric acid, HbA1C, 25-OH vitamin D3, alcohol consumption, and anemia, the multiple logistic regression revealed that participants with low TTR levels had a significantly increased risk of BPPV (OR: 5.5; 95% CI, 2.55-11.9; p<0.001). Cholecalciferol 66-76 transthyretin Homo sapiens 180-183 34587698-13 2021 After adjustments for triglycerides, BMI, uric acid, HbA1C, 25-OH vitamin D3, alcohol consumption, and anemia, the multiple logistic regression revealed that participants with low TTR levels had a significantly increased risk of BPPV (OR: 5.5; 95% CI, 2.55-11.9; p<0.001). Alcohols 78-85 transthyretin Homo sapiens 180-183 34482164-0 2021 Quality and predictors of oral anticoagulation therapy with vitamin K antagonists in adult congenital heart disease: TTR and INR variability. Vitamin K 60-69 transthyretin Homo sapiens 117-120 34297165-1 2021 Transthyretin (TTR) is an extracellular protein mainly produced in the liver and choroid plexus, with a well-stablished role in the transport of thyroxin and retinol throughout the body and brain. Thyroxine 145-153 transthyretin Homo sapiens 0-13 34297165-1 2021 Transthyretin (TTR) is an extracellular protein mainly produced in the liver and choroid plexus, with a well-stablished role in the transport of thyroxin and retinol throughout the body and brain. Thyroxine 145-153 transthyretin Homo sapiens 15-18 34297165-1 2021 Transthyretin (TTR) is an extracellular protein mainly produced in the liver and choroid plexus, with a well-stablished role in the transport of thyroxin and retinol throughout the body and brain. Vitamin A 158-165 transthyretin Homo sapiens 0-13 34297165-1 2021 Transthyretin (TTR) is an extracellular protein mainly produced in the liver and choroid plexus, with a well-stablished role in the transport of thyroxin and retinol throughout the body and brain. Vitamin A 158-165 transthyretin Homo sapiens 15-18 34502397-5 2021 Recent studies revealed that the serine protease inhibitor, SerpinA1, was differentially expressed in hepatocyte-like cells (HLCs) from ATTR patients. Serine 33-39 transthyretin Homo sapiens 136-140 34448092-0 2021 Tc-99m PYP scintigraphy identified multi-organ disease associated with transthyretin Phe64Ser mutation. Technetium 0-6 transthyretin Homo sapiens 71-84 34400480-6 2021 RocketAP also improved control following the announced meal (mean difference TBR: -0.7%, TIR: +7%, TTR: +6%), overall (TIR: +5%, TAR: -5%, TTR: +8%), and overnight (TIR: +7%, TTR: +19%, TAR: -5%). rocketap 0-8 transthyretin Homo sapiens 99-102 34225167-0 2021 Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis. Anthraquinones 25-38 transthyretin Homo sapiens 72-85 34400480-6 2021 RocketAP also improved control following the announced meal (mean difference TBR: -0.7%, TIR: +7%, TTR: +6%), overall (TIR: +5%, TAR: -5%, TTR: +8%), and overnight (TIR: +7%, TTR: +19%, TAR: -5%). rocketap 0-8 transthyretin Homo sapiens 139-142 34225167-0 2021 Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis. xanthone 43-51 transthyretin Homo sapiens 72-85 34225167-1 2021 Transthyretin is a tetrameric protein which functions as a transporter of thyroxine and retinol-binding protein. Thyroxine 74-83 transthyretin Homo sapiens 0-13 34400480-6 2021 RocketAP also improved control following the announced meal (mean difference TBR: -0.7%, TIR: +7%, TTR: +6%), overall (TIR: +5%, TAR: -5%, TTR: +8%), and overnight (TIR: +7%, TTR: +19%, TAR: -5%). rocketap 0-8 transthyretin Homo sapiens 175-178 34225167-1 2021 Transthyretin is a tetrameric protein which functions as a transporter of thyroxine and retinol-binding protein. Vitamin A 88-95 transthyretin Homo sapiens 0-13 34160527-2 2021 Herein, in this contribution, we have developed a 2-dicyanomethylenethiazole-based D-pi-A structured near-infrared photosensitizer (TTR). 2-dicyanomethylenethiazole 50-76 transthyretin Homo sapiens 132-135 34225167-4 2021 Here, we investigated the inhibitory activities of anthraquinone and xanthone derivatives against amyloid aggregation, and found that xanthone-2-carboxylic acid with one chlorine or methyl group has strong inhibitory activity comparable with that of diflunisal, which is one of the best known stabilizers of transthyretin. Anthraquinones 51-64 transthyretin Homo sapiens 308-321 34225167-4 2021 Here, we investigated the inhibitory activities of anthraquinone and xanthone derivatives against amyloid aggregation, and found that xanthone-2-carboxylic acid with one chlorine or methyl group has strong inhibitory activity comparable with that of diflunisal, which is one of the best known stabilizers of transthyretin. xanthone 69-77 transthyretin Homo sapiens 308-321 34225167-4 2021 Here, we investigated the inhibitory activities of anthraquinone and xanthone derivatives against amyloid aggregation, and found that xanthone-2-carboxylic acid with one chlorine or methyl group has strong inhibitory activity comparable with that of diflunisal, which is one of the best known stabilizers of transthyretin. xanthone-2-carboxylic acid 134-160 transthyretin Homo sapiens 308-321 34225167-4 2021 Here, we investigated the inhibitory activities of anthraquinone and xanthone derivatives against amyloid aggregation, and found that xanthone-2-carboxylic acid with one chlorine or methyl group has strong inhibitory activity comparable with that of diflunisal, which is one of the best known stabilizers of transthyretin. Chlorine 170-178 transthyretin Homo sapiens 308-321 34225167-4 2021 Here, we investigated the inhibitory activities of anthraquinone and xanthone derivatives against amyloid aggregation, and found that xanthone-2-carboxylic acid with one chlorine or methyl group has strong inhibitory activity comparable with that of diflunisal, which is one of the best known stabilizers of transthyretin. Diflunisal 250-260 transthyretin Homo sapiens 308-321 34225167-5 2021 X-ray crystallographic structures of transthyretin in complex with the compounds revealed that the introduction of chlorine, which is buried in a hydrophobic region, is important for the strong inhibitory effect of the stabilizer against amyloidogenesis. Chlorine 115-123 transthyretin Homo sapiens 37-50 34089308-6 2021 Transthyretin (TTR) is a protein that is produced by the liver and is involved in the transportation of thyroid hormones, especially thyroxine and retinol binding protein. Thyroxine 133-142 transthyretin Homo sapiens 0-13 34089308-6 2021 Transthyretin (TTR) is a protein that is produced by the liver and is involved in the transportation of thyroid hormones, especially thyroxine and retinol binding protein. Thyroxine 133-142 transthyretin Homo sapiens 15-18 34089308-6 2021 Transthyretin (TTR) is a protein that is produced by the liver and is involved in the transportation of thyroid hormones, especially thyroxine and retinol binding protein. Vitamin A 147-154 transthyretin Homo sapiens 0-13 34089308-6 2021 Transthyretin (TTR) is a protein that is produced by the liver and is involved in the transportation of thyroid hormones, especially thyroxine and retinol binding protein. Vitamin A 147-154 transthyretin Homo sapiens 15-18 34215024-9 2021 CONCLUSIONS: In a small group of patients with hereditary ATTR amyloidosis with polyneuropathy, administration of NTLA-2001 was associated with only mild adverse events and led to decreases in serum TTR protein concentrations through targeted knockout of TTR. ntla 114-118 transthyretin Homo sapiens 199-202 34215024-9 2021 CONCLUSIONS: In a small group of patients with hereditary ATTR amyloidosis with polyneuropathy, administration of NTLA-2001 was associated with only mild adverse events and led to decreases in serum TTR protein concentrations through targeted knockout of TTR. ntla 114-118 transthyretin Homo sapiens 255-258 34160527-2 2021 Herein, in this contribution, we have developed a 2-dicyanomethylenethiazole-based D-pi-A structured near-infrared photosensitizer (TTR). d-pi-a 83-89 transthyretin Homo sapiens 132-135 34160527-5 2021 With efficient ROS generation, excellent biocompatibility, two-photon imaging capability, and depth imaging (21 mum in vitro and 210 mum in vivo), TTR can effectively kill tumor cells and inhibit the growth of subcutaneous tumors. ros 15-18 transthyretin Homo sapiens 147-150 34272629-10 2022 The 2 studies that compared diflunisal versus no treatment found improvements in TTR concentration, left atrial volume index, cardiac troponin I, and global longitudinal strain. Diflunisal 28-38 transthyretin Homo sapiens 81-84 34272629-11 2022 Overall, diflunisal use was associated with decreased mortality and number of orthotopic heart transplant in ATTR-CM patients. Diflunisal 9-19 transthyretin Homo sapiens 109-113 34272629-0 2022 The use of diflunisal for transthyretin cardiac amyloidosis: a review. Diflunisal 11-21 transthyretin Homo sapiens 26-39 34272629-13 2022 This systematic review supports the use of diflunisal for ATTR-CM. Diflunisal 43-53 transthyretin Homo sapiens 58-62 34272629-2 2022 Diflunisal, an agent that stabilizes TTR, has been used as an off-label therapeutic for ATTR-CM. Diflunisal 0-10 transthyretin Homo sapiens 37-40 34359938-4 2021 The TTR structure is destabilized by mutations, oxidative modifications, aging, proteolysis, and metal cations, including Ca2+. Metals 97-102 transthyretin Homo sapiens 4-7 34272629-4 2022 We searched the PubMed, MEDLINE, and Embase databases for studies that reported on the use of diflunisal therapy for patients with ATTR-CM. Diflunisal 94-104 transthyretin Homo sapiens 131-135 34081210-4 2021 Interestingly, applying 18F-florbetapen and delayed PET imaging may even afford the possibility to not only detect cardiac amyloidosis but also to reliably differentiate between AL and TTR, respectively. 18f-florbetapen 24-39 transthyretin Homo sapiens 185-188 34207092-2 2021 TTR is a plasma protein that functions as a carrier for thyroxine (T4) and retinol (vitamin A). Thyroxine 56-65 transthyretin Homo sapiens 0-3 34207092-2 2021 TTR is a plasma protein that functions as a carrier for thyroxine (T4) and retinol (vitamin A). Vitamin A 75-82 transthyretin Homo sapiens 0-3 34207092-2 2021 TTR is a plasma protein that functions as a carrier for thyroxine (T4) and retinol (vitamin A). Vitamin A 84-93 transthyretin Homo sapiens 0-3 34136709-3 2021 The aim of this study was to determine the prevalence of TTR amyloid deposits in surgical tissue of patients undergoing carpal tunnel surgery and to clarify the clinical significance of concomitant cardiac examination with 99 mTc-labeled pyrophosphate (99 mTc-PYP) scintigraphy in those patients with TTR deposition. Mitomycin 226-229 transthyretin Homo sapiens 57-60 34199897-7 2021 Altogether, these results indicate that TTR contributes to the homeostasis of glucose by regulating the levels of glucose transporters and PKM enzyme and by protecting against mitochondrial oxidative stress. Glucose 78-85 transthyretin Homo sapiens 40-43 34199897-7 2021 Altogether, these results indicate that TTR contributes to the homeostasis of glucose by regulating the levels of glucose transporters and PKM enzyme and by protecting against mitochondrial oxidative stress. Glucose 114-121 transthyretin Homo sapiens 40-43 34136709-3 2021 The aim of this study was to determine the prevalence of TTR amyloid deposits in surgical tissue of patients undergoing carpal tunnel surgery and to clarify the clinical significance of concomitant cardiac examination with 99 mTc-labeled pyrophosphate (99 mTc-PYP) scintigraphy in those patients with TTR deposition. mtc-pyp 256-263 transthyretin Homo sapiens 57-60 34567923-6 2021 Conclusions: Fasting and nonfasting TG showed positive association with TTR in community-dwelling elderly non-obese women independently of insulin resistance, HDL cholesterol, and adiponectin. Cholesterol 163-174 transthyretin Homo sapiens 72-75 34317686-0 2021 Extracardiac Accumulation of Technetium-99m-Pyrophosphate in Transthyretin Cardiac Amyloidosis. technetium-99m-pyrophosphate 29-57 transthyretin Homo sapiens 61-74 34567923-0 2021 Associations of serum transthyretin with triglyceride in non-obese elderly Japanese women independently of insulin resistance, HDL cholesterol, and adiponectin. Triglycerides 41-53 transthyretin Homo sapiens 22-35 35289020-3 2022 Inotersen is an antisense oligonucleotide that suppresses the hepatic production of transthyretin. Oligonucleotides 26-41 transthyretin Homo sapiens 84-97 34567923-0 2021 Associations of serum transthyretin with triglyceride in non-obese elderly Japanese women independently of insulin resistance, HDL cholesterol, and adiponectin. Cholesterol 131-142 transthyretin Homo sapiens 22-35 34567923-1 2021 Objective: Studies are limited on the association between serum transthyretin (TTR), a negative acute phase reactant, and triglyceride (TG). Triglycerides 122-134 transthyretin Homo sapiens 64-77 34567923-1 2021 Objective: Studies are limited on the association between serum transthyretin (TTR), a negative acute phase reactant, and triglyceride (TG). Triglycerides 122-134 transthyretin Homo sapiens 79-82 34567923-1 2021 Objective: Studies are limited on the association between serum transthyretin (TTR), a negative acute phase reactant, and triglyceride (TG). Triglycerides 136-138 transthyretin Homo sapiens 64-77 34567923-1 2021 Objective: Studies are limited on the association between serum transthyretin (TTR), a negative acute phase reactant, and triglyceride (TG). Triglycerides 136-138 transthyretin Homo sapiens 79-82 34317486-1 2021 Assessment of absolute myocardial hydroxydimethylene diphosphonate-technetium-99m uptake using standardized uptake value with a single-photon emission computed tomography-computed tomography cadmium zinc telluride camera (Discovery NM/CT 670CZT, GE Healthcare, Chicago, Illinois) in a patient with cardiac transthyretin-related amyloidosis treated with tafamidis showed a decrease in hydroxydimethylene diphosphonate cardiac uptake. hydroxydimethylene diphosphonate 34-66 transthyretin Homo sapiens 306-319 34317486-1 2021 Assessment of absolute myocardial hydroxydimethylene diphosphonate-technetium-99m uptake using standardized uptake value with a single-photon emission computed tomography-computed tomography cadmium zinc telluride camera (Discovery NM/CT 670CZT, GE Healthcare, Chicago, Illinois) in a patient with cardiac transthyretin-related amyloidosis treated with tafamidis showed a decrease in hydroxydimethylene diphosphonate cardiac uptake. Technetium 67-81 transthyretin Homo sapiens 306-319 34317486-1 2021 Assessment of absolute myocardial hydroxydimethylene diphosphonate-technetium-99m uptake using standardized uptake value with a single-photon emission computed tomography-computed tomography cadmium zinc telluride camera (Discovery NM/CT 670CZT, GE Healthcare, Chicago, Illinois) in a patient with cardiac transthyretin-related amyloidosis treated with tafamidis showed a decrease in hydroxydimethylene diphosphonate cardiac uptake. CdZnTe 191-213 transthyretin Homo sapiens 306-319 34317486-1 2021 Assessment of absolute myocardial hydroxydimethylene diphosphonate-technetium-99m uptake using standardized uptake value with a single-photon emission computed tomography-computed tomography cadmium zinc telluride camera (Discovery NM/CT 670CZT, GE Healthcare, Chicago, Illinois) in a patient with cardiac transthyretin-related amyloidosis treated with tafamidis showed a decrease in hydroxydimethylene diphosphonate cardiac uptake. tafamidis 353-362 transthyretin Homo sapiens 306-319 34317486-1 2021 Assessment of absolute myocardial hydroxydimethylene diphosphonate-technetium-99m uptake using standardized uptake value with a single-photon emission computed tomography-computed tomography cadmium zinc telluride camera (Discovery NM/CT 670CZT, GE Healthcare, Chicago, Illinois) in a patient with cardiac transthyretin-related amyloidosis treated with tafamidis showed a decrease in hydroxydimethylene diphosphonate cardiac uptake. hydroxydimethylene diphosphonate 384-416 transthyretin Homo sapiens 306-319 35491555-5 2022 In healthy subjects, associations of serum TBG, transthyretin and albumin with TH and its metabolites were analyzed using multiple linear regression models, adjusted for sex and age. Thorium 79-81 transthyretin Homo sapiens 48-61 35549533-0 2022 Unusual presentation of rare Phe33Leu mutation hereditary TTR cardiac amyloidosis. phe33leu 29-37 transthyretin Homo sapiens 58-61 35419654-10 2022 Inotersen, an antisense oligonucleotide, degrades TTR-mRNA via activation of nuclear RNase H. Both mechanisms result in a significant reduction of TTR protein serum levels. Oligonucleotides 24-39 transthyretin Homo sapiens 50-53 35419654-10 2022 Inotersen, an antisense oligonucleotide, degrades TTR-mRNA via activation of nuclear RNase H. Both mechanisms result in a significant reduction of TTR protein serum levels. Oligonucleotides 24-39 transthyretin Homo sapiens 147-150 35181228-0 2022 Correlation of Quantitative 99mTc DPD Scintigraphy With Echocardiographic Alterations in Left Atrial Parameters in Transthyretin Amyloidosis. deoxypyridinoline 34-37 transthyretin Homo sapiens 115-128 35181228-2 2022 We evaluated echocardiographic structural and functional left atrial (LA) parameters and correlated these with technetium-99m 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) bone scintigraphy tracer uptake within the LA in ATTR patients. technetium-99m 3,3-diphosphono-1,2-propanodicarboxylic acid 111-170 transthyretin Homo sapiens 232-236 35181228-3 2022 METHODS: ATTR patients (wild-type, hereditary and asymptomatic transthyretin (TTR) variant carriers) who had undergone 99mTc-DPD and transthoracic echocardiogram (TTE) were selected. 99mtc-dpd 119-128 transthyretin Homo sapiens 9-13 35181228-11 2022 Echocardiography and 99mTc-DPD scintigraphy may have significant roles in identification and surveillance of ATTR patients likely to develop atrial arrhythmias. 99mtc-dpd 21-30 transthyretin Homo sapiens 109-113 35395343-9 2022 RESULTS: Nicotine blocks uptake of transthyretin-T4 by human placental trophoblast cells. Nicotine 9-17 transthyretin Homo sapiens 35-48 35395343-10 2022 Nicotine reduces the expression of the trophoblast scavenger receptor class B type 1 (SR-B1) that plays a role in transthyretin-T4 uptake. Nicotine 0-8 transthyretin Homo sapiens 114-127 35395343-11 2022 Molecular dynamic modelling suggests that when T4 is bound to transthyretin, nicotine binding increases tetramer stability, reducing the ability of the transthyretin-T4 complex to enter trophoblast cells. Nicotine 77-85 transthyretin Homo sapiens 62-75 35395343-12 2022 CONCLUSION: Our data suggest that nicotine exposure during pregnancy reduces transplacental transport of transthyretin and T4 to the placenta and developing fetus. Nicotine 34-42 transthyretin Homo sapiens 105-118 35491555-6 2022 Results While T3 and T4 are predominantly bound to TBG, we demonstrated that the predominant THDP of 3,3"-T2 and rT3 is albumin, of TA3 is transthyretin and albumin and of TA4 is transthyretin. flopropione 93-97 transthyretin Homo sapiens 179-192 35599006-0 2022 Extracardiac Biopsy Sensitivity in Transthyretin Amyloidosis Cardiomyopathy Patients With Positive 99 mTc-Labeled Pyrophosphate Scintigraphy Findings. diphosphoric acid 114-127 transthyretin Homo sapiens 35-48 35607996-4 2022 Mechanistic analysis was performed in hypoxia/reoxygenation-exposed PHTs and Ttr transgenic mice overexpressing transgene-encoded wild-type human TTR or Ttr-/- mice. phts 68-72 transthyretin Homo sapiens 146-149 35626697-7 2022 Intriguingly, the PDIA4-dependent retention of TTR is independent of both the single TTR cysteine residue and the redox activity of PDIA4, indicating that PDIA4 retains destabilized TTR in the ER through a redox-independent mechanism. Cysteine 89-97 transthyretin Homo sapiens 85-88 35578000-1 2022 BACKGROUND: Pyrophosphate (PYP) imaging has a high diagnostic accuracy for transthyretin cardiac amyloidosis (ATTR-CA). diphosphoric acid 12-25 transthyretin Homo sapiens 110-114 35578000-1 2022 BACKGROUND: Pyrophosphate (PYP) imaging has a high diagnostic accuracy for transthyretin cardiac amyloidosis (ATTR-CA). diphosphoric acid 27-30 transthyretin Homo sapiens 110-114 35626697-7 2022 Intriguingly, the PDIA4-dependent retention of TTR is independent of both the single TTR cysteine residue and the redox activity of PDIA4, indicating that PDIA4 retains destabilized TTR in the ER through a redox-independent mechanism. Cysteine 89-97 transthyretin Homo sapiens 182-185 35626697-7 2022 Intriguingly, the PDIA4-dependent retention of TTR is independent of both the single TTR cysteine residue and the redox activity of PDIA4, indicating that PDIA4 retains destabilized TTR in the ER through a redox-independent mechanism. Cysteine 89-97 transthyretin Homo sapiens 47-50 35081075-8 2022 The results indicated that platelet TTR can cause reactive oxygen species production and apoptosis in HK2 cells. Reactive Oxygen Species 50-73 transthyretin Homo sapiens 36-39 35629214-10 2022 TTR amyloid deposition was associated with cardiac dysfunction via increased non-cardiomyocyte area and ROS accumulation in cardiomyocytes. Reactive Oxygen Species 104-107 transthyretin Homo sapiens 0-3 35394160-0 2022 Insight on the microscopic binding mechanism of bisphenol compounds (BPs) with transthyretin (TTR) based on multi-spectroscopic methods and computational simulations. bis(4-hydroxyphenyl)sulfone 48-57 transthyretin Homo sapiens 79-92 35394160-0 2022 Insight on the microscopic binding mechanism of bisphenol compounds (BPs) with transthyretin (TTR) based on multi-spectroscopic methods and computational simulations. bis(4-hydroxyphenyl)sulfone 48-57 transthyretin Homo sapiens 94-97 35394160-0 2022 Insight on the microscopic binding mechanism of bisphenol compounds (BPs) with transthyretin (TTR) based on multi-spectroscopic methods and computational simulations. bps 69-72 transthyretin Homo sapiens 79-92 35394160-0 2022 Insight on the microscopic binding mechanism of bisphenol compounds (BPs) with transthyretin (TTR) based on multi-spectroscopic methods and computational simulations. bps 69-72 transthyretin Homo sapiens 94-97 35394160-4 2022 In this study, three typical bisphenol compounds were selected to explore the interaction between BPs and TTR by computer simulations and multi-spectroscopic methods. bis(4-hydroxyphenyl)sulfone 29-38 transthyretin Homo sapiens 106-109 35394160-4 2022 In this study, three typical bisphenol compounds were selected to explore the interaction between BPs and TTR by computer simulations and multi-spectroscopic methods. bps 98-101 transthyretin Homo sapiens 106-109 35394160-5 2022 The results revealed that BPs quenched the endogenous fluorescence of TTR via the combination of static quenching and non-radiative energy transfer, and the van der Waals forces and hydrogen bonding played a synergistic role in the binding process of BPs and TTR. bps 26-29 transthyretin Homo sapiens 70-73 35394160-5 2022 The results revealed that BPs quenched the endogenous fluorescence of TTR via the combination of static quenching and non-radiative energy transfer, and the van der Waals forces and hydrogen bonding played a synergistic role in the binding process of BPs and TTR. bps 26-29 transthyretin Homo sapiens 259-262 35394160-5 2022 The results revealed that BPs quenched the endogenous fluorescence of TTR via the combination of static quenching and non-radiative energy transfer, and the van der Waals forces and hydrogen bonding played a synergistic role in the binding process of BPs and TTR. Hydrogen 182-190 transthyretin Homo sapiens 70-73 35394160-5 2022 The results revealed that BPs quenched the endogenous fluorescence of TTR via the combination of static quenching and non-radiative energy transfer, and the van der Waals forces and hydrogen bonding played a synergistic role in the binding process of BPs and TTR. bps 251-254 transthyretin Homo sapiens 70-73 35394160-5 2022 The results revealed that BPs quenched the endogenous fluorescence of TTR via the combination of static quenching and non-radiative energy transfer, and the van der Waals forces and hydrogen bonding played a synergistic role in the binding process of BPs and TTR. bps 251-254 transthyretin Homo sapiens 259-262 35394160-6 2022 Furthermore, the three-dimensional fluorescence spectroscopy, UV-vis spectroscopy, and Fourier transform infrared (FT-IR) spectroscopy, which were employed to determine the conformation of protein, revealed that binding of BPs with TTR could induce conformational changes in TTR. bps 223-226 transthyretin Homo sapiens 232-235 35394160-6 2022 Furthermore, the three-dimensional fluorescence spectroscopy, UV-vis spectroscopy, and Fourier transform infrared (FT-IR) spectroscopy, which were employed to determine the conformation of protein, revealed that binding of BPs with TTR could induce conformational changes in TTR. bps 223-226 transthyretin Homo sapiens 275-278 35394160-7 2022 In addition, the binding sites and the residues surrounding the BPs within the TTR were determined through molecular docking and molecular dynamics simulation. bps 64-67 transthyretin Homo sapiens 79-82 35394160-8 2022 Therefore, this work provides new insights into the interaction between BPs and TTR to evaluate the potential toxicity of BPs. bps 72-75 transthyretin Homo sapiens 80-83 35113214-0 2022 Correction to: Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase (99mTc)Tc-DPD whole body scan: comparison with late (bone) phase imaging. tc-dpd 113-119 transthyretin Homo sapiens 59-63 35484710-2 2022 Free energy simulations based on all-atom molecular dynamics simulations were carried out to analyze the effects of the His88 Arg, Phe, and Tyr mutations on the stability of human TTR. Phenylalanine 133-136 transthyretin Homo sapiens 182-185 35481507-2 2022 Treatments based on antisense oligonucleotides (ASO) and small interfering RNA (siRNA) have been developed and are now commercially available to treat hereditary transthyretin amyloidosis (hTTR) and porphyria. Oligonucleotides 30-46 transthyretin Homo sapiens 189-193 35474404-4 2022 Although there is no proven therapy for patients with ATTR cardiomyopathy (ATTR-CM), tafamidis meglumine, a TTR stabilizer, a study in 2018 found it was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations, as well as with a reduction in the decline in functional capacity and quality of life compared with a placebo for patients with ATTR-CM. tafamidis 85-104 transthyretin Homo sapiens 54-58 35474404-4 2022 Although there is no proven therapy for patients with ATTR cardiomyopathy (ATTR-CM), tafamidis meglumine, a TTR stabilizer, a study in 2018 found it was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations, as well as with a reduction in the decline in functional capacity and quality of life compared with a placebo for patients with ATTR-CM. tafamidis 85-104 transthyretin Homo sapiens 75-79 35474404-4 2022 Although there is no proven therapy for patients with ATTR cardiomyopathy (ATTR-CM), tafamidis meglumine, a TTR stabilizer, a study in 2018 found it was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations, as well as with a reduction in the decline in functional capacity and quality of life compared with a placebo for patients with ATTR-CM. tafamidis 85-104 transthyretin Homo sapiens 108-111 35474404-4 2022 Although there is no proven therapy for patients with ATTR cardiomyopathy (ATTR-CM), tafamidis meglumine, a TTR stabilizer, a study in 2018 found it was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations, as well as with a reduction in the decline in functional capacity and quality of life compared with a placebo for patients with ATTR-CM. tafamidis 85-104 transthyretin Homo sapiens 376-380 35474404-5 2022 As a result of these findings, tafamidis meglumine is currently the only drug approved for patients with both wild-type and variant ATTR-CM, and should be considered for patients whose survival can be reasonably expected. tafamidis 31-50 transthyretin Homo sapiens 132-136 35484710-2 2022 Free energy simulations based on all-atom molecular dynamics simulations were carried out to analyze the effects of the His88 Arg, Phe, and Tyr mutations on the stability of human TTR. Tyrosine 142-145 transthyretin Homo sapiens 182-185 35384890-0 2022 Large Pleural Effusion: A Pitfall in the Quantitation of 99mTc-PYP Imaging for ATTR Cardiac Amyloidosis. Technetium Tc 99m Pyrophosphate 57-66 transthyretin Homo sapiens 79-83 35083944-0 2022 Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Diflunisal 0-10 transthyretin Homo sapiens 113-117 35060353-1 2022 While 99m Tc-pyrophosphate scintigraphy is clearly useful in diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM), it is necessary to know the pitfalls of this test for proper use. tc-pyrophosphate 10-26 transthyretin Homo sapiens 110-114 35060353-4 2022 99m Tc-pyrophosphate scintigraphy revealed abnormal cardiac uptake of Grade 3, a typical feature for ATTR-CM. tc-pyrophosphate 4-20 transthyretin Homo sapiens 101-105 35352593-1 2022 PURPOSE: To investigate the effect of tolcapone on cerebrospinal fluid (CSF) transthyretin (TTR) tetramer stability in patients with hereditary transthyretin (ATTRv) amyloidosis. Tolcapone 38-47 transthyretin Homo sapiens 77-90 35352593-1 2022 PURPOSE: To investigate the effect of tolcapone on cerebrospinal fluid (CSF) transthyretin (TTR) tetramer stability in patients with hereditary transthyretin (ATTRv) amyloidosis. Tolcapone 38-47 transthyretin Homo sapiens 92-95 35352593-1 2022 PURPOSE: To investigate the effect of tolcapone on cerebrospinal fluid (CSF) transthyretin (TTR) tetramer stability in patients with hereditary transthyretin (ATTRv) amyloidosis. Tolcapone 38-47 transthyretin Homo sapiens 144-157 35352593-9 2022 Orally administered tolcapone significantly increased CSF TTR concentration and decreased monomer content under semi-denaturing conditions. Tolcapone 20-29 transthyretin Homo sapiens 58-61 35322226-4 2022 Small interfering RNA (siRNA) or antisense oligonucleotide (ASO) technologies have been shown to be highly effective for the blockade of TTR expression in the liver in humans. Oligonucleotides 43-58 transthyretin Homo sapiens 137-140 35322226-4 2022 Small interfering RNA (siRNA) or antisense oligonucleotide (ASO) technologies have been shown to be highly effective for the blockade of TTR expression in the liver in humans. Oligonucleotides, Antisense 60-63 transthyretin Homo sapiens 137-140 35198228-6 2022 Tafamidis may be beneficial as alternative antiarrhythmic therapy in patients with ATTR-CM. tafamidis 0-9 transthyretin Homo sapiens 83-87 35283385-0 2022 Deterioration after Liver Transplantation and Transthyretin Stabilizer Administration in a Patient with ATTRv Amyloidosis with a Leu58Arg (p.Leu78Arg) TTR Variant. leu78arg) 141-150 transthyretin Homo sapiens 46-59 35283385-0 2022 Deterioration after Liver Transplantation and Transthyretin Stabilizer Administration in a Patient with ATTRv Amyloidosis with a Leu58Arg (p.Leu78Arg) TTR Variant. leu78arg) 141-150 transthyretin Homo sapiens 151-154 35262277-0 2022 Transthyretin deposition alters cardiomyocyte sarcomeric architecture, calcium transients, and contractile force. Calcium 71-78 transthyretin Homo sapiens 0-13 35262277-3 2022 The hypothesis tested is that TTR deposited in vitro disrupts cardiac myocyte cell-to-cell and cell-to-matrix adhesion complexes, resulting in altered calcium handling, force generation, and sarcomeric disorganization. Calcium 151-158 transthyretin Homo sapiens 30-33 35083944-0 2022 Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Diflunisal 0-10 transthyretin Homo sapiens 98-111 35083944-1 2022 BACKGROUND: Diflunisal is a non-steroidal anti-inflammatory drug that stabilises transthyretin (TTR) and reduces neurologic deterioration in patients with polyneuropathy caused by hereditary transthyretin amyloidosis (ATTRv). Diflunisal 12-22 transthyretin Homo sapiens 81-94 35083944-1 2022 BACKGROUND: Diflunisal is a non-steroidal anti-inflammatory drug that stabilises transthyretin (TTR) and reduces neurologic deterioration in patients with polyneuropathy caused by hereditary transthyretin amyloidosis (ATTRv). Diflunisal 12-22 transthyretin Homo sapiens 96-99 35083944-2 2022 METHODS: We conducted a retrospective cohort study of patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CM) treated with diflunisal for at least one year between 2009 and 2016 at the Boston University Amyloidosis Centre. Diflunisal 137-147 transthyretin Homo sapiens 78-91 34996915-8 2022 There was a significant difference in LA function with worse strain values in ATTR vs AL: left atrial reservoir (7.4 (6.3-12.8) in ATTR vs. 13.8 (6.90-24.8) in AL, p = 0.017) and booster strains (3.6 (2.6-5.5) in ATTR vs. 5.2 (3.6-12.1) in AL, p = 0.039). Aluminum 160-162 transthyretin Homo sapiens 78-82 35160656-0 2022 Effects of Preparation Procedures and Porosity on Thermoelectric Bulk Samples of Cu2SnS3 (CTS). cu2sns3 81-88 transthyretin Homo sapiens 90-93 35160656-1 2022 The thermoelectric behavior and stability of Cu2SnS3 (CTS) has been investigated in relation to different preparations and sintering conditions, leading to different microstructures and porosities. cu2sns3 45-52 transthyretin Homo sapiens 54-57 34996915-8 2022 There was a significant difference in LA function with worse strain values in ATTR vs AL: left atrial reservoir (7.4 (6.3-12.8) in ATTR vs. 13.8 (6.90-24.8) in AL, p = 0.017) and booster strains (3.6 (2.6-5.5) in ATTR vs. 5.2 (3.6-12.1) in AL, p = 0.039). Aluminum 240-242 transthyretin Homo sapiens 78-82 35317495-8 2022 Genetic testing of TTR gene identified Glu89Gln mutation. glu89gln 39-47 transthyretin Homo sapiens 19-22 34491302-9 2022 This has led to the introduction of several first-in-class pharmaceuticals with actions targeted at inhibiting the various phases of amyloidosis: TTR stabilizers include diflunisal and first-in-class, Food and Drug Administration (FDA)-approved tafamidis; TTR silencers include patisiran and inotersen; fibril disrupters include doxycycline with tauroursodeoxycholic acid; and alternative agents include green tea extract and curcumin. Diflunisal 170-180 transthyretin Homo sapiens 146-149 34491302-9 2022 This has led to the introduction of several first-in-class pharmaceuticals with actions targeted at inhibiting the various phases of amyloidosis: TTR stabilizers include diflunisal and first-in-class, Food and Drug Administration (FDA)-approved tafamidis; TTR silencers include patisiran and inotersen; fibril disrupters include doxycycline with tauroursodeoxycholic acid; and alternative agents include green tea extract and curcumin. Doxycycline 329-340 transthyretin Homo sapiens 146-149 34491302-9 2022 This has led to the introduction of several first-in-class pharmaceuticals with actions targeted at inhibiting the various phases of amyloidosis: TTR stabilizers include diflunisal and first-in-class, Food and Drug Administration (FDA)-approved tafamidis; TTR silencers include patisiran and inotersen; fibril disrupters include doxycycline with tauroursodeoxycholic acid; and alternative agents include green tea extract and curcumin. ursodoxicoltaurine 346-371 transthyretin Homo sapiens 146-149 34491302-9 2022 This has led to the introduction of several first-in-class pharmaceuticals with actions targeted at inhibiting the various phases of amyloidosis: TTR stabilizers include diflunisal and first-in-class, Food and Drug Administration (FDA)-approved tafamidis; TTR silencers include patisiran and inotersen; fibril disrupters include doxycycline with tauroursodeoxycholic acid; and alternative agents include green tea extract and curcumin. Curcumin 426-434 transthyretin Homo sapiens 146-149 35417392-6 2022 The expert panel had an agreement that tafamidis 80mg/daily is the only available drug with moderate evidence and weak recommendation for the reduction of total mortality, cardiovascular morbidity, heart failure hospitalization and progression of the disease in patients with ATTR cardiomyopathy and NYHA class = 3. tafamidis 39-48 transthyretin Homo sapiens 276-280 35417392-9 2022 When patients did not have access to tafamidis, the expert panel stated a weak recommendation to use doxycycline and ursodeoxycholic acid in patients with ATTR cardiomyopathy. Doxycycline 101-112 transthyretin Homo sapiens 155-159 35417392-9 2022 When patients did not have access to tafamidis, the expert panel stated a weak recommendation to use doxycycline and ursodeoxycholic acid in patients with ATTR cardiomyopathy. Ursodeoxycholic Acid 117-137 transthyretin Homo sapiens 155-159 35317495-13 2022 Our patient suggested that hATTR with Glu89Gln may present with atypical symptoms. glu89gln 38-46 transthyretin Homo sapiens 27-32 2543515-1 1989 This simple, reliable method for detecting the transthyretin-methionine30 [TTR(Met30)] mutation, found in patients with familial amyloidotic polyneuropathy (FAP), is based on production of an extra peptide fragment when the mutant TTR is treated with cyanogen bromide (CNBr). methionine30 61-73 transthyretin Homo sapiens 75-78 2517349-3 1989 The percent of free T4 (% free T4) was also measured by equilibrium dialysis against veronal buffer in which T4-binding by TBPA was completely abolished. Barbital 85-92 transthyretin Homo sapiens 123-127 2613237-2 1989 A mutation of thymine to adenine in the prealbumin (transthyretin) gene at the position corresponding to the second base of codon 58 in the prealbumin mRNA gives a histidine for leucine substitution in the plasma protein. Thymine 14-21 transthyretin Homo sapiens 52-65 2613237-2 1989 A mutation of thymine to adenine in the prealbumin (transthyretin) gene at the position corresponding to the second base of codon 58 in the prealbumin mRNA gives a histidine for leucine substitution in the plasma protein. Adenine 25-32 transthyretin Homo sapiens 52-65 2613237-2 1989 A mutation of thymine to adenine in the prealbumin (transthyretin) gene at the position corresponding to the second base of codon 58 in the prealbumin mRNA gives a histidine for leucine substitution in the plasma protein. Histidine 164-173 transthyretin Homo sapiens 52-65 2515958-2 1989 From the electrophoretic analysis, it was shown that thyroxine-binding proteins similar to human thyroxine-binding globulin (TBG) and thyroxine-binding prealbumin (TBPA) were present in catarrhini and prosimiae species, but not in platyrrhini (callithricidae and cebidae). Thyroxine 53-62 transthyretin Homo sapiens 134-162 2515958-2 1989 From the electrophoretic analysis, it was shown that thyroxine-binding proteins similar to human thyroxine-binding globulin (TBG) and thyroxine-binding prealbumin (TBPA) were present in catarrhini and prosimiae species, but not in platyrrhini (callithricidae and cebidae). Thyroxine 53-62 transthyretin Homo sapiens 164-168 2675831-6 1989 SDS polyacrylamide gel electrophoresis and gel filtration analysis suggested that the recombinant variant TTR can form tetramer as seen for native one. Sodium Dodecyl Sulfate 0-3 transthyretin Homo sapiens 106-109 2675831-6 1989 SDS polyacrylamide gel electrophoresis and gel filtration analysis suggested that the recombinant variant TTR can form tetramer as seen for native one. polyacrylamide 4-18 transthyretin Homo sapiens 106-109 2543515-1 1989 This simple, reliable method for detecting the transthyretin-methionine30 [TTR(Met30)] mutation, found in patients with familial amyloidotic polyneuropathy (FAP), is based on production of an extra peptide fragment when the mutant TTR is treated with cyanogen bromide (CNBr). methionine30 61-73 transthyretin Homo sapiens 231-234 2543515-1 1989 This simple, reliable method for detecting the transthyretin-methionine30 [TTR(Met30)] mutation, found in patients with familial amyloidotic polyneuropathy (FAP), is based on production of an extra peptide fragment when the mutant TTR is treated with cyanogen bromide (CNBr). Cyanogen Bromide 251-267 transthyretin Homo sapiens 75-78 2543515-1 1989 This simple, reliable method for detecting the transthyretin-methionine30 [TTR(Met30)] mutation, found in patients with familial amyloidotic polyneuropathy (FAP), is based on production of an extra peptide fragment when the mutant TTR is treated with cyanogen bromide (CNBr). Cyanogen Bromide 269-273 transthyretin Homo sapiens 75-78 2543515-2 1989 After electrophoresis of whole serum and excision of the TTR (prealbumin) band, the TTR-containing gel is incubated with CNBr, subjected to sodium dodecyl sulfate/polyacrylamide gel electrophoresis, and stained with silver to determine whether an abnormal CNBr fragment (residues 31-127) is present. Cyanogen Bromide 121-125 transthyretin Homo sapiens 84-87 2543515-2 1989 After electrophoresis of whole serum and excision of the TTR (prealbumin) band, the TTR-containing gel is incubated with CNBr, subjected to sodium dodecyl sulfate/polyacrylamide gel electrophoresis, and stained with silver to determine whether an abnormal CNBr fragment (residues 31-127) is present. Sodium Dodecyl Sulfate 140-162 transthyretin Homo sapiens 84-87 2543515-2 1989 After electrophoresis of whole serum and excision of the TTR (prealbumin) band, the TTR-containing gel is incubated with CNBr, subjected to sodium dodecyl sulfate/polyacrylamide gel electrophoresis, and stained with silver to determine whether an abnormal CNBr fragment (residues 31-127) is present. polyacrylamide 163-177 transthyretin Homo sapiens 84-87 2543515-2 1989 After electrophoresis of whole serum and excision of the TTR (prealbumin) band, the TTR-containing gel is incubated with CNBr, subjected to sodium dodecyl sulfate/polyacrylamide gel electrophoresis, and stained with silver to determine whether an abnormal CNBr fragment (residues 31-127) is present. Silver 216-222 transthyretin Homo sapiens 84-87 2498384-0 1989 Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin. Thyroxine 21-30 transthyretin Homo sapiens 39-55 2498384-4 1989 Compounds of the anthranilic acid class, such as flufenamic, meclofenamic, and mefenamic acids, interacted particularly strongly with TTR. anthranilic acid 17-33 transthyretin Homo sapiens 134-137 2498384-4 1989 Compounds of the anthranilic acid class, such as flufenamic, meclofenamic, and mefenamic acids, interacted particularly strongly with TTR. flufenamic 49-59 transthyretin Homo sapiens 134-137 2498384-4 1989 Compounds of the anthranilic acid class, such as flufenamic, meclofenamic, and mefenamic acids, interacted particularly strongly with TTR. meclofenamic 61-73 transthyretin Homo sapiens 134-137 2498384-4 1989 Compounds of the anthranilic acid class, such as flufenamic, meclofenamic, and mefenamic acids, interacted particularly strongly with TTR. Mefenamic Acid 79-94 transthyretin Homo sapiens 134-137 2498384-6 1989 T4; n = 3; P less than 0.001], while mefenamic acid, diflunisal, and meclofenamic acid were 20-26% as potent as T4 in their interaction with TTR. Mefenamic Acid 37-51 transthyretin Homo sapiens 141-144 2498384-6 1989 T4; n = 3; P less than 0.001], while mefenamic acid, diflunisal, and meclofenamic acid were 20-26% as potent as T4 in their interaction with TTR. Diflunisal 53-63 transthyretin Homo sapiens 141-144 2498384-6 1989 T4; n = 3; P less than 0.001], while mefenamic acid, diflunisal, and meclofenamic acid were 20-26% as potent as T4 in their interaction with TTR. Meclofenamic Acid 69-86 transthyretin Homo sapiens 141-144 2498384-9 1989 Aspirin and sodium salicylate were, respectively, 0.05% and 0.20% as active as unlabeled T4 as inhibitors of [125I]T4 binding to TTR, but these compounds had only 3-4 x 10(-6)% of the activity of T4 for TBG binding. Sodium Salicylate 12-29 transthyretin Homo sapiens 129-132 2926451-2 1989 The variant transthyretin was extracted by using 70% formic acid solution in which the protein was solubilized completely and rapidly. formic acid 53-64 transthyretin Homo sapiens 12-25 2659558-1 1989 In situ hybridization with 35S-labeled single stranded RNA probes was used on sections from formaldehyde-fixed and paraffin-embedded tissue specimens to provide semiquantitative data on the occurrence of transthyretin(TTR)-mRNA in human liver, choroid plexus and pancreatic islets as well as in 15 endocrine tumours of the pancreas and gut. Sulfur-35 27-30 transthyretin Homo sapiens 218-221 2492196-0 1989 Transthyretin microheterogeneity and thyroxine binding are influenced by non-amino acid components and glutathione constituents. Glutathione 103-114 transthyretin Homo sapiens 0-13 2492196-1 1989 Two non-amino acid components as well as the glutathione constituents in labile associations with transthyretin (TTR) have been detected by preparative polyacrylamide gel electrophoresis from preparations isolated by affinity chromatography on Sepharose-bound retinol-binding protein (RBP). Glutathione 45-56 transthyretin Homo sapiens 98-111 2492196-1 1989 Two non-amino acid components as well as the glutathione constituents in labile associations with transthyretin (TTR) have been detected by preparative polyacrylamide gel electrophoresis from preparations isolated by affinity chromatography on Sepharose-bound retinol-binding protein (RBP). Glutathione 45-56 transthyretin Homo sapiens 113-116 2492196-1 1989 Two non-amino acid components as well as the glutathione constituents in labile associations with transthyretin (TTR) have been detected by preparative polyacrylamide gel electrophoresis from preparations isolated by affinity chromatography on Sepharose-bound retinol-binding protein (RBP). polyacrylamide 152-166 transthyretin Homo sapiens 98-111 2492196-1 1989 Two non-amino acid components as well as the glutathione constituents in labile associations with transthyretin (TTR) have been detected by preparative polyacrylamide gel electrophoresis from preparations isolated by affinity chromatography on Sepharose-bound retinol-binding protein (RBP). polyacrylamide 152-166 transthyretin Homo sapiens 113-116 2492196-1 1989 Two non-amino acid components as well as the glutathione constituents in labile associations with transthyretin (TTR) have been detected by preparative polyacrylamide gel electrophoresis from preparations isolated by affinity chromatography on Sepharose-bound retinol-binding protein (RBP). Sepharose 244-253 transthyretin Homo sapiens 98-111 2492196-1 1989 Two non-amino acid components as well as the glutathione constituents in labile associations with transthyretin (TTR) have been detected by preparative polyacrylamide gel electrophoresis from preparations isolated by affinity chromatography on Sepharose-bound retinol-binding protein (RBP). Sepharose 244-253 transthyretin Homo sapiens 113-116 2492196-1 1989 Two non-amino acid components as well as the glutathione constituents in labile associations with transthyretin (TTR) have been detected by preparative polyacrylamide gel electrophoresis from preparations isolated by affinity chromatography on Sepharose-bound retinol-binding protein (RBP). Vitamin A 260-267 transthyretin Homo sapiens 98-111 2492196-1 1989 Two non-amino acid components as well as the glutathione constituents in labile associations with transthyretin (TTR) have been detected by preparative polyacrylamide gel electrophoresis from preparations isolated by affinity chromatography on Sepharose-bound retinol-binding protein (RBP). Vitamin A 260-267 transthyretin Homo sapiens 113-116 2492196-3 1989 Reduction of isolated TTR monomers released cysteine from the quantitatively major monomer, but non-amino-acid components from another dominating monomer. Cysteine 44-52 transthyretin Homo sapiens 22-25 2492196-5 1989 These relationships indicate that interactions in serum of TTR with constituents of glutathione and components different from T4 and retinol-RBP are important for the metabolism and function of TTR. Glutathione 84-95 transthyretin Homo sapiens 59-62 2492196-5 1989 These relationships indicate that interactions in serum of TTR with constituents of glutathione and components different from T4 and retinol-RBP are important for the metabolism and function of TTR. Glutathione 84-95 transthyretin Homo sapiens 194-197 2512001-5 1989 Since TT levels are strongly influenced by the nutritional status of patients, our results suggest that the decreased blood levels of vitamin A and its carriers observed in digestive cancer are the consequence of nutritional alterations evoked by the disease. Vitamin A 134-143 transthyretin Homo sapiens 6-8 3146151-4 1988 Ioxynil bound to TBPA but not to TBG nor albumin. ioxynil 0-7 transthyretin Homo sapiens 17-21 2503927-2 1989 The cellular localization of transthyretin (TTR)-mRNA in different organs was demonstrated by in situ hybridization with a 35S-labelled, single-stranded RNA probe. Sulfur-35 123-126 transthyretin Homo sapiens 29-42 2503927-2 1989 The cellular localization of transthyretin (TTR)-mRNA in different organs was demonstrated by in situ hybridization with a 35S-labelled, single-stranded RNA probe. Sulfur-35 123-126 transthyretin Homo sapiens 44-47 2461362-3 1988 However, TTR mRNA and RBP mRNA were both detected in F9 cell aggregates differentiated to embryoid bodies (which contain visceral endoderm-like cells) by treatment of the aggregates in suspension with retinoic acid. Tretinoin 201-214 transthyretin Homo sapiens 9-12 2461362-4 1988 TTR mRNA was observed at 3 days, and RBP mRNA at 5 days, after treatment of the F9 cell aggregates with retinoic acid. Tretinoin 104-117 transthyretin Homo sapiens 0-3 3207418-2 1988 In the plasma, retinol is transported by retinol-binding protein (RBP) in complex with transthyretin (TTR, prealbumin). Vitamin A 15-22 transthyretin Homo sapiens 87-100 3207418-2 1988 In the plasma, retinol is transported by retinol-binding protein (RBP) in complex with transthyretin (TTR, prealbumin). Vitamin A 15-22 transthyretin Homo sapiens 102-105 3207418-7 1988 We postulate that ocular RBP and TTR are involved in the intraocular translocation of retinol. Vitamin A 86-93 transthyretin Homo sapiens 33-36 3146151-5 1988 The Ka calculated for the TBPA-ioxynil complex was 2.6 x 10(6) l.mol-1. ioxynil 31-38 transthyretin Homo sapiens 26-30 3146151-6 1988 Ioxynil competed for the iodothyronine-binding sites of TBPA. ioxynil 0-7 transthyretin Homo sapiens 56-60 3146151-6 1988 Ioxynil competed for the iodothyronine-binding sites of TBPA. iodothyronine 25-38 transthyretin Homo sapiens 56-60 3149232-2 1987 TBPA was isolated by retinol-binding protein (RBP) affinity chromatography and further purified by preparative agarose gel electrophoresis or FPLC ion exchange chromatography. Sepharose 111-118 transthyretin Homo sapiens 0-4 2849421-10 1988 Transthyretin decreased the rate of uptake of [3H]retinol from RBP without substantially altering the steady-state uptake levels, suggesting that membranes take up retinol from uncomplexed RBP. Tritium 47-49 transthyretin Homo sapiens 0-13 2849421-10 1988 Transthyretin decreased the rate of uptake of [3H]retinol from RBP without substantially altering the steady-state uptake levels, suggesting that membranes take up retinol from uncomplexed RBP. Vitamin A 50-57 transthyretin Homo sapiens 0-13 2849421-10 1988 Transthyretin decreased the rate of uptake of [3H]retinol from RBP without substantially altering the steady-state uptake levels, suggesting that membranes take up retinol from uncomplexed RBP. Vitamin A 164-171 transthyretin Homo sapiens 0-13 3354492-2 1988 The purpose of this work was to study the role of TBPA-retinol-binding-protein (RBP)-retinol complex changes in the elevation of serum TBPA in HD patients. Vitamin A 55-62 transthyretin Homo sapiens 50-54 3183876-2 1988 A group of 30 infants whose mothers received a single course of betamethasone less than or equal to 1 week prior to delivery had significantly elevated mean retinol-binding protein and transthyretin but not transferrin concentrations when compared with a group of 30 gestational age- and birth weight-matched infants with no exposure to antenatal betamethasone. Betamethasone 64-77 transthyretin Homo sapiens 185-198 3183876-5 1988 We conclude that antenatal steroids increase the umbilical cord serum concentrations of retinol-binding protein, transthyretin, transferrin, retinol, and vitamin E. Steroids 27-35 transthyretin Homo sapiens 113-126 3140249-4 1988 The T4-binding site of hTBPA is a useful "receptor model" for type I deiodinase in computer aided drug design of flavonoid antagonists with improved pharmacological characteristics, bio-availability, and target-specificity for ITH-binding sites. Flavonoids 113-122 transthyretin Homo sapiens 23-28 3149232-13 1987 Thyroxine-binding was found to TBG in the beta-globulin region, TBPA in the alpha 2-region, albumin, and to the high density lipoprotein (HDL2) in the alpha 1-region and the very low density lipoprotein (VLDL) in the pre-beta region. Thyroxine 0-9 transthyretin Homo sapiens 64-68 3797988-6 1986 All mabs have been found suitable for immunohistochemical localization of hTTR even in formaldehyde fixed and paraffin embedded tissues. Paraffin 110-118 transthyretin Homo sapiens 74-78 3559267-2 1987 Retinol is distributed to target cells by the retinol-binding protein (RBP), which circulates in the plasma in complex with transthyretin (TTR). Vitamin A 0-7 transthyretin Homo sapiens 124-137 3559267-2 1987 Retinol is distributed to target cells by the retinol-binding protein (RBP), which circulates in the plasma in complex with transthyretin (TTR). Vitamin A 0-7 transthyretin Homo sapiens 139-142 3559267-4 1987 Retinol radiobinding assays, affinity chromatography with TTR coupled to Sepharose beads, polyacrylamide gel electrophoresis, and immunoblotting techniques were used to show that epidermal extracts contain retinol binding sites with no affinity for TTR. Vitamin A 206-213 transthyretin Homo sapiens 249-252 3628195-1 1987 A method is presented by which prealbumin (thyroxine-binding prealbumin; tryptophan-rich prealbumin) may be purified to homogeneity from human serum. Tryptophan 73-83 transthyretin Homo sapiens 43-71 3797988-6 1986 All mabs have been found suitable for immunohistochemical localization of hTTR even in formaldehyde fixed and paraffin embedded tissues. Formaldehyde 87-99 transthyretin Homo sapiens 74-78 3866141-5 1985 The CS- and CTS-catalyzed phosphorylations exhibit different response to increasing NaCl (or KCl) concentrations up to physiological levels (140 mM KCl, 20 mM NaCl); i.e. CS- and MS-catalyzed phosphorylations are strongly inhibited by 75-150 mM KCl (or NaCl), while CTS-catalyzed phosphorylation is practically unaffected. Cesium 4-6 transthyretin Homo sapiens 266-269 3094194-0 1986 Binding of a metabolite of 3,4,3",4"-tetrachlorobiphenyl to transthyretin reduces serum vitamin A transport by inhibiting the formation of the protein complex carrying both retinol and thyroxin. 3,4,3',4'-tetrachlorobiphenyl 27-56 transthyretin Homo sapiens 60-73 3094194-0 1986 Binding of a metabolite of 3,4,3",4"-tetrachlorobiphenyl to transthyretin reduces serum vitamin A transport by inhibiting the formation of the protein complex carrying both retinol and thyroxin. Vitamin A 88-97 transthyretin Homo sapiens 60-73 3094194-0 1986 Binding of a metabolite of 3,4,3",4"-tetrachlorobiphenyl to transthyretin reduces serum vitamin A transport by inhibiting the formation of the protein complex carrying both retinol and thyroxin. Vitamin A 173-180 transthyretin Homo sapiens 60-73 3094194-0 1986 Binding of a metabolite of 3,4,3",4"-tetrachlorobiphenyl to transthyretin reduces serum vitamin A transport by inhibiting the formation of the protein complex carrying both retinol and thyroxin. Thyroxine 185-193 transthyretin Homo sapiens 60-73 3094194-2 1986 Analysis of [3H]retinol-labeled serum proteins by polyacrylamide gel electrophoresis (PAGE) showed association of retinol with two proteins that were identified as retinol binding protein (RBP) and the RBP complex with transthyretin (TTR). Vitamin A 114-121 transthyretin Homo sapiens 219-232 3094194-2 1986 Analysis of [3H]retinol-labeled serum proteins by polyacrylamide gel electrophoresis (PAGE) showed association of retinol with two proteins that were identified as retinol binding protein (RBP) and the RBP complex with transthyretin (TTR). Vitamin A 114-121 transthyretin Homo sapiens 234-237 3094194-5 1986 Analysis of the plasma proteins by PAGE revealed the presence of four peaks of 3H-TCB label, the major ones being associated with lipoproteins and TTR. 3h-tcb 79-85 transthyretin Homo sapiens 147-150 3094194-7 1986 HPLC analysis of the radioactive compound associated with TTR showed the presence of a metabolite of TCB, rather than the parent compound. 3,4,3',4'-tetrachlorobiphenyl 101-104 transthyretin Homo sapiens 58-61 3094194-8 1986 These data indicate a direct interaction of a metabolite of TCB with TTR leading to an inhibition of formation of the serum transport protein complex carrying both retinol and thyroxin. 3,4,3',4'-tetrachlorobiphenyl 60-63 transthyretin Homo sapiens 69-72 3094194-8 1986 These data indicate a direct interaction of a metabolite of TCB with TTR leading to an inhibition of formation of the serum transport protein complex carrying both retinol and thyroxin. Vitamin A 164-171 transthyretin Homo sapiens 69-72 3094194-8 1986 These data indicate a direct interaction of a metabolite of TCB with TTR leading to an inhibition of formation of the serum transport protein complex carrying both retinol and thyroxin. Thyroxine 176-184 transthyretin Homo sapiens 69-72 2429942-6 1986 This study disclosed a positive relation of TBPA with alcohol consumption and related parameters such as body mass index or gamma-glutamyl transferase as well as a negative one with alpha 2-globulin and gamma-globulin. Alcohols 54-61 transthyretin Homo sapiens 44-48 2429942-9 1986 Positive relations were also observed between TBPA and apolipoprotein A1 and HDL cholesterol levels, which are negatively associated with coronary heart disease risk. Cholesterol 81-92 transthyretin Homo sapiens 46-50 3741189-1 1986 Ten patients of a population of 319 on chronic intermittent treatment with Cuprophan dialyzers have undergone surgery for carpal tunnel syndrome (CTS). cuprammonium cellulose 75-84 transthyretin Homo sapiens 146-149 2876953-3 1986 This activity is apparently dependent on the production of a soluble factor(s) since supernatants from adenosine treated TTR (SnA) exert a significant inhibition on the proliferative response of resting lymphocytes. Adenosine 103-112 transthyretin Homo sapiens 121-124 3714052-2 1986 Plasma transthyretin (TTR, formerly called prealbumin) is a 55-kd protein that participates in the plasma transport of both thyroxine and retinol (vitamin A). Thyroxine 124-133 transthyretin Homo sapiens 7-20 3714052-2 1986 Plasma transthyretin (TTR, formerly called prealbumin) is a 55-kd protein that participates in the plasma transport of both thyroxine and retinol (vitamin A). Thyroxine 124-133 transthyretin Homo sapiens 22-25 3714052-2 1986 Plasma transthyretin (TTR, formerly called prealbumin) is a 55-kd protein that participates in the plasma transport of both thyroxine and retinol (vitamin A). Vitamin A 138-145 transthyretin Homo sapiens 7-20 3714052-2 1986 Plasma transthyretin (TTR, formerly called prealbumin) is a 55-kd protein that participates in the plasma transport of both thyroxine and retinol (vitamin A). Vitamin A 138-145 transthyretin Homo sapiens 22-25 3714052-2 1986 Plasma transthyretin (TTR, formerly called prealbumin) is a 55-kd protein that participates in the plasma transport of both thyroxine and retinol (vitamin A). Vitamin A 147-156 transthyretin Homo sapiens 7-20 3714052-2 1986 Plasma transthyretin (TTR, formerly called prealbumin) is a 55-kd protein that participates in the plasma transport of both thyroxine and retinol (vitamin A). Vitamin A 147-156 transthyretin Homo sapiens 22-25 3866141-5 1985 The CS- and CTS-catalyzed phosphorylations exhibit different response to increasing NaCl (or KCl) concentrations up to physiological levels (140 mM KCl, 20 mM NaCl); i.e. CS- and MS-catalyzed phosphorylations are strongly inhibited by 75-150 mM KCl (or NaCl), while CTS-catalyzed phosphorylation is practically unaffected. Sodium Chloride 84-88 transthyretin Homo sapiens 12-15 3866141-5 1985 The CS- and CTS-catalyzed phosphorylations exhibit different response to increasing NaCl (or KCl) concentrations up to physiological levels (140 mM KCl, 20 mM NaCl); i.e. CS- and MS-catalyzed phosphorylations are strongly inhibited by 75-150 mM KCl (or NaCl), while CTS-catalyzed phosphorylation is practically unaffected. Potassium Chloride 93-96 transthyretin Homo sapiens 12-15 3866141-5 1985 The CS- and CTS-catalyzed phosphorylations exhibit different response to increasing NaCl (or KCl) concentrations up to physiological levels (140 mM KCl, 20 mM NaCl); i.e. CS- and MS-catalyzed phosphorylations are strongly inhibited by 75-150 mM KCl (or NaCl), while CTS-catalyzed phosphorylation is practically unaffected. Potassium Chloride 148-151 transthyretin Homo sapiens 12-15 3866141-5 1985 The CS- and CTS-catalyzed phosphorylations exhibit different response to increasing NaCl (or KCl) concentrations up to physiological levels (140 mM KCl, 20 mM NaCl); i.e. CS- and MS-catalyzed phosphorylations are strongly inhibited by 75-150 mM KCl (or NaCl), while CTS-catalyzed phosphorylation is practically unaffected. Sodium Chloride 159-163 transthyretin Homo sapiens 12-15 3866141-5 1985 The CS- and CTS-catalyzed phosphorylations exhibit different response to increasing NaCl (or KCl) concentrations up to physiological levels (140 mM KCl, 20 mM NaCl); i.e. CS- and MS-catalyzed phosphorylations are strongly inhibited by 75-150 mM KCl (or NaCl), while CTS-catalyzed phosphorylation is practically unaffected. Cesium 171-173 transthyretin Homo sapiens 12-15 3866141-5 1985 The CS- and CTS-catalyzed phosphorylations exhibit different response to increasing NaCl (or KCl) concentrations up to physiological levels (140 mM KCl, 20 mM NaCl); i.e. CS- and MS-catalyzed phosphorylations are strongly inhibited by 75-150 mM KCl (or NaCl), while CTS-catalyzed phosphorylation is practically unaffected. Potassium Chloride 148-151 transthyretin Homo sapiens 12-15 3866141-5 1985 The CS- and CTS-catalyzed phosphorylations exhibit different response to increasing NaCl (or KCl) concentrations up to physiological levels (140 mM KCl, 20 mM NaCl); i.e. CS- and MS-catalyzed phosphorylations are strongly inhibited by 75-150 mM KCl (or NaCl), while CTS-catalyzed phosphorylation is practically unaffected. Sodium Chloride 159-163 transthyretin Homo sapiens 12-15 3866141-6 1985 In the absence of added NaCl, CS- and MS-catalyzed phosphorylations are markedly inhibited by 1.5-3 mM 2,3-bisphosphoglycerate, whereas CTS-catalyzed phosphorylation appears to be practically unaffected. Cesium 30-32 transthyretin Homo sapiens 136-139 3936007-1 1985 Thyroxin binding prealbumin (TBPA) and retinol binding protein (RBP) are associated in a complex responsible for the transport of vitamin A and of about 10% of the thyroid hormones T3 and T4. Vitamin A 130-139 transthyretin Homo sapiens 0-27 3936007-1 1985 Thyroxin binding prealbumin (TBPA) and retinol binding protein (RBP) are associated in a complex responsible for the transport of vitamin A and of about 10% of the thyroid hormones T3 and T4. Vitamin A 130-139 transthyretin Homo sapiens 29-33 2987291-7 1985 Polyacrylamide gel electrophoresis of the patient"s serum in the presence of tracer amounts of [125I]T4 revealed that, compared to normal sera, [125I]T4 binding to TBPA was increased from 30.0 +/- 6.0% (mean +/- SD) to 52.0%. polyacrylamide 0-14 transthyretin Homo sapiens 164-168 3935870-5 1985 Weight loss (UBW) correlated with ALB (P less than 0.001), TBPA (P less than 0.005) and RBP (P less than 0.02) but did not correlate with TFN (P less than 0.06), TSF, and MAMC. N-[(R)-({[(Benzyloxy)carbonyl]amino}methyl)(Hydroxy)phosphoryl]-L-Leucyl-L-Norvaline 13-16 transthyretin Homo sapiens 59-63 3924724-8 1985 The thyroxine-binding capacity of TBPA in serum varied from 1000 to greater than 6000 nmol/l and that of TBG between 150 and 600 nmol/l. Thyroxine 4-13 transthyretin Homo sapiens 34-38 3924724-10 1985 The presence of TBPA in all vertebrates suggests prealbumin to be a far more important thyroxine carrier than earlier anticipated. Thyroxine 87-96 transthyretin Homo sapiens 16-20 6594681-1 1984 Differential enzymic analyses of the erythrocyte glutamic-oxaloacetic transaminase and the erythrocyte glutathione reductase of a patient with a 3-yr history of the carpal tunnel syndrome (CTS) revealed high deficiencies of both vitamin B-6 and riboflavin as based on approximately equal to 30% levels of the specific activities of these enzymes. Vitamin B 6 229-240 transthyretin Homo sapiens 189-192 3838432-2 1985 The course of one of these patients was marked by resolution of symptoms and electrophysiologic measures of CTS that paralleled the remission of Graves" disease after treatment with radioactive iodine. radioactive iodine 182-200 transthyretin Homo sapiens 108-111 6093733-1 1984 The role of insufficient pyridoxine as an etiologic factor in the development of carpal tunnel syndrome (CTS) has been reported and has led to the empirical use of pyridoxine to treat CTS. Pyridoxine 25-35 transthyretin Homo sapiens 105-108 6093733-1 1984 The role of insufficient pyridoxine as an etiologic factor in the development of carpal tunnel syndrome (CTS) has been reported and has led to the empirical use of pyridoxine to treat CTS. Pyridoxine 164-174 transthyretin Homo sapiens 105-108 6093733-1 1984 The role of insufficient pyridoxine as an etiologic factor in the development of carpal tunnel syndrome (CTS) has been reported and has led to the empirical use of pyridoxine to treat CTS. Pyridoxine 164-174 transthyretin Homo sapiens 184-187 6093733-10 1984 This finding suggested that the positive response reported previously in subjects with CTS taking supplemental pyridoxine may actually be related to an unrecognized PN, which was compounding the symptomatology. Pyridoxine 111-121 transthyretin Homo sapiens 87-90 3923758-3 1985 The concentration of free thyroxine (FT4) was calculated from the concentrations of T4, TBG and TBPA. free 21-25 transthyretin Homo sapiens 96-100 3923758-3 1985 The concentration of free thyroxine (FT4) was calculated from the concentrations of T4, TBG and TBPA. Thyroxine 26-35 transthyretin Homo sapiens 96-100 3923758-3 1985 The concentration of free thyroxine (FT4) was calculated from the concentrations of T4, TBG and TBPA. CHEMBL179036 37-40 transthyretin Homo sapiens 96-100 3921123-3 1985 Increased binding of thyroxine to thyroxine binding prealbumin was diagnosed in one woman with four unaffected relatives. Thyroxine 21-30 transthyretin Homo sapiens 34-62 3991513-3 1985 SPS was less frequent (24%) in 58 patients not operated on for CTS than in 52 operated patients (SPS incidence: 77%). Sodium phenolsulfonate 0-3 transthyretin Homo sapiens 63-66 6594681-1 1984 Differential enzymic analyses of the erythrocyte glutamic-oxaloacetic transaminase and the erythrocyte glutathione reductase of a patient with a 3-yr history of the carpal tunnel syndrome (CTS) revealed high deficiencies of both vitamin B-6 and riboflavin as based on approximately equal to 30% levels of the specific activities of these enzymes. Riboflavin 245-255 transthyretin Homo sapiens 189-192 6594681-2 1984 Riboflavin for 5 months caused nearly complete disappearance of the CTS and caused no change in the specific activity of erythrocyte glutamic-oxaloacetic transaminase. Riboflavin 0-10 transthyretin Homo sapiens 68-71 6594681-3 1984 Combined riboflavin and pyridoxine treatment increased (P less than 0.001) the specific activities of erythrocyte glutathione reductase and erythrocyte glutamic-oxaloacetic transaminase to normal levels with total disappearance of the CTS. Riboflavin 9-19 transthyretin Homo sapiens 235-238 6594681-3 1984 Combined riboflavin and pyridoxine treatment increased (P less than 0.001) the specific activities of erythrocyte glutathione reductase and erythrocyte glutamic-oxaloacetic transaminase to normal levels with total disappearance of the CTS. Pyridoxine 24-34 transthyretin Homo sapiens 235-238 6581148-5 1983 On the contrary, the minor cytosolic casein kinase CTS, is inhibited by both 2,3-DPG and heparin under all conditions tested in the assay. 2,3-Diphosphoglycerate 77-84 transthyretin Homo sapiens 51-54 6736244-7 1984 On the basis of the known amino acid sequence of TTR, comparative tryptic peptide maps showed the presence of a single aberrant tryptic peptide (peptide 4, residues 22-34) in AFp as compared with TTR. Peptides 74-81 transthyretin Homo sapiens 49-52 6736244-7 1984 On the basis of the known amino acid sequence of TTR, comparative tryptic peptide maps showed the presence of a single aberrant tryptic peptide (peptide 4, residues 22-34) in AFp as compared with TTR. Peptides 136-143 transthyretin Homo sapiens 49-52 6736244-7 1984 On the basis of the known amino acid sequence of TTR, comparative tryptic peptide maps showed the presence of a single aberrant tryptic peptide (peptide 4, residues 22-34) in AFp as compared with TTR. Peptides 136-143 transthyretin Homo sapiens 49-52 6407257-6 1983 A significant increase of serum TBPA by 24% occurred only in the group receiving both steroids and nutrition iv with only minor or no changes (0-12%) in the other three groups. Steroids 86-94 transthyretin Homo sapiens 32-36 6522183-2 1984 More precisely, TBPA serves as a valid marker for determining both protein nutritional adequacy and the optimal ratio of energy and zinc to nitrogen intake in healthy newborns and preterm infants without infection. Nitrogen 140-148 transthyretin Homo sapiens 16-20 6581148-5 1983 On the contrary, the minor cytosolic casein kinase CTS, is inhibited by both 2,3-DPG and heparin under all conditions tested in the assay. Heparin 89-96 transthyretin Homo sapiens 51-54 115198-4 1979 Comparative studies using human serum indicated that T4 binding by serum T4-binding prealbumin (TBPA) was inhibited with DNP and salicylate, and that binding of T4 and T3 by serum T4-binding globulin (TBG) was decreased only with DPH. Dinitrophenols 121-124 transthyretin Homo sapiens 73-94 6401350-12 1983 Dietary carbohydrate apparently modulates the serum concentrations of TBPA and RBP, independently of caloric intake, since ingestion of a eucaloric CRD by normal weight individuals also decreased the serum concentration of the two visceral proteins. Carbohydrates 8-20 transthyretin Homo sapiens 70-74 6293553-0 1982 Photoaffinity labeling of human thyroxine-binding prealbumin with thyroxine and N-(ethyl-2-diazomalonyl)thyroxine. N-(ethyl-2-diazomalonyl)thyroxine 80-113 transthyretin Homo sapiens 32-60 6293553-2 1982 The binding affinities of L-EDM-T4 and D-EDM-T4 to human thyroxine-binding prealbumin were 4% and 13.2%, respectively, that of L-thyroxine (L-T4). l-edm-t4 26-34 transthyretin Homo sapiens 57-85 6293553-2 1982 The binding affinities of L-EDM-T4 and D-EDM-T4 to human thyroxine-binding prealbumin were 4% and 13.2%, respectively, that of L-thyroxine (L-T4). d-edm-t4 39-47 transthyretin Homo sapiens 57-85 6293553-2 1982 The binding affinities of L-EDM-T4 and D-EDM-T4 to human thyroxine-binding prealbumin were 4% and 13.2%, respectively, that of L-thyroxine (L-T4). Thyroxine 127-138 transthyretin Homo sapiens 57-85 6293553-2 1982 The binding affinities of L-EDM-T4 and D-EDM-T4 to human thyroxine-binding prealbumin were 4% and 13.2%, respectively, that of L-thyroxine (L-T4). Thyroxine 140-144 transthyretin Homo sapiens 57-85 6801514-0 1982 Familial euthyroid hyperthyroxinemia resulting from increased thyroxine binding to thyroxine-binding prealbumin. Thyroxine 24-33 transthyretin Homo sapiens 83-111 6112755-3 1981 Thyroid hormone binding proteins are also present in the blood plasma; in humans there are two distinct binding proteins, thyroxine binding globulin (TBG) and prealbumin (PA), sometimes known as thyroxine binding (TBPA). Thyroxine 122-131 transthyretin Homo sapiens 214-218 6776904-4 1980 TBPA binding capacity for thyroxine was greatly decreased, probably due to iron overload impairing the liver function. Thyroxine 26-35 transthyretin Homo sapiens 0-4 6776904-4 1980 TBPA binding capacity for thyroxine was greatly decreased, probably due to iron overload impairing the liver function. Iron 75-79 transthyretin Homo sapiens 0-4 6776904-5 1980 The decreased circulating total thyroxine might be explained by the reduced TBPA capacity, serum free thyroid hormone concentration total thyroxine might be explained by the reduced TBPA capacity, serum free thyroid hormone concentration values being normal. Thyroxine 138-147 transthyretin Homo sapiens 182-186 6961425-4 1982 The clinical response, appraised by the diminution of the symptoms of CTS, was correlated only with the restored levels of the transaminase which presumably results from a translational long-term increase in the number of molecules of EGOT by a mechanism activated by correcting a deficiency of pyridoxal 5"-phosphate. Pyridoxal Phosphate 295-317 transthyretin Homo sapiens 70-73 6820644-1 1982 Serum thyroxine binding prealbumin (TBPA) levels in various thyroidal states were examined by radioimmunoassay (RIA). Thyroxine 6-15 transthyretin Homo sapiens 36-40 6820644-3 1982 The normal mean (+/- 2SD) level of serum TBPA is 26.9 +/- 8.0 mg/dl (29.4 +/- 5.2 in men and 24.9 +/- 7.6 mg/dl in women). (2S,3R,4R,5R,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-oxane-2-sulfonamide 21-24 transthyretin Homo sapiens 41-45 6820644-9 1982 A negative correlation between serum thyroid hormone binding protein (TBG and TBPA) and free thyroxine was observed in patients with hyperthyroidism. Thyroxine 93-102 transthyretin Homo sapiens 78-82 6820644-11 1982 From these experiments it appears that not only TBG but also TBPA may play an important role in the regulation of the free thyroxine concentration in response to various thyroidal states. Thyroxine 123-132 transthyretin Homo sapiens 61-65 7136414-11 1982 A linear correlation was found between the postprandial increases in BCAA concentrations and the levels of RBP and TBPA. Amino Acids, Branched-Chain 69-73 transthyretin Homo sapiens 115-119 115198-4 1979 Comparative studies using human serum indicated that T4 binding by serum T4-binding prealbumin (TBPA) was inhibited with DNP and salicylate, and that binding of T4 and T3 by serum T4-binding globulin (TBG) was decreased only with DPH. Dinitrophenols 121-124 transthyretin Homo sapiens 96-100 115198-4 1979 Comparative studies using human serum indicated that T4 binding by serum T4-binding prealbumin (TBPA) was inhibited with DNP and salicylate, and that binding of T4 and T3 by serum T4-binding globulin (TBG) was decreased only with DPH. Salicylates 129-139 transthyretin Homo sapiens 73-94 115198-4 1979 Comparative studies using human serum indicated that T4 binding by serum T4-binding prealbumin (TBPA) was inhibited with DNP and salicylate, and that binding of T4 and T3 by serum T4-binding globulin (TBG) was decreased only with DPH. Salicylates 129-139 transthyretin Homo sapiens 96-100 115198-4 1979 Comparative studies using human serum indicated that T4 binding by serum T4-binding prealbumin (TBPA) was inhibited with DNP and salicylate, and that binding of T4 and T3 by serum T4-binding globulin (TBG) was decreased only with DPH. Phenytoin 230-233 transthyretin Homo sapiens 96-100 407074-0 1977 [Method for determining thyroxine-binding capacity of TBG and TBPA in serum by means of dextran-coated charcoal adsorption]. Thyroxine 24-33 transthyretin Homo sapiens 62-66 100126-0 1978 [Thyroxine binding prealbumin (TBPA) and the serum proteinogram in subjects over 90 years of age]. Thyroxine 1-10 transthyretin Homo sapiens 31-35 643710-0 1978 [Studies on thyroxine binding by serum protein fractions, TBPA and TBC, using our modified methods]. Thyroxine 12-21 transthyretin Homo sapiens 58-62 414784-0 1978 [Study of the binding of thyroxine by thyroxine-binding prealbumin by a dialysis method using a fixed free concentration of ligand (author"s transl)]. Thyroxine 25-34 transthyretin Homo sapiens 38-66 414784-2 1978 The method has certain advantages and was applied to the binding of thyroxine by thyroxine-binding prealbumin, a system about which the results found in the literature are not in good agreement. Thyroxine 68-77 transthyretin Homo sapiens 81-109 407074-0 1977 [Method for determining thyroxine-binding capacity of TBG and TBPA in serum by means of dextran-coated charcoal adsorption]. dextran-coated charcoal 88-111 transthyretin Homo sapiens 62-66 66177-9 1977 In patients treated with ATD or radioiodine, TBPA but not TBG increased significantly on year after. Iodine-131 32-43 transthyretin Homo sapiens 45-49 401694-2 1977 It depends upon elution by diluted iodothyronine-free serum of protein-bound [125 I]thyroxine from the columns under conditions where binding to thyroxine-binding prealbumin and albumin are abolished. Thyroxine 84-93 transthyretin Homo sapiens 145-173 807481-5 1975 The possibility of a qualitative effect in the tetrameric TBPA structure, with the binding of additional thyroxine (T4) molecules on the secondary binding sites, has been investigated. Thyroxine 105-114 transthyretin Homo sapiens 58-62 66177-10 1977 However, in subjects with an initial very low TGB or TBPA, this phenomenon occurred on the third month after radioiodine or ATD. Iodine-131 109-120 transthyretin Homo sapiens 53-57 66177-11 1977 During the same period, DF T4 and DF T3 were inversely correlated to TBG and TBPA. df t4 24-29 transthyretin Homo sapiens 77-81 66177-11 1977 During the same period, DF T4 and DF T3 were inversely correlated to TBG and TBPA. df t3 34-39 transthyretin Homo sapiens 77-81 810274-4 1975 The high degree of sensitivity of TBPA and RBP to an inadequate protein intake is apparently related to their rapid turnover rate and to their unusual richness in tryptophan, which is known to play a key role in the control of protein synthesis. Tryptophan 163-173 transthyretin Homo sapiens 34-38 4110898-1 1972 Electrophoretic studies of triiodothyronine-TBPA interaction. Triiodothyronine 27-43 transthyretin Homo sapiens 44-48 4623165-3 1972 The increase in free T(3) was unexpected since previous data had suggested that salicylate inhibits binding of T(4) only to thyroxine-binding prealbumin (TBPA) and that T(3) is not bound to this protein. Salicylates 80-90 transthyretin Homo sapiens 124-152 4623165-3 1972 The increase in free T(3) was unexpected since previous data had suggested that salicylate inhibits binding of T(4) only to thyroxine-binding prealbumin (TBPA) and that T(3) is not bound to this protein. Salicylates 80-90 transthyretin Homo sapiens 154-158 4623165-4 1972 Using ultrafiltration techniques, we demonstrated binding of T(3) to TBPA. Triiodothyronine 61-65 transthyretin Homo sapiens 69-73 4623165-5 1972 The affinity constant for T(3)-TBPA binding appears to be slightly greater than that for albumin-T(3) binding. Triiodothyronine 26-30 transthyretin Homo sapiens 31-35 4623165-6 1972 While salicylate inhibits the binding of T(3) (and T(4)) to TBPA, it can be predicted that little change will be observed in the free T(3) (or free T(4)) without inhibition of thyroid hormone binding to thyroxine-binding globulin (TBG). Salicylates 6-16 transthyretin Homo sapiens 60-64 4110898-3 1972 The T3-TBPA interaction has been confirmed at pH 9.0 and pH 7.4 in this electrophoretic demonstration of TBPA binding of T3 in serum. Triiodothyronine 4-6 transthyretin Homo sapiens 7-11 4110898-2 1972 Thyroxine-binding prealbumin (TBPA) in normal human serum has been shown in a polyacrylamide gel electrophoresis system to bind 7-9% of tracer level purified [(125)I]triiodothyronine (T3), and more than 30% of T3 in serum deficient in thyroxinebinding globulin (TBG). polyacrylamide 78-92 transthyretin Homo sapiens 0-28 4110898-3 1972 The T3-TBPA interaction has been confirmed at pH 9.0 and pH 7.4 in this electrophoretic demonstration of TBPA binding of T3 in serum. Triiodothyronine 4-6 transthyretin Homo sapiens 105-109 4110898-5 1972 Progressive additions of unlabeled thyroxine (T4) to serum containing tracer [(125)I]T3 displace T3 from TBG, its principal carrier, to TBPA and albumin; however, T4 loading does not lead to significant T3 displacement from TBPA even at T4 levels known to saturate TBPA. Thyroxine 35-44 transthyretin Homo sapiens 136-140 4110898-5 1972 Progressive additions of unlabeled thyroxine (T4) to serum containing tracer [(125)I]T3 displace T3 from TBG, its principal carrier, to TBPA and albumin; however, T4 loading does not lead to significant T3 displacement from TBPA even at T4 levels known to saturate TBPA. Thyroxine 35-44 transthyretin Homo sapiens 224-228 4110898-5 1972 Progressive additions of unlabeled thyroxine (T4) to serum containing tracer [(125)I]T3 displace T3 from TBG, its principal carrier, to TBPA and albumin; however, T4 loading does not lead to significant T3 displacement from TBPA even at T4 levels known to saturate TBPA. Thyroxine 35-44 transthyretin Homo sapiens 224-228 4110898-7 1972 Studies carried out with serum containing diphenylhydantoin (DPH) or MK-185, known inhibitors of T4 binding by TBG, also showed T3 displacement from TBG to TBPA and albumin. Phenytoin 42-59 transthyretin Homo sapiens 156-160 4110898-7 1972 Studies carried out with serum containing diphenylhydantoin (DPH) or MK-185, known inhibitors of T4 binding by TBG, also showed T3 displacement from TBG to TBPA and albumin. Phenytoin 61-64 transthyretin Homo sapiens 156-160 4110898-7 1972 Studies carried out with serum containing diphenylhydantoin (DPH) or MK-185, known inhibitors of T4 binding by TBG, also showed T3 displacement from TBG to TBPA and albumin. Halofenate 69-75 transthyretin Homo sapiens 156-160 4110898-2 1972 Thyroxine-binding prealbumin (TBPA) in normal human serum has been shown in a polyacrylamide gel electrophoresis system to bind 7-9% of tracer level purified [(125)I]triiodothyronine (T3), and more than 30% of T3 in serum deficient in thyroxinebinding globulin (TBG). polyacrylamide 78-92 transthyretin Homo sapiens 30-34 4110898-8 1972 Although salicylate and tetraiodothyroacetic acid (TETRAC) displace T4 from sites on TBPA, they have only minimal effects on T3-TBPA interaction. Salicylates 9-19 transthyretin Homo sapiens 85-89 4110898-2 1972 Thyroxine-binding prealbumin (TBPA) in normal human serum has been shown in a polyacrylamide gel electrophoresis system to bind 7-9% of tracer level purified [(125)I]triiodothyronine (T3), and more than 30% of T3 in serum deficient in thyroxinebinding globulin (TBG). Triiodothyronine 166-182 transthyretin Homo sapiens 0-28 4110898-8 1972 Although salicylate and tetraiodothyroacetic acid (TETRAC) displace T4 from sites on TBPA, they have only minimal effects on T3-TBPA interaction. tetraiodothyroacetic acid 24-49 transthyretin Homo sapiens 85-89 4110898-2 1972 Thyroxine-binding prealbumin (TBPA) in normal human serum has been shown in a polyacrylamide gel electrophoresis system to bind 7-9% of tracer level purified [(125)I]triiodothyronine (T3), and more than 30% of T3 in serum deficient in thyroxinebinding globulin (TBG). Triiodothyronine 166-182 transthyretin Homo sapiens 30-34 4110898-8 1972 Although salicylate and tetraiodothyroacetic acid (TETRAC) displace T4 from sites on TBPA, they have only minimal effects on T3-TBPA interaction. tetraiodothyroacetic acid 51-57 transthyretin Homo sapiens 85-89 4110898-2 1972 Thyroxine-binding prealbumin (TBPA) in normal human serum has been shown in a polyacrylamide gel electrophoresis system to bind 7-9% of tracer level purified [(125)I]triiodothyronine (T3), and more than 30% of T3 in serum deficient in thyroxinebinding globulin (TBG). Triiodothyronine 184-186 transthyretin Homo sapiens 0-28 4110898-2 1972 Thyroxine-binding prealbumin (TBPA) in normal human serum has been shown in a polyacrylamide gel electrophoresis system to bind 7-9% of tracer level purified [(125)I]triiodothyronine (T3), and more than 30% of T3 in serum deficient in thyroxinebinding globulin (TBG). Triiodothyronine 184-186 transthyretin Homo sapiens 30-34 4110898-2 1972 Thyroxine-binding prealbumin (TBPA) in normal human serum has been shown in a polyacrylamide gel electrophoresis system to bind 7-9% of tracer level purified [(125)I]triiodothyronine (T3), and more than 30% of T3 in serum deficient in thyroxinebinding globulin (TBG). Triiodothyronine 210-212 transthyretin Homo sapiens 0-28 4110898-2 1972 Thyroxine-binding prealbumin (TBPA) in normal human serum has been shown in a polyacrylamide gel electrophoresis system to bind 7-9% of tracer level purified [(125)I]triiodothyronine (T3), and more than 30% of T3 in serum deficient in thyroxinebinding globulin (TBG). Triiodothyronine 210-212 transthyretin Homo sapiens 30-34 4999033-0 1971 [Effect of salicylic acid, 2,4-dinitrophenol or thiocyanate on thyroxine-binding of TBPA]. thiocyanate 48-59 transthyretin Homo sapiens 84-88 4172459-2 1968 Specimens from patients with thyrotoxicosis displayed a decrease in the thyroxine (T(4))-binding capacities of T(4)-binding globulin (TBG) and T(4)-binding prealbumin (TBPA), an increase in serum protein-bound iodine (PBI), and an increase in both the proportion and absolute concentration of free T(4). Thyroxine 72-81 transthyretin Homo sapiens 143-166 4999033-0 1971 [Effect of salicylic acid, 2,4-dinitrophenol or thiocyanate on thyroxine-binding of TBPA]. Salicylic Acid 11-25 transthyretin Homo sapiens 84-88 4999033-0 1971 [Effect of salicylic acid, 2,4-dinitrophenol or thiocyanate on thyroxine-binding of TBPA]. 2,4-Dinitrophenol 27-44 transthyretin Homo sapiens 84-88 4968525-0 1968 Effect of norethandrolone on the metabolism of 125-I-labeled thyroxine-binding prealbumin. Norethandrolone 10-25 transthyretin Homo sapiens 61-89 4968525-0 1968 Effect of norethandrolone on the metabolism of 125-I-labeled thyroxine-binding prealbumin. Iodine-125 47-52 transthyretin Homo sapiens 61-89 4999033-0 1971 [Effect of salicylic acid, 2,4-dinitrophenol or thiocyanate on thyroxine-binding of TBPA]. Thyroxine 63-72 transthyretin Homo sapiens 84-88 4106461-8 1971 During the administration of norethandrolone, the thyroxine-binding capacity of the thyroxine-binding prealbumin increased strikingly in all patients, values averaging 162% of those found during the control period. Norethandrolone 29-44 transthyretin Homo sapiens 84-112 4106461-8 1971 During the administration of norethandrolone, the thyroxine-binding capacity of the thyroxine-binding prealbumin increased strikingly in all patients, values averaging 162% of those found during the control period. Thyroxine 50-59 transthyretin Homo sapiens 84-112 4989616-13 1970 When examining the distribution of tracer amounts of thyroxine-(131)I (T4-(131)I) between the thyroxine-binding proteins, it was found that a major fraction was bound to TBPA and albumin during the early part of gestation. Thyroxine 53-62 transthyretin Homo sapiens 170-174 4968803-1 1968 An immunoadsorption technique employing a rabbit antiserum specific for human serum prealbumin has been devised to remove thyroxine (T(4))-binding prealbumin (TBPA) from serum completely without affecting the T(4)-binding activity of thyroxine-binding globulin (TBG) or the concentration of the other major proteins in serum. Thyroxine 122-131 transthyretin Homo sapiens 159-163 4164017-0 1967 Observations on the relationship between the maximal thyroxine binding capacities of thyroxine-binding interalpha globulin and thyroxine-binding prealbumin, the serum protein bound iodine concentration and sexual maturity in adolescents. Thyroxine 53-62 transthyretin Homo sapiens 127-155 4172391-0 1967 Polyacrylamide gel electrophoretic study on the effect of estrogen on human thyroxine-binding prealbumin. polyacrylamide 0-14 transthyretin Homo sapiens 76-104 4164017-0 1967 Observations on the relationship between the maximal thyroxine binding capacities of thyroxine-binding interalpha globulin and thyroxine-binding prealbumin, the serum protein bound iodine concentration and sexual maturity in adolescents. Thyroxine 85-94 transthyretin Homo sapiens 127-155 34032384-1 2021 A positive nuclear scintigraphy with hydroxy bisphosphonate bone tracer (99mTc-HPD) is believed to have high sensitivity (>99%) and specificity (91%) for the diagnosis of transthyretin amyloid cardiomyopathy. hydroxy bisphosphonate 37-59 transthyretin Homo sapiens 171-184 33686575-7 2021 In particular primitive fish TTR has an extremely high zinc content, with an increased number of histidine residues which are involved in TH binding. Histidine 97-106 transthyretin Homo sapiens 29-32 14330531-0 1965 METABOLISM OF IODINE-131--LABELED THYROXINE-BINDING PREALBUMIN IN MAN. Iodine-131 14-24 transthyretin Homo sapiens 34-62 33461327-7 2021 RESULTS: We found 11 rare variants in the promoter, coding and intron/exon boundaries of the TTR gene associated with the onset of symptoms before and after age 40 years, namely 2 novel ones and a tandem CA-dinucleotide repeat. ca-dinucleotide 204-219 transthyretin Homo sapiens 93-96 33647754-0 2021 Structure-based mimicking of hydroxylated biphenyl congeners (OHPCBs) for human transthyretin, an important enzyme of thyroid hormone system. hydroxylated biphenyl congeners 29-60 transthyretin Homo sapiens 80-93 33647754-0 2021 Structure-based mimicking of hydroxylated biphenyl congeners (OHPCBs) for human transthyretin, an important enzyme of thyroid hormone system. ohpcbs 62-68 transthyretin Homo sapiens 80-93 33647754-1 2021 In humans, transthyretin (hTTR) is a plasma protein act as a transporter of thyroxine (T4) in the blood. Thyroxine 76-85 transthyretin Homo sapiens 11-24 33647754-1 2021 In humans, transthyretin (hTTR) is a plasma protein act as a transporter of thyroxine (T4) in the blood. Thyroxine 76-85 transthyretin Homo sapiens 26-30 33647754-4 2021 Cytochrome P450 can oxidize the PCBs into hydroxylated PCBs (OHPCBs) which can further interact with hTTR results in hepatoxicity, loss of metabolic rate, memory problems, and neurotoxicity. Polychlorinated Biphenyls 32-36 transthyretin Homo sapiens 101-105 33647754-4 2021 Cytochrome P450 can oxidize the PCBs into hydroxylated PCBs (OHPCBs) which can further interact with hTTR results in hepatoxicity, loss of metabolic rate, memory problems, and neurotoxicity. hydroxylated pcbs 42-59 transthyretin Homo sapiens 101-105 33647754-4 2021 Cytochrome P450 can oxidize the PCBs into hydroxylated PCBs (OHPCBs) which can further interact with hTTR results in hepatoxicity, loss of metabolic rate, memory problems, and neurotoxicity. ohpcbs 61-67 transthyretin Homo sapiens 101-105 33647754-5 2021 Molecular docking results show that OHPCBs bind at the active site of hTTR with a more binding affinity as compared to T4. ohpcbs 36-42 transthyretin Homo sapiens 70-74 33647754-6 2021 Further, molecular dynamics simulation has been done to confirm the stability of hTTR-OHPCBs complexes. ohpcbs 86-92 transthyretin Homo sapiens 81-85 33647754-7 2021 Several analysis parameters like RMSD, RMSF, Rg, SASA, hydrogen bonds numbers, PCA, and FEL revealed that binding of OHPCBs with hTTR results in the formation of stable hTTR-OHPCBs complexes. Hydrogen 55-63 transthyretin Homo sapiens 129-133 33647754-7 2021 Several analysis parameters like RMSD, RMSF, Rg, SASA, hydrogen bonds numbers, PCA, and FEL revealed that binding of OHPCBs with hTTR results in the formation of stable hTTR-OHPCBs complexes. Hydrogen 55-63 transthyretin Homo sapiens 169-173 33647754-7 2021 Several analysis parameters like RMSD, RMSF, Rg, SASA, hydrogen bonds numbers, PCA, and FEL revealed that binding of OHPCBs with hTTR results in the formation of stable hTTR-OHPCBs complexes. ohpcbs 117-123 transthyretin Homo sapiens 129-133 33647754-7 2021 Several analysis parameters like RMSD, RMSF, Rg, SASA, hydrogen bonds numbers, PCA, and FEL revealed that binding of OHPCBs with hTTR results in the formation of stable hTTR-OHPCBs complexes. ohpcbs 117-123 transthyretin Homo sapiens 169-173 33647754-7 2021 Several analysis parameters like RMSD, RMSF, Rg, SASA, hydrogen bonds numbers, PCA, and FEL revealed that binding of OHPCBs with hTTR results in the formation of stable hTTR-OHPCBs complexes. ohpcbs 174-180 transthyretin Homo sapiens 129-133 33647754-7 2021 Several analysis parameters like RMSD, RMSF, Rg, SASA, hydrogen bonds numbers, PCA, and FEL revealed that binding of OHPCBs with hTTR results in the formation of stable hTTR-OHPCBs complexes. ohpcbs 174-180 transthyretin Homo sapiens 169-173 33647754-8 2021 Individual residues decomposition analysis confirms that Lys15, Leu17, Ala108, Ala109, Leu110, Ser117, and Thr119 of hTTR plays a major role in the binding of OHPCBs to form the lower energy hTTR-OHPCBs complexes. ohpcbs 159-165 transthyretin Homo sapiens 117-121 33647754-8 2021 Individual residues decomposition analysis confirms that Lys15, Leu17, Ala108, Ala109, Leu110, Ser117, and Thr119 of hTTR plays a major role in the binding of OHPCBs to form the lower energy hTTR-OHPCBs complexes. ohpcbs 159-165 transthyretin Homo sapiens 191-195 33647754-8 2021 Individual residues decomposition analysis confirms that Lys15, Leu17, Ala108, Ala109, Leu110, Ser117, and Thr119 of hTTR plays a major role in the binding of OHPCBs to form the lower energy hTTR-OHPCBs complexes. ohpcbs 196-202 transthyretin Homo sapiens 117-121 33647754-8 2021 Individual residues decomposition analysis confirms that Lys15, Leu17, Ala108, Ala109, Leu110, Ser117, and Thr119 of hTTR plays a major role in the binding of OHPCBs to form the lower energy hTTR-OHPCBs complexes. ohpcbs 196-202 transthyretin Homo sapiens 191-195 33647754-9 2021 Molecular docking and simulations results emphasize that OHPCBs can efficiently bind at the active site of hTTR, which further leads to inhibition of transportation of T4 in human blood. ohpcbs 57-63 transthyretin Homo sapiens 107-111 33638113-0 2021 Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Oligonucleotides 79-94 transthyretin Homo sapiens 140-153 33638113-3 2021 Unlike inotersen, AKCEA-TTR-LRx is conjugated to a triantennary N-acetylgalactosamine moiety that supports receptor-mediated uptake by hepatocytes, the primary source of circulating TTR. Acetylgalactosamine 64-85 transthyretin Homo sapiens 24-27 34047656-0 2021 Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation. ile68leu 28-36 transthyretin Homo sapiens 50-54 34047656-3 2021 METHODS: Forty-six consecutive subjects with transthyretin (TTR) Ile68Leu (p.Ile88Leu) mutation (29 patients and 17 unaffected carriers) underwent an in-depth cardiac and neurologic evaluation at a single center. ile68leu 65-73 transthyretin Homo sapiens 45-58 34047656-3 2021 METHODS: Forty-six consecutive subjects with transthyretin (TTR) Ile68Leu (p.Ile88Leu) mutation (29 patients and 17 unaffected carriers) underwent an in-depth cardiac and neurologic evaluation at a single center. ile68leu 65-73 transthyretin Homo sapiens 60-63 32974757-2 2021 This study aims to evaluate the impact of adherence to warfarin therapy on anticoagulation quality during 12 weeks of pharmaceutical care and after 1 year of follow-up for patients with atrial fibrillation and with poor TTR. Warfarin 55-63 transthyretin Homo sapiens 220-223 34013735-4 2021 Herein, we used a nonconjugated triptycene (TPE) moiety to space D and A moieties and developed two novel emitters tBuDMAC-TPE-TRZ and tBuDMAC-TPE-TTR to explore the roles of intra- and intermolecular CT transitions. triptycene 44-47 transthyretin Homo sapiens 147-150 34013735-4 2021 Herein, we used a nonconjugated triptycene (TPE) moiety to space D and A moieties and developed two novel emitters tBuDMAC-TPE-TRZ and tBuDMAC-TPE-TTR to explore the roles of intra- and intermolecular CT transitions. tbudmac 115-122 transthyretin Homo sapiens 147-150 34013735-5 2021 Along with weak intramolecular CT transitions, intermolecular CT transitions are dominant for tBuDMAC-TPE-TRZ and tBuDMAC-TPE-TTR neat films. tbudmac 94-101 transthyretin Homo sapiens 126-129 34013735-5 2021 Along with weak intramolecular CT transitions, intermolecular CT transitions are dominant for tBuDMAC-TPE-TRZ and tBuDMAC-TPE-TTR neat films. tbudmac 114-121 transthyretin Homo sapiens 126-129 33992807-7 2022 Surprisingly, single AAV-mediated Nme2Cas9 treatment resulted in 65% and 71% reduction of hTTR mRNA and reporter GFP, respectively. CHEMBL2031461 21-24 transthyretin Homo sapiens 90-94 33992807-7 2022 Surprisingly, single AAV-mediated Nme2Cas9 treatment resulted in 65% and 71% reduction of hTTR mRNA and reporter GFP, respectively. nme2cas9 34-42 transthyretin Homo sapiens 90-94 33963812-6 2021 TTR cardiac amyloidosis was diagnosed according to accepted criteria, which include positive cardiac 99-Tc-DPD scintigraphy in the absence of monoclonal protein expansion in blood. 99-tc-dpd 101-110 transthyretin Homo sapiens 0-3 34017923-6 2020 Results: Ttr and InvA primers were both able to detect all the different Salmonella serovars tested and had superior limits of detection when DNA was extracted after selenite pre-culture. Selenious Acid 166-174 transthyretin Homo sapiens 9-12 32974757-4 2021 We included 262 patients with AF and poor quality of anticoagulation therapy with warfarin (TTR < 50%). Warfarin 82-90 transthyretin Homo sapiens 92-95 33964751-4 2021 Experimental results indicated that the halogenated-thiophenols, except for pentafluorothiophenol, were powerful hTTR binders. Pentafluorothiophenol 76-97 transthyretin Homo sapiens 113-117 33928732-1 2021 AIMS: African-American carriers of the transthyretin (TTR) valine-to-isoleucine substitution (V122I) are at increased risk of heart failure, yet many have relatively subtle abnormalities of left ventricular (LV) function. Valine 59-65 transthyretin Homo sapiens 39-52 33928732-1 2021 AIMS: African-American carriers of the transthyretin (TTR) valine-to-isoleucine substitution (V122I) are at increased risk of heart failure, yet many have relatively subtle abnormalities of left ventricular (LV) function. Valine 59-65 transthyretin Homo sapiens 54-57 33928732-1 2021 AIMS: African-American carriers of the transthyretin (TTR) valine-to-isoleucine substitution (V122I) are at increased risk of heart failure, yet many have relatively subtle abnormalities of left ventricular (LV) function. Isoleucine 69-79 transthyretin Homo sapiens 39-52 33928732-1 2021 AIMS: African-American carriers of the transthyretin (TTR) valine-to-isoleucine substitution (V122I) are at increased risk of heart failure, yet many have relatively subtle abnormalities of left ventricular (LV) function. Isoleucine 69-79 transthyretin Homo sapiens 54-57 33964751-0 2021 Human transthyretin binding affinity of halogenated thiophenols and halogenated phenols: An in vitro and in silico study. halogenated thiophenols 40-63 transthyretin Homo sapiens 6-19 33964751-5 2021 The differentiated hTTR binding affinity of halogenated-thiophenols and halogenated-phenols were observed. halogenated-thiophenols 44-67 transthyretin Homo sapiens 19-23 33964751-0 2021 Human transthyretin binding affinity of halogenated thiophenols and halogenated phenols: An in vitro and in silico study. Phenols 56-63 transthyretin Homo sapiens 6-19 33964751-3 2021 Herein the potential binding affinity and underlying mechanism of action between human transthyretin (hTTR) and seven halogenated-thiophenols were examined experimentally and computationally. halogenated-thiophenols 118-141 transthyretin Homo sapiens 87-100 33964751-5 2021 The differentiated hTTR binding affinity of halogenated-thiophenols and halogenated-phenols were observed. halogenated-phenols 72-91 transthyretin Homo sapiens 19-23 33964751-3 2021 Herein the potential binding affinity and underlying mechanism of action between human transthyretin (hTTR) and seven halogenated-thiophenols were examined experimentally and computationally. halogenated-thiophenols 118-141 transthyretin Homo sapiens 102-106 33964751-6 2021 The hTTR binding affinity of mono- and di-halo-thiophenols was higher than that of corresponding phenols; while the opposite relationship was observed for tri- and penta-halo-thiophenols and phenols. mono- and di-halo-thiophenols 29-58 transthyretin Homo sapiens 4-8 33964751-4 2021 Experimental results indicated that the halogenated-thiophenols, except for pentafluorothiophenol, were powerful hTTR binders. halogenated-thiophenols 40-63 transthyretin Homo sapiens 113-117 33964751-6 2021 The hTTR binding affinity of mono- and di-halo-thiophenols was higher than that of corresponding phenols; while the opposite relationship was observed for tri- and penta-halo-thiophenols and phenols. Phenols 51-58 transthyretin Homo sapiens 4-8 33964751-6 2021 The hTTR binding affinity of mono- and di-halo-thiophenols was higher than that of corresponding phenols; while the opposite relationship was observed for tri- and penta-halo-thiophenols and phenols. tri- and penta-halo-thiophenols 155-186 transthyretin Homo sapiens 4-8 33964751-6 2021 The hTTR binding affinity of mono- and di-halo-thiophenols was higher than that of corresponding phenols; while the opposite relationship was observed for tri- and penta-halo-thiophenols and phenols. Phenols 97-104 transthyretin Homo sapiens 4-8 33964751-8 2021 Molecular modeling results implied that the dominant noncovalent interactions in the molecular recognition processes between hTTR and halogenated-thiophenols were ionic pair, hydrogen bonds and hydrophobic interactions. thiophenol 146-157 transthyretin Homo sapiens 125-129 33964751-8 2021 Molecular modeling results implied that the dominant noncovalent interactions in the molecular recognition processes between hTTR and halogenated-thiophenols were ionic pair, hydrogen bonds and hydrophobic interactions. Hydrogen 175-183 transthyretin Homo sapiens 125-129 33964751-9 2021 Finally, a model with acceptable predictive ability was developed, which can be used to computationally predict the potential hTTR binding affinity of other halogenated-thiophenols and phenols. halogenated-thiophenols 157-180 transthyretin Homo sapiens 126-130 33964751-9 2021 Finally, a model with acceptable predictive ability was developed, which can be used to computationally predict the potential hTTR binding affinity of other halogenated-thiophenols and phenols. Phenols 173-180 transthyretin Homo sapiens 126-130 33864226-5 2021 Resulting sensitivity, specificity, and accuracy for Control subjects were: 0.87, 0.9, 0.89; as far as CA patients, the sensitivity, specificity, and accuracy were respectively 0.9, 1, and 0.97 for AL-CA patients and 0.9, 0.92, 0.97 for ATTR-CA patients. Aluminum 198-200 transthyretin Homo sapiens 237-241 33863270-5 2021 The Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial is the largest and most comprehensive randomized-controlled trial to date evaluating CDT compared to anticoagulation alone for the treatment of acute symptomatic proximal lower extremity DVT. cdt 194-197 transthyretin Homo sapiens 94-101 34017661-8 2021 Subsequent tenosynovial and transverse carpal ligament biopsies were performed with Congo red stain revealing amyloid deposits of TTR monomers. Congo Red 84-93 transthyretin Homo sapiens 130-133 33907108-2 2021 On the contrary, patients with cardiac amyloidosis transthyretin (ATTR) present with positive Tc-99m PYP scanning (intensive heart uptake). Technetium Tc 99m Pyrophosphate 94-104 transthyretin Homo sapiens 66-70 34040908-4 2021 In elderly patients, as with this study, cardiac amyloidosis most often results from abnormalities in the liver protein transthyretin (TTR), a thyroxine and retinol-retinol binding complex transporter in blood. Thyroxine 143-152 transthyretin Homo sapiens 120-133 34040908-4 2021 In elderly patients, as with this study, cardiac amyloidosis most often results from abnormalities in the liver protein transthyretin (TTR), a thyroxine and retinol-retinol binding complex transporter in blood. Thyroxine 143-152 transthyretin Homo sapiens 135-138 34040908-4 2021 In elderly patients, as with this study, cardiac amyloidosis most often results from abnormalities in the liver protein transthyretin (TTR), a thyroxine and retinol-retinol binding complex transporter in blood. Vitamin A 157-164 transthyretin Homo sapiens 120-133 34040908-4 2021 In elderly patients, as with this study, cardiac amyloidosis most often results from abnormalities in the liver protein transthyretin (TTR), a thyroxine and retinol-retinol binding complex transporter in blood. Vitamin A 157-164 transthyretin Homo sapiens 135-138 34040908-4 2021 In elderly patients, as with this study, cardiac amyloidosis most often results from abnormalities in the liver protein transthyretin (TTR), a thyroxine and retinol-retinol binding complex transporter in blood. Vitamin A 165-172 transthyretin Homo sapiens 120-133 34040908-4 2021 In elderly patients, as with this study, cardiac amyloidosis most often results from abnormalities in the liver protein transthyretin (TTR), a thyroxine and retinol-retinol binding complex transporter in blood. Vitamin A 165-172 transthyretin Homo sapiens 135-138 33481097-8 2021 Cells treated with plasma from healthy controls and hereditary transthyretin amyloidosis with polyneuropathy showed an increase in Hypertrophic Index after phenylephrine stimulation, whereas stimulation after treatment with hereditary cardiac amyloidosis or wild-type transthyretin patient plasma showed a significantly attenuated response. Phenylephrine 156-169 transthyretin Homo sapiens 63-76 33918440-7 2021 Median nadroparin dosage to reach TTR was 197 (97.9-330.3) IU/kg/12 h. No therapy-related deaths occurred. Nadroparin 7-17 transthyretin Homo sapiens 34-37 33918440-13 2021 CONCLUSIONS: High nadroparin dosages are needed to reach TTR in neonates, which seem to be safe. Nadroparin 18-28 transthyretin Homo sapiens 57-60 33555371-0 2021 In vitro human cell-based TTR-TRbeta CALUX assay indicates thyroid hormone transport disruption of short-chain, medium-chain, and long-chain chlorinated paraffins. Chlorowax 40 141-162 transthyretin Homo sapiens 26-29 33555371-5 2021 All CP mixtures influenced the TTR binding of T4, giving activities of 1,300 to 17,000 microg/g PFOA equivalents and lowest observable effect concentrations (LOELs) of 0.95 to 0.029 mM/L incubate. perfluorooctanoic acid 96-100 transthyretin Homo sapiens 31-34 33728572-1 2021 BACKGROUND: Radiolabeled bisphosphonates bone scintigraphy is highly sensitive in detecting transthyretin (TTR) cardiac amyloidosis; data on the true prevalence of cardiac involvement in TTR amyloidosis are lacking. radiolabeled bisphosphonates 12-40 transthyretin Homo sapiens 92-105 33655447-0 2021 A cardiology fellow"s take-home points from ASNC"s Webinar: Cases in Tc 99m-PYP evaluation of ATTR cardiac amyloidosis - interpretation and reporting. tc 99m-pyp 69-79 transthyretin Homo sapiens 94-98 33728572-1 2021 BACKGROUND: Radiolabeled bisphosphonates bone scintigraphy is highly sensitive in detecting transthyretin (TTR) cardiac amyloidosis; data on the true prevalence of cardiac involvement in TTR amyloidosis are lacking. radiolabeled bisphosphonates 12-40 transthyretin Homo sapiens 107-110 33790810-4 2021 After associating with transthyretin (TTR), the retinol/RBP4/TTR complex is released into the bloodstream and delivers retinol to tissues via binding to specific membrane receptors. Vitamin A 48-55 transthyretin Homo sapiens 23-36 33723768-0 2021 Imaging an ATTR cardiac amyloidosis patient using fluorine-18 sodium fluoride PET/CT: A case report. Fluorine-18 50-61 transthyretin Homo sapiens 11-15 33723768-0 2021 Imaging an ATTR cardiac amyloidosis patient using fluorine-18 sodium fluoride PET/CT: A case report. Sodium Fluoride 62-77 transthyretin Homo sapiens 11-15 33689152-0 2021 Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis. technetium-99m pyrophosphate 35-63 transthyretin Homo sapiens 88-101 33689152-1 2021 BACKGROUND: 99mTc-pyrophosphate imaging has emerged as an important non-invasive method to diagnose transthyretin cardiac amyloidosis (ATTR-CM). Technetium Tc 99m Pyrophosphate 12-31 transthyretin Homo sapiens 100-113 33689152-1 2021 BACKGROUND: 99mTc-pyrophosphate imaging has emerged as an important non-invasive method to diagnose transthyretin cardiac amyloidosis (ATTR-CM). Technetium Tc 99m Pyrophosphate 12-31 transthyretin Homo sapiens 135-139 33689152-2 2021 Quantitation of 99mTc-pyrophosphate activity, on SPECT images, could be a marker of ATTR-CM disease burden. Technetium Tc 99m Pyrophosphate 16-35 transthyretin Homo sapiens 84-88 33689152-9 2021 In patients with ATTR-CM, CPA was associated with reduced left ventricular ejection fraction (adjusted odds ratio 1.28, P = .035) and heart failure hospitalizations (adjusted hazard ratio 1.29, P = .006). cpa 26-29 transthyretin Homo sapiens 17-21 33689152-10 2021 CONCLUSION: Quantitative assessment of myocardial radiotracer activity with CPA or VOI have high diagnostic accuracy for ATTR-CM. cpa 76-79 transthyretin Homo sapiens 121-125 33790810-4 2021 After associating with transthyretin (TTR), the retinol/RBP4/TTR complex is released into the bloodstream and delivers retinol to tissues via binding to specific membrane receptors. Vitamin A 48-55 transthyretin Homo sapiens 38-41 33790810-4 2021 After associating with transthyretin (TTR), the retinol/RBP4/TTR complex is released into the bloodstream and delivers retinol to tissues via binding to specific membrane receptors. Vitamin A 48-55 transthyretin Homo sapiens 61-64 33666540-7 2021 Thyroxine and 3-methyladenine give stability to human transthyretin (TTR) and activate autophagy, respectively, which are associated with the pathogenesis of Alzheimer"s disease.Conclusion: The result shows the potential of TP 3-in-1 juice which is rich in anthocyanins in improving cognitive function, particularly learning, memory, processing speed, sequencing, mental flexibility and visual-motor skills domains, among middle-aged women. Thyroxine 0-9 transthyretin Homo sapiens 54-67 33666540-7 2021 Thyroxine and 3-methyladenine give stability to human transthyretin (TTR) and activate autophagy, respectively, which are associated with the pathogenesis of Alzheimer"s disease.Conclusion: The result shows the potential of TP 3-in-1 juice which is rich in anthocyanins in improving cognitive function, particularly learning, memory, processing speed, sequencing, mental flexibility and visual-motor skills domains, among middle-aged women. Thyroxine 0-9 transthyretin Homo sapiens 69-72 33666540-7 2021 Thyroxine and 3-methyladenine give stability to human transthyretin (TTR) and activate autophagy, respectively, which are associated with the pathogenesis of Alzheimer"s disease.Conclusion: The result shows the potential of TP 3-in-1 juice which is rich in anthocyanins in improving cognitive function, particularly learning, memory, processing speed, sequencing, mental flexibility and visual-motor skills domains, among middle-aged women. 3-methyladenine 14-29 transthyretin Homo sapiens 54-67 33666540-7 2021 Thyroxine and 3-methyladenine give stability to human transthyretin (TTR) and activate autophagy, respectively, which are associated with the pathogenesis of Alzheimer"s disease.Conclusion: The result shows the potential of TP 3-in-1 juice which is rich in anthocyanins in improving cognitive function, particularly learning, memory, processing speed, sequencing, mental flexibility and visual-motor skills domains, among middle-aged women. 3-methyladenine 14-29 transthyretin Homo sapiens 69-72 33666540-7 2021 Thyroxine and 3-methyladenine give stability to human transthyretin (TTR) and activate autophagy, respectively, which are associated with the pathogenesis of Alzheimer"s disease.Conclusion: The result shows the potential of TP 3-in-1 juice which is rich in anthocyanins in improving cognitive function, particularly learning, memory, processing speed, sequencing, mental flexibility and visual-motor skills domains, among middle-aged women. Anthocyanins 258-270 transthyretin Homo sapiens 54-67 32814468-3 2021 OBJECTIVES: To compare outcomes in patients with ATTR-CA and AF treated with warfarin versus novel oral anticoagulants (NOACs). Warfarin 77-85 transthyretin Homo sapiens 49-53 33597308-5 2021 NNTTR levels were substantially reduced in patients receiving approved FAP disease-modifying therapies (e.g., the TTR stabilizer tafamidis, 20 mg once daily). tafamidis 129-138 transthyretin Homo sapiens 2-5 33716932-9 2021 The CSA variability of median nerves was significantly higher in CIDP than in TTR-FAP and HC groups, with high sensitivity (0.692) and specificity (0.833) to differentiate CIDP from TTR-FAP. Cyclosporine 4-7 transthyretin Homo sapiens 78-81 33155274-8 2021 By sequence-specific mRNA knockdown, the approved small interfering RNA (siRNA) patisiran and antisense oligonucleotide (ASO) inotersen both significantly reduce plasma TTR levels and improve neuropathy and quality of life compared to placebo. Oligonucleotides 104-119 transthyretin Homo sapiens 169-172 33155274-8 2021 By sequence-specific mRNA knockdown, the approved small interfering RNA (siRNA) patisiran and antisense oligonucleotide (ASO) inotersen both significantly reduce plasma TTR levels and improve neuropathy and quality of life compared to placebo. Oligonucleotides, Antisense 121-124 transthyretin Homo sapiens 169-172 33715921-11 2021 A 99mTc-DPD Scintigraphy showed significant myocardial tracer uptake, leading to a diagnosis of TTR amyloid infiltration. 99mtc-dpd 2-11 transthyretin Homo sapiens 96-99 33716932-9 2021 The CSA variability of median nerves was significantly higher in CIDP than in TTR-FAP and HC groups, with high sensitivity (0.692) and specificity (0.833) to differentiate CIDP from TTR-FAP. Cyclosporine 4-7 transthyretin Homo sapiens 182-185 32495366-10 2021 CONCLUSIONS: Bed side Bayesian-guided personalised dosing of vancomycin increases the proportion of patients achieving target AUC24 and the %TTR. Vancomycin 61-71 transthyretin Homo sapiens 141-144 33563689-3 2021 Positive technetium pyrophosphate scan was suspicious for TTR amyloid while serological workup revealed a monoclonal gammopathy. technetium pyrophosphate 9-33 transthyretin Homo sapiens 58-61 33428857-12 2021 We replicated two CpG sites (cg18546846 and cg06641417; p<0.05) in an external cohort of biopsy- confirmed cases of TTR amyloidosis. cg18546846 29-39 transthyretin Homo sapiens 116-119 33283485-12 2021 A maximum mean (SD) reduction in TTR levels of -86.3% (6.5) from baseline was achieved after a single dose of 120 mg AKCEA-TTR-LRx . akcea-ttr-lrx 117-130 transthyretin Homo sapiens 33-36 30834499-7 2021 CONCLUSIONS: While 18F-NaF PET/CT demonstrates good diagnostic accuracy for ATTR, particularly when using quantitative analysis, the low TBRmean values observed in ATTR indicate poor myocardial signal. tbrmean 137-144 transthyretin Homo sapiens 164-168 32599652-0 2021 Single Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting GalNAc-siRNA Conjugate, Vutrisiran, in Healthy Subjects. N-acetylgalactosaminuronic acid 77-83 transthyretin Homo sapiens 53-66 32599652-3 2021 Vutrisiran treatment achieved potent and sustained TTR reduction in a dose-dependent manner, with mean maximum TTR reduction of 57-97%, maintained for >=90 days post-dose. vutrisiran 0-10 transthyretin Homo sapiens 51-54 32599652-3 2021 Vutrisiran treatment achieved potent and sustained TTR reduction in a dose-dependent manner, with mean maximum TTR reduction of 57-97%, maintained for >=90 days post-dose. vutrisiran 0-10 transthyretin Homo sapiens 111-114 33070419-6 2021 In ATTR-ACT, the combination of all-cause mortality and cardiovascular-related hospitalizations over 30 months was significantly reduced with tafamidis 80mg (P =0.0030) and 20mg (P=0.0048) vs. placebo. tafamidis 142-151 transthyretin Homo sapiens 3-7 33070419-9 2021 In ATTR-ACT combined with the LTE there was a significantly greater survival benefit with tafamidis 80mg vs 20mg (0.700 [0.501-0.979], P=0.0374). tafamidis 90-99 transthyretin Homo sapiens 3-7 30834499-1 2021 BACKGROUND: Conventional nuclear imaging with bone-seeking radiopharmaceuticals has been shown to be a sensitive test for the detection of transthyretin cardiac amyloidosis (ATTR); however, to date, few data exist on the utility of 18F-sodium fluoride (NaF) positron emission tomography (PET) in subjects with cardiac amyloidosis (CA). 18f-sodium fluoride 232-251 transthyretin Homo sapiens 174-178 33462057-8 2021 3,3-Diphosphono-1,2-propanodicarboxylic acid scan is a cornerstone in the diagnosis of Transthyretin amyloidosis (ATTR) cardiac amyloidosis. 3,3-diphosphono-1,2-propanodicarboxylic acid 0-44 transthyretin Homo sapiens 114-118 30834499-4 2021 RESULTS: Average TBRmean was significantly increased in subjects with ATTR (0.98 +- 0.09) compared to AL (0.85 +- 0.08, P = .026) and CTL (0.82 +- 0.07, P = .020), while SUVmean was not (P = .14). tbrmean 17-24 transthyretin Homo sapiens 70-74 33504361-7 2021 After treatment with thyroxine (T4), which is transported by Ttr, the effects of T4 on neuronal histopathology and behavioral performance were determined in vivo (TBI + T4 group). Thyroxine 21-30 transthyretin Homo sapiens 61-64 33314981-11 2021 The patient was successfully treated with diuretics and enalapril, and tafamidis (potent and selective TTR stabilizer). tafamidis 71-80 transthyretin Homo sapiens 103-106 32861950-0 2021 Bisphenols emerging in Norwegian and Czech aquatic environments show transthyretin binding potency and other less-studied endocrine-disrupting activities. bis(4-hydroxyphenyl)sulfone 0-10 transthyretin Homo sapiens 69-82 32861950-3 2021 The aims of the present study were to: 1) determine the predominant bisphenols in Norwegian sewage sludge and sediment and in Czech surface waters, and 2) characterize the binding of bisphenols to a transport protein transthyretin (TTR) and their (anti-)thyroid, (anti-)progestagenic, and (anti-)androgenic activities. bis(4-hydroxyphenyl)sulfone 68-78 transthyretin Homo sapiens 217-230 32861950-3 2021 The aims of the present study were to: 1) determine the predominant bisphenols in Norwegian sewage sludge and sediment and in Czech surface waters, and 2) characterize the binding of bisphenols to a transport protein transthyretin (TTR) and their (anti-)thyroid, (anti-)progestagenic, and (anti-)androgenic activities. bis(4-hydroxyphenyl)sulfone 183-193 transthyretin Homo sapiens 217-230 32861950-3 2021 The aims of the present study were to: 1) determine the predominant bisphenols in Norwegian sewage sludge and sediment and in Czech surface waters, and 2) characterize the binding of bisphenols to a transport protein transthyretin (TTR) and their (anti-)thyroid, (anti-)progestagenic, and (anti-)androgenic activities. bis(4-hydroxyphenyl)sulfone 183-193 transthyretin Homo sapiens 232-235 32861950-10 2021 Some bisphenols have shown TTR binding potency (BPAF = BPF > BPA = BPE) and some have displayed the following endocrine-disrupting activities: anti-thyroid (BPAF), anti-progestagenic (BPTMC > BPA = BPAF), and anti-androgenic (BPAF > BPE > BPA > BPTMC > BPF > BPS). bis(4-hydroxyphenyl)sulfone 5-15 transthyretin Homo sapiens 27-30 33411102-1 2021 BACKGROUND: 99mTc-PYP scintigraphy provides differential diagnosis of ATTR cardiomyopathy (ATTR-CM) from light chain cardiac amyloidosis and other myocardial disorders without biopsy. 99mtc-pyp 12-21 transthyretin Homo sapiens 70-74 33411102-1 2021 BACKGROUND: 99mTc-PYP scintigraphy provides differential diagnosis of ATTR cardiomyopathy (ATTR-CM) from light chain cardiac amyloidosis and other myocardial disorders without biopsy. 99mtc-pyp 12-21 transthyretin Homo sapiens 91-95 33129902-1 2021 Tetrameric transthyretin (TTR) transports thyroid hormones and retinol in plasma and cerebrospinal fluid and performs protective functions under stress conditions. Vitamin A 63-70 transthyretin Homo sapiens 11-24 33469827-4 2021 Tafamidis stabilizes both wild-type and mutant TTR, inhibiting the formation of TTR amyloid fibrils. tafamidis 0-9 transthyretin Homo sapiens 47-50 33469827-4 2021 Tafamidis stabilizes both wild-type and mutant TTR, inhibiting the formation of TTR amyloid fibrils. tafamidis 0-9 transthyretin Homo sapiens 80-83 32324953-5 2021 Recently, we have repurposed tolcapone as a molecule to treat systemic ATTR. Tolcapone 29-38 transthyretin Homo sapiens 71-75 32324953-6 2021 Crystal structures and biophysical analysis converge to demonstrate that tolcapone binds with high affinity and specificity to three unstable leptomeningeal TTR variants, stabilizing them and, consequently inhibiting their aggregation. Tolcapone 73-82 transthyretin Homo sapiens 157-160 33129902-1 2021 Tetrameric transthyretin (TTR) transports thyroid hormones and retinol in plasma and cerebrospinal fluid and performs protective functions under stress conditions. Vitamin A 63-70 transthyretin Homo sapiens 26-29 33129740-4 2021 Twelve of those patients concomitantly received diflunisal as a "TTR-stabilizing" drug. Diflunisal 48-58 transthyretin Homo sapiens 65-68 33112446-10 2021 In conclusion, AL was the most common subtype in most biopsy sites except the heart, carpal tunnel, and peripheral nerve, in which ATTR was more common. Aluminum 15-17 transthyretin Homo sapiens 131-135 32769117-2 2020 TTR is a tetrameric carrier of thyroxine in blood and cerebrospinal fluid, whose pathogenic aggregation causes systemic amyloidosis. Thyroxine 31-40 transthyretin Homo sapiens 0-3 32761825-1 2020 The protein transthyretin (TTR) modulates amyloid-beta (Abeta) peptides deposition and processing and this physiological effect is further enhanced by treatment with iododiflunisal (IDIF), a small-molecule compound (SMC) with TTR tetramer stabilization properties, which behaves as chaperone of the complex. iododiflunisal 166-180 transthyretin Homo sapiens 12-25 32761825-1 2020 The protein transthyretin (TTR) modulates amyloid-beta (Abeta) peptides deposition and processing and this physiological effect is further enhanced by treatment with iododiflunisal (IDIF), a small-molecule compound (SMC) with TTR tetramer stabilization properties, which behaves as chaperone of the complex. iododiflunisal 166-180 transthyretin Homo sapiens 27-30 32761825-1 2020 The protein transthyretin (TTR) modulates amyloid-beta (Abeta) peptides deposition and processing and this physiological effect is further enhanced by treatment with iododiflunisal (IDIF), a small-molecule compound (SMC) with TTR tetramer stabilization properties, which behaves as chaperone of the complex. iododiflunisal 166-180 transthyretin Homo sapiens 226-229 32419519-3 2020 TTR is a transporter protein that under physiological condition carries thyroxine (T4) and retinol in plasma and in cerebrospinal fluid (CSF); it also has a neuroprotective role against Alzheimer"s disease (AD). Thyroxine 72-81 transthyretin Homo sapiens 0-3 32419519-3 2020 TTR is a transporter protein that under physiological condition carries thyroxine (T4) and retinol in plasma and in cerebrospinal fluid (CSF); it also has a neuroprotective role against Alzheimer"s disease (AD). Vitamin A 91-98 transthyretin Homo sapiens 0-3 33001386-2 2020 TTR transports the thyroid hormone thyroxine and the retinol-binding protein (RBP) bound to retinol (vitamin A). Thyroxine 35-44 transthyretin Homo sapiens 0-3 33001386-2 2020 TTR transports the thyroid hormone thyroxine and the retinol-binding protein (RBP) bound to retinol (vitamin A). Vitamin A 53-60 transthyretin Homo sapiens 0-3 33001386-2 2020 TTR transports the thyroid hormone thyroxine and the retinol-binding protein (RBP) bound to retinol (vitamin A). Vitamin A 101-110 transthyretin Homo sapiens 0-3 33442642-8 2020 Finally, ATTR-CM was confirmed by technetium-99m pyrophosphate scintigraphy with plans to initiate tafamidis after genetic testing. technetium-99m pyrophosphate 34-62 transthyretin Homo sapiens 9-13 33203445-6 2020 Within TTR gene region, we observed that Val30Met disrupts a methylation site, cg13139646, causing a drastic hypomethylation in carriers of this amyloidogenic mutation (standardized regression coefficient = -2.18, p = 3.34 x 10-11). cg13139646 79-89 transthyretin Homo sapiens 7-10 33121442-12 2020 CONCLUSIONS: This is a rare case of a TTR-CA with a negative Bone Scintigraphy and Congo red staining, which demonstrated that CA is frequently misdiagnosed because of the low specific clinical manifestations and the results of imaging modalities that sometimes could be misleading, with subsequent delayed diagnosis and correct treatment. Congo Red 83-92 transthyretin Homo sapiens 38-41 33348885-1 2020 Human transthyretin (hTTR), a serum protein with a main role in transporting thyroid hormones and retinol through binding to the retinol-binding protein, is an amyloidogenic protein involved in familial amyloidotic polyneuropathy (FAP), familial amyloidotic cardiomyopathy, and central nervous system selective amyloidosis. Vitamin A 98-105 transthyretin Homo sapiens 6-19 33348885-1 2020 Human transthyretin (hTTR), a serum protein with a main role in transporting thyroid hormones and retinol through binding to the retinol-binding protein, is an amyloidogenic protein involved in familial amyloidotic polyneuropathy (FAP), familial amyloidotic cardiomyopathy, and central nervous system selective amyloidosis. Vitamin A 98-105 transthyretin Homo sapiens 21-25 33348885-1 2020 Human transthyretin (hTTR), a serum protein with a main role in transporting thyroid hormones and retinol through binding to the retinol-binding protein, is an amyloidogenic protein involved in familial amyloidotic polyneuropathy (FAP), familial amyloidotic cardiomyopathy, and central nervous system selective amyloidosis. Vitamin A 129-136 transthyretin Homo sapiens 6-19 33348885-1 2020 Human transthyretin (hTTR), a serum protein with a main role in transporting thyroid hormones and retinol through binding to the retinol-binding protein, is an amyloidogenic protein involved in familial amyloidotic polyneuropathy (FAP), familial amyloidotic cardiomyopathy, and central nervous system selective amyloidosis. Vitamin A 129-136 transthyretin Homo sapiens 21-25 32578459-3 2020 We propose that TTR gene silencing with an antisense oligonucleotide or a small interfering ribonucleic acid may be a treatment for these patients.Methods: We reviewed the charts of hATTR patients POLT treated with a TTR gene silencing agent at 7 different Amyloid Clinics between 2018-2020.Results: Nine hATTR patients with POLT were treated with TTR gene silencing therapy (Inotersen). Oligonucleotides 53-68 transthyretin Homo sapiens 16-19 33091848-4 2020 Here we provide an example of the use of a novel application of the LEI methodology for prospective lead optimization by using the transthyretin (TTR) fibrillogenesis inhibitor iododiflunisal (IDIF) as example. iododiflunisal 177-191 transthyretin Homo sapiens 131-144 33091848-4 2020 Here we provide an example of the use of a novel application of the LEI methodology for prospective lead optimization by using the transthyretin (TTR) fibrillogenesis inhibitor iododiflunisal (IDIF) as example. iododiflunisal 177-191 transthyretin Homo sapiens 146-149 32524297-0 2020 Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial. tafamidis 99-108 transthyretin Homo sapiens 52-65 32948978-9 2020 However, as the efficacy of orally administered tafamidis and diflunisal, which stabilize TTR tetramers, was suggested in the early 2010s, such late-onset patients have also become targets for disease-modifying therapies. tafamidis 48-57 transthyretin Homo sapiens 90-93 32948978-9 2020 However, as the efficacy of orally administered tafamidis and diflunisal, which stabilize TTR tetramers, was suggested in the early 2010s, such late-onset patients have also become targets for disease-modifying therapies. Diflunisal 62-72 transthyretin Homo sapiens 90-93 33212973-1 2020 Transthyretin (TTR), previously named prealbumin is a plasma protein secreted mainly by the liver and choroid plexus (CP) that is a carrier for thyroid hormones (THs) and retinol (vitamin A). Vitamin A 171-178 transthyretin Homo sapiens 0-13 33212973-1 2020 Transthyretin (TTR), previously named prealbumin is a plasma protein secreted mainly by the liver and choroid plexus (CP) that is a carrier for thyroid hormones (THs) and retinol (vitamin A). Vitamin A 171-178 transthyretin Homo sapiens 15-18 33212973-1 2020 Transthyretin (TTR), previously named prealbumin is a plasma protein secreted mainly by the liver and choroid plexus (CP) that is a carrier for thyroid hormones (THs) and retinol (vitamin A). Vitamin A 180-189 transthyretin Homo sapiens 0-13 33212973-1 2020 Transthyretin (TTR), previously named prealbumin is a plasma protein secreted mainly by the liver and choroid plexus (CP) that is a carrier for thyroid hormones (THs) and retinol (vitamin A). Vitamin A 180-189 transthyretin Homo sapiens 15-18 33221204-0 2021 Diagnosing Transthyretin Cardiac Amyloidosis by Technetium 99m Pyrophosphate: A Test in Evolution. technetium 99m pyrophosphate 48-76 transthyretin Homo sapiens 11-24 33146862-1 2020 BACKGROUND: Pyrophosphate (PYP) scintigraphy provides high diagnostic accuracy for the detection of transthyretin (ATTR) cardiac amyloidosis (CA). diphosphoric acid 12-25 transthyretin Homo sapiens 115-119 33146862-1 2020 BACKGROUND: Pyrophosphate (PYP) scintigraphy provides high diagnostic accuracy for the detection of transthyretin (ATTR) cardiac amyloidosis (CA). diphosphoric acid 27-30 transthyretin Homo sapiens 115-119 33135676-0 2020 Neutron diffraction experiment with the Y116S variant of transthyretin using iBIX at J-PARC: application of a new integration method. ibix 77-81 transthyretin Homo sapiens 57-70 33118142-0 2020 The importance of SPECT cardiac reconstruction for accurate 99mTc-pyrophosphate interpretation in TTR amyloidosis. Technetium Tc 99m Pyrophosphate 60-79 transthyretin Homo sapiens 98-101 32800294-6 2020 Digoxin was used in 69 patients (42 ATTR, 27 AL) for a median duration of 6 months (IQR, 1 to 16). Digoxin 0-7 transthyretin Homo sapiens 36-40 32800294-10 2020 In conclusion, digoxin may be a therapeutic option for rate and symptom control for some patients with AL-CA and ATTR-CA. Digoxin 15-22 transthyretin Homo sapiens 113-117 33044859-0 2020 Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy". tafamidis 75-84 transthyretin Homo sapiens 97-110 32878437-2 2020 Retinal bisretinoid synthesis depends on influx of serum all-trans-retinol (1) delivered via a tertiary retinol-binding protein 4 (RBP4)-transthyretin (TTR)-retinol complex. bisretinoid 8-19 transthyretin Homo sapiens 137-150 32878437-2 2020 Retinal bisretinoid synthesis depends on influx of serum all-trans-retinol (1) delivered via a tertiary retinol-binding protein 4 (RBP4)-transthyretin (TTR)-retinol complex. bisretinoid 8-19 transthyretin Homo sapiens 152-155 32878437-2 2020 Retinal bisretinoid synthesis depends on influx of serum all-trans-retinol (1) delivered via a tertiary retinol-binding protein 4 (RBP4)-transthyretin (TTR)-retinol complex. Vitamin A 57-74 transthyretin Homo sapiens 137-150 32878437-2 2020 Retinal bisretinoid synthesis depends on influx of serum all-trans-retinol (1) delivered via a tertiary retinol-binding protein 4 (RBP4)-transthyretin (TTR)-retinol complex. Vitamin A 57-74 transthyretin Homo sapiens 152-155 32878437-2 2020 Retinal bisretinoid synthesis depends on influx of serum all-trans-retinol (1) delivered via a tertiary retinol-binding protein 4 (RBP4)-transthyretin (TTR)-retinol complex. Vitamin A 67-74 transthyretin Homo sapiens 137-150 32878437-2 2020 Retinal bisretinoid synthesis depends on influx of serum all-trans-retinol (1) delivered via a tertiary retinol-binding protein 4 (RBP4)-transthyretin (TTR)-retinol complex. Vitamin A 67-74 transthyretin Homo sapiens 152-155 32878437-3 2020 We previously identified selective RBP4 antagonists that dissociate circulating RBP4-TTR-retinol complexes, reduce serum RBP4 levels, and inhibit bisretinoid synthesis in models of enhanced retinal lipofuscinogenesis. Vitamin A 89-96 transthyretin Homo sapiens 85-88 32915538-0 2020 Conventional molecular dynamics and metadynamics simulation studies of the binding and unbinding mechanism of TTR stabilizers AG10 and tafamidis. tyrphostin 8 126-130 transthyretin Homo sapiens 110-113 32915538-0 2020 Conventional molecular dynamics and metadynamics simulation studies of the binding and unbinding mechanism of TTR stabilizers AG10 and tafamidis. tafamidis 135-144 transthyretin Homo sapiens 110-113 32915538-7 2020 AG10 stabilizes TTR tetramer by forming H-bonds with S117 to mimic the protective effect of T119M. tyrphostin 8 0-4 transthyretin Homo sapiens 16-19 32915538-7 2020 AG10 stabilizes TTR tetramer by forming H-bonds with S117 to mimic the protective effect of T119M. s117 53-57 transthyretin Homo sapiens 16-19 32196976-1 2020 Tafamidis, a non-nonsteroidal anti-inflammatory benzoxazole derivative, acts as a transthyretin (TTR) stabilizer to slow progression of TTR amyloidosis (ATTR). Benzoxazoles 48-59 transthyretin Homo sapiens 82-95 32967445-0 2020 Aortic Valve Calcium in Patients With Transthyretin Cardiac Amyloidosis: A Propensity-Matched Analysis. Calcium 13-20 transthyretin Homo sapiens 38-51 32791384-0 2020 Interactions of tolcapone analogues as stabilizers of the amyloidogenic protein transthyretin. Tolcapone 16-25 transthyretin Homo sapiens 80-93 32791384-1 2020 Transthyretin (TTR) is an amyloidogenic homotetramer involved in the transport of thyroxine and retinol in blood and cerebrospinal fluid. Thyroxine 82-91 transthyretin Homo sapiens 0-13 32791384-1 2020 Transthyretin (TTR) is an amyloidogenic homotetramer involved in the transport of thyroxine and retinol in blood and cerebrospinal fluid. Thyroxine 82-91 transthyretin Homo sapiens 15-18 32791384-1 2020 Transthyretin (TTR) is an amyloidogenic homotetramer involved in the transport of thyroxine and retinol in blood and cerebrospinal fluid. Vitamin A 96-103 transthyretin Homo sapiens 0-13 32791384-1 2020 Transthyretin (TTR) is an amyloidogenic homotetramer involved in the transport of thyroxine and retinol in blood and cerebrospinal fluid. Vitamin A 96-103 transthyretin Homo sapiens 15-18 32791384-2 2020 TTR stabilizers, such as tolcapone, an FDA approved drug for Parkinson"s disease, are able to interact with residues of the thyroxine-binding sites of TTR, both wild type and pathogenic mutant forms, thereby stabilizing its tetrameric native state and inhibiting amyloidogenesis. Tolcapone 25-34 transthyretin Homo sapiens 0-3 32791384-2 2020 TTR stabilizers, such as tolcapone, an FDA approved drug for Parkinson"s disease, are able to interact with residues of the thyroxine-binding sites of TTR, both wild type and pathogenic mutant forms, thereby stabilizing its tetrameric native state and inhibiting amyloidogenesis. Tolcapone 25-34 transthyretin Homo sapiens 151-154 32791384-2 2020 TTR stabilizers, such as tolcapone, an FDA approved drug for Parkinson"s disease, are able to interact with residues of the thyroxine-binding sites of TTR, both wild type and pathogenic mutant forms, thereby stabilizing its tetrameric native state and inhibiting amyloidogenesis. Thyroxine 124-133 transthyretin Homo sapiens 0-3 32791384-2 2020 TTR stabilizers, such as tolcapone, an FDA approved drug for Parkinson"s disease, are able to interact with residues of the thyroxine-binding sites of TTR, both wild type and pathogenic mutant forms, thereby stabilizing its tetrameric native state and inhibiting amyloidogenesis. Thyroxine 124-133 transthyretin Homo sapiens 151-154 32791384-3 2020 Herein, we report on the synthesis of 3-deoxytolcapone, a novel stabilizer of TTR. 3-deoxytolcapone 38-54 transthyretin Homo sapiens 78-81 32791384-4 2020 The high-resolution X-ray analyses of the interactions of 3-O-methyltolcapone and 3-deoxytolcapone with TTR were performed. 3-O-methyltolcapone 58-77 transthyretin Homo sapiens 104-107 32791384-4 2020 The high-resolution X-ray analyses of the interactions of 3-O-methyltolcapone and 3-deoxytolcapone with TTR were performed. 3-deoxytolcapone 82-98 transthyretin Homo sapiens 104-107 32791384-5 2020 In the two TTR-ligand complexes the tolcapone analogues establish mainly H-bond and hydrophobic interactions with residues of the thyroxine-binding site of the TTR tetramer. Tolcapone 36-45 transthyretin Homo sapiens 11-14 32791384-5 2020 In the two TTR-ligand complexes the tolcapone analogues establish mainly H-bond and hydrophobic interactions with residues of the thyroxine-binding site of the TTR tetramer. Tolcapone 36-45 transthyretin Homo sapiens 160-163 32791384-5 2020 In the two TTR-ligand complexes the tolcapone analogues establish mainly H-bond and hydrophobic interactions with residues of the thyroxine-binding site of the TTR tetramer. Thyroxine 130-139 transthyretin Homo sapiens 11-14 32791384-5 2020 In the two TTR-ligand complexes the tolcapone analogues establish mainly H-bond and hydrophobic interactions with residues of the thyroxine-binding site of the TTR tetramer. Thyroxine 130-139 transthyretin Homo sapiens 160-163 32791384-8 2020 Our data, coupled with previously reported data on the pharmacokinetics properties in humans of tolcapone and 3-O-methyltolcapone, further support the relevance of the latter tolcapone analogue as TTR stabilizer. 3-O-methyltolcapone 110-129 transthyretin Homo sapiens 197-200 32791384-8 2020 Our data, coupled with previously reported data on the pharmacokinetics properties in humans of tolcapone and 3-O-methyltolcapone, further support the relevance of the latter tolcapone analogue as TTR stabilizer. Tolcapone 120-129 transthyretin Homo sapiens 197-200 32623785-6 2020 One, 3- and 5-year survival rates were higher for ATTR patients than AL patients in the early era (100% vs 75%, 67% vs 50% and 67% vs 33%, respectively for ATTR and AL patients). Aluminum 165-167 transthyretin Homo sapiens 50-54 32196976-2 2020 Tafamidis meglumine, available as 20-mg capsules, is approved in more than 40 countries worldwide for the treatment of adults with early-stage symptomatic ATTR polyneuropathy. tafamidis 0-19 transthyretin Homo sapiens 155-159 30374850-10 2020 CONCLUSION: In case of heart failure, 123I-MIBG scintigraphy reflects cardiomyopathy rather than cardiac autonomic neuropathy in ATTRm patients and TTR mutation carriers. 3-Iodobenzylguanidine 38-47 transthyretin Homo sapiens 130-133 32476105-0 2020 Tc-99m-pyrophosphate scintigraphy for the diagnosis of ATTR cardiac amyloidosis: Comparison of quantitative and semi-quantitative approaches. Technetium Tc 99m Pyrophosphate 0-20 transthyretin Homo sapiens 55-59 32654212-1 2020 INTRODUCTION: Inotersen, an antisense oligonucleotide inhibitor of TTR protein production, demonstrated significant benefit versus placebo in the modified Neuropathy Impairment Score +7 neurophysiologic tests (mNIS+7) in patients with hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy. Oligonucleotides 38-53 transthyretin Homo sapiens 67-70 32476105-1 2020 BACKGROUND: ATTR cardiac amyloidosis (CA) can be diagnosed with Tc-99m-PYP scintigraphy. tc-99m-pyp 64-74 transthyretin Homo sapiens 12-16 33000405-2 2022 We used PET/MR imaging to quantify myocardial uptake of 18F-fluoride in ATTR and AL amyloid patients, as well as participants with aortic stenosis and age/sex-matched controls. Fluoride ion f-18 56-68 transthyretin Homo sapiens 72-76 32833564-1 2020 Inotersen (TEGSEDI ) is a 2"-O-(2-methoxyethyl)-modified antisense oligonucleotide, intended for treating hereditary transthyretin (TTR) amyloidosis with polyneuropathy. 2"-o-(2-methoxyethyl)-modified 26-56 transthyretin Homo sapiens 132-135 32833564-1 2020 Inotersen (TEGSEDI ) is a 2"-O-(2-methoxyethyl)-modified antisense oligonucleotide, intended for treating hereditary transthyretin (TTR) amyloidosis with polyneuropathy. Oligonucleotides 67-82 transthyretin Homo sapiens 132-135 33000405-7 2022 Mean myocardial TBRMEAN values in ATTR amyloid (1.13 +- 0.16) were higher than controls (0.84 +- 0.11, P = .0006), aortic stenosis (0.73 +- 0.12, P < .0001), and those with AL amyloid (0.96 +- 0.08, P = .01). Aluminum 173-175 transthyretin Homo sapiens 34-38 33000405-8 2022 TBRMEAN values within areas of late gadolinium enhancement provided discrimination between patients with ATTR (1.36 +- 0.23) and all other groups (e.g., AL [1.06 +- 0.07, P = .003]). Gadolinium 36-46 transthyretin Homo sapiens 105-109 33000405-10 2022 CONCLUSION: Quantitative 18F-fluoride PET/MR imaging can distinguish ATTR amyloid from other similar phenotypes and holds promise in improving the diagnosis of this condition. Fluoride ion f-18 25-37 transthyretin Homo sapiens 69-73 32998442-4 2020 Herein, we discovered that benzbromarone (BBM), a uricosuric drug, is an effective TTR stabilizer and inhibitor against TTR amyloid fibril formation. Benzbromarone 27-40 transthyretin Homo sapiens 83-86 32998442-4 2020 Herein, we discovered that benzbromarone (BBM), a uricosuric drug, is an effective TTR stabilizer and inhibitor against TTR amyloid fibril formation. Benzbromarone 27-40 transthyretin Homo sapiens 120-123 32998442-0 2020 Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer. Benzbromarone 12-25 transthyretin Homo sapiens 69-82 32998442-4 2020 Herein, we discovered that benzbromarone (BBM), a uricosuric drug, is an effective TTR stabilizer and inhibitor against TTR amyloid fibril formation. Benzbromarone 42-45 transthyretin Homo sapiens 83-86 32998442-4 2020 Herein, we discovered that benzbromarone (BBM), a uricosuric drug, is an effective TTR stabilizer and inhibitor against TTR amyloid fibril formation. Benzbromarone 42-45 transthyretin Homo sapiens 120-123 32998442-5 2020 BBM rendered TTR more resistant to urea denaturation, similarly to iododiflunisal (IDIF), a very potent TTR stabilizer. Urea 35-39 transthyretin Homo sapiens 13-16 32998442-6 2020 BBM competes with thyroxine for binding in the TTR central channel, with an IC50 similar to IDIF and tafamidis. Thyroxine 18-27 transthyretin Homo sapiens 47-50 32998442-8 2020 The crystal structure of the BBM-TTR complex shows two molecules binding deeply in the thyroxine binding channel, forming strong intermonomer hydrogen bonds and increasing the stability of the TTR tetramer. Thyroxine 87-96 transthyretin Homo sapiens 33-36 32998442-8 2020 The crystal structure of the BBM-TTR complex shows two molecules binding deeply in the thyroxine binding channel, forming strong intermonomer hydrogen bonds and increasing the stability of the TTR tetramer. Thyroxine 87-96 transthyretin Homo sapiens 193-196 32998442-8 2020 The crystal structure of the BBM-TTR complex shows two molecules binding deeply in the thyroxine binding channel, forming strong intermonomer hydrogen bonds and increasing the stability of the TTR tetramer. Hydrogen 142-150 transthyretin Homo sapiens 33-36 32998442-8 2020 The crystal structure of the BBM-TTR complex shows two molecules binding deeply in the thyroxine binding channel, forming strong intermonomer hydrogen bonds and increasing the stability of the TTR tetramer. Hydrogen 142-150 transthyretin Homo sapiens 193-196 32998442-9 2020 Finally, kinetic analysis of the ability of BBM to inhibit TTR fibrillogenesis at acidic pH and comparison with other stabilizers revealed that benzbromarone is a potent inhibitor of TTR amyloidogenesis, adding a new interesting scaffold for drug design of TTR stabilizers. Benzbromarone 144-157 transthyretin Homo sapiens 59-62 32998442-9 2020 Finally, kinetic analysis of the ability of BBM to inhibit TTR fibrillogenesis at acidic pH and comparison with other stabilizers revealed that benzbromarone is a potent inhibitor of TTR amyloidogenesis, adding a new interesting scaffold for drug design of TTR stabilizers. Benzbromarone 144-157 transthyretin Homo sapiens 183-186 32998442-9 2020 Finally, kinetic analysis of the ability of BBM to inhibit TTR fibrillogenesis at acidic pH and comparison with other stabilizers revealed that benzbromarone is a potent inhibitor of TTR amyloidogenesis, adding a new interesting scaffold for drug design of TTR stabilizers. Benzbromarone 144-157 transthyretin Homo sapiens 183-186 31805416-2 2020 Diflunisal is an approved non-steroidal anti-inflammatory drug (NSAID) that stabilizes TTR, with limited data available regarding effects on cardiac structure and function. Diflunisal 0-10 transthyretin Homo sapiens 87-90 32924285-3 2020 We sought to examine how NAC ATTR stage changes during follow-up and whether it maintains its prognostic value throughout the disease course. nac 25-28 transthyretin Homo sapiens 29-33 32924285-7 2020 Cox regression analyses were performed to assess the prognostic significance during follow-up of an increase in NAC ATTR stage from Stage I at diagnosis. nac 112-115 transthyretin Homo sapiens 116-120 32924285-10 2020 An increase from NAC ATTR Stage I, which occurred in 21%, 32%, and 44% of evaluable patients at 6, 12, and 24 months of follow-up respectively, was highly predictive of ongoing mortality at each time point (HRs 2.58-3.22; P < 0.001) and in each genotypic subgroup (HRs 1.86-4.38; P < 0.05). nac 17-20 transthyretin Homo sapiens 21-25 32924285-11 2020 Increase in NAC ATTR stage occurred earlier in V122I-hATTR-CM than in wtATTR-CM (43% vs. 27% at 12 months of follow-up; P = 0.003). nac 12-15 transthyretin Homo sapiens 16-20 32924285-13 2020 Serial calculation of NAC ATTR stage suggests a more aggressive phenotype in V122I-hATTR-CM than in wtATTR-CM. nac 22-25 transthyretin Homo sapiens 26-30 32157431-10 2020 CU was only observed in CA patients (n = 187), of whom 182 had ATTR-CA vs. 5 AL-CA, P < 0.001. Copper 0-2 transthyretin Homo sapiens 63-67 32828431-1 2020 Transthyretin (TTR) is a ss-sheet-rich homotetrameric protein that transports thyroxine (T4) and retinol both in plasma and in cerebrospinal fluid. Thyroxine 78-87 transthyretin Homo sapiens 0-13 32828431-1 2020 Transthyretin (TTR) is a ss-sheet-rich homotetrameric protein that transports thyroxine (T4) and retinol both in plasma and in cerebrospinal fluid. Thyroxine 78-87 transthyretin Homo sapiens 15-18 32828431-1 2020 Transthyretin (TTR) is a ss-sheet-rich homotetrameric protein that transports thyroxine (T4) and retinol both in plasma and in cerebrospinal fluid. Vitamin A 97-104 transthyretin Homo sapiens 0-13 32828431-1 2020 Transthyretin (TTR) is a ss-sheet-rich homotetrameric protein that transports thyroxine (T4) and retinol both in plasma and in cerebrospinal fluid. Vitamin A 97-104 transthyretin Homo sapiens 15-18 32828431-5 2020 We report here the synthesis, in vitro evaluation and three-dimensional crystallographic analyses of new monoaryl-derivatives in complex with TTR. monoaryl- 105-114 transthyretin Homo sapiens 142-145 32828431-6 2020 Of the derivatives reported here, the best inhibitor of TTR fibrillogenesis, 1d, exhibits an activity similar to diflunisal. Diflunisal 113-123 transthyretin Homo sapiens 56-59 32918247-1 2022 AIM: The purpose of this study was to determine the inter- and intra-observer variability in 99mtechnetium-pyrophosphate (99mTc-PYP) scan interpretation for diagnosis of transthyretin cardiac amyloidosis (ATTR). 99mtechnetium-pyrophosphate 93-120 transthyretin Homo sapiens 205-209 32918247-1 2022 AIM: The purpose of this study was to determine the inter- and intra-observer variability in 99mtechnetium-pyrophosphate (99mTc-PYP) scan interpretation for diagnosis of transthyretin cardiac amyloidosis (ATTR). 99mtc-pyp 122-131 transthyretin Homo sapiens 205-209 31805416-5 2020 At baseline, patients treated with diflunisal were younger (68 vs 77 y, p=0.0001), with lower B-type natriuretic peptide (BNP, 249 vs 545 pg/ml, p=0.009) and serum creatinine (1.1 vs 1.2 mg/dl, p=0.04), but similar TTR concentration (p=0.31), cardiac troponin I (p=0.06), and GLS (p=0.67). Diflunisal 35-45 transthyretin Homo sapiens 215-218 31805416-6 2020 At follow-up, diflunisal untreated vs. treated patients showed differences in TTR concentration (19 vs 33 mg/dl, p=0.01) and favorable differences in left atrial volume index (LAVI, +4.6 vs -1.4 ml/m2, p=0.002) and cardiac troponin I (+0.03 vs. -0.01 ng/ml, p=0.01) for the entire cohort. Diflunisal 14-24 transthyretin Homo sapiens 78-81 32664242-4 2020 The results revealed that CTR, CTS, CTL, and CTF extracts have high phenol and flavonoid content, as well as a powerful antioxidant and reducing capacity. Phenol 68-74 transthyretin Homo sapiens 31-34 32451658-9 2020 Additionally, FBG (standardized beta = - 0.306, P = 0.002) and triglyceride (TG) (beta = 0.219, P = 0.025) were independently associated with RBP4/TTR ratio. Triglycerides 63-75 transthyretin Homo sapiens 147-150 32451658-9 2020 Additionally, FBG (standardized beta = - 0.306, P = 0.002) and triglyceride (TG) (beta = 0.219, P = 0.025) were independently associated with RBP4/TTR ratio. Triglycerides 77-79 transthyretin Homo sapiens 147-150 32510984-6 2020 The primary outcome measure was the percentage of time in the therapeutic range (%TTR) of the international normalized ratio (INR) during the first 12 weeks after starting warfarin therapy. Warfarin 172-180 transthyretin Homo sapiens 82-85 32510984-10 2020 In subgroup analyses, warfarin normal sensitivity group had an even higher %TTR during the first 12 weeks compared to the control group (60.8% vs. 48.9%; 95% CI: 1.1-24.4). Warfarin 22-30 transthyretin Homo sapiens 76-79 32715418-0 2022 Quantitation of myocardial 99mTc-HMDP uptake with new SPECT/CT cadmium zinc telluride (CZT) camera in patients with transthyretin-related cardiac amyloidosis: Ready for clinical use? -hmdp 32-37 transthyretin Homo sapiens 116-129 32715418-0 2022 Quantitation of myocardial 99mTc-HMDP uptake with new SPECT/CT cadmium zinc telluride (CZT) camera in patients with transthyretin-related cardiac amyloidosis: Ready for clinical use? CdZnTe 63-85 transthyretin Homo sapiens 116-129 32715418-0 2022 Quantitation of myocardial 99mTc-HMDP uptake with new SPECT/CT cadmium zinc telluride (CZT) camera in patients with transthyretin-related cardiac amyloidosis: Ready for clinical use? CdZnTe 87-90 transthyretin Homo sapiens 116-129 32715418-1 2022 BACKGROUND: The aim of this study was to investigate the feasibility of assessing absolute myocardial 99mTc-HMDP uptake in patients with suspected cardiac ATTR using SUV with a whole-body CZT SPECT-CT camera (DNM670CZT). 99mtc-hmdp 102-112 transthyretin Homo sapiens 155-159 32708961-3 2020 In recent years, it has been shown that tolcapone is a potent inhibitor of the amyloid aggregation process of the transthyretin protein, and acts by stabilizing the structure of the protein, reducing the progression of familial amyloid polyneuropathy. Tolcapone 40-49 transthyretin Homo sapiens 114-127 32353608-7 2020 CONCLUSIONS: The monitoring strategy for asymptomatic TTR gene mutation carriers should progress toward rapid diagnosis and early intervention with DMT. dmt 148-151 transthyretin Homo sapiens 54-57 32709346-7 2020 These results appear particularly useful because both enantiomers of these 4,4"-bipyridine derivatives are currently under investigation as new inhibitors of transthyretin fibrillogenesis, a biochemical phenomenon which is implicated to cause amyloid diseases. 4,4'-bipyridyl 75-90 transthyretin Homo sapiens 158-171 32789836-4 2020 ATTR was confirmed histologically or non-invasively using 99mTc-DPD scintigraphy. 99mtc-dpd 58-67 transthyretin Homo sapiens 0-4 32944291-5 2020 Scintigraphy with a diphosphonate tracer is a diagnostic tool for the early detection of cardiac ATTR amyloidosis with high sensitivity and specificity. Diphosphonates 20-33 transthyretin Homo sapiens 97-101 32689936-5 2020 Our study aimed to investigate whether a leucine enriched BCAA dietary supplement (LEBDs) could quickly increase serum levels of albumin (Alb) or transthyretin (TTR) and decrease high-sensitivity C-reactive protein (CRP) in the development of severe malnutrition within a few days after stroke onset compared to standard BCAA dietary supplement (SBDs). Leucine 41-48 transthyretin Homo sapiens 146-159 32689936-5 2020 Our study aimed to investigate whether a leucine enriched BCAA dietary supplement (LEBDs) could quickly increase serum levels of albumin (Alb) or transthyretin (TTR) and decrease high-sensitivity C-reactive protein (CRP) in the development of severe malnutrition within a few days after stroke onset compared to standard BCAA dietary supplement (SBDs). Leucine 41-48 transthyretin Homo sapiens 161-164 32689936-5 2020 Our study aimed to investigate whether a leucine enriched BCAA dietary supplement (LEBDs) could quickly increase serum levels of albumin (Alb) or transthyretin (TTR) and decrease high-sensitivity C-reactive protein (CRP) in the development of severe malnutrition within a few days after stroke onset compared to standard BCAA dietary supplement (SBDs). Amino Acids, Branched-Chain 58-62 transthyretin Homo sapiens 146-159 32689936-5 2020 Our study aimed to investigate whether a leucine enriched BCAA dietary supplement (LEBDs) could quickly increase serum levels of albumin (Alb) or transthyretin (TTR) and decrease high-sensitivity C-reactive protein (CRP) in the development of severe malnutrition within a few days after stroke onset compared to standard BCAA dietary supplement (SBDs). Amino Acids, Branched-Chain 58-62 transthyretin Homo sapiens 161-164 32689936-17 2020 CONCLUSION: In acute stroke patients receiving leucine enriched BCAA dietary supplement, quick improvements in transthyretin and CRP were observed. Leucine 47-54 transthyretin Homo sapiens 111-124 32689936-17 2020 CONCLUSION: In acute stroke patients receiving leucine enriched BCAA dietary supplement, quick improvements in transthyretin and CRP were observed. Amino Acids, Branched-Chain 64-68 transthyretin Homo sapiens 111-124 32765269-6 2020 Methods: This is a prospective study, which evaluated about 2,620 patients and selected 262 patients with AF and poor quality of anticoagulation therapy with warfarin (TTR<50% - based on the last three values of international normalized ratio). Warfarin 158-166 transthyretin Homo sapiens 168-171 32664242-4 2020 The results revealed that CTR, CTS, CTL, and CTF extracts have high phenol and flavonoid content, as well as a powerful antioxidant and reducing capacity. Flavonoids 79-88 transthyretin Homo sapiens 31-34 32381302-6 2020 Under the optimized conditions, limits of detection (LODs) for TTR by AuNP@monolith-SPE-CE-MS were 50 times lower than by CE-MS (5 vs 250 mg L-1, with an ion trap (IT) mass spectrometer). aunp 70-74 transthyretin Homo sapiens 63-66 32476490-1 2020 Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy caused by extracellular deposition of transthyretin, normally involved in the transportation of the hormone thyroxine and retinol-binding protein, in the myocardium. Thyroxine 195-204 transthyretin Homo sapiens 0-13 32476490-1 2020 Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy caused by extracellular deposition of transthyretin, normally involved in the transportation of the hormone thyroxine and retinol-binding protein, in the myocardium. Thyroxine 195-204 transthyretin Homo sapiens 125-138 32500705-0 2020 Disruption of the CD Loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway. Cadmium 18-20 transthyretin Homo sapiens 80-93 30805796-10 2020 CONCLUSIONS: Although DM causes swelling of the median nerve at the wrist level, patients with CTS have a larger CSA regardless of preexisting DM. Cyclosporine 113-116 transthyretin Homo sapiens 95-98 32500705-0 2020 Disruption of the CD Loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway. Cadmium 18-20 transthyretin Homo sapiens 121-134 32500705-4 2020 Here, we report mechanistic studies of misfolding and aggregation of a TTR variant (G53A) in the absence and presence of a serine protease. Serine 123-129 transthyretin Homo sapiens 71-74 32417330-10 2020 [11C]PIB uptake was significantly higher in AL-CA than in ATTR-CA patients (p < 0.001) and discriminated AL-CA from controls with 100% (95% CI: 88% to 100%) accuracy for both the semiquantitative measures. Carbon-11 1-4 transthyretin Homo sapiens 58-62 32366593-11 2020 The transferrin binding proteins, TbpA and TbpB, are thought to be a key iron acquisition system in H. somni; however, despite their importance, H. somni TbpA and TbpB were previously shown to be cattle transferrin-specific. Iron 73-77 transthyretin Homo sapiens 34-38 31864976-0 2020 Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. phe64leu 50-58 transthyretin Homo sapiens 76-89 31864976-1 2020 OBJECTIVES: The aim of this study was to assess the diagnostic accuracy of bone scintigraphy in a large multicenter cohort of patients with cardiac amyloidotic involvement and Phe64Leu transthyretin (TTR) mutation. phe64leu 176-184 transthyretin Homo sapiens 185-198 32498813-1 2020 Technetium-labeled cardiac scintigraphy (i.e., Tc-PYP scan) has been repurposed for the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM). Technetium 0-10 transthyretin Homo sapiens 139-143 32498813-1 2020 Technetium-labeled cardiac scintigraphy (i.e., Tc-PYP scan) has been repurposed for the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM). Technetium Tc 99m Pyrophosphate 47-53 transthyretin Homo sapiens 139-143 31845305-6 2020 In the first case, the negative 99mTc-diphosphonate imaging was useful to support the diagnosis of cardiac amyloid light-chain; the second case emphasized the utility of whole-body scintigraphy in recognizing transthyretin-related cardiac amyloidosis and the potential role of cadmium-zinc-telluride SPECT imaging for the evaluation of segmental distribution of cardiac disease. CdZnTe 277-299 transthyretin Homo sapiens 209-222 31864976-1 2020 OBJECTIVES: The aim of this study was to assess the diagnostic accuracy of bone scintigraphy in a large multicenter cohort of patients with cardiac amyloidotic involvement and Phe64Leu transthyretin (TTR) mutation. phe64leu 176-184 transthyretin Homo sapiens 200-203 32417330-10 2020 [11C]PIB uptake was significantly higher in AL-CA than in ATTR-CA patients (p < 0.001) and discriminated AL-CA from controls with 100% (95% CI: 88% to 100%) accuracy for both the semiquantitative measures. 4-iodobenzenesulfonamide 5-8 transthyretin Homo sapiens 58-62 31864976-4 2020 METHODS: A total of 55 patients with Phe64Leu TTR mutation were retrospectively analyzed and evaluated between 1993 and 2018 at 7 specialized Italian tertiary centers. phe64leu 37-45 transthyretin Homo sapiens 46-49 31864976-11 2020 CONCLUSIONS: The sensitivity of bone scintigraphy (DPD and HMDP) in detecting TTR-CA is extremely low in patients with Phe64Leu TTR mutation, suggesting the need to assess diagnostic accuracy of bone scintigraphy to identify cardiac involvement across a wider spectrum of TTR mutations. phe64leu 119-127 transthyretin Homo sapiens 78-81 32081469-1 2020 BACKGROUND: Planar diphosphonate scintigraphy is an established diagnostic tool for amyloid transthyretin (ATTR) cardiomyopathy. Diphosphonates 19-32 transthyretin Homo sapiens 84-105 32175804-3 2020 We have developed an indirect-response pharmacokinetic-pharmacodynamic model relating plasma siRNA (ALN-18328) levels to serum TTR reduction across five clinical studies. aln-18328 100-109 transthyretin Homo sapiens 127-130 32449000-0 2021 A potential pitfall in the use of 99mTc-PYP imaging for diagnosing cardiac ATTR amyloidosis. 99mtc-pyp 34-43 transthyretin Homo sapiens 75-79 32081469-1 2020 BACKGROUND: Planar diphosphonate scintigraphy is an established diagnostic tool for amyloid transthyretin (ATTR) cardiomyopathy. Diphosphonates 19-32 transthyretin Homo sapiens 107-111 32390109-0 2021 Interpreting technetium-99m pyrophosphate cardiac scans to diagnose transthyretin cardiac amyloidosis: Need for due diligence. technetium-99m pyrophosphate 13-41 transthyretin Homo sapiens 68-81 32217467-10 2020 SIGNIFICANCE: Sudoscan can be helpful in distinguishing between CIDP and TTR-FAP. sudoscan 14-22 transthyretin Homo sapiens 73-76 32397334-0 2020 Rational Design, Synthesis, Characterization and Evaluation of Iodinated 4,4"-Bipyridines as New Transthyretin Fibrillogenesis Inhibitors. 4,4'-bipyridyl 73-89 transthyretin Homo sapiens 97-110 32397334-1 2020 The 3,3",5,5"-tetrachloro-2-iodo-4,4"-bipyridine structure is proposed as a novel chemical scaffold for the design of new transthyretin (TTR) fibrillogenesis inhibitors. 3,3",5,5"-tetrachloro-2-iodo-4,4"-bipyridine 4-48 transthyretin Homo sapiens 122-135 32397334-1 2020 The 3,3",5,5"-tetrachloro-2-iodo-4,4"-bipyridine structure is proposed as a novel chemical scaffold for the design of new transthyretin (TTR) fibrillogenesis inhibitors. 3,3",5,5"-tetrachloro-2-iodo-4,4"-bipyridine 4-48 transthyretin Homo sapiens 137-140 32397334-6 2020 In silico docking studies were carried out in order to explore possible binding modes of the 4,4"-bipyridine derivatives into the TTR. 4,4'-bipyridyl 93-108 transthyretin Homo sapiens 130-133 32397334-8 2020 Both experimental and theoretical evidences pave the way for the utilization of the iodinated 4,4"-bipyridine core as template to design new promising inhibitors of TTR amyloidogenesis. 4,4'-bipyridyl 94-109 transthyretin Homo sapiens 165-168 31735059-1 2020 Objective: To review the pharmacology, efficacy, and safety of the selective transthyretin inhibitor tafamidis for transthyretin amyloid cardiomyopathy (ATTR-CM). tafamidis 101-110 transthyretin Homo sapiens 77-90 31735059-1 2020 Objective: To review the pharmacology, efficacy, and safety of the selective transthyretin inhibitor tafamidis for transthyretin amyloid cardiomyopathy (ATTR-CM). tafamidis 101-110 transthyretin Homo sapiens 115-128 31735059-1 2020 Objective: To review the pharmacology, efficacy, and safety of the selective transthyretin inhibitor tafamidis for transthyretin amyloid cardiomyopathy (ATTR-CM). tafamidis 101-110 transthyretin Homo sapiens 153-157 31735059-6 2020 Data Synthesis: Tafamidis binds to the thyroxine-binding sites of the transthyretin tetramer and inhibits its dissociation into monomers, which is the rate-limiting step in the amyloidogenic process. tafamidis 16-25 transthyretin Homo sapiens 70-83 31735059-6 2020 Data Synthesis: Tafamidis binds to the thyroxine-binding sites of the transthyretin tetramer and inhibits its dissociation into monomers, which is the rate-limiting step in the amyloidogenic process. Thyroxine 39-48 transthyretin Homo sapiens 70-83 32241558-0 2020 Transthyretin Regulated by linc00657/miR-205-5p Promoted Cholesterol Metabolism by Inducing SREBP2-HMGCR and Inhibiting LXRalpha-CYP7A1. Cholesterol 57-68 transthyretin Homo sapiens 0-13 32241558-1 2020 BACKGROUND: Transthyretin functions as a serum transport protein for retinol. Vitamin A 69-76 transthyretin Homo sapiens 12-25 32241558-3 2020 For this study, we aimed to investigate the up and down stream molecular mechanisms of Transthyretin in cholesterol metabolism. Cholesterol 104-115 transthyretin Homo sapiens 87-100 32241558-4 2020 METHODS: We have recruited 237 fatty liver patients to evaluate the serum Transthyretin and its association with cholesterol and other clinical characteristics. Cholesterol 113-124 transthyretin Homo sapiens 74-87 32241558-7 2020 High level Transthyretin patients tended to have higher cholesterol, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) level than low level Transthyretin patients. Cholesterol 56-67 transthyretin Homo sapiens 11-24 32241558-13 2020 CONCLUSION: Transthyretin regulated cholesterol metabolism mainly through inhibiting LXRalpha-CYP7A1 and promoting SREBP2-HMGCR. Cholesterol 36-47 transthyretin Homo sapiens 12-25 32241558-14 2020 And linc00657 could negatively regulate Transthyretin by inhibiting miR-205-5p, providing novel therapeutic targets for decreasing serum cholesterol level. Cholesterol 137-148 transthyretin Homo sapiens 40-53 32311072-37 2020 Results from placebo-controlled trials indicate that tafamidis, diflunisal, patisiran, and inotersen may be beneficial in TTR-FAP, but further investigations are needed. tafamidis 53-62 transthyretin Homo sapiens 122-125 31927367-4 2020 It was noted that BDE-47 had a weak binding affinity to TTR, while 3-OH-BDE-47 and TBBPA had a stronger binding affinity than BDE-47 and thyroxine (T4). 2,2',4,4'-tetrabromodiphenyl ether 18-24 transthyretin Homo sapiens 56-59 31927367-5 2020 Hence, 3-OH-BDE-47 and TBBPA could affect the binding of TTR with its native ligand T4 by competitive binding to TTR, even at equal concentrations, which might be associated with BFR toxicity of endocrine disruption. 3-oh-bde-47 7-18 transthyretin Homo sapiens 57-60 31927367-5 2020 Hence, 3-OH-BDE-47 and TBBPA could affect the binding of TTR with its native ligand T4 by competitive binding to TTR, even at equal concentrations, which might be associated with BFR toxicity of endocrine disruption. 3-oh-bde-47 7-18 transthyretin Homo sapiens 113-116 31927367-5 2020 Hence, 3-OH-BDE-47 and TBBPA could affect the binding of TTR with its native ligand T4 by competitive binding to TTR, even at equal concentrations, which might be associated with BFR toxicity of endocrine disruption. tetrabromobisphenol A 23-28 transthyretin Homo sapiens 57-60 31927367-5 2020 Hence, 3-OH-BDE-47 and TBBPA could affect the binding of TTR with its native ligand T4 by competitive binding to TTR, even at equal concentrations, which might be associated with BFR toxicity of endocrine disruption. tetrabromobisphenol A 23-28 transthyretin Homo sapiens 113-116 31927367-6 2020 Negative cooperativity was found for 3-OH-BDE-47 and TBBPA binding to TTR, similar to T4 with a well-established negatively cooperative binding mechanism. 3-oh-bde-47 37-48 transthyretin Homo sapiens 70-73 31927367-6 2020 Negative cooperativity was found for 3-OH-BDE-47 and TBBPA binding to TTR, similar to T4 with a well-established negatively cooperative binding mechanism. tetrabromobisphenol A 53-58 transthyretin Homo sapiens 70-73 32201330-0 2020 Di-(2-ethylhexyl) phthalate inhibits expression and internalization of transthyretin in human placental trophoblastic cells. Diethylhexyl Phthalate 0-27 transthyretin Homo sapiens 71-84 32311072-37 2020 Results from placebo-controlled trials indicate that tafamidis, diflunisal, patisiran, and inotersen may be beneficial in TTR-FAP, but further investigations are needed. Diflunisal 64-74 transthyretin Homo sapiens 122-125 32333280-1 2021 We present a case of a 40-year-old Spanish man with cardiac amyloidosis in which a Tc-99m-3,3-diphosphono-1,2-propanodicarboxylic acid (Tc-99m-DPD) scintigraphy was strongly suggestive of cardiac amyloidosis by transthyretin (ATTR) but endomyocardial biopsy (EB) analyzed by immunohistochemistry demonstrated a light chain amyloidosis (AL). tc-99m-3,3-diphosphono-1,2-propanodicarboxylic acid 83-134 transthyretin Homo sapiens 226-230 31728576-7 2020 Treatment of thapsigargin (Tg) to activate the unfolded protein response (UPR) alleviates Ala97Ser M-TTR secretion. Thapsigargin 13-25 transthyretin Homo sapiens 101-104 32333280-2 2021 Even though the Tc-99m-DPD has proven in different published papers that has high sensibility and specificity for differentiating AL and ATTR cardiac amyloidosis, we present an unusual case of an AL cardiac amyloidosis with a Perugini grade 3 on the scintigraphy. Technetium 16-22 transthyretin Homo sapiens 137-141 30650043-14 2020 However, in patients presenting with an unexplained restricted cardiomyopathy, technetium-labelled bone scanning could offer a non-invasive approach to establishing the diagnosis of ATTR, mitigating the need for EMBs in a subset of patients. Technetium 79-89 transthyretin Homo sapiens 182-186 31728576-7 2020 Treatment of thapsigargin (Tg) to activate the unfolded protein response (UPR) alleviates Ala97Ser M-TTR secretion. Thapsigargin 27-29 transthyretin Homo sapiens 101-104 31728576-7 2020 Treatment of thapsigargin (Tg) to activate the unfolded protein response (UPR) alleviates Ala97Ser M-TTR secretion. ala97ser m 90-100 transthyretin Homo sapiens 101-104 31463816-2 2020 Traditionally diagnosed invasively, ATTR can be diagnosed with non-invasive 99mTechnetium pyrophosphate (99mTc-PYP) planar scintigraphy. 99mtechnetium pyrophosphate 76-103 transthyretin Homo sapiens 36-40 31463816-2 2020 Traditionally diagnosed invasively, ATTR can be diagnosed with non-invasive 99mTechnetium pyrophosphate (99mTc-PYP) planar scintigraphy. 99mtc-pyp 105-114 transthyretin Homo sapiens 36-40 31463816-4 2020 Here, we develop and validate a Cadmium Zinc Telluride (CZT) protocol for diagnosing ATTR. CdZnTe 32-54 transthyretin Homo sapiens 85-89 31463816-4 2020 Here, we develop and validate a Cadmium Zinc Telluride (CZT) protocol for diagnosing ATTR. CdZnTe 56-59 transthyretin Homo sapiens 85-89 31463816-12 2020 CZT scintigraphy had 100% sensitivity and specificity for diagnosing ATTR. CdZnTe 0-3 transthyretin Homo sapiens 69-73 32197355-1 2020 Transthyretin (TTR), an homotetrameric protein mainly synthesized by the liver and the choroid plexus, and secreted into the blood and the cerebrospinal fluid, respectively, has been specially acknowledged for its functions as a transporter protein of thyroxine and retinol (the latter through binding to the retinol-binding protein), in these fluids. Thyroxine 252-261 transthyretin Homo sapiens 0-13 32197355-1 2020 Transthyretin (TTR), an homotetrameric protein mainly synthesized by the liver and the choroid plexus, and secreted into the blood and the cerebrospinal fluid, respectively, has been specially acknowledged for its functions as a transporter protein of thyroxine and retinol (the latter through binding to the retinol-binding protein), in these fluids. Thyroxine 252-261 transthyretin Homo sapiens 15-18 32197355-1 2020 Transthyretin (TTR), an homotetrameric protein mainly synthesized by the liver and the choroid plexus, and secreted into the blood and the cerebrospinal fluid, respectively, has been specially acknowledged for its functions as a transporter protein of thyroxine and retinol (the latter through binding to the retinol-binding protein), in these fluids. Vitamin A 266-273 transthyretin Homo sapiens 0-13 32197355-1 2020 Transthyretin (TTR), an homotetrameric protein mainly synthesized by the liver and the choroid plexus, and secreted into the blood and the cerebrospinal fluid, respectively, has been specially acknowledged for its functions as a transporter protein of thyroxine and retinol (the latter through binding to the retinol-binding protein), in these fluids. Vitamin A 266-273 transthyretin Homo sapiens 15-18 32176096-3 2020 In the present study, we aim to evaluate the diagnostic role of fecal calprotectin (FC) in ATTR amyloidosis patients with GI manifestations.We recruited 21 consecutive ATTR amyloidosis patients and 42 sex and age-matched healthy controls. Fc(alpha) receptor 84-86 transthyretin Homo sapiens 91-95 31896530-5 2020 Substantive evidence pointing to the role of endogenous ouabain and marinobufagenin, the two most prominent CTS, in development of cardiovascular disease has accumulated. marinobufagenin 68-83 transthyretin Homo sapiens 108-111 32210536-2 2020 As the main transporter for thyroxine (T4) in plasma and cerebrospinal fluid, TTR contains two T4-binding sites, which are docked with T4 and subsequently maintain the structural stability of TTR homotetramer. Thyroxine 28-37 transthyretin Homo sapiens 78-81 32210536-2 2020 As the main transporter for thyroxine (T4) in plasma and cerebrospinal fluid, TTR contains two T4-binding sites, which are docked with T4 and subsequently maintain the structural stability of TTR homotetramer. Thyroxine 28-37 transthyretin Homo sapiens 192-195 32210536-8 2020 In this paper, we summarized the potent inhibitors, including bisaryl structure-based compounds, flavonoids, crown ethers, and carboranes, for treating TTR-related amyloid diseases and the combination modes of some compounds binding to TTR protein. bisaryl 62-69 transthyretin Homo sapiens 152-155 32210536-8 2020 In this paper, we summarized the potent inhibitors, including bisaryl structure-based compounds, flavonoids, crown ethers, and carboranes, for treating TTR-related amyloid diseases and the combination modes of some compounds binding to TTR protein. bisaryl 62-69 transthyretin Homo sapiens 236-239 32210536-8 2020 In this paper, we summarized the potent inhibitors, including bisaryl structure-based compounds, flavonoids, crown ethers, and carboranes, for treating TTR-related amyloid diseases and the combination modes of some compounds binding to TTR protein. Flavonoids 97-107 transthyretin Homo sapiens 152-155 32210536-8 2020 In this paper, we summarized the potent inhibitors, including bisaryl structure-based compounds, flavonoids, crown ethers, and carboranes, for treating TTR-related amyloid diseases and the combination modes of some compounds binding to TTR protein. Flavonoids 97-107 transthyretin Homo sapiens 236-239 32210536-8 2020 In this paper, we summarized the potent inhibitors, including bisaryl structure-based compounds, flavonoids, crown ethers, and carboranes, for treating TTR-related amyloid diseases and the combination modes of some compounds binding to TTR protein. Crown Ethers 109-121 transthyretin Homo sapiens 152-155 32210536-8 2020 In this paper, we summarized the potent inhibitors, including bisaryl structure-based compounds, flavonoids, crown ethers, and carboranes, for treating TTR-related amyloid diseases and the combination modes of some compounds binding to TTR protein. Crown Ethers 109-121 transthyretin Homo sapiens 236-239 32210536-8 2020 In this paper, we summarized the potent inhibitors, including bisaryl structure-based compounds, flavonoids, crown ethers, and carboranes, for treating TTR-related amyloid diseases and the combination modes of some compounds binding to TTR protein. carboranes 127-137 transthyretin Homo sapiens 152-155 32210536-8 2020 In this paper, we summarized the potent inhibitors, including bisaryl structure-based compounds, flavonoids, crown ethers, and carboranes, for treating TTR-related amyloid diseases and the combination modes of some compounds binding to TTR protein. carboranes 127-137 transthyretin Homo sapiens 236-239 31713445-3 2020 The purpose of this study was to evaluate the long term safety and efficacy of transthyretin specific antisense oligonucleotide therapy, inotersen, in transthyretin cardiomyopathy.Methods: Patients with hereditary or wildtype transthyretin cardiomyopathy (NYHA I-III) with an LV wall thickness [Formula: see text]1.3 cm and clinical evidence of congestive heart failure were eligible for this single centre, open label protocol. Oligonucleotides 112-127 transthyretin Homo sapiens 79-92 31713445-3 2020 The purpose of this study was to evaluate the long term safety and efficacy of transthyretin specific antisense oligonucleotide therapy, inotersen, in transthyretin cardiomyopathy.Methods: Patients with hereditary or wildtype transthyretin cardiomyopathy (NYHA I-III) with an LV wall thickness [Formula: see text]1.3 cm and clinical evidence of congestive heart failure were eligible for this single centre, open label protocol. Oligonucleotides 112-127 transthyretin Homo sapiens 151-164 31713445-3 2020 The purpose of this study was to evaluate the long term safety and efficacy of transthyretin specific antisense oligonucleotide therapy, inotersen, in transthyretin cardiomyopathy.Methods: Patients with hereditary or wildtype transthyretin cardiomyopathy (NYHA I-III) with an LV wall thickness [Formula: see text]1.3 cm and clinical evidence of congestive heart failure were eligible for this single centre, open label protocol. Oligonucleotides 112-127 transthyretin Homo sapiens 151-164 31669991-3 2020 Here, the potential binding potency of halo-benzoic acids, halo-benzenesulfonic acids/sulfates and halo-phenylboronic acids with hTTR was determined and analyzed by competitive fluorescence displacement assay integrated with computational methods. halo-benzoic acids 39-57 transthyretin Homo sapiens 129-133 31669991-3 2020 Here, the potential binding potency of halo-benzoic acids, halo-benzenesulfonic acids/sulfates and halo-phenylboronic acids with hTTR was determined and analyzed by competitive fluorescence displacement assay integrated with computational methods. halo-benzenesulfonic acids 59-85 transthyretin Homo sapiens 129-133 31669991-3 2020 Here, the potential binding potency of halo-benzoic acids, halo-benzenesulfonic acids/sulfates and halo-phenylboronic acids with hTTR was determined and analyzed by competitive fluorescence displacement assay integrated with computational methods. Sulfates 86-94 transthyretin Homo sapiens 129-133 31669991-3 2020 Here, the potential binding potency of halo-benzoic acids, halo-benzenesulfonic acids/sulfates and halo-phenylboronic acids with hTTR was determined and analyzed by competitive fluorescence displacement assay integrated with computational methods. halo-phenylboronic acids 99-123 transthyretin Homo sapiens 129-133 31669991-6 2020 Other halo-benzoic acids and halo-benzenesulfonic acids/sulfates were moderate and/or weak hTTR binders. halo-benzoic acids 6-24 transthyretin Homo sapiens 91-95 31669991-6 2020 Other halo-benzoic acids and halo-benzenesulfonic acids/sulfates were moderate and/or weak hTTR binders. halo-benzenesulfonic acids 29-55 transthyretin Homo sapiens 91-95 31669991-6 2020 Other halo-benzoic acids and halo-benzenesulfonic acids/sulfates were moderate and/or weak hTTR binders. Sulfates 56-64 transthyretin Homo sapiens 91-95 31669991-7 2020 The binding affinity of halo-benzoic acids and halo-benzenesulfonic acids/sulfates with hTTR was similar. halo-benzoic acids 24-42 transthyretin Homo sapiens 88-92 31669991-7 2020 The binding affinity of halo-benzoic acids and halo-benzenesulfonic acids/sulfates with hTTR was similar. halo-benzenesulfonic acids 47-73 transthyretin Homo sapiens 88-92 31669991-7 2020 The binding affinity of halo-benzoic acids and halo-benzenesulfonic acids/sulfates with hTTR was similar. Sulfates 74-82 transthyretin Homo sapiens 88-92 31669991-8 2020 The low distribution ability of the model compounds from water to hTTR may be the reason why they exhibited the binding potency observed with hTTR. Water 57-62 transthyretin Homo sapiens 66-70 31669991-8 2020 The low distribution ability of the model compounds from water to hTTR may be the reason why they exhibited the binding potency observed with hTTR. Water 57-62 transthyretin Homo sapiens 142-146 31669991-10 2020 Those results indicated that the highly hydrophobic halo-benzoic acids and halo-benzenesulfonic acids/sulfates may be high-priority hTTR disruptors. halo-benzoic acids 52-70 transthyretin Homo sapiens 132-136 31669991-10 2020 Those results indicated that the highly hydrophobic halo-benzoic acids and halo-benzenesulfonic acids/sulfates may be high-priority hTTR disruptors. halo-benzenesulfonic acids 75-101 transthyretin Homo sapiens 132-136 31669991-10 2020 Those results indicated that the highly hydrophobic halo-benzoic acids and halo-benzenesulfonic acids/sulfates may be high-priority hTTR disruptors. Sulfates 102-110 transthyretin Homo sapiens 132-136 32176096-8 2020 The presence of elevated FC concentrations could help gastroenterologists to include ATTR amyloidosis in their diagnostic work-up. Fc(alpha) receptor 25-27 transthyretin Homo sapiens 85-89 31614274-6 2020 The fluorescence emissions of DCZ1-TTR and DCZ2-TTR are predicted to show clear blue-shifting in cyclohexane with respect to their analogue DCZ-TTR. Cyclohexanes 97-108 transthyretin Homo sapiens 35-38 31614274-6 2020 The fluorescence emissions of DCZ1-TTR and DCZ2-TTR are predicted to show clear blue-shifting in cyclohexane with respect to their analogue DCZ-TTR. Cyclohexanes 97-108 transthyretin Homo sapiens 48-51 31614274-6 2020 The fluorescence emissions of DCZ1-TTR and DCZ2-TTR are predicted to show clear blue-shifting in cyclohexane with respect to their analogue DCZ-TTR. Cyclohexanes 97-108 transthyretin Homo sapiens 48-51 32019993-8 2020 Well-controlled warfarin (TTR >= 60%) reduced both thromboembolism and bleeding events. Warfarin 16-24 transthyretin Homo sapiens 26-29 31172386-1 2020 INTRODUCTION: Assessment of myocardial uptake of Tc-99m-pyrophosphate (Tc-99m PYP) is pivotal in distinguishing transthyretin-associated cardiac amyloidosis (ATTR) from light chain amyloid (AL). Technetium Tc 99m Pyrophosphate 49-69 transthyretin Homo sapiens 158-162 32063053-0 2020 Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis. technetium-99 m pyrophosphate 17-46 transthyretin Homo sapiens 85-98 32063053-1 2020 BACKGROUND: Technetium-99 m pyrophosphate protocols for transthyretin cardiac amyloidosis diagnosis have variably used 1- and 3-hour imaging time points. technetium-99 m pyrophosphate 12-41 transthyretin Homo sapiens 56-69 32063053-3 2020 METHODS: This is a registry analysis of patients with suspected transthyretin cardiac amyloidosis referred for technetium-99 m pyrophosphate at a single tertiary center from June 2015 through January 2019. technetium-99 m pyrophosphate 111-140 transthyretin Homo sapiens 64-77 30102127-1 2020 The residue generated in the aluminium cold lamination (TTR) was submitted to a direct burning and then it was calcined at 500 C. BET, FTIR, SEM with EDX and TGA techniques were performed to characterize the adsorbent before and after the adsorption. Aluminum 29-38 transthyretin Homo sapiens 56-59 30102127-3 2020 Afterwards, the TTR was applied as adsorbent of the reactive Drimaren Blue (DB), Drimaren Red (DR) and Drimaren Gold (DG). drimaren blue 61-74 transthyretin Homo sapiens 16-19 30102127-3 2020 Afterwards, the TTR was applied as adsorbent of the reactive Drimaren Blue (DB), Drimaren Red (DR) and Drimaren Gold (DG). didemnins 76-78 transthyretin Homo sapiens 16-19 30102127-3 2020 Afterwards, the TTR was applied as adsorbent of the reactive Drimaren Blue (DB), Drimaren Red (DR) and Drimaren Gold (DG). drimaren red 81-93 transthyretin Homo sapiens 16-19 30102127-3 2020 Afterwards, the TTR was applied as adsorbent of the reactive Drimaren Blue (DB), Drimaren Red (DR) and Drimaren Gold (DG). drimaren gold 103-116 transthyretin Homo sapiens 16-19 31172386-1 2020 INTRODUCTION: Assessment of myocardial uptake of Tc-99m-pyrophosphate (Tc-99m PYP) is pivotal in distinguishing transthyretin-associated cardiac amyloidosis (ATTR) from light chain amyloid (AL). PYP 78-81 transthyretin Homo sapiens 158-162 31588087-0 2020 Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis. pimobendan 21-31 transthyretin Homo sapiens 64-77 31588087-11 2020 Conclusion In clinical practice, pimobendan seems to have beneficial effects in heart failure management for improving physical activities and the quality of life in patients with transthyretin cardiac amyloidosis. pimobendan 33-43 transthyretin Homo sapiens 180-193 31172386-1 2020 INTRODUCTION: Assessment of myocardial uptake of Tc-99m-pyrophosphate (Tc-99m PYP) is pivotal in distinguishing transthyretin-associated cardiac amyloidosis (ATTR) from light chain amyloid (AL). Technetium 49-55 transthyretin Homo sapiens 158-162 31172386-11 2020 CONCLUSION: Tc-99m PYP/Tl-201 SPECT improves visual differentiation of ATTR and AL amyloidosis compared to single-isotope SPECT. Technetium 12-15 transthyretin Homo sapiens 71-75 31850420-2 2020 In this paper, the light-emitting mechanisms of PTZ-TTR and PTZ-Ph-TTR with blue-orange dual emission are studied systematically. Pentylenetetrazole 48-51 transthyretin Homo sapiens 52-55 32064392-4 2020 Poly(acrylic acid-co-methacrylamide) (P(AA-co-MAA)) and chitosan-grafted poly(acrylic acid-co-methacrylamide) (CTS-g-P(AA-co-MAA)) were prepared by aqueous solution polymerization, and their characteristics have been studied by scanning electron microscopy and Fourier transform infrared spectroscopy. poly(methacrylamide-co-acrylic acid) 73-109 transthyretin Homo sapiens 111-114 32064392-8 2020 In addition, the thermogravimetry and differential scanning calorimetry measurement of coal with the hydrogel in air proved that the CTS-g-P(AA-co-MAA) hydrogel effectively prevented the initial oxidation of coal. 3-O-methylellagic acid 4'-O-alpha-L-2''-O-acetyl-rhamnopyranoside 141-150 transthyretin Homo sapiens 133-136 32064392-9 2020 Thus, CTS-g-P(AA-co-MAA) is recommended as an inhibitor in preventing coal oxidation. 3-O-methylellagic acid 4'-O-alpha-L-2''-O-acetyl-rhamnopyranoside 14-23 transthyretin Homo sapiens 6-9 31850420-2 2020 In this paper, the light-emitting mechanisms of PTZ-TTR and PTZ-Ph-TTR with blue-orange dual emission are studied systematically. Pentylenetetrazole 48-51 transthyretin Homo sapiens 67-70 31850420-4 2020 For PTZ-TTR, the near-orthogonal conformation is only generated by the transformation from the near-planar conformation, while the near-orthogonal conformation of PTZ-Ph-TTR can be generated by both excitation and transformation. Pentylenetetrazole 4-7 transthyretin Homo sapiens 8-11 31850420-4 2020 For PTZ-TTR, the near-orthogonal conformation is only generated by the transformation from the near-planar conformation, while the near-orthogonal conformation of PTZ-Ph-TTR can be generated by both excitation and transformation. Pentylenetetrazole 4-7 transthyretin Homo sapiens 170-173 31850420-5 2020 This results in relatively strong orange emission in PTZ-Ph-TTR. N-(4'-bromophenyl)-2,2-diphenylacetanilide 53-59 transthyretin Homo sapiens 60-63 31850420-7 2020 Based on the comparison of the photophysical properties of PTZ-TTR in toluene and the aggregation state, we find that aggregation could induce a smaller energy gap between the first singlet excited state and the first triplet excited state. Pentylenetetrazole 59-62 transthyretin Homo sapiens 63-66 31850420-7 2020 Based on the comparison of the photophysical properties of PTZ-TTR in toluene and the aggregation state, we find that aggregation could induce a smaller energy gap between the first singlet excited state and the first triplet excited state. Toluene 70-77 transthyretin Homo sapiens 63-66 31676294-3 2020 A recent study reports that Hcy reacts with Cys10 of transthyretin (TTR), generating a stable covalent adduct. Homocysteine 28-31 transthyretin Homo sapiens 53-66 31676294-3 2020 A recent study reports that Hcy reacts with Cys10 of transthyretin (TTR), generating a stable covalent adduct. Homocysteine 28-31 transthyretin Homo sapiens 68-71 31676294-5 2020 METHODS: The effect of Hcy on the conformational properties of wt- and L55P-TTR were analysed using a set of biophysical techniques. Homocysteine 23-26 transthyretin Homo sapiens 76-79 31676294-12 2020 Our results suggest that high homocysteine levels are a further risk factor for TTR cardiomyopathy in patients harbouring the L55P-TTR mutation. Homocysteine 30-42 transthyretin Homo sapiens 80-83 31676294-12 2020 Our results suggest that high homocysteine levels are a further risk factor for TTR cardiomyopathy in patients harbouring the L55P-TTR mutation. Homocysteine 30-42 transthyretin Homo sapiens 131-134 33081658-6 2020 Recent several studies support the potential advantage of bone-seeking radionuclides as a screening technique for the most common types of amyloidosis, in particular ATTR form. Radioisotopes 71-84 transthyretin Homo sapiens 166-170 32990603-3 2020 In protein- depleted states, N- and Met-deficiencies operate as limiting factors for LBM protein synthesis and accretion, causing growth retardation and subnormal TTR plasma values. Nitrogen 29-30 transthyretin Homo sapiens 163-166 33081658-8 2020 Furthermore, we report the case of an 83-year old male with a history of prostate cancer, carcinoma of the cecum and kidney cancer, submitted to bone scan to detect bone metastasis, that revealed a myocardial uptake of 99mTC-HMPD suggestive of ATTR CA. 99mtc-hmpd 219-229 transthyretin Homo sapiens 244-248 32865784-4 2020 Inotersen is a second-generation antisense oligonucleotide with 2"-O-methoxyethyl modification designed to bind to the 3" untranslated region of the transthyretin mRNA in the nucleus of the liver cells. Oligonucleotides 43-58 transthyretin Homo sapiens 149-162 32003587-1 2020 BACKGROUND: House dust contains many organic contaminants that can compete with the thyroid hormone (TH) thyroxine (T4) for binding to transthyretin (TTR). Thyroxine 105-114 transthyretin Homo sapiens 135-148 32003587-1 2020 BACKGROUND: House dust contains many organic contaminants that can compete with the thyroid hormone (TH) thyroxine (T4) for binding to transthyretin (TTR). Thyroxine 105-114 transthyretin Homo sapiens 150-153 32003587-4 2020 METHODS: Twenty-five contaminants were tested for their in vitro capacity to compete for TTR-binding with a fluorescent FITC-T4 probe. Fluorescein-5-isothiocyanate 120-124 transthyretin Homo sapiens 89-92 32003587-9 2020 The ~20% inhibition in FITC-T4 binding observed for the mixtures reflecting median concentrations in maternal and infant serum was extrapolated to 1.3% inhibition of T4-TTR binding in maternal and 1.5% in infant blood. Fluorescein-5-isothiocyanate 23-27 transthyretin Homo sapiens 169-172 31762320-1 2020 Purpose: Transthyretin (TTR) is a protein with a growing number of biological functions in addition to its well-established binding and circulatory transport of thyroxine, and indirect retinoid transport through interaction with retinol-binding protein. Thyroxine 161-170 transthyretin Homo sapiens 9-22 31762320-1 2020 Purpose: Transthyretin (TTR) is a protein with a growing number of biological functions in addition to its well-established binding and circulatory transport of thyroxine, and indirect retinoid transport through interaction with retinol-binding protein. Thyroxine 161-170 transthyretin Homo sapiens 24-27 31762320-1 2020 Purpose: Transthyretin (TTR) is a protein with a growing number of biological functions in addition to its well-established binding and circulatory transport of thyroxine, and indirect retinoid transport through interaction with retinol-binding protein. Retinoids 185-193 transthyretin Homo sapiens 9-22 31762320-1 2020 Purpose: Transthyretin (TTR) is a protein with a growing number of biological functions in addition to its well-established binding and circulatory transport of thyroxine, and indirect retinoid transport through interaction with retinol-binding protein. Retinoids 185-193 transthyretin Homo sapiens 24-27 31762320-1 2020 Purpose: Transthyretin (TTR) is a protein with a growing number of biological functions in addition to its well-established binding and circulatory transport of thyroxine, and indirect retinoid transport through interaction with retinol-binding protein. Vitamin A 229-236 transthyretin Homo sapiens 9-22 31762320-1 2020 Purpose: Transthyretin (TTR) is a protein with a growing number of biological functions in addition to its well-established binding and circulatory transport of thyroxine, and indirect retinoid transport through interaction with retinol-binding protein. Vitamin A 229-236 transthyretin Homo sapiens 24-27 32513587-3 2020 In this context, cardiac scintigraphy (CS) with 99mTc-labelled diphosphonates has aroused a noticeable surge in interest by demonstrating high sensitivity and specificity for the reliable, non-invasive diagnosis of ATTR. 99mtc-labelled diphosphonates 48-77 transthyretin Homo sapiens 215-219 31977903-0 2020 99mTc-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis: Potential clinical implications. 99mtc-dpd 0-9 transthyretin Homo sapiens 60-64 31977903-5 2020 Significant Tc-DPD uptake was found in 24 organs (sensitivity = 82.8%) in AL and 9 organs (sensitivity = 75.0%) in ATTR. tc-dpd 12-18 transthyretin Homo sapiens 115-119 31977903-7 2020 Degree of Tc-DPD uptake was significantly higher in ATTR compared with AL amyloidosis (P = .017). tc-dpd 10-16 transthyretin Homo sapiens 52-56 31977903-8 2020 Diffuse soft tissue uptake with photon defects in the liver area was found only in ATTR amyloidosis.This study showed that Tc-DPD scintigraphy might have capacity to differentiate between AL and ATTR subtypes with good sensitivity in various organs involving primary systemic AL and ATTR amyloidosis. tc-dpd 123-129 transthyretin Homo sapiens 83-87 31977903-8 2020 Diffuse soft tissue uptake with photon defects in the liver area was found only in ATTR amyloidosis.This study showed that Tc-DPD scintigraphy might have capacity to differentiate between AL and ATTR subtypes with good sensitivity in various organs involving primary systemic AL and ATTR amyloidosis. tc-dpd 123-129 transthyretin Homo sapiens 195-199 31977903-8 2020 Diffuse soft tissue uptake with photon defects in the liver area was found only in ATTR amyloidosis.This study showed that Tc-DPD scintigraphy might have capacity to differentiate between AL and ATTR subtypes with good sensitivity in various organs involving primary systemic AL and ATTR amyloidosis. tc-dpd 123-129 transthyretin Homo sapiens 195-199 31921171-3 2019 The tacrolimus TTR percentage was calculated by linear interpolation with a target range (5-10 ng/ml months 0-3, 4-8 ng/ml months 4-12). Tacrolimus 4-14 transthyretin Homo sapiens 15-18 31921171-14 2019 Conclusions: Increasing the TTR of tacrolimus in the first year was associated with improved long-term outcomes in living kidney transplants, and TTR may be a novel valuable strategy to monitor tacrolimus exposure. Tacrolimus 35-45 transthyretin Homo sapiens 28-31 31921171-14 2019 Conclusions: Increasing the TTR of tacrolimus in the first year was associated with improved long-term outcomes in living kidney transplants, and TTR may be a novel valuable strategy to monitor tacrolimus exposure. Tacrolimus 194-204 transthyretin Homo sapiens 28-31 31921171-14 2019 Conclusions: Increasing the TTR of tacrolimus in the first year was associated with improved long-term outcomes in living kidney transplants, and TTR may be a novel valuable strategy to monitor tacrolimus exposure. Tacrolimus 194-204 transthyretin Homo sapiens 146-149 31835306-4 2019 The objective of this study was to determine the effectiveness of Bacopa monnieri extract (BME) in the modulation of TTR amyloidogenesis and disruption of preformed fibrils. bme 91-94 transthyretin Homo sapiens 117-120 31835306-7 2019 ANS binding and glutaraldehyde cross-linking assays showed that BME binds at the thyroxine-binding site and possibly enhanced the quaternary structural stability of native TTR. Thyroxine 81-90 transthyretin Homo sapiens 172-175 31725511-0 2019 Transthyretin Cardiac Amyloidosis as Diagnosed by 99mTc-PYP Scanning in Patients with Acute Heart Failure and Preserved Ejection Fraction. 99mtc-pyp 50-59 transthyretin Homo sapiens 0-13 31554435-5 2019 Patients with rare or known pathogenic variants in TTR underwent 99mTechnetium labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy and were retrospectively re-assessed for clinical features of amyloidosis. Technetium 65-78 transthyretin Homo sapiens 51-54 31554435-5 2019 Patients with rare or known pathogenic variants in TTR underwent 99mTechnetium labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy and were retrospectively re-assessed for clinical features of amyloidosis. 3,3-diphosphono-1,2-propanodicarboxylic acid 88-132 transthyretin Homo sapiens 51-54 31479652-9 2019 S-sulfonation of hTTR at the free cysteine residue in position 10 appears to be the result of a mixed disulfide exchange possibly with S-cysteinylated hTTR or S-cysteinylated HSA. Cysteine 34-42 transthyretin Homo sapiens 17-21 31479652-9 2019 S-sulfonation of hTTR at the free cysteine residue in position 10 appears to be the result of a mixed disulfide exchange possibly with S-cysteinylated hTTR or S-cysteinylated HSA. Disulfides 102-111 transthyretin Homo sapiens 17-21 31479652-10 2019 hTTR is a tetramer composed of four identical monomers each containing a reduced cysteine residue in position 10. Cysteine 81-89 transthyretin Homo sapiens 0-4 31479652-11 2019 S-sulfonation of hTTR at this cysteine residue can destabilize the hTTR tetramer, an important step in the formation of TTR-related amyloid fibrils. Cysteine 30-38 transthyretin Homo sapiens 17-21 31479652-11 2019 S-sulfonation of hTTR at this cysteine residue can destabilize the hTTR tetramer, an important step in the formation of TTR-related amyloid fibrils. Cysteine 30-38 transthyretin Homo sapiens 67-71 31479652-11 2019 S-sulfonation of hTTR at this cysteine residue can destabilize the hTTR tetramer, an important step in the formation of TTR-related amyloid fibrils. Cysteine 30-38 transthyretin Homo sapiens 18-21 31725511-2 2019 Technetium-pyrophosphate scintigraphy (Tc-PYP) is sensitive and specific to diagnose cardiac transthyretin amyloid deposition (ATTR). technetium-pyrophosphate 0-24 transthyretin Homo sapiens 93-106 31725511-2 2019 Technetium-pyrophosphate scintigraphy (Tc-PYP) is sensitive and specific to diagnose cardiac transthyretin amyloid deposition (ATTR). technetium-pyrophosphate 0-24 transthyretin Homo sapiens 127-131 31725511-2 2019 Technetium-pyrophosphate scintigraphy (Tc-PYP) is sensitive and specific to diagnose cardiac transthyretin amyloid deposition (ATTR). tc-pyp 39-45 transthyretin Homo sapiens 93-106 31725511-2 2019 Technetium-pyrophosphate scintigraphy (Tc-PYP) is sensitive and specific to diagnose cardiac transthyretin amyloid deposition (ATTR). tc-pyp 39-45 transthyretin Homo sapiens 127-131 31725511-3 2019 The prevalence of ATTR by Tc-PYP was evaluated along with echocardiographic parameters in patients with HFpEF. tc-pyp 26-32 transthyretin Homo sapiens 18-22 31725511-8 2019 The prevalence of ATTR myocardial deposition demonstrated by Tc-PYP in patients with HFpEF is comparable to that of autopsy studies. tc-pyp 61-67 transthyretin Homo sapiens 18-22 31777097-3 2019 Here we report the pharmacokinetics (PK) of ALN-18328, DLin-MC3-DMA, and PEG2000 -C-DMG from a phase 2 multiple-ascending-dose study and its open-label extension (OLE) in patients with hATTR amyloidosis. 2,3-didehydro-5-O-mycaminosyl-23-O-acetyltylonolide 44-67 transthyretin Homo sapiens 185-190 31659433-0 2019 Phenome-wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the genetics of hereditary and wildtype transthyretin amyloidoses. phenome 0-7 transthyretin Homo sapiens 34-37 31659433-0 2019 Phenome-wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the genetics of hereditary and wildtype transthyretin amyloidoses. phenome 0-7 transthyretin Homo sapiens 142-155 31594020-8 2019 (iii) Gene silencers (mRNA-inhibiting oligonucleotides) reduce liver-secreted TTRm and TTRwt.Liver transplantation (LTx) is an established procedure in ATTR patients. Oligonucleotides 38-54 transthyretin Homo sapiens 152-156 31741327-1 2021 BACKGROUND: To determine the capability of 99mTc-DPD scintigraphy to detect early cardiac involvement and predict clinical worsening in transthyretin (TTR) gene mutation patients. technetium Tc 99m 1,6-di-(2-thienyl)-2,5-diazahexane 43-48 transthyretin Homo sapiens 136-149 31741327-1 2021 BACKGROUND: To determine the capability of 99mTc-DPD scintigraphy to detect early cardiac involvement and predict clinical worsening in transthyretin (TTR) gene mutation patients. technetium Tc 99m 1,6-di-(2-thienyl)-2,5-diazahexane 43-48 transthyretin Homo sapiens 151-154 31741327-9 2021 CONCLUSIONS: 99mTc-DPD scan detects cardiac involvement in subjects with TTR gene mutation earlier than ECG, echocardiography and biochemical markers, occurring some years before the fulfillment of current diagnostic criteria for cardiac amyloidosis. technetium Tc 99m 1,6-di-(2-thienyl)-2,5-diazahexane 13-18 transthyretin Homo sapiens 73-76 33704267-0 2019 CORRIGENDUM: Utility of 99 mTc-Pyrophosphate Scintigraphy in Diagnosing Transthyretin Cardiac Amyloidosis in Real-World Practice. mtc-pyrophosphate 27-44 transthyretin Homo sapiens 72-85 32042354-1 2020 99mTechnetium pyrophosphate (99mTc-PYP) scintigraphy has shown utility for diagnosis of transthyretin (ATTR) cardiac amyloidosis with a high sensitivity and specificity. 99mtechnetium pyrophosphate 0-27 transthyretin Homo sapiens 103-107 32042354-1 2020 99mTechnetium pyrophosphate (99mTc-PYP) scintigraphy has shown utility for diagnosis of transthyretin (ATTR) cardiac amyloidosis with a high sensitivity and specificity. 99mtc-pyp 29-38 transthyretin Homo sapiens 103-107 31473362-0 2019 Structure-activity relationships of flurbiprofen analogues as stabilizers of the amyloidogenic protein transthyretin. Flurbiprofen 36-48 transthyretin Homo sapiens 103-116 31473362-2 2019 TTR stabilizers are able to interact with the thyroxine-binding sites of TTR, stabilizing its tetrameric native state and inhibiting amyloidogenesis. Thyroxine 46-55 transthyretin Homo sapiens 0-3 31473362-2 2019 TTR stabilizers are able to interact with the thyroxine-binding sites of TTR, stabilizing its tetrameric native state and inhibiting amyloidogenesis. Thyroxine 46-55 transthyretin Homo sapiens 73-76 31473362-3 2019 Herein, we report on in vitro, ex vivo, and X-ray analyses to assess the TTR structural stabilization by analogues of flurbiprofen, a non-steroidal anti-inflammatory drug (NSAID). Flurbiprofen 118-130 transthyretin Homo sapiens 73-76 31473362-4 2019 Overall, considering together binding selectivity and protective effects on TTR native structure by flurbiprofen analogues in the presence of plasma proteins, as determined by Western Blot,the aforementioned properties of analyzed compounds appear to be better (CHF5075 and CHF4802) or similar (CHF4795) or worse (CHF5074, also known as CSP-1103) as compared to those of diflunisal, used as a reference TTR stabilizer. Flurbiprofen 100-112 transthyretin Homo sapiens 76-79 31473362-6 2019 Distinct interactions with TTR appear to characterize flurbiprofen analogues and the NSAID diflunisal and its analogues as TTR stabilizers. Flurbiprofen 54-66 transthyretin Homo sapiens 27-30 31473362-6 2019 Distinct interactions with TTR appear to characterize flurbiprofen analogues and the NSAID diflunisal and its analogues as TTR stabilizers. Diflunisal 91-101 transthyretin Homo sapiens 27-30 31473362-6 2019 Distinct interactions with TTR appear to characterize flurbiprofen analogues and the NSAID diflunisal and its analogues as TTR stabilizers. Diflunisal 91-101 transthyretin Homo sapiens 123-126 31473362-7 2019 Relationships between stabilizing effect on TTR by flurbiprofen analogues determined experimentally and molecular details of their interactions with TTR have been established, providing the rationale for their protective effects on the native protein structure. Flurbiprofen 51-63 transthyretin Homo sapiens 44-47 31473362-7 2019 Relationships between stabilizing effect on TTR by flurbiprofen analogues determined experimentally and molecular details of their interactions with TTR have been established, providing the rationale for their protective effects on the native protein structure. Flurbiprofen 51-63 transthyretin Homo sapiens 149-152 31615521-0 2019 Transcriptome analysis identified a novel 3-LncRNA regulatory network of transthyretin attenuating glucose induced hRECs dysfunction in diabetic retinopathy. Glucose 99-106 transthyretin Homo sapiens 73-86 31502419-5 2019 METHOD: The stability of TTR tetramers was assessed by urea denaturation and differential scanning calorimetry. Urea 55-59 transthyretin Homo sapiens 25-28 31502419-10 2019 NMR revealed the binding site of A97S-TTR with tafamidis is at the thyroxine binding pocket. Thyroxine 67-76 transthyretin Homo sapiens 38-41 29473120-1 2019 In this issue of JNC, BW Spery and Coll report a retrospective analysis of 57 patients with transthyretin-related amyloidosis (ATTR) in an advanced phase of the disease who underwent 99mTechnetium-pyrophosphate (99mTcPYP) scintigraphy. 99mtechnetium-pyrophosphate 183-210 transthyretin Homo sapiens 127-131 31399774-3 2019 Two disease-modifying drugs, inotersen (an antisense oligonucleotide) and patisiran (a small interfering RNA agent), were recently approved for the treatment of hATTR polyneuropathy. UNII-0IEO0F56LV 29-38 transthyretin Homo sapiens 161-166 29344917-1 2019 BACKGROUND: Technetium-based bone scintigraphy is rapidly becoming the most common non-invasive imaging tool in the diagnosis of Transthyretin cardiac amyloidosis (ATTR). Technetium 12-22 transthyretin Homo sapiens 164-168 29344917-3 2019 We sought to investigate skeletal muscle uptake of technetium-99m-pyrophosphate (TcPYP) in patients with ATTR. technetium-99m-pyrophosphate 51-79 transthyretin Homo sapiens 105-109 29344917-3 2019 We sought to investigate skeletal muscle uptake of technetium-99m-pyrophosphate (TcPYP) in patients with ATTR. tcpyp 81-86 transthyretin Homo sapiens 105-109 29344917-4 2019 METHODS AND RESULTS: This was a retrospective analysis of 57 patients diagnosed with ATTR who underwent TcPYP scintigraphy. tcpyp 104-109 transthyretin Homo sapiens 85-89 29344917-11 2019 CONCLUSIONS: In patients with ATTR cardiac amyloidosis, skeletal muscle uptake of TcPYP is minimal when assessed by qualitative and quantitative metrics, and is not significantly different in patients with grade 2 vs 3 semiquantitative uptake. tcpyp 82-87 transthyretin Homo sapiens 30-34 31319424-3 2019 We described a pediatric case of extremely early onset TTR-FAP with a TTR Leu55Pro mutation. leu55pro 74-82 transthyretin Homo sapiens 55-58 31319424-3 2019 We described a pediatric case of extremely early onset TTR-FAP with a TTR Leu55Pro mutation. leu55pro 74-82 transthyretin Homo sapiens 70-73 31319424-8 2019 Genetic analysis of the TTR gene demonstrated that both the patient and his sister had a pathogenic mutation, c.224T > C (Leu55Pro). leu55pro 122-130 transthyretin Homo sapiens 24-27 31397996-12 2019 This disease is characterized by a mutation in the gene encoding TTR, a serum protein that transports retinol in circulation following secretion by the liver. Vitamin A 102-109 transthyretin Homo sapiens 65-68 31178489-4 2019 A genetic analysis revealed a base pair substitution of adenine to cytosine in the second codon of exon 4, residue 114, in the TTR gene (c.401A>C). Adenine 56-63 transthyretin Homo sapiens 127-130 31178489-4 2019 A genetic analysis revealed a base pair substitution of adenine to cytosine in the second codon of exon 4, residue 114, in the TTR gene (c.401A>C). Cytosine 67-75 transthyretin Homo sapiens 127-130 31393717-2 2019 The homotetrameric TTR contains two identical thyroxine binding pockets, occupation of which by specific ligands can inhibit TTR amyloidogenesis in vitro. Thyroxine 46-55 transthyretin Homo sapiens 19-22 31393717-2 2019 The homotetrameric TTR contains two identical thyroxine binding pockets, occupation of which by specific ligands can inhibit TTR amyloidogenesis in vitro. Thyroxine 46-55 transthyretin Homo sapiens 125-128 31393717-6 2019 In contrast, mds84, our prototypic "bivalent" ligand, which is a more potent stabilizer of TTR in vitro that occupies both thyroxine pockets and the intramolecular channel between them, has greater structural effects. Thyroxine 123-132 transthyretin Homo sapiens 91-94 31452021-8 2019 Droxidopa (Northera ), a synthetic norepinephrine precursor, has shown efficacy in controlled trials of neurogenic orthostatic hypotension in patients with hereditary TTR amyloidosis and is now approved in the US and Asia. Droxidopa 0-9 transthyretin Homo sapiens 167-170 31440205-6 2019 In humans, the THDPs are albumin, transthyretin (TTR), and thyroxine-binding globulin (TBG). thdps 15-20 transthyretin Homo sapiens 34-47 31298260-3 2019 The new small molecule, DTBDT-S-C8-TTR, exhibits a homogenous blend morphology with small domains and edge-on-oriented crystalline structures in blends with PC71BM, and give a maximum power conversion efficiency (PCE) of 8.43%. dtbdt-s 24-31 transthyretin Homo sapiens 35-38 31298260-4 2019 To recover the crystallinity of the DTBDT-S-C8-TTR small molecules weakened after being blended with PC71BM, a solvent vapor annealing (SVA) treatment is performed. dtbdt- 36-42 transthyretin Homo sapiens 47-50 31298260-7 2019 The maximum PCE of 9.18% achieved using DTBDT-S-C8-TTR suggests that substituting both alkylthio and alkyl groups into DTBDT can yield small-molecule-based organic photovoltaics (OPVs) displaying improved photovoltaic performances. dtbdt 40-45 transthyretin Homo sapiens 51-54 31298260-7 2019 The maximum PCE of 9.18% achieved using DTBDT-S-C8-TTR suggests that substituting both alkylthio and alkyl groups into DTBDT can yield small-molecule-based organic photovoltaics (OPVs) displaying improved photovoltaic performances. dtbdt 119-124 transthyretin Homo sapiens 51-54 31440205-6 2019 In humans, the THDPs are albumin, transthyretin (TTR), and thyroxine-binding globulin (TBG). thdps 15-20 transthyretin Homo sapiens 49-52 31358790-1 2019 We have studied the intrinsic fluorescence spectra of a monomeric variant of human transthyretin (M-TTR), a protein involved in the transport of the thyroid hormone and retinol and associated with various forms of amyloidosis, extending our analysis to the second order derivative of the spectra. Vitamin A 169-176 transthyretin Homo sapiens 83-96 31189791-0 2019 Combination of Commonly Examined Parameters Is a Useful Predictor of Positive 99 mTc-Labeled Pyrophosphate Scintigraphy Findings in Elderly Patients With Suspected Transthyretin Cardiac Amyloidosis. diphosphoric acid 93-106 transthyretin Homo sapiens 164-177 30885685-0 2019 Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. tyrphostin 8 31-35 transthyretin Homo sapiens 0-13 30885685-0 2019 Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. tyrphostin 8 31-35 transthyretin Homo sapiens 51-64 30885685-3 2019 AG10 is a selective, oral TTR stabilizer under development for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that mimics a protective TTR mutation. tyrphostin 8 0-4 transthyretin Homo sapiens 26-29 30885685-3 2019 AG10 is a selective, oral TTR stabilizer under development for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that mimics a protective TTR mutation. tyrphostin 8 0-4 transthyretin Homo sapiens 105-109 30885685-3 2019 AG10 is a selective, oral TTR stabilizer under development for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that mimics a protective TTR mutation. tyrphostin 8 0-4 transthyretin Homo sapiens 106-109 30885685-4 2019 OBJECTIVES: This randomized, double-blind, placebo-controlled study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AG10 in ATTR-CM patients with symptomatic, chronic heart failure. tyrphostin 8 142-146 transthyretin Homo sapiens 150-154 30885685-9 2019 RESULTS: AG10 treatment was well-tolerated, achieved target plasma concentrations and demonstrated near-complete stabilization of TTR. tyrphostin 8 9-13 transthyretin Homo sapiens 130-133 30885685-13 2019 AG10 treatment restored serum TTR to the normal range in all subjects. tyrphostin 8 0-4 transthyretin Homo sapiens 30-33 30885685-14 2019 CONCLUSIONS: AG10 has the potential to be a safe and effective treatment for patients with ATTR-CM. tyrphostin 8 13-17 transthyretin Homo sapiens 91-95 31358790-1 2019 We have studied the intrinsic fluorescence spectra of a monomeric variant of human transthyretin (M-TTR), a protein involved in the transport of the thyroid hormone and retinol and associated with various forms of amyloidosis, extending our analysis to the second order derivative of the spectra. Vitamin A 169-176 transthyretin Homo sapiens 100-103 31253122-2 2019 The current diagnosis of ATTRv relies on genetic identification of TTR mutations and on Congo Red-positive amyloid deposits, which are absent in most ATTRv patients that are asymptomatic or early symptomatic, supporting the need for novel biomarkers to identify patients in earlier disease phases allowing disease control. Congo Red 88-97 transthyretin Homo sapiens 26-29 31167790-9 2019 Both drugs disrupted patient-derived TTR amyloid fibrils ex vivo, and pyrvinium pamoate also stabilized the tetrameric structure of TTR ex vivo in patient plasma. pyrvinium 70-87 transthyretin Homo sapiens 132-135 31348283-5 2019 She was finally diagnosed hereditary transthyretin-related cardiac amylodosis by specific findings of cardiovascular magnetic resonance imaging (CMR), -technetium pyrophosphate (Tc-PYP) scintigraphy and genetic testing. -technetium pyrophosphate 151-176 transthyretin Homo sapiens 37-50 31348283-5 2019 She was finally diagnosed hereditary transthyretin-related cardiac amylodosis by specific findings of cardiovascular magnetic resonance imaging (CMR), -technetium pyrophosphate (Tc-PYP) scintigraphy and genetic testing. tc-pyp 178-184 transthyretin Homo sapiens 37-50 31316837-1 2019 Thyroid hormone (thyroxine, T4) is essential for the normal function of all cell types and is carried in serum bound to several proteins including transthyretin. Thyroxine 17-26 transthyretin Homo sapiens 147-160 31216785-1 2019 Transthyretin (TTR) is a thyroid hormone-binding protein which transports thyroxine from the bloodstream to the brain. Thyroxine 74-83 transthyretin Homo sapiens 0-13 31117532-4 2019 Experimental results implied that 2,4,6-trihalo-phenols, 2,6-dihalo-4-nitrophenols, and 3,5-dihalo-4-hydroxybenzaldehydes have a high binding affinity with hTTR. 2,4,6-trihalo-phenols 34-55 transthyretin Homo sapiens 156-160 31117532-4 2019 Experimental results implied that 2,4,6-trihalo-phenols, 2,6-dihalo-4-nitrophenols, and 3,5-dihalo-4-hydroxybenzaldehydes have a high binding affinity with hTTR. 2,6-dihalo-4-nitrophenols 57-82 transthyretin Homo sapiens 156-160 31117532-4 2019 Experimental results implied that 2,4,6-trihalo-phenols, 2,6-dihalo-4-nitrophenols, and 3,5-dihalo-4-hydroxybenzaldehydes have a high binding affinity with hTTR. 3,5-dihalo-4-hydroxybenzaldehydes 88-121 transthyretin Homo sapiens 156-160 31216785-1 2019 Transthyretin (TTR) is a thyroid hormone-binding protein which transports thyroxine from the bloodstream to the brain. Thyroxine 74-83 transthyretin Homo sapiens 15-18 28537040-8 2019 All TTR patients showed Tc-HMDP uptake, with three patients showing a Perugini score grade 1, 16 grade 2, and 20 grade 3, respectively. tc-hmdp 24-31 transthyretin Homo sapiens 4-7 31090446-0 2019 Tafamidis dramatically improved severe proteinuria in a patient with TTR V30M hereditary ATTR amyloidosis. tafamidis 0-9 transthyretin Homo sapiens 69-72 31090446-0 2019 Tafamidis dramatically improved severe proteinuria in a patient with TTR V30M hereditary ATTR amyloidosis. tafamidis 0-9 transthyretin Homo sapiens 89-93 31119947-0 2019 Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Tolcapone 83-92 transthyretin Homo sapiens 0-13 31119947-0 2019 Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Tolcapone 83-92 transthyretin Homo sapiens 117-121 31119947-0 2019 Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Tolcapone 94-101 transthyretin Homo sapiens 0-13 31119947-0 2019 Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Tolcapone 94-101 transthyretin Homo sapiens 117-121 31119947-1 2019 Objective: To assess the transthyretin (TTR) stabilization activity of tolcapone (SOM0226) in patients with hereditary ATTR amyloidosis, asymptomatic carriers and healthy volunteers. Tolcapone 71-80 transthyretin Homo sapiens 25-38 31119947-1 2019 Objective: To assess the transthyretin (TTR) stabilization activity of tolcapone (SOM0226) in patients with hereditary ATTR amyloidosis, asymptomatic carriers and healthy volunteers. Tolcapone 71-80 transthyretin Homo sapiens 40-43 31119947-1 2019 Objective: To assess the transthyretin (TTR) stabilization activity of tolcapone (SOM0226) in patients with hereditary ATTR amyloidosis, asymptomatic carriers and healthy volunteers. Tolcapone 71-80 transthyretin Homo sapiens 119-123 31119947-10 2019 Conclusions: The ability of tolcapone for stabilizing TTR supports further development and repositioning of the drug for the treatment of ATTR amyloidosis. Tolcapone 28-37 transthyretin Homo sapiens 54-57 31119947-10 2019 Conclusions: The ability of tolcapone for stabilizing TTR supports further development and repositioning of the drug for the treatment of ATTR amyloidosis. Tolcapone 28-37 transthyretin Homo sapiens 138-142 30733338-1 2019 The tetrameric protein transthyretin is a transporter of retinol and thyroxine in blood, cerebrospinal fluid, and the eye, and is secreted by the liver, choroid plexus, and retinal epithelium, respectively. Vitamin A 57-64 transthyretin Homo sapiens 23-36 30733338-1 2019 The tetrameric protein transthyretin is a transporter of retinol and thyroxine in blood, cerebrospinal fluid, and the eye, and is secreted by the liver, choroid plexus, and retinal epithelium, respectively. Thyroxine 69-78 transthyretin Homo sapiens 23-36 30887985-0 2019 New insights into the metal-induced oxidative degradation pathways of transthyretin. Metals 22-27 transthyretin Homo sapiens 70-83 30887985-2 2019 Transthyretin was investigated revealing a metal-induced (Cr/Cu) oxidation pathway leading to N-terminal backbone fragmentation and oligomer formation; previously hidden details were revealed only by FT-IM-Orbitrap MS and surface-induced dissociation. Metals 43-48 transthyretin Homo sapiens 0-13 30887985-2 2019 Transthyretin was investigated revealing a metal-induced (Cr/Cu) oxidation pathway leading to N-terminal backbone fragmentation and oligomer formation; previously hidden details were revealed only by FT-IM-Orbitrap MS and surface-induced dissociation. Chromium 58-60 transthyretin Homo sapiens 0-13 30887985-2 2019 Transthyretin was investigated revealing a metal-induced (Cr/Cu) oxidation pathway leading to N-terminal backbone fragmentation and oligomer formation; previously hidden details were revealed only by FT-IM-Orbitrap MS and surface-induced dissociation. Copper 61-63 transthyretin Homo sapiens 0-13 33693151-0 2019 Utility of 99 mTc-Pyrophosphate Scintigraphy in Diagnosing Transthyretin Cardiac Amyloidosis in Real-World Practice. mtc-pyrophosphate 14-31 transthyretin Homo sapiens 59-72 33693151-2 2019 The purpose of the present study was to validate the usefulness of technetium-99 m (99 mTc)-pyrophosphate (99 mTc-PYP) scintigraphy in the screening diagnosis for ATTR amyloidosis in daily clinical practice. Technetium 67-84 transthyretin Homo sapiens 163-167 33693151-2 2019 The purpose of the present study was to validate the usefulness of technetium-99 m (99 mTc)-pyrophosphate (99 mTc-PYP) scintigraphy in the screening diagnosis for ATTR amyloidosis in daily clinical practice. mtc)-pyrophosphate 87-105 transthyretin Homo sapiens 163-167 33693151-2 2019 The purpose of the present study was to validate the usefulness of technetium-99 m (99 mTc)-pyrophosphate (99 mTc-PYP) scintigraphy in the screening diagnosis for ATTR amyloidosis in daily clinical practice. mtc-pyp 110-117 transthyretin Homo sapiens 163-167 33693151-4 2019 The sensitivity and specificity of 99 mTc-PYP scintigraphy for the diagnosis of biopsy-proven ATTR amyloidosis were 0.889 and 0.950, respectively. mtc-pyp 38-45 transthyretin Homo sapiens 94-98 33693151-8 2019 Conclusions: 99 mTc-PYP scintigraphy was useful, with high sensitivity and specificity in the screening diagnosis for ATTR cardiac amyloidosis, which is difficult to diagnose on clinical characteristics alone. mtc-pyp 16-23 transthyretin Homo sapiens 118-122 33693151-9 2019 99 mTc-PYP scintigraphy should be considered to elucidate the underlying causes of heart failure, especially in elderly patients based on the higher prevalence of ATTR cardiac amyloidosis in this population. mtc-pyp 3-10 transthyretin Homo sapiens 163-167 31117178-1 2019 Tegsedi (Inotersen) is a chemically modified antisense oligonucleotide that inhibits the hepatic production of transthyretin (TTR). UNII-0IEO0F56LV 0-7 transthyretin Homo sapiens 111-124 31117178-1 2019 Tegsedi (Inotersen) is a chemically modified antisense oligonucleotide that inhibits the hepatic production of transthyretin (TTR). UNII-0IEO0F56LV 0-7 transthyretin Homo sapiens 126-129 31117178-1 2019 Tegsedi (Inotersen) is a chemically modified antisense oligonucleotide that inhibits the hepatic production of transthyretin (TTR). Oligonucleotides 55-70 transthyretin Homo sapiens 111-124 31117178-1 2019 Tegsedi (Inotersen) is a chemically modified antisense oligonucleotide that inhibits the hepatic production of transthyretin (TTR). Oligonucleotides 55-70 transthyretin Homo sapiens 126-129 30912637-0 2019 Therapeutic Potential of Polyamidoamine Dendrimer for Amyloidogenic Transthyretin Amyloidosis. polyamidoamine dendrimer 25-49 transthyretin Homo sapiens 68-81 30912637-3 2019 In this study, to discover a new drug candidate for ATTR amyloidosis therapy, we focused on polyamidoamine dendrimer (dendrimer), a 3D-structural nanomaterial, which has a branched cationic polymer repeating polyamidoamine units. polyamidoamine dendrimer 92-116 transthyretin Homo sapiens 52-56 30912637-3 2019 In this study, to discover a new drug candidate for ATTR amyloidosis therapy, we focused on polyamidoamine dendrimer (dendrimer), a 3D-structural nanomaterial, which has a branched cationic polymer repeating polyamidoamine units. Dendrimers 107-116 transthyretin Homo sapiens 52-56 30912637-3 2019 In this study, to discover a new drug candidate for ATTR amyloidosis therapy, we focused on polyamidoamine dendrimer (dendrimer), a 3D-structural nanomaterial, which has a branched cationic polymer repeating polyamidoamine units. Polymers 190-197 transthyretin Homo sapiens 52-56 30912637-3 2019 In this study, to discover a new drug candidate for ATTR amyloidosis therapy, we focused on polyamidoamine dendrimer (dendrimer), a 3D-structural nanomaterial, which has a branched cationic polymer repeating polyamidoamine units. Poly(amidoamine) 92-106 transthyretin Homo sapiens 52-56 31077750-6 2020 The TTR-TRbeta CALUX predicted 9/9 compounds and demonstrated competitive activities when analyzing waste water samples. Water 106-111 transthyretin Homo sapiens 4-7 31118583-3 2019 Inotersen, a 2"-O-methyoxyethyl-modified antisense oligonucleotide, which acts by reducing the production of transthyretin, was recently demonstrated to improve disease course and quality of life in early hereditary transthyretin amyloidosis polyneuropathy in a 15-month Phase III study. 2"-o-methyoxyethyl-modified 13-40 transthyretin Homo sapiens 109-122 31118583-3 2019 Inotersen, a 2"-O-methyoxyethyl-modified antisense oligonucleotide, which acts by reducing the production of transthyretin, was recently demonstrated to improve disease course and quality of life in early hereditary transthyretin amyloidosis polyneuropathy in a 15-month Phase III study. Oligonucleotides 51-66 transthyretin Homo sapiens 109-122 30508073-1 2019 AIMS: Patients with non-valvular atrial fibrillation (NVAF) receiving vitamin K antagonists (VKAs) with time in therapeutic international normalized ratio (INR) range (TTR) <70%, despite good adherence, are by guidelines recommended to switch to non-VKA oral anticoagulants (NOACs). Vitamin K 70-79 transthyretin Homo sapiens 168-171 28537040-10 2019 A positive Tc-HMDP scintigraphy showed a 100% sensitivity and a 96% specificity for TTR CA identification. tc-hmdp 11-18 transthyretin Homo sapiens 84-87 30883567-6 2019 RESULTS: Among those patients taking warfarin, the mean"artificial" TTR (aTTR) based on a lower INR target of 1.5-2.5 was 44.4+-33.3%. Warfarin 37-45 transthyretin Homo sapiens 73-77 30884813-3 2019 PCBs can displace T4 by binding to TTR itself, being transported into the brain and disturbing DA-synthesis, where depressive symptoms might occur. Polychlorinated Biphenyls 0-4 transthyretin Homo sapiens 35-38 30884813-4 2019 Consequently, the free T4-concentration (fT4) increases when PCBs bind to TTR. CHEMBL179036 41-44 transthyretin Homo sapiens 74-77 30884813-4 2019 Consequently, the free T4-concentration (fT4) increases when PCBs bind to TTR. Polychlorinated Biphenyls 61-65 transthyretin Homo sapiens 74-77 30688345-2 2019 In order to accelerate bone defects especially in patients with osteoporosis or other metabolic diseases, we firstly constructed lanthanum-doped mesoporous calcium silicate/chitosan (La-MCS/CTS) scaffolds by freeze-drying technology. Lanthanum 129-138 transthyretin Homo sapiens 183-193 30688345-2 2019 In order to accelerate bone defects especially in patients with osteoporosis or other metabolic diseases, we firstly constructed lanthanum-doped mesoporous calcium silicate/chitosan (La-MCS/CTS) scaffolds by freeze-drying technology. mesoporous calcium silicate 145-172 transthyretin Homo sapiens 183-193 30688345-2 2019 In order to accelerate bone defects especially in patients with osteoporosis or other metabolic diseases, we firstly constructed lanthanum-doped mesoporous calcium silicate/chitosan (La-MCS/CTS) scaffolds by freeze-drying technology. Chitosan 173-181 transthyretin Homo sapiens 183-193 30688345-6 2019 A critical-sized calvarial-defect rat model further revealed that the La-MCS/CTS scaffolds significantly promoted new bone regeneration as compared with pure MCS/CTS scaffolds. la-mcs 70-76 transthyretin Homo sapiens 77-80 30688345-7 2019 In conclusion, the La-MCS/CTS scaffold showed the prominent ability in osteogenesis and bone regeneration, which showed its application potential for bone defect therapy. la-mcs 19-25 transthyretin Homo sapiens 26-29 30883567-10 2019 The NOAC group showed a comparable risk of composite outcome to the warfarin subgroup with aTTR of >70% (P = 0.485). Warfarin 68-76 transthyretin Homo sapiens 91-95 30875761-0 2019 Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis. Curcumin 45-53 transthyretin Homo sapiens 57-70 30875761-6 2019 The effects of curcumin on ATTR amyloidosis will be reviewed and discussed in the current work in order to contribute to knowledge of the molecular mechanisms involved in TTR amyloidosis and propose more efficient drugs for therapy. Curcumin 15-23 transthyretin Homo sapiens 28-31 30688456-0 2019 Crown Ethers as Transthyretin Amyloidogenesis Inhibitors. Crown Ethers 0-12 transthyretin Homo sapiens 16-29 30767672-0 2019 Tafamidis for the treatment of transthyretin amyloidosis. tafamidis 0-9 transthyretin Homo sapiens 31-44 30660664-2 2019 METHODS AND RESULTS: We report the clinical experience of 53 ATTR CA patients treated with doxycycline and ursodiol. Ursodeoxycholic Acid 107-115 transthyretin Homo sapiens 61-65 30726714-0 2019 Doxycycline and Ursodiol for ATTR Amyloidosis: Not Ready for Prime Time. Ursodeoxycholic Acid 16-24 transthyretin Homo sapiens 29-33 29863957-2 2019 The current study aimed to develop a localized controlled delivery system from RSV by incorporating RSV-loaded chitosan/chondroitin sulfate (CTS/CS) nanoparticles into thermosensitive Pluronic F127/hyaluronic acid (PF127/HA) hydrogel. Rosuvastatin Calcium 100-103 transthyretin Homo sapiens 141-147 29863957-2 2019 The current study aimed to develop a localized controlled delivery system from RSV by incorporating RSV-loaded chitosan/chondroitin sulfate (CTS/CS) nanoparticles into thermosensitive Pluronic F127/hyaluronic acid (PF127/HA) hydrogel. Chondroitin Sulfates 120-139 transthyretin Homo sapiens 141-147 29863957-3 2019 RSV-loaded CTS/CS nanoparticles were prepared by ionic gelation, and the impact of various formulation variables was assessed using the Box-Behnken design. Rosuvastatin Calcium 0-3 transthyretin Homo sapiens 11-17 29863957-7 2019 The hydrogel containing 3% w/v CTS/CS nanoparticles existed as a solution with low viscosity at room temperature converted to a semisolid upon increasing the temperature to 35 C. Hydrogel engrafted with CTS/CS showed controlled release of RSV during 48 h with superior in vitro gel stability. Rosuvastatin Calcium 240-243 transthyretin Homo sapiens 31-37 29863957-7 2019 The hydrogel containing 3% w/v CTS/CS nanoparticles existed as a solution with low viscosity at room temperature converted to a semisolid upon increasing the temperature to 35 C. Hydrogel engrafted with CTS/CS showed controlled release of RSV during 48 h with superior in vitro gel stability. Rosuvastatin Calcium 240-243 transthyretin Homo sapiens 204-210 30660664-0 2019 Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis. Doxycycline 36-47 transthyretin Homo sapiens 94-107 30660664-0 2019 Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis. Ursodeoxycholic Acid 52-72 transthyretin Homo sapiens 94-107 30660664-1 2019 BACKGROUND: The tolerability and utility of combination doxycycline and ursodeoxycholic acid (ursodiol) amyloid fibril disruption therapy for transthyretin cardiac amyloidosis (ATTR CA) in clinical practice is poorly described. Doxycycline 56-67 transthyretin Homo sapiens 142-155 30660664-1 2019 BACKGROUND: The tolerability and utility of combination doxycycline and ursodeoxycholic acid (ursodiol) amyloid fibril disruption therapy for transthyretin cardiac amyloidosis (ATTR CA) in clinical practice is poorly described. Ursodeoxycholic Acid 72-92 transthyretin Homo sapiens 142-155 30660664-1 2019 BACKGROUND: The tolerability and utility of combination doxycycline and ursodeoxycholic acid (ursodiol) amyloid fibril disruption therapy for transthyretin cardiac amyloidosis (ATTR CA) in clinical practice is poorly described. Ursodeoxycholic Acid 94-102 transthyretin Homo sapiens 142-155 30660664-2 2019 METHODS AND RESULTS: We report the clinical experience of 53 ATTR CA patients treated with doxycycline and ursodiol. Doxycycline 91-102 transthyretin Homo sapiens 61-65 30451573-3 2019 MATERIAL & METHODS: We performed an observational study to evaluate Nucleo CMP ForteTM in patients with electromyography-confirmed, mild-moderate CTS. Adenosine Monophosphate 10-13 transthyretin Homo sapiens 150-153 30688456-3 2019 Here, we report our discovery of the anti-TTR amyloidogenesis activities of crown ethers. Crown Ethers 76-88 transthyretin Homo sapiens 42-45 30688456-4 2019 X-ray crystallographic analysis, binding assay, and chemical cross-linking assay showed that 4"-carboxybenzo-18C6 (4) stabilized the TTR tetramer by binding to the allosteric sites on the molecular surface of the TTR tetramer. 4"-carboxybenzo-18c6 (4) 93-117 transthyretin Homo sapiens 133-136 30688456-4 2019 X-ray crystallographic analysis, binding assay, and chemical cross-linking assay showed that 4"-carboxybenzo-18C6 (4) stabilized the TTR tetramer by binding to the allosteric sites on the molecular surface of the TTR tetramer. 4"-carboxybenzo-18c6 (4) 93-117 transthyretin Homo sapiens 213-216 30688456-5 2019 In addition, 4 synergistically increased the stabilization activity of diflunisal, one of the most potent TTR amyloidogenesis inhibitors. Diflunisal 71-81 transthyretin Homo sapiens 106-109 30414409-0 2019 The Accumulation of Heparan Sulfate S-Domains in Kidney Transthyretin Deposits Accelerates Fibril Formation and Promotes Cytotoxicity. Heparitin Sulfate 20-35 transthyretin Homo sapiens 56-69 30811423-6 2019 For these two patients a positive 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy indicated ATTR Type A. 99mtc-3,3-diphosphono-1,2-propanodicarboxylic acid 34-84 transthyretin Homo sapiens 108-112 30394286-0 2019 Destabilised human transthyretin shapes the morphology of calcium carbonate crystals. Calcium Carbonate 58-75 transthyretin Homo sapiens 19-32 30394286-1 2019 Human transthyretin (TTR) is a homotetramer that transports thyroid hormones and retinol in the serum and cerebrospinal fluid. Vitamin A 81-88 transthyretin Homo sapiens 6-19 30394286-1 2019 Human transthyretin (TTR) is a homotetramer that transports thyroid hormones and retinol in the serum and cerebrospinal fluid. Vitamin A 81-88 transthyretin Homo sapiens 21-24 30394286-7 2019 Using an in vitro assay, we found that TTR affected calcium carbonate crystal growth and morphology, producing asymmetric crystals with a complex nanocrystalline composition. Calcium Carbonate 52-69 transthyretin Homo sapiens 39-42 30414409-4 2019 In in vitro assays with cells stably expressing human Sulfs, heparin, a structural analog of HS S-domains, promoted aggregation of transthyretin in an HS S-domain-dependent manner. Heparin 61-68 transthyretin Homo sapiens 131-144 30567728-8 2019 Further analyses showed that TTR treatment enhanced the reactive oxygen species production in myeloid cells and enabled them to become functional myeloid-derived suppressive cells. Reactive Oxygen Species 56-79 transthyretin Homo sapiens 29-32 30478886-1 2019 Tafamidis meglumine, a transthyretin (TTR) stabilizer, is effective in delaying the progression of neuropathy in TTR amyloidosis with Val30Met mutations. tafamidis 0-19 transthyretin Homo sapiens 23-36 30478886-1 2019 Tafamidis meglumine, a transthyretin (TTR) stabilizer, is effective in delaying the progression of neuropathy in TTR amyloidosis with Val30Met mutations. tafamidis 0-19 transthyretin Homo sapiens 38-41 30478886-1 2019 Tafamidis meglumine, a transthyretin (TTR) stabilizer, is effective in delaying the progression of neuropathy in TTR amyloidosis with Val30Met mutations. tafamidis 0-19 transthyretin Homo sapiens 113-116 30478886-3 2019 Herein, we report a 73-year-old Japanese man with a diagnosis of TTR amyloid cardiomyopathy with Val30Met mutation treated with tafamidis. tafamidis 128-137 transthyretin Homo sapiens 65-68 30478886-6 2019 Our case suggests that serial native T1 and extracellular volume may be novel non-invasive imaging methods to monitor the treatment response to TTR stabilizers in cardiac amyloidosis and also that tafamidis may be effective in suppressing cardiac progression in TTR amyloid cardiomyopathy with Val30Met mutation. tafamidis 197-206 transthyretin Homo sapiens 262-265 30561247-4 2019 Inotersen/Tegsedi (Akcea Therapeutics, MA, USA) is a second-generation antisense oligonucleotide (ASO) specific for TTR that inhibits production of TTR by the liver. Oligonucleotides, Antisense 99-102 transthyretin Homo sapiens 117-120 30561247-4 2019 Inotersen/Tegsedi (Akcea Therapeutics, MA, USA) is a second-generation antisense oligonucleotide (ASO) specific for TTR that inhibits production of TTR by the liver. Oligonucleotides, Antisense 99-102 transthyretin Homo sapiens 149-152 30561247-0 2019 Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis. Oligonucleotides 44-59 transthyretin Homo sapiens 11-24 30561247-4 2019 Inotersen/Tegsedi (Akcea Therapeutics, MA, USA) is a second-generation antisense oligonucleotide (ASO) specific for TTR that inhibits production of TTR by the liver. Oligonucleotides 82-97 transthyretin Homo sapiens 117-120 30561247-4 2019 Inotersen/Tegsedi (Akcea Therapeutics, MA, USA) is a second-generation antisense oligonucleotide (ASO) specific for TTR that inhibits production of TTR by the liver. Oligonucleotides 82-97 transthyretin Homo sapiens 149-152 30582704-3 2019 Acetyl tert-butyl peroxide (TBPA) was used as the radical relay precursor, providing the initiated methyl radical to start the radical relay process. acetyl tert-butyl peroxide 0-26 transthyretin Homo sapiens 28-32 30675021-4 2019 We show that inhibiting PERK signaling impairs secretion of destabilized TTR during thapsigargin (Tg)-induced ER stress by increasing its ER retention in chaperone-bound complexes. Thapsigargin 84-96 transthyretin Homo sapiens 73-76 30675021-4 2019 We show that inhibiting PERK signaling impairs secretion of destabilized TTR during thapsigargin (Tg)-induced ER stress by increasing its ER retention in chaperone-bound complexes. Thapsigargin 98-100 transthyretin Homo sapiens 73-76 30687694-6 2018 The amphiphilic properties of CTS permit simultaneous entrapment of PTX and RB, while the encapsulation efficiency of RB was further improved by increasing the amount of short-chain bPEI. Paclitaxel 68-71 transthyretin Homo sapiens 30-33 30687694-6 2018 The amphiphilic properties of CTS permit simultaneous entrapment of PTX and RB, while the encapsulation efficiency of RB was further improved by increasing the amount of short-chain bPEI. Rose Bengal 76-78 transthyretin Homo sapiens 30-33 30687694-8 2018 Hyaluronic acid (HA) was subsequently grafted onto the surface of BNCs through electrostatic interaction, leading to the formation of HA-BSA/CTS/PVA/bPEI-blended nanocarriers (HBNCs) to achieve an efficient prostate-cancer-cell uptake. Hyaluronic Acid 0-15 transthyretin Homo sapiens 134-174 30582704-3 2019 Acetyl tert-butyl peroxide (TBPA) was used as the radical relay precursor, providing the initiated methyl radical to start the radical relay process. methyl radical 99-113 transthyretin Homo sapiens 28-32 30687694-8 2018 Hyaluronic acid (HA) was subsequently grafted onto the surface of BNCs through electrostatic interaction, leading to the formation of HA-BSA/CTS/PVA/bPEI-blended nanocarriers (HBNCs) to achieve an efficient prostate-cancer-cell uptake. Hyaluronic Acid 17-19 transthyretin Homo sapiens 134-174 31343363-0 2019 Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen. Oligonucleotides 63-78 transthyretin Homo sapiens 13-17 31343363-0 2019 Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, inotersen. Oligonucleotides 63-78 transthyretin Homo sapiens 14-17 31343364-0 2019 Serum diacron-reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) in patients with ATTR-PN. Oxygen 23-29 transthyretin Homo sapiens 111-115 20301373-7 1993 TTR amyloid deposition in tissue is demonstrated using Congo red staining and, ideally, immunohistochemical study. Congo Red 55-64 transthyretin Homo sapiens 0-3 31005793-6 2019 Transthyretin-related amyloidosis was demonstrated by histochemical Congo Red staining under polarized light and by immunohistochemistry, corresponding to the intimal thickening. Congo Red 68-77 transthyretin Homo sapiens 0-13 31474634-1 2019 While percent time within therapeutic range (%TTR) of international normalized ratio of prothrombin time (PT-INR) represents the quality of anticoagulation therapy with warfarin, it is often maintained less than 50% in patients with non-valvular atrial fibrillation (NVAF). Warfarin 169-177 transthyretin Homo sapiens 46-49 31582656-0 2019 Hepatocyte-Targeted Delivery of siRNA Polyplex with PEG-Modified Lactosylated Dendrimer/Cyclodextrin Conjugates for Transthyretin-Related Amyloidosis Therapy. Polyethylene Glycols 52-55 transthyretin Homo sapiens 116-129 31582656-0 2019 Hepatocyte-Targeted Delivery of siRNA Polyplex with PEG-Modified Lactosylated Dendrimer/Cyclodextrin Conjugates for Transthyretin-Related Amyloidosis Therapy. Dendrimers 78-87 transthyretin Homo sapiens 116-129 31582656-0 2019 Hepatocyte-Targeted Delivery of siRNA Polyplex with PEG-Modified Lactosylated Dendrimer/Cyclodextrin Conjugates for Transthyretin-Related Amyloidosis Therapy. Cyclodextrins 88-100 transthyretin Homo sapiens 116-129 31582656-3 2019 Herein, we report on a hepatocyte-specific small interfering RNA (siRNA) delivery system using polyethylene glycol (PEG)-modified lactosylated dendrimer (generation 3; G3) conjugates with alpha-cyclodextrin (PEG-LalphaCs (G3)) for TTR-related amyloidosis therapy, and investigated the in vitro and in vivo gene silencing effect of PEG-LalphaCs (G3)/siRNA polyplexes. Polyethylene Glycols 95-114 transthyretin Homo sapiens 231-234 31582656-3 2019 Herein, we report on a hepatocyte-specific small interfering RNA (siRNA) delivery system using polyethylene glycol (PEG)-modified lactosylated dendrimer (generation 3; G3) conjugates with alpha-cyclodextrin (PEG-LalphaCs (G3)) for TTR-related amyloidosis therapy, and investigated the in vitro and in vivo gene silencing effect of PEG-LalphaCs (G3)/siRNA polyplexes. Polyethylene Glycols 116-119 transthyretin Homo sapiens 231-234 31582656-3 2019 Herein, we report on a hepatocyte-specific small interfering RNA (siRNA) delivery system using polyethylene glycol (PEG)-modified lactosylated dendrimer (generation 3; G3) conjugates with alpha-cyclodextrin (PEG-LalphaCs (G3)) for TTR-related amyloidosis therapy, and investigated the in vitro and in vivo gene silencing effect of PEG-LalphaCs (G3)/siRNA polyplexes. alpha-cyclodextrin 188-206 transthyretin Homo sapiens 231-234 31582656-4 2019 PEG-LalphaC (G3, average degree of substitution of PEG (DSP) 2)/TTR siRNA (siTTR) polyplex exhibited the asialoglycoprotein receptor (ASGPR)-mediated cellular uptake, high endosomal escaping ability and localization of the siRNA in cytoplasm, resulting in significant TTR silencing in HepG2 cells. peg-lalphac 0-11 transthyretin Homo sapiens 64-67 31582656-4 2019 PEG-LalphaC (G3, average degree of substitution of PEG (DSP) 2)/TTR siRNA (siTTR) polyplex exhibited the asialoglycoprotein receptor (ASGPR)-mediated cellular uptake, high endosomal escaping ability and localization of the siRNA in cytoplasm, resulting in significant TTR silencing in HepG2 cells. peg-lalphac 0-11 transthyretin Homo sapiens 77-80 31582656-4 2019 PEG-LalphaC (G3, average degree of substitution of PEG (DSP) 2)/TTR siRNA (siTTR) polyplex exhibited the asialoglycoprotein receptor (ASGPR)-mediated cellular uptake, high endosomal escaping ability and localization of the siRNA in cytoplasm, resulting in significant TTR silencing in HepG2 cells. Polyethylene Glycols 0-3 transthyretin Homo sapiens 64-67 31582656-4 2019 PEG-LalphaC (G3, average degree of substitution of PEG (DSP) 2)/TTR siRNA (siTTR) polyplex exhibited the asialoglycoprotein receptor (ASGPR)-mediated cellular uptake, high endosomal escaping ability and localization of the siRNA in cytoplasm, resulting in significant TTR silencing in HepG2 cells. Polyethylene Glycols 0-3 transthyretin Homo sapiens 77-80 30553273-9 2018 Technetium pyrophosphate scintigraphy indicated marked diffuse myocardial uptake of technetium pyrophosphate, strongly suggesting transthyretin cardiac amyloidosis, which was firmly confirmed by a left ventricular endomyocardial biopsy. technetium pyrophosphate 0-24 transthyretin Homo sapiens 130-143 30540442-2 2018 The native TTR tetramer (a dimer of dimers) is stabilized by packing of phenylalanine 87 (F87) into a hydrophobic cavity of a neighboring protomer across the strong dimer interface. Phenylalanine 72-85 transthyretin Homo sapiens 11-14 30540442-8 2018 Compared to the TTR tetramer in which the dimers are correctly packed, mispacking of one or both dimer pairs leads to an increase in the urea unfolding rate of 4-fold or at least 15-fold, respectively. Urea 137-141 transthyretin Homo sapiens 16-19 30553273-9 2018 Technetium pyrophosphate scintigraphy indicated marked diffuse myocardial uptake of technetium pyrophosphate, strongly suggesting transthyretin cardiac amyloidosis, which was firmly confirmed by a left ventricular endomyocardial biopsy. technetium pyrophosphate 84-108 transthyretin Homo sapiens 130-143 30553273-11 2018 Tafamidis, a transthyretin stabilizer, was started. tafamidis 0-9 transthyretin Homo sapiens 13-26 30274077-9 2018 Moreover, this study indicates that BTE using a SAP/nHA/CTS scaffold may be a novel prospective strategy for healing extensive bone defects. 2,1,3-Benzothiadiazol-4-amine 36-39 transthyretin Homo sapiens 48-59 30552363-7 2018 By using this C. elegans model system, we found that (-)-epigallocatechin-3-gallate, a major polyphenol in green tea, significantly inhibited the formation of aggregates, the defective motility, and the shortened lifespan caused by residues 81-127 of TTR. epigallocatechin gallate 53-83 transthyretin Homo sapiens 251-254 30638075-0 2018 Sudoscan in the evaluation and follow-up of patients and carriers with TTR mutations: experience from an Italian Centre. sudoscan 0-8 transthyretin Homo sapiens 71-74 29534342-4 2018 RESULTS: The serum TTR levels exhibited a statistically significant inverse correlation with interleukin-6 (r = -0.412, P = 0.041), and showed statistically significant correlations with retinol-binding protein (r = 0.919, P < 0.001) and albumin (r = 0.442, P = 0.027). Vitamin A 187-194 transthyretin Homo sapiens 19-22 30187524-1 2018 OBJECTIVE: Perineural injection with 5% dextrose (D5W) is a novel strategy in the treatment of carpal tunnel syndrome (CTS). Glucose 40-48 transthyretin Homo sapiens 119-122 30462941-0 2018 Oligonucleotide Drugs for Transthyretin Amyloidosis. Oligonucleotides 0-15 transthyretin Homo sapiens 26-39 30039176-1 2018 Transthyretin is a transport protein for thyroxine and retinol-binding protein, which is mainly produced in the liver. Thyroxine 41-50 transthyretin Homo sapiens 0-13 30226982-8 2018 Molecular dynamics and in silico alanine scanning simulation also suggested that the protein backbone of seabream TTR is more rigid than the human one and that Thr117 provides fewer electrostatic contributions than Ser117 to ligand binding. Alanine 33-40 transthyretin Homo sapiens 114-117 30093010-6 2018 The catalytic condition was extensively optimized among a range of pH and temperature, as well as initial concentrations of the substrate and H2O2, and MNP@CTS removed over 95% phenol from an aqueous solution within 5 h under the optimum conditions. Phenol 177-183 transthyretin Homo sapiens 152-159 30484623-0 2018 Oligonucleotide Drugs for Transthyretin Amyloidosis. Oligonucleotides 0-15 transthyretin Homo sapiens 26-39 30484624-0 2018 Oligonucleotide Drugs for Transthyretin Amyloidosis. Oligonucleotides 0-15 transthyretin Homo sapiens 26-39 31020184-1 2018 Background: Approximately 4% of the African-American population possess a valine-to-isoleucine (V122I) substitution within the transthyretin protein that results in a tendency for a normally tetrameric protein to dissociate into misfolded, monomeric subunits. Valine 74-80 transthyretin Homo sapiens 127-140 31020184-1 2018 Background: Approximately 4% of the African-American population possess a valine-to-isoleucine (V122I) substitution within the transthyretin protein that results in a tendency for a normally tetrameric protein to dissociate into misfolded, monomeric subunits. Isoleucine 84-94 transthyretin Homo sapiens 127-140 29499210-2 2018 To know how an ancient TTR had high affinity for THs, molecular and TH binding properties of lamprey TTRs were investigated. Thorium 49-52 transthyretin Homo sapiens 23-26 29499210-6 2018 [125I]T3 binding to wild type TTR and mutant TTRDelta3-11, was differentially modulated by Zn2+. Zinc 91-95 transthyretin Homo sapiens 30-33 29499210-7 2018 Zn2+ contents of wild type TTR were 7-10/TTR (mol/mol). Zinc 0-4 transthyretin Homo sapiens 27-30 29499210-7 2018 Zn2+ contents of wild type TTR were 7-10/TTR (mol/mol). Zinc 0-4 transthyretin Homo sapiens 41-44 29499210-9 2018 The N-terminal histidine-rich segment may be essential for neo-functionalization (i.e., high-affinity T3 binding activity) of an ancient TTR after gene duplication. Histidine 15-24 transthyretin Homo sapiens 137-140 30187524-1 2018 OBJECTIVE: Perineural injection with 5% dextrose (D5W) is a novel strategy in the treatment of carpal tunnel syndrome (CTS). Glucose 50-53 transthyretin Homo sapiens 119-122 30187524-12 2018 INTERPRETATION: Our study demonstrates that perineural injection of D5W is more beneficial than that of corticosteroid in patients with mild-to-moderate CTS at 4 to 6 months postinjection. Glucose 68-71 transthyretin Homo sapiens 153-156 28176254-0 2018 18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. 18fluorine sodium fluoride 0-26 transthyretin Homo sapiens 82-95 30198232-8 2018 A particularly noteworthy finding was that the valine at position 30 (Val30Met) mutation, which was previously reported as the most-common TTR mutation worldwide and also the most common in the Japanese population, was not detected in the present South Korean patients. Valine 47-53 transthyretin Homo sapiens 139-142 29687207-9 2018 CONCLUSION: Our evidence-based data demonstrate that bone scintigraphy using technetium-labelled radiotracers provides very high diagnostic accuracy in the non-invasive assessment of cardiac ATTR. technetium-labelled radiotracers 77-109 transthyretin Homo sapiens 191-195 30175839-0 2018 The mechanism and conformational changes of polybrominated diphenyl ethers to TTR by fluorescence spectroscopy, molecular simulation, and quantum chemistry. Phenyl Ethers 59-74 transthyretin Homo sapiens 78-81 30175839-2 2018 The interaction mechanism of TTR with different polybrominated diphenyl ethers (PBDEs), such as BDE49, BDE108 and BDE155, was studied by a variety of spectroscopic techniques and computer simulations. Halogenated Diphenyl Ethers 48-78 transthyretin Homo sapiens 29-32 30175839-2 2018 The interaction mechanism of TTR with different polybrominated diphenyl ethers (PBDEs), such as BDE49, BDE108 and BDE155, was studied by a variety of spectroscopic techniques and computer simulations. Halogenated Diphenyl Ethers 80-85 transthyretin Homo sapiens 29-32 30175839-5 2018 Quantum chemistry and energy contribution analysis of the ligand and residue LYS15 revealed that the binding was mainly due to the cation-pi formed by the C atom of the benzene ring and the polar residue LYS15 (NH3+) of TTR. Benzene 169-176 transthyretin Homo sapiens 220-223 30145929-0 2018 Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. tafamidis 0-9 transthyretin Homo sapiens 38-51 30298004-6 2018 The aim of this study was to prospectively evaluate a pharmacist"s warfarin management in patients with poor quality of anticoagulation therapy (Time in the Therapeutic Range- TTR < 50%). Warfarin 67-75 transthyretin Homo sapiens 176-179 30298004-15 2018 In conclusion, pharmaceutical care was able to improve TTR values in patients with AF and poor quality of anticoagulation with warfarin. Warfarin 127-135 transthyretin Homo sapiens 55-58 30388377-2 2018 Diflunisal, a nonsteroidal anti-inflammatory drug (NSAID), has demonstrated transthyretin stabilization in vitro and slowing of polyneuropathy progression in the hereditary ATTR subtype (ATTRm). Diflunisal 0-10 transthyretin Homo sapiens 173-177 30133298-5 2018 The same excited state dynamics was observed when 1 was generated by electron-transfer oxidation of 2 using different one-electron oxidants such as Cu(OTf)2 (OTf- = triflate anion), [Fe(bpy)3]3+ (bpy = 2,2"-bipyridine), and tris(4-bromophenyl)ammoniumyl radical cation (TBPA +). otf- 158-162 transthyretin Homo sapiens 270-274 30213975-0 2018 Copper mediated amyloid-beta binding to Transthyretin. Copper 0-6 transthyretin Homo sapiens 40-53 30213975-1 2018 Transthyretin (TTR), a homotetrameric protein that transports thyroxine and retinol both in plasma and in cerebrospinal (CSF) fluid provides a natural protective response against Alzheimer"s disease (AD), modulates amyloid-beta (Abeta) deposition by direct interaction and co-localizes with Abeta in plaques. Thyroxine 62-71 transthyretin Homo sapiens 0-13 30213975-1 2018 Transthyretin (TTR), a homotetrameric protein that transports thyroxine and retinol both in plasma and in cerebrospinal (CSF) fluid provides a natural protective response against Alzheimer"s disease (AD), modulates amyloid-beta (Abeta) deposition by direct interaction and co-localizes with Abeta in plaques. Thyroxine 62-71 transthyretin Homo sapiens 15-18 30213975-1 2018 Transthyretin (TTR), a homotetrameric protein that transports thyroxine and retinol both in plasma and in cerebrospinal (CSF) fluid provides a natural protective response against Alzheimer"s disease (AD), modulates amyloid-beta (Abeta) deposition by direct interaction and co-localizes with Abeta in plaques. Vitamin A 76-83 transthyretin Homo sapiens 0-13 30213975-1 2018 Transthyretin (TTR), a homotetrameric protein that transports thyroxine and retinol both in plasma and in cerebrospinal (CSF) fluid provides a natural protective response against Alzheimer"s disease (AD), modulates amyloid-beta (Abeta) deposition by direct interaction and co-localizes with Abeta in plaques. Vitamin A 76-83 transthyretin Homo sapiens 15-18 30213975-3 2018 Zn2+, Mn2+ and Fe2+ transform TTR into a protease able to cleave Abeta. Zinc 0-4 transthyretin Homo sapiens 30-33 30213975-3 2018 Zn2+, Mn2+ and Fe2+ transform TTR into a protease able to cleave Abeta. Manganese(2+) 6-10 transthyretin Homo sapiens 30-33 30213975-3 2018 Zn2+, Mn2+ and Fe2+ transform TTR into a protease able to cleave Abeta. ammonium ferrous sulfate 15-19 transthyretin Homo sapiens 30-33 30213975-5 2018 Here, we report that when TTR crystals are exposed to copper or iron salts, the tetramer undergoes a significant conformational change that alters the dimer-dimer interface and rearranges residues implicated in TTR"s ability to neutralize Abeta. Copper 54-60 transthyretin Homo sapiens 26-29 30213975-5 2018 Here, we report that when TTR crystals are exposed to copper or iron salts, the tetramer undergoes a significant conformational change that alters the dimer-dimer interface and rearranges residues implicated in TTR"s ability to neutralize Abeta. Copper 54-60 transthyretin Homo sapiens 211-214 30213975-5 2018 Here, we report that when TTR crystals are exposed to copper or iron salts, the tetramer undergoes a significant conformational change that alters the dimer-dimer interface and rearranges residues implicated in TTR"s ability to neutralize Abeta. ferric oxide 64-74 transthyretin Homo sapiens 26-29 30213975-5 2018 Here, we report that when TTR crystals are exposed to copper or iron salts, the tetramer undergoes a significant conformational change that alters the dimer-dimer interface and rearranges residues implicated in TTR"s ability to neutralize Abeta. ferric oxide 64-74 transthyretin Homo sapiens 211-214 30213975-6 2018 We also describe the conformational changes in TTR upon the binding of the various metal ions. Metals 83-88 transthyretin Homo sapiens 47-50 30213975-7 2018 Furthermore, using bio-layer interferometry (BLI) with immobilized Abeta(1-28), we observe the binding of TTR only in the presence of copper. Copper 134-140 transthyretin Homo sapiens 106-109 30213975-8 2018 Such Cu2+-dependent binding suggests a recognition mechanism whereby Cu2+ modulates both the TTR conformation, induces a complementary Abeta structure and may participate in the interaction. cupric ion 5-9 transthyretin Homo sapiens 93-96 30213975-8 2018 Such Cu2+-dependent binding suggests a recognition mechanism whereby Cu2+ modulates both the TTR conformation, induces a complementary Abeta structure and may participate in the interaction. cupric ion 69-73 transthyretin Homo sapiens 93-96 30213975-9 2018 Cu2+-soaked TTR crystals show a conformation different from that induced by Fe2+, and intriguingly, TTR crystals grown in presence of Abeta(1-28) show different positions for the copper sites from those grown its absence. cupric ion 0-4 transthyretin Homo sapiens 12-15 30213975-9 2018 Cu2+-soaked TTR crystals show a conformation different from that induced by Fe2+, and intriguingly, TTR crystals grown in presence of Abeta(1-28) show different positions for the copper sites from those grown its absence. Copper 179-185 transthyretin Homo sapiens 12-15 30213975-9 2018 Cu2+-soaked TTR crystals show a conformation different from that induced by Fe2+, and intriguingly, TTR crystals grown in presence of Abeta(1-28) show different positions for the copper sites from those grown its absence. Copper 179-185 transthyretin Homo sapiens 100-103 30233492-3 2018 The retinol circulating complex is transported in the bloodstream in the form of a trimolecular edifice made up of transthyretin (TTR), retinol-binding protein (RBP) and its retinol ligand. Vitamin A 4-11 transthyretin Homo sapiens 115-128 30233492-3 2018 The retinol circulating complex is transported in the bloodstream in the form of a trimolecular edifice made up of transthyretin (TTR), retinol-binding protein (RBP) and its retinol ligand. Vitamin A 4-11 transthyretin Homo sapiens 130-133 30233492-6 2018 The steep drop in TTR and RBP plasma values releases thyroxine and retinol ligands in their physiologically active forms, creating free pools estimated to be 10-20 times larger than those described in healthy subjects. Thyroxine 53-62 transthyretin Homo sapiens 18-21 30233492-6 2018 The steep drop in TTR and RBP plasma values releases thyroxine and retinol ligands in their physiologically active forms, creating free pools estimated to be 10-20 times larger than those described in healthy subjects. Vitamin A 67-74 transthyretin Homo sapiens 18-21 29310464-5 2018 Results Our results show elevated TTR concentrations after tafamidis treatment. tafamidis 59-68 transthyretin Homo sapiens 34-37 30388377-3 2018 However, the use of diflunisal has only been described in a small cohort of patients with ATTR cardiac amyloidosis (CA). Diflunisal 20-30 transthyretin Homo sapiens 90-94 30388377-4 2018 We hypothesized that selected patients with ATTR-CA, both hereditary and wild-type (ATTRwt), would tolerate diflunisal with limited adverse events. Diflunisal 108-118 transthyretin Homo sapiens 44-48 30388377-5 2018 MATERIALS AND METHODS: This is a retrospective, longitudinal study of 23 patients with ATTR-CA (10 ATTRm and 13 ATTRwt) diagnosed at the Cleveland Clinic from May 2007 to August 2017 who were treated with diflunisal. Diflunisal 205-215 transthyretin Homo sapiens 87-91 30388377-16 2018 Diflunisal can be safely used in a selected group of ATTR-CA patients with appropriate clinical, renal and hematologic monitoring. Diflunisal 0-10 transthyretin Homo sapiens 53-57 30486686-2 2018 99mTc-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD), initially developed as a bone-seeking radiotracer, is remarkably sensitive for imaging cardiac ATTR amyloid deposits. 3,3-diphosphono-1,2-propanodicarboxylic acid 15-59 transthyretin Homo sapiens 162-166 30486686-2 2018 99mTc-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD), initially developed as a bone-seeking radiotracer, is remarkably sensitive for imaging cardiac ATTR amyloid deposits. dpd 61-64 transthyretin Homo sapiens 162-166 30120737-1 2018 Ionis Pharmaceuticals and Akcea Therapeutics have developed inotersen (Tegsedi ), an antisense oligonucleotide inhibitor of mutant and wild-type human transthyretin (TTR), for the treatment of hereditary transthyretin amyloidosis (hATTR). Oligonucleotides 95-110 transthyretin Homo sapiens 166-169 29882023-0 2018 Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. epigallocatechin gallate 0-26 transthyretin Homo sapiens 92-105 29882023-4 2018 We sought to explore prognostic impact of EGCG in a cohort of lone cardiac ATTR patients. epigallocatechin gallate 42-46 transthyretin Homo sapiens 75-79 29882023-5 2018 From the Florence Tuscan Regional Amyloid Centre database, we retrospectively selected ATTR patients treated with EGCG (675mg daily dose) for a minimum of 9 months, between March 2013 and December 2016. epigallocatechin gallate 114-118 transthyretin Homo sapiens 87-91 29882023-13 2018 In a real-world cohort of ATTR patients with lone cardiac involvement, EGCG was a safe therapeutic option, but was not associated with survival improvement. epigallocatechin gallate 71-75 transthyretin Homo sapiens 26-30 29943762-5 2018 We present the case of an 80-year-old male diagnosed with non-hereditary cardiac ATTR by means of gammagraphy with 99mTc diphosfonate scintigraphy (99mTc-DPD) following the new criteria of non-invasive diagnosis. diphosfonate 121-133 transthyretin Homo sapiens 81-85 28050864-1 2018 BACKGROUND: Quantitative uptake of Technetium 99 m-pyrophosphate (TcPYP) is sensitive and specific for diagnosing transthyretin cardiac amyloidosis (ATTR). technetium 99 m-pyrophosphate 35-64 transthyretin Homo sapiens 149-153 30024734-2 2018 On the basis of in vitro and transgenic animal studies, transthyretin (TTR) is hypothesized to provide neuroprotection against Abeta toxicity by binding to Abeta and inhibiting its aggregation. UNII-042A8N37WH 127-132 transthyretin Homo sapiens 56-69 30024734-2 2018 On the basis of in vitro and transgenic animal studies, transthyretin (TTR) is hypothesized to provide neuroprotection against Abeta toxicity by binding to Abeta and inhibiting its aggregation. UNII-042A8N37WH 127-132 transthyretin Homo sapiens 71-74 30024734-3 2018 TTR is a homotetrameric protein that circulates in blood and cerebrospinal fluid; its normal physiological role is as a carrier for thyroxine and retinol-binding protein (RBP). Thyroxine 132-141 transthyretin Homo sapiens 0-3 28050864-1 2018 BACKGROUND: Quantitative uptake of Technetium 99 m-pyrophosphate (TcPYP) is sensitive and specific for diagnosing transthyretin cardiac amyloidosis (ATTR). tcpyp 66-71 transthyretin Homo sapiens 149-153 28050864-9 2018 CONCLUSION: In patients with suspected ATTR, quantitative and semiquantitative uptake intensity of TcPYP is associated with all-cause mortality as well as all-cause mortality or heart failure hospitalization. tcpyp 99-104 transthyretin Homo sapiens 39-43 28150156-0 2018 Technetium 99m pyrophosphate radioisotope for diagnosis and prognosis of transthyretin cardiac amyloidosis: A call for collaboration. technetium 99m pyrophosphate 0-28 transthyretin Homo sapiens 73-86 29972750-0 2018 Oligonucleotide Drugs for Transthyretin Amyloidosis. Oligonucleotides 0-15 transthyretin Homo sapiens 26-39 29941560-12 2018 Our studies of a unique duplication mutation explain its diflunisal-resistant nature, identify misfolding pathways for amyloidogenic TTR variants, and provide therapeutic targets to inhibit amyloid fibril formation by variant TTR. Diflunisal 57-67 transthyretin Homo sapiens 133-136 29941560-12 2018 Our studies of a unique duplication mutation explain its diflunisal-resistant nature, identify misfolding pathways for amyloidogenic TTR variants, and provide therapeutic targets to inhibit amyloid fibril formation by variant TTR. Diflunisal 57-67 transthyretin Homo sapiens 226-229 30093927-5 2018 We present a case of transthyretin-related cardiac amyloidosis with a negative endomyocardial biopsy but positive 99m-technetium pyrophosphate single photon emission computed tomography scan and cardiac magnetic resonance imaging. 99m-technetium pyrophosphate 114-142 transthyretin Homo sapiens 21-34 29972757-3 2018 Inotersen, a 2"- O-methoxyethyl-modified antisense oligonucleotide, inhibits hepatic production of transthyretin. 2"- o-methoxyethyl-modified 13-40 transthyretin Homo sapiens 99-112 29972757-3 2018 Inotersen, a 2"- O-methoxyethyl-modified antisense oligonucleotide, inhibits hepatic production of transthyretin. Oligonucleotides 51-66 transthyretin Homo sapiens 99-112 29804846-4 2018 The transthyretin levels exhibited statistically significant correlations with total protein (r = 0.598, P < 0.001), albumin (r = 0.626, P < 0.001), and retinol binding protein (r = 0.753, P < 0.001). Vitamin A 159-166 transthyretin Homo sapiens 4-17 29511839-9 2018 CONCLUSIONS: In TTR mutation carriers, cardiac sympathetic denervation evidenced by decreased MIBG uptake is detected earlier than amyloid burden evidenced by DPD. 3-Iodobenzylguanidine 94-98 transthyretin Homo sapiens 16-19 29511839-10 2018 These results raise the possibility of a diagnostic role for MIBG scintigraphy at an early stage of cardiac involvement in TTR-mutated carriers, in addition to its well-established prognostic value. 3-Iodobenzylguanidine 61-65 transthyretin Homo sapiens 123-126 29803981-0 2018 Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. Warfarin 50-58 transthyretin Homo sapiens 46-49 29626847-4 2018 TTR is a transporter of thyroxine and retinol in the blood and cerebrospinal fluid. Thyroxine 24-33 transthyretin Homo sapiens 0-3 29626847-4 2018 TTR is a transporter of thyroxine and retinol in the blood and cerebrospinal fluid. Vitamin A 38-45 transthyretin Homo sapiens 0-3 29958388-1 2018 In this study, ternary Cu2SnS3 (CTS) nanostructure materials with high crystallinity were successfully prepared via a facile solvothermal method, which was followed by high-temperature treatment. cu2sns3 23-30 transthyretin Homo sapiens 32-35 29958388-3 2018 Sodium storage measurements demonstrate that the annealed CTS electrodes have high initial reversible capacity (447.7 mAh&middot;g&minus;1 at a current density of 100 mA&middot;g&minus;1), good capacity retention (200.6 mAh&middot;g&minus;1 after 50 cycles at a current density of 100 mA&middot;g&minus;1) and considerable rate capability because of their high crystallinity and unique morphology. Sodium 0-6 transthyretin Homo sapiens 58-61 29958388-3 2018 Sodium storage measurements demonstrate that the annealed CTS electrodes have high initial reversible capacity (447.7 mAh&middot;g&minus;1 at a current density of 100 mA&middot;g&minus;1), good capacity retention (200.6 mAh&middot;g&minus;1 after 50 cycles at a current density of 100 mA&middot;g&minus;1) and considerable rate capability because of their high crystallinity and unique morphology. Adenosine Monophosphate 122-125 transthyretin Homo sapiens 58-61 29958388-3 2018 Sodium storage measurements demonstrate that the annealed CTS electrodes have high initial reversible capacity (447.7 mAh&middot;g&minus;1 at a current density of 100 mA&middot;g&minus;1), good capacity retention (200.6 mAh&middot;g&minus;1 after 50 cycles at a current density of 100 mA&middot;g&minus;1) and considerable rate capability because of their high crystallinity and unique morphology. Adenosine Monophosphate 135-138 transthyretin Homo sapiens 58-61 29958388-3 2018 Sodium storage measurements demonstrate that the annealed CTS electrodes have high initial reversible capacity (447.7 mAh&middot;g&minus;1 at a current density of 100 mA&middot;g&minus;1), good capacity retention (200.6 mAh&middot;g&minus;1 after 50 cycles at a current density of 100 mA&middot;g&minus;1) and considerable rate capability because of their high crystallinity and unique morphology. Adenosine Monophosphate 135-138 transthyretin Homo sapiens 58-61 29958388-3 2018 Sodium storage measurements demonstrate that the annealed CTS electrodes have high initial reversible capacity (447.7 mAh&middot;g&minus;1 at a current density of 100 mA&middot;g&minus;1), good capacity retention (200.6 mAh&middot;g&minus;1 after 50 cycles at a current density of 100 mA&middot;g&minus;1) and considerable rate capability because of their high crystallinity and unique morphology. Adenosine Monophosphate 135-138 transthyretin Homo sapiens 58-61 29958388-3 2018 Sodium storage measurements demonstrate that the annealed CTS electrodes have high initial reversible capacity (447.7 mAh&middot;g&minus;1 at a current density of 100 mA&middot;g&minus;1), good capacity retention (200.6 mAh&middot;g&minus;1 after 50 cycles at a current density of 100 mA&middot;g&minus;1) and considerable rate capability because of their high crystallinity and unique morphology. Adenosine Monophosphate 135-138 transthyretin Homo sapiens 58-61 29958388-3 2018 Sodium storage measurements demonstrate that the annealed CTS electrodes have high initial reversible capacity (447.7 mAh&middot;g&minus;1 at a current density of 100 mA&middot;g&minus;1), good capacity retention (200.6 mAh&middot;g&minus;1 after 50 cycles at a current density of 100 mA&middot;g&minus;1) and considerable rate capability because of their high crystallinity and unique morphology. Adenosine Monophosphate 135-138 transthyretin Homo sapiens 58-61 29958388-3 2018 Sodium storage measurements demonstrate that the annealed CTS electrodes have high initial reversible capacity (447.7 mAh&middot;g&minus;1 at a current density of 100 mA&middot;g&minus;1), good capacity retention (200.6 mAh&middot;g&minus;1 after 50 cycles at a current density of 100 mA&middot;g&minus;1) and considerable rate capability because of their high crystallinity and unique morphology. Adenosine Monophosphate 135-138 transthyretin Homo sapiens 58-61 29958388-3 2018 Sodium storage measurements demonstrate that the annealed CTS electrodes have high initial reversible capacity (447.7 mAh&middot;g&minus;1 at a current density of 100 mA&middot;g&minus;1), good capacity retention (200.6 mAh&middot;g&minus;1 after 50 cycles at a current density of 100 mA&middot;g&minus;1) and considerable rate capability because of their high crystallinity and unique morphology. Adenosine Monophosphate 135-138 transthyretin Homo sapiens 58-61 29520877-6 2018 In the non-pathogenic group, we only found two mutations, including TTR Gly6Ser and TTR Thr119Thr. thr119thr 88-97 transthyretin Homo sapiens 84-87 30034649-5 2018 While the expression level of TTR is significantly decreased in OCD patients before any treatments, the trend is partially normalized after treatment with fluoxetine in positive responders. Fluoxetine 155-165 transthyretin Homo sapiens 30-33 29747616-0 2018 Association of retinol binding protein 4 and transthyretin with triglyceride levels and insulin resistance in rural thais with high type 2 diabetes risk. Triglycerides 64-76 transthyretin Homo sapiens 45-58 29747616-5 2018 RESULTS: RBP4 and TTR levels, as well as homeostatic model assessment of insulin resistance (HOMA-IR) values, were significantly elevated among subjects with high triglyceride levels (p < 0.01, p < 0.05, p < 0.05, respectively). Triglycerides 163-175 transthyretin Homo sapiens 18-21 29747616-6 2018 Triglyceride levels correlated with RBP4 (r = 0.34, p < 0.001) and TTR (r = 0.26, p < 0.01) levels, as well as HOMA-IR values (r = 0.16, p < 0.05). Triglycerides 0-12 transthyretin Homo sapiens 70-73 29747616-9 2018 The correlation between TTR and blood glucose was statistically significant (r = 0.18, p < 0.05), but not found this relationship in RBP4. Glucose 38-45 transthyretin Homo sapiens 24-27 29249054-7 2018 Indeed, positive results have just been released from 2 phase III trials on TTR gene modifiers, namely silencing RNA and antisense oligonucleotide therapies. Oligonucleotides 131-146 transthyretin Homo sapiens 76-79 29161598-12 2018 Taken together, selenium could ameliorate DEHP-caused TH dyshomeostasis via modulations of the redox status, Dio1, TTR, TRHr, and hepatic enzymes. Selenium 16-24 transthyretin Homo sapiens 115-118 29306024-0 2018 Organophosphate triesters and selected metabolites enhance binding of thyroxine to human transthyretin in vitro. organophosphate triesters 0-25 transthyretin Homo sapiens 89-102 29427707-3 2018 Triclosan (TCS), bisphenol-A (BPA), and technical nonylphenol (TNP) had affinity for the TTR with relative potencies of 0.3, 0.03, and 0.076 respectively. Triclosan 0-9 transthyretin Homo sapiens 89-92 29427707-3 2018 Triclosan (TCS), bisphenol-A (BPA), and technical nonylphenol (TNP) had affinity for the TTR with relative potencies of 0.3, 0.03, and 0.076 respectively. Triclosan 11-14 transthyretin Homo sapiens 89-92 29427707-3 2018 Triclosan (TCS), bisphenol-A (BPA), and technical nonylphenol (TNP) had affinity for the TTR with relative potencies of 0.3, 0.03, and 0.076 respectively. bisphenol A 17-28 transthyretin Homo sapiens 89-92 29427707-3 2018 Triclosan (TCS), bisphenol-A (BPA), and technical nonylphenol (TNP) had affinity for the TTR with relative potencies of 0.3, 0.03, and 0.076 respectively. bisphenol A 30-33 transthyretin Homo sapiens 89-92 29427707-3 2018 Triclosan (TCS), bisphenol-A (BPA), and technical nonylphenol (TNP) had affinity for the TTR with relative potencies of 0.3, 0.03, and 0.076 respectively. nonylphenol 50-61 transthyretin Homo sapiens 89-92 29427707-3 2018 Triclosan (TCS), bisphenol-A (BPA), and technical nonylphenol (TNP) had affinity for the TTR with relative potencies of 0.3, 0.03, and 0.076 respectively. IP3K Inhibitor 63-66 transthyretin Homo sapiens 89-92 29161598-10 2018 However, selenium supplementation led to elevations of selenium, Dio1 and TTR, and reductions of Ugt1a1, Sult1e1, CYP2b1, and TRHr. Selenium 9-17 transthyretin Homo sapiens 74-77 29427707-4 2018 Further, binding to TTR was the only toxicological response observed for carbamazepine, which induced sub-maximal response and relative potency of 0.0017. Carbamazepine 73-86 transthyretin Homo sapiens 20-23 29520480-8 2018 Bone scintigraphy with 99mTc-PYP or 99mTc-DPD can be a useful tool with high sensitivity and specificity for detecting TTR-related cardiac amyloidosis in patients with HFpEF. 99mtc-pyp 23-32 transthyretin Homo sapiens 119-122 29520480-8 2018 Bone scintigraphy with 99mTc-PYP or 99mTc-DPD can be a useful tool with high sensitivity and specificity for detecting TTR-related cardiac amyloidosis in patients with HFpEF. 99mtc-dpd 36-45 transthyretin Homo sapiens 119-122 29306024-0 2018 Organophosphate triesters and selected metabolites enhance binding of thyroxine to human transthyretin in vitro. Thyroxine 70-79 transthyretin Homo sapiens 89-102 29407121-0 2018 Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: An underestimated phenomenon. 99mtc-hydroxymethylene diphosphonate 19-55 transthyretin Homo sapiens 85-88 29599825-14 2018 Smoking, alcohol and diabetes mellitus can be predictors of moderate and severe CTS. Alcohols 9-16 transthyretin Homo sapiens 80-83 29383369-6 2018 Transposition of the optimized conditions, developed with BApNA, to TTR digestion in the TE-based trypsin microreactor was successfully performed. Tellurium 89-91 transthyretin Homo sapiens 68-71 29360284-2 2018 In certain patients, MP accumulation is systemic (e.g. TTR amyloid), and in others, this is localized to a specific cell type (e.g. Alzheimer"s disease). mp 21-23 transthyretin Homo sapiens 55-58 29449366-9 2018 Further, TTR values at 1- and 2-year follow-ups were significantly lower (P<0.001) in untreated patients (n=23) compared with those treated with TTR stabilizer, diflunisal (n=12), after baseline evaluation. Diflunisal 164-174 transthyretin Homo sapiens 9-12 29449366-10 2018 During 2-year follow-up, unchanged TTR corresponded to increased cTn-I (P=0.006) in untreated patients; conversely, the diflunisal-treated group showed increased TTR (P=0.001) and stabilized cTn-I and left ventricular ejection fraction at 1 year. Diflunisal 120-130 transthyretin Homo sapiens 162-165 27580616-0 2018 Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. 99mtechnetium pyrophosphate 19-46 transthyretin Homo sapiens 79-82 27580616-1 2018 BACKGROUND: Technetium pyrophosphate (99mTc-PYP) imaging to diagnose transthyretin cardiac amyloidosis (ATTR-CA) has been increasingly utilized. technetium pyrophosphate 12-36 transthyretin Homo sapiens 104-108 27650442-0 2018 Erratum to: Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. 99mtechnetium pyrophosphate 31-58 transthyretin Homo sapiens 91-94 28917675-0 2018 Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality. technetium pyrophosphate 22-46 transthyretin Homo sapiens 57-70 28917675-1 2018 OBJECTIVES: This study sought to investigate the regional uptake of technetium 99m-pyrophosphate (TcPYP) in transthyretin cardiac amyloidosis (ATTR) and its association with mortality. technetium 99m-pyrophosphate 68-96 transthyretin Homo sapiens 108-121 28917675-1 2018 OBJECTIVES: This study sought to investigate the regional uptake of technetium 99m-pyrophosphate (TcPYP) in transthyretin cardiac amyloidosis (ATTR) and its association with mortality. technetium 99m-pyrophosphate 68-96 transthyretin Homo sapiens 143-147 28917675-1 2018 OBJECTIVES: This study sought to investigate the regional uptake of technetium 99m-pyrophosphate (TcPYP) in transthyretin cardiac amyloidosis (ATTR) and its association with mortality. tcpyp 98-103 transthyretin Homo sapiens 108-121 28917675-1 2018 OBJECTIVES: This study sought to investigate the regional uptake of technetium 99m-pyrophosphate (TcPYP) in transthyretin cardiac amyloidosis (ATTR) and its association with mortality. tcpyp 98-103 transthyretin Homo sapiens 143-147 28917675-2 2018 BACKGROUND: TcPYP nuclear scintigraphy is a diagnostic and prognostic tool in ATTR. tcpyp 12-17 transthyretin Homo sapiens 78-82 28917675-4 2018 METHODS: Consecutive patients with ATTR were evaluated who underwent TcPYP nuclear scintigraphy with planar and attenuation corrected single-photon emission computed tomography (SPECT). tcpyp 69-74 transthyretin Homo sapiens 35-39 29607936-9 2018 Moreover, we found that STT3B-dependent posttranslational N-glycosylation at N98 residue occurred in G101S TTR but not in other TTR variants, possibly due to amino acid alterations that increase N-glycosylation preference or accelerate rigid structure formation susceptible to N-glycosylation. N98 77-80 transthyretin Homo sapiens 107-110 28960480-0 2018 Evidence that glial cells attenuate G47R transthyretin accumulation in the central nervous system. g47r 36-40 transthyretin Homo sapiens 41-54 28960480-12 2018 The vascular expressions of type IV collagen and smooth muscle actin were severely reduced in areas with ATTR G47R deposition, but not in areas with Abeta deposition. g47r 110-114 transthyretin Homo sapiens 105-109 29607936-1 2018 Transthyretin (TTR) is a tetrameric beta-sheet-rich protein that is important in the plasma transport of thyroxine and retinol. Thyroxine 105-114 transthyretin Homo sapiens 0-13 29607936-9 2018 Moreover, we found that STT3B-dependent posttranslational N-glycosylation at N98 residue occurred in G101S TTR but not in other TTR variants, possibly due to amino acid alterations that increase N-glycosylation preference or accelerate rigid structure formation susceptible to N-glycosylation. N98 77-80 transthyretin Homo sapiens 128-131 29607936-1 2018 Transthyretin (TTR) is a tetrameric beta-sheet-rich protein that is important in the plasma transport of thyroxine and retinol. Thyroxine 105-114 transthyretin Homo sapiens 15-18 29607936-1 2018 Transthyretin (TTR) is a tetrameric beta-sheet-rich protein that is important in the plasma transport of thyroxine and retinol. Vitamin A 119-126 transthyretin Homo sapiens 0-13 29607936-1 2018 Transthyretin (TTR) is a tetrameric beta-sheet-rich protein that is important in the plasma transport of thyroxine and retinol. Vitamin A 119-126 transthyretin Homo sapiens 15-18 29607936-9 2018 Moreover, we found that STT3B-dependent posttranslational N-glycosylation at N98 residue occurred in G101S TTR but not in other TTR variants, possibly due to amino acid alterations that increase N-glycosylation preference or accelerate rigid structure formation susceptible to N-glycosylation. Nitrogen 77-78 transthyretin Homo sapiens 107-110 29607936-8 2018 Cycloheximide (CHX)-based assay in HEK293 cells revealed that intracellular G101S TTR expression level was lower, but extracellular expression was higher than WT TTR, implying enhanced secretion efficiency of G101S TTR protein compared with WT TTR. Cycloheximide 0-13 transthyretin Homo sapiens 82-85 29607936-9 2018 Moreover, we found that STT3B-dependent posttranslational N-glycosylation at N98 residue occurred in G101S TTR but not in other TTR variants, possibly due to amino acid alterations that increase N-glycosylation preference or accelerate rigid structure formation susceptible to N-glycosylation. Nitrogen 77-78 transthyretin Homo sapiens 107-110 29607936-8 2018 Cycloheximide (CHX)-based assay in HEK293 cells revealed that intracellular G101S TTR expression level was lower, but extracellular expression was higher than WT TTR, implying enhanced secretion efficiency of G101S TTR protein compared with WT TTR. Cycloheximide 15-18 transthyretin Homo sapiens 82-85 30504675-0 2018 Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects. Oligonucleotides 19-34 transthyretin Homo sapiens 53-66 29607936-9 2018 Moreover, we found that STT3B-dependent posttranslational N-glycosylation at N98 residue occurred in G101S TTR but not in other TTR variants, possibly due to amino acid alterations that increase N-glycosylation preference or accelerate rigid structure formation susceptible to N-glycosylation. Nitrogen 58-59 transthyretin Homo sapiens 107-110 30504675-5 2018 Therefore, an oligonucleotide-based therapy for ATTR-FAP, which reduces the production of TTR by the liver, has recently been developed in preclinical and clinical studies. Oligonucleotides 14-29 transthyretin Homo sapiens 49-52 28249735-8 2017 Of these THDPs, TTR is the only one known to be synthesised in the brain and is involved in moving THs from the blood into the cerebrospinal fluid. thdps 9-14 transthyretin Homo sapiens 16-19 29288196-0 2018 Hydroxychloroquine-Mediated Cardiotoxicity With a False-Positive 99mTechnetium-Labeled Pyrophosphate Scan for Transthyretin-Related Cardiac Amyloidosis. Hydroxychloroquine 0-18 transthyretin Homo sapiens 110-123 29288196-0 2018 Hydroxychloroquine-Mediated Cardiotoxicity With a False-Positive 99mTechnetium-Labeled Pyrophosphate Scan for Transthyretin-Related Cardiac Amyloidosis. Technetium 65-78 transthyretin Homo sapiens 110-123 29288196-0 2018 Hydroxychloroquine-Mediated Cardiotoxicity With a False-Positive 99mTechnetium-Labeled Pyrophosphate Scan for Transthyretin-Related Cardiac Amyloidosis. diphosphoric acid 87-100 transthyretin Homo sapiens 110-123 29780234-2 2018 The aim of this study is to evaluate the body mass index (BMI) and vitamin D levels in CTS patients. Vitamin D 67-76 transthyretin Homo sapiens 87-90 29780234-9 2018 Those with severe CTS had a significantly higher BMI and lower vitamin D levels than the others (p = 0.03 and p = 0.01 respectively). Vitamin D 63-72 transthyretin Homo sapiens 18-21 30504105-5 2018 The aim of this work was to assess the utility of 99m Tc-phosphate tracers for the diagnosis of ATTR. tc-phosphate 54-66 transthyretin Homo sapiens 96-100 28249735-9 2017 We analysed the rates of evolution of these three THDPs: TTR has been most highly conserved and albumin has had the highest rate of divergence. thdps 50-55 transthyretin Homo sapiens 57-60 29240759-2 2017 In this work, human transthyretin (TTR), a homotetrameric plasma transport protein with two binding sites for the thyroid hormone thyroxine (T4), is considered as a case study. Thyroxine 130-139 transthyretin Homo sapiens 20-33 29240759-2 2017 In this work, human transthyretin (TTR), a homotetrameric plasma transport protein with two binding sites for the thyroid hormone thyroxine (T4), is considered as a case study. Thyroxine 130-139 transthyretin Homo sapiens 35-38 29016222-3 2017 We re-examined proteomics results from a number of formalin-fixed paraffin-embedded amyloid samples, which were positive for transthyretin (TTR) by immunohistochemistry and proteomics, using the UniProt human protein database modified to include TTR variants. Formaldehyde 51-59 transthyretin Homo sapiens 125-138 29016222-3 2017 We re-examined proteomics results from a number of formalin-fixed paraffin-embedded amyloid samples, which were positive for transthyretin (TTR) by immunohistochemistry and proteomics, using the UniProt human protein database modified to include TTR variants. Formaldehyde 51-59 transthyretin Homo sapiens 140-143 28906148-6 2017 Compared to the general population, both THA and TKA were significantly more common among patients with ATTR-CA (THA: RR 5.61, 95% CI 2.25-4.64; TKA: RR 3.32, 95% CI 2.25-4.64) but not those with AL-CA (THA: RR 1.87, 95% CI 0.85-4.08; TKA: RR 1.42, 95% CI 0.73-2.84). Aluminum 196-198 transthyretin Homo sapiens 104-108 28906150-0 2017 Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Oligonucleotides 48-63 transthyretin Homo sapiens 25-28 28906150-0 2017 Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Oligonucleotides 48-63 transthyretin Homo sapiens 81-94 28906150-4 2017 METHODS: The present study was designed to prospectively monitor changes in cardiac parameters, both structural and functional, in patients with ATTR cardiomyopathy while treated with a TTR specific antisense oligonucleotide (ASO; IONIS-TTRRx) designed to lower blood levels of the amyloid fibril precursor protein. Oligonucleotides 209-224 transthyretin Homo sapiens 146-149 28906150-4 2017 METHODS: The present study was designed to prospectively monitor changes in cardiac parameters, both structural and functional, in patients with ATTR cardiomyopathy while treated with a TTR specific antisense oligonucleotide (ASO; IONIS-TTRRx) designed to lower blood levels of the amyloid fibril precursor protein. Oligonucleotides, Antisense 226-229 transthyretin Homo sapiens 146-149 29016222-3 2017 We re-examined proteomics results from a number of formalin-fixed paraffin-embedded amyloid samples, which were positive for transthyretin (TTR) by immunohistochemistry and proteomics, using the UniProt human protein database modified to include TTR variants. Paraffin 66-74 transthyretin Homo sapiens 140-143 29016222-4 2017 The amyloidogenic variant, V122I TTR, was incorrectly identified in 26/27 wild-type and non-V122I variant samples due to its close mass spectral similarity with the methyl lysine-modified WT peptide [126KMe]105-127 (p.[146 KMe]125-147) generated during formalin fixation. Lysine 172-178 transthyretin Homo sapiens 33-36 29016222-4 2017 The amyloidogenic variant, V122I TTR, was incorrectly identified in 26/27 wild-type and non-V122I variant samples due to its close mass spectral similarity with the methyl lysine-modified WT peptide [126KMe]105-127 (p.[146 KMe]125-147) generated during formalin fixation. Formaldehyde 253-261 transthyretin Homo sapiens 33-36 29264721-3 2017 OBJECTIVE: Our objective was to assess the effects of LAC on neuroprotection, pain, and function in carpal tunnel syndrome (CTS), a very frequent chronic compressive neuropathy. Acetylcarnitine 54-57 transthyretin Homo sapiens 124-127 29264721-13 2017 LAC reduced pain in patients with mild and moderate CTS, a result that is possibly due to both its neuroprotective action and its central anti-nociceptive properties. Acetylcarnitine 0-3 transthyretin Homo sapiens 52-55 29290976-2 2017 Here, we present evidence that neuron-derived transthyretin (TTR) stimulates expression of glycolytic enzymes in astrocytes which is reflected by an increased synthesis of ATP. Adenosine Triphosphate 172-175 transthyretin Homo sapiens 46-59 28326465-3 2017 We present a case of a man with ATTR studied with [18F]-florbetaben PET-CT. 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 50-67 transthyretin Homo sapiens 32-36 29155884-2 2017 Quality in warfarin therapy is often summarized by the time patients spend within the therapeutic range (percent time in therapeutic range, TTR). Warfarin 11-19 transthyretin Homo sapiens 140-143 29155884-3 2017 The correlation between TTR and the occurrence of complications during warfarin therapy has been established, but the influence of patient characteristics in that respect remains undetermined. Warfarin 71-79 transthyretin Homo sapiens 24-27 29155884-14 2017 CONCLUSIONS: Although higher mean TTR in warfarin therapy was associated with lower complication rates in atrial fibrillation, the strength of the association was decreased when adjusting for differences in relevant clinical characteristics of the patient cohorts. Warfarin 41-49 transthyretin Homo sapiens 34-37 29155884-15 2017 This study suggests that mainly the safety of warfarin therapy increases with higher mean TTR, whereas effectiveness appears not to be substantially improved. Warfarin 46-54 transthyretin Homo sapiens 90-93 29290976-2 2017 Here, we present evidence that neuron-derived transthyretin (TTR) stimulates expression of glycolytic enzymes in astrocytes which is reflected by an increased synthesis of ATP. Adenosine Triphosphate 172-175 transthyretin Homo sapiens 61-64 29290976-5 2017 TTR induced expression of PKM and PFK is mediated by the cAMP/PKA-dependent pathway and is antagonized by the PI3K/Akt pathway. Cyclic AMP 57-61 transthyretin Homo sapiens 0-3 29290976-7 2017 The data presented here suggest that TTR is involved in a mechanism in which neurons stimulate degradation of glycogen-derived glucosyl units without significant modulation of glucose uptake by glial cells. Glycogen 110-118 transthyretin Homo sapiens 37-40 29068665-1 2017 We produced a functional polymer whose framework comprised transthyretin (TTR) amyloid fibrils. Polymers 25-32 transthyretin Homo sapiens 59-72 29226076-1 2017 Transthyretin (TTR) is a transporter for thyroid hormone (TH) and retinol, the latter via binding with retinol binding protein (RBP). Vitamin A 66-73 transthyretin Homo sapiens 15-18 29068665-1 2017 We produced a functional polymer whose framework comprised transthyretin (TTR) amyloid fibrils. Polymers 25-32 transthyretin Homo sapiens 74-77 29184431-4 2017 TTR is a protein produced in the liver, and functions as a carrier for retinol-binding protein and also thyroxine. Thyroxine 104-113 transthyretin Homo sapiens 0-3 29283575-6 2018 This model para-OH-TB-DiPhOBz was found to be capable of competing with thyroxine (T4) for the binding site on hTTR and hALB. para-oh-tb-diphobz 11-29 transthyretin Homo sapiens 111-115 29283575-6 2018 This model para-OH-TB-DiPhOBz was found to be capable of competing with thyroxine (T4) for the binding site on hTTR and hALB. Thyroxine 72-81 transthyretin Homo sapiens 111-115 28256403-2 2017 99mTc-DPD has been shown to be highly sensitive for cardiac transthyretin (ATTR) amyloid in an overseas population, but is not registered for use in Australia. 99mtc-dpd 0-9 transthyretin Homo sapiens 75-79 29283575-8 2018 This analysis found all three TB-DiPhOBz analogues to be potential ligands for gull TTR and have similar binding efficacies to THs. Terbium 30-32 transthyretin Homo sapiens 84-87 29283575-8 2018 This analysis found all three TB-DiPhOBz analogues to be potential ligands for gull TTR and have similar binding efficacies to THs. diphobz 33-40 transthyretin Homo sapiens 84-87 29102992-8 2017 Multivariable linear regression adjusting for age, sex, ethnicity, duration of CTS, smoking status, alcohol consumption, employment status, body mass index and comorbidities showed a highly statistically significant relationship between CTS-6 and anxiety, depression and the EQ-5D (p<0.0001 in each case). Alcohols 100-107 transthyretin Homo sapiens 237-240 28256403-16 2017 CONCLUSIONS: 99mTc-DPD scintigraphy is highly sensitive for the diagnosis of cardiac ATTR amyloid, but less so for AL amyloid. 99mtc-dpd 13-22 transthyretin Homo sapiens 85-89 28985740-5 2017 RESULTS: Here we have designed an amyloidogenic peptide based on the TTR105-115 fragment of transthyretin to form fibrils that display an alkyne functionality, important for bioorthogonal chemical reactions, on their surface. Alkynes 138-144 transthyretin Homo sapiens 69-72 28688921-0 2017 Plasma Retinol Concentration Is Mainly Driven by Transthyretin in Hemodialysis Patients. Vitamin A 7-14 transthyretin Homo sapiens 49-62 28688921-7 2017 MAIN OUTCOME MEASURE: Plasma concentration of lipophilic micronutrients retinol and its two co-transporters transthyretin and retinol-binding protein 4, tocopherol, and carotenoids (alpha-carotene and beta-carotene, beta-cryptoxanthin, lycopene, lutein, and zeaxanthin), and all factors associated with 1-year mortality. Vitamin A 72-79 transthyretin Homo sapiens 108-121 28688921-12 2017 Nevertheless, the correlation between retinol and mortality disappeared as soon as transthyretin was added in the statistical model, suggesting an effect of transthyretin as confusing bias. Vitamin A 38-45 transthyretin Homo sapiens 83-96 28688921-12 2017 Nevertheless, the correlation between retinol and mortality disappeared as soon as transthyretin was added in the statistical model, suggesting an effect of transthyretin as confusing bias. Vitamin A 38-45 transthyretin Homo sapiens 157-170 29124017-0 2017 Optimization of an in vitro assay methodology for competitive binding of thyroidogenic xenobiotics with thyroxine on human transthyretin and albumin. Thyroxine 104-113 transthyretin Homo sapiens 123-136 28920433-3 2017 To obtain such information, tryptophan labeled with fluorine at the 5 and 6 positions (5FW and 6FW) was incorporated into TTR. Fluorine 52-60 transthyretin Homo sapiens 122-125 28920433-4 2017 Fluorescence of 5FW and 6FW-labeled WT-TTR (WT-5FW and WT-6FW) and a single-Trp mutant W41Y showed that the photophysics of incorporated fluoro-Trp is consistent with site-specific solvation of the indole ring of W41 and W79. Tryptophan 144-147 transthyretin Homo sapiens 39-42 28920433-10 2017 The differences in behavior that arise from the replacement of a fluorine at the 5-position of a tryptophan with one at the adjacent 6-position emphasize the delicate balance of stability in the TTR tetramer. Fluorine 65-73 transthyretin Homo sapiens 195-198 28920433-10 2017 The differences in behavior that arise from the replacement of a fluorine at the 5-position of a tryptophan with one at the adjacent 6-position emphasize the delicate balance of stability in the TTR tetramer. Tryptophan 97-107 transthyretin Homo sapiens 195-198 28622647-2 2017 PFASs can compete with thyroxine (T4) for binding to the human thyroid hormone transport protein transthyretin (TTR) which may lead to reduce thyroid hormone levels leading to endocrine disrupting adverse effects. Thyroxine 23-32 transthyretin Homo sapiens 97-110 28622647-2 2017 PFASs can compete with thyroxine (T4) for binding to the human thyroid hormone transport protein transthyretin (TTR) which may lead to reduce thyroid hormone levels leading to endocrine disrupting adverse effects. Thyroxine 23-32 transthyretin Homo sapiens 112-115 28920684-0 2017 Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation. stilbene boronic acids 0-22 transthyretin Homo sapiens 55-68 28552837-7 2017 In the mild CTS patients, vitamin D levels were significantly lower than those electrophysiologically normal patients (P=0.003). Vitamin D 26-35 transthyretin Homo sapiens 12-15 28552837-9 2017 There was no significant relationship between the pain and vitamin D levels in the normal group, while vitamin D level was significantly lower in the mild CTS group (P=0.730 and P=0.002; respectively). Vitamin D 103-112 transthyretin Homo sapiens 155-158 28552837-10 2017 DISCUSSION: Vitamin D deficiency increases the pain intensity in patients with CTS. Vitamin D 12-21 transthyretin Homo sapiens 79-82 28552837-12 2017 Further studies involving analyses of post-vitamin D replacement therapy are warranted to confirm the association between vitamin D deficiency and pain due to CTS. Vitamin D 122-131 transthyretin Homo sapiens 159-162 28920433-0 2017 Fluorotryptophan Incorporation Modulates the Structure and Stability of Transthyretin in a Site-Specific Manner. fluorotryptophan 0-16 transthyretin Homo sapiens 72-85 28920433-3 2017 To obtain such information, tryptophan labeled with fluorine at the 5 and 6 positions (5FW and 6FW) was incorporated into TTR. Tryptophan 28-38 transthyretin Homo sapiens 122-125 28396999-12 2017 CONCLUSION: Among men undergoing a 2-year repeat prostate biopsy, the use of dutasteride for 2 years was associated with a reduced the risk of overall and severe TBPA-UTI. Dutasteride 77-88 transthyretin Homo sapiens 162-166 29870623-1 2017 Background and purpose: This study aimed to assess the correlation between vitamin D deficiency and electrophysiological findings and pain level in patients with symptoms of carpal tunnel syndrome (CTS). Vitamin D 75-84 transthyretin Homo sapiens 198-201 29870623-5 2017 Results: Although the rate of CTS in the patients with a low vitamin D level was found to be high, no statistically significant correlation was observed between low vitamin D level and the frequency and severity of CTS. Vitamin D 61-70 transthyretin Homo sapiens 30-33 29870623-6 2017 Additionally, the pain and functional loss ratio induced by CTS was found to be higher in the group with a lower vitamin D level than in the group with normal levels. Vitamin D 113-122 transthyretin Homo sapiens 60-63 29870623-7 2017 Conclusion: Low vitamin D levels may increase the severity of CTS symptoms. Vitamin D 16-25 transthyretin Homo sapiens 62-65 29870623-8 2017 Treatment of vitamin D deficiency in patients with CTS can play a role in reducing pain and disability. Vitamin D 13-22 transthyretin Homo sapiens 51-54 28920684-4 2017 Herein, we report on boronic acid-substituted stilbenes that limit TTR amyloidosis in vitro. Boronic Acids 21-33 transthyretin Homo sapiens 67-70 28920684-4 2017 Herein, we report on boronic acid-substituted stilbenes that limit TTR amyloidosis in vitro. Stilbenes 46-55 transthyretin Homo sapiens 67-70 28920684-7 2017 This diboronic acid inhibits fibril formation by both wild-type TTR and a common disease-related variant, V30M TTR, as effectively as does tafamidis, a small-molecule drug used to treat TTR-related amyloidosis in the clinic. diboronic acid 5-19 transthyretin Homo sapiens 64-67 28920684-7 2017 This diboronic acid inhibits fibril formation by both wild-type TTR and a common disease-related variant, V30M TTR, as effectively as does tafamidis, a small-molecule drug used to treat TTR-related amyloidosis in the clinic. diboronic acid 5-19 transthyretin Homo sapiens 111-114 28920684-7 2017 This diboronic acid inhibits fibril formation by both wild-type TTR and a common disease-related variant, V30M TTR, as effectively as does tafamidis, a small-molecule drug used to treat TTR-related amyloidosis in the clinic. diboronic acid 5-19 transthyretin Homo sapiens 111-114 28508350-3 2017 18F labeled and 11C labeled amyloid binding radiotracers developed for imaging Alzheimer"s disease, have been repurposed since 2013, to image light chain and transthyretin cardiac amyloidosis. Carbon-11 16-19 transthyretin Homo sapiens 158-171 28951406-9 2017 CONCLUSION: The implementation of a clinical pathway and OSS for the management of CTS was safe with good long-term symptom relief and high patient satisfaction. OSS 57-60 transthyretin Homo sapiens 83-86 28820582-4 2017 Analyses of the 13C-13C correlation solid-state NMR spectra revealed that WT TTR aggregates contain an amyloid core consisting of nativelike CBEF and DAGH beta-sheet structures, and the mutant TTR amyloids adopt a similar amyloid core structure with nativelike CBEF and AGH beta-structures. 13c 16-19 transthyretin Homo sapiens 77-80 28820582-4 2017 Analyses of the 13C-13C correlation solid-state NMR spectra revealed that WT TTR aggregates contain an amyloid core consisting of nativelike CBEF and DAGH beta-sheet structures, and the mutant TTR amyloids adopt a similar amyloid core structure with nativelike CBEF and AGH beta-structures. 13c 20-23 transthyretin Homo sapiens 77-80 28501163-2 2017 The IA sorbent was prepared by covalent attachment of Fab" fragments obtained from a polyclonal IgG antibody against TTR to succinimidyl silica particles. succinimidyl silica 124-143 transthyretin Homo sapiens 117-120 28051995-7 2017 In comparison to healthy control iPS cells, we demonstrated the formation of transthyretin amyloid fibril-like structures in FAP HLC supernatants using the amyloid-specific dyes Congo red and thioflavin T. Congo Red 178-187 transthyretin Homo sapiens 77-90 28051995-7 2017 In comparison to healthy control iPS cells, we demonstrated the formation of transthyretin amyloid fibril-like structures in FAP HLC supernatants using the amyloid-specific dyes Congo red and thioflavin T. thioflavin T 192-204 transthyretin Homo sapiens 77-90 28434967-1 2017 BACKGROUND: The cysteine residue on transthyretin (TTR) is susceptible to be oxidized, and serum cysteinylated TTR (Cys-TTR) level is thought to reflect oxidative stress. Cysteine 16-24 transthyretin Homo sapiens 36-49 28434967-1 2017 BACKGROUND: The cysteine residue on transthyretin (TTR) is susceptible to be oxidized, and serum cysteinylated TTR (Cys-TTR) level is thought to reflect oxidative stress. Cysteine 16-24 transthyretin Homo sapiens 51-54 28434967-2 2017 The purpose of this study was to elucidate the relationship between Cys-TTR and arterial stiffness, a known predictor of cardiovascular disease, in patients with type 2 diabetes. Cysteine 68-71 transthyretin Homo sapiens 72-75 28434967-5 2017 The relationship between CAVI and ratio of Cys-TTR to total TTR (Cys-TTR ratio) was analyzed. Cysteine 43-46 transthyretin Homo sapiens 47-50 28434967-6 2017 RESULTS: Cys-TTR ratio was significantly correlated with CAVI (Pearson"s correlation coefficient: 0.316, p<0.01), and CAVI was significantly higher in the 3rd tertile group for Cys-TTR ratio than in its 1st tertile group. Cysteine 9-12 transthyretin Homo sapiens 13-16 28434967-6 2017 RESULTS: Cys-TTR ratio was significantly correlated with CAVI (Pearson"s correlation coefficient: 0.316, p<0.01), and CAVI was significantly higher in the 3rd tertile group for Cys-TTR ratio than in its 1st tertile group. Cysteine 9-12 transthyretin Homo sapiens 184-187 28434967-6 2017 RESULTS: Cys-TTR ratio was significantly correlated with CAVI (Pearson"s correlation coefficient: 0.316, p<0.01), and CAVI was significantly higher in the 3rd tertile group for Cys-TTR ratio than in its 1st tertile group. Cysteine 180-183 transthyretin Homo sapiens 184-187 28434967-8 2017 Prevalence of high CAVI (>=10.0) was significantly higher in the 3rd tertile for Cys-TTR ratio than in its 1st tertile and tended to be higher with an increase in tertile (28.6% in the 1st tertile, 42.9% in the 2nd tertile and 60.0% in the 3rd tertile). Cysteine 84-87 transthyretin Homo sapiens 88-91 28434967-9 2017 Odds ratio (OR) for high CAVI of the 3rd vs. 1st tertile groups for Cys-TTR ratio was significantly higher than the reference level of 1.00 both before and after adjustment for the above cardiovascular risk factors (crude OR, 3.75 [1.38-10.17]; adjusted OR, 5.09 [1.39-18.64]). Cysteine 68-71 transthyretin Homo sapiens 72-75 28434967-10 2017 CONCLUSIONS: Cys-TTR ratio is associated with arterial stiffness in patients with diabetes and is proposed as a new discriminator of cardiovascular risk. Cysteine 13-16 transthyretin Homo sapiens 17-20 28525871-5 2017 The ionized groups of PFCs can form electrostatic interactions with the -NH+3 groups of Lys 15 residues in hTTR and form hydrogen bonds with the residues of hTTR. Lysine 88-91 transthyretin Homo sapiens 107-111 28525871-5 2017 The ionized groups of PFCs can form electrostatic interactions with the -NH+3 groups of Lys 15 residues in hTTR and form hydrogen bonds with the residues of hTTR. Hydrogen 121-129 transthyretin Homo sapiens 157-161 28422428-1 2017 Transthyretin (TTR) is the primary carrier for thyroxine (T4 ) in cerebrospinal fluid and a secondary carrier in blood. Thyroxine 47-56 transthyretin Homo sapiens 0-13 28422428-1 2017 Transthyretin (TTR) is the primary carrier for thyroxine (T4 ) in cerebrospinal fluid and a secondary carrier in blood. Thyroxine 47-56 transthyretin Homo sapiens 15-18 28802308-7 2017 Laser microdissection of salivary gland Congo-red deposits and tandem mass spectrometry-based proteomic analysis identified the mutated transthyretin peptide containing the arginine residue at position 87 of the mature protein. Arginine 173-181 transthyretin Homo sapiens 136-149 28625364-2 2017 Small molecules that bind to the generally unoccupied thyroxine binding pockets in the native TTR tetramer kinetically stabilize the tetramer, slowing subunit dissociation proportional to the extent that the molecules stabilize the native state over the dissociative transition state-thereby inhibiting amyloidogenesis. Thyroxine 54-63 transthyretin Homo sapiens 94-97 28598015-11 2017 Both AL amyloidosis and 2 of 10 TTR-noPN subjects were Congo red-positive. Congo Red 55-64 transthyretin Homo sapiens 32-35 28570028-3 2017 METHODS: We firstly investigated TTR folding status in human plasma measuring the resistance to urea denaturation. Urea 96-100 transthyretin Homo sapiens 33-36 28412068-21 2017 Gene sequencing revealed a phenylalanine isoleucine mutation in the 33rd position of exon 2 of TTR in 1 patient of 1 pedigree, confirming the diagnosis of FAP. phenylalanine isoleucine 27-51 transthyretin Homo sapiens 95-98 28563699-2 2017 A previous study on the neutron crystal structure of TTR suggested that a large hydrogen bond network around H88 which includes water molecules is significantly involved in the stability of wild-type TTR (WT-TTR). Hydrogen 80-88 transthyretin Homo sapiens 53-56 28563699-2 2017 A previous study on the neutron crystal structure of TTR suggested that a large hydrogen bond network around H88 which includes water molecules is significantly involved in the stability of wild-type TTR (WT-TTR). Hydrogen 80-88 transthyretin Homo sapiens 200-203 28563699-2 2017 A previous study on the neutron crystal structure of TTR suggested that a large hydrogen bond network around H88 which includes water molecules is significantly involved in the stability of wild-type TTR (WT-TTR). Hydrogen 80-88 transthyretin Homo sapiens 200-203 28563699-2 2017 A previous study on the neutron crystal structure of TTR suggested that a large hydrogen bond network around H88 which includes water molecules is significantly involved in the stability of wild-type TTR (WT-TTR). Water 128-133 transthyretin Homo sapiens 53-56 28563699-2 2017 A previous study on the neutron crystal structure of TTR suggested that a large hydrogen bond network around H88 which includes water molecules is significantly involved in the stability of wild-type TTR (WT-TTR). Water 128-133 transthyretin Homo sapiens 200-203 28563699-2 2017 A previous study on the neutron crystal structure of TTR suggested that a large hydrogen bond network around H88 which includes water molecules is significantly involved in the stability of wild-type TTR (WT-TTR). Water 128-133 transthyretin Homo sapiens 200-203 28563699-4 2017 In order to clarify the role of H88 and the hydrogen bond network in the stability of TTR, we determined the thermodynamic stability and the crystal structure of H88 mutants (H88A, H88F, H88Y, and H88S). Hydrogen 44-52 transthyretin Homo sapiens 86-89 28563699-5 2017 Our results suggest that in some cases TTR is destabilized due to alterations in bound water molecules as well as structural changes in TTR itself. Water 87-92 transthyretin Homo sapiens 39-42 28627187-0 2017 [Is plasma selenium correlated to transthyretin levels in critically ill patients?] Selenium 11-19 transthyretin Homo sapiens 34-47 28627187-3 2017 Recent studies have shown that transthyretin may reflect the selenium intake and could be considered a biomarker. Selenium 61-69 transthyretin Homo sapiens 31-44 28627187-5 2017 OBJECTIVE: This study aims to investigate the correlation of transthyretin with the plasma selenium of critically ill patients receiving PN. Selenium 91-99 transthyretin Homo sapiens 61-74 28627187-12 2017 During two weeks, there was a positive correlation of transthyretin with plasma selenium (r = 0.71; p = 0.05) regardless of the CRP values. Selenium 80-88 transthyretin Homo sapiens 54-67 28627187-13 2017 CONCLUSION: Transthyretin may have reflected plasma selenium, mainly because the correlation was verified after the acute phase. Selenium 52-60 transthyretin Homo sapiens 12-25 28434259-0 2017 Establishing and validating the fluorescent amyloid ligand h-FTAA (heptamer formyl thiophene acetic acid) to identify transthyretin amyloid deposits in carpal tunnel syndrome. h-ftaa 59-65 transthyretin Homo sapiens 118-131 28434259-0 2017 Establishing and validating the fluorescent amyloid ligand h-FTAA (heptamer formyl thiophene acetic acid) to identify transthyretin amyloid deposits in carpal tunnel syndrome. heptamer formyl thiophene acetic acid 67-104 transthyretin Homo sapiens 118-131 28434259-8 2017 Congo red-staining combined with fluorescence microscopy was significantly less sensitive than h-FTAA-fluorescence and TTR-immunostaining: the highest percentage area was found in TTR-immunostained sections, followed by h-FTAA and Congo red. Congo Red 0-9 transthyretin Homo sapiens 180-183 27568122-0 2017 Can 99mTc-Pyrophosphate Aid in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis? Technetium Tc 99m Pyrophosphate 4-23 transthyretin Homo sapiens 94-97 28338000-0 2017 Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Thyroxine 32-41 transthyretin Homo sapiens 77-90 27016106-1 2017 BACKGROUND: Tc99m-pyrophosphate (Tc99m-PYP) scintigraphy has emerged as a diagnostic modality for transthyretin (TTR) cardiac amyloidosis (CA). Technetium Tc 99m Pyrophosphate 12-31 transthyretin Homo sapiens 98-111 27016106-1 2017 BACKGROUND: Tc99m-pyrophosphate (Tc99m-PYP) scintigraphy has emerged as a diagnostic modality for transthyretin (TTR) cardiac amyloidosis (CA). Technetium Tc 99m Pyrophosphate 12-31 transthyretin Homo sapiens 113-116 27016106-1 2017 BACKGROUND: Tc99m-pyrophosphate (Tc99m-PYP) scintigraphy has emerged as a diagnostic modality for transthyretin (TTR) cardiac amyloidosis (CA). Technetium Tc 99m Pyrophosphate 33-42 transthyretin Homo sapiens 98-111 27016106-1 2017 BACKGROUND: Tc99m-pyrophosphate (Tc99m-PYP) scintigraphy has emerged as a diagnostic modality for transthyretin (TTR) cardiac amyloidosis (CA). Technetium Tc 99m Pyrophosphate 33-42 transthyretin Homo sapiens 113-116 28214948-7 2017 TTR was highest in Fiix-warfarin patients without CRVE (median 82%;IQR 72-91) and lowest in PT-warfarin patients with TE (62%;56-81). Warfarin 24-32 transthyretin Homo sapiens 0-3 28214948-7 2017 TTR was highest in Fiix-warfarin patients without CRVE (median 82%;IQR 72-91) and lowest in PT-warfarin patients with TE (62%;56-81). Warfarin 95-103 transthyretin Homo sapiens 0-3 28479268-4 2017 Cardiac sympathetic denervation detected by iodine-123 labeled metaiodobenzylguanidine (MIBG) is an important prognostic marker in TTR-V30M FAP. Iodine-123 44-54 transthyretin Homo sapiens 131-134 28479268-4 2017 Cardiac sympathetic denervation detected by iodine-123 labeled metaiodobenzylguanidine (MIBG) is an important prognostic marker in TTR-V30M FAP. 3-Iodobenzylguanidine 63-86 transthyretin Homo sapiens 131-134 28479268-4 2017 Cardiac sympathetic denervation detected by iodine-123 labeled metaiodobenzylguanidine (MIBG) is an important prognostic marker in TTR-V30M FAP. 3-Iodobenzylguanidine 88-92 transthyretin Homo sapiens 131-134 28479268-7 2017 METHODS: In this observational study, patients with the TTR-V30M mutation underwent annual cardiac assessment and serial MIBG imaging with quantification of the late heart-to-mediastinum (H/M) ratio. 3-Iodobenzylguanidine 121-125 transthyretin Homo sapiens 56-59 28366957-5 2017 RESULTS: The prevalence rate of CTS was highest for the NMQ (51.9%), followed by physician"s diagnosis (49.5% for the right hand, 29.9% for the left hand), physical examination (54.7%), and nerve conduction test (motor nerve 27.5% and 25%, sensory nerve 21.7% and 15%, for right and left hands, respectively). N-METHYL O-NITROPHENYL AMINOETHYLDIPHOSPHATE BERYLLIUM TRIFLUORIDE 56-59 transthyretin Homo sapiens 32-35 28366957-6 2017 Based on logistic regression models for the NMQ and physician"s diagnoses, there was a dose-dependently higher risk of CTS with the upper extremity index among participants, but this was non-significant based on the physical examination and nerve conduction tests. N-METHYL O-NITROPHENYL AMINOETHYLDIPHOSPHATE BERYLLIUM TRIFLUORIDE 44-47 transthyretin Homo sapiens 119-122 28093848-8 2017 In addition, the presence of C-terminal ATTR fragments has an impact on the affinity for various tracers used for noninvasive imaging of amyloid depositions such as 99 m-technetium-diphosphono-propanodicarboxylic acid scintigraphy and positron emission tomography utilizing Pittsburgh component B, and even for the gold standard diagnostic procedure, tissue biopsy stained by Congo red and examined under polarized light. technetium-diphosphono-propanodicarboxylic acid 170-217 transthyretin Homo sapiens 40-44 28093848-8 2017 In addition, the presence of C-terminal ATTR fragments has an impact on the affinity for various tracers used for noninvasive imaging of amyloid depositions such as 99 m-technetium-diphosphono-propanodicarboxylic acid scintigraphy and positron emission tomography utilizing Pittsburgh component B, and even for the gold standard diagnostic procedure, tissue biopsy stained by Congo red and examined under polarized light. Congo Red 376-385 transthyretin Homo sapiens 40-44 28217795-0 2017 Understanding the microscopic binding mechanism of hydroxylated and sulfated polybrominated diphenyl ethers with transthyretin by molecular docking, molecular dynamics simulations and binding free energy calculations. Phenyl Ethers 92-107 transthyretin Homo sapiens 113-126 28217795-2 2017 The high binding affinities of hydroxylated metabolites of PBDEs (OH-PBDEs) with transthyretin (TTR) were considered to be one major reason for their extraordinary capacity of passing through the blood-brain barrier via competitive thyroid hormone (T4) transport protein binding. Halogenated Diphenyl Ethers 59-64 transthyretin Homo sapiens 81-94 28217795-2 2017 The high binding affinities of hydroxylated metabolites of PBDEs (OH-PBDEs) with transthyretin (TTR) were considered to be one major reason for their extraordinary capacity of passing through the blood-brain barrier via competitive thyroid hormone (T4) transport protein binding. Halogenated Diphenyl Ethers 59-64 transthyretin Homo sapiens 96-99 28217795-2 2017 The high binding affinities of hydroxylated metabolites of PBDEs (OH-PBDEs) with transthyretin (TTR) were considered to be one major reason for their extraordinary capacity of passing through the blood-brain barrier via competitive thyroid hormone (T4) transport protein binding. oh-pbdes 66-74 transthyretin Homo sapiens 81-94 28217795-2 2017 The high binding affinities of hydroxylated metabolites of PBDEs (OH-PBDEs) with transthyretin (TTR) were considered to be one major reason for their extraordinary capacity of passing through the blood-brain barrier via competitive thyroid hormone (T4) transport protein binding. oh-pbdes 66-74 transthyretin Homo sapiens 96-99 28217795-5 2017 Therefore, molecular docking and molecular dynamics (MD) simulations were employed in the present study to probe the molecular basis of TTR interacting with hydroxylated and sulfated PBDEs at the atomic level. Halogenated Diphenyl Ethers 183-188 transthyretin Homo sapiens 136-139 28217795-7 2017 The calculated results showed that the sulfated PBDEs have stronger affinity for TTR than the corresponding OH-PBDEs. Halogenated Diphenyl Ethers 48-53 transthyretin Homo sapiens 81-84 28217795-8 2017 Further analysis of structural characteristics based on MD simulations indicated that upon the binding of PBDE metabolites, the stability of TTR was enhanced and the dissociation rate of the tetrameric protein structure was potentially decreased. Halogenated Diphenyl Ethers 106-110 transthyretin Homo sapiens 141-144 28217795-9 2017 Subsequent binding free energy calculations implied that van der Waals interactions are the dominant forces for the binding of these metabolites of PBDEs at the T4 site of TTR. Halogenated Diphenyl Ethers 148-153 transthyretin Homo sapiens 172-175 28217795-11 2017 In general, the combination of docking calculations with MD simulations provided a theoretically toxicological assessment for the metabolites of PBDEs, deep insight into the recognition mechanism of TTR for these compounds, and thus more comprehensive understanding of the thyroid-related toxic effects of PBDEs as well. Halogenated Diphenyl Ethers 145-150 transthyretin Homo sapiens 199-202 28217795-11 2017 In general, the combination of docking calculations with MD simulations provided a theoretically toxicological assessment for the metabolites of PBDEs, deep insight into the recognition mechanism of TTR for these compounds, and thus more comprehensive understanding of the thyroid-related toxic effects of PBDEs as well. Halogenated Diphenyl Ethers 306-311 transthyretin Homo sapiens 199-202 28393633-5 2017 In vitro, CSP-1103 stabilizes the TTR tetramer by binding to the thyroxine (T4) binding site. Thyroxine 65-74 transthyretin Homo sapiens 34-37 27896444-7 2017 For each initial (index) CBG, the TTR for individuals with T2DM-on insulin or sulphonylurea-was compared with the TTR for individuals with T1DM, using a t test for significance performed on log(TTR). Sulfonylurea Compounds 78-91 transthyretin Homo sapiens 34-37 27896444-11 2017 The TTR in T2DM individuals on sulphonylurea was significantly greater than in T1DM individuals where index CBG was >=2.3 mmol/L (except index CBG 2.6 mmol/L). Sulfonylurea Compounds 31-44 transthyretin Homo sapiens 4-7 27896444-11 2017 The TTR in T2DM individuals on sulphonylurea was significantly greater than in T1DM individuals where index CBG was >=2.3 mmol/L (except index CBG 2.6 mmol/L). cannabigerol 108-111 transthyretin Homo sapiens 4-7 28298647-5 2017 Tolcapone, which is bound with similar high affinity in both TTR binding sites without the usual negative cooperativity, is therefore of interest. Tolcapone 0-9 transthyretin Homo sapiens 61-64 28298647-6 2017 Here we show that TTR fibrillogenesis by the mechano-enzymatic pathway is indeed more potently inhibited by tolcapone than by tafamidis but neither, even in large molar excess, completely prevents amyloid fibril formation. Tolcapone 108-117 transthyretin Homo sapiens 18-21 28434337-0 2017 Treatment of transthyretin cardiomyopathy with a TTR-specific antisense oligonucleotide (IONIS-TTRRx). Oligonucleotides 72-87 transthyretin Homo sapiens 13-26 28434337-0 2017 Treatment of transthyretin cardiomyopathy with a TTR-specific antisense oligonucleotide (IONIS-TTRRx). Oligonucleotides 72-87 transthyretin Homo sapiens 49-52 28111409-4 2017 The patient started taking diflunisal as a stabilizer which is one of the advanced therapies for ATTR, and then the heart failure symptoms and brain natriuretic peptide (BNP) level improved in short-term follow-up. Diflunisal 27-37 transthyretin Homo sapiens 97-101 28042702-0 2017 Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis. Ursodeoxycholic Acid 26-46 transthyretin Homo sapiens 50-63 27890571-3 2017 To address this problem, a versatile platform based on poly(acrylic acid) (PAA) coated ionically cross-linked chitosan/tripolyphosphate nanoparticles (CTS/TPP-PAA NPs), is reported. carbopol 940 55-73 transthyretin Homo sapiens 151-154 27890571-3 2017 To address this problem, a versatile platform based on poly(acrylic acid) (PAA) coated ionically cross-linked chitosan/tripolyphosphate nanoparticles (CTS/TPP-PAA NPs), is reported. carbopol 940 75-78 transthyretin Homo sapiens 151-154 27890571-3 2017 To address this problem, a versatile platform based on poly(acrylic acid) (PAA) coated ionically cross-linked chitosan/tripolyphosphate nanoparticles (CTS/TPP-PAA NPs), is reported. Chitosan 110-118 transthyretin Homo sapiens 151-154 27890571-5 2017 CTS/TPP NPs quickly aggregate in PBS (phosphate buffered saline) and DMEM (Dulbecco"s modified Eagle"s medium). pbs 33-36 transthyretin Homo sapiens 0-3 27890571-5 2017 CTS/TPP NPs quickly aggregate in PBS (phosphate buffered saline) and DMEM (Dulbecco"s modified Eagle"s medium). Phosphate-Buffered Saline 38-63 transthyretin Homo sapiens 0-3 27890571-5 2017 CTS/TPP NPs quickly aggregate in PBS (phosphate buffered saline) and DMEM (Dulbecco"s modified Eagle"s medium). dmem 69-73 transthyretin Homo sapiens 0-3 27890571-5 2017 CTS/TPP NPs quickly aggregate in PBS (phosphate buffered saline) and DMEM (Dulbecco"s modified Eagle"s medium). dulbecco"s modified eagle"s medium 75-109 transthyretin Homo sapiens 0-3 28081656-7 2017 Disease duration and age at examination inversely correlated with serum levels of free triiodothyronine (fT3) in hereditary TTR amyloidosis. Triiodothyronine 87-103 transthyretin Homo sapiens 124-127 28081656-7 2017 Disease duration and age at examination inversely correlated with serum levels of free triiodothyronine (fT3) in hereditary TTR amyloidosis. CHEMBL240806 105-108 transthyretin Homo sapiens 124-127 27749616-9 2017 CONCLUSIONS: Both US-guided and LM-guided steroid injections were effective in reducing the symptoms, improving the function and electrodiagnostic findings of CTS. Steroids 42-49 transthyretin Homo sapiens 159-162 28454241-4 2017 Transthyretin (TTR) is a 56-kDa homotetrameric protein that binds thyroid hormone and retinol binding protein. Vitamin A 86-93 transthyretin Homo sapiens 0-13 28454241-4 2017 Transthyretin (TTR) is a 56-kDa homotetrameric protein that binds thyroid hormone and retinol binding protein. Vitamin A 86-93 transthyretin Homo sapiens 15-18 27590664-8 2017 CONCLUSIONS: A high warfarin treatment quality improves outcome after MHV implantation, both measured with TTR and INR variability. Warfarin 20-28 transthyretin Homo sapiens 107-110 27590664-8 2017 CONCLUSIONS: A high warfarin treatment quality improves outcome after MHV implantation, both measured with TTR and INR variability. mhv 70-73 transthyretin Homo sapiens 107-110 29040977-13 2017 TTR reduced apoptosis by decreasing the accumulation of reactive oxygen species (ROS). Reactive Oxygen Species 56-79 transthyretin Homo sapiens 0-3 28152524-1 2017 Tafamidis meglumine is a novel medicine that has been shown to slow the progression of peripheral neurological impairment in patients with hereditary transthyretin amyloidosis (ATTR). tafamidis 0-19 transthyretin Homo sapiens 177-181 28075349-2 2017 Herein, we report indispensable role of transthyretin (TTR) in maintaining cellular thyroxine level. Thyroxine 84-93 transthyretin Homo sapiens 40-53 28075349-2 2017 Herein, we report indispensable role of transthyretin (TTR) in maintaining cellular thyroxine level. Thyroxine 84-93 transthyretin Homo sapiens 55-58 28075349-6 2017 Moreover, use of a coumarin derivative (CD) revealed a significant reduction in cellular thyroxine, thereby indicating that TTR play a role in the transport of thyroxine. coumarin 19-27 transthyretin Homo sapiens 124-127 28075349-6 2017 Moreover, use of a coumarin derivative (CD) revealed a significant reduction in cellular thyroxine, thereby indicating that TTR play a role in the transport of thyroxine. Thyroxine 89-98 transthyretin Homo sapiens 124-127 28075349-6 2017 Moreover, use of a coumarin derivative (CD) revealed a significant reduction in cellular thyroxine, thereby indicating that TTR play a role in the transport of thyroxine. Thyroxine 160-169 transthyretin Homo sapiens 124-127 28075349-7 2017 Taken together, these findings suggest that TTR mediated transport of thyroxine represents a survival mechanism necessary for the myogenic program. Thyroxine 70-79 transthyretin Homo sapiens 44-47 29040977-13 2017 TTR reduced apoptosis by decreasing the accumulation of reactive oxygen species (ROS). Reactive Oxygen Species 81-84 transthyretin Homo sapiens 0-3 29040977-14 2017 CONCLUSION: This study reports a possible mechanism for RM-induced AKI and suggests that reductions in TTR could increase the generation of ROS and induce apoptosis. Reactive Oxygen Species 140-143 transthyretin Homo sapiens 103-106 27852403-6 2016 Results: MTT assay showed that RPECs with 0 mumol/L TTR glowed faster than with 4 mumol/L TTR (t=18.08, P<0.0001). monooxyethylene trimethylolpropane tristearate 9-12 transthyretin Homo sapiens 52-55 28090046-0 2017 An Isolated Case of Late-onset Amyloidogenic Transthyretin Type Familial Amyloid Polyneuropathy Associated with a Mutant Transthyretin Substituting Methionine for Valine at Position 30 Showing Latent Progressive Cardiac Involvement Confirmed by Serial Annual Electrocardiograms. Methionine 148-158 transthyretin Homo sapiens 45-58 28090046-0 2017 An Isolated Case of Late-onset Amyloidogenic Transthyretin Type Familial Amyloid Polyneuropathy Associated with a Mutant Transthyretin Substituting Methionine for Valine at Position 30 Showing Latent Progressive Cardiac Involvement Confirmed by Serial Annual Electrocardiograms. Valine 163-169 transthyretin Homo sapiens 45-58 27319745-11 2017 CONCLUSIONS: This retrospective study demonstrated that the CHADS2 score component accumulation and hepatorenal dysfunction are factors significantly contributing to the low TTR, which is indicative of poor warfarin treatment stability, in patients such as those with AF. Warfarin 207-215 transthyretin Homo sapiens 174-177 28202889-12 2017 CONCLUSIONS: Tafamidis was effective in slowing the neurologic progression over one year in a FAP patient with the TTR Val30Met mutation, and NCS and EMG were useful for assessing this therapeutic effect. tafamidis 13-22 transthyretin Homo sapiens 115-118 27914501-3 2016 METHODS: LEVO-CTS is a phase 3 randomized, controlled, multicenter study evaluating the efficacy, safety, and cost-effectiveness of levosimendan in reducing morbidity and mortality in high-risk patients with reduced left ventricular ejection fraction (<=35%) undergoing cardiac surgery on CPB. Simendan 132-144 transthyretin Homo sapiens 14-17 27914501-9 2016 CONCLUSION: LEVO-CTS, a large randomized multicenter clinical trial, will evaluate the efficacy, safety, and cost-effectiveness of levosimendan in reducing adverse outcomes in high-risk patients undergoing cardiac surgery on CPB. Simendan 131-143 transthyretin Homo sapiens 17-20 26453570-0 2016 Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis. technetium pyrophosphate 21-45 transthyretin Homo sapiens 70-74 27062466-2 2016 The goal of the present study was to investigate the relationship between vitamin D levels and carpal tunnel syndrome (CTS). Vitamin D 74-83 transthyretin Homo sapiens 119-122 27062466-5 2016 RESULTS: The severity levels of CTS were at a 75% mild level in the vitamin D deficiency group and a 47.1% mild level in the vitamin D normal group, with a significant difference between groups (p = 0.008). Vitamin D 68-77 transthyretin Homo sapiens 32-35 27062466-5 2016 RESULTS: The severity levels of CTS were at a 75% mild level in the vitamin D deficiency group and a 47.1% mild level in the vitamin D normal group, with a significant difference between groups (p = 0.008). Vitamin D 125-134 transthyretin Homo sapiens 32-35 27062466-6 2016 Correlation analyses revealed positive correlations between body mass index and DN4 scores (r = 0.499, p = 0.025) and between vitamin D levels and CTS severity (r = 0.364, p = 0.004) in the vitamin D deficiency group. Vitamin D 126-135 transthyretin Homo sapiens 147-150 27062466-7 2016 CONCLUSIONS: The present findings demonstrated that CTS may be triggered by vitamin D deficiency, and that the severity of CTS was correlated with vitamin D levels in the deficiency group. Vitamin D 76-85 transthyretin Homo sapiens 52-55 27062466-7 2016 CONCLUSIONS: The present findings demonstrated that CTS may be triggered by vitamin D deficiency, and that the severity of CTS was correlated with vitamin D levels in the deficiency group. Vitamin D 147-156 transthyretin Homo sapiens 123-126 27062466-8 2016 Additionally, there was a correlation between weight gain and neuropathic pain intensity in CTS patients with vitamin D deficiency. Vitamin D 110-119 transthyretin Homo sapiens 92-95 27062466-9 2016 The present findings indicate that vitamin D levels should be assessed in CTS patients. Vitamin D 35-44 transthyretin Homo sapiens 74-77 27852403-6 2016 Results: MTT assay showed that RPECs with 0 mumol/L TTR glowed faster than with 4 mumol/L TTR (t=18.08, P<0.0001). monooxyethylene trimethylolpropane tristearate 9-12 transthyretin Homo sapiens 90-93 27569004-0 2016 Tetraiodothyroacetic acid and transthyretin silencing inhibit pro-metastatic effect of L-thyroxin in anoikis-resistant prostate cancer cells through regulation of MAPK/ERK pathway. Thyroxine 87-97 transthyretin Homo sapiens 30-43 27541261-3 2016 The resulting 2-alkynylquinoline derivatives, (E)-2-alkenylquinoline derivatives, and (E)-3-alkenylquinoline derivatives were evaluated to inhibit TTR amyloidogenesis by utilizing the acid-mediated TTR fibril formation. (e)-3-alkenylquinoline 86-108 transthyretin Homo sapiens 147-150 27541261-3 2016 The resulting 2-alkynylquinoline derivatives, (E)-2-alkenylquinoline derivatives, and (E)-3-alkenylquinoline derivatives were evaluated to inhibit TTR amyloidogenesis by utilizing the acid-mediated TTR fibril formation. (e)-3-alkenylquinoline 86-108 transthyretin Homo sapiens 198-201 27541261-4 2016 Among these quinoline derivatives, compound 14c exhibited the most potent anti-TTR fibril formation activity in the screening studies, with IC50 values of 1.49 muM against WT-TTR and 1.63 muM against more amyloidogenic V30 M TTR mutant. quinoline 12-21 transthyretin Homo sapiens 79-82 27541261-4 2016 Among these quinoline derivatives, compound 14c exhibited the most potent anti-TTR fibril formation activity in the screening studies, with IC50 values of 1.49 muM against WT-TTR and 1.63 muM against more amyloidogenic V30 M TTR mutant. quinoline 12-21 transthyretin Homo sapiens 175-178 27541261-8 2016 Taken together, the novel quinoline derivatives could potentially be explored as potential drug candidates to treat the human TTR amyloidosis. quinoline 26-35 transthyretin Homo sapiens 126-129 27557400-0 2016 Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. Technetium 28-42 transthyretin Homo sapiens 112-116 27557400-0 2016 Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. diphosphoric acid 43-56 transthyretin Homo sapiens 112-116 27557400-2 2016 In single-center studies, technetium 99m pyrophosphate (Tc 99m PYP) cardiac imaging noninvasively detects ATTR cardiac amyloidosis, but the accuracy of this technique in a multicenter study and the association of Tc 99m PYP myocardial uptake with survival are unknown. technetium 99m pyrophosphate 26-54 transthyretin Homo sapiens 106-110 27557400-2 2016 In single-center studies, technetium 99m pyrophosphate (Tc 99m PYP) cardiac imaging noninvasively detects ATTR cardiac amyloidosis, but the accuracy of this technique in a multicenter study and the association of Tc 99m PYP myocardial uptake with survival are unknown. Technetium 56-58 transthyretin Homo sapiens 106-110 27546596-5 2016 However, the early stages of abnormal Abeta, alpha-synuclein, and TTR assembly are redirected upon tweezer binding towards the generation of amorphous non-toxic materials that can be degraded by the intracellular and extracellular clearance mechanisms. tweezer 99-106 transthyretin Homo sapiens 66-69 27546596-6 2016 Thus, specific host-guest chemistry between aggregation-prone proteins and lysine/arginine binders rescues cell viability and restores animal health in models of AD, PD, and TTR amyloidosis. Lysine 75-81 transthyretin Homo sapiens 174-177 27546596-6 2016 Thus, specific host-guest chemistry between aggregation-prone proteins and lysine/arginine binders rescues cell viability and restores animal health in models of AD, PD, and TTR amyloidosis. Arginine 82-90 transthyretin Homo sapiens 174-177 27541261-2 2016 To develop potent TTR amyloidogenesis inhibitors, we have designed and synthesized a focused library of quinoline derivatives by Pd-catalyzed coupling reaction and by the Horner-Wadsworth-Emmons reaction. quinoline 104-113 transthyretin Homo sapiens 18-21 27541261-2 2016 To develop potent TTR amyloidogenesis inhibitors, we have designed and synthesized a focused library of quinoline derivatives by Pd-catalyzed coupling reaction and by the Horner-Wadsworth-Emmons reaction. Palladium 129-131 transthyretin Homo sapiens 18-21 27541261-3 2016 The resulting 2-alkynylquinoline derivatives, (E)-2-alkenylquinoline derivatives, and (E)-3-alkenylquinoline derivatives were evaluated to inhibit TTR amyloidogenesis by utilizing the acid-mediated TTR fibril formation. 2-alkynylquinoline 14-32 transthyretin Homo sapiens 147-150 27668830-2 2016 One possible molecular target of thyroid hormone disrupting chemicals (THDCs) is transthyretin (TTR), a thyroid hormone transporter in vertebrates. thdcs 71-76 transthyretin Homo sapiens 81-94 27668830-2 2016 One possible molecular target of thyroid hormone disrupting chemicals (THDCs) is transthyretin (TTR), a thyroid hormone transporter in vertebrates. thdcs 71-76 transthyretin Homo sapiens 96-99 27668830-3 2016 To better understand the interactions between TTR and THDCs, we determined the crystallographic structures of human TTR in complex with perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and 2,2",4,4"-tetrahydroxybenzophenone (BP2). thdcs 54-59 transthyretin Homo sapiens 116-119 27668830-3 2016 To better understand the interactions between TTR and THDCs, we determined the crystallographic structures of human TTR in complex with perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and 2,2",4,4"-tetrahydroxybenzophenone (BP2). perfluorooctane sulfonic acid 136-164 transthyretin Homo sapiens 116-119 27668830-3 2016 To better understand the interactions between TTR and THDCs, we determined the crystallographic structures of human TTR in complex with perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and 2,2",4,4"-tetrahydroxybenzophenone (BP2). perfluorooctane sulfonic acid 166-170 transthyretin Homo sapiens 46-49 27668830-3 2016 To better understand the interactions between TTR and THDCs, we determined the crystallographic structures of human TTR in complex with perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and 2,2",4,4"-tetrahydroxybenzophenone (BP2). perfluorooctane sulfonic acid 166-170 transthyretin Homo sapiens 116-119 27668830-3 2016 To better understand the interactions between TTR and THDCs, we determined the crystallographic structures of human TTR in complex with perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and 2,2",4,4"-tetrahydroxybenzophenone (BP2). perfluorooctanoic acid 173-195 transthyretin Homo sapiens 116-119 27668830-3 2016 To better understand the interactions between TTR and THDCs, we determined the crystallographic structures of human TTR in complex with perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and 2,2",4,4"-tetrahydroxybenzophenone (BP2). perfluorooctanoic acid 197-201 transthyretin Homo sapiens 116-119 27668830-3 2016 To better understand the interactions between TTR and THDCs, we determined the crystallographic structures of human TTR in complex with perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and 2,2",4,4"-tetrahydroxybenzophenone (BP2). 2,2',4,4'-tetrahydroxybenzophenone 208-242 transthyretin Homo sapiens 116-119 27668830-3 2016 To better understand the interactions between TTR and THDCs, we determined the crystallographic structures of human TTR in complex with perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and 2,2",4,4"-tetrahydroxybenzophenone (BP2). naphtha 244-247 transthyretin Homo sapiens 116-119 27668830-7 2016 To elucidate structural details in their binding to TTR, crystal structures were determined of TTR in complex with four of the identified compounds including 2,6-dinitro-p-cresol, bisphenol S, clonixin, and triclopyr. 2,6-dinitro-p-cresol 158-178 transthyretin Homo sapiens 52-55 27668830-7 2016 To elucidate structural details in their binding to TTR, crystal structures were determined of TTR in complex with four of the identified compounds including 2,6-dinitro-p-cresol, bisphenol S, clonixin, and triclopyr. 2,6-dinitro-p-cresol 158-178 transthyretin Homo sapiens 95-98 27668830-7 2016 To elucidate structural details in their binding to TTR, crystal structures were determined of TTR in complex with four of the identified compounds including 2,6-dinitro-p-cresol, bisphenol S, clonixin, and triclopyr. bis(4-hydroxyphenyl)sulfone 180-191 transthyretin Homo sapiens 52-55 27668830-7 2016 To elucidate structural details in their binding to TTR, crystal structures were determined of TTR in complex with four of the identified compounds including 2,6-dinitro-p-cresol, bisphenol S, clonixin, and triclopyr. bis(4-hydroxyphenyl)sulfone 180-191 transthyretin Homo sapiens 95-98 27668830-7 2016 To elucidate structural details in their binding to TTR, crystal structures were determined of TTR in complex with four of the identified compounds including 2,6-dinitro-p-cresol, bisphenol S, clonixin, and triclopyr. triclopyr 207-216 transthyretin Homo sapiens 52-55 27668830-7 2016 To elucidate structural details in their binding to TTR, crystal structures were determined of TTR in complex with four of the identified compounds including 2,6-dinitro-p-cresol, bisphenol S, clonixin, and triclopyr. triclopyr 207-216 transthyretin Homo sapiens 95-98 27353397-0 2016 The genes that encode the gonococcal transferrin binding proteins, TbpB and TbpA, are differentially regulated by MisR under iron-replete and iron-depleted conditions. Iron 125-129 transthyretin Homo sapiens 76-80 26235916-0 2016 X-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitors. fluorenyl 40-49 transthyretin Homo sapiens 69-82 26235916-1 2016 Transthyretin (TTR) is a 54 kDa homotetrameric protein that transports thyroxine (T4) and retinol (vitamin A), through its association with retinol binding protein (RBP). Thyroxine 71-80 transthyretin Homo sapiens 0-13 26235916-1 2016 Transthyretin (TTR) is a 54 kDa homotetrameric protein that transports thyroxine (T4) and retinol (vitamin A), through its association with retinol binding protein (RBP). Thyroxine 71-80 transthyretin Homo sapiens 15-18 26235916-1 2016 Transthyretin (TTR) is a 54 kDa homotetrameric protein that transports thyroxine (T4) and retinol (vitamin A), through its association with retinol binding protein (RBP). Vitamin A 90-97 transthyretin Homo sapiens 0-13 26235916-1 2016 Transthyretin (TTR) is a 54 kDa homotetrameric protein that transports thyroxine (T4) and retinol (vitamin A), through its association with retinol binding protein (RBP). Vitamin A 90-97 transthyretin Homo sapiens 15-18 27497715-10 2016 Pharmacologic agents, including diflunisal, tafamidis, small interfering ribonucleic acid, and doxycycline, have shown promising activity in stabilizing TTR from misfolding into fibrils and are being actively investigated. Diflunisal 32-42 transthyretin Homo sapiens 153-156 27497715-10 2016 Pharmacologic agents, including diflunisal, tafamidis, small interfering ribonucleic acid, and doxycycline, have shown promising activity in stabilizing TTR from misfolding into fibrils and are being actively investigated. Doxycycline 95-106 transthyretin Homo sapiens 153-156 26235916-1 2016 Transthyretin (TTR) is a 54 kDa homotetrameric protein that transports thyroxine (T4) and retinol (vitamin A), through its association with retinol binding protein (RBP). Vitamin A 99-108 transthyretin Homo sapiens 0-13 27353397-0 2016 The genes that encode the gonococcal transferrin binding proteins, TbpB and TbpA, are differentially regulated by MisR under iron-replete and iron-depleted conditions. Iron 142-146 transthyretin Homo sapiens 76-80 26235916-1 2016 Transthyretin (TTR) is a 54 kDa homotetrameric protein that transports thyroxine (T4) and retinol (vitamin A), through its association with retinol binding protein (RBP). Vitamin A 99-108 transthyretin Homo sapiens 15-18 26235916-4 2016 The use of polyethylene glycol (PEG) instead of ammonium sulphate or citrate has been evaluated as an alternative to obtain new TTR complexes with (R)-3-(9-fluoren-9-ylideneaminooxy)-2-methyl-N-(methylsulfonyl) propionamide (48R(1)) and 2-(9H-fluoren-9-ylideneaminooxy) acetic acid (ES8(2)). Polyethylene Glycols 11-30 transthyretin Homo sapiens 128-131 27353397-1 2016 Neisseria gonorrhoeae produces two transferrin binding proteins, TbpA and TbpB, which together enable efficient iron transport from human transferrin. Iron 112-116 transthyretin Homo sapiens 65-69 26235916-4 2016 The use of polyethylene glycol (PEG) instead of ammonium sulphate or citrate has been evaluated as an alternative to obtain new TTR complexes with (R)-3-(9-fluoren-9-ylideneaminooxy)-2-methyl-N-(methylsulfonyl) propionamide (48R(1)) and 2-(9H-fluoren-9-ylideneaminooxy) acetic acid (ES8(2)). Polyethylene Glycols 32-35 transthyretin Homo sapiens 128-131 26235916-4 2016 The use of polyethylene glycol (PEG) instead of ammonium sulphate or citrate has been evaluated as an alternative to obtain new TTR complexes with (R)-3-(9-fluoren-9-ylideneaminooxy)-2-methyl-N-(methylsulfonyl) propionamide (48R(1)) and 2-(9H-fluoren-9-ylideneaminooxy) acetic acid (ES8(2)). (r)-3-(9-fluoren-9-ylideneaminooxy)-2-methyl-n-(methylsulfonyl) propionamide 147-223 transthyretin Homo sapiens 128-131 27355239-2 2016 IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2"-O-(2-methoxyethyl) modified "2"-MOE" antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. 2"-o-(2-methoxyethyl) 46-67 transthyretin Homo sapiens 6-9 26235916-4 2016 The use of polyethylene glycol (PEG) instead of ammonium sulphate or citrate has been evaluated as an alternative to obtain new TTR complexes with (R)-3-(9-fluoren-9-ylideneaminooxy)-2-methyl-N-(methylsulfonyl) propionamide (48R(1)) and 2-(9H-fluoren-9-ylideneaminooxy) acetic acid (ES8(2)). 2-(9H-fluoren-9-ylideneaminooxy)acetic acid 237-281 transthyretin Homo sapiens 128-131 26235916-4 2016 The use of polyethylene glycol (PEG) instead of ammonium sulphate or citrate has been evaluated as an alternative to obtain new TTR complexes with (R)-3-(9-fluoren-9-ylideneaminooxy)-2-methyl-N-(methylsulfonyl) propionamide (48R(1)) and 2-(9H-fluoren-9-ylideneaminooxy) acetic acid (ES8(2)). es8 283-286 transthyretin Homo sapiens 128-131 27355239-2 2016 IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2"-O-(2-methoxyethyl) modified "2"-MOE" antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. 2"-o-(2-methoxyethyl) 46-67 transthyretin Homo sapiens 135-138 27355239-2 2016 IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2"-O-(2-methoxyethyl) modified "2"-MOE" antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. 2"-o-(2-methoxyethyl) 46-67 transthyretin Homo sapiens 135-138 27355239-2 2016 IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2"-O-(2-methoxyethyl) modified "2"-MOE" antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. Oligonucleotides 96-111 transthyretin Homo sapiens 6-9 27355239-2 2016 IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2"-O-(2-methoxyethyl) modified "2"-MOE" antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. Oligonucleotides 96-111 transthyretin Homo sapiens 135-138 27355239-2 2016 IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2"-O-(2-methoxyethyl) modified "2"-MOE" antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. Oligonucleotides 96-111 transthyretin Homo sapiens 135-138 27355239-2 2016 IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2"-O-(2-methoxyethyl) modified "2"-MOE" antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. Oligonucleotides, Antisense 113-116 transthyretin Homo sapiens 6-9 27355239-2 2016 IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2"-O-(2-methoxyethyl) modified "2"-MOE" antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. Oligonucleotides, Antisense 113-116 transthyretin Homo sapiens 135-138 27355239-2 2016 IONIS-TTRRx (ISIS 420915) is a 2nd-Generation 2"-O-(2-methoxyethyl) modified "2"-MOE" antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the TTR transcript through an RNaseH1 mechanism of action, leading to reductions in both mutant and wild-type TTR protein. Oligonucleotides, Antisense 113-116 transthyretin Homo sapiens 135-138 27402536-1 2016 Transthyretin (TTR) is a 54 kDa homotetrameric serum protein that transports thyroxine (T4) and retinol. Thyroxine 77-86 transthyretin Homo sapiens 0-13 25379806-1 2016 Glycyrrhetinic acid-modified chitosan (mGA-suc-CTS) is used as liver-targeted carrier for drug delivery. Glycyrrhetinic Acid 0-19 transthyretin Homo sapiens 47-50 27402536-1 2016 Transthyretin (TTR) is a 54 kDa homotetrameric serum protein that transports thyroxine (T4) and retinol. Thyroxine 77-86 transthyretin Homo sapiens 15-18 27402536-1 2016 Transthyretin (TTR) is a 54 kDa homotetrameric serum protein that transports thyroxine (T4) and retinol. Vitamin A 96-103 transthyretin Homo sapiens 0-13 27402536-1 2016 Transthyretin (TTR) is a 54 kDa homotetrameric serum protein that transports thyroxine (T4) and retinol. Vitamin A 96-103 transthyretin Homo sapiens 15-18 27402536-4 2016 Soaking TTR crystals in a solution containing rhenium tris-carbonyl derivatives yields a TTR conformer never observed before. rhenium tris 46-58 transthyretin Homo sapiens 8-11 27402536-4 2016 Soaking TTR crystals in a solution containing rhenium tris-carbonyl derivatives yields a TTR conformer never observed before. rhenium tris 46-58 transthyretin Homo sapiens 89-92 27402536-8 2016 The conformational changes observed, which include Leu(82), may represent a form of TTR better at scavenging beta-Amyloid. Leucine 51-54 transthyretin Homo sapiens 84-87 27528273-5 2016 Based on these results, it was estimated that displacement of T4 from TTR by perfluorooctane sulfonate and perfluorooctanoic acids would be significant for the occupationally exposed workers but not the general population. perfluorooctane sulfonic acid 77-102 transthyretin Homo sapiens 70-73 27584576-2 2016 Two compounds that knockdown TTR, comprising a small interfering RNA (siRNA; ALN-TTR-02) and an antisense oligonucleotide (ASO; IONIS-TTRRx), are currently being evaluated in clinical trials. Oligonucleotides 106-121 transthyretin Homo sapiens 29-32 27584576-2 2016 Two compounds that knockdown TTR, comprising a small interfering RNA (siRNA; ALN-TTR-02) and an antisense oligonucleotide (ASO; IONIS-TTRRx), are currently being evaluated in clinical trials. Oligonucleotides, Antisense 123-126 transthyretin Homo sapiens 29-32 27584576-8 2016 A significant downregulation (>80%) of TTR mRNA was induced in the HLCs by both oligonucleotides. Oligonucleotides 80-96 transthyretin Homo sapiens 39-42 27311939-3 2016 Here MS, thioflavin T fluorescence, and crystallographic data demonstrate that while the X-ray structures of unlabeled and deuterium-labeled TTR are essentially identical, subunit exchange kinetics and amyloid formation are accelerated for the deuterated protein. Deuterium 123-132 transthyretin Homo sapiens 141-144 27085542-1 2016 Anticoagulation (AC) clinics use the percentage of time in the therapeutic INR range (%TTR) to characterize the quality of management for patients treated with warfarin. Warfarin 160-168 transthyretin Homo sapiens 87-90 27528273-3 2016 Most of the tested PFASs bound TTR with relative potency (RP) values of 3x10(-4) to 0.24 when compared with that of the natural ligand thyroxine, whereas fluorotelomer alcohols did not bind. Thyroxine 135-144 transthyretin Homo sapiens 31-34 27159149-2 2016 Some nutraceuticals, such as flavonoids and natural polyphenols, have recently been investigated as modulators of the self-assembly process of TTR, but they generally suffer from limited bioavailability. Flavonoids 29-39 transthyretin Homo sapiens 143-146 27159149-2 2016 Some nutraceuticals, such as flavonoids and natural polyphenols, have recently been investigated as modulators of the self-assembly process of TTR, but they generally suffer from limited bioavailability. Polyphenols 52-63 transthyretin Homo sapiens 143-146 27501389-1 2016 Ageing and mutations of transthyretin (TTR), the thyroid hormones and retinol transporting protein lead to amyloidosis by destabilizing the structure of TTR. Vitamin A 70-77 transthyretin Homo sapiens 24-37 27501389-1 2016 Ageing and mutations of transthyretin (TTR), the thyroid hormones and retinol transporting protein lead to amyloidosis by destabilizing the structure of TTR. Vitamin A 70-77 transthyretin Homo sapiens 153-156 27501389-4 2016 Surprisingly, despite our presumptions, we found that Ubc9 fused to TTR was SUMOylated at a unique set of lysine residues. Lysine 106-112 transthyretin Homo sapiens 68-71 27501389-7 2016 SUMOylation of the lysine residues of TTR fused to Ubc9 was hardly detectable. Lysine 19-25 transthyretin Homo sapiens 38-41 27528273-5 2016 Based on these results, it was estimated that displacement of T4 from TTR by perfluorooctane sulfonate and perfluorooctanoic acids would be significant for the occupationally exposed workers but not the general population. perfluorooctanoic acid 107-130 transthyretin Homo sapiens 70-73 27528273-9 2016 Molecular docking showed that the PFASs bind to TTR with their acid group forming a hydrogen bond with K15 and the hydrophobic chain towards the interior. Hydrogen 84-92 transthyretin Homo sapiens 48-51 27350016-4 2016 Diagnosis of TTR-CA was based on echocardiography and either gadolinium-enhanced (LGE) cardiac magnetic resonance (cMRI) or radionuclide imaging. Gadolinium 61-71 transthyretin Homo sapiens 13-16 27652282-2 2016 It results from a G to A transition at a CG dinucleotide in the codon for amino acid 122 of the mature protein (TTR V122I). cytidylyl-3'-5'-guanosine 41-56 transthyretin Homo sapiens 112-115 27144293-0 2016 Novel trans-Stilbene-based Fluorophores as Probes for Spectral Discrimination of Native and Protofibrillar Transthyretin. Stilbenes 6-20 transthyretin Homo sapiens 107-120 27144293-0 2016 Novel trans-Stilbene-based Fluorophores as Probes for Spectral Discrimination of Native and Protofibrillar Transthyretin. fluorophores 27-39 transthyretin Homo sapiens 107-120 27144293-4 2016 Other compounds, such as thioflavin T, bind TTR amyloid fibrils. thioflavin T 25-37 transthyretin Homo sapiens 44-47 27144293-5 2016 The probe 1-anilinonaphthalene-8-sulfonate (ANS) binds to both native and fibrillar TTR, becoming highly fluorescent, but with indistinguishable emission spectra for native and fibrillar TTR. 1-anilinonaphthalene-8-sulfonate 10-42 transthyretin Homo sapiens 84-87 27144293-5 2016 The probe 1-anilinonaphthalene-8-sulfonate (ANS) binds to both native and fibrillar TTR, becoming highly fluorescent, but with indistinguishable emission spectra for native and fibrillar TTR. 1-anilinonaphthalene-8-sulfonate 10-42 transthyretin Homo sapiens 187-190 27144293-5 2016 The probe 1-anilinonaphthalene-8-sulfonate (ANS) binds to both native and fibrillar TTR, becoming highly fluorescent, but with indistinguishable emission spectra for native and fibrillar TTR. 1-anilino-8-naphthalenesulfonate 44-47 transthyretin Homo sapiens 84-87 27144293-5 2016 The probe 1-anilinonaphthalene-8-sulfonate (ANS) binds to both native and fibrillar TTR, becoming highly fluorescent, but with indistinguishable emission spectra for native and fibrillar TTR. 1-anilino-8-naphthalenesulfonate 44-47 transthyretin Homo sapiens 187-190 27144293-9 2016 We successfully developed two naphthyl-based trans-stilbenes probes that detect both TTR states at physiological concentrations. naphthyl-based trans-stilbenes 30-60 transthyretin Homo sapiens 85-88 27144293-13 2016 In conclusion, we identified two trans-stilbene-based fluorescent probes, (E)-4-(2-(naphthalen-1-yl)vinyl)benzene-1,2-diol (11) and (E)-4-(2-(naphthalen-2-yl)vinyl)benzene-1,2-diol (14), that bind native and protofibrillar TTR, providing a wide difference in emission maxima allowing conformational discrimination by fluorescence spectroscopy. Stilbenes 33-47 transthyretin Homo sapiens 223-226 27144293-13 2016 In conclusion, we identified two trans-stilbene-based fluorescent probes, (E)-4-(2-(naphthalen-1-yl)vinyl)benzene-1,2-diol (11) and (E)-4-(2-(naphthalen-2-yl)vinyl)benzene-1,2-diol (14), that bind native and protofibrillar TTR, providing a wide difference in emission maxima allowing conformational discrimination by fluorescence spectroscopy. (e)-4-(2-(naphthalen-1-yl)vinyl)benzene-1,2-diol 74-122 transthyretin Homo sapiens 223-226 27208169-3 2016 We previously discovered that amyloid fibrils from ATTR patients are glycated by methylglyoxal. Pyruvaldehyde 81-94 transthyretin Homo sapiens 51-55 27208169-7 2016 Here we show the existence of a proteostasis imbalance in ATTR linked to fibrinogen glycation by methylglyoxal. Pyruvaldehyde 97-110 transthyretin Homo sapiens 58-62 26939675-1 2016 The aim of this study was to evaluate the relationship between 25-hydroxyvitamin D (25(OH)D) levels and carpal tunnel syndrome (CTS). 25-hydroxyvitamin D 63-82 transthyretin Homo sapiens 128-131 27091638-0 2016 Sources of variation of transthyretin in healthy subjects in East and Southeast Asia: Clinical and experimental evidence for the effect of alcohol on transthyretin metabolism. Alcohols 139-146 transthyretin Homo sapiens 150-163 27091638-5 2016 We also investigated the direct alcohol effect of TTR expression by assessing TTR mRNA and protein levels in vivo and in vitro experiments. Alcohols 32-39 transthyretin Homo sapiens 50-53 27091638-7 2016 Multiple regression analysis revealed that serum TTR concentrations increased with age, BMI, and the level of daily alcohol consumption after adjustment for a slight regional difference. Alcohols 116-123 transthyretin Homo sapiens 49-52 27091638-8 2016 Moreover, TTR expression was up-regulated by alcohol treatment through hepatocyte nuclear factor 4alpha (HNF-4alpha) in vitro and in vivo experiments. Alcohols 45-52 transthyretin Homo sapiens 10-13 27091638-9 2016 CONCLUSIONS: Sex, aging, BMI, and the level of daily alcohol consumption may be the factors affecting serum TTR concentrations in healthy subjects. Alcohols 53-60 transthyretin Homo sapiens 108-111 27274067-4 2016 A comparison of experimental and simulated 2D TTR spectra of bromoform (CHBr3), carbon tetrachloride (CCl4), and dibromodichloromethane (CBr2Cl2) shows previously unobserved off-diagonal anharmonic coupling between thermally populated vibrational modes. bromoform 72-77 transthyretin Homo sapiens 46-49 27159901-9 2016 The ACGIH TLV method predicted both CTS symptoms [HR between AL and TLV 2.18, 95% confidence interval (95% CI) 1.86-2.56; above TLV 2.07, 95% CI 1.52-2.81] and CTS confirmed by NCS (HR between AL and TLV 1.93, 95% CI 1.38-2.71; above TLV 1.95, 95% CI 1.27-3.00). Aluminum 62-64 transthyretin Homo sapiens 37-40 27159901-9 2016 The ACGIH TLV method predicted both CTS symptoms [HR between AL and TLV 2.18, 95% confidence interval (95% CI) 1.86-2.56; above TLV 2.07, 95% CI 1.52-2.81] and CTS confirmed by NCS (HR between AL and TLV 1.93, 95% CI 1.38-2.71; above TLV 1.95, 95% CI 1.27-3.00). Aluminum 194-196 transthyretin Homo sapiens 37-40 27274067-4 2016 A comparison of experimental and simulated 2D TTR spectra of bromoform (CHBr3), carbon tetrachloride (CCl4), and dibromodichloromethane (CBr2Cl2) shows previously unobserved off-diagonal anharmonic coupling between thermally populated vibrational modes. Carbon Tetrachloride 80-100 transthyretin Homo sapiens 46-49 27274067-4 2016 A comparison of experimental and simulated 2D TTR spectra of bromoform (CHBr3), carbon tetrachloride (CCl4), and dibromodichloromethane (CBr2Cl2) shows previously unobserved off-diagonal anharmonic coupling between thermally populated vibrational modes. DIBROMODICHLOROMETHANE 113-135 transthyretin Homo sapiens 46-49 27274067-4 2016 A comparison of experimental and simulated 2D TTR spectra of bromoform (CHBr3), carbon tetrachloride (CCl4), and dibromodichloromethane (CBr2Cl2) shows previously unobserved off-diagonal anharmonic coupling between thermally populated vibrational modes. Dibromodichlorosilane 137-144 transthyretin Homo sapiens 46-49 27376049-9 2016 Distal sensory latency and distal motor latency (DML) of median nerve and fourth digit median-ulnar peak latency differences (PM4-PU4) for CTS group was significantly higher (P < 0.001) and mean for sensory nerve conduction velocity was significantly higher in control group (P < 0.001). pm4-pu4 126-133 transthyretin Homo sapiens 139-142 27345002-3 2016 We evaluated the utility of the premotor potential latency analysis (i.e., premotor potential study; PPS) for CTS electrodiagnosis. Pentosan Sulfuric Polyester 101-104 transthyretin Homo sapiens 110-113 27366679-9 2016 CONCLUSION: hREC growth is inhibited by exogenous TTR under simulated DR environments with high-glucose and hypoxic, particularly in the medium containing 25 mmol/L glucose. Glucose 96-103 transthyretin Homo sapiens 50-53 27366679-9 2016 CONCLUSION: hREC growth is inhibited by exogenous TTR under simulated DR environments with high-glucose and hypoxic, particularly in the medium containing 25 mmol/L glucose. Glucose 165-172 transthyretin Homo sapiens 50-53 26987044-3 2016 Here we report that a luminescent conjugated oligothiophene, h-FTAA, rapidly and with high sensitivity and selectivity detects amyloid deposits in verified clinical samples from systemic amyloidosis patients with AA, AL and ATTR types; as well as in tissues laden with localized amyloidosis of AANF, AIAPP and ASem1 type. oligothiophene 45-59 transthyretin Homo sapiens 224-228 26987044-3 2016 Here we report that a luminescent conjugated oligothiophene, h-FTAA, rapidly and with high sensitivity and selectivity detects amyloid deposits in verified clinical samples from systemic amyloidosis patients with AA, AL and ATTR types; as well as in tissues laden with localized amyloidosis of AANF, AIAPP and ASem1 type. h-ftaa 61-67 transthyretin Homo sapiens 224-228 27224432-10 2016 DISCUSSION: In patients with CTS, PCP is not associated with cervical radiculopathy. pcp 34-37 transthyretin Homo sapiens 29-32 27446786-8 2016 CONCLUSION: The results of our study suggest that the symptoms of CTS in patients with diabetes are related to CSA of the median nerve, which is consistent with swelling of the nerve. Cyclosporine 111-114 transthyretin Homo sapiens 66-69 26243339-2 2016 The UK population is unique in that the majority of patients have the T60A missense mutation in ATTR where tyrosine is replaced by adenine at position 60. Tyrosine 107-115 transthyretin Homo sapiens 96-100 26243339-2 2016 The UK population is unique in that the majority of patients have the T60A missense mutation in ATTR where tyrosine is replaced by adenine at position 60. Adenine 131-138 transthyretin Homo sapiens 96-100 26812789-6 2016 alphaB-crystallin, clusterin and M-TTR can diminish the cytotoxic effects of the HypF-N oligomers at all chaperone concentration, as demonstrated by MTT reduction and Ca2+ influx measurements. monooxyethylene trimethylolpropane tristearate 149-152 transthyretin Homo sapiens 35-38 26943652-5 2016 The specific expression and cellular distribution of TTR were also evaluated in 104 paraffin-embedded lung cancer samples and 3 normal lung tissues by immunohistochemistry. Paraffin 84-92 transthyretin Homo sapiens 53-56 26894299-1 2016 Transthyretin (TTR) transports the retinol-binding protein-vitamin A complex and is a minor transporter of thyroxine in blood. Vitamin A 59-68 transthyretin Homo sapiens 0-13 26894299-1 2016 Transthyretin (TTR) transports the retinol-binding protein-vitamin A complex and is a minor transporter of thyroxine in blood. Vitamin A 59-68 transthyretin Homo sapiens 15-18 26894299-1 2016 Transthyretin (TTR) transports the retinol-binding protein-vitamin A complex and is a minor transporter of thyroxine in blood. Thyroxine 107-116 transthyretin Homo sapiens 0-13 26894299-1 2016 Transthyretin (TTR) transports the retinol-binding protein-vitamin A complex and is a minor transporter of thyroxine in blood. Thyroxine 107-116 transthyretin Homo sapiens 15-18 26894299-7 2016 Tafamidis meglumine is a rationally designed, non-NSAID benzoxazole derivative that binds with high affinity and selectivity to TTR and kinetically stabilizes the tetramer, slowing monomer formation, misfolding, and amyloidogenesis. tafamidis 0-19 transthyretin Homo sapiens 128-131 26894299-7 2016 Tafamidis meglumine is a rationally designed, non-NSAID benzoxazole derivative that binds with high affinity and selectivity to TTR and kinetically stabilizes the tetramer, slowing monomer formation, misfolding, and amyloidogenesis. Benzoxazoles 56-67 transthyretin Homo sapiens 128-131 27099354-8 2016 In vivo, the lone cysteine in TTR is frequently modified by S-cysteinylation or S-sulfonation. Cysteine 18-26 transthyretin Homo sapiens 30-33 27052822-3 2016 Furthermore, it is also presented a novel sample pretreatment based on immunoprecipitation (IP) using Protein A Ultrarapid Agarose (UAPA) magnetic beads (MBs) to purify TTR from serum samples. Sepharose 123-130 transthyretin Homo sapiens 170-173 26984605-2 2016 There have been a few encouraging studies on Tafamidis efficacy in early-onset inherited transthyretin amyloidosis (ATTR) due to Val30Met mutation. tafamidis 45-54 transthyretin Homo sapiens 116-120 26984605-4 2016 We performed a multi-center observational study on symptomatic ATTR patients prescribed to receive Tafamidis. tafamidis 99-108 transthyretin Homo sapiens 63-67 26729422-1 2016 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP4) which, in turn, associates with another serum protein, transthyretin (TTR), to form a ternary retinol-RBP4-TTR complex. Vitamin A 0-9 transthyretin Homo sapiens 135-148 26729422-1 2016 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP4) which, in turn, associates with another serum protein, transthyretin (TTR), to form a ternary retinol-RBP4-TTR complex. Vitamin A 0-9 transthyretin Homo sapiens 150-153 26729422-1 2016 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP4) which, in turn, associates with another serum protein, transthyretin (TTR), to form a ternary retinol-RBP4-TTR complex. Vitamin A 0-9 transthyretin Homo sapiens 187-190 26729422-1 2016 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP4) which, in turn, associates with another serum protein, transthyretin (TTR), to form a ternary retinol-RBP4-TTR complex. Vitamin A 11-18 transthyretin Homo sapiens 135-148 26729422-1 2016 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP4) which, in turn, associates with another serum protein, transthyretin (TTR), to form a ternary retinol-RBP4-TTR complex. Vitamin A 11-18 transthyretin Homo sapiens 150-153 26729422-1 2016 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP4) which, in turn, associates with another serum protein, transthyretin (TTR), to form a ternary retinol-RBP4-TTR complex. Vitamin A 11-18 transthyretin Homo sapiens 187-190 27072093-12 2016 SIGNIFICANCE: Abnormal feet responses on Sudoscan support early diagnosis in TTR-FAP. sudoscan 41-49 transthyretin Homo sapiens 77-80 27052822-3 2016 Furthermore, it is also presented a novel sample pretreatment based on immunoprecipitation (IP) using Protein A Ultrarapid Agarose (UAPA) magnetic beads (MBs) to purify TTR from serum samples. uapa 133-137 transthyretin Homo sapiens 170-173 27093678-0 2016 Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer. tetrabromobisphenol A 0-21 transthyretin Homo sapiens 56-69 27093678-4 2016 In this study we show that the commonly used flame retardant tetrabromobisphenol A (TBBPA) efficiently stabilizes the tetrameric structure of TTR. tetrabromobisphenol A 61-82 transthyretin Homo sapiens 142-145 27093678-4 2016 In this study we show that the commonly used flame retardant tetrabromobisphenol A (TBBPA) efficiently stabilizes the tetrameric structure of TTR. tetrabromobisphenol A 84-89 transthyretin Homo sapiens 142-145 27093678-6 2016 Interestingly, TBBPA binds TTR with an extremely high selectivity in human plasma, and the effect is equal to the recently approved drug tafamidis and better than diflunisal, both of which have shown therapeutic effects against FAP. tetrabromobisphenol A 15-20 transthyretin Homo sapiens 27-30 27048727-3 2016 The change in Si atom coordinate, Six, gives Ttr - Tc = 0.49 K, which indicates an alpha beta transition that is weakly first order and nearly tricritical in character (Q(4) T). Silicon 14-16 transthyretin Homo sapiens 45-48 27050398-3 2016 We have recently shown that the flavonoid luteolin stabilizes TTR in human plasma with a very high selectivity. Flavonoids 32-41 transthyretin Homo sapiens 62-65 26796656-0 2016 A new crystal form of human transthyretin obtained with a curcumin derived ligand. Curcumin 58-66 transthyretin Homo sapiens 28-41 26657237-2 2016 In this study, the authors aimed at comparing the clinical and electrophysiologic recovery of CTS after local steroid injection and operation. Steroids 110-117 transthyretin Homo sapiens 94-97 26657237-12 2016 And surgery is more effective technique than steroid injection for the treatment of the moderate CTS in the long term. Steroids 45-52 transthyretin Homo sapiens 97-100 26796656-1 2016 Transthyretin (TTR), a 54kDa homotetrameric protein that transports thyroxine (T4), has been associated with clinical cases of TTR amyloidosis for its tendency to aggregate to form fibrils. Thyroxine 68-77 transthyretin Homo sapiens 0-13 26796656-1 2016 Transthyretin (TTR), a 54kDa homotetrameric protein that transports thyroxine (T4), has been associated with clinical cases of TTR amyloidosis for its tendency to aggregate to form fibrils. Thyroxine 68-77 transthyretin Homo sapiens 15-18 26796656-1 2016 Transthyretin (TTR), a 54kDa homotetrameric protein that transports thyroxine (T4), has been associated with clinical cases of TTR amyloidosis for its tendency to aggregate to form fibrils. Thyroxine 68-77 transthyretin Homo sapiens 127-130 26796656-6 2016 Further investigations with the use of polyethylene glycol (PEG) to crystallize TTR complexes have resulted in a new trigonal polymorph with two tetramers in the asymmetric unit. Polyethylene Glycols 39-58 transthyretin Homo sapiens 80-83 26796656-6 2016 Further investigations with the use of polyethylene glycol (PEG) to crystallize TTR complexes have resulted in a new trigonal polymorph with two tetramers in the asymmetric unit. Polyethylene Glycols 60-63 transthyretin Homo sapiens 80-83 26592430-14 2016 Canadian clinicians are encouraged to adhere to the AANEM/AAN/AAPM&R Practice Parameter for Electrodiagnostic Studies in CTS. Adenosine Monophosphate 67-70 transthyretin Homo sapiens 125-128 26585303-5 2016 Our efforts so far have focused on transthyretin (TTR), a transporter of thyroxine and retinol, and amyloid precursor protein whose aggregates were detected in the PE placenta. Thyroxine 73-82 transthyretin Homo sapiens 35-48 26585303-5 2016 Our efforts so far have focused on transthyretin (TTR), a transporter of thyroxine and retinol, and amyloid precursor protein whose aggregates were detected in the PE placenta. Thyroxine 73-82 transthyretin Homo sapiens 50-53 26384643-1 2016 We developed a surface plasmon resonance (SPR) assay to estimate the competitive inhibition by pharmaceuticals for thyroxine (T4) binding to thyroid hormone transport proteins, transthyretin (TTR) and thyroxine binding globulin (TBG). Thyroxine 115-124 transthyretin Homo sapiens 177-190 26384643-1 2016 We developed a surface plasmon resonance (SPR) assay to estimate the competitive inhibition by pharmaceuticals for thyroxine (T4) binding to thyroid hormone transport proteins, transthyretin (TTR) and thyroxine binding globulin (TBG). Thyroxine 115-124 transthyretin Homo sapiens 192-195 26384643-5 2016 To estimate the competitive inhibition of tetraiodothyroacetic acid, diclofenac, genistein, ibuprofen, carbamazepine, and furosemide, reported to be competitive or noncompetitive pharmaceuticals for T4 binding to TTR or TBG, their 50% inhibition concentrations (IC50) (or 80% inhibition concentration, IC80) were calculated from the change of T4 responses in sensorgrams obtained with various concentrations of the pharmaceuticals. Furosemide 122-132 transthyretin Homo sapiens 213-216 26902880-0 2016 Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Tolcapone 14-23 transthyretin Homo sapiens 49-62 26902880-4 2016 Here we repurpose tolcapone, an FDA-approved molecule for Parkinson"s disease, as a potent TTR aggregation inhibitor. Tolcapone 18-27 transthyretin Homo sapiens 91-94 26902880-5 2016 Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity. Tolcapone 0-9 transthyretin Homo sapiens 32-35 26902880-5 2016 Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity. Tolcapone 0-9 transthyretin Homo sapiens 124-127 26902880-6 2016 Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. Tolcapone 22-31 transthyretin Homo sapiens 51-54 26902880-6 2016 Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. Tolcapone 22-31 transthyretin Homo sapiens 141-144 26902880-6 2016 Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. Tolcapone 22-31 transthyretin Homo sapiens 141-144 24176031-9 2016 Educational level, presence of arthrosis, myalgia, bone pain, arthralgia, CTS, VAS-hand and VAS-upper extremities scales, DHI and BDI scores significantly affected both physical and mental areas of KDQOL-36, whereas age, shoulder periarthritis, mobilization scores and presence of hypertension only had effects on physical areas. kdqol 198-203 transthyretin Homo sapiens 74-77 26869763-4 2016 This study aimed to prepare and optimize the formulation of chitosan/phospholipid/beta-cyclodextrin (CTS/PL/beta-CD) microspheres that can improve cognitive impairment. betadex 82-99 transthyretin Homo sapiens 101-107 26869763-9 2016 Fourier transform infrared spectroscopy and differential scanning calorimetry proved that PLs formed hydrogen bonds with the amide group of CTS and the hydroxyl group of beta-CD. Hydrogen 101-109 transthyretin Homo sapiens 140-143 26869763-9 2016 Fourier transform infrared spectroscopy and differential scanning calorimetry proved that PLs formed hydrogen bonds with the amide group of CTS and the hydroxyl group of beta-CD. Amides 125-130 transthyretin Homo sapiens 140-143 27228663-1 2016 By means of spectrophotometric assay we investigated interaction of the dye Congo red (CR) with fibrils of model proteins--hen egg white lysozyme, recombinant human beta2-microglobulin (b2M) and recombinant human transthyretin (TTR). Congo Red 76-85 transthyretin Homo sapiens 213-226 27650990-1 2016 Since transthyretin (TTR) was discovered, it has been regarded as a serum protein carrier of thyroid hormones and retinol. Vitamin A 114-121 transthyretin Homo sapiens 6-19 27650990-1 2016 Since transthyretin (TTR) was discovered, it has been regarded as a serum protein carrier of thyroid hormones and retinol. Vitamin A 114-121 transthyretin Homo sapiens 21-24 26800456-7 2016 EXPERT OPINION: Due to the data on efficacy, tolerability, safety, tafamidis and diflunisal became the first line anti-amyloid treatment in stage 1 TTR-FAP. tafamidis 67-76 transthyretin Homo sapiens 148-151 26800456-7 2016 EXPERT OPINION: Due to the data on efficacy, tolerability, safety, tafamidis and diflunisal became the first line anti-amyloid treatment in stage 1 TTR-FAP. Diflunisal 81-91 transthyretin Homo sapiens 148-151 27067161-0 2016 Synthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR). Halogens 37-44 transthyretin Homo sapiens 94-107 27067161-0 2016 Synthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR). Halogens 37-44 transthyretin Homo sapiens 109-112 27067161-3 2016 Here, we report the synthesis, the in vitro evaluation of several halogen substituted 9-fluorenyl- and di-benzophenon-based ligands and their three-dimensional crystallographic analysis in complex with TTR. Halogens 66-73 transthyretin Homo sapiens 202-205 27067161-3 2016 Here, we report the synthesis, the in vitro evaluation of several halogen substituted 9-fluorenyl- and di-benzophenon-based ligands and their three-dimensional crystallographic analysis in complex with TTR. 9-fluorenyl- and di-benzophenon 86-117 transthyretin Homo sapiens 202-205 27228663-1 2016 By means of spectrophotometric assay we investigated interaction of the dye Congo red (CR) with fibrils of model proteins--hen egg white lysozyme, recombinant human beta2-microglobulin (b2M) and recombinant human transthyretin (TTR). Congo Red 76-85 transthyretin Homo sapiens 228-231 27228663-5 2016 According to the data on titration of fibril solutions with excess of the dye, CR binds to lysozyme fibrils at a ratio of about 5 molecules per protein monomer within fibril structure, to b2M fibrils--about 4 molecules per monomer, to TTR fibrils--about 4 molecules per subunit of the protein. Congo Red 79-81 transthyretin Homo sapiens 235-238 26662359-2 2015 Tafamidis, or 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylic acid, selectively binds to TTR with negative cooperativity and kinetically stabilizes wild-type native TTR and mutant TTR; tafamidis therefore has the potential to halt the amyloidogenic cascade initiated by TTR tetramer dissociation, monomer misfolding, and aggregation. tafamidis 14-67 transthyretin Homo sapiens 90-93 26468275-0 2015 Transthyretin Binding Heterogeneity and Anti-amyloidogenic Activity of Natural Polyphenols and Their Metabolites. Polyphenols 79-90 transthyretin Homo sapiens 0-13 26468275-2 2015 The ability to inhibit TTR fibrillogenesis is known for several classes of compounds, including natural polyphenols, which protect the native state of TTR by specifically interacting with its thyroxine binding sites. Polyphenols 104-115 transthyretin Homo sapiens 23-26 26468275-2 2015 The ability to inhibit TTR fibrillogenesis is known for several classes of compounds, including natural polyphenols, which protect the native state of TTR by specifically interacting with its thyroxine binding sites. Polyphenols 104-115 transthyretin Homo sapiens 151-154 26468275-2 2015 The ability to inhibit TTR fibrillogenesis is known for several classes of compounds, including natural polyphenols, which protect the native state of TTR by specifically interacting with its thyroxine binding sites. Thyroxine 192-201 transthyretin Homo sapiens 23-26 26468275-2 2015 The ability to inhibit TTR fibrillogenesis is known for several classes of compounds, including natural polyphenols, which protect the native state of TTR by specifically interacting with its thyroxine binding sites. Thyroxine 192-201 transthyretin Homo sapiens 151-154 26468275-3 2015 Comparative analyses of the interaction and of the ability to protect the TTR native state for polyphenols, both stilbenoids and flavonoids, and some of their main metabolites have been carried out. Polyphenols 95-106 transthyretin Homo sapiens 74-77 26468275-3 2015 Comparative analyses of the interaction and of the ability to protect the TTR native state for polyphenols, both stilbenoids and flavonoids, and some of their main metabolites have been carried out. stilbenoids 113-124 transthyretin Homo sapiens 74-77 26468275-3 2015 Comparative analyses of the interaction and of the ability to protect the TTR native state for polyphenols, both stilbenoids and flavonoids, and some of their main metabolites have been carried out. Flavonoids 129-139 transthyretin Homo sapiens 74-77 26468275-4 2015 A main finding of this investigation was the highly preferential binding of resveratrol and thyroxine, both characterized by negative binding cooperativity, to distinct sites in TTR, consistent with the data of x-ray analysis of TTR in complex with both ligands. Resveratrol 76-87 transthyretin Homo sapiens 178-181 26468275-4 2015 A main finding of this investigation was the highly preferential binding of resveratrol and thyroxine, both characterized by negative binding cooperativity, to distinct sites in TTR, consistent with the data of x-ray analysis of TTR in complex with both ligands. Resveratrol 76-87 transthyretin Homo sapiens 229-232 26468275-4 2015 A main finding of this investigation was the highly preferential binding of resveratrol and thyroxine, both characterized by negative binding cooperativity, to distinct sites in TTR, consistent with the data of x-ray analysis of TTR in complex with both ligands. Thyroxine 92-101 transthyretin Homo sapiens 178-181 26468275-4 2015 A main finding of this investigation was the highly preferential binding of resveratrol and thyroxine, both characterized by negative binding cooperativity, to distinct sites in TTR, consistent with the data of x-ray analysis of TTR in complex with both ligands. Thyroxine 92-101 transthyretin Homo sapiens 229-232 26468275-5 2015 Although revealing the ability of the two thyroxine binding sites of TTR to discriminate between different ligands, this feature has allowed us to evaluate the interactions of polyphenols with both resveratrol and thyroxine preferential binding sites, by using resveratrol and radiolabeled T4 as probes. Thyroxine 42-51 transthyretin Homo sapiens 69-72 26468275-9 2015 A rationale for the in vitro properties found for polyphenol metabolites was provided by x-ray analysis of their complexes with TTR. Polyphenols 50-60 transthyretin Homo sapiens 128-131 26306725-6 2015 The amyloid fibril deposits in the ATTR Y114H patient had an altered structure compared with that in wild-type ATTR patients, as determined by luminescent conjugated poly/oligo-thiophene fluorescence spectroscopy. poly/oligo-thiophene 166-186 transthyretin Homo sapiens 35-39 26849806-5 2016 (99m)Tc-DPD scintigraphy is a highly sensitive method for diagnosing heart involvement in ATTR amyloidosis. tc-dpd 5-11 transthyretin Homo sapiens 90-94 26849806-6 2016 The objective of this study was to determine the relationship between ATTR fibril composition and (99m)Tc-DPD scintigraphy outcome in patients with biopsy-proven ATTR amyloidosis. tc-dpd 103-109 transthyretin Homo sapiens 70-74 26849806-6 2016 The objective of this study was to determine the relationship between ATTR fibril composition and (99m)Tc-DPD scintigraphy outcome in patients with biopsy-proven ATTR amyloidosis. tc-dpd 103-109 transthyretin Homo sapiens 162-166 26849806-13 2016 Conclusion In ATTR amyloidosis, the outcome of (99m)Tc-DPD scintigraphy is strongly related to the patients" transthyretin amyloid fibril composition. tc-dpd 52-58 transthyretin Homo sapiens 14-18 26849806-13 2016 Conclusion In ATTR amyloidosis, the outcome of (99m)Tc-DPD scintigraphy is strongly related to the patients" transthyretin amyloid fibril composition. tc-dpd 52-58 transthyretin Homo sapiens 109-122 26662359-2 2015 Tafamidis, or 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylic acid, selectively binds to TTR with negative cooperativity and kinetically stabilizes wild-type native TTR and mutant TTR; tafamidis therefore has the potential to halt the amyloidogenic cascade initiated by TTR tetramer dissociation, monomer misfolding, and aggregation. tafamidis 14-67 transthyretin Homo sapiens 166-169 26662359-2 2015 Tafamidis, or 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylic acid, selectively binds to TTR with negative cooperativity and kinetically stabilizes wild-type native TTR and mutant TTR; tafamidis therefore has the potential to halt the amyloidogenic cascade initiated by TTR tetramer dissociation, monomer misfolding, and aggregation. tafamidis 14-67 transthyretin Homo sapiens 166-169 26662359-2 2015 Tafamidis, or 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylic acid, selectively binds to TTR with negative cooperativity and kinetically stabilizes wild-type native TTR and mutant TTR; tafamidis therefore has the potential to halt the amyloidogenic cascade initiated by TTR tetramer dissociation, monomer misfolding, and aggregation. tafamidis 14-67 transthyretin Homo sapiens 166-169 26444498-1 2015 An effective Friedel-Crafts alkylation reaction of electron-rich aromatics with N-vinylamides, induced by electrochemically in situ-generated TBPA radical cation, has been developed; the resulting adducts are produced in good to excellent yields. friedel 13-20 transthyretin Homo sapiens 142-146 26444498-1 2015 An effective Friedel-Crafts alkylation reaction of electron-rich aromatics with N-vinylamides, induced by electrochemically in situ-generated TBPA radical cation, has been developed; the resulting adducts are produced in good to excellent yields. n-vinylamides 80-93 transthyretin Homo sapiens 142-146 26441309-0 2015 Free Thiol of Transthyretin in Human Plasma Most Accessible to Modification/Oxidation. Sulfhydryl Compounds 5-10 transthyretin Homo sapiens 14-27 26441309-6 2015 However, contrary to our expectations, transthyretin (TTR), which also has a single free thiol, was found to be the major protein that was the most susceptible to modification/oxidation. Sulfhydryl Compounds 89-94 transthyretin Homo sapiens 39-52 26441309-6 2015 However, contrary to our expectations, transthyretin (TTR), which also has a single free thiol, was found to be the major protein that was the most susceptible to modification/oxidation. Sulfhydryl Compounds 89-94 transthyretin Homo sapiens 54-57 26441309-8 2015 The findings show that the levels of the free-thiol form of TTR in plasma was significantly lowered after a hydrogen peroxide treatment, even at low concentrations (0.1 mM), suggesting that TTR could be a useful biomarker for monitoring a ROS imbalance in relation to various oxidative stress conditions. Sulfhydryl Compounds 46-51 transthyretin Homo sapiens 60-63 26441309-8 2015 The findings show that the levels of the free-thiol form of TTR in plasma was significantly lowered after a hydrogen peroxide treatment, even at low concentrations (0.1 mM), suggesting that TTR could be a useful biomarker for monitoring a ROS imbalance in relation to various oxidative stress conditions. Sulfhydryl Compounds 46-51 transthyretin Homo sapiens 190-193 26441309-8 2015 The findings show that the levels of the free-thiol form of TTR in plasma was significantly lowered after a hydrogen peroxide treatment, even at low concentrations (0.1 mM), suggesting that TTR could be a useful biomarker for monitoring a ROS imbalance in relation to various oxidative stress conditions. Hydrogen Peroxide 108-125 transthyretin Homo sapiens 60-63 26441309-8 2015 The findings show that the levels of the free-thiol form of TTR in plasma was significantly lowered after a hydrogen peroxide treatment, even at low concentrations (0.1 mM), suggesting that TTR could be a useful biomarker for monitoring a ROS imbalance in relation to various oxidative stress conditions. Hydrogen Peroxide 108-125 transthyretin Homo sapiens 190-193 26441309-8 2015 The findings show that the levels of the free-thiol form of TTR in plasma was significantly lowered after a hydrogen peroxide treatment, even at low concentrations (0.1 mM), suggesting that TTR could be a useful biomarker for monitoring a ROS imbalance in relation to various oxidative stress conditions. Reactive Oxygen Species 239-242 transthyretin Homo sapiens 60-63 26441309-8 2015 The findings show that the levels of the free-thiol form of TTR in plasma was significantly lowered after a hydrogen peroxide treatment, even at low concentrations (0.1 mM), suggesting that TTR could be a useful biomarker for monitoring a ROS imbalance in relation to various oxidative stress conditions. Reactive Oxygen Species 239-242 transthyretin Homo sapiens 190-193 27532451-5 2015 Among those on warfarin, the median TTR was 39.2%. Warfarin 15-23 transthyretin Homo sapiens 36-39 26527142-0 2015 The putative role of some conserved water molecules in the structure and function of human transthyretin. Water 36-41 transthyretin Homo sapiens 91-104 26527142-3 2015 Extensive analyses of 32 high-resolution X-ray and neutron diffraction structures of hTTR followed by molecular-dynamics simulation studies using a set of 15 selected structures affirmed the presence of 44 conserved water molecules in its dimeric structure. Water 216-221 transthyretin Homo sapiens 85-89 26527142-8 2015 Some other water molecules control the orientation and dynamics of different structural elements of hTTR. Water 11-16 transthyretin Homo sapiens 100-104 26527142-10 2015 The present study may also provide some rational clues about the conserved water-mediated architecture and stability of hTTR. Water 75-80 transthyretin Homo sapiens 120-124 26123257-25 2015 If OAC was initiated, most received VKAs with a poor TTR during follow-up. SDZ 33-243 3-6 transthyretin Homo sapiens 53-56 26455975-7 2015 CONCLUSIONS: Transthyretin amyloidosis is usually confirmed with positive Congo red staining for amyloid identified by biopsy of peripheral nerves, salivary glands, or abdominal fat. Congo Red 74-83 transthyretin Homo sapiens 13-26 27532451-8 2015 For patients on warfarin, the incidence of gastrointestinal haemorrhage increased progressively with higher HAS-BLED scores, from 0.93%/year for those with a HAS-BLED score of <=1 to 1.68%/year for those with a HAS-BLED score of >=3, and decreased progressively with an increasing TTR from 1.69%/year for patients in the lowest quartile of TTR to only 0.51%/year for those in the top quartile. Warfarin 16-24 transthyretin Homo sapiens 287-290 27532451-8 2015 For patients on warfarin, the incidence of gastrointestinal haemorrhage increased progressively with higher HAS-BLED scores, from 0.93%/year for those with a HAS-BLED score of <=1 to 1.68%/year for those with a HAS-BLED score of >=3, and decreased progressively with an increasing TTR from 1.69%/year for patients in the lowest quartile of TTR to only 0.51%/year for those in the top quartile. Warfarin 16-24 transthyretin Homo sapiens 346-349 26437390-6 2015 Here we describe major developments that have led to the advent of therapeutic oligonucleotides for treatment of TTR-related disease. Oligonucleotides 79-95 transthyretin Homo sapiens 113-116 26367058-3 2015 Specifically, we show that HMW aggregates and dimeric pAbs present in commercial preparations of pAbs, intravenous immunoglobulin (IVIg), had up to ~200- and ~7-fold stronger binding to aggregates of Abeta and transthyretin (TTR) than the monomeric antibody. 4-Aminobenzoic Acid 97-101 transthyretin Homo sapiens 210-223 26815187-7 2015 CONCLUSION: DCS is a common clinical syndrome, and patients with DCS may have neck and shoulder symptoms in addition to the common manifestations of simple-CTS. Cycloserine 65-68 transthyretin Homo sapiens 156-159 26367058-3 2015 Specifically, we show that HMW aggregates and dimeric pAbs present in commercial preparations of pAbs, intravenous immunoglobulin (IVIg), had up to ~200- and ~7-fold stronger binding to aggregates of Abeta and transthyretin (TTR) than the monomeric antibody. 4-Aminobenzoic Acid 97-101 transthyretin Homo sapiens 225-228 26367058-3 2015 Specifically, we show that HMW aggregates and dimeric pAbs present in commercial preparations of pAbs, intravenous immunoglobulin (IVIg), had up to ~200- and ~7-fold stronger binding to aggregates of Abeta and transthyretin (TTR) than the monomeric antibody. 4-Aminobenzoic Acid 54-58 transthyretin Homo sapiens 210-223 26308415-14 2015 CONCLUSIONS: Long-term survival after Ltx, especially for early-onset TTR Val30Met patients, is excellent. Leukotriene C4 38-41 transthyretin Homo sapiens 70-73 26367058-3 2015 Specifically, we show that HMW aggregates and dimeric pAbs present in commercial preparations of pAbs, intravenous immunoglobulin (IVIg), had up to ~200- and ~7-fold stronger binding to aggregates of Abeta and transthyretin (TTR) than the monomeric antibody. 4-Aminobenzoic Acid 54-58 transthyretin Homo sapiens 225-228 25604431-8 2015 Moreover, antisense oligonucleotides and small interfering RNAs for suppression of variant and wild-type TTR synthesis are promising therapeutic approaches to ameliorate ATTR amyloidosis and are currently in phase III clinical trials. Oligonucleotides 20-36 transthyretin Homo sapiens 105-108 25604431-8 2015 Moreover, antisense oligonucleotides and small interfering RNAs for suppression of variant and wild-type TTR synthesis are promising therapeutic approaches to ameliorate ATTR amyloidosis and are currently in phase III clinical trials. Oligonucleotides 20-36 transthyretin Homo sapiens 170-174 25781688-0 2015 First trimester concentrations of the TTR-RBP4-retinol complex components as early markers of insulin-treated gestational diabetes mellitus. Vitamin A 47-54 transthyretin Homo sapiens 38-41 25781688-1 2015 BACKGROUND: The objective of the study was to investigate the relationship between first trimester maternal serum levels of the TTR-RBP4-ROH complex components and the later insurgence of an altered glucose metabolism during pregnancy. Glucose 199-206 transthyretin Homo sapiens 128-131 25781688-6 2015 TTR containing Gly10 in place of Cys10 was lower in the iGDM group (p<0.05) compared to controls. decaglycine 15-20 transthyretin Homo sapiens 0-3 26665211-7 2015 SUBJECTS AND METHODS: In this pilot study technetium-99m pyrophosphate ((99m)Tc-PYP) was administered to patients suffering from CA, aiming to differentiate scintigraphically between AL and ATTR. Technetium 42-56 transthyretin Homo sapiens 190-194 26665211-7 2015 SUBJECTS AND METHODS: In this pilot study technetium-99m pyrophosphate ((99m)Tc-PYP) was administered to patients suffering from CA, aiming to differentiate scintigraphically between AL and ATTR. diphosphoric acid 57-70 transthyretin Homo sapiens 190-194 26665211-14 2015 (99m)Tc-PYP scintigraphy revealed diffuse intense myocardial uptake upon visual evaluation that was also verified semi-quantitatively in 6 patients, all of which had ATTR. Technetium Tc 99m Pyrophosphate 5-11 transthyretin Homo sapiens 166-170 26665211-20 2015 IN CONCLUSION: These preliminary results are compatible with current international literature, and demonstrate that scintigraphy with (99m)Tc-PYP may prove a simple, non-invasive and widely available method in the identification of patients with the ATTR subtype, thus optimizing therapeutic decisions. (99m) 134-139 transthyretin Homo sapiens 250-254 26665211-20 2015 IN CONCLUSION: These preliminary results are compatible with current international literature, and demonstrate that scintigraphy with (99m)Tc-PYP may prove a simple, non-invasive and widely available method in the identification of patients with the ATTR subtype, thus optimizing therapeutic decisions. Technetium Tc 99m Pyrophosphate 139-145 transthyretin Homo sapiens 250-254 25372987-8 2015 The rest four water molecules (W6, W*, W(#) and W( )) form a distorted tetrahedral cluster and impart stability to the catalytic core of hTTR. Water 14-19 transthyretin Homo sapiens 137-141 25372987-9 2015 The conserved water mediated recognition dynamics of the different functional sites may provide some rational clues towards the understanding of the activity and mechanism of hTTR. Water 14-19 transthyretin Homo sapiens 175-179 26400472-5 2015 In order to crosslink pairs of TTR molecules, promote their accelerated clearance and thus therapeutically deplete plasma TTR, we prepared a range of bivalent specific ligands for the thyroxine binding sites of TTR. Thyroxine 184-193 transthyretin Homo sapiens 31-34 26400472-5 2015 In order to crosslink pairs of TTR molecules, promote their accelerated clearance and thus therapeutically deplete plasma TTR, we prepared a range of bivalent specific ligands for the thyroxine binding sites of TTR. Thyroxine 184-193 transthyretin Homo sapiens 122-125 26400472-5 2015 In order to crosslink pairs of TTR molecules, promote their accelerated clearance and thus therapeutically deplete plasma TTR, we prepared a range of bivalent specific ligands for the thyroxine binding sites of TTR. Thyroxine 184-193 transthyretin Homo sapiens 122-125 26308415-15 2015 The risk of delaying Ltx by testing alternative treatments, especially in early-onset TTR Val30Met patients, requires consideration. Leukotriene C4 21-24 transthyretin Homo sapiens 86-89 26214366-3 2015 Binding of small molecule ligands within the thyroxine binding site of TTR can stabilize the tetrameric integrity and is a potential therapeutic approach. Thyroxine 45-54 transthyretin Homo sapiens 71-74 26207645-2 2015 Indoor dust ingestion is a major route of THDCs exposure in humans, and one of the molecular targets of these chemicals is the hormone transporter transthyretin (TTR). thdcs 42-47 transthyretin Homo sapiens 162-165 26310724-3 2015 Herein, we discovered that gamma-mangostin (gamma-M) is an effective inhibitor against the amyloid fibril formation of V30M amyloidogenic TTR. gamma-mangostin 27-42 transthyretin Homo sapiens 138-141 26310724-8 2015 The present study establishes gamma-M as a novel inhibitor of TTR fibrillization. gamma-mangostin 30-37 transthyretin Homo sapiens 62-65 26207645-3 2015 To virtually screen indoor dust contaminants and their metabolites for THDCs targeting TTR, we developed a quantitative structure-activity relationship (QSAR) classification model. thdcs 71-76 transthyretin Homo sapiens 87-90 26207645-6 2015 Four new THDCs were identified after testing 23 selected parent dust contaminants in a radio-ligand TTR binding assay; 2,2",4,4"-tetrahydroxybenzophenone, perfluoroheptanesulfonic acid, 3,5,6-trichloro-2-pyridinol, and 2,4,5-trichlorophenoxyacetic acid. thdcs 9-14 transthyretin Homo sapiens 100-103 26207645-8 2015 Molecular docking studies suggested that these THDCs interacted similarly with TTR via the residue Ser117A, but their binding poses were dissimilar to the endogenous ligand T4. thdcs 47-52 transthyretin Homo sapiens 79-82 26207645-9 2015 This study identified new THDCs using an in silico approach in combination with bioassay testing and highlighted the importance of metabolic activation for TTR binding. thdcs 26-31 transthyretin Homo sapiens 156-159 26249340-2 2015 The two thyroxine (T4) binding sites present in the TTR tetramer display negative binding cooperativity. Thyroxine 8-17 transthyretin Homo sapiens 52-55 25828388-11 2015 In conclusion, our study suggests for the first time that MSGB, in addition to its high sensitivity for amyloidosis diagnosis, is a simple and effective tool for the recognition of ATTR amyloidosis. msgb 58-62 transthyretin Homo sapiens 181-185 26249340-3 2015 Here, structures of TTR in complex with three natural polyphenols (pterostilbene, quercetin and apigenin) have been determined, in which this asymmetry manifests itself as the presence of a main binding site with clear ligand occupancy and related electron density and a second minor site with a much lower ligand occupancy. Polyphenols 54-65 transthyretin Homo sapiens 20-23 26249340-3 2015 Here, structures of TTR in complex with three natural polyphenols (pterostilbene, quercetin and apigenin) have been determined, in which this asymmetry manifests itself as the presence of a main binding site with clear ligand occupancy and related electron density and a second minor site with a much lower ligand occupancy. pterostilbene 67-80 transthyretin Homo sapiens 20-23 26249340-3 2015 Here, structures of TTR in complex with three natural polyphenols (pterostilbene, quercetin and apigenin) have been determined, in which this asymmetry manifests itself as the presence of a main binding site with clear ligand occupancy and related electron density and a second minor site with a much lower ligand occupancy. Quercetin 82-91 transthyretin Homo sapiens 20-23 26249340-3 2015 Here, structures of TTR in complex with three natural polyphenols (pterostilbene, quercetin and apigenin) have been determined, in which this asymmetry manifests itself as the presence of a main binding site with clear ligand occupancy and related electron density and a second minor site with a much lower ligand occupancy. Apigenin 96-104 transthyretin Homo sapiens 20-23 26249340-9 2015 Competition binding assays carried out in solution revealed the presence of a preferential binding site in TTR for the polyphenols pterostilbene and quercetin that was different from the preferential binding site for T4. polyphenols pterostilbene 119-144 transthyretin Homo sapiens 107-110 26249340-9 2015 Competition binding assays carried out in solution revealed the presence of a preferential binding site in TTR for the polyphenols pterostilbene and quercetin that was different from the preferential binding site for T4. Quercetin 149-158 transthyretin Homo sapiens 107-110 26259579-0 2015 18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study. florbetapir 0-15 transthyretin Homo sapiens 65-78 29124175-0 2015 Transthyretin chemical chaperoning by flavonoids: Structure-activity insights towards the design of potent amyloidosis inhibitors. Flavonoids 38-48 transthyretin Homo sapiens 0-13 29124175-2 2015 To investigate structure-activity relationships relevant for the interaction of flavonoids with transthyretin (TTR), the protein associated with familial amyloid polyneuropathy (FAP), we compared the effects of major tea catechins and their larger polymers theaflavins, side-by-side, on TTR amyloid formation process. Flavonoids 80-90 transthyretin Homo sapiens 96-109 29124175-2 2015 To investigate structure-activity relationships relevant for the interaction of flavonoids with transthyretin (TTR), the protein associated with familial amyloid polyneuropathy (FAP), we compared the effects of major tea catechins and their larger polymers theaflavins, side-by-side, on TTR amyloid formation process. Flavonoids 80-90 transthyretin Homo sapiens 111-114 29124175-3 2015 Methods: Interaction of flavonoids with TTR and effect on TTR stability were assessed through binding assays and isoelectric focusing in polyacrylamide gel. Flavonoids 24-34 transthyretin Homo sapiens 40-43 29124175-5 2015 Results: Tested flavonoids bound to TTR and stabilized the TTR tetramer, with different potencies. Flavonoids 16-26 transthyretin Homo sapiens 36-39 29124175-5 2015 Results: Tested flavonoids bound to TTR and stabilized the TTR tetramer, with different potencies. Flavonoids 16-26 transthyretin Homo sapiens 59-62 29124175-6 2015 The flavonoids also inhibited in vitro formation of TTR small oligomeric species and in cell culture inhibited pathways involving caspase-3 activation and ER stress that are induced by TTR oligomers. Flavonoids 4-14 transthyretin Homo sapiens 52-55 29124175-6 2015 The flavonoids also inhibited in vitro formation of TTR small oligomeric species and in cell culture inhibited pathways involving caspase-3 activation and ER stress that are induced by TTR oligomers. Flavonoids 4-14 transthyretin Homo sapiens 185-188 29124175-8 2015 Conclusions: Our results highlight the presence of gallate ester moiety as key structural feature of flavonoids in chemical chaperoning of TTR aggregation. Flavonoids 101-111 transthyretin Homo sapiens 139-142 29124175-9 2015 Upon binding to the native tetramer, gallated flavonoids redirect the TTR amyloidogenic pathway into unstructured nontoxic aggregation assemblies more efficiently than their non-gallated forms. Flavonoids 46-56 transthyretin Homo sapiens 70-73 26259579-1 2015 BACKGROUND: (18)F-florbetapir is a promising imaging biomarker for cardiac light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). f-florbetapir 16-29 transthyretin Homo sapiens 135-139 26259579-2 2015 Our aim, using human autopsy myocardial specimens, was to test the hypothesis that (18)F-florbetapir binds specifically to myocardial AL and ATTR amyloid deposits. f-florbetapir 87-100 transthyretin Homo sapiens 141-145 26259579-6 2015 Diffuse or focally increased (18)F-florbetapir uptake was noted in all AL and ATTR samples and in none of the control samples. f-florbetapir 33-46 transthyretin Homo sapiens 78-82 26259579-7 2015 Compared with control samples, mean (18)F-florbetapir-specific uptake was significantly higher in the amyloid samples (0.94+-0.43 versus 2.00+-0.58 DPM/mm(2); P<0.001), and in the AL compared with the ATTR samples (2.48+-0.40 versus 1.52+-0.22 DPM/mm(2); P<0.001). f-florbetapir 40-53 transthyretin Homo sapiens 201-205 26259579-9 2015 CONCLUSIONS: (18)F-florbetapir specifically binds to myocardial AL and ATTR deposits in humans and offers the potential to screen for the 2 most common types of myocardial amyloid. f-florbetapir 17-30 transthyretin Homo sapiens 71-75 25986900-7 2015 Two compounds could be confirmed to contribute to the detected TTR-binding potency in the sediment sample, i.e., triclosan and nonylphenol technical mixture. Triclosan 113-122 transthyretin Homo sapiens 63-66 26121433-10 2015 CONCLUSION: Circulatory levels of RBP4 and TTR showed a significant associations with glucose intolerance, obesity, T2DM and RBP4 additionally, with insulin resistance. Glucose 86-93 transthyretin Homo sapiens 43-46 25855392-3 2015 Recent reports indicated a reduction of left ventricular (LV) myocardial mass in WT-ATTR after consumption of epigallocatechin-3-gallate, the main catechin in green tea. epigallocatechin gallate 110-136 transthyretin Homo sapiens 84-88 25855392-3 2015 Recent reports indicated a reduction of left ventricular (LV) myocardial mass in WT-ATTR after consumption of epigallocatechin-3-gallate, the main catechin in green tea. Catechin 118-126 transthyretin Homo sapiens 84-88 26073321-1 2015 BACKGROUND: The safety and effectiveness of warfarin therapy depends critically on the quality of anticoagulation control, often assessed using the percentage time in therapeutic International Normalised Ratio (INR) range (TTR). Warfarin 44-52 transthyretin Homo sapiens 223-226 26073321-2 2015 We aimed to identify patient characteristics related to anticoagulation control with warfarin, measured by TTR. Warfarin 85-93 transthyretin Homo sapiens 107-110 25986900-7 2015 Two compounds could be confirmed to contribute to the detected TTR-binding potency in the sediment sample, i.e., triclosan and nonylphenol technical mixture. nonylphenol 127-138 transthyretin Homo sapiens 63-66 25940464-9 2015 The noticeable increase of K(+) and Mg(2+) release indicated that CTS/NMMT damaged the integrity of most MA cells in the flocs and liberated the intracellular MC-LR. magnesium ion 36-42 transthyretin Homo sapiens 66-69 25940464-9 2015 The noticeable increase of K(+) and Mg(2+) release indicated that CTS/NMMT damaged the integrity of most MA cells in the flocs and liberated the intracellular MC-LR. cyanoginosin LR 159-164 transthyretin Homo sapiens 66-69 25940464-10 2015 Meanwhile, NMMT and CTS polymers assisted the adsorptive removal of extracellular MC-LR released to water. Polymers 24-32 transthyretin Homo sapiens 20-23 25940464-10 2015 Meanwhile, NMMT and CTS polymers assisted the adsorptive removal of extracellular MC-LR released to water. cyanoginosin LR 82-87 transthyretin Homo sapiens 20-23 25940464-10 2015 Meanwhile, NMMT and CTS polymers assisted the adsorptive removal of extracellular MC-LR released to water. Water 100-105 transthyretin Homo sapiens 20-23 25819286-8 2015 The patient is being treated with diflunisal, an oral TTR stabilising agent. Diflunisal 34-44 transthyretin Homo sapiens 54-57 26131827-2 2015 In addition, we also examined the association between HNC risk and 2 single nucleotide polymorphisms, TTR rs1667255 and RBP4 rs10882272, that have been associated with serum retinol levels. Vitamin A 174-181 transthyretin Homo sapiens 102-105 26131827-7 2015 TTR rs1667255 was associated with serum retinol levels; however, neither TTR rs1667255 nor RBP4 rs10882272 was associated with HNC risk. Vitamin A 40-47 transthyretin Homo sapiens 0-3 26108284-2 2015 Here, using a combination of primarily small -angle X-ray scattering (SAXS) and hydrogen exchange mass spectrometry (HXMS) analysis, we describe an unexpectedly dynamic TTR protofibril structure which exchanges protomers with highly unfolded monomers in solution. Hydrogen 80-88 transthyretin Homo sapiens 169-172 26051248-2 2015 Herein, we report fluorogenic probe 4, a 1,3,4-oxadiazole designed to bind selectively to transthyretin (TTR). 1,3,4-oxadiazole 41-57 transthyretin Homo sapiens 105-108 26051248-8 2015 An analogue of fluorosulfate probe 4 does react selectively with TTR without labeling the remainder of the cellular proteome. Fluorosulfate 15-28 transthyretin Homo sapiens 65-68 25867019-1 2015 A kind of Gd@C82 salt, Gd@C82/TBPA, was prepared through chemical oxidation. Gadolinium 10-12 transthyretin Homo sapiens 30-34 25867019-1 2015 A kind of Gd@C82 salt, Gd@C82/TBPA, was prepared through chemical oxidation. Gadolinium 23-25 transthyretin Homo sapiens 30-34 25742226-1 2015 Tc-DPD (Tc-3,3-diphosphono-1,2-propanodicarboxylic acid) has a high affinity for transthyretin (TTR)-infiltrated myocardium, allowing a differential diagnosis with light chain cardiac amyloidosis and other nonamyloidotic cardiomyopathies with a hypertrophic phenotype, in which myocardial tracer uptake is low or absent. tc-dpd 0-6 transthyretin Homo sapiens 81-94 25940564-12 2015 TTR-induced cytotoxicity was inhibited by resveratrol, a plant polyphenol that stabilizes the native tetrameric structure of TTR. Resveratrol 42-53 transthyretin Homo sapiens 0-3 25940564-12 2015 TTR-induced cytotoxicity was inhibited by resveratrol, a plant polyphenol that stabilizes the native tetrameric structure of TTR. Resveratrol 42-53 transthyretin Homo sapiens 125-128 25940564-12 2015 TTR-induced cytotoxicity was inhibited by resveratrol, a plant polyphenol that stabilizes the native tetrameric structure of TTR. Polyphenols 63-73 transthyretin Homo sapiens 0-3 25940564-12 2015 TTR-induced cytotoxicity was inhibited by resveratrol, a plant polyphenol that stabilizes the native tetrameric structure of TTR. Polyphenols 63-73 transthyretin Homo sapiens 125-128 25742226-1 2015 Tc-DPD (Tc-3,3-diphosphono-1,2-propanodicarboxylic acid) has a high affinity for transthyretin (TTR)-infiltrated myocardium, allowing a differential diagnosis with light chain cardiac amyloidosis and other nonamyloidotic cardiomyopathies with a hypertrophic phenotype, in which myocardial tracer uptake is low or absent. tc-dpd 0-6 transthyretin Homo sapiens 96-99 25742226-1 2015 Tc-DPD (Tc-3,3-diphosphono-1,2-propanodicarboxylic acid) has a high affinity for transthyretin (TTR)-infiltrated myocardium, allowing a differential diagnosis with light chain cardiac amyloidosis and other nonamyloidotic cardiomyopathies with a hypertrophic phenotype, in which myocardial tracer uptake is low or absent. tc-3,3-diphosphono-1,2-propanodicarboxylic acid 8-55 transthyretin Homo sapiens 81-94 25742226-1 2015 Tc-DPD (Tc-3,3-diphosphono-1,2-propanodicarboxylic acid) has a high affinity for transthyretin (TTR)-infiltrated myocardium, allowing a differential diagnosis with light chain cardiac amyloidosis and other nonamyloidotic cardiomyopathies with a hypertrophic phenotype, in which myocardial tracer uptake is low or absent. tc-3,3-diphosphono-1,2-propanodicarboxylic acid 8-55 transthyretin Homo sapiens 96-99 25736441-8 2015 CONCLUSIONS: TTR, the standard measure of control of warfarin anticoagulation, depends on imputing daily INR values for the vast majority of follow-up days. Warfarin 53-61 transthyretin Homo sapiens 13-16 25884193-10 2015 Patients with above-average ABQ scores (increased number and/or strength of existing adherence barriers) were significantly (p < 0.005, Pearson Chi-Square) more likely to have a poor anticoagulation quality (TTR < 60%) than patients with a lower ABQ score (44.6% versus 27.3%). CHEMBL1938415 28-31 transthyretin Homo sapiens 211-214 25737004-2 2015 TTR synthesised in the liver is secreted into the bloodstream and distributes THs around the body, whereas TTR synthesised in the choroid plexus is involved in movement of thyroxine from the blood into the cerebrospinal fluid and the distribution of THs in the brain. Thyroxine 172-181 transthyretin Homo sapiens 0-3 25737004-2 2015 TTR synthesised in the liver is secreted into the bloodstream and distributes THs around the body, whereas TTR synthesised in the choroid plexus is involved in movement of thyroxine from the blood into the cerebrospinal fluid and the distribution of THs in the brain. Thyroxine 172-181 transthyretin Homo sapiens 107-110 25225131-7 2015 This observation was due to the protonation of a histidine residue as an imidazolium cation, which was not accessible when TTR was in its tetrameric structure. Histidine 49-58 transthyretin Homo sapiens 123-126 25225131-7 2015 This observation was due to the protonation of a histidine residue as an imidazolium cation, which was not accessible when TTR was in its tetrameric structure. imidazolium 73-84 transthyretin Homo sapiens 123-126 25694367-3 2015 In this work, we have investigated the kinetics of TTR aggregation into amyloid fibrils produced by the addition of NaCl to acid-unfolded TTR monomers and we propose a mathematically simple kinetic mechanism to analyse the aggregation kinetics of TTR. Sodium Chloride 116-120 transthyretin Homo sapiens 51-54 25694367-3 2015 In this work, we have investigated the kinetics of TTR aggregation into amyloid fibrils produced by the addition of NaCl to acid-unfolded TTR monomers and we propose a mathematically simple kinetic mechanism to analyse the aggregation kinetics of TTR. Sodium Chloride 116-120 transthyretin Homo sapiens 138-141 25694367-3 2015 In this work, we have investigated the kinetics of TTR aggregation into amyloid fibrils produced by the addition of NaCl to acid-unfolded TTR monomers and we propose a mathematically simple kinetic mechanism to analyse the aggregation kinetics of TTR. Sodium Chloride 116-120 transthyretin Homo sapiens 138-141 25736441-9 2015 Our TTR calculation method may better reflect the impact of warfarin dose changes than the Rosendaal approach. Warfarin 60-68 transthyretin Homo sapiens 4-7 25595224-0 2015 Modulating inhibitors of transthyretin fibrillogenesis via sulfation: polychlorinated biphenyl sulfates as models. polychlorinated biphenyl sulfates 70-103 transthyretin Homo sapiens 25-38 25767421-2 2015 Our pilot study was the first to assess the utility of the six-item CTS symptom scale (CTS-6) with steroid injections as a patient-directed outcome measure for the treatment of CTS. Steroids 99-106 transthyretin Homo sapiens 68-71 25767421-15 2015 CONCLUSIONS: The six-item CTS symptoms scale and portable NCS are both useful measures for evaluating the results of steroid injections. Steroids 117-124 transthyretin Homo sapiens 26-29 25767421-16 2015 The CTS-6 is an effective tool because of its ease of use, low cost, correspondence with changes in NCS, and ability to monitor the outcome of steroid treatment for carpal tunnel syndrome. Steroids 143-150 transthyretin Homo sapiens 4-7 25595224-3 2015 In order to test the hypothesis that sulfate group substituents can improve the efficiencies of such inhibitors, we evaluated the potential of six polychlorinated biphenyl sulfates to inhibit TTR amyloid fibril formation in vitro. polychlorinated biphenyl sulfates 147-180 transthyretin Homo sapiens 192-195 25743445-1 2015 A phase 2, open-label study in 21 patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis showed that tafamidis (20 mg daily for 12 months) stabilized these transthyretin variants. tafamidis 128-137 transthyretin Homo sapiens 90-103 25595224-1 2015 Small molecules that bind with high affinity to thyroxine (T4) binding sites on transthyretin (TTR) kinetically stabilize the protein"s tetrameric structure, thereby efficiently decreasing the rate of tetramer dissociation in TTR related amyloidoses. Thyroxine 48-57 transthyretin Homo sapiens 80-93 25595224-1 2015 Small molecules that bind with high affinity to thyroxine (T4) binding sites on transthyretin (TTR) kinetically stabilize the protein"s tetrameric structure, thereby efficiently decreasing the rate of tetramer dissociation in TTR related amyloidoses. Thyroxine 48-57 transthyretin Homo sapiens 95-98 25595224-1 2015 Small molecules that bind with high affinity to thyroxine (T4) binding sites on transthyretin (TTR) kinetically stabilize the protein"s tetrameric structure, thereby efficiently decreasing the rate of tetramer dissociation in TTR related amyloidoses. Thyroxine 48-57 transthyretin Homo sapiens 226-229 25478940-12 2015 The interactions of CLU with monomeric and aggregated TTR proceed in a cooperative manner in the presence of diflunisal, a small molecule drug used to stabilize TTR tetramers. Diflunisal 109-119 transthyretin Homo sapiens 54-57 25311081-0 2015 Post-translational modifications of transthyretin affect the triiodonine-binding potential. triiodonine 61-72 transthyretin Homo sapiens 36-49 25311081-3 2015 Each TTR subunit provides a single cysteine residue (Cys10 ), which is frequently affected by oxidative post-translational modifications. Cysteine 35-43 transthyretin Homo sapiens 5-8 25481334-1 2015 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP) which, in turn, associates with transthyretin (TTR) to form a retinol-RBP-TTR ternary complex. Vitamin A 0-9 transthyretin Homo sapiens 111-124 25481334-1 2015 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP) which, in turn, associates with transthyretin (TTR) to form a retinol-RBP-TTR ternary complex. Vitamin A 0-9 transthyretin Homo sapiens 126-129 25481334-1 2015 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP) which, in turn, associates with transthyretin (TTR) to form a retinol-RBP-TTR ternary complex. Vitamin A 0-9 transthyretin Homo sapiens 153-156 25481334-1 2015 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP) which, in turn, associates with transthyretin (TTR) to form a retinol-RBP-TTR ternary complex. Vitamin A 11-18 transthyretin Homo sapiens 111-124 25481334-1 2015 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP) which, in turn, associates with transthyretin (TTR) to form a retinol-RBP-TTR ternary complex. Vitamin A 11-18 transthyretin Homo sapiens 126-129 25481334-1 2015 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP) which, in turn, associates with transthyretin (TTR) to form a retinol-RBP-TTR ternary complex. Vitamin A 11-18 transthyretin Homo sapiens 153-156 25481334-1 2015 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP) which, in turn, associates with transthyretin (TTR) to form a retinol-RBP-TTR ternary complex. Vitamin A 49-56 transthyretin Homo sapiens 111-124 25481334-1 2015 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP) which, in turn, associates with transthyretin (TTR) to form a retinol-RBP-TTR ternary complex. Vitamin A 49-56 transthyretin Homo sapiens 126-129 25481334-1 2015 Vitamin A, retinol, circulates in blood bound to retinol-binding protein (RBP) which, in turn, associates with transthyretin (TTR) to form a retinol-RBP-TTR ternary complex. Vitamin A 49-56 transthyretin Homo sapiens 153-156 25224922-0 2015 Transthyretin complexes with curcumin and bromo-estradiol: evaluation of solubilizing multicomponent mixtures. Curcumin 29-37 transthyretin Homo sapiens 0-13 25224922-4 2015 Here we present a new strategy for the co-crystallization of TTR using high molecular weight polyethylene glycol instead of high ionic strength precipitants, with ligands solubilized in multicomponent mixtures of compounds. Polyethylene Glycols 93-112 transthyretin Homo sapiens 61-64 25224922-5 2015 This strategy is applied to the crystallization of TTR complexes with curcumin and 16alpha-bromo-estradiol. Curcumin 70-78 transthyretin Homo sapiens 51-54 25224922-5 2015 This strategy is applied to the crystallization of TTR complexes with curcumin and 16alpha-bromo-estradiol. 16alpha-bromo-estradiol 83-106 transthyretin Homo sapiens 51-54 25481444-7 2015 Conjugation of doxycycline exhibited greater potential towards TTR fibril disaggregation in vitro compared to the parent drug. Doxycycline 15-26 transthyretin Homo sapiens 63-66 25617835-9 2015 The mean inlet CSA was 8.7 mm2 in healthy controls and 14.6mm2 in CTS group (P<0.001). Cyclosporine 15-18 transthyretin Homo sapiens 66-69 25478940-12 2015 The interactions of CLU with monomeric and aggregated TTR proceed in a cooperative manner in the presence of diflunisal, a small molecule drug used to stabilize TTR tetramers. Diflunisal 109-119 transthyretin Homo sapiens 161-164 25394203-0 2015 Tuning transthyretin amyloidosis inhibition properties of iododiflunisal by combinatorial engineering of the nonsalicylic ring substitutions. iododiflunisal 58-72 transthyretin Homo sapiens 7-20 25394203-3 2015 From a selected set of 77 noniodinated and 77 iodinated diflunisal analogues, a subset of good transthyretin amyloid inhibitors has been obtained with improved turbidimetry inhibition constants, high binding affinity to transthyretin, and good selectivity for TTR compared to other thyroxine binding proteins. Diflunisal 56-66 transthyretin Homo sapiens 95-108 25394203-3 2015 From a selected set of 77 noniodinated and 77 iodinated diflunisal analogues, a subset of good transthyretin amyloid inhibitors has been obtained with improved turbidimetry inhibition constants, high binding affinity to transthyretin, and good selectivity for TTR compared to other thyroxine binding proteins. Thyroxine 282-291 transthyretin Homo sapiens 95-108 26193961-2 2015 Currently, Pfizer, Inc. is enrolling a 400-person clinical trial to test the efficacy of 20 or 80 mg of tafamidis to ameliorate transthyretin (TTR)-associated cardiomyopathy using clinical endpoints. tafamidis 104-113 transthyretin Homo sapiens 128-141 25395306-7 2015 The TTR internalization process is highly dependent on membrane cholesterol content. Cholesterol 64-75 transthyretin Homo sapiens 4-7 25395306-10 2015 Finally, incubation of the human cardiomyocytes with V122I TTR but not with T119M TTR, generates superoxide species and activates caspase 3/7. Superoxides 97-107 transthyretin Homo sapiens 59-62 26193961-2 2015 Currently, Pfizer, Inc. is enrolling a 400-person clinical trial to test the efficacy of 20 or 80 mg of tafamidis to ameliorate transthyretin (TTR)-associated cardiomyopathy using clinical endpoints. tafamidis 104-113 transthyretin Homo sapiens 143-146 26193961-5 2015 Hence, we measure the TTR tetramer dissociation rate (kinetic stability) in the patient"s plasma as a function of tafamidis dose to optimize the dose employed to maximize kinetic stability. tafamidis 114-123 transthyretin Homo sapiens 22-25 26465835-9 2015 (99m)Tc-HMDP cardiac uptake occurred in all wt-TTR, in m-TTR with CA except two and in one AL. tc-hmdp 5-12 transthyretin Homo sapiens 47-50 26465835-9 2015 (99m)Tc-HMDP cardiac uptake occurred in all wt-TTR, in m-TTR with CA except two and in one AL. tc-hmdp 5-12 transthyretin Homo sapiens 57-60 26465835-14 2015 CONCLUSIONS: This preliminary study suggests that (99m)Tc-HMDP-scintigraphy may aid differentiation between transthyretin and AL-CA as well as CA from other LVHs. tc-hmdp 55-62 transthyretin Homo sapiens 108-121 26229954-7 2015 Only 35.04% (CI = 95%, 33.7-36.3) of AF patients treated with vitamin K antagonists (VKAs) achieve the goal of TTR > 60%. Vitamin K 62-71 transthyretin Homo sapiens 111-114 26611723-6 2015 The TTR stabilizers tafamidis and diflunisal slow disease progression in some patients with ATTR amyloidosis with polyneuropathy, and the postulated synergistic effect of doxycycline and tauroursodeoxycholic acid on dissolution of amyloid is under investigation. Diflunisal 34-44 transthyretin Homo sapiens 92-96 26611723-8 2015 Plasma TTR concentration can be significantly reduced with ISIS-TTR(Rx), an investigational antisense oligonucleotide-based drug, or with patisiran and revusiran, which are investigational RNA interference-based therapeutics that target the liver. Oligonucleotides 102-117 transthyretin Homo sapiens 7-10 25740746-0 2015 Associations of decreased serum transthyretin with elevated high-sensitivity CRP, serum copper and decreased hemoglobin in ambulatory elderly women. Copper 88-94 transthyretin Homo sapiens 32-45 25740746-5 2015 After controlling for age, TTR was negatively associated with log high-sensitivity CRP (hsCRP) and serum copper. Copper 105-111 transthyretin Homo sapiens 27-30 25740746-7 2015 In addition, TTR was positively correlated with systolic and diastolic blood pressure and postprandial triglyceride (TG). Triglycerides 103-115 transthyretin Homo sapiens 13-16 25740746-7 2015 In addition, TTR was positively correlated with systolic and diastolic blood pressure and postprandial triglyceride (TG). Triglycerides 117-119 transthyretin Homo sapiens 13-16 25488473-2 2015 Here, we present the first case of leptomeningeal amyloidosis associated with the TTR variant Leu12Pro mutation in an African patient. leu12pro 94-102 transthyretin Homo sapiens 82-85 26444765-10 2015 In the lumbar CSF samples, soluble TTR levels showed a significant positive correlation with sAbetaPPalpha and sAbetaPPbeta, but TTR levels did not predict the brain pathology or the shunt response. sabetappalpha 93-106 transthyretin Homo sapiens 35-38 26444765-10 2015 In the lumbar CSF samples, soluble TTR levels showed a significant positive correlation with sAbetaPPalpha and sAbetaPPbeta, but TTR levels did not predict the brain pathology or the shunt response. sabetappbeta 111-123 transthyretin Homo sapiens 35-38 26406002-6 2015 C1-INH shows a high expression in TBPE and a low expression in MPE while TTR and C3 show low expression in TBPE and high expressions in MPE. tbpe 107-111 transthyretin Homo sapiens 73-76 25380591-2 2015 Transthyretin (TTR) is a plasma protein mainly secreted by the liver within a trimolecular TTR-RBP-retinol complex revealing from birth to old age strikingly similar evolutionary patterns with LBM in health and disease. Vitamin A 99-106 transthyretin Homo sapiens 0-13 25380591-2 2015 Transthyretin (TTR) is a plasma protein mainly secreted by the liver within a trimolecular TTR-RBP-retinol complex revealing from birth to old age strikingly similar evolutionary patterns with LBM in health and disease. Vitamin A 99-106 transthyretin Homo sapiens 15-18 25380591-2 2015 Transthyretin (TTR) is a plasma protein mainly secreted by the liver within a trimolecular TTR-RBP-retinol complex revealing from birth to old age strikingly similar evolutionary patterns with LBM in health and disease. Vitamin A 99-106 transthyretin Homo sapiens 91-94 25504720-3 2014 We show that the iron transport protein transferrin is engaged in ancient and ongoing evolutionary conflicts with TbpA, a transferrin surface receptor from bacteria. Iron 17-21 transthyretin Homo sapiens 114-118 25551524-1 2015 BACKGROUND: Approximately 4% of black Americans carry a valine-to-isoleucine substitution (V122I) in the transthyretin protein, which has been associated with late-onset restrictive amyloid cardiomyopathy and increased risks of death and heart failure. Valine 56-62 transthyretin Homo sapiens 105-118 25551524-1 2015 BACKGROUND: Approximately 4% of black Americans carry a valine-to-isoleucine substitution (V122I) in the transthyretin protein, which has been associated with late-onset restrictive amyloid cardiomyopathy and increased risks of death and heart failure. Isoleucine 66-76 transthyretin Homo sapiens 105-118 25504720-4 2014 Single substitutions in transferrin at rapidly evolving sites reverse TbpA binding, providing a mechanism to counteract bacterial iron piracy among great apes. Iron 130-134 transthyretin Homo sapiens 70-74 25550818-2 2014 Mainly synthesized in the live, TTR is transferred in the form of tetramer bound with thyroxine, retinol-binding protein (RBP) and lipoprotein in the blood. Thyroxine 86-95 transthyretin Homo sapiens 32-35 25432650-2 2014 Transthyretin cardiac amyloidosis, particularly the type caused by the mutation that replaces the amino acid valine with the amino acid isoleucine at position 122 (Val122Ile), is most common among African- Americans above 65 years of age. amino acid valine 98-115 transthyretin Homo sapiens 0-13 25432650-2 2014 Transthyretin cardiac amyloidosis, particularly the type caused by the mutation that replaces the amino acid valine with the amino acid isoleucine at position 122 (Val122Ile), is most common among African- Americans above 65 years of age. amino acid isoleucine 125-146 transthyretin Homo sapiens 0-13 23976768-4 2014 RESULTS: When we classified patients with severity according to mortality, percentage of TBSA burned, serum lactic acid, and CRP, mean serum TTR level was significantly higher in the less severe patient group than in the severe patient group in each week for every severity index. Lactic Acid 108-119 transthyretin Homo sapiens 141-144 25416603-7 2014 Two multicentric clinical trials are now ongoing to evaluate TTR gene silencing by antisense Oligonucleotides (ASO) or siRNA. Oligonucleotides 93-109 transthyretin Homo sapiens 61-64 25881426-1 2014 Silver nanoparticles were prepared by chemical method using citricacid trisodiumsalt (Ag-CTS) and polyvinylpyrrolidone (Ag-PVP) as surface modifiers, respectively. Silver 0-6 transthyretin Homo sapiens 89-92 25881426-2 2014 When Ag-CTS or Ag-PVP nanoparticles were added into methyl orange (MO) solution, the enhanced-fluorescence of S1-->S0 and quenched-fluorescence of S2-->S0 were simultaneously observed. methyl orange 52-65 transthyretin Homo sapiens 8-11 25314129-0 2014 Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin. caffeic acid phenethyl ester 63-91 transthyretin Homo sapiens 126-139 25314129-4 2014 Thioflavin T assay showed that CAPE suppressed the amyloid fibril formation of TTR. thioflavin T 0-12 transthyretin Homo sapiens 79-82 25314129-4 2014 Thioflavin T assay showed that CAPE suppressed the amyloid fibril formation of TTR. caffeic acid phenethyl ester 31-35 transthyretin Homo sapiens 79-82 25314129-6 2014 The binding of phenethyl ferulate and the selected compounds to TTR were confirmed by the 8-anilino-1-naphthalenesulfonic acid displacement and X-ray crystallography. phenethyl ferulate 15-33 transthyretin Homo sapiens 64-67 25314129-6 2014 The binding of phenethyl ferulate and the selected compounds to TTR were confirmed by the 8-anilino-1-naphthalenesulfonic acid displacement and X-ray crystallography. 8-anilino-1-naphthalenesulfonic acid 90-126 transthyretin Homo sapiens 64-67 25382970-0 2014 Curcumin could reduce the monomer of TTR with Tyr114Cys mutation via autophagy in cell model of familial amyloid polyneuropathy. Curcumin 0-8 transthyretin Homo sapiens 37-40 25382970-4 2014 Treatment with curcumin resulted in a significant decrease of monomeric TTR by recovering autophagy. Curcumin 15-23 transthyretin Homo sapiens 72-75 25245430-6 2014 We demonstrate that subunit exchange of TTR with FT2 TTR can be analyzed and quantified using a semi-native polyacrylamide gel electrophoresis technique. polyacrylamide 108-122 transthyretin Homo sapiens 40-43 25245430-6 2014 We demonstrate that subunit exchange of TTR with FT2 TTR can be analyzed and quantified using a semi-native polyacrylamide gel electrophoresis technique. polyacrylamide 108-122 transthyretin Homo sapiens 53-56 25012480-1 2014 Protein stabilization and oligonucleotide therapies are being tested in transthyretin amyloid polyneuropathy (TTR FAP) trials. Oligonucleotides 26-41 transthyretin Homo sapiens 110-113 25060417-10 2014 CONCLUSION: Diflunisal might be effective especially for autonomic dysfunction in late-onset FAP with a TTR Val30Met mutation. Diflunisal 12-22 transthyretin Homo sapiens 104-107 24947831-1 2014 BACKGROUND: novel oral anticoagulants may be particularly cost-effective when INR control (TTR) with warfarin is poor or monitoring difficult. Warfarin 101-109 transthyretin Homo sapiens 91-94 25055225-7 2014 Only Ttr,Rct is strongly dependent on film thickness, salt concentration, and outermost layer, for which values ranging from 50 to 64 C were observed. Salts 54-58 transthyretin Homo sapiens 5-8 25055225-8 2014 As the assembly salt concentration increases from 0.5 M to 1.0 M NaCl, Ttr,Rct increases by about 10 C. Below 20 layers, deviations of Ttr,Rct with respect to outermost layer appear, in which PSS-capped LbL films tend to show elevated Ttr,Rct values. Salts 16-20 transthyretin Homo sapiens 71-74 25055225-8 2014 As the assembly salt concentration increases from 0.5 M to 1.0 M NaCl, Ttr,Rct increases by about 10 C. Below 20 layers, deviations of Ttr,Rct with respect to outermost layer appear, in which PSS-capped LbL films tend to show elevated Ttr,Rct values. Salts 16-20 transthyretin Homo sapiens 136-139 25055225-8 2014 As the assembly salt concentration increases from 0.5 M to 1.0 M NaCl, Ttr,Rct increases by about 10 C. Below 20 layers, deviations of Ttr,Rct with respect to outermost layer appear, in which PSS-capped LbL films tend to show elevated Ttr,Rct values. Salts 16-20 transthyretin Homo sapiens 136-139 25055225-8 2014 As the assembly salt concentration increases from 0.5 M to 1.0 M NaCl, Ttr,Rct increases by about 10 C. Below 20 layers, deviations of Ttr,Rct with respect to outermost layer appear, in which PSS-capped LbL films tend to show elevated Ttr,Rct values. Sodium Chloride 65-69 transthyretin Homo sapiens 71-74 25055225-8 2014 As the assembly salt concentration increases from 0.5 M to 1.0 M NaCl, Ttr,Rct increases by about 10 C. Below 20 layers, deviations of Ttr,Rct with respect to outermost layer appear, in which PSS-capped LbL films tend to show elevated Ttr,Rct values. polystyrene sulfonic acid 193-196 transthyretin Homo sapiens 136-139 25055225-8 2014 As the assembly salt concentration increases from 0.5 M to 1.0 M NaCl, Ttr,Rct increases by about 10 C. Below 20 layers, deviations of Ttr,Rct with respect to outermost layer appear, in which PSS-capped LbL films tend to show elevated Ttr,Rct values. polystyrene sulfonic acid 193-196 transthyretin Homo sapiens 136-139 25003808-8 2014 EXPERT OPINION: Suppression of TTR synthesis by antisense oligonucleotides and small-interfering RNA is presently one of the most promising therapeutic approaches. Oligonucleotides 58-74 transthyretin Homo sapiens 31-34 24779883-5 2014 Our amyloidogenic propensity analysis of TTR missense substitutions has highlighted a similar pattern for wild-type and mutated TTR amino beta acid sequences. amino beta acid 132-147 transthyretin Homo sapiens 128-131 24867207-14 2014 Finally, we demonstrated that fibrinogen interacts with transthyretin and alpha-synuclein in TCL lysates. Triclosan 93-96 transthyretin Homo sapiens 56-69 25193838-1 2014 Montmorillonite (MMT) modified with chitosan (CTS, molecular weight=5x10(4)) was applied to remove heavy metal cations by using Co(2+) as a model ion. Cobalt(2+) 128-134 transthyretin Homo sapiens 46-49 25193838-2 2014 An increase in MMT interlayer distance observed from X-ray diffraction indicates the intercalation of CTS into MMT. Bentonite 15-18 transthyretin Homo sapiens 102-105 25193838-2 2014 An increase in MMT interlayer distance observed from X-ray diffraction indicates the intercalation of CTS into MMT. Bentonite 111-114 transthyretin Homo sapiens 102-105 25193838-4 2014 The mass ratio of CTS to MMT had a strong influence on the adsorption performance of CTS-MMT. Bentonite 25-28 transthyretin Homo sapiens 85-88 25193838-4 2014 The mass ratio of CTS to MMT had a strong influence on the adsorption performance of CTS-MMT. Bentonite 89-92 transthyretin Homo sapiens 18-21 25193838-4 2014 The mass ratio of CTS to MMT had a strong influence on the adsorption performance of CTS-MMT. Bentonite 89-92 transthyretin Homo sapiens 85-88 25193838-5 2014 The highest adsorption value of 150mg/g was obtained over the composite material with CTS to MMT mass ratio of 0.25, which is much higher than those reported in other studies. Bentonite 93-96 transthyretin Homo sapiens 86-89 25193838-6 2014 The adsorption isotherms and kinetic results indicated that Co(2+) was adsorbed over CTS-MMT in a multilayer model, and the chemical sorption of Co(2+) was determined to be the rate-limiting step. Cobalt(2+) 60-66 transthyretin Homo sapiens 85-88 25193838-6 2014 The adsorption isotherms and kinetic results indicated that Co(2+) was adsorbed over CTS-MMT in a multilayer model, and the chemical sorption of Co(2+) was determined to be the rate-limiting step. Cobalt(2+) 145-151 transthyretin Homo sapiens 85-88 25022953-1 2014 Oral tafamidis (Vyndaqel( )) is indicated in the EU for the treatment of transthyretin (TTR) amyloidosis in adult patients with early stage symptomatic polyneuropathy to delay peripheral neurologic impairment and, in Argentina, Japan and Mexico, for delaying the peripheral neurological impairment of TTR familial amyloid polyneuropathy (TTR-FAP). tafamidis 5-14 transthyretin Homo sapiens 73-86 24681594-3 2014 Structures of TbpA/B and HmuUV provided new insight into iron uptake by pathogenic bacteria while the structures of NarK, ASBT, and VcINDY revealed molecular details about the transport of nitrate, bile acids and dicarboxylates, respectively. Iron 57-61 transthyretin Homo sapiens 14-18 23906384-2 2014 This pilot study was conducted to evaluate the heated lidocaine/tetracaine patch (HLT patch) as a conservative treatment for pain of CTS. Lidocaine 54-63 transthyretin Homo sapiens 133-136 23906384-2 2014 This pilot study was conducted to evaluate the heated lidocaine/tetracaine patch (HLT patch) as a conservative treatment for pain of CTS. Tetracaine 64-74 transthyretin Homo sapiens 133-136 25022953-1 2014 Oral tafamidis (Vyndaqel( )) is indicated in the EU for the treatment of transthyretin (TTR) amyloidosis in adult patients with early stage symptomatic polyneuropathy to delay peripheral neurologic impairment and, in Argentina, Japan and Mexico, for delaying the peripheral neurological impairment of TTR familial amyloid polyneuropathy (TTR-FAP). tafamidis 5-14 transthyretin Homo sapiens 88-91 25022953-1 2014 Oral tafamidis (Vyndaqel( )) is indicated in the EU for the treatment of transthyretin (TTR) amyloidosis in adult patients with early stage symptomatic polyneuropathy to delay peripheral neurologic impairment and, in Argentina, Japan and Mexico, for delaying the peripheral neurological impairment of TTR familial amyloid polyneuropathy (TTR-FAP). tafamidis 5-14 transthyretin Homo sapiens 301-304 25022953-1 2014 Oral tafamidis (Vyndaqel( )) is indicated in the EU for the treatment of transthyretin (TTR) amyloidosis in adult patients with early stage symptomatic polyneuropathy to delay peripheral neurologic impairment and, in Argentina, Japan and Mexico, for delaying the peripheral neurological impairment of TTR familial amyloid polyneuropathy (TTR-FAP). tafamidis 16-24 transthyretin Homo sapiens 73-86 25022953-1 2014 Oral tafamidis (Vyndaqel( )) is indicated in the EU for the treatment of transthyretin (TTR) amyloidosis in adult patients with early stage symptomatic polyneuropathy to delay peripheral neurologic impairment and, in Argentina, Japan and Mexico, for delaying the peripheral neurological impairment of TTR familial amyloid polyneuropathy (TTR-FAP). tafamidis 16-24 transthyretin Homo sapiens 88-91 25022953-1 2014 Oral tafamidis (Vyndaqel( )) is indicated in the EU for the treatment of transthyretin (TTR) amyloidosis in adult patients with early stage symptomatic polyneuropathy to delay peripheral neurologic impairment and, in Argentina, Japan and Mexico, for delaying the peripheral neurological impairment of TTR familial amyloid polyneuropathy (TTR-FAP). tafamidis 16-24 transthyretin Homo sapiens 301-304 24992960-6 2014 GalNAc conjugation also enhanced potency and duration of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice. N-acetylgalactosaminuronic acid 0-6 transthyretin Homo sapiens 127-140 24528201-7 2014 Cell treatment with the tyrosine kinase inhibitor Gleevec (imatinib) or with the alkalizing agent NH4 Cl causes an accumulation of "functional" AICD capable of up-regulating both TTR and NEP, leading to a reduction in total cellular Abeta levels. Imatinib Mesylate 59-67 transthyretin Homo sapiens 179-182 24528201-7 2014 Cell treatment with the tyrosine kinase inhibitor Gleevec (imatinib) or with the alkalizing agent NH4 Cl causes an accumulation of "functional" AICD capable of up-regulating both TTR and NEP, leading to a reduction in total cellular Abeta levels. Ammonium Chloride 98-104 transthyretin Homo sapiens 179-182 24687294-8 2014 Many of these small molecule compounds currently undergo preclinical and clinical pharmaceutical development and two have been approved: saproterin dihydrochloride for the treatment of phenylketonuria and tafamidis for the treatment of transthyretin-related hereditary amyloidosis. saproterin dihydrochloride 137-163 transthyretin Homo sapiens 236-249 24992960-6 2014 GalNAc conjugation also enhanced potency and duration of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice. N-acetylgalactosaminuronic acid 0-6 transthyretin Homo sapiens 142-145 24781992-6 2014 This observation revealed that the TTR amyloid deposits and serum TTR were oxidized by the MPO/H2O2/NO(-) system. Hydrogen Peroxide 95-99 transthyretin Homo sapiens 66-69 24754426-3 2014 Investigating oligomerization and ligand binding of transthyretin (TTR) and the chaperone domain from prosurfactant protein C, we found that dimethyl sulfoxide (DMSO) can improve the stability of the noncovalent interactions during the electrospray process, both regarding ligand binding and the protein quaternary structure. Dimethyl Sulfoxide 141-159 transthyretin Homo sapiens 52-65 24754426-3 2014 Investigating oligomerization and ligand binding of transthyretin (TTR) and the chaperone domain from prosurfactant protein C, we found that dimethyl sulfoxide (DMSO) can improve the stability of the noncovalent interactions during the electrospray process, both regarding ligand binding and the protein quaternary structure. Dimethyl Sulfoxide 141-159 transthyretin Homo sapiens 67-70 24754426-3 2014 Investigating oligomerization and ligand binding of transthyretin (TTR) and the chaperone domain from prosurfactant protein C, we found that dimethyl sulfoxide (DMSO) can improve the stability of the noncovalent interactions during the electrospray process, both regarding ligand binding and the protein quaternary structure. Dimethyl Sulfoxide 161-165 transthyretin Homo sapiens 52-65 24754426-3 2014 Investigating oligomerization and ligand binding of transthyretin (TTR) and the chaperone domain from prosurfactant protein C, we found that dimethyl sulfoxide (DMSO) can improve the stability of the noncovalent interactions during the electrospray process, both regarding ligand binding and the protein quaternary structure. Dimethyl Sulfoxide 161-165 transthyretin Homo sapiens 67-70 24632442-9 2014 In addition, hydrogen bond network at the interface of the two monomers plays a part in stabilizing TTR dimer. Hydrogen 13-21 transthyretin Homo sapiens 100-103 24781992-0 2014 Effect of MPO/H2O2/NO(-) system on nitric oxide-mediated modification of TTR amyloid and serum TTR in FAP ATTR Val30Met patients. Hydrogen Peroxide 14-18 transthyretin Homo sapiens 73-76 24781992-0 2014 Effect of MPO/H2O2/NO(-) system on nitric oxide-mediated modification of TTR amyloid and serum TTR in FAP ATTR Val30Met patients. Nitric Oxide 35-47 transthyretin Homo sapiens 73-76 24781992-0 2014 Effect of MPO/H2O2/NO(-) system on nitric oxide-mediated modification of TTR amyloid and serum TTR in FAP ATTR Val30Met patients. Nitric Oxide 35-47 transthyretin Homo sapiens 106-110 24749898-10 2014 In addition, gene therapies with antisense oligonucleotides and small interfering RNAs are promising strategies to ameliorate TTR amyloidoses and are currently in clinical trials. Oligonucleotides 43-59 transthyretin Homo sapiens 126-129 24713691-7 2014 Expression of xenobiotic metabolizing enzyme (XME) and thyroxine transport protein (Ttr) genes in liver was measured by PCR to assess aryl hydrocarbon-mediated responses. aryl hydrocarbon 134-150 transthyretin Homo sapiens 84-87 24713691-8 2014 TCDD, TBDF, TCDF, 1PeBDF, 4PeBDF, 4PeCDF, and DBDCDD suppressed the IgM antibody response and Ttr gene expression, and upregulated phase I XME genes. Polychlorinated Dibenzodioxins 0-4 transthyretin Homo sapiens 94-97 24713691-8 2014 TCDD, TBDF, TCDF, 1PeBDF, 4PeBDF, 4PeCDF, and DBDCDD suppressed the IgM antibody response and Ttr gene expression, and upregulated phase I XME genes. tbdf 6-10 transthyretin Homo sapiens 94-97 24713691-8 2014 TCDD, TBDF, TCDF, 1PeBDF, 4PeBDF, 4PeCDF, and DBDCDD suppressed the IgM antibody response and Ttr gene expression, and upregulated phase I XME genes. dbdcdd 46-52 transthyretin Homo sapiens 94-97 24726252-4 2014 METHODS: A total of 70 patients with ATTR were evaluated by echocardiography, cardiac biomarkers, and (99m)Tc-DPD scintigraphy. tc-dpd 107-113 transthyretin Homo sapiens 37-41 24781992-5 2014 Nitrotyrosine was present in amyloid deposits after being exposed to the MPO/H2O2/NO(-) system by immunohistochemical staining, and the oxide mediated modification of serum transthyretin (TTR) was observed upon exposure to the MPO/H2O2 system using two-dimensional gel electrophoresis and TTR Western blotting. 3-nitrotyrosine 0-13 transthyretin Homo sapiens 188-191 24781992-5 2014 Nitrotyrosine was present in amyloid deposits after being exposed to the MPO/H2O2/NO(-) system by immunohistochemical staining, and the oxide mediated modification of serum transthyretin (TTR) was observed upon exposure to the MPO/H2O2 system using two-dimensional gel electrophoresis and TTR Western blotting. 3-nitrotyrosine 0-13 transthyretin Homo sapiens 289-292 24781992-7 2014 Nitric oxide-mediated modification of TTR may play a role in amyloidogenesis in vivo. Nitric Oxide 0-12 transthyretin Homo sapiens 38-41 24781992-5 2014 Nitrotyrosine was present in amyloid deposits after being exposed to the MPO/H2O2/NO(-) system by immunohistochemical staining, and the oxide mediated modification of serum transthyretin (TTR) was observed upon exposure to the MPO/H2O2 system using two-dimensional gel electrophoresis and TTR Western blotting. Hydrogen Peroxide 77-81 transthyretin Homo sapiens 173-186 24781992-5 2014 Nitrotyrosine was present in amyloid deposits after being exposed to the MPO/H2O2/NO(-) system by immunohistochemical staining, and the oxide mediated modification of serum transthyretin (TTR) was observed upon exposure to the MPO/H2O2 system using two-dimensional gel electrophoresis and TTR Western blotting. Oxides 136-141 transthyretin Homo sapiens 173-186 24781992-5 2014 Nitrotyrosine was present in amyloid deposits after being exposed to the MPO/H2O2/NO(-) system by immunohistochemical staining, and the oxide mediated modification of serum transthyretin (TTR) was observed upon exposure to the MPO/H2O2 system using two-dimensional gel electrophoresis and TTR Western blotting. Oxides 136-141 transthyretin Homo sapiens 188-191 24781992-5 2014 Nitrotyrosine was present in amyloid deposits after being exposed to the MPO/H2O2/NO(-) system by immunohistochemical staining, and the oxide mediated modification of serum transthyretin (TTR) was observed upon exposure to the MPO/H2O2 system using two-dimensional gel electrophoresis and TTR Western blotting. Oxides 136-141 transthyretin Homo sapiens 289-292 24487346-13 2014 Transthyretin, complement 5, and matrilin 3 proteins revealed a trend of increasing western immunoblotting band densities after hyaluronic acid injections. Hyaluronic Acid 128-143 transthyretin Homo sapiens 0-13 24781992-5 2014 Nitrotyrosine was present in amyloid deposits after being exposed to the MPO/H2O2/NO(-) system by immunohistochemical staining, and the oxide mediated modification of serum transthyretin (TTR) was observed upon exposure to the MPO/H2O2 system using two-dimensional gel electrophoresis and TTR Western blotting. Hydrogen Peroxide 231-235 transthyretin Homo sapiens 173-186 24781992-5 2014 Nitrotyrosine was present in amyloid deposits after being exposed to the MPO/H2O2/NO(-) system by immunohistochemical staining, and the oxide mediated modification of serum transthyretin (TTR) was observed upon exposure to the MPO/H2O2 system using two-dimensional gel electrophoresis and TTR Western blotting. Hydrogen Peroxide 231-235 transthyretin Homo sapiens 188-191 24781992-6 2014 This observation revealed that the TTR amyloid deposits and serum TTR were oxidized by the MPO/H2O2/NO(-) system. Hydrogen Peroxide 95-99 transthyretin Homo sapiens 35-38 24487346-14 2014 Transthyretin revealed significant increases in protein band densities in both the high and low molecular weight hyaluronic acid injection groups. Hyaluronic Acid 113-128 transthyretin Homo sapiens 0-13 24347127-9 2014 Recent data with (99m)Tc-phosphate derivatives, previously used as bone seeking radioactive tracers, have shown promising results; these radiotracers selectively bind ATTR, but not AL subtype, and can differentiate subtypes with high diagnostic accuracy. tc-phosphate 22-34 transthyretin Homo sapiens 167-171 24577370-10 2014 Pharmacist-managed INR PST is associated with an increased %TTR in patients with LVADs. lvads 81-86 transthyretin Homo sapiens 60-63 24455993-0 2014 Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. technetium-hydroxymethylene diphosphonate 28-69 transthyretin Homo sapiens 133-146 24455993-1 2014 OBJECTIVE: To assess the usefulness of bone scintigraphy with (99m)Technetium-hydroxymethylene diphosphonate ((99m)Tc-HDP) for the detection of cardiac involvement in a group of patients with ATTR amyloidosis in different phases of disease, to relate the findings to echocardiography, ECG and cardiac biomarkers, and to evaluate different bone scintigraphic techniques and calculation methods for quantification of the cardiac uptake and for correlation with echocardiographic features and cardiac biomarkers. technetium-hydroxymethylene diphosphonate 67-108 transthyretin Homo sapiens 192-196 24455993-7 2014 CONCLUSIONS: Bone scintigraphy with (99m)Tc-HDP may detect cardiac involvement in patients with ATTR amyloidosis prior to echocardiographic evidence of cardiac involvement. tc-hdp 41-47 transthyretin Homo sapiens 96-100 24678637-1 2014 BACKGROUND: Transthyretin (TTR), an abundant protein in cerebrospinal fluid (CSF), contains a free, oxidation-prone cysteine residue that gives rise to TTR isoforms. Cysteine 116-124 transthyretin Homo sapiens 12-25 24678637-1 2014 BACKGROUND: Transthyretin (TTR), an abundant protein in cerebrospinal fluid (CSF), contains a free, oxidation-prone cysteine residue that gives rise to TTR isoforms. Cysteine 116-124 transthyretin Homo sapiens 27-30 24678637-1 2014 BACKGROUND: Transthyretin (TTR), an abundant protein in cerebrospinal fluid (CSF), contains a free, oxidation-prone cysteine residue that gives rise to TTR isoforms. Cysteine 116-124 transthyretin Homo sapiens 152-155 24678637-8 2014 The results show that TTR is significantly more modified on Cys(10) in the AD and MCI groups than in controls (NPH and HC) (p <= 0.0012). Cysteine 60-63 transthyretin Homo sapiens 22-25 25372741-7 2014 The aim of this review is to stress the relevance of TTR, besides its well-known role on transport of thyroxine and retinol-binding protein. Thyroxine 102-111 transthyretin Homo sapiens 53-56 25672679-7 2014 Recently, the clinical effects of TTR tetramer stabilizers, tafamidis and diflunisal, were demonstrated in randomised clinical trials, and tafamidis has been approved for the treatment of hereditary ATTR amyloidosis in European countries and in Japan. Diflunisal 74-84 transthyretin Homo sapiens 34-37 24422526-2 2014 Several small molecules that bind to the thyroxine-binding site of TTR have been shown to stabilize the TTR tetramer and to inhibit amyloid fibril formation of TTR. Thyroxine 41-50 transthyretin Homo sapiens 67-70 24422526-2 2014 Several small molecules that bind to the thyroxine-binding site of TTR have been shown to stabilize the TTR tetramer and to inhibit amyloid fibril formation of TTR. Thyroxine 41-50 transthyretin Homo sapiens 104-107 24422526-2 2014 Several small molecules that bind to the thyroxine-binding site of TTR have been shown to stabilize the TTR tetramer and to inhibit amyloid fibril formation of TTR. Thyroxine 41-50 transthyretin Homo sapiens 104-107 24422526-3 2014 Herein, we demonstrated that glabridin (Glab), a prenylated isoflavan isolated from Glycyrrhiza glabra L., inhibited aggregation of TTR in a thioflavin assay. glabridin 29-38 transthyretin Homo sapiens 132-135 24422526-3 2014 Herein, we demonstrated that glabridin (Glab), a prenylated isoflavan isolated from Glycyrrhiza glabra L., inhibited aggregation of TTR in a thioflavin assay. thioflavin T 141-151 transthyretin Homo sapiens 132-135 24422526-4 2014 The TTR-Glab complex structure revealed a novel binding mode including a CH-pi interaction with A108 and a hydrogen bond with K15. Propane 96-100 transthyretin Homo sapiens 4-7 24422526-4 2014 The TTR-Glab complex structure revealed a novel binding mode including a CH-pi interaction with A108 and a hydrogen bond with K15. Hydrogen 107-115 transthyretin Homo sapiens 4-7 24422526-4 2014 The TTR-Glab complex structure revealed a novel binding mode including a CH-pi interaction with A108 and a hydrogen bond with K15. 5'-{[(3s)-3-Amino-3-Carboxypropyl](Hexyl)amino}-5'-Deoxyadenosine 126-129 transthyretin Homo sapiens 4-7 24286569-10 2014 INTERPRETATION: This is the first study to indicate that patients who received a greater number of local steroid injections preoperatively were more likely to have postoperative complaints associated with CTS. Steroids 105-112 transthyretin Homo sapiens 205-208 24474780-8 2014 Binding of the natural ligands thyroxine or retinol-binding protein (RBP) by Ser52Pro variant TTR stabilizes the native tetrameric assembly, but neither protected the variant from proteolysis. Thyroxine 31-40 transthyretin Homo sapiens 94-97 24269517-4 2014 Metformin use on treatment related outcomes (TTR: time to recurrence; RFS: recurrence free survival; OS: overall survival) were evaluated using univariate and multivariate modeling. Metformin 0-9 transthyretin Homo sapiens 45-48 24147937-4 2013 Analysis of the halogenated derivatives of two well-known TTR inhibitors has shown that while flufenamic acid affinity for TTR was unchanged by halogenation, diflunisal gradually improves binding up to 1 order of magnitude after iodination through interactions that can be interpreted as a suboptimal XB (carbonyl Thr106: I...O distance 3.96-4.05 A; C-I...O angle 152-156 ) or as rather optimized van der Waals contacts or as a mixture of both. Flufenamic Acid 94-109 transthyretin Homo sapiens 58-61 24101373-0 2013 Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. tafamidis 11-20 transthyretin Homo sapiens 24-37 24101373-8 2013 In conclusion, our findings suggest that tafamidis 20 mg QD effectively stabilized TTR associated with several non-Val30Met variants. tafamidis 41-50 transthyretin Homo sapiens 83-86 24336709-3 2013 We now show that substoichiometric concentrations of TTR tetramers suppress Abeta aggregation in vitro via an interaction between the thyroxine binding pocket of the TTR tetramer and Abeta residues 18-21 (nuclear magnetic resonance and epitope mapping). Thyroxine 134-143 transthyretin Homo sapiens 53-56 24336709-3 2013 We now show that substoichiometric concentrations of TTR tetramers suppress Abeta aggregation in vitro via an interaction between the thyroxine binding pocket of the TTR tetramer and Abeta residues 18-21 (nuclear magnetic resonance and epitope mapping). Thyroxine 134-143 transthyretin Homo sapiens 166-169 24147937-4 2013 Analysis of the halogenated derivatives of two well-known TTR inhibitors has shown that while flufenamic acid affinity for TTR was unchanged by halogenation, diflunisal gradually improves binding up to 1 order of magnitude after iodination through interactions that can be interpreted as a suboptimal XB (carbonyl Thr106: I...O distance 3.96-4.05 A; C-I...O angle 152-156 ) or as rather optimized van der Waals contacts or as a mixture of both. Flufenamic Acid 94-109 transthyretin Homo sapiens 123-126 24160776-2 2013 Some POPs, i.e., hydroxylated metabolites of polychlorinated biphenyls (OH-PCBs), pentachlorophenol (PCP), and perfluorooctane sulfonate (PFOS), compete with thyroxin (T4) for binding sites on transthyretin (TTR), a T4 transport protein found in plasma and cerebrospinal fluid. POPS 5-9 transthyretin Homo sapiens 193-206 24147937-4 2013 Analysis of the halogenated derivatives of two well-known TTR inhibitors has shown that while flufenamic acid affinity for TTR was unchanged by halogenation, diflunisal gradually improves binding up to 1 order of magnitude after iodination through interactions that can be interpreted as a suboptimal XB (carbonyl Thr106: I...O distance 3.96-4.05 A; C-I...O angle 152-156 ) or as rather optimized van der Waals contacts or as a mixture of both. Diflunisal 158-168 transthyretin Homo sapiens 58-61 24160776-2 2013 Some POPs, i.e., hydroxylated metabolites of polychlorinated biphenyls (OH-PCBs), pentachlorophenol (PCP), and perfluorooctane sulfonate (PFOS), compete with thyroxin (T4) for binding sites on transthyretin (TTR), a T4 transport protein found in plasma and cerebrospinal fluid. POPS 5-9 transthyretin Homo sapiens 208-211 24160776-4 2013 We measured the concentration of T4-TTR in plasma samples obtained from 120 Inuit women (18-39 years old) by combining native-polyacrylamide gel electrophoresis and liquid chromatography-tandem mass spectrometry (LC-MS/MS) techniques. polyacrylamide 126-140 transthyretin Homo sapiens 33-39 24160776-7 2013 Linear regression analysis revealed that TTR, TBG, and total T4 concentrations were significant predictors (p < 0.002) of T4-TTR levels (total adjusted R-squared = 0.26, p < 0.0001) but not levels of OH-PCBs, chlorophenols, or PFOS. oh-pcbs 206-213 transthyretin Homo sapiens 41-44 24160776-7 2013 Linear regression analysis revealed that TTR, TBG, and total T4 concentrations were significant predictors (p < 0.002) of T4-TTR levels (total adjusted R-squared = 0.26, p < 0.0001) but not levels of OH-PCBs, chlorophenols, or PFOS. oh-pcbs 206-213 transthyretin Homo sapiens 125-131 24180271-0 2013 Stilbene vinyl sulfonamides as fluorogenic sensors of and traceless covalent kinetic stabilizers of transthyretin that prevent amyloidogenesis. stilbene vinyl sulfonamides 0-27 transthyretin Homo sapiens 100-113 24180271-3 2013 These small molecules bind selectively to TTR in complex biological environments and then undergo a rapid and chemoselective 1,4-Michael addition with the pKa-perturbed Lys-15 epsilon-amino group of TTR. Lysine 169-172 transthyretin Homo sapiens 42-45 24180271-3 2013 These small molecules bind selectively to TTR in complex biological environments and then undergo a rapid and chemoselective 1,4-Michael addition with the pKa-perturbed Lys-15 epsilon-amino group of TTR. Lysine 169-172 transthyretin Homo sapiens 199-202 24180271-5 2013 X-ray cocrystallography verified the formation of the secondary amine bond mediating the conjugation in the case of 2 and 4 and confirmed the expected orientation of the stilbene within the TTR binding sites. Stilbenes 170-178 transthyretin Homo sapiens 190-193 24180271-6 2013 Vinyl amide 2 and vinyl sulfonamide 4 potently inhibit TTR dissociation and amyloid fibril formation in vitro. Acrylamide 0-11 transthyretin Homo sapiens 55-58 24180271-6 2013 Vinyl amide 2 and vinyl sulfonamide 4 potently inhibit TTR dissociation and amyloid fibril formation in vitro. vinyl sulfonamide 18-35 transthyretin Homo sapiens 55-58 24180271-7 2013 The TTR binding selectivity, modification yield, and reaction chemoselectivity of vinyl sulfonamide 4 are good enough in human plasma to serve as a starting point for medicinal chemistry efforts. vinyl sulfonamide 82-99 transthyretin Homo sapiens 4-7 24180271-8 2013 Moreover, vinyl sulfonamide 4 is fluorogenic: it exhibits minimal background fluorescence in complex biological environments, remains dark upon binding to TTR, and becomes fluorescent only upon reaction with TTR. vinyl sulfonamide 10-27 transthyretin Homo sapiens 155-158 24180271-8 2013 Moreover, vinyl sulfonamide 4 is fluorogenic: it exhibits minimal background fluorescence in complex biological environments, remains dark upon binding to TTR, and becomes fluorescent only upon reaction with TTR. vinyl sulfonamide 10-27 transthyretin Homo sapiens 208-211 23974642-1 2013 Tafamidis, a transthyretin (TTR) kinetic stabilizer, delayed neuropathic progression in patients with Val30Met TTR familial amyloid polyneuropathy (TTR-FAP) in an 18-month randomized controlled trial (study Fx-005). tafamidis 0-9 transthyretin Homo sapiens 111-114 24035612-3 2013 Herein, we provide evidence that transthyretin, a transporter of thyroxine and retinol, is aggregated in preeclampsia and is present at reduced levels in sera of preeclamptic women, as detected by proteomic screen. Thyroxine 65-74 transthyretin Homo sapiens 33-46 24035612-3 2013 Herein, we provide evidence that transthyretin, a transporter of thyroxine and retinol, is aggregated in preeclampsia and is present at reduced levels in sera of preeclamptic women, as detected by proteomic screen. Vitamin A 79-86 transthyretin Homo sapiens 33-46 24160776-7 2013 Linear regression analysis revealed that TTR, TBG, and total T4 concentrations were significant predictors (p < 0.002) of T4-TTR levels (total adjusted R-squared = 0.26, p < 0.0001) but not levels of OH-PCBs, chlorophenols, or PFOS. Chlorophenols 215-228 transthyretin Homo sapiens 41-44 24160776-7 2013 Linear regression analysis revealed that TTR, TBG, and total T4 concentrations were significant predictors (p < 0.002) of T4-TTR levels (total adjusted R-squared = 0.26, p < 0.0001) but not levels of OH-PCBs, chlorophenols, or PFOS. Chlorophenols 215-228 transthyretin Homo sapiens 125-131 24160776-7 2013 Linear regression analysis revealed that TTR, TBG, and total T4 concentrations were significant predictors (p < 0.002) of T4-TTR levels (total adjusted R-squared = 0.26, p < 0.0001) but not levels of OH-PCBs, chlorophenols, or PFOS. perfluorooctane sulfonic acid 233-237 transthyretin Homo sapiens 41-44 24160776-7 2013 Linear regression analysis revealed that TTR, TBG, and total T4 concentrations were significant predictors (p < 0.002) of T4-TTR levels (total adjusted R-squared = 0.26, p < 0.0001) but not levels of OH-PCBs, chlorophenols, or PFOS. perfluorooctane sulfonic acid 233-237 transthyretin Homo sapiens 125-131 24148365-0 2013 Investigating of labelling and detection of transthyretin synthetic peptide derivatized with naphthalene-2,3-dicarboxaldehyde. 2,3-naphthalenedicarboxaldehyde 93-125 transthyretin Homo sapiens 44-57 23811617-9 2013 CONCLUSIONS: Although both US-guided and blind steroid injections were effective in reducing the symptoms of CTS and improving the function, an earlier onset/better improvement of symptom relief suggests that US-guided steroid injection may be more effective than are blind injections in CTS. Steroids 47-54 transthyretin Homo sapiens 109-112 23811617-9 2013 CONCLUSIONS: Although both US-guided and blind steroid injections were effective in reducing the symptoms of CTS and improving the function, an earlier onset/better improvement of symptom relief suggests that US-guided steroid injection may be more effective than are blind injections in CTS. Steroids 219-226 transthyretin Homo sapiens 288-291 23974642-1 2013 Tafamidis, a transthyretin (TTR) kinetic stabilizer, delayed neuropathic progression in patients with Val30Met TTR familial amyloid polyneuropathy (TTR-FAP) in an 18-month randomized controlled trial (study Fx-005). tafamidis 0-9 transthyretin Homo sapiens 111-114 23974642-8 2013 Plasma TTR was stabilized in 94.1 % of patients treated with tafamidis for 30 months. tafamidis 61-70 transthyretin Homo sapiens 7-10 24121323-0 2013 Hydrogen-bond network and pH sensitivity in human transthyretin. Hydrogen 0-8 transthyretin Homo sapiens 50-63 24121323-8 2013 This hydrogen-bond network is involved in monomer-monomer and dimer-dimer interactions, suggesting that the double protonation of His88 by acidification breaks the hydrogen-bond network and causes the destabilization of the TTR tetramer. Hydrogen 5-13 transthyretin Homo sapiens 224-227 24121323-8 2013 This hydrogen-bond network is involved in monomer-monomer and dimer-dimer interactions, suggesting that the double protonation of His88 by acidification breaks the hydrogen-bond network and causes the destabilization of the TTR tetramer. Hydrogen 164-172 transthyretin Homo sapiens 224-227 23249342-0 2013 Does N-acetylcysteine modulate post-translational modifications of transthyretin in hemodialysis patients? Acetylcysteine 5-21 transthyretin Homo sapiens 67-80 24108193-9 2013 Dietary vitamin K intake higher than 200 mcg/day improved international normalized ratio control (%TTR 73.3+-17 vs. 67.7+-18, respectively, P=0.04). Vitamin K 8-17 transthyretin Homo sapiens 99-102 23987340-4 2013 The highest proton conductivity for the CTS/Csx-PTA membranes was obtained with x=2 and Cs2-PTA content of 5 wt%. Phosphotungstic Acid 48-51 transthyretin Homo sapiens 40-43 23987340-4 2013 The highest proton conductivity for the CTS/Csx-PTA membranes was obtained with x=2 and Cs2-PTA content of 5 wt%. Carbon Disulfide 88-91 transthyretin Homo sapiens 40-43 23987340-4 2013 The highest proton conductivity for the CTS/Csx-PTA membranes was obtained with x=2 and Cs2-PTA content of 5 wt%. Phosphotungstic Acid 92-95 transthyretin Homo sapiens 40-43 23987340-6 2013 The methanol permeability of CTS/Cs2-PTA membrane is about 5.6x10(-7), 90% lower than that of Nafion-212 membrane. Methanol 4-12 transthyretin Homo sapiens 29-32 23987340-6 2013 The methanol permeability of CTS/Cs2-PTA membrane is about 5.6x10(-7), 90% lower than that of Nafion-212 membrane. perfluorosulfonic acid 94-100 transthyretin Homo sapiens 29-32 23987340-7 2013 The highest selectivity factor (phi) was obtained on CTS/Cs2-PTA-5 wt% composite membrane, 1.1x10(4)/Scm(-3)s. The present study indicates the promising potential of CTS/Csx-PTA composite membrane as alternative proton exchange membranes in direct methanol fuel cells. Methanol 248-256 transthyretin Homo sapiens 53-56 23987340-7 2013 The highest selectivity factor (phi) was obtained on CTS/Cs2-PTA-5 wt% composite membrane, 1.1x10(4)/Scm(-3)s. The present study indicates the promising potential of CTS/Csx-PTA composite membrane as alternative proton exchange membranes in direct methanol fuel cells. Methanol 248-256 transthyretin Homo sapiens 166-169 23989101-1 2013 We describe coumarin derivatives that are non-fluorescent in aqueous buffers and that very selectively bind to transthyretin (TTR) in complex biological environments potently inhibiting TTR amyloidogenesis while also exhibiting sensitive off-on fluorescent sensing of the properly folded quaternary structure of TTR. coumarin 12-20 transthyretin Homo sapiens 126-129 23989101-1 2013 We describe coumarin derivatives that are non-fluorescent in aqueous buffers and that very selectively bind to transthyretin (TTR) in complex biological environments potently inhibiting TTR amyloidogenesis while also exhibiting sensitive off-on fluorescent sensing of the properly folded quaternary structure of TTR. coumarin 12-20 transthyretin Homo sapiens 186-189 23989101-1 2013 We describe coumarin derivatives that are non-fluorescent in aqueous buffers and that very selectively bind to transthyretin (TTR) in complex biological environments potently inhibiting TTR amyloidogenesis while also exhibiting sensitive off-on fluorescent sensing of the properly folded quaternary structure of TTR. coumarin 12-20 transthyretin Homo sapiens 186-189 23249342-3 2013 TTR was selected due to its low molecular weight and the free cysteine residue in the polypeptide chain, which is known to be extensively modified by formation of mixed disulfides. Cysteine 62-70 transthyretin Homo sapiens 0-3 23249342-3 2013 TTR was selected due to its low molecular weight and the free cysteine residue in the polypeptide chain, which is known to be extensively modified by formation of mixed disulfides. Disulfides 169-179 transthyretin Homo sapiens 0-3 23249342-4 2013 The intravenous application of NAC during a hemodialysis session resulted in a substantial increase of native TTR from median 15% (range 8.8%-30%) to median 40% (37-50) and reduction of S-cysteinylated TTR [51% (44-60) vs. 6.6% (2.4-10)]. Acetylcysteine 31-34 transthyretin Homo sapiens 110-113 23249342-4 2013 The intravenous application of NAC during a hemodialysis session resulted in a substantial increase of native TTR from median 15% (range 8.8%-30%) to median 40% (37-50) and reduction of S-cysteinylated TTR [51% (44-60) vs. 6.6% (2.4-10)]. Acetylcysteine 31-34 transthyretin Homo sapiens 202-205 24144522-7 2013 Oral administration of tafamidis, which prevents deposition of mutated TTR, is now available to delay neurologic complications in early stages of the disease. tafamidis 23-32 transthyretin Homo sapiens 71-74 23249342-2 2013 Therefore, we analyzed NAC-induced modifications of the protein transthyretin (TTR) in plasma of hemodialysis patients in a randomized, placebo-controlled study. Acetylcysteine 23-26 transthyretin Homo sapiens 64-77 23249342-2 2013 Therefore, we analyzed NAC-induced modifications of the protein transthyretin (TTR) in plasma of hemodialysis patients in a randomized, placebo-controlled study. Acetylcysteine 23-26 transthyretin Homo sapiens 79-82 23249342-5 2013 Additionally the pronounced formation of a TTR-NAC adduct was detected. Acetylcysteine 47-50 transthyretin Homo sapiens 43-46 23860318-1 2013 Previous studies reported that 17 beta-estradiol (E2) is responsible for the up-regulation of transthyretin (TTR) expression via an estrogen receptor (ER)-dependent pathway in rat choroid plexus (CP) and liver. Estradiol 31-48 transthyretin Homo sapiens 94-107 23249342-7 2013 Additionally, in vitro incubation of plasma with NAC confirmed the in vivo results and indicated that changes in post-translational modification pattern of TTR were a function of NAC concentration. Acetylcysteine 49-52 transthyretin Homo sapiens 156-159 23249342-7 2013 Additionally, in vitro incubation of plasma with NAC confirmed the in vivo results and indicated that changes in post-translational modification pattern of TTR were a function of NAC concentration. Acetylcysteine 179-182 transthyretin Homo sapiens 156-159 24347943-1 2013 BACKGROUND: Local steroid injection is one of the treatment modalities for carpal tunnel syndrome (CTS). Steroids 18-25 transthyretin Homo sapiens 99-102 24347943-16 2013 CONCLUSION: One month after local steroid injection among the electrophysiological parameters studied distal motor latencies showed most consistent and recordable improvement across the severity spectrum of CTS. Steroids 34-41 transthyretin Homo sapiens 207-210 24000164-1 2013 Slowing FAP progression: Tafamidis meglumine is a small molecule capable of stabilizing the transthyretin (TTR) tetramer. tafamidis 25-44 transthyretin Homo sapiens 107-110 23860318-1 2013 Previous studies reported that 17 beta-estradiol (E2) is responsible for the up-regulation of transthyretin (TTR) expression via an estrogen receptor (ER)-dependent pathway in rat choroid plexus (CP) and liver. Estradiol 31-48 transthyretin Homo sapiens 109-112 23836816-1 2013 The transferrin-binding proteins TbpA and TbpB enable Neisseria gonorrhoeae to obtain iron from human transferrin. Iron 86-90 transthyretin Homo sapiens 33-37 24026316-1 2013 BACKGROUND: Steroid injections are used in idiopathic carpal tunnel syndrome (CTS), but evidence of efficacy beyond 1 month is lacking. Steroids 12-19 transthyretin Homo sapiens 78-81 24026316-2 2013 OBJECTIVE: To assess the efficacy of local methylprednisolone injections in CTS. Methylprednisolone 43-61 transthyretin Homo sapiens 76-79 24026316-12 2013 RESULTS: Improvement in CTS symptom severity scores at 10 weeks was greater in patients who received 80 mg of methylprednisolone and 40 mg of methylprednisolone than in those who received placebo (difference in change from baseline, -0.64 [95% CI, -1.06 to -0.21; P = 0.003] and -0.88 [CI, -1.30 to -0.46; P < 0.001], respectively), but there were no significant differences at 1 year. Methylprednisolone 110-128 transthyretin Homo sapiens 24-27 24026316-12 2013 RESULTS: Improvement in CTS symptom severity scores at 10 weeks was greater in patients who received 80 mg of methylprednisolone and 40 mg of methylprednisolone than in those who received placebo (difference in change from baseline, -0.64 [95% CI, -1.06 to -0.21; P = 0.003] and -0.88 [CI, -1.30 to -0.46; P < 0.001], respectively), but there were no significant differences at 1 year. Methylprednisolone 142-160 transthyretin Homo sapiens 24-27 24026316-17 2013 CONCLUSION: Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year. Methylprednisolone 12-30 transthyretin Homo sapiens 46-49 23941687-8 2013 The aromatic rings of the compounds also form cation-pi interactions with the -NH3(+) group of Lys 15 residues in hTTR. Lysine 95-98 transthyretin Homo sapiens 114-118 23833285-4 2013 We aimed to study the long-term prognostic value of myocardial sympathetic denervation detected by MIBG imaging in transthyretin familial amyloid polyneuropathy. 3-Iodobenzylguanidine 99-103 transthyretin Homo sapiens 115-128 23833285-14 2013 CONCLUSIONS: Cardiac sympathetic denervation as assessed by MIBG imaging is a useful prognostic marker in transthyretin familial amyloid polyneuropathy. 3-Iodobenzylguanidine 60-64 transthyretin Homo sapiens 106-119 23836816-9 2013 When these mutant TbpB proteins were produced in a strain expressing a form of TbpA that requires TbpB for iron acquisition, growth on transferrin was either abrogated or dramatically diminished. tert-butyl peroxybenzoate 18-22 transthyretin Homo sapiens 79-83 23836816-9 2013 When these mutant TbpB proteins were produced in a strain expressing a form of TbpA that requires TbpB for iron acquisition, growth on transferrin was either abrogated or dramatically diminished. Iron 107-111 transthyretin Homo sapiens 79-83 23969461-7 2013 Our results include the striking finding that the triple point of the metallic phase and two insulating phases is at the transition temperature, Ttr = Tc, which we determine to be 65.0 +- 0.1 C. The findings have profound implications for the mechanism of the metal-insulator transition in VO2, but they also demonstrate the importance of this approach for mastering phase transitions in many other strongly correlated materials, such as manganites and iron-based superconductors. Technetium 151-153 transthyretin Homo sapiens 145-148 23969461-7 2013 Our results include the striking finding that the triple point of the metallic phase and two insulating phases is at the transition temperature, Ttr = Tc, which we determine to be 65.0 +- 0.1 C. The findings have profound implications for the mechanism of the metal-insulator transition in VO2, but they also demonstrate the importance of this approach for mastering phase transitions in many other strongly correlated materials, such as manganites and iron-based superconductors. Metals 70-75 transthyretin Homo sapiens 145-148 23969461-7 2013 Our results include the striking finding that the triple point of the metallic phase and two insulating phases is at the transition temperature, Ttr = Tc, which we determine to be 65.0 +- 0.1 C. The findings have profound implications for the mechanism of the metal-insulator transition in VO2, but they also demonstrate the importance of this approach for mastering phase transitions in many other strongly correlated materials, such as manganites and iron-based superconductors. vo2 291-294 transthyretin Homo sapiens 145-148 23969461-7 2013 Our results include the striking finding that the triple point of the metallic phase and two insulating phases is at the transition temperature, Ttr = Tc, which we determine to be 65.0 +- 0.1 C. The findings have profound implications for the mechanism of the metal-insulator transition in VO2, but they also demonstrate the importance of this approach for mastering phase transitions in many other strongly correlated materials, such as manganites and iron-based superconductors. manganite 439-449 transthyretin Homo sapiens 145-148 23969461-7 2013 Our results include the striking finding that the triple point of the metallic phase and two insulating phases is at the transition temperature, Ttr = Tc, which we determine to be 65.0 +- 0.1 C. The findings have profound implications for the mechanism of the metal-insulator transition in VO2, but they also demonstrate the importance of this approach for mastering phase transitions in many other strongly correlated materials, such as manganites and iron-based superconductors. Iron 454-458 transthyretin Homo sapiens 145-148 23792159-1 2013 Several classes of chemicals are able to bind to the thyroxine binding sites of transthyretin (TTR), stabilizing its native state and inhibiting in vitro the amyloidogenic process. Thyroxine 53-62 transthyretin Homo sapiens 80-93 23792159-1 2013 Several classes of chemicals are able to bind to the thyroxine binding sites of transthyretin (TTR), stabilizing its native state and inhibiting in vitro the amyloidogenic process. Thyroxine 53-62 transthyretin Homo sapiens 95-98 23732306-3 2013 The MD simulation study of several solvated X-ray structures of apo and holo TTR has indicated the role of a conserved water molecule and its interaction with T4 binding residues Ser117 and Thr119. Water 119-124 transthyretin Homo sapiens 77-80 23733168-0 2013 Synthesis of 4H-1,4-oxazines as transthyretin amyloid fibril inhibitors. 4h-1,4-oxazines 13-28 transthyretin Homo sapiens 32-45 23733168-1 2013 4H-1,4-oxazines were designed as transthyretin (TTR) amyloid fibril inhibitors based on an analysis of the interactions between known small molecule inhibitors and TTR by molecular docking. 4h-1,4-oxazines 0-15 transthyretin Homo sapiens 33-46 23733168-1 2013 4H-1,4-oxazines were designed as transthyretin (TTR) amyloid fibril inhibitors based on an analysis of the interactions between known small molecule inhibitors and TTR by molecular docking. 4h-1,4-oxazines 0-15 transthyretin Homo sapiens 48-51 23733168-1 2013 4H-1,4-oxazines were designed as transthyretin (TTR) amyloid fibril inhibitors based on an analysis of the interactions between known small molecule inhibitors and TTR by molecular docking. 4h-1,4-oxazines 0-15 transthyretin Homo sapiens 164-167 23733168-4 2013 The results indicate that 4H-1,4-oxazines significantly inhibit TTR amyloid fibril at a concentration of 7.2 muM. 4h-1,4-oxazines 26-41 transthyretin Homo sapiens 64-67 23523753-6 2013 The V30A TTR induced apoptosis and autophagy concomitant with the accumulation of reactive oxygen species (ROS) and DNA double-strand breaks, reflected in the induction of phosphor-H2A.X. Reactive Oxygen Species 82-105 transthyretin Homo sapiens 9-12 23523753-6 2013 The V30A TTR induced apoptosis and autophagy concomitant with the accumulation of reactive oxygen species (ROS) and DNA double-strand breaks, reflected in the induction of phosphor-H2A.X. Reactive Oxygen Species 107-110 transthyretin Homo sapiens 9-12 23732306-6 2013 Theoretically investigated pharmacological parameters along with the binding energy data indicate the potentiality of 3",5"-diacetyl-3,5-dichloro-l-thyronine (Mod4) to act as a better inhibitor for TTR-related amyloid diseases. 3",5"-diacetyl-3,5-dichloro-l-thyronine 118-157 transthyretin Homo sapiens 198-201 23732306-6 2013 Theoretically investigated pharmacological parameters along with the binding energy data indicate the potentiality of 3",5"-diacetyl-3,5-dichloro-l-thyronine (Mod4) to act as a better inhibitor for TTR-related amyloid diseases. mod4 159-163 transthyretin Homo sapiens 198-201 23664144-1 2013 Since its discovery, transthyretin (TTR) has been regarded as an important hepatically derived protein carrier of thyroid hormones and retinol in blood. Vitamin A 135-142 transthyretin Homo sapiens 21-34 23664144-1 2013 Since its discovery, transthyretin (TTR) has been regarded as an important hepatically derived protein carrier of thyroid hormones and retinol in blood. Vitamin A 135-142 transthyretin Homo sapiens 36-39 23546595-9 2013 The ELISA results revealed that the sensitivity and specificity for TTR and CA19-9 in distinguishing PDAC patients from normal individuals were 90.5, 47.6, 66.7 and 85.7 %, respectively, and 81.0 and 85.7 % for their combination. pdac 101-105 transthyretin Homo sapiens 68-71 23546595-10 2013 CONCLUSIONS: These results suggest that the level of transthyretin is elevated in patients with PDAC. pdac 96-100 transthyretin Homo sapiens 53-66 23542486-5 2013 An in vitro competitive binding assay was used to assess capacity to interfere with binding of the thyroid hormone, thyroxine (T4) to the recombinant human thyroid hormone transport protein, transthyretin (i.e. hTTR). Thyroxine 116-125 transthyretin Homo sapiens 211-215 23584369-1 2013 BACKGROUND: The displacement of l-thyroxine (T4) from binding sites on transthyretin (TTR) is considered a significant contributing mechanism in polychlorinated biphenyl (PCB)-induced thyroid disruption. Thyroxine 32-43 transthyretin Homo sapiens 71-84 23584369-1 2013 BACKGROUND: The displacement of l-thyroxine (T4) from binding sites on transthyretin (TTR) is considered a significant contributing mechanism in polychlorinated biphenyl (PCB)-induced thyroid disruption. Thyroxine 32-43 transthyretin Homo sapiens 86-89 23584369-1 2013 BACKGROUND: The displacement of l-thyroxine (T4) from binding sites on transthyretin (TTR) is considered a significant contributing mechanism in polychlorinated biphenyl (PCB)-induced thyroid disruption. Polychlorinated Biphenyls 145-169 transthyretin Homo sapiens 71-84 23584369-1 2013 BACKGROUND: The displacement of l-thyroxine (T4) from binding sites on transthyretin (TTR) is considered a significant contributing mechanism in polychlorinated biphenyl (PCB)-induced thyroid disruption. Polychlorinated Biphenyls 145-169 transthyretin Homo sapiens 86-89 23584369-1 2013 BACKGROUND: The displacement of l-thyroxine (T4) from binding sites on transthyretin (TTR) is considered a significant contributing mechanism in polychlorinated biphenyl (PCB)-induced thyroid disruption. Polychlorinated Biphenyls 171-174 transthyretin Homo sapiens 71-84 23584369-1 2013 BACKGROUND: The displacement of l-thyroxine (T4) from binding sites on transthyretin (TTR) is considered a significant contributing mechanism in polychlorinated biphenyl (PCB)-induced thyroid disruption. Polychlorinated Biphenyls 171-174 transthyretin Homo sapiens 86-89 23584369-2 2013 Previous research has discovered hydroxylated PCB metabolites (OH-PCBs) as high-affinity ligands for TTR, but the binding potential of conjugated PCB metabolites such as PCB sulfates has not been explored. Polychlorinated Biphenyls 46-49 transthyretin Homo sapiens 101-104 23584369-2 2013 Previous research has discovered hydroxylated PCB metabolites (OH-PCBs) as high-affinity ligands for TTR, but the binding potential of conjugated PCB metabolites such as PCB sulfates has not been explored. oh-pcbs 63-70 transthyretin Homo sapiens 101-104 23584369-2 2013 Previous research has discovered hydroxylated PCB metabolites (OH-PCBs) as high-affinity ligands for TTR, but the binding potential of conjugated PCB metabolites such as PCB sulfates has not been explored. Polychlorinated Biphenyls 66-69 transthyretin Homo sapiens 101-104 23584369-3 2013 OBJECTIVES: We evaluated the binding of five lower-chlorinated PCB sulfates to human TTR and compared their binding characteristics to those determined for their OH-PCB precursors and for T4. pcb sulfates 63-75 transthyretin Homo sapiens 85-88 23584369-4 2013 METHODS: We used fluorescence probe displacement studies and molecular docking simulations to characterize the binding of PCB sulfates to TTR. pcb sulfates 122-134 transthyretin Homo sapiens 138-141 23584369-5 2013 The stability of PCB sulfates and the reversibility of these interactions were characterized by HPLC analysis of PCB sulfates after their binding to TTR. pcb sulfates 17-29 transthyretin Homo sapiens 149-152 23584369-5 2013 The stability of PCB sulfates and the reversibility of these interactions were characterized by HPLC analysis of PCB sulfates after their binding to TTR. pcb sulfates 113-125 transthyretin Homo sapiens 149-152 23584369-7 2013 RESULTS: All five PCB sulfates were able to bind to the high-affinity binding site of TTR with equilibrium dissociation constants (Kd values) in the low nanomolar range (4.8-16.8 nM), similar to that observed for T4 (4.7 nM). pcb sulfates 18-30 transthyretin Homo sapiens 86-89 23584369-10 2013 CONCLUSIONS: Our findings show that PCB sulfates are high-affinity ligands for human TTR and therefore indicate, for the first time, a potential relevance for these metabolites in PCB-induced thyroid disruption. pcb sulfates 36-48 transthyretin Homo sapiens 85-88 23584369-10 2013 CONCLUSIONS: Our findings show that PCB sulfates are high-affinity ligands for human TTR and therefore indicate, for the first time, a potential relevance for these metabolites in PCB-induced thyroid disruption. Polychlorinated Biphenyls 36-39 transthyretin Homo sapiens 85-88 23716704-8 2013 Here, we report the development of AG10, a potent and selective kinetic stabilizer of TTR. tyrphostin 8 35-39 transthyretin Homo sapiens 86-89 23716704-9 2013 AG10 prevents dissociation of V122I-TTR in serum samples obtained from patients with familial amyloid cardiomyopathy. tyrphostin 8 0-4 transthyretin Homo sapiens 36-39 23716704-11 2013 Crystallographic studies of AG10 bound to V122I-TTR give valuable insights into how AG10 achieves such effective kinetic stabilization of TTR, which will also aid in designing better TTR stabilizers. tyrphostin 8 28-32 transthyretin Homo sapiens 48-51 23716704-11 2013 Crystallographic studies of AG10 bound to V122I-TTR give valuable insights into how AG10 achieves such effective kinetic stabilization of TTR, which will also aid in designing better TTR stabilizers. tyrphostin 8 28-32 transthyretin Homo sapiens 138-141 23716704-11 2013 Crystallographic studies of AG10 bound to V122I-TTR give valuable insights into how AG10 achieves such effective kinetic stabilization of TTR, which will also aid in designing better TTR stabilizers. tyrphostin 8 28-32 transthyretin Homo sapiens 138-141 23584369-0 2013 Sulfated metabolites of polychlorinated biphenyls are high-affinity ligands for the thyroid hormone transport protein transthyretin. Polychlorinated Biphenyls 24-49 transthyretin Homo sapiens 118-131 23542486-9 2013 There was a positive relationship between the degree of response in the T4-hTTR assay and the amounts of polybrominated diphenyl ether (PBDE) congeners 47 and 99, triclosan and the PBDE metabolite, 4-OH-BDE17. phenyl ether 120-134 transthyretin Homo sapiens 75-79 23542486-9 2013 There was a positive relationship between the degree of response in the T4-hTTR assay and the amounts of polybrominated diphenyl ether (PBDE) congeners 47 and 99, triclosan and the PBDE metabolite, 4-OH-BDE17. Halogenated Diphenyl Ethers 136-140 transthyretin Homo sapiens 75-79 23542486-9 2013 There was a positive relationship between the degree of response in the T4-hTTR assay and the amounts of polybrominated diphenyl ether (PBDE) congeners 47 and 99, triclosan and the PBDE metabolite, 4-OH-BDE17. Triclosan 163-172 transthyretin Homo sapiens 75-79 23397077-2 2013 Furthermore, recent advanced systems allow controlled expression of the effector RNA via coexpression of a tetracycline/doxycycline (DOX) responsive repressor (tTR-KRAB). Tetracycline 107-119 transthyretin Homo sapiens 160-163 23542486-9 2013 There was a positive relationship between the degree of response in the T4-hTTR assay and the amounts of polybrominated diphenyl ether (PBDE) congeners 47 and 99, triclosan and the PBDE metabolite, 4-OH-BDE17. Halogenated Diphenyl Ethers 181-185 transthyretin Homo sapiens 75-79 23397077-2 2013 Furthermore, recent advanced systems allow controlled expression of the effector RNA via coexpression of a tetracycline/doxycycline (DOX) responsive repressor (tTR-KRAB). Doxycycline 120-131 transthyretin Homo sapiens 160-163 23542486-9 2013 There was a positive relationship between the degree of response in the T4-hTTR assay and the amounts of polybrominated diphenyl ether (PBDE) congeners 47 and 99, triclosan and the PBDE metabolite, 4-OH-BDE17. 4-oh-bde17 198-208 transthyretin Homo sapiens 75-79 23397077-2 2013 Furthermore, recent advanced systems allow controlled expression of the effector RNA via coexpression of a tetracycline/doxycycline (DOX) responsive repressor (tTR-KRAB). Doxorubicin 133-136 transthyretin Homo sapiens 160-163 23319365-1 2013 Transthyretin (TTR) is a homotetrameric protein of the CNS that plays a role of as the major thyroxine (T4) carrier from blood to cerebrospinal fluid (CSF). Thyroxine 93-102 transthyretin Homo sapiens 0-13 23466880-10 2013 They were also effective in inhibiting WT-TTR and L55P acid- or HHP-induced aggregation; in particular, LUM and IND were very effective, inhibiting almost 100% of the aggregation of both proteins under certain conditions. Indomethacin 112-115 transthyretin Homo sapiens 42-45 23350588-1 2013 BACKGROUND: Serum retinol binding protein (RBP4) is the binding protein for retinol, being delivered into the circulation through the carrier protein transthyretin (TTR) together with thyroxin (T4). Vitamin A 18-25 transthyretin Homo sapiens 150-163 23350588-1 2013 BACKGROUND: Serum retinol binding protein (RBP4) is the binding protein for retinol, being delivered into the circulation through the carrier protein transthyretin (TTR) together with thyroxin (T4). Vitamin A 18-25 transthyretin Homo sapiens 165-168 23414091-5 2013 Our studies show that methionine/cysteine-oxidized TTR and carbonylated TTR from either the WT or the V122I variant are thermodynamically less stable than their nonoxidized counterparts. Methionine 22-32 transthyretin Homo sapiens 51-54 23414091-5 2013 Our studies show that methionine/cysteine-oxidized TTR and carbonylated TTR from either the WT or the V122I variant are thermodynamically less stable than their nonoxidized counterparts. Cysteine 33-41 transthyretin Homo sapiens 51-54 23414091-8 2013 Here, we report that carbonylated WT TTR is less amenable to resveratrol-mediated tetramer stabilization than WT TTR. Resveratrol 61-72 transthyretin Homo sapiens 37-40 23231421-2 2013 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) has proven highly sensitive for detecting amyloidotic cardiomyopathy due to transthyretin-related amyloid deposition. 99mtc-3,3-diphosphono-1,2-propanodicarboxylic acid 0-50 transthyretin Homo sapiens 139-152 23319365-1 2013 Transthyretin (TTR) is a homotetrameric protein of the CNS that plays a role of as the major thyroxine (T4) carrier from blood to cerebrospinal fluid (CSF). Thyroxine 93-102 transthyretin Homo sapiens 15-18 23319365-3 2013 We investigated post-translational oxidative modifications of serum and CSF TTR in multiple sclerosis subjects, highlighting high levels of S-sulfhydration and S-sulfonation of cysteine in position ten only in the cerebral TTR, which correlate with an anomalous TTR protein folding as well as with disease duration. Cysteine 177-185 transthyretin Homo sapiens 76-79 23319365-3 2013 We investigated post-translational oxidative modifications of serum and CSF TTR in multiple sclerosis subjects, highlighting high levels of S-sulfhydration and S-sulfonation of cysteine in position ten only in the cerebral TTR, which correlate with an anomalous TTR protein folding as well as with disease duration. Cysteine 177-185 transthyretin Homo sapiens 223-226 23319365-3 2013 We investigated post-translational oxidative modifications of serum and CSF TTR in multiple sclerosis subjects, highlighting high levels of S-sulfhydration and S-sulfonation of cysteine in position ten only in the cerebral TTR, which correlate with an anomalous TTR protein folding as well as with disease duration. Cysteine 177-185 transthyretin Homo sapiens 223-226 23483184-7 2013 Other innovative medicines have been developed by biopharmaceutical companies to block the hepatic production of mutant and wild type TTR which are harmful in late-onset FAP (> 50 years old), including RNA interference therapeutics and antisense oligonucleotides, and to remove the amyloid deposits (monoclonal antibody antiserum amyloid P). Oligonucleotides 249-265 transthyretin Homo sapiens 134-137 23000319-1 2013 Transthyretin (TTR) is a plasma protein transporter of thyroxine (T(4)) and retinol and also has peptidase activity. Thyroxine 55-64 transthyretin Homo sapiens 0-13 23000319-1 2013 Transthyretin (TTR) is a plasma protein transporter of thyroxine (T(4)) and retinol and also has peptidase activity. Thyroxine 55-64 transthyretin Homo sapiens 15-18 23000319-1 2013 Transthyretin (TTR) is a plasma protein transporter of thyroxine (T(4)) and retinol and also has peptidase activity. Vitamin A 76-83 transthyretin Homo sapiens 0-13 23000319-1 2013 Transthyretin (TTR) is a plasma protein transporter of thyroxine (T(4)) and retinol and also has peptidase activity. Vitamin A 76-83 transthyretin Homo sapiens 15-18 23000319-4 2013 The more relevant observation was that the peptides containing E or D were cleaved at only one peptide bond and TTR was competitively inhibited by glutathione analog peptide gamma-E-A-G-OH that contains two free carboxyl groups. Glutathione 147-158 transthyretin Homo sapiens 112-115 23000319-5 2013 The dependence on ionic interactions of TTR hydrolytic activity was confirmed by the large inhibitory effects of salt and ionic surfactants. Salts 113-117 transthyretin Homo sapiens 40-43 23000319-6 2013 TTR was not inhibited by any usual peptidase inhibitors, except by ortho-phenanthroline and EDTA. ferroin 67-87 transthyretin Homo sapiens 0-3 23000319-6 2013 TTR was not inhibited by any usual peptidase inhibitors, except by ortho-phenanthroline and EDTA. Edetic Acid 92-96 transthyretin Homo sapiens 0-3 23000319-9 2013 These results support the recently proposed inducible metalloprotease mechanism for TTR based on its 3D structure in presence of Zn(2+) and a series of point mutations [Liz et al., Biochem. Zinc 129-131 transthyretin Homo sapiens 84-87 23619538-1 2013 OBJECTIVE: The aim of this study was to sonographically evaluate the anatomy of the transverse carpal ligament (TCL) after open surgical release in the treatment of carpal tunnel syndrome (CTS) and to establish new ultrasonographic criteria for the completeness of TCL release. Triclosan 112-115 transthyretin Homo sapiens 189-192 22975527-7 2013 Furthermore, the kinetic parameters of the interactions between abnormal TTRs and a thyroxine-like fluorescent probe were quite different from those of natural TTR. Thyroxine 84-93 transthyretin Homo sapiens 73-76 23931808-5 2013 TTR-Val30Met is the most frequent substitution, resulting in a guanine to cytosine mutation in exon 2 of the gene. Guanine 63-70 transthyretin Homo sapiens 0-3 24312849-3 2013 The present study set out to assess the effect of vitamin B6 in patients with CTS. Vitamin B 6 50-60 transthyretin Homo sapiens 78-81 24312849-10 2013 CONCLUSION: The present study suggests that vitamin B6 treatment improves clinical symptoms and sensory electrodiagnostic results in CTS patients, and thus is recommended for CTS treatment. Vitamin B 6 44-54 transthyretin Homo sapiens 133-136 24312849-10 2013 CONCLUSION: The present study suggests that vitamin B6 treatment improves clinical symptoms and sensory electrodiagnostic results in CTS patients, and thus is recommended for CTS treatment. Vitamin B 6 44-54 transthyretin Homo sapiens 175-178 23931808-5 2013 TTR-Val30Met is the most frequent substitution, resulting in a guanine to cytosine mutation in exon 2 of the gene. Cytosine 74-82 transthyretin Homo sapiens 0-3 22627469-8 2013 Moreover, cells treated with agTTR exhibited decreases in metabolic activity relative to TTR- or non-TTR-treated cells (p < 0.05) as assessed by reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). thiazolyl blue 166-226 transthyretin Homo sapiens 31-34 23563245-0 2013 Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer"s disease: the OmegAD study. Dihydroalprenolol 62-65 transthyretin Homo sapiens 11-24 23563245-0 2013 Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer"s disease: the OmegAD study. Fatty Acids, Omega-3 71-87 transthyretin Homo sapiens 11-24 23563245-3 2013 We studied effects of n - 3 FA supplementation on TTR-levels in patients with AD. Fatty Acids, Omega-3 22-30 transthyretin Homo sapiens 50-53 23563245-12 2013 Repeated measures ANOVA indicated an increase in TTR over time (p = 0.04) in those receiving n - 3 FA for 12 months. Fatty Acids, Omega-3 93-101 transthyretin Homo sapiens 49-52 23563245-14 2013 Thus, n - 3 FA treatment appeared to increase plasma-TTR in patients with AD. Fatty Acids, Omega-3 6-14 transthyretin Homo sapiens 53-56 22627469-0 2013 Transthyretin aggregates induce production of reactive nitrogen species. Reactive Nitrogen Species 46-71 transthyretin Homo sapiens 0-13 23034895-0 2012 Purification of transthyretin as nutritional biomarker of selenium status. Selenium 58-66 transthyretin Homo sapiens 16-29 22627469-8 2013 Moreover, cells treated with agTTR exhibited decreases in metabolic activity relative to TTR- or non-TTR-treated cells (p < 0.05) as assessed by reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). monooxyethylene trimethylolpropane tristearate 161-164 transthyretin Homo sapiens 31-34 23240369-9 2012 In four patients of Yemenite descent, genetic analysis of the TTR gene demonstrated ser77tyr mutation. ser77tyr 84-92 transthyretin Homo sapiens 62-65 23270597-4 2012 Transthyretin (TTR) is a plasma transport protein for thyroid hormone and forms a complex with retinol-binding protein. Vitamin A 95-102 transthyretin Homo sapiens 0-13 23270597-4 2012 Transthyretin (TTR) is a plasma transport protein for thyroid hormone and forms a complex with retinol-binding protein. Vitamin A 95-102 transthyretin Homo sapiens 15-18 23041219-4 2012 In this study, we investigated the possibility of improving the targeting potential by employing the surface modification on Chitosan/poly(ethylene glycol) (CTS/PEG) Nanoparticles. Polyethylene Glycols 134-155 transthyretin Homo sapiens 157-160 23041219-5 2012 We demonstrate formulation and characterization of chitosan/poly(ethylene glycol)-anisamide (CTS/PEG-AA) and compared its efficiency with CTS/PEG and free gemcitabine. Chitosan 51-59 transthyretin Homo sapiens 93-103 23041219-5 2012 We demonstrate formulation and characterization of chitosan/poly(ethylene glycol)-anisamide (CTS/PEG-AA) and compared its efficiency with CTS/PEG and free gemcitabine. Chitosan 51-59 transthyretin Homo sapiens 93-96 23041219-5 2012 We demonstrate formulation and characterization of chitosan/poly(ethylene glycol)-anisamide (CTS/PEG-AA) and compared its efficiency with CTS/PEG and free gemcitabine. poly(ethylene glycol)-anisamide 60-91 transthyretin Homo sapiens 93-103 23041219-5 2012 We demonstrate formulation and characterization of chitosan/poly(ethylene glycol)-anisamide (CTS/PEG-AA) and compared its efficiency with CTS/PEG and free gemcitabine. poly(ethylene glycol)-anisamide 60-91 transthyretin Homo sapiens 93-96 23129325-1 2012 Retinol-binding protein 4 (RBP4) is the principle carrier of retinol in the human plasma, which circulates as a complex with transthyretin (TTR), a homotetrameric thyroxine transport protein. Vitamin A 61-68 transthyretin Homo sapiens 125-138 23129325-1 2012 Retinol-binding protein 4 (RBP4) is the principle carrier of retinol in the human plasma, which circulates as a complex with transthyretin (TTR), a homotetrameric thyroxine transport protein. Vitamin A 61-68 transthyretin Homo sapiens 140-143 22747647-0 2012 Diflunisal for ATTR cardiac amyloidosis. Diflunisal 0-10 transthyretin Homo sapiens 15-19 22747647-3 2012 Diflunisal, a nonsteroidal anti-inflammatory drug, can stabilize the TTR tetramer in vitro and may prevent misfolding monomers and dimers from forming amyloid deposits in the heart. Diflunisal 0-10 transthyretin Homo sapiens 69-72 22747647-5 2012 The authors conducted a single-arm, open-label investigation with a mean follow-up of 0.9 +- 0.3 years to determine the safety and efficacy of diflunisal administration in a cohort of 13 patients with confirmed wild-type or mutant TTR cardiac amyloidosis. Diflunisal 143-153 transthyretin Homo sapiens 231-234 23034895-1 2012 Transthyretin has been proposed as nutritional biomarker of selenium intake. Selenium 60-68 transthyretin Homo sapiens 0-13 23034895-4 2012 This work proposes a new, promissory, and cheap two-step process to purify transthyretin from blood plasma, composed by a first aqueous two-phase system fractionation followed by affinity chromatography, using thyroxine-immobilized on epoxy-activated Sepharose CL-6B. Thyroxine 210-219 transthyretin Homo sapiens 75-88 23034895-4 2012 This work proposes a new, promissory, and cheap two-step process to purify transthyretin from blood plasma, composed by a first aqueous two-phase system fractionation followed by affinity chromatography, using thyroxine-immobilized on epoxy-activated Sepharose CL-6B. sepharose CL 6B 251-266 transthyretin Homo sapiens 75-88 23034895-6 2012 Thyroxine affinity chromatography was designed to bind transthyretin with high affinity, and was demonstrated to be useful to purify transthyretin, but was unable to completely resolve transthyretin from thyroxine-binding globulin and serum albumin, although the relative amount of albumin was lowered in the eluates. Thyroxine 0-9 transthyretin Homo sapiens 55-68 23034895-6 2012 Thyroxine affinity chromatography was designed to bind transthyretin with high affinity, and was demonstrated to be useful to purify transthyretin, but was unable to completely resolve transthyretin from thyroxine-binding globulin and serum albumin, although the relative amount of albumin was lowered in the eluates. Thyroxine 0-9 transthyretin Homo sapiens 133-146 23034895-6 2012 Thyroxine affinity chromatography was designed to bind transthyretin with high affinity, and was demonstrated to be useful to purify transthyretin, but was unable to completely resolve transthyretin from thyroxine-binding globulin and serum albumin, although the relative amount of albumin was lowered in the eluates. Thyroxine 0-9 transthyretin Homo sapiens 133-146 22859314-4 2012 However, quantification of the potency of in vitro metabolized PCBs and PBDEs has drawbacks related to the coextraction of compounds disturbing the T(4)-TTR competitive binding assay. Polychlorinated Biphenyls 63-67 transthyretin Homo sapiens 153-156 22859314-4 2012 However, quantification of the potency of in vitro metabolized PCBs and PBDEs has drawbacks related to the coextraction of compounds disturbing the T(4)-TTR competitive binding assay. Halogenated Diphenyl Ethers 72-77 transthyretin Homo sapiens 153-156 23815016-4 2012 Transthyretin is a tetramer composed of four identical subunits linked by non covalent bonds and bearing binding sites for thyroxine (T4) and retinol-binding protein (RBP). Thyroxine 123-132 transthyretin Homo sapiens 0-13 23815018-5 2012 Other innovative medicines (RNA interference, antisense oligonucleotides) have been developed to block hepatic production of both mutant and wildtype TTR (noxious in late-onset forms of NAH after age 50 years), and to remove amyloid deposits (monoclonal anti-SAP). Oligonucleotides 56-72 transthyretin Homo sapiens 150-153 22698061-8 2012 Importantly, we assessed thyroxine binding to TTR in plasma and found, in both MCI and AD groups, that TTR had reduced capacity to carry the hormone. Thyroxine 25-34 transthyretin Homo sapiens 103-106 22843282-1 2012 OBJECTIVES: To evaluate the efficacy and safety of 18 months of tafamidis treatment in patients with early-stage V30M transthyretin familial amyloid polyneuropathy (TTR-FAP). tafamidis 64-73 transthyretin Homo sapiens 165-168 22727520-6 2012 The assay was used to follow the binding of Ca(2+) to calmodulin (CaM) and thiamine monophosphate (ThMP) to thiamine binding protein A (TbpA). Thiamine Monophosphate 75-97 transthyretin Homo sapiens 108-134 22727520-6 2012 The assay was used to follow the binding of Ca(2+) to calmodulin (CaM) and thiamine monophosphate (ThMP) to thiamine binding protein A (TbpA). Thiamine Monophosphate 75-97 transthyretin Homo sapiens 136-140 22727520-6 2012 The assay was used to follow the binding of Ca(2+) to calmodulin (CaM) and thiamine monophosphate (ThMP) to thiamine binding protein A (TbpA). Thiamine Monophosphate 99-103 transthyretin Homo sapiens 108-134 22727520-6 2012 The assay was used to follow the binding of Ca(2+) to calmodulin (CaM) and thiamine monophosphate (ThMP) to thiamine binding protein A (TbpA). Thiamine Monophosphate 99-103 transthyretin Homo sapiens 136-140 22842046-0 2012 Flavonoid interactions with human transthyretin: combined structural and thermodynamic analysis. Flavonoids 0-9 transthyretin Homo sapiens 34-47 22842046-3 2012 Here we selected and characterized the interaction of flavonoids with the wild type and the V30M amyloidogenic mutant TTR. Flavonoids 54-64 transthyretin Homo sapiens 118-121 22842046-4 2012 TTR acid aggregation was evaluated in vitro in the presence of the different flavonoids. Flavonoids 77-87 transthyretin Homo sapiens 0-3 22842046-6 2012 Crystal structures of TTRwt in complex with the top binders were also obtained, enabling us to in depth inspect TTR interactions with these flavonoids. Flavonoids 140-150 transthyretin Homo sapiens 22-25 22842046-7 2012 The results indicate that changing the number and position of hydroxyl groups attached to the flavonoid core strongly influence flavonoid recognition by TTR, either by changing ligand affinity or its mechanism of interaction with the two sites of TTR. Flavonoids 94-103 transthyretin Homo sapiens 153-156 22842046-7 2012 The results indicate that changing the number and position of hydroxyl groups attached to the flavonoid core strongly influence flavonoid recognition by TTR, either by changing ligand affinity or its mechanism of interaction with the two sites of TTR. Flavonoids 94-103 transthyretin Homo sapiens 247-250 22842046-7 2012 The results indicate that changing the number and position of hydroxyl groups attached to the flavonoid core strongly influence flavonoid recognition by TTR, either by changing ligand affinity or its mechanism of interaction with the two sites of TTR. Flavonoids 128-137 transthyretin Homo sapiens 153-156 22842046-7 2012 The results indicate that changing the number and position of hydroxyl groups attached to the flavonoid core strongly influence flavonoid recognition by TTR, either by changing ligand affinity or its mechanism of interaction with the two sites of TTR. Flavonoids 128-137 transthyretin Homo sapiens 247-250 22957710-6 2012 These efforts have been boosted by recent reports of the crystal structures of the neisserial receptor proteins TbpA and TbpB, each solved in complex with human transferrin, an iron binding protein normally responsible for delivering iron to human cells. Iron 177-181 transthyretin Homo sapiens 112-116 22957710-6 2012 These efforts have been boosted by recent reports of the crystal structures of the neisserial receptor proteins TbpA and TbpB, each solved in complex with human transferrin, an iron binding protein normally responsible for delivering iron to human cells. Iron 234-238 transthyretin Homo sapiens 112-116 22806059-18 2012 Also, (123)I-MIBG scintigraphy can detect cardiac denervation in ATTR patients before signs of amyloidosis are evident on echocardiography. i-mibg 11-17 transthyretin Homo sapiens 65-69 22620966-3 2012 Our recent studies revealed that cyclodextrins (CyDs), cyclic oligosaccharides composed of glucose units, might interact with TTR and prevent the protein misfolding. Cyclodextrins 33-46 transthyretin Homo sapiens 126-129 22785530-1 2012 We emphasize the role of Tc-99m-3,3-diphosphono-1,2-propanodicarboxylicacid (DPD) scintigraphy as a noninvasive tool to distinguish transthyretin (TTR)-related cardiac amyloidosis from other forms of cardiac amyloidosis. tc-99m-3,3-diphosphono-1,2-propanodicarboxylicacid 25-75 transthyretin Homo sapiens 132-145 22785530-1 2012 We emphasize the role of Tc-99m-3,3-diphosphono-1,2-propanodicarboxylicacid (DPD) scintigraphy as a noninvasive tool to distinguish transthyretin (TTR)-related cardiac amyloidosis from other forms of cardiac amyloidosis. tc-99m-3,3-diphosphono-1,2-propanodicarboxylicacid 25-75 transthyretin Homo sapiens 147-150 22785530-1 2012 We emphasize the role of Tc-99m-3,3-diphosphono-1,2-propanodicarboxylicacid (DPD) scintigraphy as a noninvasive tool to distinguish transthyretin (TTR)-related cardiac amyloidosis from other forms of cardiac amyloidosis. dpd 77-80 transthyretin Homo sapiens 132-145 22785530-1 2012 We emphasize the role of Tc-99m-3,3-diphosphono-1,2-propanodicarboxylicacid (DPD) scintigraphy as a noninvasive tool to distinguish transthyretin (TTR)-related cardiac amyloidosis from other forms of cardiac amyloidosis. dpd 77-80 transthyretin Homo sapiens 147-150 22171554-3 2012 COMMENT: The duration of time a patient"s international normalized ratio (INR) is maintained within the therapeutic range (time in the therapeutic range, TTR) for his or her particular indication for the drug impacts the effectiveness and safety of warfarin therapy. Warfarin 249-257 transthyretin Homo sapiens 154-157 22607976-3 2012 We report here the cryptic N-glycosylation site as a recognition signal for unfolding of a natively nonglycosylated protein, transthyretin (TTR), involved in familial amyloidosis. Nitrogen 27-28 transthyretin Homo sapiens 125-138 22607976-3 2012 We report here the cryptic N-glycosylation site as a recognition signal for unfolding of a natively nonglycosylated protein, transthyretin (TTR), involved in familial amyloidosis. Nitrogen 27-28 transthyretin Homo sapiens 140-143 22607976-4 2012 Folding and ER-associated degradation (ERAD) perturbation analyses revealed that prolonged TTR unfolding induces externalization of cryptic N-glycosylation site and triggers STT3B-dependent posttranslational N-glycosylation. Nitrogen 140-141 transthyretin Homo sapiens 91-94 22607976-4 2012 Folding and ER-associated degradation (ERAD) perturbation analyses revealed that prolonged TTR unfolding induces externalization of cryptic N-glycosylation site and triggers STT3B-dependent posttranslational N-glycosylation. Nitrogen 208-209 transthyretin Homo sapiens 91-94 22494066-5 2012 Using second-generation antisense technology, we identified an antisense oligonucleotide (ASO) targeting TTR, ISIS-TTR(Rx), for the treatment of TTR-associated amyloidosis. Oligonucleotides 73-88 transthyretin Homo sapiens 105-108 22494066-5 2012 Using second-generation antisense technology, we identified an antisense oligonucleotide (ASO) targeting TTR, ISIS-TTR(Rx), for the treatment of TTR-associated amyloidosis. Oligonucleotides 73-88 transthyretin Homo sapiens 115-118 22494066-5 2012 Using second-generation antisense technology, we identified an antisense oligonucleotide (ASO) targeting TTR, ISIS-TTR(Rx), for the treatment of TTR-associated amyloidosis. Oligonucleotides 73-88 transthyretin Homo sapiens 115-118 22494066-5 2012 Using second-generation antisense technology, we identified an antisense oligonucleotide (ASO) targeting TTR, ISIS-TTR(Rx), for the treatment of TTR-associated amyloidosis. Oligonucleotides, Antisense 90-93 transthyretin Homo sapiens 105-108 22494066-5 2012 Using second-generation antisense technology, we identified an antisense oligonucleotide (ASO) targeting TTR, ISIS-TTR(Rx), for the treatment of TTR-associated amyloidosis. Oligonucleotides, Antisense 90-93 transthyretin Homo sapiens 115-118 22494066-5 2012 Using second-generation antisense technology, we identified an antisense oligonucleotide (ASO) targeting TTR, ISIS-TTR(Rx), for the treatment of TTR-associated amyloidosis. Oligonucleotides, Antisense 90-93 transthyretin Homo sapiens 115-118 21916933-5 2012 Amyloidogenic TTR mutations cause significant calcium influx via L-type calcium channels in neuronal cell lines, while in primary sensory neurons, TTR mediates a calcium influx via a novel mechanism of transient receptor potential melanostatin (TRPM8) and voltage-gated sodium and calcium channel activation. Calcium 46-53 transthyretin Homo sapiens 14-17 21916933-5 2012 Amyloidogenic TTR mutations cause significant calcium influx via L-type calcium channels in neuronal cell lines, while in primary sensory neurons, TTR mediates a calcium influx via a novel mechanism of transient receptor potential melanostatin (TRPM8) and voltage-gated sodium and calcium channel activation. Calcium 72-79 transthyretin Homo sapiens 14-17 21916933-5 2012 Amyloidogenic TTR mutations cause significant calcium influx via L-type calcium channels in neuronal cell lines, while in primary sensory neurons, TTR mediates a calcium influx via a novel mechanism of transient receptor potential melanostatin (TRPM8) and voltage-gated sodium and calcium channel activation. Calcium 72-79 transthyretin Homo sapiens 14-17 21916933-5 2012 Amyloidogenic TTR mutations cause significant calcium influx via L-type calcium channels in neuronal cell lines, while in primary sensory neurons, TTR mediates a calcium influx via a novel mechanism of transient receptor potential melanostatin (TRPM8) and voltage-gated sodium and calcium channel activation. Sodium 270-276 transthyretin Homo sapiens 14-17 21916933-5 2012 Amyloidogenic TTR mutations cause significant calcium influx via L-type calcium channels in neuronal cell lines, while in primary sensory neurons, TTR mediates a calcium influx via a novel mechanism of transient receptor potential melanostatin (TRPM8) and voltage-gated sodium and calcium channel activation. Sodium 270-276 transthyretin Homo sapiens 147-150 21916933-5 2012 Amyloidogenic TTR mutations cause significant calcium influx via L-type calcium channels in neuronal cell lines, while in primary sensory neurons, TTR mediates a calcium influx via a novel mechanism of transient receptor potential melanostatin (TRPM8) and voltage-gated sodium and calcium channel activation. Calcium 72-79 transthyretin Homo sapiens 14-17 22607976-5 2012 Inhibition of posttranslational N-glycosylation increases detergent-insoluble TTR aggregates and decreases cell proliferation of mutant TTR-expressing cells. Nitrogen 32-33 transthyretin Homo sapiens 78-81 22607976-5 2012 Inhibition of posttranslational N-glycosylation increases detergent-insoluble TTR aggregates and decreases cell proliferation of mutant TTR-expressing cells. Nitrogen 32-33 transthyretin Homo sapiens 136-139 22645360-2 2012 ATTR are caused by aggregation of transthyretin (TTR), a natively tetrameric protein involved in the transport of thyroxine and the vitamin A-retinol-binding protein complex. Thyroxine 114-123 transthyretin Homo sapiens 0-4 22645360-2 2012 ATTR are caused by aggregation of transthyretin (TTR), a natively tetrameric protein involved in the transport of thyroxine and the vitamin A-retinol-binding protein complex. Thyroxine 114-123 transthyretin Homo sapiens 34-47 22645360-2 2012 ATTR are caused by aggregation of transthyretin (TTR), a natively tetrameric protein involved in the transport of thyroxine and the vitamin A-retinol-binding protein complex. Thyroxine 114-123 transthyretin Homo sapiens 1-4 22645360-2 2012 ATTR are caused by aggregation of transthyretin (TTR), a natively tetrameric protein involved in the transport of thyroxine and the vitamin A-retinol-binding protein complex. Vitamin A 132-141 transthyretin Homo sapiens 0-4 22645360-2 2012 ATTR are caused by aggregation of transthyretin (TTR), a natively tetrameric protein involved in the transport of thyroxine and the vitamin A-retinol-binding protein complex. Vitamin A 132-141 transthyretin Homo sapiens 34-47 22645360-2 2012 ATTR are caused by aggregation of transthyretin (TTR), a natively tetrameric protein involved in the transport of thyroxine and the vitamin A-retinol-binding protein complex. Vitamin A 132-141 transthyretin Homo sapiens 1-4 22645360-5 2012 One such compound, tafamidis meglumine (Fx-1006A), has recently completed Phase II/III trials for the treatment of Transthyretin Type Familial Amyloid Polyneuropathy (TTR-FAP) and demonstrated a slowing of disease progression in patients heterozygous for the V30M TTR mutation. tafamidis 19-38 transthyretin Homo sapiens 167-170 22645360-5 2012 One such compound, tafamidis meglumine (Fx-1006A), has recently completed Phase II/III trials for the treatment of Transthyretin Type Familial Amyloid Polyneuropathy (TTR-FAP) and demonstrated a slowing of disease progression in patients heterozygous for the V30M TTR mutation. tafamidis 19-38 transthyretin Homo sapiens 264-267 22506915-4 2012 Moreover, MAb ATTR indeed showed the high consistency with Congo red positive areas in tissue specimens from FAP ATTR V30M patients, indicating that MAb ATTR showed binding affinity and specificity for TTR amyloid fibrils in vitro and in vivo. Congo Red 59-68 transthyretin Homo sapiens 14-18 22506915-4 2012 Moreover, MAb ATTR indeed showed the high consistency with Congo red positive areas in tissue specimens from FAP ATTR V30M patients, indicating that MAb ATTR showed binding affinity and specificity for TTR amyloid fibrils in vitro and in vivo. Congo Red 59-68 transthyretin Homo sapiens 113-117 22506915-4 2012 Moreover, MAb ATTR indeed showed the high consistency with Congo red positive areas in tissue specimens from FAP ATTR V30M patients, indicating that MAb ATTR showed binding affinity and specificity for TTR amyloid fibrils in vitro and in vivo. Congo Red 59-68 transthyretin Homo sapiens 113-117 22506915-4 2012 Moreover, MAb ATTR indeed showed the high consistency with Congo red positive areas in tissue specimens from FAP ATTR V30M patients, indicating that MAb ATTR showed binding affinity and specificity for TTR amyloid fibrils in vitro and in vivo. Congo Red 59-68 transthyretin Homo sapiens 15-18 22519861-0 2012 Systemic delivery of transthyretin siRNA mediated by lactosylated dendrimer/alpha-cyclodextrin conjugates into hepatocyte for familial amyloidotic polyneuropathy therapy. alpha-cyclodextrin 76-94 transthyretin Homo sapiens 21-34 22620966-3 2012 Our recent studies revealed that cyclodextrins (CyDs), cyclic oligosaccharides composed of glucose units, might interact with TTR and prevent the protein misfolding. Cyclodextrins 48-52 transthyretin Homo sapiens 126-129 22620966-3 2012 Our recent studies revealed that cyclodextrins (CyDs), cyclic oligosaccharides composed of glucose units, might interact with TTR and prevent the protein misfolding. cyclic oligosaccharides 55-78 transthyretin Homo sapiens 126-129 22620966-3 2012 Our recent studies revealed that cyclodextrins (CyDs), cyclic oligosaccharides composed of glucose units, might interact with TTR and prevent the protein misfolding. Glucose 91-98 transthyretin Homo sapiens 126-129 22620966-4 2012 In this study, we focused on and elucidated the inhibitory effect of 6-O-alpha-(4-O-alpha-D-Glucuronyl)-D-glucosyl-beta-CyD (GUG-beta-CyD) on TTR amyloid formation. 6-o-alpha-(4-o-alpha-d-glucuronyl)-d-glucosyl-beta-cyd 69-123 transthyretin Homo sapiens 142-145 22620966-4 2012 In this study, we focused on and elucidated the inhibitory effect of 6-O-alpha-(4-O-alpha-D-Glucuronyl)-D-glucosyl-beta-CyD (GUG-beta-CyD) on TTR amyloid formation. gug-beta-cyd 125-137 transthyretin Homo sapiens 142-145 22620966-5 2012 Tryptophan (Trp) fluorescence and (1)H-NMR spectroscopy analyses indicated that GUG-beta-CyD stabilized TTR conformation via interaction with the hydrophobic amino acids of TTR. Tryptophan 12-15 transthyretin Homo sapiens 104-107 22620966-5 2012 Tryptophan (Trp) fluorescence and (1)H-NMR spectroscopy analyses indicated that GUG-beta-CyD stabilized TTR conformation via interaction with the hydrophobic amino acids of TTR. Tryptophan 12-15 transthyretin Homo sapiens 173-176 22620966-5 2012 Tryptophan (Trp) fluorescence and (1)H-NMR spectroscopy analyses indicated that GUG-beta-CyD stabilized TTR conformation via interaction with the hydrophobic amino acids of TTR. gug-beta-cyd 80-92 transthyretin Homo sapiens 104-107 22620966-5 2012 Tryptophan (Trp) fluorescence and (1)H-NMR spectroscopy analyses indicated that GUG-beta-CyD stabilized TTR conformation via interaction with the hydrophobic amino acids of TTR. gug-beta-cyd 80-92 transthyretin Homo sapiens 173-176 22620966-6 2012 Moreover, GUG-beta-CyD suppressed TTR deposition in transgenic rats possessing a human ATTR V30M gene in vivo. gug-beta-cyd 10-22 transthyretin Homo sapiens 87-91 22620966-7 2012 Collectively, these data indicate that GUG-beta-CyD may inhibit TTR misfolding by stabilizing its conformation, which, in turn, suppresses TTR amyloid formation. gug-beta-cyd 39-51 transthyretin Homo sapiens 64-67 22620966-7 2012 Collectively, these data indicate that GUG-beta-CyD may inhibit TTR misfolding by stabilizing its conformation, which, in turn, suppresses TTR amyloid formation. gug-beta-cyd 39-51 transthyretin Homo sapiens 139-142 22332999-5 2012 However, metal chelators abolished TTR activity. Metals 9-14 transthyretin Homo sapiens 35-38 22336701-3 2012 Therefore, the aim of our study was to explore in-vivo the effects of steroid with repetitive procaine HCl injection on the median nerve of patients with CTS. Steroids 70-77 transthyretin Homo sapiens 154-157 22336701-3 2012 Therefore, the aim of our study was to explore in-vivo the effects of steroid with repetitive procaine HCl injection on the median nerve of patients with CTS. PROCAINE HYDROCHLORIDE 94-106 transthyretin Homo sapiens 154-157 22336701-9 2012 CONCLUSION: Steroid injection with repetitive procaine HCl injection effectively reduced the symptoms of CTS, improved the Boston carpal tunnel symptom and function assessment scale and also electrophysiological and ultrasonographic findings. Steroids 12-19 transthyretin Homo sapiens 105-108 22336701-9 2012 CONCLUSION: Steroid injection with repetitive procaine HCl injection effectively reduced the symptoms of CTS, improved the Boston carpal tunnel symptom and function assessment scale and also electrophysiological and ultrasonographic findings. PROCAINE HYDROCHLORIDE 46-58 transthyretin Homo sapiens 105-108 22332999-7 2012 These observations, supported by analysis of three-dimensional structures of TTR complexed with Zn2+, led to the hypothesis that TTR is a metallopeptidase. Zinc 96-100 transthyretin Homo sapiens 77-80 22332999-7 2012 These observations, supported by analysis of three-dimensional structures of TTR complexed with Zn2+, led to the hypothesis that TTR is a metallopeptidase. Zinc 96-100 transthyretin Homo sapiens 129-132 22332999-10 2012 The side chain of His88 is shifted near His90 and Glu92 establishing a Zn2+-chelating pattern HXHXE not found previously in any metallopeptidase and only conserved in TTR of humans and some other primates. Zinc 71-75 transthyretin Homo sapiens 167-170 22482873-2 2012 In this report, a nonradioactive, site-specific fluorescein-thyroxine (F-T4) conjugate was designed and synthesized as a fluorescence probe to study the binding interaction of hydroxylated PBDEs to thyroxine-binding globulin (TBG) and transthyretin (TTR), two major TH transport proteins in human plasma. fluorescein-thyroxine 48-69 transthyretin Homo sapiens 235-248 22645721-1 2012 Tafamidis meglumine (Vyndaqel , Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare neurodegenerative disorder characterized by progressive sensory, motor and autonomic impairment that is ultimately fatal. tafamidis 0-19 transthyretin Homo sapiens 93-106 22645721-1 2012 Tafamidis meglumine (Vyndaqel , Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare neurodegenerative disorder characterized by progressive sensory, motor and autonomic impairment that is ultimately fatal. tafamidis 0-19 transthyretin Homo sapiens 140-143 22645721-1 2012 Tafamidis meglumine (Vyndaqel , Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare neurodegenerative disorder characterized by progressive sensory, motor and autonomic impairment that is ultimately fatal. tafamidis 21-29 transthyretin Homo sapiens 93-106 22645721-1 2012 Tafamidis meglumine (Vyndaqel , Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare neurodegenerative disorder characterized by progressive sensory, motor and autonomic impairment that is ultimately fatal. tafamidis 21-29 transthyretin Homo sapiens 140-143 22482873-2 2012 In this report, a nonradioactive, site-specific fluorescein-thyroxine (F-T4) conjugate was designed and synthesized as a fluorescence probe to study the binding interaction of hydroxylated PBDEs to thyroxine-binding globulin (TBG) and transthyretin (TTR), two major TH transport proteins in human plasma. fluorescein-thyroxine 48-69 transthyretin Homo sapiens 250-253 22482873-2 2012 In this report, a nonradioactive, site-specific fluorescein-thyroxine (F-T4) conjugate was designed and synthesized as a fluorescence probe to study the binding interaction of hydroxylated PBDEs to thyroxine-binding globulin (TBG) and transthyretin (TTR), two major TH transport proteins in human plasma. f-t4 71-75 transthyretin Homo sapiens 235-248 22482873-2 2012 In this report, a nonradioactive, site-specific fluorescein-thyroxine (F-T4) conjugate was designed and synthesized as a fluorescence probe to study the binding interaction of hydroxylated PBDEs to thyroxine-binding globulin (TBG) and transthyretin (TTR), two major TH transport proteins in human plasma. f-t4 71-75 transthyretin Homo sapiens 250-253 22482873-2 2012 In this report, a nonradioactive, site-specific fluorescein-thyroxine (F-T4) conjugate was designed and synthesized as a fluorescence probe to study the binding interaction of hydroxylated PBDEs to thyroxine-binding globulin (TBG) and transthyretin (TTR), two major TH transport proteins in human plasma. Halogenated Diphenyl Ethers 189-194 transthyretin Homo sapiens 235-248 22482873-2 2012 In this report, a nonradioactive, site-specific fluorescein-thyroxine (F-T4) conjugate was designed and synthesized as a fluorescence probe to study the binding interaction of hydroxylated PBDEs to thyroxine-binding globulin (TBG) and transthyretin (TTR), two major TH transport proteins in human plasma. Halogenated Diphenyl Ethers 189-194 transthyretin Homo sapiens 250-253 22482873-5 2012 Based on fluorescence quantum yield and lifetime measurements, the fluorescence intensity enhancement was likely due to the elimination of intramolecular fluorescence quenching of fluorescein by T4 after F-T4 was bound to TTR. Fluorescein 180-191 transthyretin Homo sapiens 222-225 22482873-7 2012 By using F-T4 as the fluorescence probe in competitive binding assays, 11 OH-PBDEs with different levels of bromination and different hydroxylation positions were assessed for their binding affinity with TBG and TTR, respectively. 11 oh-pbdes 71-82 transthyretin Homo sapiens 212-215 22482873-9 2012 3-OH-BDE-47 and 3"-OH-BDE-154 bound to TTR and TBG even stronger, respectively, than T4. 3-oh 0-4 transthyretin Homo sapiens 39-42 22329529-3 2012 Abnormalities in the protein transthyretin (TTR), a serum transporter of thyroxine and retinol, is the most common cause of cardiac amyloidoses in elderly adults. Thyroxine 73-82 transthyretin Homo sapiens 29-42 21962473-12 2012 CONCLUSION: Patients with an electrodiagnostically mild CTS (i.e., abnormal comparative tests or prolonged median DSL>3.5 ms but normal median DML) are good candidates for a local steroid injection with 50% having a good long term effect for more than 15 months. Steroids 183-190 transthyretin Homo sapiens 56-59 21962473-13 2012 SIGNIFICANCE: This study shows that the EMG severity of CTS is an important prognostic factor for the long term effect of a local steroid injection. Steroids 130-137 transthyretin Homo sapiens 56-59 22399131-3 2012 Previous reports by our laboratories show that the sequence EIEYE in the plug domain is highly conserved among various bacterial species that express TbpA and plays a crucial role in iron utilization for gonococci. Iron 183-187 transthyretin Homo sapiens 150-154 22399131-4 2012 We hypothesize that this highly conserved EIEYE sequence in the TbpA plug, rich in hard oxygen donor groups, binds with Fe(3+) through the transport process across the outer membrane through the beta-barrel. Oxygen 88-94 transthyretin Homo sapiens 64-68 22399131-4 2012 We hypothesize that this highly conserved EIEYE sequence in the TbpA plug, rich in hard oxygen donor groups, binds with Fe(3+) through the transport process across the outer membrane through the beta-barrel. ferric sulfate 120-126 transthyretin Homo sapiens 64-68 22399131-5 2012 Sequestration of Fe(3+) by the TbpA-plug supports the paradigm that the ferric iron must always remain chelated and controlled throughout the transport process. ferric sulfate 17-23 transthyretin Homo sapiens 31-35 22329529-3 2012 Abnormalities in the protein transthyretin (TTR), a serum transporter of thyroxine and retinol, is the most common cause of cardiac amyloidoses in elderly adults. Thyroxine 73-82 transthyretin Homo sapiens 44-47 22399131-5 2012 Sequestration of Fe(3+) by the TbpA-plug supports the paradigm that the ferric iron must always remain chelated and controlled throughout the transport process. ferric sulfate 72-83 transthyretin Homo sapiens 31-35 22329529-3 2012 Abnormalities in the protein transthyretin (TTR), a serum transporter of thyroxine and retinol, is the most common cause of cardiac amyloidoses in elderly adults. Vitamin A 87-94 transthyretin Homo sapiens 29-42 22329529-3 2012 Abnormalities in the protein transthyretin (TTR), a serum transporter of thyroxine and retinol, is the most common cause of cardiac amyloidoses in elderly adults. Vitamin A 87-94 transthyretin Homo sapiens 44-47 30764010-0 2012 Transthyretin: roles in the nervous system beyond thyroxine and retinol transport. Vitamin A 64-71 transthyretin Homo sapiens 0-13 22399131-8 2012 Although CD and SUPREX spectroscopies suggest that a non-native structure is observed for the recombinant plug, fluorescence quenching titrations indicate that the wild-type recombinant TbpA plug binds Fe (3+) with a conditional log K(d) = 7 at pH 7.5, with no evidence of binding at pH 6.3. fe (3+) 202-209 transthyretin Homo sapiens 186-190 22399131-11 2012 These in vitro observations are consistent with the hypothesis that the EIEYE sequence in the wild-type TbpA plug binds Fe(3+) during the outer membrane transport process in vivo. ferric sulfate 120-126 transthyretin Homo sapiens 104-108 22264585-4 2012 We also investigated translocation of Alexa Fluor-594 labelled TTR from incubation medium into the fetal placental capillaries in early (14-15 weeks) and term placental villus explants. alexa fluor-594 38-53 transthyretin Homo sapiens 63-66 22264585-10 2012 This may have important implications for materno-fetal transfer of thyroid hormones, retinol/retinol binding protein and xenobiotics (such as polychlorinated biphenyls) all of which bind to TTR. Vitamin A 85-92 transthyretin Homo sapiens 190-193 22264585-10 2012 This may have important implications for materno-fetal transfer of thyroid hormones, retinol/retinol binding protein and xenobiotics (such as polychlorinated biphenyls) all of which bind to TTR. Vitamin A 93-100 transthyretin Homo sapiens 190-193 22264585-10 2012 This may have important implications for materno-fetal transfer of thyroid hormones, retinol/retinol binding protein and xenobiotics (such as polychlorinated biphenyls) all of which bind to TTR. Polychlorinated Biphenyls 142-167 transthyretin Homo sapiens 190-193 30764010-0 2012 Transthyretin: roles in the nervous system beyond thyroxine and retinol transport. Thyroxine 50-59 transthyretin Homo sapiens 0-13 22496929-9 2012 Overall, this study indicated that TTR and CLU might be used to monitor the efficacy of AAT therapy and serve as biomarkers for the prognosis of Pca. o-Aminoazotoluene 88-91 transthyretin Homo sapiens 35-38 22149423-0 2012 Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review. technetium pyrophosphate 0-24 transthyretin Homo sapiens 99-112 22149423-0 2012 Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review. technetium pyrophosphate 0-24 transthyretin Homo sapiens 114-117 22149423-6 2012 We add to the current ATTR literature that in patients with the rare Ser23Asn mutation, peripheral nerve in addition to cardiac involvement can occur and (99m)Tc-PYP scintigraphy can be used as an imaging modality to visualize myocardial amyloid. Technetium Tc 99m Pyrophosphate 159-165 transthyretin Homo sapiens 22-26 23449748-2 2012 This study investigated whether astaxanthin (a beta-carotenoid) increased the effectiveness of splinting in managing CTS. astaxanthine 32-43 transthyretin Homo sapiens 117-120 23449748-13 2012 CONCLUSION: At present, the role for astaxanthin as an adjunct in conservative management of CTS has not been established. astaxanthine 37-48 transthyretin Homo sapiens 93-96 30764010-2 2012 Besides the primordially attributed systemic role as a transporter molecule of thyroxine (T4) and retinol (through the binding to retinol-binding protein [RBP]), TTR has been recognized as a protein with important functions in several aspects of the nervous system physiology. Thyroxine 79-88 transthyretin Homo sapiens 162-165 30764010-2 2012 Besides the primordially attributed systemic role as a transporter molecule of thyroxine (T4) and retinol (through the binding to retinol-binding protein [RBP]), TTR has been recognized as a protein with important functions in several aspects of the nervous system physiology. Vitamin A 98-105 transthyretin Homo sapiens 162-165 30764010-6 2012 The purpose of this review is to highlight the roles of TTR in the nervous system, beyond its systemic role as a transporter molecule of T4 and RBP-retinol. Vitamin A 148-155 transthyretin Homo sapiens 56-59 22327295-7 2012 Our studies provide a rational basis for the specificity of TbpA for human transferrin, show how TbpA promotes iron release from transferrin, and elucidate how TbpB facilitates this process. Iron 111-115 transthyretin Homo sapiens 97-101 22353991-3 2012 AIM: To identify CTS at an earlier stage and hence improve the potential future outcome, the authors propose incorporating a new method of using the second lumbricalis (2L-MC) to register the nerve conduction. 2l-mc 169-174 transthyretin Homo sapiens 17-20 22353991-7 2012 RESULTS: Seventeen of 109 (15.6%) hands showed a significant difference in latency using 2L-MC within the mild CTS group, while only 4 of 107 (3.7%) within the moderate CTS group remained undiagnosed using this method. 2l-mc 89-94 transthyretin Homo sapiens 111-114 22353991-10 2012 Therefore, this new 2L-MC study represents a useful technique for assessing early motor involvement in CTS and would only add a few extra minutes to the standard diagnostic procedures. 2l-mc 20-25 transthyretin Homo sapiens 103-106 22248451-0 2012 Hydrogen-bond network and pH sensitivity in transthyretin: Neutron crystal structure of human transthyretin. Hydrogen 0-8 transthyretin Homo sapiens 44-57 22045754-0 2012 Expression and uptake of the thyroxine-binding protein transthyretin is regulated by oxygen in primary trophoblast placental cells. Oxygen 85-91 transthyretin Homo sapiens 55-68 22045754-7 2012 We observed significantly higher uptake of 125I-TTR and Alexa-594-TTR when cells were cultured at 1 and 3% O2 and in the presence of 200 muM DFO than at 8 and 21% O2. Oxygen 107-109 transthyretin Homo sapiens 48-51 22045754-7 2012 We observed significantly higher uptake of 125I-TTR and Alexa-594-TTR when cells were cultured at 1 and 3% O2 and in the presence of 200 muM DFO than at 8 and 21% O2. Deferoxamine 141-144 transthyretin Homo sapiens 48-51 22045754-7 2012 We observed significantly higher uptake of 125I-TTR and Alexa-594-TTR when cells were cultured at 1 and 3% O2 and in the presence of 200 muM DFO than at 8 and 21% O2. Deferoxamine 141-144 transthyretin Homo sapiens 66-69 22045754-7 2012 We observed significantly higher uptake of 125I-TTR and Alexa-594-TTR when cells were cultured at 1 and 3% O2 and in the presence of 200 muM DFO than at 8 and 21% O2. Oxygen 163-165 transthyretin Homo sapiens 48-51 22045754-8 2012 When JEG-3 choriocarcinoma cells were transfected with TTR promoter reporter constructs, increased luciferase activity was measured in cells cultured at 1 and 3% O2 in comparison to 8 and 21% O2. Oxygen 162-164 transthyretin Homo sapiens 55-58 22045754-8 2012 When JEG-3 choriocarcinoma cells were transfected with TTR promoter reporter constructs, increased luciferase activity was measured in cells cultured at 1 and 3% O2 in comparison to 8 and 21% O2. Oxygen 192-194 transthyretin Homo sapiens 55-58 22248451-9 2012 Our neutron model provides insights into the molecular stability of TTR related to the hydrogen-bond network, the pH sensitivity and the CH O weak hydrogen bond. Hydrogen 149-157 transthyretin Homo sapiens 68-71 22248451-9 2012 Our neutron model provides insights into the molecular stability of TTR related to the hydrogen-bond network, the pH sensitivity and the CH O weak hydrogen bond. Hydrogen 87-95 transthyretin Homo sapiens 68-71 22248451-0 2012 Hydrogen-bond network and pH sensitivity in transthyretin: Neutron crystal structure of human transthyretin. Hydrogen 0-8 transthyretin Homo sapiens 94-107 22248451-3 2012 Here we show the neutron structure of TTR, focusing on the hydrogen bonds, protonation states and pH sensitivities. Hydrogen 59-67 transthyretin Homo sapiens 38-41 22248451-7 2012 This hydrogen-bond network is composed of Thr75, Trp79, His88, Ser112, Pro113, Thr118-B and four water molecules, and is involved in both monomer-monomer and dimer-dimer interactions, suggesting that the double protonation of His88 by acidification breaks the hydrogen-bond network and causes the destabilization of the TTR tetramer. Hydrogen 5-13 transthyretin Homo sapiens 320-323 22248451-7 2012 This hydrogen-bond network is composed of Thr75, Trp79, His88, Ser112, Pro113, Thr118-B and four water molecules, and is involved in both monomer-monomer and dimer-dimer interactions, suggesting that the double protonation of His88 by acidification breaks the hydrogen-bond network and causes the destabilization of the TTR tetramer. Water 97-102 transthyretin Homo sapiens 320-323 22248451-7 2012 This hydrogen-bond network is composed of Thr75, Trp79, His88, Ser112, Pro113, Thr118-B and four water molecules, and is involved in both monomer-monomer and dimer-dimer interactions, suggesting that the double protonation of His88 by acidification breaks the hydrogen-bond network and causes the destabilization of the TTR tetramer. Hydrogen 260-268 transthyretin Homo sapiens 320-323 23430848-7 2012 The former hypothesis may be a more plausible explanation for the development of CTS, as histology of the flexor retinaculae from our patients has demonstrated fibroblasts with characteristic vacuolation and excessive myxomatous stroma, despite endothelial clearance of GL3 in these patients receiving ERT. GL3 270-273 transthyretin Homo sapiens 81-84 22286025-3 2012 Human transthyretin (TTR) is a transporter of thyroxine and retinol in blood and cerebrospinal fluid (CSF). Thyroxine 46-55 transthyretin Homo sapiens 6-19 22286025-3 2012 Human transthyretin (TTR) is a transporter of thyroxine and retinol in blood and cerebrospinal fluid (CSF). Thyroxine 46-55 transthyretin Homo sapiens 21-24 22286025-3 2012 Human transthyretin (TTR) is a transporter of thyroxine and retinol in blood and cerebrospinal fluid (CSF). Vitamin A 60-67 transthyretin Homo sapiens 6-19 22286025-3 2012 Human transthyretin (TTR) is a transporter of thyroxine and retinol in blood and cerebrospinal fluid (CSF). Vitamin A 60-67 transthyretin Homo sapiens 21-24 22286025-4 2012 A single free cysteine thiol group in TTR possesses the ability to form mixed disulfides potentially related to diseases such as TTR amyloidosis and Alzheimer"s disease (AD). cysteine thiol 14-28 transthyretin Homo sapiens 38-41 22286025-4 2012 A single free cysteine thiol group in TTR possesses the ability to form mixed disulfides potentially related to diseases such as TTR amyloidosis and Alzheimer"s disease (AD). cysteine thiol 14-28 transthyretin Homo sapiens 129-132 22286025-4 2012 A single free cysteine thiol group in TTR possesses the ability to form mixed disulfides potentially related to diseases such as TTR amyloidosis and Alzheimer"s disease (AD). Disulfides 78-88 transthyretin Homo sapiens 38-41 22286025-4 2012 A single free cysteine thiol group in TTR possesses the ability to form mixed disulfides potentially related to diseases such as TTR amyloidosis and Alzheimer"s disease (AD). Disulfides 78-88 transthyretin Homo sapiens 129-132 22106876-6 2012 We applied the SDS trapping of proteins (S-TraP) method to superoxide dismutase (SOD) and transthyretin (TTR), which are highly KSPs with native unfolding rates that are difficult to measure by conventional spectroscopic methods. Sodium Dodecyl Sulfate 15-18 transthyretin Homo sapiens 90-103 22106876-6 2012 We applied the SDS trapping of proteins (S-TraP) method to superoxide dismutase (SOD) and transthyretin (TTR), which are highly KSPs with native unfolding rates that are difficult to measure by conventional spectroscopic methods. Sodium Dodecyl Sulfate 15-18 transthyretin Homo sapiens 105-108 22471981-1 2012 Transthyretin (TTR), a beta-strand rich tetrameric protein present in human serum and cerebrospinal fluid is involved in the transport of thyroxine and retinol binding protein:retinol complex (holo-RBP). Thyroxine 138-147 transthyretin Homo sapiens 0-13 22471981-1 2012 Transthyretin (TTR), a beta-strand rich tetrameric protein present in human serum and cerebrospinal fluid is involved in the transport of thyroxine and retinol binding protein:retinol complex (holo-RBP). Thyroxine 138-147 transthyretin Homo sapiens 15-18 22471981-1 2012 Transthyretin (TTR), a beta-strand rich tetrameric protein present in human serum and cerebrospinal fluid is involved in the transport of thyroxine and retinol binding protein:retinol complex (holo-RBP). Vitamin A 152-159 transthyretin Homo sapiens 0-13 22471981-1 2012 Transthyretin (TTR), a beta-strand rich tetrameric protein present in human serum and cerebrospinal fluid is involved in the transport of thyroxine and retinol binding protein:retinol complex (holo-RBP). Vitamin A 152-159 transthyretin Homo sapiens 15-18 22471981-1 2012 Transthyretin (TTR), a beta-strand rich tetrameric protein present in human serum and cerebrospinal fluid is involved in the transport of thyroxine and retinol binding protein:retinol complex (holo-RBP). Vitamin A 176-183 transthyretin Homo sapiens 0-13 22471981-1 2012 Transthyretin (TTR), a beta-strand rich tetrameric protein present in human serum and cerebrospinal fluid is involved in the transport of thyroxine and retinol binding protein:retinol complex (holo-RBP). Vitamin A 176-183 transthyretin Homo sapiens 15-18 22471982-2 2012 TTR is a transport protein for thyroid hormones and vitamin A and is predominantly synthesised in the liver. Vitamin A 52-61 transthyretin Homo sapiens 0-3 22015466-0 2012 Nitrofen interferes with trophoblastic expression of retinol-binding protein and transthyretin during lung morphogenesis in the nitrofen-induced congenital diaphragmatic hernia model. nitrofen 0-8 transthyretin Homo sapiens 81-94 22015466-0 2012 Nitrofen interferes with trophoblastic expression of retinol-binding protein and transthyretin during lung morphogenesis in the nitrofen-induced congenital diaphragmatic hernia model. nitrofen 128-136 transthyretin Homo sapiens 81-94 22015466-3 2012 Retinol-binding protein (RBP) and transthyretin (TTR) are transport proteins for delivery of retinol to the tissues via circulation. Vitamin A 93-100 transthyretin Homo sapiens 34-47 22015466-3 2012 Retinol-binding protein (RBP) and transthyretin (TTR) are transport proteins for delivery of retinol to the tissues via circulation. Vitamin A 93-100 transthyretin Homo sapiens 49-52 22015466-7 2012 RBP and TTR synthesized in the fetus are essential for retinol transport to the developing organs including lung morphogenesis. Vitamin A 55-62 transthyretin Homo sapiens 8-11 22015466-8 2012 We hypothesized that nitrofen interferes with the trophoblastic expression of RBP and TTR during lung morphogenesis and designed this study to examine the trophoblastic expression of RBP and TTR, and the total level of RBP and TTR in the lung in the nitrofen model of CDH. nitrofen 21-29 transthyretin Homo sapiens 86-89 22015466-15 2012 CONCLUSIONS: Decreased trophoblast expression of retinol transport proteins suggest that nitrofen may interfere with the fetal retinol transport resulting in reduced pulmonary RBP and TTR levels and causing pulmonary hypoplasia in CDH. nitrofen 89-97 transthyretin Homo sapiens 184-187 22002789-3 2012 Among these, one of the most interesting candidates is transthyretin (TTR), the carrier of thyroxine and retinol, which also binds with amyloid-beta (Abeta), and it has been suggested that it protects against Abeta deposition. Thyroxine 91-100 transthyretin Homo sapiens 55-68 22002789-3 2012 Among these, one of the most interesting candidates is transthyretin (TTR), the carrier of thyroxine and retinol, which also binds with amyloid-beta (Abeta), and it has been suggested that it protects against Abeta deposition. Thyroxine 91-100 transthyretin Homo sapiens 70-73 22002789-3 2012 Among these, one of the most interesting candidates is transthyretin (TTR), the carrier of thyroxine and retinol, which also binds with amyloid-beta (Abeta), and it has been suggested that it protects against Abeta deposition. Vitamin A 105-112 transthyretin Homo sapiens 55-68 22002789-3 2012 Among these, one of the most interesting candidates is transthyretin (TTR), the carrier of thyroxine and retinol, which also binds with amyloid-beta (Abeta), and it has been suggested that it protects against Abeta deposition. Vitamin A 105-112 transthyretin Homo sapiens 70-73 23049730-1 2012 INTRODUCTION: The percentage of time within the target INR range 2.0 to 3.0 (TTR) in patients treated with vitamin K antagonists varies considerably among efficacy-studies of novel anticoagulants. Vitamin K 107-116 transthyretin Homo sapiens 77-80 23049730-4 2012 Randomized controlled trials and cohort studies reporting the TTR in patients with objectively confirmed venous thromboembolism treated with vitamin K antagonists (VKA) were eligible. Vitamin K 141-150 transthyretin Homo sapiens 62-65 23028965-9 2012 Here we showed that iododiflunisal, 3-dinitrophenol, resveratrol, [2-(3,5-dichlorophenyl)amino] (DCPA) and [4-(3,5-difluorophenyl)] (DFPB) were able to increase TTR binding to A-Beta; however only DCPA and DFPB improved TTR proteolytic activity. [2-(3,5-dichlorophenyl)amino] 66-95 transthyretin Homo sapiens 161-164 23028965-9 2012 Here we showed that iododiflunisal, 3-dinitrophenol, resveratrol, [2-(3,5-dichlorophenyl)amino] (DCPA) and [4-(3,5-difluorophenyl)] (DFPB) were able to increase TTR binding to A-Beta; however only DCPA and DFPB improved TTR proteolytic activity. [2-(3,5-dichlorophenyl)amino] 66-95 transthyretin Homo sapiens 220-223 23028965-9 2012 Here we showed that iododiflunisal, 3-dinitrophenol, resveratrol, [2-(3,5-dichlorophenyl)amino] (DCPA) and [4-(3,5-difluorophenyl)] (DFPB) were able to increase TTR binding to A-Beta; however only DCPA and DFPB improved TTR proteolytic activity. [4-(3,5-difluorophenyl)] 107-131 transthyretin Homo sapiens 161-164 23028965-9 2012 Here we showed that iododiflunisal, 3-dinitrophenol, resveratrol, [2-(3,5-dichlorophenyl)amino] (DCPA) and [4-(3,5-difluorophenyl)] (DFPB) were able to increase TTR binding to A-Beta; however only DCPA and DFPB improved TTR proteolytic activity. [4-(3,5-difluorophenyl)] 107-131 transthyretin Homo sapiens 220-223 22253829-10 2012 CONCLUSIONS AND SIGNIFICANCE: The dual effect of EGCG both as TTR aggregation inhibitor and amyloid fibril disruptor together with the high tolerability and low toxicity of EGCG in humans, point towards the potential use of this compound, or optimized derivatives, in the treatment of TTR-related amyloidoses. epigallocatechin gallate 49-53 transthyretin Homo sapiens 62-65 22973437-0 2012 Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two thyroxine binding sites. Thyroxine 100-109 transthyretin Homo sapiens 32-45 22973437-1 2012 BACKGROUND: Transthyretin (TTR) is a homotetrameric serum and cerebrospinal fluid protein that transports thyroxine (T4) and retinol by binding to retinol binding protein. Thyroxine 106-115 transthyretin Homo sapiens 12-25 22973437-1 2012 BACKGROUND: Transthyretin (TTR) is a homotetrameric serum and cerebrospinal fluid protein that transports thyroxine (T4) and retinol by binding to retinol binding protein. Thyroxine 106-115 transthyretin Homo sapiens 27-30 22973437-1 2012 BACKGROUND: Transthyretin (TTR) is a homotetrameric serum and cerebrospinal fluid protein that transports thyroxine (T4) and retinol by binding to retinol binding protein. Vitamin A 125-132 transthyretin Homo sapiens 12-25 22973437-1 2012 BACKGROUND: Transthyretin (TTR) is a homotetrameric serum and cerebrospinal fluid protein that transports thyroxine (T4) and retinol by binding to retinol binding protein. Vitamin A 125-132 transthyretin Homo sapiens 27-30 22973437-8 2012 CONCLUSION: Novel biphenyl ether based compounds exhibit negative-cooperativity while binding to two T4 sites which suggests that binding of only single ligand molecule is sufficient to inhibit the TTR tetramer dissociation. biphenyl ether 18-32 transthyretin Homo sapiens 198-201 22253829-10 2012 CONCLUSIONS AND SIGNIFICANCE: The dual effect of EGCG both as TTR aggregation inhibitor and amyloid fibril disruptor together with the high tolerability and low toxicity of EGCG in humans, point towards the potential use of this compound, or optimized derivatives, in the treatment of TTR-related amyloidoses. epigallocatechin gallate 49-53 transthyretin Homo sapiens 285-288 22187309-11 2011 However, a TTR Gly-54 point mutation in the 2nd exon was detected in two patients and 1 unaffected family member (one of the patients" daughters). Glycine 15-18 transthyretin Homo sapiens 11-14 22531659-6 2012 Gene analysis disclosed Val30Met missense mutation of transthyretin, which is responsible for familial amyloid polyneuropathy. val30met 24-32 transthyretin Homo sapiens 54-67 22531659-8 2012 These two sibling cases suggest correlation of the transthyretin Val30Met mutation with hydrocephalus, a rare phenotype of this disease. val30met 65-73 transthyretin Homo sapiens 51-64 22120741-9 2011 The TTR L55P-Zn(2+) structure offers the first molecular insights into the role of Zn(2+) as a mediator of cross-beta-type structure in TTR amyloidosis and the relevance of a Zn(2+)-dependent pathway leading to the production of early amyloidogenic intermediates is discussed. Zinc 13-15 transthyretin Homo sapiens 4-7 22120741-9 2011 The TTR L55P-Zn(2+) structure offers the first molecular insights into the role of Zn(2+) as a mediator of cross-beta-type structure in TTR amyloidosis and the relevance of a Zn(2+)-dependent pathway leading to the production of early amyloidogenic intermediates is discussed. Zinc 13-15 transthyretin Homo sapiens 136-139 22120741-9 2011 The TTR L55P-Zn(2+) structure offers the first molecular insights into the role of Zn(2+) as a mediator of cross-beta-type structure in TTR amyloidosis and the relevance of a Zn(2+)-dependent pathway leading to the production of early amyloidogenic intermediates is discussed. Zinc 83-85 transthyretin Homo sapiens 4-7 22120741-9 2011 The TTR L55P-Zn(2+) structure offers the first molecular insights into the role of Zn(2+) as a mediator of cross-beta-type structure in TTR amyloidosis and the relevance of a Zn(2+)-dependent pathway leading to the production of early amyloidogenic intermediates is discussed. Zinc 83-85 transthyretin Homo sapiens 136-139 22352429-4 2012 In this study, local classification models for PFCs were developed to predict their T4-TTR (thyroxin-transthyretin) competing potency. thyroxin-transthyretin 92-114 transthyretin Homo sapiens 84-90 22120741-4 2011 The effect of Zn(2+) in increasing TTR L55P amyloidogenecity has been reported. Zinc 14-16 transthyretin Homo sapiens 35-38 22035563-3 2011 The main purpose with this report was to elucidate a possible relationship between estimates of HRV and TPT in a selected group of early and late-onset Swedish Val30Met ATTR patients. tpt 104-107 transthyretin Homo sapiens 169-173 21878437-3 2011 We identified two independent single-nucleotide polymorphisms associated with circulating retinol levels, which are located near the transthyretin (TTR) and retinol binding protein 4 (RBP4) genes which encode major carrier proteins of retinol: rs1667255 (P =2.30x 10(-17)) and rs10882272 (P =6.04x 10(-12)). Vitamin A 90-97 transthyretin Homo sapiens 148-151 22187309-13 2011 CONCLUSION: This pedigree affected with familial vitreous amyloidosis was characterized by autosomal dominant inheritance; a TTR Gly-54 point mutation in the 2nd exon is presumed to be the cause. Glycine 129-132 transthyretin Homo sapiens 125-128 22187309-14 2011 This Gly-54 point mutation of the TTR gene is a novel mutation in vitreous amyloidosis. Glycine 5-8 transthyretin Homo sapiens 34-37 22098747-1 2011 Transthyretin (TTR) is a largely beta-sheet serum protein responsible for transporting thyroxine and vitamin A. Thyroxine 87-96 transthyretin Homo sapiens 0-13 22094129-9 2011 Oral administration of tafamidis meglumine, which prevents misfolding and deposition of mutated TTR, is under evaluation in patients with TTR FAP. tafamidis 23-42 transthyretin Homo sapiens 96-99 22094129-9 2011 Oral administration of tafamidis meglumine, which prevents misfolding and deposition of mutated TTR, is under evaluation in patients with TTR FAP. tafamidis 23-42 transthyretin Homo sapiens 138-141 22098747-1 2011 Transthyretin (TTR) is a largely beta-sheet serum protein responsible for transporting thyroxine and vitamin A. Thyroxine 87-96 transthyretin Homo sapiens 15-18 22098747-1 2011 Transthyretin (TTR) is a largely beta-sheet serum protein responsible for transporting thyroxine and vitamin A. Vitamin A 101-110 transthyretin Homo sapiens 0-13 22098747-1 2011 Transthyretin (TTR) is a largely beta-sheet serum protein responsible for transporting thyroxine and vitamin A. Vitamin A 101-110 transthyretin Homo sapiens 15-18 22098747-8 2011 We also find that the TTR amyloid is incapable of binding thyroxine as monitored by either isothermal calorimetry or 1,8-anilinonaphthalene sulfonate competition. 1,8-anilinonaphthalene sulfonate 117-149 transthyretin Homo sapiens 22-25 21842493-1 2011 Molecular docking and three-dimensional quantitative structure-activity relationships (3D-QSAR) were used to develop models to predict binding affinity of polybrominated diphenyl ether (PBDE) compounds to the human transthyretin (TTR). Halogenated Diphenyl Ethers 155-184 transthyretin Homo sapiens 215-228 21842493-1 2011 Molecular docking and three-dimensional quantitative structure-activity relationships (3D-QSAR) were used to develop models to predict binding affinity of polybrominated diphenyl ether (PBDE) compounds to the human transthyretin (TTR). Halogenated Diphenyl Ethers 155-184 transthyretin Homo sapiens 230-233 21842493-1 2011 Molecular docking and three-dimensional quantitative structure-activity relationships (3D-QSAR) were used to develop models to predict binding affinity of polybrominated diphenyl ether (PBDE) compounds to the human transthyretin (TTR). Halogenated Diphenyl Ethers 186-190 transthyretin Homo sapiens 215-228 21842493-1 2011 Molecular docking and three-dimensional quantitative structure-activity relationships (3D-QSAR) were used to develop models to predict binding affinity of polybrominated diphenyl ether (PBDE) compounds to the human transthyretin (TTR). Halogenated Diphenyl Ethers 186-190 transthyretin Homo sapiens 230-233 21842493-5 2011 In addition, the interaction mechanism between hydroxylated polybrominated diphenyl ethers (HO-PBDEs) and the TTR was explored. Phenyl Ethers 75-90 transthyretin Homo sapiens 110-113 21842493-5 2011 In addition, the interaction mechanism between hydroxylated polybrominated diphenyl ethers (HO-PBDEs) and the TTR was explored. ho-pbdes 92-100 transthyretin Homo sapiens 110-113 21842493-6 2011 Hydrogen bonding with amino acid residues Asp74, Ala29, and Asn27 may be an important determinant for HO-PBDEs binding to TTR. Hydrogen 0-8 transthyretin Homo sapiens 122-125 21842493-6 2011 Hydrogen bonding with amino acid residues Asp74, Ala29, and Asn27 may be an important determinant for HO-PBDEs binding to TTR. ho-pbdes 102-110 transthyretin Homo sapiens 122-125 21764405-9 2011 In the group of Indeterminate CTS, combined blood flow and CSA showed abnormality in 77% and NCS 47%. N-chlorosuccinimide 93-96 transthyretin Homo sapiens 30-33 22299423-2 2011 Retinol is carried and transported to the tissues bound to retinol binding protein 4 (RBP4) and transthyretin (TTR). Vitamin A 0-7 transthyretin Homo sapiens 96-109 22299423-2 2011 Retinol is carried and transported to the tissues bound to retinol binding protein 4 (RBP4) and transthyretin (TTR). Vitamin A 0-7 transthyretin Homo sapiens 111-114 22299423-11 2011 These results suggest calcium, minerals, vitamins and the retinol transport protein, transthyretin may be involved in the pathogenesis of osteoporosis. Calcium 22-29 transthyretin Homo sapiens 85-98 21744407-7 2011 This newly developed methodology has been successfully applied to the syntheses of febuxostat (a xanthine oxidase inhibitor that is effective for the treatment of gout and hyperuricemia), tafamidis (effective for the treatment of TTR amyloid polyneuropathy), and texaline (a natural product having antitubercular activity). Febuxostat 83-93 transthyretin Homo sapiens 230-233 21777382-8 2011 These results suggest an influence of the N-terminal primary structure of TTR on its function as a co-carrier for retinol with RBP. Vitamin A 114-121 transthyretin Homo sapiens 74-77 21865185-8 2011 The coccidioidal IgG antigen (Cts1) was shown to be diminished when cultures were grown in the presence of fluconazole, lending further in vitro plausibility to our findings. Fluconazole 107-118 transthyretin Homo sapiens 30-34 21865539-8 2011 Several of these ligands stabilized TTR in human serum more effectively than diflunisal, which is a well-studied inhibitor of TTR aggregation, and may be promising leads for the treatment or prevention of TTR-mediated cardiomyopathy. Diflunisal 77-87 transthyretin Homo sapiens 126-129 21865539-8 2011 Several of these ligands stabilized TTR in human serum more effectively than diflunisal, which is a well-studied inhibitor of TTR aggregation, and may be promising leads for the treatment or prevention of TTR-mediated cardiomyopathy. Diflunisal 77-87 transthyretin Homo sapiens 126-129 21668413-0 2011 Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis. Cyclodextrins 0-12 transthyretin Homo sapiens 69-82 21740906-0 2011 Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. Polyphenols 8-19 transthyretin Homo sapiens 62-75 21740906-0 2011 Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. Polyphenols 8-19 transthyretin Homo sapiens 77-80 21740906-2 2011 Herein, we studied modulation of transthyretin (TTR) fibrillogenesis by selected polyphenols. Polyphenols 81-92 transthyretin Homo sapiens 33-46 21740906-2 2011 Herein, we studied modulation of transthyretin (TTR) fibrillogenesis by selected polyphenols. Polyphenols 81-92 transthyretin Homo sapiens 48-51 21740906-3 2011 We demonstrate that both curcumin and nordihydroguaiaretic acid (NDGA) bind to TTR and stabilize the TTR tetramer. Curcumin 25-33 transthyretin Homo sapiens 79-82 21740906-3 2011 We demonstrate that both curcumin and nordihydroguaiaretic acid (NDGA) bind to TTR and stabilize the TTR tetramer. Curcumin 25-33 transthyretin Homo sapiens 101-104 21740906-3 2011 We demonstrate that both curcumin and nordihydroguaiaretic acid (NDGA) bind to TTR and stabilize the TTR tetramer. Masoprocol 38-63 transthyretin Homo sapiens 79-82 21740906-3 2011 We demonstrate that both curcumin and nordihydroguaiaretic acid (NDGA) bind to TTR and stabilize the TTR tetramer. Masoprocol 38-63 transthyretin Homo sapiens 101-104 21740906-3 2011 We demonstrate that both curcumin and nordihydroguaiaretic acid (NDGA) bind to TTR and stabilize the TTR tetramer. Masoprocol 65-69 transthyretin Homo sapiens 79-82 21740906-3 2011 We demonstrate that both curcumin and nordihydroguaiaretic acid (NDGA) bind to TTR and stabilize the TTR tetramer. Masoprocol 65-69 transthyretin Homo sapiens 101-104 21740906-4 2011 However, while NDGA slightly reduced TTR aggregation, curcumin strongly suppressed TTR amyloid fibril formation by generating small "off-pathway" oligomers and EGCG maintained most of the protein in a non-aggregated soluble form. Curcumin 54-62 transthyretin Homo sapiens 83-86 21740906-6 2011 Moreover, EGCG and curcumin efficiently disaggregated pre-formed TTR amyloid fibrils. epigallocatechin gallate 10-14 transthyretin Homo sapiens 65-68 21740906-6 2011 Moreover, EGCG and curcumin efficiently disaggregated pre-formed TTR amyloid fibrils. Curcumin 19-27 transthyretin Homo sapiens 65-68 21557933-0 2011 Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Resveratrol 65-76 transthyretin Homo sapiens 14-27 21557933-3 2011 We have employed this cardiac amyloidosis tissue culture model to screen 23 resveratrol analogs as inhibitors of amyloidogenic TTR-induced cytotoxicity and to investigate their mechanisms of protection. Resveratrol 76-87 transthyretin Homo sapiens 127-130 21557933-5 2011 In addition, we demonstrate that resveratrol can accelerate the formation of soluble non-toxic aggregates and that the resveratrol analogs tested can bring together monomeric TTR subunits to form non-toxic native tetrameric TTR. Resveratrol 119-130 transthyretin Homo sapiens 175-178 21557933-5 2011 In addition, we demonstrate that resveratrol can accelerate the formation of soluble non-toxic aggregates and that the resveratrol analogs tested can bring together monomeric TTR subunits to form non-toxic native tetrameric TTR. Resveratrol 119-130 transthyretin Homo sapiens 224-227 21591606-0 2011 Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor. Fenretinide 0-11 transthyretin Homo sapiens 103-116 21591606-1 2011 Serum retinol binding protein (sRBP) is released from the liver as a complex with transthyretin (TTR), a process under the control of dietary retinol. Vitamin A 6-13 transthyretin Homo sapiens 82-95 21591606-1 2011 Serum retinol binding protein (sRBP) is released from the liver as a complex with transthyretin (TTR), a process under the control of dietary retinol. Vitamin A 6-13 transthyretin Homo sapiens 97-100 21591606-3 2011 A series of retinoid analogues were synthesized and examined for their binding to sRBP and their ability to disrupt the sRBP-TTR and sRBP-sRBP receptor interactions. Retinoids 12-20 transthyretin Homo sapiens 125-128 21668413-4 2011 Of various branched beta-CyDs, GUG-beta-CyD [6-O-alpha-(4-O-alpha-D-glucuronyl)-D-glucosyl-beta-CyD] showed potent inhibition of TTR amyloid formation. Cyclodextrins 24-29 transthyretin Homo sapiens 129-132 21668413-4 2011 Of various branched beta-CyDs, GUG-beta-CyD [6-O-alpha-(4-O-alpha-D-glucuronyl)-D-glucosyl-beta-CyD] showed potent inhibition of TTR amyloid formation. Cyclodextrins 24-28 transthyretin Homo sapiens 129-132 21668413-4 2011 Of various branched beta-CyDs, GUG-beta-CyD [6-O-alpha-(4-O-alpha-D-glucuronyl)-D-glucosyl-beta-CyD] showed potent inhibition of TTR amyloid formation. 6-o-alpha-(4-o-alpha-d-glucuronyl)-d-glucosyl-beta-cyd 45-99 transthyretin Homo sapiens 129-132 21668413-6 2011 In addition, tryptophan fluorescence and 1H-NMR spectroscopy analyses indicated that GUG-beta-CyD stabilized the TTR conformation via interaction with the hydrophobic amino acids of TTR, especially tryptophan. Tryptophan 13-23 transthyretin Homo sapiens 182-185 21668413-6 2011 In addition, tryptophan fluorescence and 1H-NMR spectroscopy analyses indicated that GUG-beta-CyD stabilized the TTR conformation via interaction with the hydrophobic amino acids of TTR, especially tryptophan. gug-beta-cyd 85-97 transthyretin Homo sapiens 113-116 21668413-6 2011 In addition, tryptophan fluorescence and 1H-NMR spectroscopy analyses indicated that GUG-beta-CyD stabilized the TTR conformation via interaction with the hydrophobic amino acids of TTR, especially tryptophan. gug-beta-cyd 85-97 transthyretin Homo sapiens 182-185 21668413-6 2011 In addition, tryptophan fluorescence and 1H-NMR spectroscopy analyses indicated that GUG-beta-CyD stabilized the TTR conformation via interaction with the hydrophobic amino acids of TTR, especially tryptophan. Tryptophan 198-208 transthyretin Homo sapiens 113-116 21668413-6 2011 In addition, tryptophan fluorescence and 1H-NMR spectroscopy analyses indicated that GUG-beta-CyD stabilized the TTR conformation via interaction with the hydrophobic amino acids of TTR, especially tryptophan. Tryptophan 198-208 transthyretin Homo sapiens 182-185 21668413-0 2011 Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis. Cyclodextrins 0-12 transthyretin Homo sapiens 97-110 21668413-8 2011 Collectively, these results indicate that GUG-beta-CyD may inhibit TTR misfolding by stabilizing its conformation, which, in turn, suppresses TTR amyloid formation. N-(propan-2-yl)quinoline-2-carboxamide 42-45 transthyretin Homo sapiens 67-70 21668413-8 2011 Collectively, these results indicate that GUG-beta-CyD may inhibit TTR misfolding by stabilizing its conformation, which, in turn, suppresses TTR amyloid formation. N-(propan-2-yl)quinoline-2-carboxamide 42-45 transthyretin Homo sapiens 142-145 21668413-3 2011 In the present study, we focused on CyDs (cyclodextrins), cyclic oligosaccharides composed of glucose units, and reported the inhibitory effect of CyDs on TTR amyloid formation. Glucose 94-101 transthyretin Homo sapiens 155-158 21668413-8 2011 Collectively, these results indicate that GUG-beta-CyD may inhibit TTR misfolding by stabilizing its conformation, which, in turn, suppresses TTR amyloid formation. betadex 46-54 transthyretin Homo sapiens 67-70 21668413-8 2011 Collectively, these results indicate that GUG-beta-CyD may inhibit TTR misfolding by stabilizing its conformation, which, in turn, suppresses TTR amyloid formation. betadex 46-54 transthyretin Homo sapiens 142-145 22506149-1 2011 OBJECTIVE: To verify the feasibility of initial parameters of ultrasonography or electromyography for the prediction of effect after steroid injection therapy in a carpal tunnel syndrome (CTS) patient. Steroids 133-140 transthyretin Homo sapiens 188-191 21674517-2 2011 The purpose of this study was to use neuromuscular ultrasound to assess the changes that occur in the median nerve after steroid injection for carpal tunnel syndrome (CTS). Steroids 121-128 transthyretin Homo sapiens 167-170 21838416-0 2011 Age-dependent increase in thiol conjugated forms of transthyretin (TTR) in the elderly: quantitative analyses by the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) protein chip system. Sulfhydryl Compounds 26-31 transthyretin Homo sapiens 52-65 21838416-0 2011 Age-dependent increase in thiol conjugated forms of transthyretin (TTR) in the elderly: quantitative analyses by the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) protein chip system. Sulfhydryl Compounds 26-31 transthyretin Homo sapiens 67-70 21838433-0 2011 Antisense oligonucleotide therapy for TTR amyloidosis. Oligonucleotides 10-25 transthyretin Homo sapiens 38-41 21679902-1 2011 OBJECTIVES: In a cohort of patients with hereditary transthyretin-related amyloidosis (ATTR), we aimed to assess the role of (99m)Tc-3,3-diphosphono-1,2-propanodicarboxylic acid ((99m)Tc-DPD) in detecting myocardial amyloid infiltration across a wide spectrum of cardiac involvement and in predicting major adverse cardiac events (MACE). tc-3,3-diphosphono-1,2-propanodicarboxylic acid 130-177 transthyretin Homo sapiens 87-91 21679902-9 2011 CONCLUSIONS: In ATTR, (99m)Tc-DPD scintigraphy can identify myocardial infiltration across a wide spectrum of morphologic/functional cardiac involvement, allowing an early diagnosis of the disease (even before the appearance of echocardiographic abnormalities). tc-dpd 27-33 transthyretin Homo sapiens 16-20 21679902-10 2011 The (99m)Tc-DPD myocardial uptake is a prognostic determinant of "cardiac" outcome in ATTR, either alone or in combination with LV wall thickness. tc-dpd 9-15 transthyretin Homo sapiens 86-90 21842642-1 2011 OBJECTIVE: To prepare cinnamic acid derivatives-g-CTS and to study its antioxidation activity. cinnamic acid 22-35 transthyretin Homo sapiens 50-53 21504025-5 2011 TTR protofibrils obtained by mild acidification appeared as flexible filaments with variable length and were able to bind amyloid markers (thioflavin T and Congo red). thioflavin T 139-151 transthyretin Homo sapiens 0-3 21504025-5 2011 TTR protofibrils obtained by mild acidification appeared as flexible filaments with variable length and were able to bind amyloid markers (thioflavin T and Congo red). Congo Red 156-165 transthyretin Homo sapiens 0-3 21675127-3 2011 RESULTS: Wrist splinting and local steroid injection are effective in patients with mild to moderate CTS in the short-term, however, patients with recurrent CTS have to accept surgical treatment. Steroids 35-42 transthyretin Homo sapiens 101-104 21357386-8 2011 Several NDL-PCBs inhibited estradiol-sulfotransferase activity and bound to transthyretin (TTR) but with much weaker potencies than reported for hydroxylated PCB metabolites. ndl-pcbs 8-16 transthyretin Homo sapiens 91-94 21842642-4 2011 CONCLUSION: Cinnamic acid derivatives-g-CTS is suitable as the O2-* -capture agent. cinnamic acid 12-25 transthyretin Homo sapiens 40-43 21842642-0 2011 [Preparation and anti-oxidant activity of cinnamic acid derivatives-g-CTS]. cinnamic acid 42-55 transthyretin Homo sapiens 70-73 21273900-10 2011 CONCLUSIONS: Local procaine HCl injection and steroid injection effectively reduced the symptoms of CTS and equally improved electrophysiologic findings. Procaine 19-31 transthyretin Homo sapiens 100-103 21422279-1 2011 Transthyretin (TTR) is a homotetrameric protein that transports thyroxine and retinol. Thyroxine 64-73 transthyretin Homo sapiens 15-18 21422279-1 2011 Transthyretin (TTR) is a homotetrameric protein that transports thyroxine and retinol. Vitamin A 78-85 transthyretin Homo sapiens 15-18 21422279-10 2011 The effect of heparin on TTR fibril formation was further demonstrated in a Drosophila model that overexpresses TTR. Heparin 14-21 transthyretin Homo sapiens 25-28 21422279-10 2011 The effect of heparin on TTR fibril formation was further demonstrated in a Drosophila model that overexpresses TTR. Heparin 14-21 transthyretin Homo sapiens 112-115 21422279-11 2011 Heparin was colocalized with TTR deposits in the head of the flies reared on heparin-supplemented medium, whereas no heparin was detected in the nontreated flies. Heparin 0-7 transthyretin Homo sapiens 29-32 21422279-11 2011 Heparin was colocalized with TTR deposits in the head of the flies reared on heparin-supplemented medium, whereas no heparin was detected in the nontreated flies. Heparin 77-84 transthyretin Homo sapiens 29-32 21273900-2 2011 Steroids are usually mixed with local anesthetics, which have positive effects that can aid the treatment of CTS by inhibiting the spontaneous discharge ability of excitable cells. Steroids 0-8 transthyretin Homo sapiens 109-112 21273900-3 2011 The aim of this study was 3-fold: (1) to determine the efficacy of triamcinolone acetonide injection in the treatment of CTS, (2) to determine the efficacy of procaine hydrochloride (HCl) in the treatment of CTS, and (3) to compare the efficacy of triamcinolone acetonide and that of procaine HCl in the treatment of CTS. Triamcinolone Acetonide 67-90 transthyretin Homo sapiens 121-124 21273900-3 2011 The aim of this study was 3-fold: (1) to determine the efficacy of triamcinolone acetonide injection in the treatment of CTS, (2) to determine the efficacy of procaine hydrochloride (HCl) in the treatment of CTS, and (3) to compare the efficacy of triamcinolone acetonide and that of procaine HCl in the treatment of CTS. Procaine 159-181 transthyretin Homo sapiens 208-211 21273900-3 2011 The aim of this study was 3-fold: (1) to determine the efficacy of triamcinolone acetonide injection in the treatment of CTS, (2) to determine the efficacy of procaine hydrochloride (HCl) in the treatment of CTS, and (3) to compare the efficacy of triamcinolone acetonide and that of procaine HCl in the treatment of CTS. Procaine 159-181 transthyretin Homo sapiens 208-211 21273900-10 2011 CONCLUSIONS: Local procaine HCl injection and steroid injection effectively reduced the symptoms of CTS and equally improved electrophysiologic findings. Steroids 46-53 transthyretin Homo sapiens 100-103 21273900-11 2011 As such, procaine HCl can be used in CTS patients in whom steroid use is contraindicated. Procaine 9-21 transthyretin Homo sapiens 37-40 21348526-8 2011 Estrone, 17beta-estradiol, 9H-benz[de]anthracen-7-one, and 4-nonylphenol were identified as possible estrogenic and TTR-binding compounds. Estrone 0-7 transthyretin Homo sapiens 116-119 21348526-8 2011 Estrone, 17beta-estradiol, 9H-benz[de]anthracen-7-one, and 4-nonylphenol were identified as possible estrogenic and TTR-binding compounds. Estradiol 9-25 transthyretin Homo sapiens 116-119 21348526-8 2011 Estrone, 17beta-estradiol, 9H-benz[de]anthracen-7-one, and 4-nonylphenol were identified as possible estrogenic and TTR-binding compounds. 9h-benz[de]anthracen-7-one 27-53 transthyretin Homo sapiens 116-119 21348526-8 2011 Estrone, 17beta-estradiol, 9H-benz[de]anthracen-7-one, and 4-nonylphenol were identified as possible estrogenic and TTR-binding compounds. 4-nonylphenol 59-72 transthyretin Homo sapiens 116-119 21348526-9 2011 Thus, not only nonpolar compounds such as PAHs, PCBs, and PCDD/Fs but also the less characterized and investigated more polar substances should be considered as potent mutagenic, estrogenic, AhR-inducing, TTR-binding, and GJIC-inhibiting components for future studies. Polycyclic Aromatic Hydrocarbons 42-46 transthyretin Homo sapiens 205-208 21348526-9 2011 Thus, not only nonpolar compounds such as PAHs, PCBs, and PCDD/Fs but also the less characterized and investigated more polar substances should be considered as potent mutagenic, estrogenic, AhR-inducing, TTR-binding, and GJIC-inhibiting components for future studies. Polychlorinated Biphenyls 48-52 transthyretin Homo sapiens 205-208 21348526-9 2011 Thus, not only nonpolar compounds such as PAHs, PCBs, and PCDD/Fs but also the less characterized and investigated more polar substances should be considered as potent mutagenic, estrogenic, AhR-inducing, TTR-binding, and GJIC-inhibiting components for future studies. pcdd/fs 58-65 transthyretin Homo sapiens 205-208 21498348-12 2011 CONCLUSION: A combination of high-resolution and color Doppler ultrasound can be used as a non-invasive alternative to EDT in diagnosis of CTS. edt 119-122 transthyretin Homo sapiens 139-142 21490715-0 2011 Tyr78Phe Transthyretin Mutation with Predominant Motor Neuropathy as the Initial Presentation. tyr78phe 0-8 transthyretin Homo sapiens 9-22 21069320-1 2011 PURPOSE: We previously reported in a small series of patients that (99m)Tc-3,3-diphosphono-1,2-propanodicarboxylic acid ((99m)Tc-DPD) scintigraphy tested positive in transthyretin-related (TTR) (both mutant and wild-type) but not in primary (AL) amyloidotic cardiomyopathy (AC). tc-3,3-diphosphono-1,2-propanodicarboxylic acid 72-119 transthyretin Homo sapiens 166-187 21069320-1 2011 PURPOSE: We previously reported in a small series of patients that (99m)Tc-3,3-diphosphono-1,2-propanodicarboxylic acid ((99m)Tc-DPD) scintigraphy tested positive in transthyretin-related (TTR) (both mutant and wild-type) but not in primary (AL) amyloidotic cardiomyopathy (AC). tc-3,3-diphosphono-1,2-propanodicarboxylic acid 72-119 transthyretin Homo sapiens 189-192 21069320-1 2011 PURPOSE: We previously reported in a small series of patients that (99m)Tc-3,3-diphosphono-1,2-propanodicarboxylic acid ((99m)Tc-DPD) scintigraphy tested positive in transthyretin-related (TTR) (both mutant and wild-type) but not in primary (AL) amyloidotic cardiomyopathy (AC). tc-dpd 126-132 transthyretin Homo sapiens 166-187 21069320-1 2011 PURPOSE: We previously reported in a small series of patients that (99m)Tc-3,3-diphosphono-1,2-propanodicarboxylic acid ((99m)Tc-DPD) scintigraphy tested positive in transthyretin-related (TTR) (both mutant and wild-type) but not in primary (AL) amyloidotic cardiomyopathy (AC). tc-dpd 126-132 transthyretin Homo sapiens 189-192 21069320-7 2011 At adjusted linear regression analysis, TTR aetiology turned out to be the only positive predictor of increasing (99m)Tc-DPD uptake in terms of both HR [beta 2.5, 95% confidence interval (CI) 1.5-3.5; p < 0.0001] and H/WB (beta 3.5, 95% CI 2.1-4.9; p < 0.0001). tc-dpd 118-124 transthyretin Homo sapiens 40-43 21069320-8 2011 CONCLUSION: While (99m)Tc-DPD scintigraphy was confirmed to be useful for differentiating TTR from AL-related AC, diagnostic accuracy was lower than previously reported due to a mild degree of tracer uptake in about one third of AL patients. tc-dpd 23-29 transthyretin Homo sapiens 90-93 21490715-9 2011 The sural nerve biopsy disclosed amyloid deposition, and the sequence analysis of the TTR gene detected a heterozygous Tyr78Phe substitution. tyr78phe 119-127 transthyretin Homo sapiens 86-89 20937391-0 2011 The binding of synthetic triiodo l-thyronine analogs to human transthyretin: molecular basis of cooperative and non-cooperative ligand recognition. Triiodothyronine 25-44 transthyretin Homo sapiens 62-75 21254080-9 2011 We conclude that the PPT is a valid and reliable tool to quantify functional impairment caused by CTS. 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol 21-24 transthyretin Homo sapiens 98-101 21273081-1 2011 Herein we demonstrate that competition between candidate kinetic stabilizer binding to transthyretin (TTR) and stilbene binding to and reaction with the same thyroxine sites within TTR can be utilized to discover potent and highly selective non-covalent TTR amyloidogenesis inhibitors. Stilbenes 111-119 transthyretin Homo sapiens 181-184 21273081-1 2011 Herein we demonstrate that competition between candidate kinetic stabilizer binding to transthyretin (TTR) and stilbene binding to and reaction with the same thyroxine sites within TTR can be utilized to discover potent and highly selective non-covalent TTR amyloidogenesis inhibitors. Stilbenes 111-119 transthyretin Homo sapiens 181-184 21273081-1 2011 Herein we demonstrate that competition between candidate kinetic stabilizer binding to transthyretin (TTR) and stilbene binding to and reaction with the same thyroxine sites within TTR can be utilized to discover potent and highly selective non-covalent TTR amyloidogenesis inhibitors. Thyroxine 158-167 transthyretin Homo sapiens 102-105 21273081-1 2011 Herein we demonstrate that competition between candidate kinetic stabilizer binding to transthyretin (TTR) and stilbene binding to and reaction with the same thyroxine sites within TTR can be utilized to discover potent and highly selective non-covalent TTR amyloidogenesis inhibitors. Thyroxine 158-167 transthyretin Homo sapiens 181-184 21273081-1 2011 Herein we demonstrate that competition between candidate kinetic stabilizer binding to transthyretin (TTR) and stilbene binding to and reaction with the same thyroxine sites within TTR can be utilized to discover potent and highly selective non-covalent TTR amyloidogenesis inhibitors. Thyroxine 158-167 transthyretin Homo sapiens 181-184 21273081-3 2011 Each bind selectively to TTR and then chemoselectively react to form an amide bond with the Lys-15 residue of TTR, creating a fluorescent conjugate. Amides 72-77 transthyretin Homo sapiens 25-28 21273081-3 2011 Each bind selectively to TTR and then chemoselectively react to form an amide bond with the Lys-15 residue of TTR, creating a fluorescent conjugate. Amides 72-77 transthyretin Homo sapiens 110-113 21273081-3 2011 Each bind selectively to TTR and then chemoselectively react to form an amide bond with the Lys-15 residue of TTR, creating a fluorescent conjugate. Lysine 92-95 transthyretin Homo sapiens 25-28 21273081-3 2011 Each bind selectively to TTR and then chemoselectively react to form an amide bond with the Lys-15 residue of TTR, creating a fluorescent conjugate. Lysine 92-95 transthyretin Homo sapiens 110-113 21273081-6 2011 In both assay scenarios, we demonstrate that the lower the TTR-stilbene conjugate fluorescence after a 3 h competition, the greater the binding selectivity and potency of the candidate TTR kinetic stabilizer. Stilbenes 63-71 transthyretin Homo sapiens 59-62 21273081-6 2011 In both assay scenarios, we demonstrate that the lower the TTR-stilbene conjugate fluorescence after a 3 h competition, the greater the binding selectivity and potency of the candidate TTR kinetic stabilizer. Stilbenes 63-71 transthyretin Homo sapiens 185-188 20937391-3 2011 In the present study, we characterized the interactions of the synthetic triiodo L-thyronine analogs and thyroid hormone nuclear receptor TRbeta-selective agonists GC-1 and GC-24 with the wild type and V30M variant of human transthyretin (TTR). Triiodothyronine 73-92 transthyretin Homo sapiens 224-237 20937391-6 2011 Analysis of the crystal structures of TTRwt:GC-1(24) complexes and their comparison with the TTRwt X-ray structure bound to its natural ligand thyroxine (T4) suggests, at the molecular level, the basis for the cooperative process displayed by T4 and the non-cooperative process provoked by both GC-1 and GC-24 during binding to TTR. Thyroxine 143-152 transthyretin Homo sapiens 38-41 22553674-0 2011 Transthyretin Arg-83 mutation in vitreous amyloidosis. Arginine 14-17 transthyretin Homo sapiens 0-13 21146209-0 2011 Oxygen concentration regulates expression and uptake of transthyretin, a thyroxine binding protein, in JEG-3 choriocarcinoma cells. Oxygen 0-6 transthyretin Homo sapiens 56-69 21146209-6 2011 This suggests that increased carrier mediated T(4) transport by placental TTR may be induced by the low oxygen environment of early pregnancy, a time when the fetus has its highest requirement for transport of maternal T(4). Oxygen 104-110 transthyretin Homo sapiens 74-77 21190671-2 2011 By using synchrotron x-ray diffraction at high pressure in a diamond anvil cell we determined the bulk modulus of TTR105-115 amyloid fibrils in water and in silicone oil to be 2.6 and 8.1 GPa, respectively. Water 144-149 transthyretin Homo sapiens 114-117 21190671-2 2011 By using synchrotron x-ray diffraction at high pressure in a diamond anvil cell we determined the bulk modulus of TTR105-115 amyloid fibrils in water and in silicone oil to be 2.6 and 8.1 GPa, respectively. Silicone Oils 157-169 transthyretin Homo sapiens 114-117 22553674-7 2011 Bi-directional sequencing of the transthyretin gene revealed a single base-pair substitution, which results in an amino acid substitution at position83, glycine to arginine (transthyretin Arg-83). Glycine 153-160 transthyretin Homo sapiens 33-46 22553674-7 2011 Bi-directional sequencing of the transthyretin gene revealed a single base-pair substitution, which results in an amino acid substitution at position83, glycine to arginine (transthyretin Arg-83). Glycine 153-160 transthyretin Homo sapiens 174-187 22553674-7 2011 Bi-directional sequencing of the transthyretin gene revealed a single base-pair substitution, which results in an amino acid substitution at position83, glycine to arginine (transthyretin Arg-83). Arginine 164-172 transthyretin Homo sapiens 33-46 22553674-7 2011 Bi-directional sequencing of the transthyretin gene revealed a single base-pair substitution, which results in an amino acid substitution at position83, glycine to arginine (transthyretin Arg-83). Arginine 164-172 transthyretin Homo sapiens 174-187 22553674-7 2011 Bi-directional sequencing of the transthyretin gene revealed a single base-pair substitution, which results in an amino acid substitution at position83, glycine to arginine (transthyretin Arg-83). Arginine 188-191 transthyretin Homo sapiens 33-46 22553674-7 2011 Bi-directional sequencing of the transthyretin gene revealed a single base-pair substitution, which results in an amino acid substitution at position83, glycine to arginine (transthyretin Arg-83). Arginine 188-191 transthyretin Homo sapiens 174-187 21517007-4 2011 In this study, the binding interactions of BPA, T4, and T3 with three thyroid hormone transport proteins, human serum albumin (HSA), transthyretin (TTR), and thyroxine-binding globulin (TBG) were investigated by fluorescence measurement. bisphenol A 43-46 transthyretin Homo sapiens 133-146 21517007-4 2011 In this study, the binding interactions of BPA, T4, and T3 with three thyroid hormone transport proteins, human serum albumin (HSA), transthyretin (TTR), and thyroxine-binding globulin (TBG) were investigated by fluorescence measurement. bisphenol A 43-46 transthyretin Homo sapiens 148-151 21517007-7 2011 Similarly, by employing 8-anilino-1-naphthalenesulfonic acid as fluorescence probe, the binding affinity of BPA with TTR and TBG was measured to be 3.10 x 10(5) and 5.90 x 10(5) L/mol, respectively. 8-anilino-1-naphthalenesulfonic acid 24-60 transthyretin Homo sapiens 117-120 21517007-7 2011 Similarly, by employing 8-anilino-1-naphthalenesulfonic acid as fluorescence probe, the binding affinity of BPA with TTR and TBG was measured to be 3.10 x 10(5) and 5.90 x 10(5) L/mol, respectively. bisphenol A 108-111 transthyretin Homo sapiens 117-120 20845945-0 2010 Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex. Vitamin A 0-7 transthyretin Homo sapiens 46-59 21446232-3 2011 OBJECTIVES: To evaluate the effect of our novel approach of LCI for the treatment of CTS on repeated electrophysiologic studies of the median nerve. Casein Kinase inhibitor A86 60-63 transthyretin Homo sapiens 85-88 21461579-3 2011 This study is the first to combine blue native polyacrylamide gel electrophoresis (BN-PAGE) with surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) to detect new TTR interaction partners and to determine whether these TTR interaction partners can themselves be used as biomarkers. polyacrylamide 47-61 transthyretin Homo sapiens 204-207 20845945-6 2010 Our results demonstrate new roles for RBP and retinoids as stabilizers of transthyretin. Retinoids 46-55 transthyretin Homo sapiens 74-87 20845945-0 2010 Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex. Vitamin A 12-19 transthyretin Homo sapiens 46-59 20845945-2 2010 Plasma transport of retinol is carried out exclusively by the retinol-binding protein (RBP), through complexation with transthyretin. Vitamin A 20-27 transthyretin Homo sapiens 119-132 20845945-3 2010 Using mass spectrometry to examine the subunit exchange dynamics, we find that retinol stabilizes the quaternary structure of transthyretin, through its interactions with RBP, reducing the rate of transthyretin disassembly ~17-fold compared to apoTTR. Vitamin A 79-86 transthyretin Homo sapiens 126-139 20845945-3 2010 Using mass spectrometry to examine the subunit exchange dynamics, we find that retinol stabilizes the quaternary structure of transthyretin, through its interactions with RBP, reducing the rate of transthyretin disassembly ~17-fold compared to apoTTR. Vitamin A 79-86 transthyretin Homo sapiens 197-210 20845945-5 2010 Surprisingly, we found two retinoids that stabilize transthyretin directly, in the absence of RBP, whereas retinol itself requires RBP in order to stabilize transthyretin. Retinoids 27-36 transthyretin Homo sapiens 52-65 20845945-5 2010 Surprisingly, we found two retinoids that stabilize transthyretin directly, in the absence of RBP, whereas retinol itself requires RBP in order to stabilize transthyretin. Vitamin A 107-114 transthyretin Homo sapiens 157-170 21179214-5 2010 METHODS AND FINDING: We used a combined pharmacogenetics and iTRAQ-coupled LC-MS/MS pharmacoproteomics approach to analyze plasma protein profiles of 53 patients, and identified significantly upregulated level of transthyretin precursor in patients receiving low dose of warfarin but not in those on high dose of warfarin. Warfarin 271-279 transthyretin Homo sapiens 213-226 21179214-5 2010 METHODS AND FINDING: We used a combined pharmacogenetics and iTRAQ-coupled LC-MS/MS pharmacoproteomics approach to analyze plasma protein profiles of 53 patients, and identified significantly upregulated level of transthyretin precursor in patients receiving low dose of warfarin but not in those on high dose of warfarin. Warfarin 313-321 transthyretin Homo sapiens 213-226 20832065-1 2010 OBJECTIVE: Retinol is transported in a complex with retinol-binding protein 4 (RBP4) and transthyretin (TTR) in the circulation. Vitamin A 11-18 transthyretin Homo sapiens 89-102 20832065-1 2010 OBJECTIVE: Retinol is transported in a complex with retinol-binding protein 4 (RBP4) and transthyretin (TTR) in the circulation. Vitamin A 11-18 transthyretin Homo sapiens 104-107 20813176-1 2010 Two kinds of glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles (CTS/PEG-GA NPs) were prepared by an ionic gelation process in which the liver targeting ligand glycyrrhetinic acid (GA) was introduced into the nanoparticles at the C(30)-carboxyl group (CTS/PEG-GA(c) NPs) or the C(3)-hydroxyl group (CTS/PEG-GA(h) NPs). Glycyrrhetinic Acid 13-32 transthyretin Homo sapiens 88-91 21104416-3 2010 Transthyretin helps internalize thyroxine and retinol-binding protein into cells by binding to megalin, which is a multi-ligand receptor expressed on the luminal surface of various epithelia. Thyroxine 32-41 transthyretin Homo sapiens 0-13 20813176-1 2010 Two kinds of glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles (CTS/PEG-GA NPs) were prepared by an ionic gelation process in which the liver targeting ligand glycyrrhetinic acid (GA) was introduced into the nanoparticles at the C(30)-carboxyl group (CTS/PEG-GA(c) NPs) or the C(3)-hydroxyl group (CTS/PEG-GA(h) NPs). Glycyrrhetinic Acid 13-32 transthyretin Homo sapiens 275-278 20813176-1 2010 Two kinds of glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles (CTS/PEG-GA NPs) were prepared by an ionic gelation process in which the liver targeting ligand glycyrrhetinic acid (GA) was introduced into the nanoparticles at the C(30)-carboxyl group (CTS/PEG-GA(c) NPs) or the C(3)-hydroxyl group (CTS/PEG-GA(h) NPs). Glycyrrhetinic Acid 13-32 transthyretin Homo sapiens 275-278 20813176-1 2010 Two kinds of glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles (CTS/PEG-GA NPs) were prepared by an ionic gelation process in which the liver targeting ligand glycyrrhetinic acid (GA) was introduced into the nanoparticles at the C(30)-carboxyl group (CTS/PEG-GA(c) NPs) or the C(3)-hydroxyl group (CTS/PEG-GA(h) NPs). Chitosan 42-50 transthyretin Homo sapiens 88-91 20813176-1 2010 Two kinds of glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles (CTS/PEG-GA NPs) were prepared by an ionic gelation process in which the liver targeting ligand glycyrrhetinic acid (GA) was introduced into the nanoparticles at the C(30)-carboxyl group (CTS/PEG-GA(c) NPs) or the C(3)-hydroxyl group (CTS/PEG-GA(h) NPs). Polyethylene Glycols 51-72 transthyretin Homo sapiens 88-91 20813176-4 2010 The accumulation in the liver is 51.3% and 56.5% of the injected dose for the CTS/PEG-GA(c)(4.60%) NPs (the subscript number denotes the GA content as weight percent in nanoparticles) and the CTS/PEG-GA(h)(4.57%) NPs at 3 h after injection, respectively. Polyethylene Glycols 82-85 transthyretin Homo sapiens 78-81 20813176-4 2010 The accumulation in the liver is 51.3% and 56.5% of the injected dose for the CTS/PEG-GA(c)(4.60%) NPs (the subscript number denotes the GA content as weight percent in nanoparticles) and the CTS/PEG-GA(h)(4.57%) NPs at 3 h after injection, respectively. Polyethylene Glycols 196-199 transthyretin Homo sapiens 78-81 20813176-5 2010 This is nearly 2.6-2.8 times higher than that obtained with the CTS/PEG NPs. Polyethylene Glycols 68-71 transthyretin Homo sapiens 64-67 20659897-0 2010 Novel Zn2+-binding sites in human transthyretin: implications for amyloidogenesis and retinol-binding protein recognition. Zinc 6-10 transthyretin Homo sapiens 34-47 20804816-4 2010 Binding affinity of the 14 OH-PBDEs with transthyretin (TTR) and thyroxine-binding globulin (TBG) was measured by competitive fluorescence displacement assay. 14 oh-pbdes 24-35 transthyretin Homo sapiens 56-59 20804816-7 2010 Protein secondary structural change of TTR and TBG upon binding with 5-OH-BDE-047 was investigated by circular dichroism. 5-oh-bde 69-77 transthyretin Homo sapiens 39-42 20804816-9 2010 In molecular docking analysis, a ligand-binding channel in TTR was revealed for OH-PBDEs binding, which appeared to be mostly hydrophobic inside but guarded by positively charged residue Lys15 at the entrance. oh-pbdes 80-88 transthyretin Homo sapiens 59-62 20804816-10 2010 Binding affinity of the 14 OH-PBDEs with TTR could be rationalized reasonably well by their pocket binding mode and hydrophobic characteristics. 14 oh-pbdes 24-35 transthyretin Homo sapiens 41-44 20883031-5 2010 Our predictions show that the top-scoring molecules possess distinctive features from the known TTR binders, holding better solubility, fraction of halogen atoms, and binding affinity profiles. Halogens 148-155 transthyretin Homo sapiens 96-99 20659897-2 2010 Zn(2+) enhances TTR aggregation in vitro, and is a component of ex vivo TTR amyloid fibrils. Zinc 0-6 transthyretin Homo sapiens 16-19 20659897-2 2010 Zn(2+) enhances TTR aggregation in vitro, and is a component of ex vivo TTR amyloid fibrils. Zinc 0-6 transthyretin Homo sapiens 72-75 20659897-3 2010 We report the first crystal structure of human TTR in complex with Zn(2+) at pH 4.6-7.5. Zinc 67-69 transthyretin Homo sapiens 47-50 20659897-5 2010 Zn(2+) binding perturbs loop E-alpha-helix-loop F, the region involved in holo-retinol-binding protein (holo-RBP) recognition, mainly at acidic pH; TTR affinity for holo-RBP decreases ~5-fold in the presence of Zn(2+). Zinc 211-213 transthyretin Homo sapiens 148-151 20659897-6 2010 Interestingly, this same region is disrupted in the crystal structure of the amyloidogenic intermediate of TTR formed at acidic pH in the absence of Zn(2+). Zinc 149-151 transthyretin Homo sapiens 107-110 20659897-8 2010 While stability of the monomer of TTR decreases in the presence of Zn(2+), which is consistent with the tertiary structural perturbation provoked by Zn(2+) binding, tetramer stability is only marginally affected by Zn(2+). Zinc 67-69 transthyretin Homo sapiens 34-37 20659897-8 2010 While stability of the monomer of TTR decreases in the presence of Zn(2+), which is consistent with the tertiary structural perturbation provoked by Zn(2+) binding, tetramer stability is only marginally affected by Zn(2+). Zinc 149-151 transthyretin Homo sapiens 34-37 20659897-8 2010 While stability of the monomer of TTR decreases in the presence of Zn(2+), which is consistent with the tertiary structural perturbation provoked by Zn(2+) binding, tetramer stability is only marginally affected by Zn(2+). Zinc 149-151 transthyretin Homo sapiens 34-37 20659897-9 2010 These data highlight structural and functional roles of Zn(2+) in TTR-related amyloidoses, as well as in holo-RBP recognition and vitamin A homeostasis. Zinc 56-58 transthyretin Homo sapiens 66-69 20493928-4 2010 Moreover, 17beta-estradiol resulted in elevated brain levels of transthyretin, which inhibits aggregation of Abeta into plaques; though the insulin-degrading enzyme, which breaks down Abeta, was significantly reduced. Estradiol 10-26 transthyretin Homo sapiens 64-77 20553985-6 2010 This analysis confirmed the early increases of haptoglobin and transthyretin in response to intranigral injection of LPS or 6-OHDA in the bundle in plasma and CSF. Oxidopamine 124-130 transthyretin Homo sapiens 63-76 20116281-7 2010 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis showed that a protein band migrating just above the 14 kDa marker band contained transthyretin (P02766; M(r) (avg. Sodium Dodecyl Sulfate 0-22 transthyretin Homo sapiens 159-172 20116281-7 2010 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis showed that a protein band migrating just above the 14 kDa marker band contained transthyretin (P02766; M(r) (avg. polyacrylamide 23-37 transthyretin Homo sapiens 159-172 20116281-7 2010 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis showed that a protein band migrating just above the 14 kDa marker band contained transthyretin (P02766; M(r) (avg. Sodium Dodecyl Sulfate 59-62 transthyretin Homo sapiens 159-172 20673327-9 2010 The observed synergistic effect of doxycycline/TUDCA in the range of human tolerable quantities, in the transgenic TTR mice models prompts their application in FAP, particularly in the early stages of disease. Doxycycline 35-46 transthyretin Homo sapiens 115-118 21174946-2 2010 The Tyr116-->Ser (Y116S) mutant TTR is an important amyloidogenic variant responsible for FAP. Serine 16-19 transthyretin Homo sapiens 35-38 20673327-9 2010 The observed synergistic effect of doxycycline/TUDCA in the range of human tolerable quantities, in the transgenic TTR mice models prompts their application in FAP, particularly in the early stages of disease. ursodoxicoltaurine 47-52 transthyretin Homo sapiens 115-118 20388560-7 2010 In conclusion, this study showed that the formation of S-sulfonation of TTR through oxidative modifications of the thiol residue on the 10th cysteine of TTR is an important trigger step in the formation of transthyretin-related amyloid fibril. Sulfhydryl Compounds 115-120 transthyretin Homo sapiens 153-156 20660862-3 2010 Ratio of variant to wild-type TTR in the fibrils was determined by amino acid sequencing of tryptic peptides containing either the variant amino acid residue or the corresponding normal amino acid. Peptides 100-108 transthyretin Homo sapiens 30-33 20388560-7 2010 In conclusion, this study showed that the formation of S-sulfonation of TTR through oxidative modifications of the thiol residue on the 10th cysteine of TTR is an important trigger step in the formation of transthyretin-related amyloid fibril. Sulfhydryl Compounds 115-120 transthyretin Homo sapiens 72-75 20565072-0 2010 The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site. Thyroxine 148-157 transthyretin Homo sapiens 79-92 20565072-2 2010 Familial amyloid polyneuropathy (FAP) is a hereditary disease caused by a point mutation of the human plasma protein, transthyretin (TTR), which binds and transports thyroxine (T(4)). Thyroxine 166-175 transthyretin Homo sapiens 118-131 20565072-2 2010 Familial amyloid polyneuropathy (FAP) is a hereditary disease caused by a point mutation of the human plasma protein, transthyretin (TTR), which binds and transports thyroxine (T(4)). Thyroxine 166-175 transthyretin Homo sapiens 133-136 20565072-4 2010 A recent report showed that epigallocatechin 3-gallate (EGCG), the major polyphenol component of green tea, binds to TTR and suppresses TTR amyloid fibril formation. epigallocatechin gallate 28-54 transthyretin Homo sapiens 117-120 20565072-4 2010 A recent report showed that epigallocatechin 3-gallate (EGCG), the major polyphenol component of green tea, binds to TTR and suppresses TTR amyloid fibril formation. epigallocatechin gallate 28-54 transthyretin Homo sapiens 136-139 20565072-4 2010 A recent report showed that epigallocatechin 3-gallate (EGCG), the major polyphenol component of green tea, binds to TTR and suppresses TTR amyloid fibril formation. epigallocatechin gallate 56-60 transthyretin Homo sapiens 117-120 20565072-4 2010 A recent report showed that epigallocatechin 3-gallate (EGCG), the major polyphenol component of green tea, binds to TTR and suppresses TTR amyloid fibril formation. epigallocatechin gallate 56-60 transthyretin Homo sapiens 136-139 20565072-4 2010 A recent report showed that epigallocatechin 3-gallate (EGCG), the major polyphenol component of green tea, binds to TTR and suppresses TTR amyloid fibril formation. Polyphenols 73-83 transthyretin Homo sapiens 117-120 20565072-5 2010 However, structural analysis of EGCG binding to TTR has not yet been conducted. epigallocatechin gallate 32-36 transthyretin Homo sapiens 48-51 20565072-6 2010 Here we first investigated the crystal structure of the EGCG-V30M TTR complex and found novel binding sites distinct from the thyroxine binding site, suggesting that EGCG has a mode of action different from those of previous chemical compounds that were shown to bind and stabilize the TTR tetramer structure. epigallocatechin gallate 56-60 transthyretin Homo sapiens 66-69 20565072-6 2010 Here we first investigated the crystal structure of the EGCG-V30M TTR complex and found novel binding sites distinct from the thyroxine binding site, suggesting that EGCG has a mode of action different from those of previous chemical compounds that were shown to bind and stabilize the TTR tetramer structure. epigallocatechin gallate 166-170 transthyretin Homo sapiens 66-69 20565072-6 2010 Here we first investigated the crystal structure of the EGCG-V30M TTR complex and found novel binding sites distinct from the thyroxine binding site, suggesting that EGCG has a mode of action different from those of previous chemical compounds that were shown to bind and stabilize the TTR tetramer structure. epigallocatechin gallate 166-170 transthyretin Homo sapiens 286-289 20565072-7 2010 Furthermore, EGCG induced the oligomerization and monomer suppression in the cellular system of clinically reported TTR variants. epigallocatechin gallate 13-17 transthyretin Homo sapiens 116-119 20388560-2 2010 We identified oxidative modification of the 10th cysteine of TTR through S-sulfonation in vitro. Cysteine 49-57 transthyretin Homo sapiens 61-64 20388560-4 2010 The absorption of the aggregated TTR molecules increased more with incubation time and the concentration of cysteine-S-sulfonate at pH 4 than at pH 8. S-sulphocysteine 108-128 transthyretin Homo sapiens 33-36 20388560-7 2010 In conclusion, this study showed that the formation of S-sulfonation of TTR through oxidative modifications of the thiol residue on the 10th cysteine of TTR is an important trigger step in the formation of transthyretin-related amyloid fibril. Sulfhydryl Compounds 115-120 transthyretin Homo sapiens 206-219 20388560-7 2010 In conclusion, this study showed that the formation of S-sulfonation of TTR through oxidative modifications of the thiol residue on the 10th cysteine of TTR is an important trigger step in the formation of transthyretin-related amyloid fibril. Cysteine 141-149 transthyretin Homo sapiens 72-75 20388560-7 2010 In conclusion, this study showed that the formation of S-sulfonation of TTR through oxidative modifications of the thiol residue on the 10th cysteine of TTR is an important trigger step in the formation of transthyretin-related amyloid fibril. Cysteine 141-149 transthyretin Homo sapiens 153-156 20388560-7 2010 In conclusion, this study showed that the formation of S-sulfonation of TTR through oxidative modifications of the thiol residue on the 10th cysteine of TTR is an important trigger step in the formation of transthyretin-related amyloid fibril. Cysteine 141-149 transthyretin Homo sapiens 206-219 20462362-0 2010 Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Oligonucleotides 64-79 transthyretin Homo sapiens 30-43 20185361-8 2010 CONCLUSIONS: The Hi-Ob-Db is a clinical scale which correlates with the neurophysiological impairment of the median nerve and with patient-oriented findings in patients with CTS. hi-ob-db 17-25 transthyretin Homo sapiens 174-177 23496148-2 2010 Transthyretin (TTR) Val30Met-associated FAP (FAP ATTR Val30Met) is the most common form of FAP. val30met 20-28 transthyretin Homo sapiens 0-13 23496148-2 2010 Transthyretin (TTR) Val30Met-associated FAP (FAP ATTR Val30Met) is the most common form of FAP. val30met 20-28 transthyretin Homo sapiens 15-18 23496148-2 2010 Transthyretin (TTR) Val30Met-associated FAP (FAP ATTR Val30Met) is the most common form of FAP. val30met 20-28 transthyretin Homo sapiens 49-53 23496148-2 2010 Transthyretin (TTR) Val30Met-associated FAP (FAP ATTR Val30Met) is the most common form of FAP. val30met 54-62 transthyretin Homo sapiens 0-13 23496148-2 2010 Transthyretin (TTR) Val30Met-associated FAP (FAP ATTR Val30Met) is the most common form of FAP. val30met 54-62 transthyretin Homo sapiens 15-18 23496148-2 2010 Transthyretin (TTR) Val30Met-associated FAP (FAP ATTR Val30Met) is the most common form of FAP. val30met 54-62 transthyretin Homo sapiens 49-53 23496148-6 2010 Clinical, electrophysiological and histopathological features in early-onset FAP ATTR Val30Met cases from endemic foci and those in late-onset cases from non-endemic areas in Japan are comparatively described. val30met 86-94 transthyretin Homo sapiens 81-85 23496148-7 2010 WHAT THE READER WILL GAIN: Patients with FAP ATTR Val30Met from endemic foci and those from non-endemic areas show different clinical, electrophysiological and histopathological features. val30met 50-58 transthyretin Homo sapiens 45-49 20381118-6 2010 Histologic examination revealed a massive deposition of Congo red-positive amyloid identified as amyloid protein transthyretin by both immunohistochemistry and mass spectrometry using formalin-fixed, paraffin-embedded tissues. Congo Red 56-65 transthyretin Homo sapiens 113-126 20381118-6 2010 Histologic examination revealed a massive deposition of Congo red-positive amyloid identified as amyloid protein transthyretin by both immunohistochemistry and mass spectrometry using formalin-fixed, paraffin-embedded tissues. Formaldehyde 184-192 transthyretin Homo sapiens 113-126 20381118-6 2010 Histologic examination revealed a massive deposition of Congo red-positive amyloid identified as amyloid protein transthyretin by both immunohistochemistry and mass spectrometry using formalin-fixed, paraffin-embedded tissues. Paraffin 200-208 transthyretin Homo sapiens 113-126 20462362-3 2010 In previous studies, we have shown that antisense oligonucleotides (ASOs) specific for human TTR could inhibit hepatic synthesis of TTR in mice transgenic for a human amyloid-associated TTR and may offer a medical means of treating systemic TTR amyloidosis. Oligonucleotides, Antisense 68-72 transthyretin Homo sapiens 132-135 20462362-5 2010 In the present study, mice transgenic for the human TTR amyloid-associated mutation Ile84Ser were treated by administration of TTR-specific ASO (50 microg or 75 microg per day) via an osmotic pump into the cerebral ventricular system over a 4-week period. ile84ser 84-92 transthyretin Homo sapiens 52-55 20462362-3 2010 In previous studies, we have shown that antisense oligonucleotides (ASOs) specific for human TTR could inhibit hepatic synthesis of TTR in mice transgenic for a human amyloid-associated TTR and may offer a medical means of treating systemic TTR amyloidosis. Oligonucleotides 50-66 transthyretin Homo sapiens 93-96 20462362-5 2010 In the present study, mice transgenic for the human TTR amyloid-associated mutation Ile84Ser were treated by administration of TTR-specific ASO (50 microg or 75 microg per day) via an osmotic pump into the cerebral ventricular system over a 4-week period. ile84ser 84-92 transthyretin Homo sapiens 127-130 20462362-3 2010 In previous studies, we have shown that antisense oligonucleotides (ASOs) specific for human TTR could inhibit hepatic synthesis of TTR in mice transgenic for a human amyloid-associated TTR and may offer a medical means of treating systemic TTR amyloidosis. Oligonucleotides 50-66 transthyretin Homo sapiens 132-135 20462362-5 2010 In the present study, mice transgenic for the human TTR amyloid-associated mutation Ile84Ser were treated by administration of TTR-specific ASO (50 microg or 75 microg per day) via an osmotic pump into the cerebral ventricular system over a 4-week period. Oligonucleotides, Antisense 140-143 transthyretin Homo sapiens 52-55 20462362-5 2010 In the present study, mice transgenic for the human TTR amyloid-associated mutation Ile84Ser were treated by administration of TTR-specific ASO (50 microg or 75 microg per day) via an osmotic pump into the cerebral ventricular system over a 4-week period. Oligonucleotides, Antisense 140-143 transthyretin Homo sapiens 127-130 20462362-3 2010 In previous studies, we have shown that antisense oligonucleotides (ASOs) specific for human TTR could inhibit hepatic synthesis of TTR in mice transgenic for a human amyloid-associated TTR and may offer a medical means of treating systemic TTR amyloidosis. Oligonucleotides 50-66 transthyretin Homo sapiens 132-135 20462362-7 2010 Suppression of choroid TTR expression by intraventricular administered ASO may offer a medical means of treating leptomeningeal amyloidosis. Oligonucleotides, Antisense 71-74 transthyretin Homo sapiens 23-26 20462362-3 2010 In previous studies, we have shown that antisense oligonucleotides (ASOs) specific for human TTR could inhibit hepatic synthesis of TTR in mice transgenic for a human amyloid-associated TTR and may offer a medical means of treating systemic TTR amyloidosis. Oligonucleotides 50-66 transthyretin Homo sapiens 132-135 20462362-3 2010 In previous studies, we have shown that antisense oligonucleotides (ASOs) specific for human TTR could inhibit hepatic synthesis of TTR in mice transgenic for a human amyloid-associated TTR and may offer a medical means of treating systemic TTR amyloidosis. Oligonucleotides, Antisense 68-72 transthyretin Homo sapiens 93-96 20462362-3 2010 In previous studies, we have shown that antisense oligonucleotides (ASOs) specific for human TTR could inhibit hepatic synthesis of TTR in mice transgenic for a human amyloid-associated TTR and may offer a medical means of treating systemic TTR amyloidosis. Oligonucleotides, Antisense 68-72 transthyretin Homo sapiens 132-135 20462362-3 2010 In previous studies, we have shown that antisense oligonucleotides (ASOs) specific for human TTR could inhibit hepatic synthesis of TTR in mice transgenic for a human amyloid-associated TTR and may offer a medical means of treating systemic TTR amyloidosis. Oligonucleotides, Antisense 68-72 transthyretin Homo sapiens 132-135 20303163-1 2010 A liver-targeted drug delivery carrier, composed of chitosan/poly(ethylene glycol)-glycyrrhetinic acid (CTS/PEG-GA) nanoparticles, was prepared by an ionic gelation process, in which glycyrrhetinic acid (GA) acted as the targeting ligand. poly(ethylene glycol)-glycyrrhetinic acid 61-102 transthyretin Homo sapiens 104-114 20303163-1 2010 A liver-targeted drug delivery carrier, composed of chitosan/poly(ethylene glycol)-glycyrrhetinic acid (CTS/PEG-GA) nanoparticles, was prepared by an ionic gelation process, in which glycyrrhetinic acid (GA) acted as the targeting ligand. Glycyrrhetinic Acid 83-102 transthyretin Homo sapiens 104-114 20303163-7 2010 The DOX-loaded nanoparticles were greatly cytotoxic to QGY-7703 cells, and the IC(50) (50% inhibitory concentration) for the free doxorubicin.HCl (DOX.HCl) and the DOX-loaded CTS/PEG-GA nanoparticles were 47 and 79 ng/mL, respectively. Doxorubicin 4-7 transthyretin Homo sapiens 175-185 20303163-7 2010 The DOX-loaded nanoparticles were greatly cytotoxic to QGY-7703 cells, and the IC(50) (50% inhibitory concentration) for the free doxorubicin.HCl (DOX.HCl) and the DOX-loaded CTS/PEG-GA nanoparticles were 47 and 79 ng/mL, respectively. Hydrochloric Acid 142-145 transthyretin Homo sapiens 175-185 20211733-2 2010 It was recently found that the isoflavone genistein (GEN) potently inhibits TTR amyloid fibril formation (Green et al., 2005) and is therefore a promising candidate for TTR amyloidosis treatment. Isoflavones 31-41 transthyretin Homo sapiens 76-79 20211733-2 2010 It was recently found that the isoflavone genistein (GEN) potently inhibits TTR amyloid fibril formation (Green et al., 2005) and is therefore a promising candidate for TTR amyloidosis treatment. Isoflavones 31-41 transthyretin Homo sapiens 169-172 20211733-2 2010 It was recently found that the isoflavone genistein (GEN) potently inhibits TTR amyloid fibril formation (Green et al., 2005) and is therefore a promising candidate for TTR amyloidosis treatment. Genistein 42-51 transthyretin Homo sapiens 76-79 20211733-2 2010 It was recently found that the isoflavone genistein (GEN) potently inhibits TTR amyloid fibril formation (Green et al., 2005) and is therefore a promising candidate for TTR amyloidosis treatment. Genistein 42-51 transthyretin Homo sapiens 169-172 20503435-1 2010 Transthyretin (TTR) is a plasma and cerebrospinal fluid protein mainly recognized as the transporter of thyroxine (T(4)) and retinol. Thyroxine 104-113 transthyretin Homo sapiens 0-13 20211733-2 2010 It was recently found that the isoflavone genistein (GEN) potently inhibits TTR amyloid fibril formation (Green et al., 2005) and is therefore a promising candidate for TTR amyloidosis treatment. Genistein 53-56 transthyretin Homo sapiens 76-79 20503435-1 2010 Transthyretin (TTR) is a plasma and cerebrospinal fluid protein mainly recognized as the transporter of thyroxine (T(4)) and retinol. Thyroxine 104-113 transthyretin Homo sapiens 15-18 20211733-2 2010 It was recently found that the isoflavone genistein (GEN) potently inhibits TTR amyloid fibril formation (Green et al., 2005) and is therefore a promising candidate for TTR amyloidosis treatment. Genistein 53-56 transthyretin Homo sapiens 169-172 20503435-1 2010 Transthyretin (TTR) is a plasma and cerebrospinal fluid protein mainly recognized as the transporter of thyroxine (T(4)) and retinol. Vitamin A 125-132 transthyretin Homo sapiens 0-13 20426459-8 2010 The differences in concentrations and profiles of OH-PCBs may suggest species-specific diets, metabolic capability, and the transthyretin (TTR) binding specificity. oh-pcbs 50-57 transthyretin Homo sapiens 139-142 20503435-1 2010 Transthyretin (TTR) is a plasma and cerebrospinal fluid protein mainly recognized as the transporter of thyroxine (T(4)) and retinol. Vitamin A 125-132 transthyretin Homo sapiens 15-18 20420674-2 2010 BACKGROUND: Local corticosteroid injection for carpal tunnel syndrome (CTS) provides greater clinical improvement in symptoms one month after injection compared to placebo but significant symptom relief beyond one month has not been demonstrated and the relapse of symptoms is possible.Neuroprotection and myelin repair actions of the progesterone was demonstrated in vivo and in vitro study.We report the design of a randomized controlled trial for the local injection of cortisone versus progesterone in "mild" idiopathic CTS. Cortisone 473-482 transthyretin Homo sapiens 71-74 20420674-2 2010 BACKGROUND: Local corticosteroid injection for carpal tunnel syndrome (CTS) provides greater clinical improvement in symptoms one month after injection compared to placebo but significant symptom relief beyond one month has not been demonstrated and the relapse of symptoms is possible.Neuroprotection and myelin repair actions of the progesterone was demonstrated in vivo and in vitro study.We report the design of a randomized controlled trial for the local injection of cortisone versus progesterone in "mild" idiopathic CTS. Progesterone 335-347 transthyretin Homo sapiens 71-74 20420674-4 2010 The clinical, electrophysiological and ultasonographic findings of the patients will be evaluate at baseline, 1, 6 and 12 months after injection.The major outcome of this study is to determine whether locally-injected progesterone may be more beneficial than cortisone in CTS at clinical levels, tested with symptoms severity self-administered Boston Questionnaire and with visual analogue pain scale.Secondary outcome measures are: duration of experimental therapy; improvement of electrodiagnostic and ultrasonographic anomalies at various follow-up; comparison of the beneficial and harmful effects of the cortisone versus progesterone. Progesterone 218-230 transthyretin Homo sapiens 272-275 20345174-2 2010 Metabolism of PCB and polybrominated biphenyl ether (PBDE) flame-retardants alter their toxicological properties and these metabolites are known to interfere with the binding of thyroid hormone (TH) to transthyretin (TTR) in rodents and humans. polybrominated biphenyl ether 22-51 transthyretin Homo sapiens 217-220 20345174-2 2010 Metabolism of PCB and polybrominated biphenyl ether (PBDE) flame-retardants alter their toxicological properties and these metabolites are known to interfere with the binding of thyroid hormone (TH) to transthyretin (TTR) in rodents and humans. pbde 53-57 transthyretin Homo sapiens 217-220 20166687-3 2010 Reaction with the hexachloroantimonate(V) salt of tris(4-bromophenyl)aminium (TBPA(+)) results in complex redox chemistry, involving the platinum complex, SbCl(5)(2-) and TBPA(+). hexachloroantimonate 18-38 transthyretin Homo sapiens 78-82 20166687-3 2010 Reaction with the hexachloroantimonate(V) salt of tris(4-bromophenyl)aminium (TBPA(+)) results in complex redox chemistry, involving the platinum complex, SbCl(5)(2-) and TBPA(+). hexachloroantimonate 18-38 transthyretin Homo sapiens 171-175 20166687-3 2010 Reaction with the hexachloroantimonate(V) salt of tris(4-bromophenyl)aminium (TBPA(+)) results in complex redox chemistry, involving the platinum complex, SbCl(5)(2-) and TBPA(+). Salts 42-46 transthyretin Homo sapiens 78-82 20166687-3 2010 Reaction with the hexachloroantimonate(V) salt of tris(4-bromophenyl)aminium (TBPA(+)) results in complex redox chemistry, involving the platinum complex, SbCl(5)(2-) and TBPA(+). Salts 42-46 transthyretin Homo sapiens 171-175 20166687-3 2010 Reaction with the hexachloroantimonate(V) salt of tris(4-bromophenyl)aminium (TBPA(+)) results in complex redox chemistry, involving the platinum complex, SbCl(5)(2-) and TBPA(+). tris(4-bromophenyl)aminium 50-76 transthyretin Homo sapiens 78-82 20166687-3 2010 Reaction with the hexachloroantimonate(V) salt of tris(4-bromophenyl)aminium (TBPA(+)) results in complex redox chemistry, involving the platinum complex, SbCl(5)(2-) and TBPA(+). tris(4-bromophenyl)aminium 50-76 transthyretin Homo sapiens 171-175 20166687-3 2010 Reaction with the hexachloroantimonate(V) salt of tris(4-bromophenyl)aminium (TBPA(+)) results in complex redox chemistry, involving the platinum complex, SbCl(5)(2-) and TBPA(+). Platinum 137-145 transthyretin Homo sapiens 78-82 20166687-3 2010 Reaction with the hexachloroantimonate(V) salt of tris(4-bromophenyl)aminium (TBPA(+)) results in complex redox chemistry, involving the platinum complex, SbCl(5)(2-) and TBPA(+). Platinum 137-145 transthyretin Homo sapiens 171-175 20166687-3 2010 Reaction with the hexachloroantimonate(V) salt of tris(4-bromophenyl)aminium (TBPA(+)) results in complex redox chemistry, involving the platinum complex, SbCl(5)(2-) and TBPA(+). sbcl 155-159 transthyretin Homo sapiens 78-82 20166687-3 2010 Reaction with the hexachloroantimonate(V) salt of tris(4-bromophenyl)aminium (TBPA(+)) results in complex redox chemistry, involving the platinum complex, SbCl(5)(2-) and TBPA(+). sbcl 155-159 transthyretin Homo sapiens 171-175 19946178-4 2010 Treatment of HepG2 cells with phenylalanine or phenylpyruvic acid decreased transcription of the TTR gene and decreased the transcriptional activity of the TTR promoter site, which was partly mediated through HNF4alpha. Phenylalanine 30-43 transthyretin Homo sapiens 97-100 19946178-4 2010 Treatment of HepG2 cells with phenylalanine or phenylpyruvic acid decreased transcription of the TTR gene and decreased the transcriptional activity of the TTR promoter site, which was partly mediated through HNF4alpha. Phenylalanine 30-43 transthyretin Homo sapiens 156-159 19946178-4 2010 Treatment of HepG2 cells with phenylalanine or phenylpyruvic acid decreased transcription of the TTR gene and decreased the transcriptional activity of the TTR promoter site, which was partly mediated through HNF4alpha. phenylpyruvic acid 47-65 transthyretin Homo sapiens 156-159 19946178-4 2010 Treatment of HepG2 cells with phenylalanine or phenylpyruvic acid decreased transcription of the TTR gene and decreased the transcriptional activity of the TTR promoter site, which was partly mediated through HNF4alpha. phenylpyruvic acid 47-65 transthyretin Homo sapiens 97-100 20043671-7 2010 Of the 92 stilbene and dihydrostilbene analogues synthesized, nearly all potently inhibit TTR fibril formation. Stilbenes 10-18 transthyretin Homo sapiens 90-93 20043671-7 2010 Of the 92 stilbene and dihydrostilbene analogues synthesized, nearly all potently inhibit TTR fibril formation. 1,2-dihydrostilbene 23-38 transthyretin Homo sapiens 90-93 20081815-2 2010 Herein, we report a family of designed stilbenes that selectively and covalently modify the prominent plasma protein transthyretin in preference to more than 4,000 other human plasma proteins. Stilbenes 39-48 transthyretin Homo sapiens 117-130 20133122-1 2010 Small molecules that bind to normally unoccupied thyroxine (T(4)) binding sites within transthyretin (TTR) in the blood stabilize the tetrameric ground state of TTR relative to the dissociative transition state and dramatically slow tetramer dissociation, the rate-limiting step for the process of amyloid fibril formation linked to neurodegeneration and cell death. Thyroxine 49-58 transthyretin Homo sapiens 87-100 20133122-1 2010 Small molecules that bind to normally unoccupied thyroxine (T(4)) binding sites within transthyretin (TTR) in the blood stabilize the tetrameric ground state of TTR relative to the dissociative transition state and dramatically slow tetramer dissociation, the rate-limiting step for the process of amyloid fibril formation linked to neurodegeneration and cell death. Thyroxine 49-58 transthyretin Homo sapiens 102-105 20133122-1 2010 Small molecules that bind to normally unoccupied thyroxine (T(4)) binding sites within transthyretin (TTR) in the blood stabilize the tetrameric ground state of TTR relative to the dissociative transition state and dramatically slow tetramer dissociation, the rate-limiting step for the process of amyloid fibril formation linked to neurodegeneration and cell death. Thyroxine 49-58 transthyretin Homo sapiens 161-164 20091939-7 2010 Height, weight, FT(4) x TSH, and transthyretin(TTR) at year 2; and height, triiodothyronine, and IGF-1 at year 5 differed significantly by PCDD/Fs level. pcdd/fs 139-146 transthyretin Homo sapiens 47-50 19937650-5 2010 Our simulations in explicit water allow the identification of events that clearly discriminate the unfolding behavior of WT and L55P-TTR. Water 28-33 transthyretin Homo sapiens 133-136 20081815-3 2010 They react chemoselectively with only one of eight lysine e-amino groups within transthyretin. Lysine 51-57 transthyretin Homo sapiens 80-93 19950966-7 2010 Furthermore, the entrance of the thyroxine (T(4)) binding pocket in TTR was markedly narrower in E54K TTR and wider in E54G TTR compared with wild-type TTR. Thyroxine 33-42 transthyretin Homo sapiens 68-71 19950966-7 2010 Furthermore, the entrance of the thyroxine (T(4)) binding pocket in TTR was markedly narrower in E54K TTR and wider in E54G TTR compared with wild-type TTR. Thyroxine 33-42 transthyretin Homo sapiens 102-105 19950966-7 2010 Furthermore, the entrance of the thyroxine (T(4)) binding pocket in TTR was markedly narrower in E54K TTR and wider in E54G TTR compared with wild-type TTR. Thyroxine 33-42 transthyretin Homo sapiens 102-105 19950966-7 2010 Furthermore, the entrance of the thyroxine (T(4)) binding pocket in TTR was markedly narrower in E54K TTR and wider in E54G TTR compared with wild-type TTR. Thyroxine 33-42 transthyretin Homo sapiens 102-105 20164553-8 2010 In our cross-sectional study, use of oral snuff also yielded statistically significantly increased serum TTR concentrations and nicotine has been associated with decreased risk for AD and to upregulate the TTR gene in choroid plexus but not in the liver, another source of serum TTR. Nicotine 128-136 transthyretin Homo sapiens 206-209 19954984-2 2010 Such feature is highlighted by the interactions of TTR with diclofenac, a compound with high affinity for TTR, in two dissimilar modes, as evidenced by crystal structure of the complex. Diclofenac 60-70 transthyretin Homo sapiens 51-54 19954984-2 2010 Such feature is highlighted by the interactions of TTR with diclofenac, a compound with high affinity for TTR, in two dissimilar modes, as evidenced by crystal structure of the complex. Diclofenac 60-70 transthyretin Homo sapiens 106-109 19954984-3 2010 We report here structural analysis of the interactions of TTR with two small molecules, 1-amino-5-naphthalene sulfonate (1,5-AmNS) and 1-anilino-8-naphthalene sulfonate (1,8-ANS). 5-AMINO-1-NAPHTHALENESULFONIC ACID 88-119 transthyretin Homo sapiens 58-61 19954984-3 2010 We report here structural analysis of the interactions of TTR with two small molecules, 1-amino-5-naphthalene sulfonate (1,5-AmNS) and 1-anilino-8-naphthalene sulfonate (1,8-ANS). 1,5-amns 121-129 transthyretin Homo sapiens 58-61 19954984-3 2010 We report here structural analysis of the interactions of TTR with two small molecules, 1-amino-5-naphthalene sulfonate (1,5-AmNS) and 1-anilino-8-naphthalene sulfonate (1,8-ANS). 1-anilino-8-naphthalenesulfonate 135-168 transthyretin Homo sapiens 58-61 19954984-3 2010 We report here structural analysis of the interactions of TTR with two small molecules, 1-amino-5-naphthalene sulfonate (1,5-AmNS) and 1-anilino-8-naphthalene sulfonate (1,8-ANS). 1-anilino-8-naphthalenesulfonate 170-177 transthyretin Homo sapiens 58-61 19954984-4 2010 Crystal structure of TTR:1,8-ANS complex reveals a peculiar interaction, through the stacking of the naphthalene ring between the side-chain of Lys15 and Leu17. 1-anilino-8-naphthalenesulfonate 25-32 transthyretin Homo sapiens 21-24 19954984-4 2010 Crystal structure of TTR:1,8-ANS complex reveals a peculiar interaction, through the stacking of the naphthalene ring between the side-chain of Lys15 and Leu17. naphthalene 101-112 transthyretin Homo sapiens 21-24 19954984-6 2010 The uniqueness of this mode of ligand recognition is corroborated by the crystal structure of TTR in complex with the weak analogue 1,5-AmNS, the binding of which is driven mainly by hydrophobic partition and one electrostatic interaction between the sulfonate group and the Lys15. 1,5-amns 132-140 transthyretin Homo sapiens 94-97 19954984-6 2010 The uniqueness of this mode of ligand recognition is corroborated by the crystal structure of TTR in complex with the weak analogue 1,5-AmNS, the binding of which is driven mainly by hydrophobic partition and one electrostatic interaction between the sulfonate group and the Lys15. sulfonate 251-260 transthyretin Homo sapiens 94-97 19954984-7 2010 The ligand binding motif unraveled by 1,8-ANS may open new possibilities to treat TTR amyloid diseases by the elucidation of novel candidates for a more specific pharmacophoric pattern. 1-anilino-8-naphthalenesulfonate 38-45 transthyretin Homo sapiens 82-85 22400056-4 2010 Whole body scintigraphy using TC99m-DPD showed end stage hereditary amyloidosis caused by ATTR with predominant tracer retention in the myocardium. technetium Tc 99m 1,1-diphosphonopropane-2,3-dicarboxylic acid 30-39 transthyretin Homo sapiens 90-94 20164553-8 2010 In our cross-sectional study, use of oral snuff also yielded statistically significantly increased serum TTR concentrations and nicotine has been associated with decreased risk for AD and to upregulate the TTR gene in choroid plexus but not in the liver, another source of serum TTR. Nicotine 128-136 transthyretin Homo sapiens 206-209 20552431-2 2010 In this assay, the intrinsic fluorescence from the RBP-retinol complex excites a probe molecule which is covalently coupled to TTR. Vitamin A 55-62 transthyretin Homo sapiens 127-130 21089199-1 2010 In this report, two cases presenting with CTS including a fracture of the silicone implant for Kienbock"s disease after replacement over 20 years postoperatively where CTR ceased the symptoms of CTS. Silicones 74-82 transthyretin Homo sapiens 42-45 21089199-1 2010 In this report, two cases presenting with CTS including a fracture of the silicone implant for Kienbock"s disease after replacement over 20 years postoperatively where CTR ceased the symptoms of CTS. Silicones 74-82 transthyretin Homo sapiens 195-198 21089199-3 2010 There was an unlikely association between the fracture of the implant and CTS, which was confirmed by the operative findings of tenosynovitis and thickness of the degenerated transverse ligament without a significant protrusion of the silicone implant. Silicones 235-243 transthyretin Homo sapiens 74-77 20552430-1 2010 The retinol carrier retinol-binding protein (RBP) forms in blood a complex with the thyroid hormone carrier transthyretin (TTR). Vitamin A 4-11 transthyretin Homo sapiens 108-121 20552431-3 2010 Generation of an emission signal from the TTR probe indicates interaction between RBP-retinol and TTR. Vitamin A 86-93 transthyretin Homo sapiens 42-45 20552430-1 2010 The retinol carrier retinol-binding protein (RBP) forms in blood a complex with the thyroid hormone carrier transthyretin (TTR). Vitamin A 4-11 transthyretin Homo sapiens 123-126 20552431-3 2010 Generation of an emission signal from the TTR probe indicates interaction between RBP-retinol and TTR. Vitamin A 86-93 transthyretin Homo sapiens 98-101 20552430-2 2010 The interactions of retinoid-RBP complexes, as well as of unliganded RBP, with TTR can be investigated by means of fluorescence anisotropy. Retinoids 20-28 transthyretin Homo sapiens 79-82 20552431-5 2010 Thus, compounds which bind to RBP must compete with retinol in order to affect RBP-TTR interaction. Vitamin A 52-59 transthyretin Homo sapiens 83-86 20552430-5 2010 The addition of TTR to the retinol-RBP complex (holoRBP) causes a marked increase in the fluorescence anisotropy of the RBP-bound retinol within the system, due to the formation of the holoRBP-TTR complex, which allows the interaction between the two proteins to be monitored. Vitamin A 27-34 transthyretin Homo sapiens 16-19 20552430-5 2010 The addition of TTR to the retinol-RBP complex (holoRBP) causes a marked increase in the fluorescence anisotropy of the RBP-bound retinol within the system, due to the formation of the holoRBP-TTR complex, which allows the interaction between the two proteins to be monitored. Vitamin A 27-34 transthyretin Homo sapiens 193-196 19861125-0 2009 Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. epigallocatechin gallate 11-37 transthyretin Homo sapiens 41-54 20552430-6 2010 The fluorescence anisotropy technique is also suitable to study the interaction of TTR with apoRBP and RBP in complex with non-fluorescent retinoids. Retinoids 139-148 transthyretin Homo sapiens 83-86 19922331-1 2009 Transthyretin (TTR) is a homotetrameric protein involved in thyroid hormone transport in blood and in retinol binding in the central nervous system. Vitamin A 102-109 transthyretin Homo sapiens 0-13 19922331-1 2009 Transthyretin (TTR) is a homotetrameric protein involved in thyroid hormone transport in blood and in retinol binding in the central nervous system. Vitamin A 102-109 transthyretin Homo sapiens 15-18 19861125-3 2009 In this study we tested (-)-epigallocatechin-3-gallate (EGCG), the most abundant catechin of green tea, as an inhibitor of TTR amyloid formation. epigallocatechin gallate 24-54 transthyretin Homo sapiens 123-126 19861125-3 2009 In this study we tested (-)-epigallocatechin-3-gallate (EGCG), the most abundant catechin of green tea, as an inhibitor of TTR amyloid formation. epigallocatechin gallate 56-60 transthyretin Homo sapiens 123-126 19861125-3 2009 In this study we tested (-)-epigallocatechin-3-gallate (EGCG), the most abundant catechin of green tea, as an inhibitor of TTR amyloid formation. Catechin 36-44 transthyretin Homo sapiens 123-126 19861125-4 2009 We demonstrate that EGCG binds to TTR "in vitro" and "ex vivo" and that EGCG inhibits TTR aggregation "in vitro" and in a cell culture system. epigallocatechin gallate 20-24 transthyretin Homo sapiens 34-37 19861125-4 2009 We demonstrate that EGCG binds to TTR "in vitro" and "ex vivo" and that EGCG inhibits TTR aggregation "in vitro" and in a cell culture system. epigallocatechin gallate 72-76 transthyretin Homo sapiens 86-89 19861125-5 2009 These findings together with the low toxicity of the compound raise the possibility of using EGCG in a therapeutic approach for familial amyloidotic polyneuropathy, the most frequent form of hereditary TTR amyloidosis. epigallocatechin gallate 93-97 transthyretin Homo sapiens 202-205 19493541-0 2009 Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. C10Ph 11-14 transthyretin Homo sapiens 83-86 19665514-1 2009 Transthyretin (TTR) is a plasma protein mostly known for being the transporter of thyroxine and retinol. Thyroxine 82-91 transthyretin Homo sapiens 0-13 19665514-1 2009 Transthyretin (TTR) is a plasma protein mostly known for being the transporter of thyroxine and retinol. Thyroxine 82-91 transthyretin Homo sapiens 15-18 19665514-1 2009 Transthyretin (TTR) is a plasma protein mostly known for being the transporter of thyroxine and retinol. Vitamin A 96-103 transthyretin Homo sapiens 0-13 19665514-1 2009 Transthyretin (TTR) is a plasma protein mostly known for being the transporter of thyroxine and retinol. Vitamin A 96-103 transthyretin Homo sapiens 15-18 19752338-5 2009 RESULTS: After 100 months of follow-up, 80 cases (2.6%) of CTS were reported in the anastrozole arm, compared with 23 cases (0.7%) in the tamoxifen arm (P < .0001). Anastrozole 84-95 transthyretin Homo sapiens 59-62 19752338-10 2009 CONCLUSION: Although the use of anastrozole is associated with a greater incidence of CTS, it is rare, and most cases were of mild to moderate intensity and short duration. Anastrozole 32-43 transthyretin Homo sapiens 86-89 19725880-6 2009 All transthyretin-like proteins studied to date have been demonstrated to function in purine metabolism by hydrolysing the oxidative product of uric acid, 5-hydroxyisourate. purine 86-92 transthyretin Homo sapiens 4-17 19725880-6 2009 All transthyretin-like proteins studied to date have been demonstrated to function in purine metabolism by hydrolysing the oxidative product of uric acid, 5-hydroxyisourate. Uric Acid 144-153 transthyretin Homo sapiens 4-17 19725880-6 2009 All transthyretin-like proteins studied to date have been demonstrated to function in purine metabolism by hydrolysing the oxidative product of uric acid, 5-hydroxyisourate. 5-hydroxyisourate 155-172 transthyretin Homo sapiens 4-17 20030258-7 2009 TTR tetramer dissociation is an initial step for the process of TTR-derived amyloid fibril formation associated with FAP and diflinisal can inhibit this process by stabilization of the TTR tetramer. diflinisal 125-135 transthyretin Homo sapiens 0-3 20030258-7 2009 TTR tetramer dissociation is an initial step for the process of TTR-derived amyloid fibril formation associated with FAP and diflinisal can inhibit this process by stabilization of the TTR tetramer. diflinisal 125-135 transthyretin Homo sapiens 64-67 20030258-7 2009 TTR tetramer dissociation is an initial step for the process of TTR-derived amyloid fibril formation associated with FAP and diflinisal can inhibit this process by stabilization of the TTR tetramer. diflinisal 125-135 transthyretin Homo sapiens 64-67 19644733-1 2009 Transthyretin (TTR) (formerly, thyroxine binding prealbumin) is an evolutionarily conserved serum and cerebrospinal fluid protein that transports holo-retinol-binding protein and thyroxine. Thyroxine 31-40 transthyretin Homo sapiens 0-13 19644733-1 2009 Transthyretin (TTR) (formerly, thyroxine binding prealbumin) is an evolutionarily conserved serum and cerebrospinal fluid protein that transports holo-retinol-binding protein and thyroxine. Thyroxine 31-40 transthyretin Homo sapiens 15-18 19644733-1 2009 Transthyretin (TTR) (formerly, thyroxine binding prealbumin) is an evolutionarily conserved serum and cerebrospinal fluid protein that transports holo-retinol-binding protein and thyroxine. Thyroxine 179-188 transthyretin Homo sapiens 0-13 19644733-1 2009 Transthyretin (TTR) (formerly, thyroxine binding prealbumin) is an evolutionarily conserved serum and cerebrospinal fluid protein that transports holo-retinol-binding protein and thyroxine. Thyroxine 179-188 transthyretin Homo sapiens 15-18 19651509-0 2009 Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors. Isatin 0-6 transthyretin Homo sapiens 37-50 19501449-5 2009 The STD profile of backbone amide protons is in good agreement with an earlier computational study predicting hydrogen bonding propensity for each residue in small TTR(105-115) aggregates (Paci et al., J. Mol. Hydrogen 110-118 transthyretin Homo sapiens 164-167 19651509-1 2009 The isatin core structure was found to be a novel chemical scaffold in transthyretin (TTR) fibrillogenesis inhibitor design. Isatin 4-10 transthyretin Homo sapiens 71-84 19651509-1 2009 The isatin core structure was found to be a novel chemical scaffold in transthyretin (TTR) fibrillogenesis inhibitor design. Isatin 4-10 transthyretin Homo sapiens 86-89 19651509-2 2009 Among the series of isatin analogues prepared and tested, the nitro compound 1,3-dihydro-3-[(4-nitrophenyl)imino]-2H-indol-2-one (2r) is as potent as triiodophenol, which is one of the most active known TTR inhibitors. nitro compound 1,3-dihydro-3-[(4-nitrophenyl)imino]-2h-indol-2-one 62-128 transthyretin Homo sapiens 203-206 19515935-5 2009 Although the histidine-tagged CTD (hCTD) was monomeric in solution, hCTD bound cooperatively to three of the recombination substrates (attB, attL and attR). Histidine 13-22 transthyretin Homo sapiens 150-154 19551197-0 2009 UV resonance Raman spectroscopy of TTR(105-115): determination of the pKa of tyrosine. Tyrosine 77-85 transthyretin Homo sapiens 35-38 19621084-5 2009 Based on an in vitro fibril formation assay, five of these compounds showed significant inhibition of TTR amyloidogenesis, with two fluorenyl compounds displaying inhibitor efficacy comparable to the well-known TTR inhibitor diflunisal. Diflunisal 225-235 transthyretin Homo sapiens 211-214 19621084-7 2009 Crystal structures of the TTR:inhibitor complexes, in agreement with molecular docking studies, revealed that the aromatic moiety, linked to the sp(2)-hybridized oxime carbon, specifically directed the ligand in either a forward or reverse binding mode. sp(2) 145-150 transthyretin Homo sapiens 26-29 19621084-7 2009 Crystal structures of the TTR:inhibitor complexes, in agreement with molecular docking studies, revealed that the aromatic moiety, linked to the sp(2)-hybridized oxime carbon, specifically directed the ligand in either a forward or reverse binding mode. Oximes 162-167 transthyretin Homo sapiens 26-29 19621084-7 2009 Crystal structures of the TTR:inhibitor complexes, in agreement with molecular docking studies, revealed that the aromatic moiety, linked to the sp(2)-hybridized oxime carbon, specifically directed the ligand in either a forward or reverse binding mode. Carbon 168-174 transthyretin Homo sapiens 26-29 19621084-8 2009 Compared to the aryl family members, the bulkier fluorenyl analogs achieved more extensive interactions with the binding pockets of TTR and demonstrated better inhibitory activity in the fibril formation assay. fluorenyl 49-58 transthyretin Homo sapiens 132-135 19401362-1 2009 CONTEXT: The serum protein transthyretin (TTR) plays an important role in the transport of thyroid hormone and retinol, which are critical for normal development of the human fetus. Vitamin A 111-118 transthyretin Homo sapiens 27-40 19401362-1 2009 CONTEXT: The serum protein transthyretin (TTR) plays an important role in the transport of thyroid hormone and retinol, which are critical for normal development of the human fetus. Vitamin A 111-118 transthyretin Homo sapiens 42-45 19401362-8 2009 Human placental explants and JEG-3 cells internalize Alexa Fluor488-labeled TTR and (125)I-TTR. alexa fluor488 53-67 transthyretin Homo sapiens 76-79 19361464-0 2009 Characterization of cysteine and homocysteine bound to human serum transthyretin. Cysteine 20-28 transthyretin Homo sapiens 67-80 19588843-14 2009 PCBs are metabolized to produce HO-PCBs, which bind to TTR and retain in blood medium. Polychlorinated Biphenyls 0-4 transthyretin Homo sapiens 55-58 19588843-14 2009 PCBs are metabolized to produce HO-PCBs, which bind to TTR and retain in blood medium. ho-pcbs 32-39 transthyretin Homo sapiens 55-58 19293372-3 2009 In the present study, we investigated if PFCs can compete with thyroxine (T(4), i.e., the transport form of thyroid hormone) for binding to the human thyroid hormone transport protein transthyretin (TTR). Thyroxine 63-72 transthyretin Homo sapiens 184-197 19293372-3 2009 In the present study, we investigated if PFCs can compete with thyroxine (T(4), i.e., the transport form of thyroid hormone) for binding to the human thyroid hormone transport protein transthyretin (TTR). Thyroxine 63-72 transthyretin Homo sapiens 199-202 19293372-6 2009 The binding potency decreased in the order: perfluorohexane sulfonate > perfluorooctane sulfonate/perfluorooctanoic acid > perfluoroheptanoic acid > sodium perfluoro-1-octanesulfinate > perfluorononanoic acid, with TTR binding potencies 12.5-50 times lower than the natural ligand T(4). perfluorooctane sulfonic acid 75-100 transthyretin Homo sapiens 227-230 19590482-17 2009 CONCLUSIONS: Short-term acupuncture treatment is as effective as short-term low-dose prednisolone for mild-to-moderate CTS. Prednisolone 85-97 transthyretin Homo sapiens 119-122 19361464-0 2009 Characterization of cysteine and homocysteine bound to human serum transthyretin. Homocysteine 33-45 transthyretin Homo sapiens 67-80 19361464-1 2009 BACKGROUND: Cysteine-bound transthyretin (TTR) in serum is believed to be associated with deposition of amyloid in familial amyloidotic polyneuropathy (FAP). Cysteine 12-20 transthyretin Homo sapiens 27-40 19361464-1 2009 BACKGROUND: Cysteine-bound transthyretin (TTR) in serum is believed to be associated with deposition of amyloid in familial amyloidotic polyneuropathy (FAP). Cysteine 12-20 transthyretin Homo sapiens 42-45 19361464-2 2009 We examined the binding of cysteine and homocysteine with TTR, and the effect of such binding on TTR structure. Cysteine 27-35 transthyretin Homo sapiens 58-61 19361464-2 2009 We examined the binding of cysteine and homocysteine with TTR, and the effect of such binding on TTR structure. Homocysteine 40-52 transthyretin Homo sapiens 58-61 19361464-4 2009 TTR was analyzed using isoelectric focusing (IEF), SDS-polyacrylamide gel electrophoresis (PAGE) and mass spectrometry. Sodium Dodecyl Sulfate 51-54 transthyretin Homo sapiens 0-3 19361464-4 2009 TTR was analyzed using isoelectric focusing (IEF), SDS-polyacrylamide gel electrophoresis (PAGE) and mass spectrometry. polyacrylamide 55-69 transthyretin Homo sapiens 0-3 19361464-5 2009 RESULTS: Incubation of serum at 4 degrees C resulted in an approximate doubling of the amount of both cysteine and homocysteine bound to TTR. Cysteine 102-110 transthyretin Homo sapiens 137-140 19361464-5 2009 RESULTS: Incubation of serum at 4 degrees C resulted in an approximate doubling of the amount of both cysteine and homocysteine bound to TTR. Homocysteine 115-127 transthyretin Homo sapiens 137-140 19361464-6 2009 Incubation of serum TTR with cysteine-HCl at 37 degrees C markedly altered the IEF and SDS-PAGE profiles of TTR. Cysteine 29-41 transthyretin Homo sapiens 20-23 19361464-6 2009 Incubation of serum TTR with cysteine-HCl at 37 degrees C markedly altered the IEF and SDS-PAGE profiles of TTR. Cysteine 29-41 transthyretin Homo sapiens 108-111 19361464-6 2009 Incubation of serum TTR with cysteine-HCl at 37 degrees C markedly altered the IEF and SDS-PAGE profiles of TTR. Sodium Dodecyl Sulfate 87-90 transthyretin Homo sapiens 20-23 19361464-6 2009 Incubation of serum TTR with cysteine-HCl at 37 degrees C markedly altered the IEF and SDS-PAGE profiles of TTR. Sodium Dodecyl Sulfate 87-90 transthyretin Homo sapiens 108-111 19361464-7 2009 The main ion peaks of TTR were observed at m/z 13,761 and 13,881, and assigned as free TTR and TTR+cysteine respectively. Cysteine 99-107 transthyretin Homo sapiens 22-25 19361464-8 2009 Incubation of purified TTR with dithiothreitol followed by cysteine-HCl resulted in loss of the latter peak and an increase in the m/z 13,761 peak, while incubation with cysteine-HCl alone did not cause such a change. Dithiothreitol 32-46 transthyretin Homo sapiens 23-26 19361464-8 2009 Incubation of purified TTR with dithiothreitol followed by cysteine-HCl resulted in loss of the latter peak and an increase in the m/z 13,761 peak, while incubation with cysteine-HCl alone did not cause such a change. Cysteine 59-71 transthyretin Homo sapiens 23-26 19361464-8 2009 Incubation of purified TTR with dithiothreitol followed by cysteine-HCl resulted in loss of the latter peak and an increase in the m/z 13,761 peak, while incubation with cysteine-HCl alone did not cause such a change. Cysteine 170-182 transthyretin Homo sapiens 23-26 19361464-9 2009 CONCLUSION: Cysteine- and homocysteine-bound TTR was more easily denatured by cysteine-HCl than free TTR. Cysteine 12-20 transthyretin Homo sapiens 45-48 19361464-9 2009 CONCLUSION: Cysteine- and homocysteine-bound TTR was more easily denatured by cysteine-HCl than free TTR. Homocysteine 26-38 transthyretin Homo sapiens 45-48 19361464-9 2009 CONCLUSION: Cysteine- and homocysteine-bound TTR was more easily denatured by cysteine-HCl than free TTR. Homocysteine 26-38 transthyretin Homo sapiens 101-104 19361464-9 2009 CONCLUSION: Cysteine- and homocysteine-bound TTR was more easily denatured by cysteine-HCl than free TTR. Cysteine 78-90 transthyretin Homo sapiens 45-48 19361464-10 2009 Binding of cysteine and homocysteine may alter the structure and characteristics of serum TTR, and may facilitate TTR denaturation and deposition. Cysteine 11-19 transthyretin Homo sapiens 90-93 19361464-10 2009 Binding of cysteine and homocysteine may alter the structure and characteristics of serum TTR, and may facilitate TTR denaturation and deposition. Cysteine 11-19 transthyretin Homo sapiens 114-117 19361464-10 2009 Binding of cysteine and homocysteine may alter the structure and characteristics of serum TTR, and may facilitate TTR denaturation and deposition. Homocysteine 24-36 transthyretin Homo sapiens 90-93 19361464-10 2009 Binding of cysteine and homocysteine may alter the structure and characteristics of serum TTR, and may facilitate TTR denaturation and deposition. Homocysteine 24-36 transthyretin Homo sapiens 114-117 20719115-7 2009 The candidate biomarkers obtained from 1-D SDS gel bands by matching the molecular weight with peaks on CM10 chips were identified by Mass spectrometry as the native transthyretin (nativeTTR), cysTTR and glutTTR, and the identity was further validated by immunoprecipitation using commercial TTR antibodies. Sodium Dodecyl Sulfate 43-46 transthyretin Homo sapiens 187-190 19347928-2 2009 This study was designed to investigate the effectiveness of dexamethasone iontophoresis as a noninvasive method of treating CTS. Dexamethasone 60-73 transthyretin Homo sapiens 124-127 18937531-2 2009 These assays test the potency of competitive binding with the active form of TH, 3,3",5-[(125)I]triiodo-l-thyronine (T(3)), to the plasma transport protein transthyretin (TTR) and TH receptor (TR; the TTR assay and TR assay, respectively) and the interference with the cellular T(3)-signaling pathway through TR-mediated luciferase gene activation (the luc assay). -l-thyronine 103-115 transthyretin Homo sapiens 156-169 19250316-6 2009 hTTR and sbTTR formed thin, curved fibrils at low pH (pH 2-3) that bound thioflavin-T (thioflavin-T-positive) but did not stain with Congo Red (CR) (CR-negative). thioflavin T 73-85 transthyretin Homo sapiens 0-4 19250316-6 2009 hTTR and sbTTR formed thin, curved fibrils at low pH (pH 2-3) that bound thioflavin-T (thioflavin-T-positive) but did not stain with Congo Red (CR) (CR-negative). thioflavin T 87-99 transthyretin Homo sapiens 0-4 19250316-6 2009 hTTR and sbTTR formed thin, curved fibrils at low pH (pH 2-3) that bound thioflavin-T (thioflavin-T-positive) but did not stain with Congo Red (CR) (CR-negative). Congo Red 144-146 transthyretin Homo sapiens 0-4 19250316-6 2009 hTTR and sbTTR formed thin, curved fibrils at low pH (pH 2-3) that bound thioflavin-T (thioflavin-T-positive) but did not stain with Congo Red (CR) (CR-negative). Congo Red 149-151 transthyretin Homo sapiens 0-4 19250316-8 2009 CR-positive material of hTTR was found in this material, in agreement with previous results. Congo Red 0-2 transthyretin Homo sapiens 24-28 19073163-8 2009 Expression of TTR decreased in a time-dependent manner in phenylalanine-treated HepG2 cells. Phenylalanine 58-71 transthyretin Homo sapiens 14-17 18937531-2 2009 These assays test the potency of competitive binding with the active form of TH, 3,3",5-[(125)I]triiodo-l-thyronine (T(3)), to the plasma transport protein transthyretin (TTR) and TH receptor (TR; the TTR assay and TR assay, respectively) and the interference with the cellular T(3)-signaling pathway through TR-mediated luciferase gene activation (the luc assay). -l-thyronine 103-115 transthyretin Homo sapiens 171-174 18952041-3 2009 This can be accomplished by administration of small molecules, such as fenretinide, that compete with retinol for binding to RBP4 and disrupt the protein-protein interaction between RBP4 and transthyretin (TTR), another serum protein that protects RBP4 from renal clearance. Fenretinide 71-82 transthyretin Homo sapiens 191-204 19363993-1 2009 Transthyretin (TTR) was previously called prealbumin because the band it formed on agarose gel electrophoresis at pH 8.6 was at the prealbumin position. Sepharose 83-90 transthyretin Homo sapiens 15-18 19333155-1 2009 OBJECTIVES: This study is to assess the effectiveness of steroid injections to improve the clinical and electrodiagnostic (EDX) parameters associated with moderate and severe carpal tunnel syndrome (CTS). Steroids 57-64 transthyretin Homo sapiens 199-202 19333155-9 2009 DISCUSSION: Steroid injection is an effective method to improve clinical scales but has limited ability to restore nerve conduction in moderate or severe CTS. Steroids 12-19 transthyretin Homo sapiens 154-157 19363993-1 2009 Transthyretin (TTR) was previously called prealbumin because the band it formed on agarose gel electrophoresis at pH 8.6 was at the prealbumin position. Sepharose 83-90 transthyretin Homo sapiens 0-13 18952041-3 2009 This can be accomplished by administration of small molecules, such as fenretinide, that compete with retinol for binding to RBP4 and disrupt the protein-protein interaction between RBP4 and transthyretin (TTR), another serum protein that protects RBP4 from renal clearance. Fenretinide 71-82 transthyretin Homo sapiens 206-209 18952041-5 2009 We present an allosteric model that describes the pharmacology of interaction among RBP4, TTR, retinol, and fenretinide, and we show data that support the model. Fenretinide 108-119 transthyretin Homo sapiens 90-93 18952041-6 2009 We show that retinol increases the affinity of RBP4 for TTR by a factor of 4 and determine the affinity constants of fenretinide and retinyl acetate. Vitamin A 13-20 transthyretin Homo sapiens 56-59 19183833-5 2009 Transthyretin at postoperative 28 days in group I was 15.6 +/- 6.2, higher than that in group E. Retinol-binding protein at postoperative 28 days in group I was 2.6 +/- 1.0 and also higher than that in group E. CONCLUSION: HJ with no-stented internal biliary drainage was not associated with systemic infections and mortality, but showed the possibility of improving nutritional status. Vitamin A 97-104 transthyretin Homo sapiens 0-13 19682646-1 2009 Transthyretin (TTR), a plasma and cerebrospinal fluid protein secreted by the liver and choroid plexus, is mainly known as the physiological carrier of thyroxine (T(4)) and retinol. Thyroxine 152-161 transthyretin Homo sapiens 0-13 19682646-1 2009 Transthyretin (TTR), a plasma and cerebrospinal fluid protein secreted by the liver and choroid plexus, is mainly known as the physiological carrier of thyroxine (T(4)) and retinol. Thyroxine 152-161 transthyretin Homo sapiens 15-18 19682646-1 2009 Transthyretin (TTR), a plasma and cerebrospinal fluid protein secreted by the liver and choroid plexus, is mainly known as the physiological carrier of thyroxine (T(4)) and retinol. Vitamin A 173-180 transthyretin Homo sapiens 0-13 19682646-1 2009 Transthyretin (TTR), a plasma and cerebrospinal fluid protein secreted by the liver and choroid plexus, is mainly known as the physiological carrier of thyroxine (T(4)) and retinol. Vitamin A 173-180 transthyretin Homo sapiens 15-18 18984591-1 2009 Transthyretin (TTR) is a 127-residue homotetrameric beta-sheet-rich protein that transports thyroxine in the blood and cerebrospinal fluid. Thyroxine 92-101 transthyretin Homo sapiens 0-13 18984591-1 2009 Transthyretin (TTR) is a 127-residue homotetrameric beta-sheet-rich protein that transports thyroxine in the blood and cerebrospinal fluid. Thyroxine 92-101 transthyretin Homo sapiens 15-18 20023332-1 2009 OBJECTIVE: To evaluate the clinical and electrophysiological effects of local depo-methylprednisolone injection in patients with carpal tunnel syndrome (CTS) over a 6-months period. Methylprednisolone Acetate 78-101 transthyretin Homo sapiens 153-156 20023332-2 2009 METHODS: Twenty one patients, of whom 7 were lost for follow-up (mean age 57.9 +/- 8.4) with clinical and electrophysiological evidence of CTS were treated by injection of depo-methylprednisolone 40 mg proximal to the carpal tunnel. Methylprednisolone Acetate 172-195 transthyretin Homo sapiens 139-142 19214684-5 2009 The present study investigated the diagnostic role of gadolinium-enhanced MR imaging of CTS. Gadolinium 54-64 transthyretin Homo sapiens 88-91 19214684-12 2009 Gadolinium enhancement was found in only 87% of patients with CTS who visited the hospital at an early stage and therefore had no nerve deficiency on electrophysiological studies (39%). Gadolinium 0-10 transthyretin Homo sapiens 62-65 19214684-15 2009 CONCLUSIONS: We conclude that gadolinium-enhanced MR imaging can detect not only morphological changes but also pathological changes of the median nerve in patients with CTS. Gadolinium 30-40 transthyretin Homo sapiens 170-173 19214684-16 2009 Currently, gadolinium-enhanced-MR imaging is probably most commonly used to image patients who have ambiguous electrodiagnostic studies and clinical examination in an early stage of CTS. Gadolinium 11-21 transthyretin Homo sapiens 182-185 19801348-12 2009 Iron deficiency was also associated with reduced levels of thyroxine-binding prealbumin (TBPA) and albumin (p < 0.05). Iron 0-4 transthyretin Homo sapiens 59-87 19125186-0 2009 Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. Iodine 0-6 transthyretin Homo sapiens 63-76 19125186-4 2009 Up to now, TTR aggregation inhibitors have been designed looking at various structural features of this binding channel others than its ability to host iodine atoms. Iodine 152-158 transthyretin Homo sapiens 11-14 19125186-5 2009 In the present work, greatly improved inhibitors have been designed and tested by taking into account that thyroid hormones are unique in human biochemistry owing to the presence of multiple iodine atoms in their molecules which are probed to interact with specific halogen binding domains sitting at the TTR binding channel. Iodine 191-197 transthyretin Homo sapiens 305-308 19125186-5 2009 In the present work, greatly improved inhibitors have been designed and tested by taking into account that thyroid hormones are unique in human biochemistry owing to the presence of multiple iodine atoms in their molecules which are probed to interact with specific halogen binding domains sitting at the TTR binding channel. Halogens 266-273 transthyretin Homo sapiens 305-308 19125186-6 2009 The new TTR fibrillogenesis inhibitors are based on the diflunisal core structure because diflunisal is a registered salicylate drug with NSAID activity now undergoing clinical trials for TTR amyloid diseases. Diflunisal 56-66 transthyretin Homo sapiens 8-11 19125186-6 2009 The new TTR fibrillogenesis inhibitors are based on the diflunisal core structure because diflunisal is a registered salicylate drug with NSAID activity now undergoing clinical trials for TTR amyloid diseases. Diflunisal 56-66 transthyretin Homo sapiens 188-191 19125186-6 2009 The new TTR fibrillogenesis inhibitors are based on the diflunisal core structure because diflunisal is a registered salicylate drug with NSAID activity now undergoing clinical trials for TTR amyloid diseases. Diflunisal 90-100 transthyretin Homo sapiens 8-11 19125186-6 2009 The new TTR fibrillogenesis inhibitors are based on the diflunisal core structure because diflunisal is a registered salicylate drug with NSAID activity now undergoing clinical trials for TTR amyloid diseases. Diflunisal 90-100 transthyretin Homo sapiens 188-191 19125186-6 2009 The new TTR fibrillogenesis inhibitors are based on the diflunisal core structure because diflunisal is a registered salicylate drug with NSAID activity now undergoing clinical trials for TTR amyloid diseases. Salicylates 117-127 transthyretin Homo sapiens 8-11 19125186-7 2009 Biochemical and biophysical evidence confirms that iodine atoms can be an important design feature in the search for candidate drugs for TTR related amyloidosis. Iodine 51-57 transthyretin Homo sapiens 137-140 18983486-1 2009 BACKGROUND: Little is known about how patterns of warfarin dose management contribute to percentage time in the therapeutic International Normalized Ratio (INR) range (TTR). Warfarin 50-58 transthyretin Homo sapiens 168-171 18983486-2 2009 OBJECTIVES: To quantify the contribution of warfarin dose management to TTR and to define an optimal dose management strategy. Warfarin 44-52 transthyretin Homo sapiens 72-75 20143571-1 2009 A case of familial transthyretin amyloidosis with TTR Cys 114 gene polymorphism is described (first in Russia and third in the world). Cysteine 54-57 transthyretin Homo sapiens 50-53 20143571-7 2009 The proband, his daughter, brother (monozygous twin), and brother"s daughter had mutant TTR Cys 114 gene. Cysteine 92-95 transthyretin Homo sapiens 88-91 18983977-3 2008 Employing ThT fluorescence, time-resolved fluorescence anisotropy of pyrene-labeled TTR, chemical cross-linking, and electron microscopy we demonstrated that early formed soluble oligomers (within minutes) from A-state TTR comprised on the average 20-30 TTR monomers. pyrene 69-75 transthyretin Homo sapiens 84-87 19801348-12 2009 Iron deficiency was also associated with reduced levels of thyroxine-binding prealbumin (TBPA) and albumin (p < 0.05). Iron 0-4 transthyretin Homo sapiens 89-93 19801348-18 2009 The reduction in albumin and TBPA associated with the iron deficiency but in the absence of any sign of malnutrition (W/H > 96%) or inflammatory risk (PINI < 2) in either study group shows that iron may play a dominant role during protein synthesis. Iron 54-58 transthyretin Homo sapiens 29-33 19801348-18 2009 The reduction in albumin and TBPA associated with the iron deficiency but in the absence of any sign of malnutrition (W/H > 96%) or inflammatory risk (PINI < 2) in either study group shows that iron may play a dominant role during protein synthesis. Iron 200-204 transthyretin Homo sapiens 29-33 19021760-1 2008 Transthyretin is a tetrameric binding protein involved in the transport of thyroid hormones and in the cotransport of retinol by forming a complex in plasma with retinol-binding protein. Vitamin A 118-125 transthyretin Homo sapiens 0-13 19065295-3 2008 The amyloid structure of TTR contains non-native inter-molecular disulphide linkages via the cysteine at position 10 (Cys10). disulphide 65-75 transthyretin Homo sapiens 25-28 19065295-3 2008 The amyloid structure of TTR contains non-native inter-molecular disulphide linkages via the cysteine at position 10 (Cys10). Cysteine 93-101 transthyretin Homo sapiens 25-28 19065295-6 2008 By probing Cys10Ser TTR variants to the human neuroblastoma SH-SY5Y cell line, we have addressed this question, and our results clearly show that formation of an inter-molecular disulphide bridge is not a pre-requisite for TTR cytotoxicity. disulphide 178-188 transthyretin Homo sapiens 20-23 19021760-1 2008 Transthyretin is a tetrameric binding protein involved in the transport of thyroid hormones and in the cotransport of retinol by forming a complex in plasma with retinol-binding protein. Vitamin A 162-169 transthyretin Homo sapiens 0-13 19021760-3 2008 The main interactions, both polar and apolar, between retinol-binding protein and transthyretin involve the retinol hydroxyl group and a limited number of solvent exposed residues. Vitamin A 54-61 transthyretin Homo sapiens 82-95 19021760-3 2008 The main interactions, both polar and apolar, between retinol-binding protein and transthyretin involve the retinol hydroxyl group and a limited number of solvent exposed residues. retinol hydroxyl 108-124 transthyretin Homo sapiens 82-95 19021760-6 2008 The effect is particularly evident when the mutation affects an interacting residue present in two distinct subunits of transthyretin participating simultaneously in two interactions with a retinol-binding protein molecule. Vitamin A 190-197 transthyretin Homo sapiens 120-133 19021760-8 2008 Remarkably, some of the residues in mutated human transthyretin that weaken or abolish the interaction with retinol-binding protein are present in piscine transthyretin, consistent with the lack of interaction between retinol-binding protein and transthyretin in fish. Vitamin A 108-115 transthyretin Homo sapiens 50-63 19021760-8 2008 Remarkably, some of the residues in mutated human transthyretin that weaken or abolish the interaction with retinol-binding protein are present in piscine transthyretin, consistent with the lack of interaction between retinol-binding protein and transthyretin in fish. Vitamin A 108-115 transthyretin Homo sapiens 155-168 19021760-8 2008 Remarkably, some of the residues in mutated human transthyretin that weaken or abolish the interaction with retinol-binding protein are present in piscine transthyretin, consistent with the lack of interaction between retinol-binding protein and transthyretin in fish. Vitamin A 108-115 transthyretin Homo sapiens 155-168 19021760-8 2008 Remarkably, some of the residues in mutated human transthyretin that weaken or abolish the interaction with retinol-binding protein are present in piscine transthyretin, consistent with the lack of interaction between retinol-binding protein and transthyretin in fish. Vitamin A 218-225 transthyretin Homo sapiens 50-63 18620020-1 2008 Transthyretin (TTR) transports thyroid hormones (THs), thyroxine (T4) and triiodothyronine (T3) in the blood of vertebrates. Thyroxine 55-64 transthyretin Homo sapiens 15-18 18620020-1 2008 Transthyretin (TTR) transports thyroid hormones (THs), thyroxine (T4) and triiodothyronine (T3) in the blood of vertebrates. Triiodothyronine 74-90 transthyretin Homo sapiens 15-18 18620020-1 2008 Transthyretin (TTR) transports thyroid hormones (THs), thyroxine (T4) and triiodothyronine (T3) in the blood of vertebrates. Triiodothyronine 92-94 transthyretin Homo sapiens 15-18 18811132-4 2008 Coconsideration of amyloid inhibition and ex vivo plasma TTR binding selectivity data reveal that direct connection of the two aryls or linkage through nonpolar E-olefin or -CH 2CH 2- substructures generates the most potent and selective TTR amyloidogenesis inhibitors exhibiting minimal undesirable binding to the thyroid hormone nuclear receptor or the COX-1 enzyme. e-olefin 161-169 transthyretin Homo sapiens 57-60 18811132-4 2008 Coconsideration of amyloid inhibition and ex vivo plasma TTR binding selectivity data reveal that direct connection of the two aryls or linkage through nonpolar E-olefin or -CH 2CH 2- substructures generates the most potent and selective TTR amyloidogenesis inhibitors exhibiting minimal undesirable binding to the thyroid hormone nuclear receptor or the COX-1 enzyme. e-olefin 161-169 transthyretin Homo sapiens 238-241 18682830-3 2008 The known physiological functions of TTR are the transport of thyroid hormone T(4) and retinol, through binding to the retinol binding protein. Vitamin A 87-94 transthyretin Homo sapiens 37-40 18647617-8 2008 The TTR assay confirmed the activity of previously identified hydroxylated metabolites of PCBs and PBDEs, halogenated BPA and genistein. Polychlorinated Biphenyls 90-94 transthyretin Homo sapiens 4-7 18647617-8 2008 The TTR assay confirmed the activity of previously identified hydroxylated metabolites of PCBs and PBDEs, halogenated BPA and genistein. Halogenated Diphenyl Ethers 99-104 transthyretin Homo sapiens 4-7 18647617-8 2008 The TTR assay confirmed the activity of previously identified hydroxylated metabolites of PCBs and PBDEs, halogenated BPA and genistein. bisphenol A 118-121 transthyretin Homo sapiens 4-7 18647617-8 2008 The TTR assay confirmed the activity of previously identified hydroxylated metabolites of PCBs and PBDEs, halogenated BPA and genistein. Genistein 126-135 transthyretin Homo sapiens 4-7 18647617-9 2008 These results show that the hydroxylated metabolites of the ubiquitous PBDEs not only target the T4 transport at the TTR level, but also, and to a great extent, at the TBG level where most of the T4 in humans is circulating. Halogenated Diphenyl Ethers 71-76 transthyretin Homo sapiens 117-120 18682830-3 2008 The known physiological functions of TTR are the transport of thyroid hormone T(4) and retinol, through binding to the retinol binding protein. Vitamin A 119-126 transthyretin Homo sapiens 37-40 18596990-0 2008 Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition. carborane 75-84 transthyretin Homo sapiens 30-43 18537267-2 2008 Urea denaturation of TTR involves at least two equilibria: dissociation of tetramers into folded monomers and monomer unfolding. Urea 0-4 transthyretin Homo sapiens 21-24 18537267-9 2008 L55P TTR has a complicated denaturation pathway that includes dimers and trimers, so globally fitting its concentration-dependent urea denaturation data yielded error-laden estimates of stability parameters. Urea 130-134 transthyretin Homo sapiens 5-8 18484337-3 2008 It is the aim of this study to determine the metal concentrations in the serum and in the transthyretin (TTR) amyloid fibrils of FAP amyloidogenic TTR (ATTR) V30M patients. Metals 45-50 transthyretin Homo sapiens 105-108 18484337-3 2008 It is the aim of this study to determine the metal concentrations in the serum and in the transthyretin (TTR) amyloid fibrils of FAP amyloidogenic TTR (ATTR) V30M patients. Metals 45-50 transthyretin Homo sapiens 147-150 18484337-3 2008 It is the aim of this study to determine the metal concentrations in the serum and in the transthyretin (TTR) amyloid fibrils of FAP amyloidogenic TTR (ATTR) V30M patients. Metals 45-50 transthyretin Homo sapiens 152-156 18596990-2 2008 One such amyloidogenic protein is transthyretin (TTR), a 55-kDa homotetrameric protein found in the blood plasma and cerebrospinal fluid where it binds and transports thyroxine. Thyroxine 167-176 transthyretin Homo sapiens 34-47 18596990-2 2008 One such amyloidogenic protein is transthyretin (TTR), a 55-kDa homotetrameric protein found in the blood plasma and cerebrospinal fluid where it binds and transports thyroxine. Thyroxine 167-176 transthyretin Homo sapiens 49-52 18596990-4 2008 Studies have indicated that a diverse range of small molecules may also bind TTR in the thyroxine-binding pocket and subsequently kinetically stabilize the protein"s native conformation in vitro, preventing the misfolding that has been implicated in the progression of several diseases. Thyroxine 88-97 transthyretin Homo sapiens 77-80 18326041-0 2008 The modulation of transthyretin tetramer stability by cysteine 10 adducts and the drug diflunisal. Cysteine 54-62 transthyretin Homo sapiens 18-31 18424512-3 2008 The dansyl-tryptophan fluorescence resonance energy transfer (FRET) pair was shown to be able to detect the inter-peptide arrangement of the Transthyretin (105-115) amyloid fibril. N-((5-(Dimethylamino)-1-naphthalenyl)sulfonyl)-L-tryptophan 4-21 transthyretin Homo sapiens 141-154 18326041-7 2008 It has been suggested that amyloidogenicity may be conferred to wild-type TTR (the form deposited in SSA) by chemical modification of the lone cysteine residue (Cys(10)) through mixed disulfide bonds. Cysteine 143-151 transthyretin Homo sapiens 74-77 18326041-7 2008 It has been suggested that amyloidogenicity may be conferred to wild-type TTR (the form deposited in SSA) by chemical modification of the lone cysteine residue (Cys(10)) through mixed disulfide bonds. Cysteine 161-164 transthyretin Homo sapiens 74-77 18326041-7 2008 It has been suggested that amyloidogenicity may be conferred to wild-type TTR (the form deposited in SSA) by chemical modification of the lone cysteine residue (Cys(10)) through mixed disulfide bonds. Disulfides 184-193 transthyretin Homo sapiens 74-77 18326041-9 2008 In the present study, we have used fluorescence-detected sedimentation velocity to determine the effect of S-sulfonate and S-cysteine on the quaternary structural stability of fluorophore-conjugated recombinant TTR under nondenaturing conditions. s-sulfonate 107-118 transthyretin Homo sapiens 211-214 18326041-9 2008 In the present study, we have used fluorescence-detected sedimentation velocity to determine the effect of S-sulfonate and S-cysteine on the quaternary structural stability of fluorophore-conjugated recombinant TTR under nondenaturing conditions. Cysteine 123-133 transthyretin Homo sapiens 211-214 18243807-0 2008 Interaction of diethylstilbestrol and ioxynil with transthyretin in chicken serum. Diethylstilbestrol 15-33 transthyretin Homo sapiens 51-64 18243807-5 2008 Although all chemicals were detected in the gel filtration chromatography 50-100 kDa fractions, DES and ioxynil, but not PCP, were co-eluted with TTR during affinity chromatography. Diethylstilbestrol 96-99 transthyretin Homo sapiens 146-149 18546893-3 2008 We have found a kind of amyloid protein, transthyretin(TTR), that is S-sulfonated at the residue of cysteine in blood from patients with deficiency of molybdenum cofactor, which is essential to sulfite oxidase. Cysteine 100-108 transthyretin Homo sapiens 41-54 18546893-3 2008 We have found a kind of amyloid protein, transthyretin(TTR), that is S-sulfonated at the residue of cysteine in blood from patients with deficiency of molybdenum cofactor, which is essential to sulfite oxidase. Cysteine 100-108 transthyretin Homo sapiens 55-58 18546893-4 2008 The S-sulfonated TTR was easily stained with congo red, whereas TTR itself was not. Congo Red 45-54 transthyretin Homo sapiens 17-20 18546893-7 2008 We have studied reaction products from TTR and its synthetic octapeptide around the cysteine residue under moderate conditions by mass-spectrometry and estimated the reaction mechanism. Cysteine 84-92 transthyretin Homo sapiens 39-42 18243807-5 2008 Although all chemicals were detected in the gel filtration chromatography 50-100 kDa fractions, DES and ioxynil, but not PCP, were co-eluted with TTR during affinity chromatography. ioxynil 104-111 transthyretin Homo sapiens 146-149 18243807-0 2008 Interaction of diethylstilbestrol and ioxynil with transthyretin in chicken serum. ioxynil 38-45 transthyretin Homo sapiens 51-64 18243807-6 2008 Our results indicated that a significant proportion of DES and ioxynil, but a low proportion of PCP, interacted with TTR in whole chicken serum. Diethylstilbestrol 55-58 transthyretin Homo sapiens 117-120 18243807-2 2008 All of these chemicals strongly inhibited l-[(125)I]thyroxine ([(125)I]T(4)) binding to purified transthyretin (TTR) whereas PCP was less potent inhibitor than DES and ioxynil of [(125)I]T(4) binding to diluted whole chicken serum. l-[(125)i]thyroxine 42-61 transthyretin Homo sapiens 97-110 18243807-6 2008 Our results indicated that a significant proportion of DES and ioxynil, but a low proportion of PCP, interacted with TTR in whole chicken serum. ioxynil 63-70 transthyretin Homo sapiens 117-120 18243807-6 2008 Our results indicated that a significant proportion of DES and ioxynil, but a low proportion of PCP, interacted with TTR in whole chicken serum. Pentachlorophenol 96-99 transthyretin Homo sapiens 117-120 18243807-2 2008 All of these chemicals strongly inhibited l-[(125)I]thyroxine ([(125)I]T(4)) binding to purified transthyretin (TTR) whereas PCP was less potent inhibitor than DES and ioxynil of [(125)I]T(4) binding to diluted whole chicken serum. l-[(125)i]thyroxine 42-61 transthyretin Homo sapiens 112-115 18155178-0 2008 Iodination of salicylic acid improves its binding to transthyretin. Salicylic Acid 14-28 transthyretin Homo sapiens 53-66 18370581-13 2008 CONCLUSIONS: Both GM and TM treatments resulted in an improvement of subjective measures associated with CTS, but improvement in grip strength was only detected with the TM protocol. gm 18-20 transthyretin Homo sapiens 105-108 18155178-3 2008 The four TTR monomers associate around a central hydrophobic channel where two thyroxine molecules can bind simultaneously. Thyroxine 79-88 transthyretin Homo sapiens 9-12 18155178-6 2008 In order to take advantage of the high propensity to interactions between iodine substituents and the TTR channel we have identified two iodinated derivatives of salicylic acid, 5-iodosalicylic acid and 3,5-diiodosalicylic acid, available commercially. Iodine 74-80 transthyretin Homo sapiens 102-105 18155178-6 2008 In order to take advantage of the high propensity to interactions between iodine substituents and the TTR channel we have identified two iodinated derivatives of salicylic acid, 5-iodosalicylic acid and 3,5-diiodosalicylic acid, available commercially. Salicylic Acid 162-176 transthyretin Homo sapiens 102-105 18155178-6 2008 In order to take advantage of the high propensity to interactions between iodine substituents and the TTR channel we have identified two iodinated derivatives of salicylic acid, 5-iodosalicylic acid and 3,5-diiodosalicylic acid, available commercially. 5-iodosalicylic acid 178-198 transthyretin Homo sapiens 102-105 18155178-6 2008 In order to take advantage of the high propensity to interactions between iodine substituents and the TTR channel we have identified two iodinated derivatives of salicylic acid, 5-iodosalicylic acid and 3,5-diiodosalicylic acid, available commercially. 3,5-diiodosalicylic acid 203-227 transthyretin Homo sapiens 102-105 18155178-7 2008 We report in this paper the relative binding affinities of salicylic acid and the two iodinated derivatives and the crystal structure of TTR complexed with 3,5-diiodosalicylic acid, to elucidate the higher binding affinity of this compound towards TTR. 3,5-diiodosalicylic acid 156-180 transthyretin Homo sapiens 137-140 18155178-7 2008 We report in this paper the relative binding affinities of salicylic acid and the two iodinated derivatives and the crystal structure of TTR complexed with 3,5-diiodosalicylic acid, to elucidate the higher binding affinity of this compound towards TTR. 3,5-diiodosalicylic acid 156-180 transthyretin Homo sapiens 248-251